(lp0
(dp1
S'line'
p2
S'All the results indicate that CCR7 can promote lymph node metastasis in lung adenocarcinoma by regulating VEGF-C/D-R3 pathway.\n'
p3
sS'genes'
p4
(lp5
(dp6
S'index'
p7
I30
sS'uniprot'
p8
VP32248
p9
sS'lengthInChars'
p10
I4
sS'name'
p11
VCCR7
p12
sS'lengthInWords'
p13
I1
sa(dp14
g7
I106
sg8
VP49767
p15
sg10
I6
sg11
VVEGF-C
p16
sg13
I1
sasS'diseases'
p17
(lp18
(dp19
g7
I72
sS'cui'
p20
VC0152013
p21
sg10
I19
sg11
Vlung adenocarcinoma
p22
sg13
I2
sa(dp23
g7
I47
sg20
VC0686619
p24
sg10
I21
sg11
Vlymph node metastasis
p25
sg13
I3
sasa(dp26
g2
S'Thus CCR7 is proposed to be a potential prediction for poor prognosis of lung adenocarcinoma, and a therapeutic target for lymph node metastasis.\n'
p27
sg4
(lp28
(dp29
g7
I5
sg8
VP32248
p30
sg10
I4
sg11
VCCR7
p31
sg13
I1
sasg17
(lp32
(dp33
g7
I123
sg20
VC0686619
p34
sg10
I21
sg11
Vlymph node metastasis
p35
sg13
I3
sa(dp36
g7
I73
sg20
VC0152013
p37
sg10
I19
sg11
Vlung adenocarcinoma
p38
sg13
I2
sasa(dp39
g2
S'We examined the effects of CC chemokine receptor 7 (CCR7), CCR7 ligands and CrkL and c-ABL in lung adenocarcinoma.\n'
p40
sg4
(lp41
(dp42
g7
I85
sg8
VP00519
p43
sg10
I5
sg11
Vc-ABL
p44
sg13
I1
sa(dp45
g7
I76
sg8
VP46109
p46
sg10
I4
sg11
VCrkL
p47
sg13
I1
sa(dp48
g7
I52
sg8
VP32248
p49
sg10
I4
sg11
VCCR7
p50
sg13
I1
sa(dp51
g7
I27
sg8
VP32248
p52
sg10
I23
sg11
VCC chemokine receptor 7
p53
sg13
I4
sa(dp54
g7
I59
sg8
VP32248
p55
sg10
I12
sg11
VCCR7 ligands
p56
sg13
I2
sasg17
(lp57
(dp58
g7
I87
sg20
VC0000744
p59
sg10
I3
sg11
VABL
p60
sg13
I1
sa(dp61
g7
I94
sg20
VC0152013
p62
sg10
I19
sg11
Vlung adenocarcinoma
p63
sg13
I2
sasa(dp64
g2
S'We examined CCR7 and CCR7 ligands and CrkL and c-ABL mRNA expressions in surgically resected lung adenocarcinoma specimens and evaluated their contribution to prognosis, and the relationship with epidermal growth factor receptor (EGFR) and TP53 mutations.\n'
p65
sg4
(lp66
(dp67
g7
I47
sg8
VP00519
p68
sg10
I10
sg11
Vc-ABL mRNA
p69
sg13
I2
sa(dp70
g7
I38
sg8
VP46109
p71
sg10
I4
sg11
VCrkL
p72
sg13
I1
sa(dp73
g7
I12
sg8
VP32248
p74
sg10
I4
sg11
VCCR7
p75
sg13
I1
sa(dp76
g7
I230
sg8
VP01133
p77
sg10
I4
sg11
VEGFR
p78
sg13
I1
sa(dp79
g7
I196
sg8
VP01133
p80
sg10
I32
sg11
Vepidermal growth factor receptor
p81
sg13
I4
sa(dp82
g7
I21
sg8
VP32248
p83
sg10
I12
sg11
VCCR7 ligands
p84
sg13
I2
sasg17
(lp85
(dp86
g7
I93
sg20
VC0152013
p87
sg10
I19
sg11
Vlung adenocarcinoma
p88
sg13
I2
sa(dp89
g7
I49
sg20
VC0000744
p90
sg10
I3
sg11
VABL
p91
sg13
I1
sasa(dp92
g2
S'In lung adenocarcinoma, CrkL and c-ABL mRNAs were related to CCR7 mRNA expression (P&lt;0.0001).\n'
p93
sg4
(lp94
(dp95
g7
I33
sg8
VP00519
p96
sg10
I11
sg11
Vc-ABL mRNAs
p97
sg13
I2
sa(dp98
g7
I61
sg8
VP32248
p99
sg10
I9
sg11
VCCR7 mRNA
p100
sg13
I2
sa(dp101
g7
I24
sg8
VP46109
p102
sg10
I4
sg11
VCrkL
p103
sg13
I1
sasg17
(lp104
(dp105
g7
I3
sg20
VC0152013
p106
sg10
I19
sg11
Vlung adenocarcinoma
p107
sg13
I2
sa(dp108
g7
I35
sg20
VC0000744
p109
sg10
I3
sg11
VABL
p110
sg13
I1
sasa(dp111
g2
S'We propose that CCR7 and CCL19 are clinically good prognostic factors and that CCR7 is strongly related to CrkL and c-ABL kinase mRNA expression in lung adenocarcinoma.\n'
p112
sg4
(lp113
(dp114
g7
I107
sg8
VP46109
p115
sg10
I4
sg11
VCrkL
p116
sg13
I1
sa(dp117
g7
I16
sg8
VP32248
p118
sg10
I4
sg11
VCCR7
p119
sg13
I1
sa(dp120
g7
I116
sg8
VP00519
p121
sg10
I17
sg11
Vc-ABL kinase mRNA
p122
sg13
I3
sa(dp123
g7
I16
sg8
VP32248
p124
sg10
I4
sg11
VCCR7
p125
sg13
I1
sa(dp126
g7
I25
sg8
S''
p127
sg10
I5
sg11
VCCL19
p128
sg13
I1
sasg17
(lp129
(dp130
g7
I118
sg20
VC0000744
p131
sg10
I3
sg11
VABL
p132
sg13
I1
sa(dp133
g7
I148
sg20
VC0152013
p134
sg10
I19
sg11
Vlung adenocarcinoma
p135
sg13
I2
sasa(dp136
g2
S'The aim of this investigate is to evaluate the effects of hypoxia on the expression of CCR7 and the invasiveness of lung adenocarcinoma A549 cells.\n'
p137
sg4
(lp138
(dp139
g7
I87
sg8
VP32248
p140
sg10
I4
sg11
VCCR7
p141
sg13
I1
sasg17
(lp142
(dp143
g7
I58
sg20
VC0242184
p144
sg10
I7
sg11
Vhypoxia
p145
sg13
I1
sa(dp146
g7
I116
sg20
VC0152013
p147
sg10
I19
sg11
Vlung adenocarcinoma
p148
sg13
I2
sasa(dp149
g2
S'RT-PCR and Western blotting showed that the expression of CCR7 was detected in lung adenocarcinoma A549 cells, CCR7 mRNA and protein expression level were increased with culture time along either in normoxia or hypoxia condition; Furthermore, compared with normoxia group, the CCR7 mRNA and protein expression level in hypoxia group was increased (P &lt;0.01).\n'
p150
sg4
(lp151
(dp152
g7
I58
sg8
VP32248
p153
sg10
I4
sg11
VCCR7
p154
sg13
I1
sa(dp155
g7
I111
sg8
VP32248
p156
sg10
I9
sg11
VCCR7 mRNA
p157
sg13
I2
sa(dp158
g7
I111
sg8
VP32248
p159
sg10
I9
sg11
VCCR7 mRNA
p160
sg13
I2
sasg17
(lp161
(dp162
g7
I219
sg20
VC0012634
p163
sg10
I9
sg11
Vcondition
p164
sg13
I1
sa(dp165
g7
I79
sg20
VC0152013
p166
sg10
I19
sg11
Vlung adenocarcinoma
p167
sg13
I2
sa(dp168
g7
I211
sg20
VC0242184
p169
sg10
I7
sg11
Vhypoxia
p170
sg13
I1
sa(dp171
g7
I211
sg20
VC0242184
p172
sg10
I7
sg11
Vhypoxia
p173
sg13
I1
sasa(dp174
g2
S'In this study, we examined the expression and function of these two chemokine receptors (CCR7 and CXCR3) in lung adenocarcinoma.\n'
p175
sg4
(lp176
(dp177
g7
I98
sg8
VP49682
p178
sg10
I5
sg11
VCXCR3
p179
sg13
I1
sa(dp180
g7
I89
sg8
VP32248
p181
sg10
I4
sg11
VCCR7
p182
sg13
I1
sa(dp183
g7
I68
sg8
VP55773
p184
sg10
I19
sg11
Vchemokine receptors
p185
sg13
I2
sasg17
(lp186
(dp187
g7
I108
sg20
VC0152013
p188
sg10
I19
sg11
Vlung adenocarcinoma
p189
sg13
I2
sasa(dp190
g2
S'In clinical lung adenocarcinoma samples, we found the expression of CCR7 and CXCR3 in 65 and 90% cases, respectively, most of which had lymph node metastasis.\n'
p191
sg4
(lp192
(dp193
g7
I68
sg8
VP32248
p194
sg10
I4
sg11
VCCR7
p195
sg13
I1
sa(dp196
g7
I77
sg8
VP49682
p197
sg10
I5
sg11
VCXCR3
p198
sg13
I1
sasg17
(lp199
(dp200
g7
I12
sg20
VC0152013
p201
sg10
I19
sg11
Vlung adenocarcinoma
p202
sg13
I2
sa(dp203
g7
I136
sg20
VC0686619
p204
sg10
I21
sg11
Vlymph node metastasis
p205
sg13
I3
sasa(dp206
g2
S'These results suggest that the activation of CCR7 and CXCR3 with their ligands preferentially stimulates lung adenocarcinoma metastasis to the draining lymph nodes.\n'
p207
sg4
(lp208
(dp209
g7
I54
sg8
VP49682
p210
sg10
I5
sg11
VCXCR3
p211
sg13
I1
sa(dp212
g7
I45
sg8
VP32248
p213
sg10
I4
sg11
VCCR7
p214
sg13
I1
sasg17
(lp215
(dp216
g7
I125
sg20
VC0027627
p217
sg10
I10
sg11
Vmetastasis
p218
sg13
I1
sa(dp219
g7
I105
sg20
VC0152013
p220
sg10
I19
sg11
Vlung adenocarcinoma
p221
sg13
I2
sasa(dp222
g2
S'describe context-dependent oncogenic and tumor-suppressive functions for the mammalian SWI/SNF (BAF) complex subunit ARID1A in the development and progression of hepatocellular carcinoma (HCC).\n'
p223
sg4
(lp224
(dp225
g7
I87
sg8
VP28370
p226
sg10
I36
sg11
VSWI/SNF (BAF) complex subunit ARID1A
p227
sg13
I5
sasg17
(lp228
(dp229
g7
I188
sg20
VC2239176
p230
sg10
I3
sg11
VHCC
p231
sg13
I1
sa(dp232
g7
I162
sg20
VC2239176
p233
sg10
I24
sg11
Vhepatocellular carcinoma
p234
sg13
I2
sa(dp235
g7
I41
sg20
VC0027651
p236
sg10
I5
sg11
Vtumor
p237
sg13
I1
sasa(dp238
g2
S'The findings suggest novel molecular markers of BANF1, PLOD3 and SF3B4 indicating early-stage HCC in precancerous lesion, and also suggest drivers for understanding the development of hepatocarcinogenesis.\n'
p239
sg4
(lp240
(dp241
g7
I55
sg8
g127
sg10
I5
sg11
VPLOD3
p242
sg13
I1
sa(dp243
g7
I48
sg8
g127
sg10
I5
sg11
VBANF1
p244
sg13
I1
sa(dp245
g7
I65
sg8
g127
sg10
I5
sg11
VSF3B4
p246
sg13
I1
sasg17
(lp247
(dp248
g7
I184
sg20
VC1512409
p249
sg10
I20
sg11
Vhepatocarcinogenesis
p250
sg13
I1
sa(dp251
g7
I94
sg20
VC2239176
p252
sg10
I3
sg11
VHCC
p253
sg13
I1
sasa(dp254
g2
S'Perturbations to mammalian SWI/SNF (mSWI/SNF or BAF) complexes contribute to more than 20% of human cancers, with driving roles first identified in malignant rhabdoid tumor, an aggressive pediatric cancer characterized by biallelic inactivation of the core BAF complex subunit SMARCB1 (BAF47).\n'
p255
sg4
(lp256
(dp257
g7
I27
sg8
VP28370
p258
sg10
I3
sg11
VSWI
p259
sg13
I1
sa(dp260
g7
I48
sg8
g127
sg10
I3
sg11
VBAF
p261
sg13
I1
sa(dp262
g7
I286
sg8
g127
sg10
I5
sg11
VBAF47
p263
sg13
I1
sa(dp264
g7
I31
sg8
g127
sg10
I3
sg11
VSNF
p265
sg13
I1
sa(dp266
g7
I31
sg8
g127
sg10
I3
sg11
VSNF
p267
sg13
I1
sa(dp268
g7
I252
sg8
g127
sg10
I32
sg11
Vcore BAF complex subunit SMARCB1
p269
sg13
I5
sasg17
(lp270
(dp271
g7
I232
sg20
VC0544461
p272
sg10
I12
sg11
Vinactivation
p273
sg13
I1
sa(dp274
g7
I177
sg20
VC0001807
p275
sg10
I10
sg11
Vaggressive
p276
sg13
I1
sa(dp277
g7
I188
sg20
VC0278704
p278
sg10
I16
sg11
Vpediatric cancer
p279
sg13
I2
sa(dp280
g7
I100
sg20
VC0006826
p281
sg10
I7
sg11
Vcancers
p282
sg13
I1
sa(dp283
g7
I148
sg20
VC0206743
p284
sg10
I24
sg11
Vmalignant rhabdoid tumor
p285
sg13
I3
sasa(dp286
g2
S'BAF recruitment to GGAA microsatellites activates the Ewing sarcoma transcriptional program.\n'
p287
sg4
(lp288
sg17
(lp289
(dp290
g7
I54
sg20
VC0553580
p291
sg10
I13
sg11
VEwing sarcoma
p292
sg13
I2
sa(dp293
g7
I4
sg20
VC0271510
p294
sg10
I11
sg11
Vrecruitment
p295
sg13
I1
sasa(dp296
g2
S'We identified a new set of genes encoding subunits of the BAF chromatin remodeling complex that exhibited Ras-mediated dependence on PRC2 histone methyltransferase activity, a finding that is similar to what has been observed for other BAF subunits in cancer cells.\n'
p297
sg4
(lp298
(dp299
g7
I106
sg8
VP01116
p300
sg10
I3
sg11
VRas
p301
sg13
I1
sa(dp302
g7
I133
sg8
VP50135
p303
sg10
I30
sg11
VPRC2 histone methyltransferase
p304
sg13
I3
sa(dp305
g7
I236
sg8
g127
sg10
I12
sg11
VBAF subunits
p306
sg13
I2
sasg17
(lp307
(dp308
g7
I119
sg20
VC0439857
p309
sg10
I13
sg11
Vdependence on
p310
sg13
I2
sa(dp311
g7
I252
sg20
VC0006826
p312
sg10
I6
sg11
Vcancer
p313
sg13
I1
sasa(dp314
g2
S'Among the affected BAF complex subunits, we determined Smarcd2 and Smarcc1 as putative driver candidates not yet fully identified by large-scale cancer genome sequencing projects.\n'
p315
sg4
(lp316
(dp317
g7
I55
sg8
g127
sg10
I7
sg11
VSmarcd2
p318
sg13
I1
sa(dp319
g7
I67
sg8
g127
sg10
I7
sg11
VSmarcc1
p320
sg13
I1
sasg17
(lp321
(dp322
g7
I145
sg20
VC0006826
p323
sg10
I6
sg11
Vcancer
p324
sg13
I1
sasa(dp325
g2
S'We demonstrated de novo expression of VWF in glioma as well as osteosarcoma cells.\n'
p326
sg4
(lp327
(dp328
g7
I38
sg8
VP04275
p329
sg10
I3
sg11
VVWF
p330
sg13
I1
sasg17
(lp331
(dp332
g7
I45
sg20
VC0017638
p333
sg10
I6
sg11
Vglioma
p334
sg13
I1
sa(dp335
g7
I63
sg20
VC0029463
p336
sg10
I12
sg11
Vosteosarcoma
p337
sg13
I1
sasa(dp338
g2
S'To investigate whether preoperative antigen plasma level of von Willebrand Factor (VWF:Ag) might be possible marker for GBM onset, progression, and prognosis, we retrospectively examined 57 patients with histological diagnosis for GBM and 23 meningiomas (MNGs), benign intracranial expansive lesions, enrolled as controls.\n'
p339
sg4
(lp340
(dp341
g7
I60
sg8
VP04275
p342
sg10
I30
sg11
Vvon Willebrand Factor (VWF:Ag)
p343
sg13
I4
sasg17
(lp344
(dp345
g7
I120
sg20
VC0017636
p346
sg10
I3
sg11
VGBM
p347
sg13
I1
sa(dp348
g7
I242
sg20
VC0025286
p349
sg10
I11
sg11
Vmeningiomas
p350
sg13
I1
sa(dp351
g7
I120
sg20
VC0017636
p352
sg10
I3
sg11
VGBM
p353
sg13
I1
sa(dp354
g7
I255
sg20
VC0025286
p355
sg10
I4
sg11
VMNGs
p356
sg13
I1
sasa(dp357
g2
S'The median levels of vWF:Ag were significantly higher in GBMs than in meningiomas (MNGs) (183 vs. 133 IU/dL, P = 0.01).\n'
p358
sg4
(lp359
(dp360
g7
I21
sg8
VP04275
p361
sg10
I3
sg11
VvWF
p362
sg13
I1
sasg17
(lp363
(dp364
g7
I70
sg20
VC0025286
p365
sg10
I11
sg11
Vmeningiomas
p366
sg13
I1
sa(dp367
g7
I83
sg20
VC0025286
p368
sg10
I4
sg11
VMNGs
p369
sg13
I1
sasa(dp370
g2
S'The cumulative 1-year survival was significantly shorter in patients with VWF:Ag levels &gt;200 IU/dL than in those with levels &lt;200 IU/dL and increased VWF levels were associated with a threefold higher risk of death in GBM patients.\n'
p371
sg4
(lp372
sg17
(lp373
(dp374
g7
I224
sg20
VC0017636
p375
sg10
I3
sg11
VGBM
p376
sg13
I1
sasa(dp377
g2
S'Our data suggest that VWF:Ag could be a circulating biomarker of disease malignancy, that could be considered, in association with other genetic and epigenetic factors, currently available in the GBM management.\n'
p378
sg4
(lp379
(dp380
g7
I22
sg8
VP04275
p381
sg10
I3
sg11
VVWF
p382
sg13
I1
sasg17
(lp383
(dp384
g7
I73
sg20
VC0006826
p385
sg10
I10
sg11
Vmalignancy
p386
sg13
I1
sa(dp387
g7
I196
sg20
VC0017636
p388
sg10
I3
sg11
VGBM
p389
sg13
I1
sasa(dp390
g2
S'A 3D cell culture induced microenvironment (containing only glial cells) is sufficient to promote expression of the endothelial markers CD105, CD31 and vWF in a proportion of glioma aggregates in vitro.\n'
p391
sg4
(lp392
(dp393
g7
I136
sg8
VP17813
p394
sg10
I5
sg11
VCD105
p395
sg13
I1
sa(dp396
g7
I152
sg8
VP04275
p397
sg10
I3
sg11
VvWF
p398
sg13
I1
sa(dp399
g7
I143
sg8
VP69905
p400
sg10
I4
sg11
VCD31
p401
sg13
I1
sasg17
(lp402
(dp403
g7
I175
sg20
VC0017638
p404
sg10
I6
sg11
Vglioma
p405
sg13
I1
sasa(dp406
g2
S'This observation was reproduced in vitro: when tumor stem cells derived from GBM were grown in the presence of human endothelial cells, a fraction of them acquired endothelial markers (CD31, CD105, VE-cadherin, and vWF).\n'
p407
sg4
(lp408
(dp409
g7
I191
sg8
VP17813
p410
sg10
I5
sg11
VCD105
p411
sg13
I1
sa(dp412
g7
I185
sg8
VP69905
p413
sg10
I4
sg11
VCD31
p414
sg13
I1
sa(dp415
g7
I215
sg8
VP04275
p416
sg10
I3
sg11
VvWF
p417
sg13
I1
sa(dp418
g7
I198
sg8
VP33151
p419
sg10
I11
sg11
VVE-cadherin
p420
sg13
I1
sasg17
(lp421
(dp422
g7
I47
sg20
VC0027651
p423
sg10
I5
sg11
Vtumor
p424
sg13
I1
sa(dp425
g7
I77
sg20
VC0017636
p426
sg10
I3
sg11
VGBM
p427
sg13
I1
sasa(dp428
g2
S'The majority of melanomas emerge from clear skin without a precursor lesion, but it is unknown whether these melanomas can arise from melanocyte stem cells (MCSCs).\n'
p429
sg4
(lp430
sg17
(lp431
(dp432
g7
I16
sg20
VC0025202
p433
sg10
I9
sg11
Vmelanomas
p434
sg13
I1
sa(dp435
g7
I16
sg20
VC0025202
p436
sg10
I9
sg11
Vmelanomas
p437
sg13
I1
sasa(dp438
g2
S'Here we employ mouse models to define the role of MCSCs as melanoma cells of origin, demonstrate that MCSC quiescence acts as a tumor suppressor, and identify the extrinsic environmental and molecular factors required for the critical early steps of melanoma initiation.\n'
p439
sg4
(lp440
sg17
(lp441
(dp442
g7
I59
sg20
VC0025202
p443
sg10
I8
sg11
Vmelanoma
p444
sg13
I1
sa(dp445
g7
I59
sg20
VC0025202
p446
sg10
I8
sg11
Vmelanoma
p447
sg13
I1
sa(dp448
g7
I128
sg20
VC0027651
p449
sg10
I5
sg11
Vtumor
p450
sg13
I1
sasa(dp451
g2
S'Specifically, melanomas originate from melanoma-competent MCSCs upon stimulation by UVB, which induces MCSC activation and translocation via an inflammation-dependent process.\n'
p452
sg4
(lp453
sg17
(lp454
(dp455
g7
I123
sg20
VC0040715
p456
sg10
I13
sg11
Vtranslocation
p457
sg13
I1
sa(dp458
g7
I14
sg20
VC0025202
p459
sg10
I8
sg11
Vmelanoma
p460
sg13
I1
sa(dp461
g7
I144
sg20
VC0021368
p462
sg10
I12
sg11
Vinflammation
p463
sg13
I1
sa(dp464
g7
I14
sg20
VC0025202
p465
sg10
I9
sg11
Vmelanomas
p466
sg13
I1
sasa(dp467
g2
S'These findings delineate melanoma formation from melanoma-competent MCSCs following extrinsic stimuli, and they suggest that abrogation of Hmga2 function in the microenvironment can suppress MCSC-originating cutaneous melanomas.\n'
p468
sg4
(lp469
(dp470
g7
I139
sg8
VP52926
p471
sg10
I5
sg11
VHmga2
p472
sg13
I1
sasg17
(lp473
(dp474
g7
I25
sg20
VC0025202
p475
sg10
I8
sg11
Vmelanoma
p476
sg13
I1
sa(dp477
g7
I218
sg20
VC0025202
p478
sg10
I9
sg11
Vmelanomas
p479
sg13
I1
sa(dp480
g7
I25
sg20
VC0025202
p481
sg10
I8
sg11
Vmelanoma
p482
sg13
I1
sasa(dp483
g2
S'The main goal of this work was to verify whether transplantation of microencapsulated prepubertal porcine Sertoli cells (MC-SC) in the subcutaneous abdominal fat depot of spontaneously diabetic and obese db/db mice (homozygous for the diabetes spontaneous mutation [Leprdb ]) would: (i) improve glucose homeostasis and (ii) modulate local and systemic immune response and adipokines profiles.\n'
p484
sg4
(lp485
sg17
(lp486
(dp487
g7
I235
sg20
VC0011849
p488
sg10
I8
sg11
Vdiabetes
p489
sg13
I1
sa(dp490
g7
I198
sg20
VC0028754
p491
sg10
I5
sg11
Vobese
p492
sg13
I1
sasa(dp493
g2
S'In this study, to establish an in vitro SL model, human epidermal squamous carcinoma cell line HSC-1, which expresses higher levels of WNT1 than normal human epidermal keratinocytes, was co-cultured with early passage normal human epidermal melanocytes (NHEMs) as an in vitro McSC model.\n'
p494
sg4
(lp495
(dp496
g7
I135
sg8
VP04628
p497
sg10
I4
sg11
VWNT1
p498
sg13
I1
sasg17
(lp499
(dp500
g7
I66
sg20
VC0007137
p501
sg10
I18
sg11
Vsquamous carcinoma
p502
sg13
I2
sasa(dp503
g2
S'Recently, we found that LNCaP androgen-responsive prostate cancer cells treated with MCS-C3 rapidly undergo intrinsic apoptosis through dramatic up-regulation of p21(CIP1).\n'
p504
sg4
(lp505
(dp506
g7
I166
sg8
VP38936
p507
sg10
I4
sg11
VCIP1
p508
sg13
I1
sa(dp509
g7
I162
sg8
VP42857
p510
sg10
I3
sg11
Vp21
p511
sg13
I1
sa(dp512
g7
I85
sg8
VP49901
p513
sg10
I6
sg11
VMCS-C3
p514
sg13
I1
sasg17
(lp515
(dp516
g7
I85
sg20
VC0036221
p517
sg10
I3
sg11
VMCS
p518
sg13
I1
sa(dp519
g7
I50
sg20
VC0600139
p520
sg10
I15
sg11
Vprostate cancer
p521
sg13
I2
sasa(dp522
g2
S'Expression of miR-33a/b was markedly increased in human carotid atherosclerotic plaques compared with normal arteries, and there was a concomitant decrease in mitochondrial regulatory genes PGC-1Alfa, SLC25A25, NRF1, and TFAM, suggesting these genes are associated with advanced atherosclerosis in humans.\n'
p523
sg4
(lp524
(dp525
g7
I211
sg8
g127
sg10
I4
sg11
VNRF1
p526
sg13
I1
sa(dp527
g7
I14
sg8
g127
sg10
I9
sg11
VmiR-33a/b
p528
sg13
I1
sa(dp529
g7
I190
sg8
VP20142
p530
sg10
I9
sg11
VPGC-1Alfa
p531
sg13
I1
sa(dp532
g7
I221
sg8
g127
sg10
I4
sg11
VTFAM
p533
sg13
I1
sasg17
(lp534
(dp535
g7
I279
sg20
VC0004153
p536
sg10
I15
sg11
Vatherosclerosis
p537
sg13
I1
sa(dp538
g7
I80
sg20
VC0333463
p539
sg10
I7
sg11
Vplaques
p540
sg13
I1
sasa(dp541
g2
S'Considering its anti-proliferative action, principally given by inhibiting the MCs c-KitR anti-angiogenic pathway that leads cancer progression, and its role as chemosensitizer, masitinib is under clinical investigation in several human malignancies (Gastro-Intestinal Stromal Tumors, acute myeloid leukemia, systemic mastocytosis, pancreatic cancer, multiple myeloma, non-small cell lung cancer, melanoma, ovarian and prostate cancer), which are characterized by similar canine c-KIT proto-oncogene mutations.\n'
p542
sg4
(lp543
(dp544
g7
I479
sg8
VP10721
p545
sg10
I30
sg11
Vc-KIT proto-oncogene mutations
p546
sg13
I3
sa(dp547
g7
I79
sg8
VP49901
p548
sg10
I3
sg11
VMCs
p549
sg13
I1
sasg17
(lp550
(dp551
g7
I79
sg20
VC0036221
p552
sg10
I3
sg11
VMCs
p553
sg13
I1
sa(dp554
g7
I419
sg20
VC0600139
p555
sg10
I15
sg11
Vprostate cancer
p556
sg13
I2
sa(dp557
g7
I351
sg20
VC0026764
p558
sg10
I16
sg11
Vmultiple myeloma
p559
sg13
I2
sa(dp560
g7
I369
sg20
VC0007131
p561
sg10
I26
sg11
Vnon-small cell lung cancer
p562
sg13
I4
sa(dp563
g7
I237
sg20
VC0006826
p564
sg10
I12
sg11
Vmalignancies
p565
sg13
I1
sa(dp566
g7
I332
sg20
VC0235974
p567
sg10
I17
sg11
Vpancreatic cancer
p568
sg13
I2
sa(dp569
g7
I21
sg20
VC0334094
p570
sg10
I13
sg11
Vproliferative
p571
sg13
I1
sa(dp572
g7
I397
sg20
VC0025202
p573
sg10
I8
sg11
Vmelanoma
p574
sg13
I1
sa(dp575
g7
I269
sg20
VC0879615
p576
sg10
I14
sg11
VStromal Tumors
p577
sg13
I2
sa(dp578
g7
I309
sg20
VC0221013
p579
sg10
I21
sg11
Vsystemic mastocytosis
p580
sg13
I2
sa(dp581
g7
I285
sg20
VC0023467
p582
sg10
I22
sg11
Vacute myeloid leukemia
p583
sg13
I3
sa(dp584
g7
I125
sg20
VC0178874
p585
sg10
I18
sg11
Vcancer progression
p586
sg13
I2
sasa(dp587
g2
S'We investigate the unknown tumor-killing activity of cytokine-induced killer (CIK) cells against autologous metastatic melanoma and the elusive subset of putative cancer stem cells (mCSC).\n'
p588
sg4
(lp589
sg17
(lp590
(dp591
g7
I108
sg20
VC0278883
p592
sg10
I19
sg11
Vmetastatic melanoma
p593
sg13
I2
sa(dp594
g7
I163
sg20
VC0006826
p595
sg10
I6
sg11
Vcancer
p596
sg13
I1
sa(dp597
g7
I27
sg20
VC0027651
p598
sg10
I5
sg11
Vtumor
p599
sg13
I1
sasa(dp600
g2
S'The metastatic melanoma cultures presented an average of 11.5% +/- 2.5% putative mCSCs, which was assessed by Oct4 promoter activity and stemness marker expression (Oct4, ABCG2, ALDH, MITF).\n'
p601
sg4
(lp602
(dp603
g7
I184
sg8
g127
sg10
I4
sg11
VMITF
p604
sg13
I1
sa(dp605
g7
I178
sg8
VP00352
p606
sg10
I4
sg11
VALDH
p607
sg13
I1
sasg17
(lp608
(dp609
g7
I4
sg20
VC0278883
p610
sg10
I19
sg11
Vmetastatic melanoma
p611
sg13
I2
sasa(dp612
g2
S'CIK tumor killing activity against mCSCs was intense (up to 71%, n = 4) and comparable with results reported against differentiated metastatic melanoma cells (P = 0.8).\n'
p613
sg4
(lp614
sg17
(lp615
(dp616
g7
I4
sg20
VC0027651
p617
sg10
I5
sg11
Vtumor
p618
sg13
I1
sa(dp619
g7
I132
sg20
VC0278883
p620
sg10
I19
sg11
Vmetastatic melanoma
p621
sg13
I2
sasa(dp622
g2
S'For the first time, the intense killing activity of CIK cells against autologous metastatic melanoma, including mCSCs, has been shown.\n'
p623
sg4
(lp624
sg17
(lp625
(dp626
g7
I81
sg20
VC0278883
p627
sg10
I19
sg11
Vmetastatic melanoma
p628
sg13
I2
sasa(dp629
g2
S'These findings move clinical investigation of a new immunotherapy for metastatic melanoma, including mCSCs, closer.\n'
p630
sg4
(lp631
sg17
(lp632
(dp633
g7
I70
sg20
VC0278883
p634
sg10
I19
sg11
Vmetastatic melanoma
p635
sg13
I2
sasa(dp636
g2
S'In addition, FKBP51 induced some melanoma stem cell (MCSC) genes.\n'
p637
sg4
(lp638
(dp639
g7
I13
sg8
g127
sg10
I6
sg11
VFKBP51
p640
sg13
I1
sasg17
(lp641
(dp642
g7
I33
sg20
VC0025202
p643
sg10
I8
sg11
Vmelanoma
p644
sg13
I1
sasa(dp645
g2
S'Results: Expressions of hsa-mir-1180, hsa-mir-149, hsa-mir-744 and hsa-mir-940 were all up regulated in high invasion capable cell lines (SNU423, SNU449) and vascular invasion patients with hepatocellular carcinoma (logFC&gt;1, P&lt;0.05).\n'
p646
sg4
(lp647
(dp648
g7
I24
sg8
g127
sg10
I3
sg11
Vhsa
p649
sg13
I1
sa(dp650
g7
I38
sg8
g127
sg10
I11
sg11
Vhsa-mir-149
p651
sg13
I1
sa(dp652
g7
I51
sg8
g127
sg10
I11
sg11
Vhsa-mir-744
p653
sg13
I1
sa(dp654
g7
I24
sg8
g127
sg10
I12
sg11
Vhsa-mir-1180
p655
sg13
I1
sasg17
(lp656
(dp657
g7
I24
sg20
VC0393754
p658
sg10
I3
sg11
Vhsa
p659
sg13
I1
sa(dp660
g7
I24
sg20
VC0393754
p661
sg10
I3
sg11
Vhsa
p662
sg13
I1
sa(dp663
g7
I24
sg20
VC0393754
p664
sg10
I3
sg11
Vhsa
p665
sg13
I1
sa(dp666
g7
I24
sg20
VC0393754
p667
sg10
I3
sg11
Vhsa
p668
sg13
I1
sa(dp669
g7
I109
sg20
VC2699153
p670
sg10
I8
sg11
Vinvasion
p671
sg13
I1
sa(dp672
g7
I190
sg20
VC1512411
p673
sg10
I24
sg11
Vhepatocellular carcinoma
p674
sg13
I2
sa(dp675
g7
I109
sg20
VC2699153
p676
sg10
I8
sg11
Vinvasion
p677
sg13
I1
sasa(dp678
g2
S'Results from the Survival analysis showed that hsa-mir-1180 (HR=1.623, 95% CI: 1.114-2.365, P=0.012), hsa-mir-149 (HR=2.400, 95% CI: 1.639-3.514) and hsa-mir-940 (HR=1.704, 95%CI: 1.188-2.443, P=0.004) were independent risk factors on the prognosis of patients with hepatocellular carcinoma (P&lt;0.05).\n'
p679
sg4
(lp680
(dp681
g7
I47
sg8
g127
sg10
I3
sg11
Vhsa
p682
sg13
I1
sa(dp683
g7
I47
sg8
g127
sg10
I3
sg11
Vhsa
p684
sg13
I1
sa(dp685
g7
I47
sg8
g127
sg10
I3
sg11
Vhsa
p686
sg13
I1
sasg17
(lp687
(dp688
g7
I47
sg20
VC0393754
p689
sg10
I3
sg11
Vhsa
p690
sg13
I1
sa(dp691
g7
I47
sg20
VC0393754
p692
sg10
I3
sg11
Vhsa
p693
sg13
I1
sa(dp694
g7
I266
sg20
VC1512411
p695
sg10
I24
sg11
Vhepatocellular carcinoma
p696
sg13
I2
sa(dp697
g7
I47
sg20
VC0393754
p698
sg10
I3
sg11
Vhsa
p699
sg13
I1
sasa(dp700
g2
S'Conclusion: With TCGA and GEO data mining, we found that hsa-mir-1180, hsa-mir-149, hsa-mir-744 and hsa-mir-940 were all highly related to the prognosis of hepatocellular carcinoma, that enabled it to be used to further study the biomarkers related to the prognosis of hepatocellular carcinoma.\n'
p701
sg4
(lp702
(dp703
g7
I57
sg8
g127
sg10
I12
sg11
Vhsa-mir-1180
p704
sg13
I1
sa(dp705
g7
I71
sg8
g127
sg10
I11
sg11
Vhsa-mir-149
p706
sg13
I1
sa(dp707
g7
I84
sg8
g127
sg10
I11
sg11
Vhsa-mir-744
p708
sg13
I1
sa(dp709
g7
I57
sg8
g127
sg10
I3
sg11
Vhsa
p710
sg13
I1
sasg17
(lp711
(dp712
g7
I57
sg20
VC0393754
p713
sg10
I3
sg11
Vhsa
p714
sg13
I1
sa(dp715
g7
I156
sg20
VC1512411
p716
sg10
I24
sg11
Vhepatocellular carcinoma
p717
sg13
I2
sa(dp718
g7
I156
sg20
VC1512411
p719
sg10
I24
sg11
Vhepatocellular carcinoma
p720
sg13
I2
sa(dp721
g7
I57
sg20
VC0393754
p722
sg10
I3
sg11
Vhsa
p723
sg13
I1
sa(dp724
g7
I57
sg20
VC0393754
p725
sg10
I3
sg11
Vhsa
p726
sg13
I1
sa(dp727
g7
I57
sg20
VC0393754
p728
sg10
I3
sg11
Vhsa
p729
sg13
I1
sasa(dp730
g2
S'Recently, several studies have investigated the association between polymorphisms in miR-146a rs2910164, miR-196a2 rs11614913, miR-499 rs3746444, miR-149 rs229283, miR-34b/c rs4938723, and hepatocellular carcinoma (HCC), which showed inconclusive results.\n'
p731
sg4
(lp732
(dp733
g7
I146
sg8
g127
sg10
I16
sg11
VmiR-149 rs229283
p734
sg13
I2
sa(dp735
g7
I105
sg8
g127
sg10
I20
sg11
VmiR-196a2 rs11614913
p736
sg13
I2
sa(dp737
g7
I127
sg8
g127
sg10
I17
sg11
VmiR-499 rs3746444
p738
sg13
I2
sa(dp739
g7
I164
sg8
g127
sg10
I19
sg11
VmiR-34b/c rs4938723
p740
sg13
I2
sa(dp741
g7
I85
sg8
g127
sg10
I18
sg11
VmiR-146a rs2910164
p742
sg13
I2
sasg17
(lp743
(dp744
g7
I189
sg20
VC2239176
p745
sg10
I24
sg11
Vhepatocellular carcinoma
p746
sg13
I2
sa(dp747
g7
I215
sg20
VC2239176
p748
sg10
I3
sg11
VHCC
p749
sg13
I1
sasa(dp750
g2
S'Numerous studies have explored the association between MIR-149 gene rs2292832 polymorphism and hepatocellular carcinoma (HCC) risk, but the results remains inconsistent.\n'
p751
sg4
(lp752
sg17
(lp753
(dp754
g7
I121
sg20
VC2239176
p755
sg10
I3
sg11
VHCC
p756
sg13
I1
sa(dp757
g7
I95
sg20
VC2239176
p758
sg10
I24
sg11
Vhepatocellular carcinoma
p759
sg13
I2
sasa(dp760
g2
S'When all the eligible studies were pooled into this meta-analysis, a significant association between MIR-149 gene rs2292832 polymorphism and hepatocellular carcinoma risk was found, while no association was found between this gene polymorphism and overall cancer risk.\n'
p761
sg4
(lp762
sg17
(lp763
(dp764
g7
I141
sg20
VC1512411
p765
sg10
I24
sg11
Vhepatocellular carcinoma
p766
sg13
I2
sa(dp767
g7
I256
sg20
VC0006826
p768
sg10
I6
sg11
Vcancer
p769
sg13
I1
sasa(dp770
g2
S'We used"hepatocellular carcinoma/HCC","miRNA-149/miR-149/microRNA-149", and"miRNA-499/miR-499/microRNA-499"as key words to search papers in databases including China National Knowledge Internet (CNKI), Chinese BioMedical Literature (CBM), Vip Citation Databases (VIP), Wanfang, PubMed and Web of Science databases, and collected the case-control studies on the association of rs2292832 or rs3746444 and the susceptibility to hepatocellular carcinoma from updated to May 31st 2015.\n'
p771
sg4
(lp772
sg17
(lp773
(dp774
g7
I8
sg20
VC2239176
p775
sg10
I24
sg11
Vhepatocellular carcinoma
p776
sg13
I2
sa(dp777
g7
I8
sg20
VC2239176
p778
sg10
I24
sg11
Vhepatocellular carcinoma
p779
sg13
I2
sa(dp780
g7
I33
sg20
VC2239176
p781
sg10
I3
sg11
VHCC
p782
sg13
I1
sa(dp783
g7
I289
sg20
VC0332875
p784
sg10
I3
sg11
VWeb
p785
sg13
I1
sasa(dp786
g2
S'Numerous studies have explored the association between miR-149 gene rs2292832 polymorphism and hepatocellular carcinoma risk, but the results remains inconsistent.\n'
p787
sg4
(lp788
(dp789
g7
I55
sg8
g127
sg10
I12
sg11
VmiR-149 gene
p790
sg13
I2
sasg17
(lp791
(dp792
g7
I95
sg20
VC1512411
p793
sg10
I24
sg11
Vhepatocellular carcinoma
p794
sg13
I2
sasa(dp795
g2
S'Odds ratios (OR) with 95% confidence intervals (CI), calculated by STATA software, were used to determine whether miR-149 gene rs2292832 polymorphism contributes to the risk of Hepatocellular carcinoma.\n'
p796
sg4
(lp797
(dp798
g7
I114
sg8
g127
sg10
I12
sg11
VmiR-149 gene
p799
sg13
I2
sasg17
(lp800
(dp801
g7
I177
sg20
VC1512411
p802
sg10
I24
sg11
VHepatocellular carcinoma
p803
sg13
I2
sasa(dp804
g2
S'When all the eligible studies were pooled into this meta-analysis, a significant association between miR-149 gene rs2292832 polymorphism and hepatocellular carcinoma risk was found.\n'
p805
sg4
(lp806
(dp807
g7
I101
sg8
g127
sg10
I12
sg11
VmiR-149 gene
p808
sg13
I2
sasg17
(lp809
(dp810
g7
I141
sg20
VC1512411
p811
sg10
I24
sg11
Vhepatocellular carcinoma
p812
sg13
I2
sasa(dp813
g2
S'Our meta-analysis supports that the miR-149 gene rs2292832 polymorphism contributed to the risk of hepatocellular carcinoma from currently available evidence.\n'
p814
sg4
(lp815
(dp816
g7
I36
sg8
g127
sg10
I12
sg11
VmiR-149 gene
p817
sg13
I2
sasg17
(lp818
(dp819
g7
I99
sg20
VC1512411
p820
sg10
I24
sg11
Vhepatocellular carcinoma
p821
sg13
I2
sasa(dp822
g2
S'However, a study with a larger sample size is needed to further evaluate gene-environment interaction on MiR-149 gene rs2292832 polymorphism and hepatocellular carcinoma risk.\n'
p823
sg4
(lp824
(dp825
g7
I105
sg8
g127
sg10
I12
sg11
VMiR-149 gene
p826
sg13
I2
sasg17
(lp827
(dp828
g7
I145
sg20
VC1512411
p829
sg10
I24
sg11
Vhepatocellular carcinoma
p830
sg13
I2
sasa(dp831
g2
S'We conducted a case-control study to evaluate the association of miR-146a rs2910164 (C&gt;G), miR-149 rs2292832 (T&gt;C), miR-196a2 rs11614913 (T&gt;C) and miR-499 rs3746444 (T&gt;C) polymorphisms with the risk of hepatocellular carcinoma.\n'
p832
sg4
(lp833
(dp834
g7
I65
sg8
g127
sg10
I18
sg11
VmiR-146a rs2910164
p835
sg13
I2
sa(dp836
g7
I94
sg8
g127
sg10
I17
sg11
VmiR-149 rs2292832
p837
sg13
I2
sa(dp838
g7
I122
sg8
g127
sg10
I20
sg11
VmiR-196a2 rs11614913
p839
sg13
I2
sa(dp840
g7
I156
sg8
g127
sg10
I17
sg11
VmiR-499 rs3746444
p841
sg13
I2
sasg17
(lp842
(dp843
g7
I214
sg20
VC1512411
p844
sg10
I24
sg11
Vhepatocellular carcinoma
p845
sg13
I2
sasa(dp846
g2
S'To examine the outcomes of allogeneic stem cell transplantation (HSCT) in first complete remission (CR1) compared with chemotherapy alone in a population-based setting, we identified a cohort of patients with acute myelogenous leukemia (AML) aged 15 to 70 years diagnosed between 2000 and 2014 in Denmark.\n'
p847
sg4
(lp848
sg17
(lp849
(dp850
g7
I237
sg20
VC0023467
p851
sg10
I3
sg11
VAML
p852
sg13
I1
sa(dp853
g7
I209
sg20
VC0023467
p854
sg10
I26
sg11
Vacute myelogenous leukemia
p855
sg13
I3
sa(dp856
g7
I89
sg20
VC0687702
p857
sg10
I9
sg11
Vremission
p858
sg13
I1
sasa(dp859
g2
S'Using the Danish National Acute Leukemia Registry, we compared relapse risk, relapse-free survival (RFS), and overall survival (OS) between patients with unfavorable cytogenetic features receiving postremission therapy with conventional chemotherapy only versus those undergoing HSCT in CR1.\n'
p860
sg4
(lp861
sg17
(lp862
(dp863
g7
I63
sg20
VC0277556
p864
sg10
I7
sg11
Vrelapse
p865
sg13
I1
sa(dp866
g7
I26
sg20
VC0085669
p867
sg10
I14
sg11
VAcute Leukemia
p868
sg13
I2
sa(dp869
g7
I77
sg20
VC0015624
p870
sg10
I21
sg11
Vrelapse-free survival
p871
sg13
I2
sa(dp872
g7
I100
sg20
VC0015624
p873
sg10
I3
sg11
VRFS
p874
sg13
I1
sasa(dp875
g2
S'Our analyses indicated that VP16/CY/TBI significantly reduced relapse compared with CY/TBI (risk ratio, 0.75; 95% confidence interval [CI], 0.56-1.00; P = .05) with a corresponding improvement in leukemia-free survival (hazard ratio [HR], 0.76; 95%CI, 0.62-0.93; P = .01), particularly in patients transplanted at CR1 with advanced-risk (positive minimal residual disease, presence of poor-risk cytogenetics, or an initial elevated leukocyte count) (HR, 0.75; 95%CI, 0.56-1.00; P = .05) or those transplanted beyond CR2 (HR, 0.58; 95%CI, 0.39-0.88; P = .01).\n'
p876
sg4
(lp877
sg17
(lp878
(dp879
g7
I62
sg20
VC0277556
p880
sg10
I7
sg11
Vrelapse
p881
sg13
I1
sa(dp882
g7
I196
sg20
VC0023418
p883
sg10
I8
sg11
Vleukemia
p884
sg13
I1
sa(dp885
g7
I347
sg20
VC0242596
p886
sg10
I24
sg11
Vminimal residual disease
p887
sg13
I3
sasa(dp888
g2
S'The aim of the present study was to observe the dynamic changes of the growth arrest and DNA damage-inducible 153 (GADD153) gene and caspase-12 in the brain tissue of rats with cerebral ischemia-reperfusion injury (CIRI) and the impact of curcumin pretreatment.\n'
p889
sg4
(lp890
(dp891
g7
I133
sg8
VP39880
p892
sg10
I10
sg11
Vcaspase-12
p893
sg13
I1
sasg17
(lp894
(dp895
g7
I71
sg20
VC0333951
p896
sg10
I13
sg11
Vgrowth arrest
p897
sg13
I2
sa(dp898
g7
I89
sg20
VC0012860
p899
sg10
I10
sg11
VDNA damage
p900
sg13
I2
sa(dp901
g7
I177
sg20
VC0917798
p902
sg10
I17
sg11
Vcerebral ischemia
p903
sg13
I2
sasa(dp904
g2
S'In Dahl salt-sensitive rats that were fed a high-salt diet, a model for hypertension-induced congestive heart failure, spermidine feeding reduced systemic blood pressure, increased titin phosphorylation and prevented cardiac hypertrophy and a decline in diastolic function, thus delaying the progression to heart failure.\n'
p905
sg4
(lp906
(dp907
g7
I181
sg8
g127
sg10
I5
sg11
Vtitin
p908
sg13
I1
sasg17
(lp909
(dp910
g7
I104
sg20
VC0018802
p911
sg10
I13
sg11
Vheart failure
p912
sg13
I2
sa(dp913
g7
I72
sg20
VC0020538
p914
sg10
I12
sg11
Vhypertension
p915
sg13
I1
sa(dp916
g7
I217
sg20
VC1383860
p917
sg10
I19
sg11
Vcardiac hypertrophy
p918
sg13
I2
sa(dp919
g7
I93
sg20
VC0018802
p920
sg10
I24
sg11
Vcongestive heart failure
p921
sg13
I3
sasa(dp922
g2
S'Along the way we distinguish among titin alterations in systolic and in diastolic heart failure and ponder the evidence for titin stiffness as a potential target for pharmacological intervention in heart disease.\n'
p923
sg4
(lp924
(dp925
g7
I35
sg8
g127
sg10
I5
sg11
Vtitin
p926
sg13
I1
sasg17
(lp927
(dp928
g7
I198
sg20
VC0018799
p929
sg10
I13
sg11
Vheart disease
p930
sg13
I2
sa(dp931
g7
I130
sg20
VC0427008
p932
sg10
I9
sg11
Vstiffness
p933
sg13
I1
sa(dp934
g7
I72
sg20
VC1135196
p935
sg10
I23
sg11
Vdiastolic heart failure
p936
sg13
I3
sasa(dp937
g2
S"A mutation in the tenth Ig-like domain of titin's spring region is associated with arrhythmogenic cardiomyopathy, a disease characterized by ventricular arrhythmias leading to cardiac arrest and sudden death.\n"
p938
sg4
(lp939
(dp940
g7
I42
sg8
g127
sg10
I5
sg11
Vtitin
p941
sg13
I1
sasg17
(lp942
(dp943
g7
I195
sg20
VC0011071
p944
sg10
I12
sg11
Vsudden death
p945
sg13
I2
sa(dp946
g7
I141
sg20
VC0085612
p947
sg10
I23
sg11
Vventricular arrhythmias
p948
sg13
I2
sa(dp949
g7
I176
sg20
VC0018790
p950
sg10
I14
sg11
Vcardiac arrest
p951
sg13
I2
sa(dp952
g7
I98
sg20
VC0878544
p953
sg10
I14
sg11
Vcardiomyopathy
p954
sg13
I1
sasa(dp955
g2
S'The alterations in the relative expression of the two titin isoforms or alterations in their state of phosphorylation have been implicated in the pathophysiology of several diseases, such as diastolic heart failure, dilated cardiomyopathy, ischemic cardiomyopathy and aortic stenosis.\n'
p956
sg4
(lp957
(dp958
g7
I54
sg8
g127
sg10
I5
sg11
Vtitin
p959
sg13
I1
sasg17
(lp960
(dp961
g7
I216
sg20
VC0007193
p962
sg10
I22
sg11
Vdilated cardiomyopathy
p963
sg13
I2
sa(dp964
g7
I191
sg20
VC1135196
p965
sg10
I23
sg11
Vdiastolic heart failure
p966
sg13
I3
sa(dp967
g7
I240
sg20
VC0349782
p968
sg10
I23
sg11
Vischemic cardiomyopathy
p969
sg13
I2
sa(dp970
g7
I268
sg20
VC0003507
p971
sg10
I15
sg11
Vaortic stenosis
p972
sg13
I2
sasa(dp973
g2
S'The aim of this study is to describe, in brief, the structure and location of titin, its association with different cardiomyopathies and understand how alterations in this macromolecule influence the pathophysiology of diastolic heart failure, emphasizing the therapeutic potential of the manipulation of this macromolecule.\n'
p974
sg4
(lp975
(dp976
g7
I78
sg8
g127
sg10
I5
sg11
Vtitin
p977
sg13
I1
sasg17
(lp978
(dp979
g7
I116
sg20
VC0878544
p980
sg10
I16
sg11
Vcardiomyopathies
p981
sg13
I1
sa(dp982
g7
I219
sg20
VC1135196
p983
sg10
I23
sg11
Vdiastolic heart failure
p984
sg13
I3
sasa(dp985
g2
S'Using whole blood mRNA samples from patients with prostate cancer, we have identified the four-gene panel of FAM129A, MME, KRT7 and SOD2 in circulating mRNA that are differentially expressed in a discovery cohort of metastatic samples.\n'
p986
sg4
(lp987
(dp988
g7
I123
sg8
VP08729
p989
sg10
I4
sg11
VKRT7
p990
sg13
I1
sa(dp991
g7
I109
sg8
g127
sg10
I7
sg11
VFAM129A
p992
sg13
I1
sa(dp993
g7
I132
sg8
VP04179
p994
sg10
I4
sg11
VSOD2
p995
sg13
I1
sa(dp996
g7
I118
sg8
VP39900
p997
sg10
I3
sg11
VMME
p998
sg13
I1
sasg17
(lp999
(dp1000
g7
I50
sg20
VC0600139
p1001
sg10
I15
sg11
Vprostate cancer
p1002
sg13
I2
sasa(dp1003
g2
S'The combination of expression patterns of AGR2 (anterior gradient 2) and CD10 by prostate cancer provided four phenotypes that correlated with clinical outcome.\n'
p1004
sg4
(lp1005
(dp1006
g7
I48
sg8
g127
sg10
I19
sg11
Vanterior gradient 2
p1007
sg13
I3
sa(dp1008
g7
I42
sg8
g127
sg10
I4
sg11
VAGR2
p1009
sg13
I1
sa(dp1010
g7
I73
sg8
VP08473
p1011
sg10
I4
sg11
VCD10
p1012
sg13
I1
sasg17
(lp1013
(dp1014
g7
I81
sg20
VC0600139
p1015
sg10
I15
sg11
Vprostate cancer
p1016
sg13
I2
sasa(dp1017
g2
S'Neutral endopeptidase loss is associated with prostate cancer growth, progression, and increased angiogenesis.\n'
p1018
sg4
(lp1019
(dp1020
g7
I0
sg8
VP08473
p1021
sg10
I21
sg11
VNeutral endopeptidase
p1022
sg13
I2
sasg17
(lp1023
(dp1024
g7
I46
sg20
VC0600139
p1025
sg10
I15
sg11
Vprostate cancer
p1026
sg13
I2
sasa(dp1027
g2
S'NEP expression was compared in prostate cancer cell lines cultured in normoxic and hypoxic conditions.\n'
p1028
sg4
(lp1029
sg17
(lp1030
(dp1031
g7
I31
sg20
VC0600139
p1032
sg10
I15
sg11
Vprostate cancer
p1033
sg13
I2
sa(dp1034
g7
I83
sg20
VC0242184
p1035
sg10
I7
sg11
Vhypoxic
p1036
sg13
I1
sasa(dp1037
g2
S'Our data indicate a novel mechanism where hypoxia negatively regulates the tumor suppressor function of NEP in prostate cancer.\n'
p1038
sg4
(lp1039
(dp1040
g7
I104
sg8
VP08473
p1041
sg10
I3
sg11
VNEP
p1042
sg13
I1
sasg17
(lp1043
(dp1044
g7
I111
sg20
VC0600139
p1045
sg10
I15
sg11
Vprostate cancer
p1046
sg13
I2
sa(dp1047
g7
I42
sg20
VC0242184
p1048
sg10
I7
sg11
Vhypoxia
p1049
sg13
I1
sa(dp1050
g7
I75
sg20
VC0027651
p1051
sg10
I5
sg11
Vtumor
p1052
sg13
I1
sasa(dp1053
g2
S'We showed here that Wnt5a activated Dvl2, Daam1 and RhoA, and promoted migration of breast cancer cells, which was, however, abolished by Secreted Frizzled-related protein 2 (sFRP2) pretreatment.\n'
p1054
sg4
(lp1055
(dp1056
g7
I52
sg8
VP61586
p1057
sg10
I4
sg11
VRhoA
p1058
sg13
I1
sa(dp1059
g7
I36
sg8
g127
sg10
I4
sg11
VDvl2
p1060
sg13
I1
sa(dp1061
g7
I20
sg8
VP41221
p1062
sg10
I5
sg11
VWnt5a
p1063
sg13
I1
sa(dp1064
g7
I42
sg8
g127
sg10
I5
sg11
VDaam1
p1065
sg13
I1
sa(dp1066
g7
I175
sg8
g127
sg10
I5
sg11
VsFRP2
p1067
sg13
I1
sa(dp1068
g7
I138
sg8
g127
sg10
I35
sg11
VSecreted Frizzled-related protein 2
p1069
sg13
I4
sasg17
(lp1070
(dp1071
g7
I84
sg20
VC0678222
p1072
sg10
I13
sg11
Vbreast cancer
p1073
sg13
I2
sasa(dp1074
g2
S'Taken together, we demonstrated for the first time that Wnt5a promotes breast cancer cell migration via Dvl2/Daam1/RhoA.\n'
p1075
sg4
(lp1076
(dp1077
g7
I109
sg8
g127
sg10
I5
sg11
VDaam1
p1078
sg13
I1
sa(dp1079
g7
I56
sg8
VP41221
p1080
sg10
I5
sg11
VWnt5a
p1081
sg13
I1
sa(dp1082
g7
I104
sg8
g127
sg10
I4
sg11
VDvl2
p1083
sg13
I1
sa(dp1084
g7
I115
sg8
VP61586
p1085
sg10
I4
sg11
VRhoA
p1086
sg13
I1
sasg17
(lp1087
(dp1088
g7
I71
sg20
VC0678222
p1089
sg10
I13
sg11
Vbreast cancer
p1090
sg13
I2
sasa(dp1091
g2
S'Notably, the oncogenic effects of miR-335 and siDAAM1 together with anti-tumor effects of antagomir-335 are also confirmed in human astrocytoma U87-MG cells.\n'
p1092
sg4
(lp1093
sg17
(lp1094
(dp1095
g7
I73
sg20
VC0027651
p1096
sg10
I5
sg11
Vtumor
p1097
sg13
I1
sa(dp1098
g7
I132
sg20
VC0004114
p1099
sg10
I11
sg11
Vastrocytoma
p1100
sg13
I1
sasa(dp1101
g2
S'The S-a1A concentration is determining the risk for development of byssinosis.\n'
p1102
sg4
(lp1103
sg17
(lp1104
(dp1105
g7
I67
sg20
VC0006542
p1106
sg10
I10
sg11
Vbyssinosis
p1107
sg13
I1
sasa(dp1108
g2
S'We found a dose-response relationship between endotoxin exposure and byssinosis, and a significant association between A-1-A serum concentrations less than or equal to 35 mumol/liter and byssinosis, a finding we are further evaluating in subsequent studies.\n'
p1109
sg4
(lp1110
sg17
(lp1111
(dp1112
g7
I69
sg20
VC0006542
p1113
sg10
I10
sg11
Vbyssinosis
p1114
sg13
I1
sa(dp1115
g7
I69
sg20
VC0006542
p1116
sg10
I10
sg11
Vbyssinosis
p1117
sg13
I1
sasa(dp1118
g2
S'The level of IgG, IgA, IgM, alpha1-antitrypsin and alpha2-macroglobulin was determined by radial immunodiffusion in 27 workmen in the flax processing industry, exposed to the risk of byssinosis and 33 retired workmen with a diagnosis of byssinosis.\n'
p1119
sg4
(lp1120
(dp1121
g7
I23
sg8
VP29965
p1122
sg10
I3
sg11
VIgM
p1123
sg13
I1
sa(dp1124
g7
I28
sg8
VP25100
p1125
sg10
I18
sg11
Valpha1-antitrypsin
p1126
sg13
I1
sa(dp1127
g7
I51
sg8
VP01023
p1128
sg10
I20
sg11
Valpha2-macroglobulin
p1129
sg13
I1
sa(dp1130
g7
I18
sg8
VP11912
p1131
sg10
I3
sg11
VIgA
p1132
sg13
I1
sasg17
(lp1133
(dp1134
g7
I183
sg20
VC0006542
p1135
sg10
I10
sg11
Vbyssinosis
p1136
sg13
I1
sa(dp1137
g7
I183
sg20
VC0006542
p1138
sg10
I10
sg11
Vbyssinosis
p1139
sg13
I1
sasa(dp1140
g2
S"This review summarizes the emerging role of fractalkine/CX3CL1 from a functional and clinical perspective and provides evidence to validate it as a potential therapeutic target in rheumatic diseases such as rheumatoid arthritis, Sjoegren's syndrome, systemic lupus erythematosus, scleroderma, as well as diseases related to vascular inflammation.\n"
p1141
sg4
(lp1142
(dp1143
g7
I44
sg8
VP78423
p1144
sg10
I18
sg11
Vfractalkine/CX3CL1
p1145
sg13
I1
sasg17
(lp1146
(dp1147
g7
I280
sg20
VC0011644
p1148
sg10
I11
sg11
Vscleroderma
p1149
sg13
I1
sa(dp1150
g7
I180
sg20
VC0035435
p1151
sg10
I18
sg11
Vrheumatic diseases
p1152
sg13
I2
sa(dp1153
g7
I207
sg20
VC0003873
p1154
sg10
I20
sg11
Vrheumatoid arthritis
p1155
sg13
I2
sa(dp1156
g7
I250
sg20
VC0024141
p1157
sg10
I28
sg11
Vsystemic lupus erythematosus
p1158
sg13
I3
sa(dp1159
g7
I229
sg20
VC1527336
p1160
sg10
I19
sg11
VSjoegren's syndrome
p1161
sg13
I2
sa(dp1162
g7
I324
sg20
VC0947751
p1163
sg10
I21
sg11
Vvascular inflammation
p1164
sg13
I2
sasa(dp1165
g2
S'To evaluate serum levels of fractalkine (FKN), a mediator of leukocyte transmigration, C-reactive protein (CRP) and expression of integrins CD11a and CD49d on peripheral blood lymphocytes in systemic sclerosis (SSc) and to investigate whether they are modulated by intravenous prostaglandin E1 (PGE1).\n'
p1166
sg4
(lp1167
(dp1168
g7
I140
sg8
VP20701
p1169
sg10
I5
sg11
VCD11a
p1170
sg13
I1
sa(dp1171
g7
I150
sg8
VP13612
p1172
sg10
I5
sg11
VCD49d
p1173
sg13
I1
sa(dp1174
g7
I107
sg8
VP02741
p1175
sg10
I3
sg11
VCRP
p1176
sg13
I1
sa(dp1177
g7
I87
sg8
VP02741
p1178
sg10
I18
sg11
VC-reactive protein
p1179
sg13
I2
sasg17
(lp1180
(dp1181
g7
I211
sg20
VC0036421
p1182
sg10
I3
sg11
VSSc
p1183
sg13
I1
sa(dp1184
g7
I191
sg20
VC0036421
p1185
sg10
I18
sg11
Vsystemic sclerosis
p1186
sg13
I2
sasa(dp1187
g2
S'Fractalkine may play an important role in the pathogenesis of vascular dysfunction in systemic sclerosis.\n'
p1188
sg4
(lp1189
sg17
(lp1190
(dp1191
g7
I86
sg20
VC0036421
p1192
sg10
I18
sg11
Vsystemic sclerosis
p1193
sg13
I2
sa(dp1194
g7
I46
sg20
VC0699748
p1195
sg10
I12
sg11
Vpathogenesis
p1196
sg13
I1
sasa(dp1197
g2
S'Prostaglandin E1 down-regulates serum fractalkine level, as well as CD11a and CD49d expression on peripheral blood lymphocytes, which suggests additional mechanisms in which this vasodilatatory agent exerts its efficacy in systemic sclerosis.\n'
p1198
sg4
(lp1199
(dp1200
g7
I78
sg8
VP13612
p1201
sg10
I5
sg11
VCD49d
p1202
sg13
I1
sa(dp1203
g7
I68
sg8
VP20701
p1204
sg10
I5
sg11
VCD11a
p1205
sg13
I1
sasg17
(lp1206
(dp1207
g7
I223
sg20
VC0036421
p1208
sg10
I18
sg11
Vsystemic sclerosis
p1209
sg13
I2
sasa(dp1210
g2
S'Fractalkine (FKN) and its receptor CX3CR1 are critical mediators in the vascular and tissue damage of several chronic diseases, including systemic sclerosis (SSc) and pulmonary arterial hypertension (PAH).\n'
p1211
sg4
(lp1212
(dp1213
g7
I35
sg8
VP78423
p1214
sg10
I6
sg11
VCX3CR1
p1215
sg13
I1
sasg17
(lp1216
(dp1217
g7
I138
sg20
VC0036421
p1218
sg10
I18
sg11
Vsystemic sclerosis
p1219
sg13
I2
sa(dp1220
g7
I158
sg20
VC0036421
p1221
sg10
I3
sg11
VSSc
p1222
sg13
I1
sa(dp1223
g7
I200
sg20
VC0152171
p1224
sg10
I3
sg11
VPAH
p1225
sg13
I1
sa(dp1226
g7
I167
sg20
VC0152171
p1227
sg10
I31
sg11
Vpulmonary arterial hypertension
p1228
sg13
I3
sa(dp1229
g7
I110
sg20
VC0008679
p1230
sg10
I16
sg11
Vchronic diseases
p1231
sg13
I2
sasa(dp1232
g2
S'To determine the role of fractalkine and its receptor in systemic sclerosis (SSc) by assessing their expression levels in patients with this disease.\n'
p1233
sg4
(lp1234
sg17
(lp1235
(dp1236
g7
I77
sg20
VC0036421
p1237
sg10
I3
sg11
VSSc
p1238
sg13
I1
sa(dp1239
g7
I57
sg20
VC0036421
p1240
sg10
I18
sg11
Vsystemic sclerosis
p1241
sg13
I2
sasa(dp1242
g2
S'Notably, LipoNP outperformed SNP 1 in terms of pharmacokinetics and in vivo therapeutic efficacy in both human BEL-7402 hepatocellular carcinoma (HCC) and HCT-116 colorectal cancer-derived xenograft mouse models.\n'
p1243
sg4
(lp1244
(dp1245
g7
I29
sg8
g127
sg10
I5
sg11
VSNP 1
p1246
sg13
I2
sasg17
(lp1247
(dp1248
g7
I163
sg20
VC1527249
p1249
sg10
I17
sg11
Vcolorectal cancer
p1250
sg13
I2
sa(dp1251
g7
I146
sg20
VC2239176
p1252
sg10
I3
sg11
VHCC
p1253
sg13
I1
sa(dp1254
g7
I120
sg20
VC2239176
p1255
sg10
I24
sg11
Vhepatocellular carcinoma
p1256
sg13
I2
sasa(dp1257
g2
S'There was no significant difference between Akt1 gene polymorphisms of patients (SNP1, SNP2 and SNP3) with endometrial cancer and controls (p &gt; 0.05).\n'
p1258
sg4
(lp1259
(dp1260
g7
I44
sg8
VP31749
p1261
sg10
I9
sg11
VAkt1 gene
p1262
sg13
I2
sasg17
(lp1263
(dp1264
g7
I107
sg20
VC0476089
p1265
sg10
I18
sg11
Vendometrial cancer
p1266
sg13
I2
sasa(dp1267
g2
S'Difference between alleles frequency of SNP1, SNP2, SNP3 of patients with endometrial cancer and controls was not significant (p &gt; 0.05).\n'
p1268
sg4
(lp1269
sg17
(lp1270
(dp1271
g7
I74
sg20
VC0476089
p1272
sg10
I18
sg11
Vendometrial cancer
p1273
sg13
I2
sasa(dp1274
g2
S'The results showed that SNP -1,687 (T/T) occurred more frequently in the healthy individuals than that in the prostate cancer patients compared to SNP -1,687 (C/C).\n'
p1275
sg4
(lp1276
sg17
(lp1277
(dp1278
g7
I110
sg20
VC0600139
p1279
sg10
I15
sg11
Vprostate cancer
p1280
sg13
I2
sasa(dp1281
g2
S'In conclusion, SNP -1,687, located in the NKX3.1 binding site within the L-plastin promoter, might reduce the expression of L-plastin and potentially decrease the tumorigenesis and progression of prostate cancer.\n'
p1282
sg4
(lp1283
(dp1284
g7
I73
sg8
VP13796
p1285
sg10
I18
sg11
VL-plastin promoter
p1286
sg13
I2
sa(dp1287
g7
I73
sg8
VP13796
p1288
sg10
I9
sg11
VL-plastin
p1289
sg13
I1
sa(dp1290
g7
I42
sg8
g127
sg10
I19
sg11
VNKX3.1 binding site
p1291
sg13
I3
sasg17
(lp1292
(dp1293
g7
I181
sg20
VC1739135
p1294
sg10
I30
sg11
Vprogression of prostate cancer
p1295
sg13
I4
sa(dp1296
g7
I163
sg20
VC0007621
p1297
sg10
I13
sg11
Vtumorigenesis
p1298
sg13
I1
sasa(dp1299
g2
S"Two investigators independently extracted data on study design, patient characteristics, and clinical features (interstitial lung disease [ILD], fever, mechanic's hands [MH], Raynaud's phenomenon [RPh], arthralgia, sclerodactyly, cancer and dermatomyositis-specific rash) according to the presence of myositis-specific (anti-aminoacyl-transfer RNA synthetase [ARS], anti-signal recognition particle [anti-SRP] and anti-Mi2) and myositis-associated (anti-PM/Scl, anti-U1-RNP and anti-Ku) autoantibodies.\n"
p1300
sg4
(lp1301
(dp1302
g7
I457
sg8
VP17542
p1303
sg10
I3
sg11
VScl
p1304
sg13
I1
sa(dp1305
g7
I428
sg8
VP04280
p1306
sg10
I19
sg11
Vmyositis-associated
p1307
sg13
I1
sa(dp1308
g7
I414
sg8
g127
sg10
I8
sg11
Vanti-Mi2
p1309
sg13
I1
sa(dp1310
g7
I366
sg8
VP61011
p1311
sg10
I32
sg11
Vanti-signal recognition particle
p1312
sg13
I3
sa(dp1313
g7
I462
sg8
g127
sg10
I11
sg11
Vanti-U1-RNP
p1314
sg13
I1
sasg17
(lp1315
(dp1316
g7
I266
sg20
VC0015230
p1317
sg10
I4
sg11
Vrash
p1318
sg13
I1
sa(dp1319
g7
I248
sg20
VC0027121
p1320
sg10
I8
sg11
Vmyositis
p1321
sg13
I1
sa(dp1322
g7
I215
sg20
VC0150988
p1323
sg10
I13
sg11
Vsclerodactyly
p1324
sg13
I1
sa(dp1325
g7
I175
sg20
VC0034735
p1326
sg10
I20
sg11
VRaynaud's phenomenon
p1327
sg13
I2
sa(dp1328
g7
I248
sg20
VC0027121
p1329
sg10
I8
sg11
Vmyositis
p1330
sg13
I1
sa(dp1331
g7
I241
sg20
VC0221056
p1332
sg10
I15
sg11
Vdermatomyositis
p1333
sg13
I1
sa(dp1334
g7
I112
sg20
VC0206062
p1335
sg10
I25
sg11
Vinterstitial lung disease
p1336
sg13
I3
sa(dp1337
g7
I203
sg20
VC0003862
p1338
sg10
I10
sg11
Varthralgia
p1339
sg13
I1
sa(dp1340
g7
I230
sg20
VC0006826
p1341
sg10
I6
sg11
Vcancer
p1342
sg13
I1
sasa(dp1343
g2
S'To examine serum interleukin 18 (IL-18), fetuin-A, soluble intercellular adhesion molecule-1 (sICAM-1), and endothelin-1 (ET-1) levels in ankylosing spondylitis (AS), psoriatic arthritis (PsA), and Synovitis Acne Pustulosis Hyperostosis Osteitis syndrome (SAPHO).\n'
p1344
sg4
(lp1345
(dp1346
g7
I108
sg8
VP20800
p1347
sg10
I12
sg11
Vendothelin-1
p1348
sg13
I1
sa(dp1349
g7
I122
sg8
VP05305
p1350
sg10
I4
sg11
VET-1
p1351
sg13
I1
sa(dp1352
g7
I59
sg8
VP05362
p1353
sg10
I33
sg11
Vintercellular adhesion molecule-1
p1354
sg13
I3
sa(dp1355
g7
I17
sg8
g127
sg10
I14
sg11
Vinterleukin 18
p1356
sg13
I2
sa(dp1357
g7
I33
sg8
g127
sg10
I5
sg11
VIL-18
p1358
sg13
I1
sasg17
(lp1359
(dp1360
g7
I167
sg20
VC0003872
p1361
sg10
I19
sg11
Vpsoriatic arthritis
p1362
sg13
I2
sa(dp1363
g7
I237
sg20
VC0029400
p1364
sg10
I8
sg11
VOsteitis
p1365
sg13
I1
sa(dp1366
g7
I208
sg20
VC0001144
p1367
sg10
I4
sg11
VAcne
p1368
sg13
I1
sa(dp1369
g7
I138
sg20
VC0038013
p1370
sg10
I22
sg11
Vankylosing spondylitis
p1371
sg13
I2
sa(dp1372
g7
I246
sg20
VC0039082
p1373
sg10
I8
sg11
Vsyndrome
p1374
sg13
I1
sa(dp1375
g7
I73
sg20
VC0001511
p1376
sg10
I8
sg11
Vadhesion
p1377
sg13
I1
sa(dp1378
g7
I162
sg20
VC0038013
p1379
sg10
I2
sg11
VAS
p1380
sg13
I1
sa(dp1381
g7
I188
sg20
VC1519176
p1382
sg10
I3
sg11
VPsA
p1383
sg13
I1
sa(dp1384
g7
I198
sg20
VC0039103
p1385
sg10
I9
sg11
VSynovitis
p1386
sg13
I1
sa(dp1387
g7
I224
sg20
VC0020492
p1388
sg10
I12
sg11
VHyperostosis
p1389
sg13
I1
sasa(dp1390
g2
S'Therefore, we aim to assess the correlation of endothelin-1 concentrations with the development and severity of knee osteoarthritis (OA).\n'
p1391
sg4
(lp1392
(dp1393
g7
I47
sg8
VP20800
p1394
sg10
I12
sg11
Vendothelin-1
p1395
sg13
I1
sasg17
(lp1396
(dp1397
g7
I112
sg20
VC0409959
p1398
sg10
I19
sg11
Vknee osteoarthritis
p1399
sg13
I2
sasa(dp1400
g2
S'Notably, inactivating mutations in genes encoding the catalytic and regulatory subunits of the switch/sucrose non-fermenting chromatin remodeling complex have been detected in several solid cancers: sucrose non-fermenting/switch/sucrose non-fermenting-related, matrix-associated, actin-dependent regulator of chromatin, subfamily b, member 1/Brahma-related gene 1-associated factor 47/integrase interactor 1 mutations in rhabdoid tumors; AT-rich interactive domain-containing protein 1 A/Brahma-related gene 1-associated factor 250a mutations in ovarian clear cell carcinoma, hepatocellular carcinoma and gastric adenocarcinoma; polybromo 1/Brahma-related gene 1-associated factor 180 mutations in renal clear cell carcinoma; Brahma-related gene 1/switch/sucrose non-fermenting-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 4 mutations in non-small-cell lung carcinoma and AT-rich interactive domain-containing protein 2/Brahma-related gene 1-associated factor 200 mutations in hepatocellular carcinoma and malignant melanoma.\n'
p1401
sg4
(lp1402
(dp1403
g7
I476
sg8
VP14222
p1404
sg10
I11
sg11
Vprotein 1 A
p1405
sg13
I3
sa(dp1406
g7
I656
sg8
g127
sg10
I38
sg11
Vgene 1-associated factor 180 mutations
p1407
sg13
I5
sa(dp1408
g7
I309
sg8
g127
sg10
I32
sg11
Vchromatin, subfamily b, member 1
p1409
sg13
I5
sa(dp1410
g7
I342
sg8
g127
sg10
I65
sg11
VBrahma-related gene 1-associated factor 47/integrase interactor 1
p1411
sg13
I7
sa(dp1412
g7
I488
sg8
g127
sg10
I44
sg11
VBrahma-related gene 1-associated factor 250a
p1413
sg13
I5
sasg17
(lp1414
(dp1415
g7
I605
sg20
VC0278701
p1416
sg10
I22
sg11
Vgastric adenocarcinoma
p1417
sg13
I2
sa(dp1418
g7
I565
sg20
VC0007097
p1419
sg10
I9
sg11
Vcarcinoma
p1420
sg13
I1
sa(dp1421
g7
I698
sg20
VC0279702
p1422
sg10
I26
sg11
Vrenal clear cell carcinoma
p1423
sg13
I4
sa(dp1424
g7
I190
sg20
VC0006826
p1425
sg10
I7
sg11
Vcancers
p1426
sg13
I1
sa(dp1427
g7
I565
sg20
VC2239176
p1428
sg10
I25
sg11
Vcarcinoma, hepatocellular
p1429
sg13
I2
sa(dp1430
g7
I881
sg20
VC0007131
p1431
sg10
I29
sg11
Vnon-small-cell lung carcinoma
p1432
sg13
I3
sa(dp1433
g7
I421
sg20
VC0206743
p1434
sg10
I15
sg11
Vrhabdoid tumors
p1435
sg13
I2
sa(dp1436
g7
I1049
sg20
VC0025202
p1437
sg10
I18
sg11
Vmalignant melanoma
p1438
sg13
I2
sa(dp1439
g7
I576
sg20
VC2239176
p1440
sg10
I24
sg11
Vhepatocellular carcinoma
p1441
sg13
I2
sasa(dp1442
g2
S'Highest urinary 1-OHP concentration was observed in digestive tract cancer patients (median 1.25 mymol/mol-Cr) with GSTM-1 genotype.\n'
p1443
sg4
(lp1444
(dp1445
g7
I116
sg8
VP28161
p1446
sg10
I15
sg11
VGSTM-1 genotype
p1447
sg13
I2
sasg17
(lp1448
(dp1449
g7
I68
sg20
VC0006826
p1450
sg10
I6
sg11
Vcancer
p1451
sg13
I1
sasa(dp1452
g2
S'We found that GSTM1 and GSTT1 null genotypes (GSTT1-/GSTM1-) increased the risk of ESRD by 1.8 times (p &lt; 0.001) and the increased risk of ESRD for GSTM-null (T1+-M1-) genotype was 3.04 times (p = 0.002).\n'
p1453
sg4
(lp1454
(dp1455
g7
I14
sg8
VP09488
p1456
sg10
I5
sg11
VGSTM1
p1457
sg13
I1
sa(dp1458
g7
I24
sg8
VP30711
p1459
sg10
I5
sg11
VGSTT1
p1460
sg13
I1
sa(dp1461
g7
I24
sg8
VP30711
p1462
sg10
I5
sg11
VGSTT1
p1463
sg13
I1
sa(dp1464
g7
I14
sg8
VP28161
p1465
sg10
I4
sg11
VGSTM
p1466
sg13
I1
sa(dp1467
g7
I14
sg8
VP09488
p1468
sg10
I5
sg11
VGSTM1
p1469
sg13
I1
sasg17
(lp1470
(dp1471
g7
I83
sg20
VC0022661
p1472
sg10
I4
sg11
VESRD
p1473
sg13
I1
sa(dp1474
g7
I83
sg20
VC0022661
p1475
sg10
I4
sg11
VESRD
p1476
sg13
I1
sasa(dp1477
g2
S'ESRD patients carriers the GST (GSTM1-null + GSTT1-null + GST-null) genotypes compared to GST normal genotype increased the risk of ESRD by 3.3 (p &lt; 0.001) times.\n'
p1478
sg4
(lp1479
(dp1480
g7
I27
sg8
g127
sg10
I3
sg11
VGST
p1481
sg13
I1
sa(dp1482
g7
I58
sg8
g127
sg10
I8
sg11
VGST-null
p1483
sg13
I1
sa(dp1484
g7
I32
sg8
VP09488
p1485
sg10
I23
sg11
VGSTM1-null + GSTT1-null
p1486
sg13
I3
sa(dp1487
g7
I27
sg8
g127
sg10
I3
sg11
VGST
p1488
sg13
I1
sasg17
(lp1489
(dp1490
g7
I0
sg20
VC0022661
p1491
sg10
I4
sg11
VESRD
p1492
sg13
I1
sa(dp1493
g7
I0
sg20
VC0022661
p1494
sg10
I4
sg11
VESRD
p1495
sg13
I1
sasa(dp1496
g2
S'ESRD patients carriers of GST-null, GSTM1-null, and GSTT1-null genotypes had greater MDA concentration compared with the same genotypes of control subjects.\n'
p1497
sg4
(lp1498
(dp1499
g7
I26
sg8
g127
sg10
I3
sg11
VGST
p1500
sg13
I1
sa(dp1501
g7
I52
sg8
VP30711
p1502
sg10
I5
sg11
VGSTT1
p1503
sg13
I1
sa(dp1504
g7
I36
sg8
VP09488
p1505
sg10
I5
sg11
VGSTM1
p1506
sg13
I1
sasg17
(lp1507
(dp1508
g7
I0
sg20
VC0022661
p1509
sg10
I4
sg11
VESRD
p1510
sg13
I1
sasa(dp1511
g2
S'Our results indicated that the GST-null allele (GSTT1-null/GSTM1-null) is a risk factor for ESRD and carriers of this allele have high levels of MDA.\n'
p1512
sg4
(lp1513
(dp1514
g7
I48
sg8
VP30711
p1515
sg10
I5
sg11
VGSTT1
p1516
sg13
I1
sa(dp1517
g7
I59
sg8
VP09488
p1518
sg10
I5
sg11
VGSTM1
p1519
sg13
I1
sa(dp1520
g7
I31
sg8
g127
sg10
I15
sg11
VGST-null allele
p1521
sg13
I2
sasg17
(lp1522
(dp1523
g7
I35
sg20
VC2985437
p1524
sg10
I11
sg11
Vnull allele
p1525
sg13
I2
sa(dp1526
g7
I92
sg20
VC0022661
p1527
sg10
I4
sg11
VESRD
p1528
sg13
I1
sasa(dp1529
g2
S'Unlike mouse GSTM1, the human GSTM1 gene tends to be deleted in bladder cancers.\n'
p1530
sg4
(lp1531
(dp1532
g7
I24
sg8
VP09488
p1533
sg10
I16
sg11
Vhuman GSTM1 gene
p1534
sg13
I3
sa(dp1535
g7
I7
sg8
VP09488
p1536
sg10
I11
sg11
Vmouse GSTM1
p1537
sg13
I2
sasg17
(lp1538
(dp1539
g7
I64
sg20
VC0005684
p1540
sg10
I15
sg11
Vbladder cancers
p1541
sg13
I2
sasa(dp1542
g2
S'Among 7 human bladder cancer cell lines, GSTM1 gene is really null in 6 cell lines except one, T24 cells.\n'
p1543
sg4
(lp1544
(dp1545
g7
I41
sg8
VP09488
p1546
sg10
I10
sg11
VGSTM1 gene
p1547
sg13
I2
sasg17
(lp1548
(dp1549
g7
I14
sg20
VC0699885
p1550
sg10
I14
sg11
Vbladder cancer
p1551
sg13
I2
sasa(dp1552
g2
S'One is the GSTM1 gene which is down-regulated in mice bladder carcinogenesis and is usually deleted in human urothelial carcinoma, while the other is the GSTM5 gene, which is inactivated by DNA CpG methylation.\n'
p1553
sg4
(lp1554
(dp1555
g7
I154
sg8
VP46439
p1556
sg10
I10
sg11
VGSTM5 gene
p1557
sg13
I2
sa(dp1558
g7
I11
sg8
VP09488
p1559
sg10
I10
sg11
VGSTM1 gene
p1560
sg13
I2
sasg17
(lp1561
(dp1562
g7
I109
sg20
VC0007138
p1563
sg10
I20
sg11
Vurothelial carcinoma
p1564
sg13
I2
sa(dp1565
g7
I62
sg20
VC0596263
p1566
sg10
I14
sg11
Vcarcinogenesis
p1567
sg13
I1
sasa(dp1568
g2
S'The regulation of TSP2 by hypoxia is supported by the in vivo observation that TSP2 has spatiotemporal expression distinct from regions of hypoxia in gastrocnemius muscle following murine hindlimb ischemia (HLI).\n'
p1569
sg4
(lp1570
(dp1571
g7
I18
sg8
VP35442
p1572
sg10
I4
sg11
VTSP2
p1573
sg13
I1
sa(dp1574
g7
I18
sg8
VP35442
p1575
sg10
I4
sg11
VTSP2
p1576
sg13
I1
sasg17
(lp1577
(dp1578
g7
I197
sg20
VC0022116
p1579
sg10
I8
sg11
Vischemia
p1580
sg13
I1
sa(dp1581
g7
I26
sg20
VC0242184
p1582
sg10
I7
sg11
Vhypoxia
p1583
sg13
I1
sa(dp1584
g7
I26
sg20
VC0242184
p1585
sg10
I7
sg11
Vhypoxia
p1586
sg13
I1
sasa(dp1587
g2
S'These findings identify a novel, ischemia-induced pro-angiogenic mechanism involving the transcriptional repression of TSP2 by HIF-1Alfa.\n'
p1588
sg4
(lp1589
(dp1590
g7
I119
sg8
VP35442
p1591
sg10
I4
sg11
VTSP2
p1592
sg13
I1
sasg17
(lp1593
(dp1594
g7
I33
sg20
VC0022116
p1595
sg10
I8
sg11
Vischemia
p1596
sg13
I1
sasa(dp1597
g2
S'Therefore, we designed this study to demonstrate the role of THBS-2 and LECT-2 in atherosclerosis at the tissue level in fresh specimens.\n'
p1598
sg4
(lp1599
(dp1600
g7
I61
sg8
VP07996
p1601
sg10
I6
sg11
VTHBS-2
p1602
sg13
I1
sasg17
(lp1603
(dp1604
g7
I82
sg20
VC0004153
p1605
sg10
I15
sg11
Vatherosclerosis
p1606
sg13
I1
sasa(dp1607
g2
S'The study results suggest that the tissue levels of THBS2 and LECT-2 may correlate with the stage of atherosclerosis.\n'
p1608
sg4
(lp1609
(dp1610
g7
I52
sg8
VP35442
p1611
sg10
I5
sg11
VTHBS2
p1612
sg13
I1
sasg17
(lp1613
(dp1614
g7
I101
sg20
VC0004153
p1615
sg10
I15
sg11
Vatherosclerosis
p1616
sg13
I1
sasa(dp1617
g2
S'In the current study, we aimed to evaluate the predictive value of circulating thrombospondin-2 (TSP-2) for cumulative survival in patients with ischemic CHF due to coronary artery disease (CAD).\n'
p1618
sg4
(lp1619
(dp1620
g7
I79
sg8
VP35442
p1621
sg10
I16
sg11
Vthrombospondin-2
p1622
sg13
I1
sa(dp1623
g7
I97
sg8
VP35442
p1624
sg10
I5
sg11
VTSP-2
p1625
sg13
I1
sasg17
(lp1626
(dp1627
g7
I165
sg20
VC0010054
p1628
sg10
I23
sg11
Vcoronary artery disease
p1629
sg13
I3
sa(dp1630
g7
I154
sg20
VC0018802
p1631
sg10
I3
sg11
VCHF
p1632
sg13
I1
sa(dp1633
g7
I190
sg20
VC0010054
p1634
sg10
I3
sg11
VCAD
p1635
sg13
I1
sasa(dp1636
g2
S'Knockdown of Klf15 in Foxd1-expressing cells (Foxd1-Cre Klf15fl/fl) increased extracellular matrix deposition and myofibroblast proliferation as compared to wildtype (Foxd1-Cre Klf15+/+) mice after three and seven days of ureteral obstruction.\n'
p1637
sg4
(lp1638
(dp1639
g7
I13
sg8
g127
sg10
I5
sg11
VKlf15
p1640
sg13
I1
sa(dp1641
g7
I46
sg8
g127
sg10
I17
sg11
VFoxd1-Cre Klf15fl
p1642
sg13
I2
sa(dp1643
g7
I22
sg8
g127
sg10
I5
sg11
VFoxd1
p1644
sg13
I1
sasg17
(lp1645
(dp1646
g7
I128
sg20
VC0334094
p1647
sg10
I13
sg11
Vproliferation
p1648
sg13
I1
sa(dp1649
g7
I222
sg20
VC0041956
p1650
sg10
I20
sg11
Vureteral obstruction
p1651
sg13
I2
sasa(dp1652
g2
S'Kidney fibrosis was induced in FoxD1-GC;Z/Red-mice by unilateral ureteral obstruction followed by FACS sorting of dsRed-positive FoxD1-derivative cells and miRNA profiling.\n'
p1653
sg4
(lp1654
(dp1655
g7
I31
sg8
g127
sg10
I8
sg11
VFoxD1-GC
p1656
sg13
I1
sa(dp1657
g7
I42
sg8
VP16435
p1658
sg10
I3
sg11
VRed
p1659
sg13
I1
sasg17
(lp1660
(dp1661
g7
I0
sg20
VC0151650
p1662
sg10
I15
sg11
VKidney fibrosis
p1663
sg13
I2
sa(dp1664
g7
I65
sg20
VC0041956
p1665
sg10
I20
sg11
Vureteral obstruction
p1666
sg13
I2
sasa(dp1667
g2
S'Serum NT-pCNP is a promising diagnostic biomarker for sepsis but is a poor indicator of septic peritonitis.\n'
p1668
sg4
(lp1669
(dp1670
g7
I0
sg8
g127
sg10
I13
sg11
VSerum NT-pCNP
p1671
sg13
I2
sasg17
(lp1672
(dp1673
g7
I95
sg20
VC0031154
p1674
sg10
I11
sg11
Vperitonitis
p1675
sg13
I1
sa(dp1676
g7
I54
sg20
VC0243026
p1677
sg10
I6
sg11
Vsepsis
p1678
sg13
I1
sasa(dp1679
g2
S'Concurrent with the inhibition of Wnt/Beta-catenin signaling, 1-benzyl-I3C strongly down regulated expression of the melanoma master regulator, Microphthalmia Associated Transcription Factor isoform-M (MITF-M) by inhibiting promoter activity through the consensus LEF-1/TCF DNA binding site.\n'
p1680
sg4
(lp1681
(dp1682
g7
I202
sg8
g127
sg10
I6
sg11
VMITF-M
p1683
sg13
I1
sa(dp1684
g7
I38
sg8
VP35222
p1685
sg10
I12
sg11
VBeta-catenin
p1686
sg13
I1
sa(dp1687
g7
I264
sg8
g127
sg10
I5
sg11
VLEF-1
p1688
sg13
I1
sa(dp1689
g7
I144
sg8
g127
sg10
I56
sg11
VMicrophthalmia Associated Transcription Factor isoform-M
p1690
sg13
I5
sa(dp1691
g7
I117
sg8
g127
sg10
I25
sg11
Vmelanoma master regulator
p1692
sg13
I3
sasg17
(lp1693
(dp1694
g7
I117
sg20
VC0025202
p1695
sg10
I8
sg11
Vmelanoma
p1696
sg13
I1
sa(dp1697
g7
I144
sg20
VC0026010
p1698
sg10
I14
sg11
VMicrophthalmia
p1699
sg13
I1
sasa(dp1700
g2
S'These data allow us to hypothesize a dedifferentiation process of adipocytes toward fibroblast-like cells, which can promote migration of melanoma cells through activation of Wnt5a and the intracellular pathways of Beta-catenin and LEF-1.International Journal of Obesity advance online publication, 24 October 2017; doi:10.1038/ijo.2017.218.\n'
p1701
sg4
(lp1702
(dp1703
g7
I232
sg8
g127
sg10
I5
sg11
VLEF-1
p1704
sg13
I1
sa(dp1705
g7
I215
sg8
VP35222
p1706
sg10
I12
sg11
VBeta-catenin
p1707
sg13
I1
sa(dp1708
g7
I175
sg8
VP41221
p1709
sg10
I5
sg11
VWnt5a
p1710
sg13
I1
sasg17
(lp1711
(dp1712
g7
I37
sg20
VC0002793
p1713
sg10
I17
sg11
Vdedifferentiation
p1714
sg13
I1
sa(dp1715
g7
I138
sg20
VC0025202
p1716
sg10
I8
sg11
Vmelanoma
p1717
sg13
I1
sa(dp1718
g7
I263
sg20
VC0028754
p1719
sg10
I7
sg11
VObesity
p1720
sg13
I1
sa(dp1721
g7
I328
sg20
VC0264080
p1722
sg10
I3
sg11
Vijo
p1723
sg13
I1
sasa(dp1724
g2
S'About 90% of the melanoma signature genes belong to an intrinsic network of transcription factors governing neural development (TFAP2A, DLX2, ALX1, MITF, PAX3, SOX10, LEF1, and GAS7) and miRNAs (211-5p, 221-3p, and 10a-5p).\n'
p1725
sg4
(lp1726
(dp1727
g7
I167
sg8
g127
sg10
I4
sg11
VLEF1
p1728
sg13
I1
sa(dp1729
g7
I136
sg8
g127
sg10
I4
sg11
VDLX2
p1730
sg13
I1
sa(dp1731
g7
I148
sg8
g127
sg10
I4
sg11
VMITF
p1732
sg13
I1
sa(dp1733
g7
I128
sg8
VP05549
p1734
sg10
I6
sg11
VTFAP2A
p1735
sg13
I1
sa(dp1736
g7
I154
sg8
VP23760
p1737
sg10
I4
sg11
VPAX3
p1738
sg13
I1
sa(dp1739
g7
I177
sg8
g127
sg10
I4
sg11
VGAS7
p1740
sg13
I1
sa(dp1741
g7
I160
sg8
VP56693
p1742
sg10
I5
sg11
VSOX10
p1743
sg13
I1
sa(dp1744
g7
I142
sg8
g127
sg10
I4
sg11
VALX1
p1745
sg13
I1
sasg17
(lp1746
(dp1747
g7
I17
sg20
VC0025202
p1748
sg10
I8
sg11
Vmelanoma
p1749
sg13
I1
sasa(dp1750
g2
S"To determine the expression of Beta-catenin, lymphoid enhancer-binding protein-1 (LEF-1), and heparanase-1 (HPA-1) and to evaluate these proteins' potential prognostic values in malignant acral melanoma without mutations in BRAF exons 11 and 15 and NRAS exons 1 and 2, specimens from 90 patients with wild-type BRAF and NRAS were assessed and analyzed by immunohistochemistry and western blotting.\n"
p1751
sg4
(lp1752
(dp1753
g7
I82
sg8
g127
sg10
I5
sg11
VLEF-1
p1754
sg13
I1
sa(dp1755
g7
I45
sg8
g127
sg10
I35
sg11
Vlymphoid enhancer-binding protein-1
p1756
sg13
I3
sa(dp1757
g7
I31
sg8
VP35222
p1758
sg10
I12
sg11
VBeta-catenin
p1759
sg13
I1
sa(dp1760
g7
I94
sg8
g127
sg10
I12
sg11
Vheparanase-1
p1761
sg13
I1
sa(dp1762
g7
I249
sg8
VP01111
p1763
sg10
I4
sg11
VNRAS
p1764
sg13
I1
sa(dp1765
g7
I224
sg8
VP15056
p1766
sg10
I4
sg11
VBRAF
p1767
sg13
I1
sa(dp1768
g7
I108
sg8
g127
sg10
I5
sg11
VHPA-1
p1769
sg13
I1
sasg17
(lp1770
(dp1771
g7
I194
sg20
VC0025202
p1772
sg10
I8
sg11
Vmelanoma
p1773
sg13
I1
sasa(dp1774
g2
S'The expression of Beta-catenin, LEF-1, and HPA-1 was assessed and compared in malignant melanoma with that of peritumoral tissue and benign nevus in the patients with negative mutations in BRAF exons 11 and 15 and NRAS exons 1 and 2.\n'
p1775
sg4
(lp1776
(dp1777
g7
I32
sg8
g127
sg10
I5
sg11
VLEF-1
p1778
sg13
I1
sa(dp1779
g7
I43
sg8
g127
sg10
I5
sg11
VHPA-1
p1780
sg13
I1
sa(dp1781
g7
I18
sg8
VP35222
p1782
sg10
I12
sg11
VBeta-catenin
p1783
sg13
I1
sasg17
(lp1784
(dp1785
g7
I133
sg20
VC1456781
p1786
sg10
I12
sg11
Vbenign nevus
p1787
sg13
I2
sa(dp1788
g7
I78
sg20
VC0025202
p1789
sg10
I18
sg11
Vmalignant melanoma
p1790
sg13
I2
sasa(dp1791
g2
S'The study may provide the basis for Beta-catenin, LEF-1, and HPA-1 as new targets in the treatment of malignant invasion and metastasis in melanoma cancer.\n'
p1792
sg4
(lp1793
(dp1794
g7
I50
sg8
g127
sg10
I5
sg11
VLEF-1
p1795
sg13
I1
sa(dp1796
g7
I61
sg8
g127
sg10
I5
sg11
VHPA-1
p1797
sg13
I1
sa(dp1798
g7
I36
sg8
VP35222
p1799
sg10
I12
sg11
VBeta-catenin
p1800
sg13
I1
sasg17
(lp1801
(dp1802
g7
I112
sg20
VC2699153
p1803
sg10
I8
sg11
Vinvasion
p1804
sg13
I1
sa(dp1805
g7
I125
sg20
VC0027627
p1806
sg10
I10
sg11
Vmetastasis
p1807
sg13
I1
sa(dp1808
g7
I148
sg20
VC0006826
p1809
sg10
I6
sg11
Vcancer
p1810
sg13
I1
sa(dp1811
g7
I139
sg20
VC0025202
p1812
sg10
I8
sg11
Vmelanoma
p1813
sg13
I1
sasa(dp1814
g2
S'We identified a panel of novel melanoma-associated markers: frizzled-related protein, an antagonist of Wnt; tranducin-like enhancer of split 1, a transcription factor partner of TCF/LEF-1; CNTN1, an activator of Notch signalling; two Serpin peptidase inhibitors, Serpin B3/B4 and the TGF-Beta family member GDF15, the latter with association to MAPK-signalling.\n'
p1815
sg4
(lp1816
(dp1817
g7
I60
sg8
g127
sg10
I24
sg11
Vfrizzled-related protein
p1818
sg13
I2
sa(dp1819
g7
I345
sg8
VP53779
p1820
sg10
I4
sg11
VMAPK
p1821
sg13
I1
sa(dp1822
g7
I284
sg8
VP18075
p1823
sg10
I22
sg11
VTGF-Beta family member
p1824
sg13
I3
sa(dp1825
g7
I234
sg8
g127
sg10
I16
sg11
VSerpin peptidase
p1826
sg13
I2
sa(dp1827
g7
I182
sg8
g127
sg10
I5
sg11
VLEF-1
p1828
sg13
I1
sa(dp1829
g7
I189
sg8
g127
sg10
I5
sg11
VCNTN1
p1830
sg13
I1
sa(dp1831
g7
I307
sg8
g127
sg10
I5
sg11
VGDF15
p1832
sg13
I1
sasg17
(lp1833
(dp1834
g7
I31
sg20
VC0025202
p1835
sg10
I8
sg11
Vmelanoma
p1836
sg13
I1
sasa(dp1837
g2
S'Calprotectin, eosinophil-derived neurotoxin (EDN), and protein S100A12 were measured in colorectal mucus self-collected following defecation by 58 patients with IBD (before therapy), 50 patients with irritable bowel syndrome, and 33 healthy volunteers.\n'
p1838
sg4
(lp1839
(dp1840
g7
I14
sg8
VP10153
p1841
sg10
I56
sg11
Veosinophil-derived neurotoxin (EDN), and protein S100A12
p1842
sg13
I6
sasg17
(lp1843
(dp1844
g7
I200
sg20
VC0022104
p1845
sg10
I24
sg11
Virritable bowel syndrome
p1846
sg13
I3
sa(dp1847
g7
I161
sg20
VC0022104
p1848
sg10
I3
sg11
VIBD
p1849
sg13
I1
sasa(dp1850
g2
S'Calprotectin, EDN, M2PK, soluble cytokeratin 18 and d-dimer showed dramatic increase in a few cases of inflammatory bowel disease (IBD) detected among trial participants.\n'
p1851
sg4
(lp1852
(dp1853
g7
I25
sg8
VP35558
p1854
sg10
I22
sg11
Vsoluble cytokeratin 18
p1855
sg13
I3
sa(dp1856
g7
I52
sg8
g127
sg10
I7
sg11
Vd-dimer
p1857
sg13
I1
sa(dp1858
g7
I14
sg8
VP10153
p1859
sg10
I3
sg11
VEDN
p1860
sg13
I1
sasg17
(lp1861
(dp1862
g7
I131
sg20
VC0021390
p1863
sg10
I3
sg11
VIBD
p1864
sg13
I1
sa(dp1865
g7
I103
sg20
VC0021390
p1866
sg10
I26
sg11
Vinflammatory bowel disease
p1867
sg13
I3
sasa(dp1868
g2
S'In cancer cell spheroids, SLC4A4 or SLC4A9 disruption by either genetic or pharmaceutical approaches acidified intracellular pH and reduced cell growth.\n'
p1869
sg4
(lp1870
(dp1871
g7
I36
sg8
g127
sg10
I6
sg11
VSLC4A9
p1872
sg13
I1
sa(dp1873
g7
I26
sg8
g127
sg10
I6
sg11
VSLC4A4
p1874
sg13
I1
sasg17
(lp1875
(dp1876
g7
I3
sg20
VC0006826
p1877
sg10
I6
sg11
Vcancer
p1878
sg13
I1
sasa(dp1879
g2
S'Although SSCP analysis of 62 WT samples and 10 BWS patients did not result in the identification of any mutations in ORCTL2 or ORCTL2S, it will be important to examine their expression pattern in tumors and BWS patients, since epigenetic alteration at these loci may play a role in the etiology of these diseases.\n'
p1880
sg4
(lp1881
(dp1882
g7
I127
sg8
g127
sg10
I7
sg11
VORCTL2S
p1883
sg13
I1
sa(dp1884
g7
I117
sg8
g127
sg10
I6
sg11
VORCTL2
p1885
sg13
I1
sasg17
(lp1886
(dp1887
g7
I47
sg20
VC0004903
p1888
sg10
I3
sg11
VBWS
p1889
sg13
I1
sa(dp1890
g7
I196
sg20
VC0027651
p1891
sg10
I6
sg11
Vtumors
p1892
sg13
I1
sa(dp1893
g7
I47
sg20
VC0004903
p1894
sg10
I3
sg11
VBWS
p1895
sg13
I1
sasa(dp1896
g2
S'By Northern blot analysis, the expression of OPN mRNA was increased in pyelonephritis and hydronephrosis models compared with the control, but no changes were observed in dietary-acid or base-loading models.\n'
p1897
sg4
(lp1898
(dp1899
g7
I45
sg8
VP10451
p1900
sg10
I8
sg11
VOPN mRNA
p1901
sg13
I2
sasg17
(lp1902
(dp1903
g7
I90
sg20
VC0020295
p1904
sg10
I14
sg11
Vhydronephrosis
p1905
sg13
I1
sa(dp1906
g7
I71
sg20
VC0034186
p1907
sg10
I14
sg11
Vpyelonephritis
p1908
sg13
I1
sasa(dp1909
g2
S'We aimed to evaluate possible clinical application of urinary monocyte chemotactic protein-1 (MCP-1), osteopontin (OPN), and regulated upon activation, normal T-cell expressed and secreted (RANTES) chemokine as useful noninvasive markers in children with congenital hydronephrosis (HN) caused by ureteropelvic junction obstruction (UPJO).\n'
p1910
sg4
(lp1911
(dp1912
g7
I94
sg8
VP41597
p1913
sg10
I5
sg11
VMCP-1
p1914
sg13
I1
sa(dp1915
g7
I62
sg8
g127
sg10
I30
sg11
Vmonocyte chemotactic protein-1
p1916
sg13
I3
sa(dp1917
g7
I102
sg8
VP10451
p1918
sg10
I11
sg11
Vosteopontin
p1919
sg13
I1
sa(dp1920
g7
I115
sg8
VP10451
p1921
sg10
I3
sg11
VOPN
p1922
sg13
I1
sasg17
(lp1923
(dp1924
g7
I296
sg20
VC0948710
p1925
sg10
I34
sg11
Vureteropelvic junction obstruction
p1926
sg13
I3
sa(dp1927
g7
I282
sg20
VC0020295
p1928
sg10
I2
sg11
VHN
p1929
sg13
I1
sa(dp1930
g7
I255
sg20
VC0266316
p1931
sg10
I25
sg11
Vcongenital hydronephrosis
p1932
sg13
I2
sa(dp1933
g7
I332
sg20
VC0948710
p1934
sg10
I4
sg11
VUPJO
p1935
sg13
I1
sasa(dp1936
g2
S"Characterization of the Fe65L2 gene structure will be useful in the linkage analysis and search for mutations in the Fe65L2 gene in patients with Alzheimer's disease.\n"
p1937
sg4
(lp1938
(dp1939
g7
I24
sg8
VP48436
p1940
sg10
I11
sg11
VFe65L2 gene
p1941
sg13
I2
sa(dp1942
g7
I24
sg8
VP48436
p1943
sg10
I11
sg11
VFe65L2 gene
p1944
sg13
I2
sasg17
(lp1945
(dp1946
g7
I146
sg20
VC1521724
p1947
sg10
I19
sg11
VAlzheimer's disease
p1948
sg13
I2
sasa(dp1949
g2
S'This study was designed to shed light on the function of ANGPTL7 in obesity and its modulation by physical exercise as well as its potential association with lipid profile.\n'
p1950
sg4
(lp1951
(dp1952
g7
I57
sg8
g127
sg10
I7
sg11
VANGPTL7
p1953
sg13
I1
sasg17
(lp1954
(dp1955
g7
I68
sg20
VC0028754
p1956
sg10
I7
sg11
Vobesity
p1957
sg13
I1
sasa(dp1958
g2
S'In conclusion, our data shows for the first time that obesity increases the level of ANGPTL7 in both plasma and adipose tissue.\n'
p1959
sg4
(lp1960
(dp1961
g7
I85
sg8
g127
sg10
I7
sg11
VANGPTL7
p1962
sg13
I1
sasg17
(lp1963
(dp1964
g7
I54
sg20
VC0028754
p1965
sg10
I7
sg11
Vobesity
p1966
sg13
I1
sasa(dp1967
g2
S'Physical exercise reduced the level of ANGPTL7 highlighting the potential for targeting this protein as a therapeutic target for regulating dyslipidemia.\n'
p1968
sg4
(lp1969
(dp1970
g7
I39
sg8
g127
sg10
I7
sg11
VANGPTL7
p1971
sg13
I1
sasg17
(lp1972
(dp1973
g7
I140
sg20
VC0242339
p1974
sg10
I12
sg11
Vdyslipidemia
p1975
sg13
I1
sasa(dp1976
g2
S'In this study, we recorded event-related potentials (ERPs) from four groups of 36-month-olds: low-risk control (LRC), high risk for ASD defined as having an older sibling with ASD (HRA) but who do not have ASD or milder autism-like symptoms (HRA-Typ), HRA children who do not have ASD but exhibit milder autism-like symptoms (HRA-Atyp) and HRA children diagnosed with ASD (ASD).\n'
p1977
sg4
(lp1978
sg17
(lp1979
(dp1980
g7
I181
sg20
VC1619700
p1981
sg10
I3
sg11
VHRA
p1982
sg13
I1
sa(dp1983
g7
I132
sg20
VC1510586
p1984
sg10
I3
sg11
VASD
p1985
sg13
I1
sa(dp1986
g7
I147
sg20
VC1619700
p1987
sg10
I32
sg11
Vhaving an older sibling with ASD
p1988
sg13
I6
sa(dp1989
g7
I181
sg20
VC1619700
p1990
sg10
I3
sg11
VHRA
p1991
sg13
I1
sa(dp1992
g7
I132
sg20
VC1510586
p1993
sg10
I3
sg11
VASD
p1994
sg13
I1
sa(dp1995
g7
I132
sg20
VC1510586
p1996
sg10
I3
sg11
VASD
p1997
sg13
I1
sa(dp1998
g7
I132
sg20
VC1510586
p1999
sg10
I3
sg11
VASD
p2000
sg13
I1
sa(dp2001
g7
I181
sg20
VC1619700
p2002
sg10
I3
sg11
VHRA
p2003
sg13
I1
sa(dp2004
g7
I220
sg20
VC0004352
p2005
sg10
I6
sg11
Vautism
p2006
sg13
I1
sa(dp2007
g7
I181
sg20
VC1619700
p2008
sg10
I3
sg11
VHRA
p2009
sg13
I1
sa(dp2010
g7
I181
sg20
VC1619700
p2011
sg10
I3
sg11
VHRA
p2012
sg13
I1
sa(dp2013
g7
I220
sg20
VC0004352
p2014
sg10
I6
sg11
Vautism
p2015
sg13
I1
sa(dp2016
g7
I132
sg20
VC1510586
p2017
sg10
I3
sg11
VASD
p2018
sg13
I1
sasa(dp2019
g2
S'The goal of this study was to determine whether unique profiles of psychophysiological responses to such stimuli could be identified in individuals diagnosed with autism spectrum disorder (ASD), with fragile X syndrome (FXS), and with comorbid autism and fragile X syndrome (ASD + FXS), and in typically developing (TYP) individuals.\n'
p2020
sg4
(lp2021
sg17
(lp2022
(dp2023
g7
I200
sg20
VC0016667
p2024
sg10
I18
sg11
Vfragile X syndrome
p2025
sg13
I3
sa(dp2026
g7
I163
sg20
VC1510586
p2027
sg10
I24
sg11
Vautism spectrum disorder
p2028
sg13
I3
sa(dp2029
g7
I220
sg20
VC0016667
p2030
sg10
I3
sg11
VFXS
p2031
sg13
I1
sa(dp2032
g7
I220
sg20
VC0016667
p2033
sg10
I3
sg11
VFXS
p2034
sg13
I1
sa(dp2035
g7
I189
sg20
VC1510586
p2036
sg10
I3
sg11
VASD
p2037
sg13
I1
sa(dp2038
g7
I189
sg20
VC1510586
p2039
sg10
I3
sg11
VASD
p2040
sg13
I1
sa(dp2041
g7
I200
sg20
VC0016667
p2042
sg10
I18
sg11
Vfragile X syndrome
p2043
sg13
I3
sa(dp2044
g7
I163
sg20
VC0004352
p2045
sg10
I6
sg11
Vautism
p2046
sg13
I1
sasa(dp2047
g2
S'Mutations in CCBE1 may yield a phenotype not only of lymphatic dysplasia, but also of LCS or fetal hydrops; however, the possibility that the sibling with LCS also carries a homozygous mutation in an unidentified gene influencing cholestasis cannot be excluded.\n'
p2048
sg4
(lp2049
(dp2050
g7
I13
sg8
g127
sg10
I5
sg11
VCCBE1
p2051
sg13
I1
sasg17
(lp2052
(dp2053
g7
I86
sg20
VC0268314
p2054
sg10
I3
sg11
VLCS
p2055
sg13
I1
sa(dp2056
g7
I230
sg20
VC0008370
p2057
sg10
I11
sg11
Vcholestasis
p2058
sg13
I1
sa(dp2059
g7
I93
sg20
VC0020305
p2060
sg10
I13
sg11
Vfetal hydrops
p2061
sg13
I2
sa(dp2062
g7
I86
sg20
VC0268314
p2063
sg10
I3
sg11
VLCS
p2064
sg13
I1
sa(dp2065
g7
I63
sg20
VC0334044
p2066
sg10
I9
sg11
Vdysplasia
p2067
sg13
I1
sasa(dp2068
g2
S'We performed hierarchical clustering on these profiles to study the extent to which HIV infection associated immune dysfunction, adaptive immune factors (pre-existing influenza-specific antibodies, T cell responses), an innate immune factor (Mannose Binding Lectin, MBL), demographic characteristics (gender, age), or the vaccine preparation (split vs. virosomal) impacted the immune response to influenza vaccination.\n'
p2069
sg4
(lp2070
(dp2071
g7
I242
sg8
VP63244
p2072
sg10
I22
sg11
VMannose Binding Lectin
p2073
sg13
I3
sa(dp2074
g7
I266
sg8
VP11226
p2075
sg10
I3
sg11
VMBL
p2076
sg13
I1
sasg17
(lp2077
(dp2078
g7
I167
sg20
VC0021400
p2079
sg10
I9
sg11
Vinfluenza
p2080
sg13
I1
sa(dp2081
g7
I167
sg20
VC0021400
p2082
sg10
I9
sg11
Vinfluenza
p2083
sg13
I1
sa(dp2084
g7
I364
sg20
VC0040456
p2085
sg10
I8
sg11
Vimpacted
p2086
sg13
I1
sa(dp2087
g7
I109
sg20
VC0021053
p2088
sg10
I18
sg11
Vimmune dysfunction
p2089
sg13
I2
sa(dp2090
g7
I84
sg20
VC0019693
p2091
sg10
I13
sg11
VHIV infection
p2092
sg13
I2
sasa(dp2093
g2
S'The present study provides the first direct comparison of anti-influenza A virus (IAV) activities of the collectins surfactant protein (SP) A and SP-D, mannose-binding lectin (MBL), and conglutinin.\n'
p2094
sg4
(lp2095
(dp2096
g7
I146
sg8
VP35247
p2097
sg10
I4
sg11
VSP-D
p2098
sg13
I1
sa(dp2099
g7
I58
sg8
g127
sg10
I28
sg11
Vanti-influenza A virus (IAV)
p2100
sg13
I4
sa(dp2101
g7
I152
sg8
VP11226
p2102
sg10
I22
sg11
Vmannose-binding lectin
p2103
sg13
I2
sa(dp2104
g7
I176
sg8
VP11226
p2105
sg10
I3
sg11
VMBL
p2106
sg13
I1
sasg17
(lp2107
(dp2108
g7
I63
sg20
VC0021400
p2109
sg10
I9
sg11
Vinfluenza
p2110
sg13
I1
sasa(dp2111
g2
S'The purpose of this case-control study was to assess the association of abdominal aortic aneurysm (AAA) in Croatian patients with four genetic polymorphisms: SNP 1166A&gt;C in the angiotensin II type 1 receptor gene (AT1R); SNP -1562C&gt;T in the matrix metalloproteinase-9 gene (MMP-9); the deletion of 32 bp in the chemokine receptor 5 gene (CCR5); and the insertion/deletion (I/D) of 287 bp in the angiotensin-converting enzyme gene (ACE).\n'
p2112
sg4
(lp2113
(dp2114
g7
I247
sg8
VP14780
p2115
sg10
I31
sg11
Vmatrix metalloproteinase-9 gene
p2116
sg13
I3
sa(dp2117
g7
I437
sg8
VP12821
p2118
sg10
I3
sg11
VACE
p2119
sg13
I1
sa(dp2120
g7
I344
sg8
VP32302
p2121
sg10
I4
sg11
VCCR5
p2122
sg13
I1
sa(dp2123
g7
I280
sg8
VP14780
p2124
sg10
I5
sg11
VMMP-9
p2125
sg13
I1
sa(dp2126
g7
I401
sg8
VP12821
p2127
sg10
I34
sg11
Vangiotensin-converting enzyme gene
p2128
sg13
I3
sa(dp2129
g7
I180
sg8
VP30556
p2130
sg10
I35
sg11
Vangiotensin II type 1 receptor gene
p2131
sg13
I6
sa(dp2132
g7
I317
sg8
VP61073
p2133
sg10
I25
sg11
Vchemokine receptor 5 gene
p2134
sg13
I4
sa(dp2135
g7
I217
sg8
VP30556
p2136
sg10
I4
sg11
VAT1R
p2137
sg13
I1
sasg17
(lp2138
(dp2139
g7
I99
sg20
VC0162871
p2140
sg10
I3
sg11
VAAA
p2141
sg13
I1
sa(dp2142
g7
I72
sg20
VC0162871
p2143
sg10
I25
sg11
Vabdominal aortic aneurysm
p2144
sg13
I3
sasa(dp2145
g2
S'The expression status of ZKSCAN3, a zinc-finger transcription factor containing KRAB and SCAN domains, as well as its biological significance, in human bladder cancer remains largely unknown.\n'
p2146
sg4
(lp2147
(dp2148
g7
I36
sg8
VP35398
p2149
sg10
I32
sg11
Vzinc-finger transcription factor
p2150
sg13
I3
sa(dp2151
g7
I80
sg8
g127
sg10
I4
sg11
VKRAB
p2152
sg13
I1
sa(dp2153
g7
I25
sg8
g127
sg10
I7
sg11
VZKSCAN3
p2154
sg13
I1
sasg17
(lp2155
(dp2156
g7
I152
sg20
VC0699885
p2157
sg10
I14
sg11
Vbladder cancer
p2158
sg13
I2
sasa(dp2159
g2
S'In the current study, we aimed to determine the functional role of ZKSCAN3 in bladder cancer progression.\n'
p2160
sg4
(lp2161
(dp2162
g7
I67
sg8
g127
sg10
I7
sg11
VZKSCAN3
p2163
sg13
I1
sasg17
(lp2164
(dp2165
g7
I86
sg20
VC0178874
p2166
sg10
I18
sg11
Vcancer progression
p2167
sg13
I2
sasa(dp2168
g2
S'Two bladder cancer cell lines, UMUC3 and 647V, were found to strongly express ZKSCAN3 protein/mRNA, whereas its expression in 5637 bladder cancer and SVHUC normal urothelium cell lines was very weak.\n'
p2169
sg4
(lp2170
(dp2171
g7
I78
sg8
g127
sg10
I7
sg11
VZKSCAN3
p2172
sg13
I1
sasg17
(lp2173
(dp2174
g7
I4
sg20
VC0699885
p2175
sg10
I14
sg11
Vbladder cancer
p2176
sg13
I2
sa(dp2177
g7
I4
sg20
VC0699885
p2178
sg10
I14
sg11
Vbladder cancer
p2179
sg13
I2
sasa(dp2180
g2
S'These results suggest that ZKSCAN3 plays an important role in bladder cancer outgrowth.\n'
p2181
sg4
(lp2182
(dp2183
g7
I27
sg8
g127
sg10
I7
sg11
VZKSCAN3
p2184
sg13
I1
sasg17
(lp2185
(dp2186
g7
I62
sg20
VC0699885
p2187
sg10
I14
sg11
Vbladder cancer
p2188
sg13
I2
sasa(dp2189
g2
S'Thus, ZKSCAN3 inhibition has the potential of being a therapeutic approach for bladder cancer.\n'
p2190
sg4
(lp2191
(dp2192
g7
I6
sg8
g127
sg10
I7
sg11
VZKSCAN3
p2193
sg13
I1
sasg17
(lp2194
(dp2195
g7
I79
sg20
VC0699885
p2196
sg10
I14
sg11
Vbladder cancer
p2197
sg13
I2
sasa(dp2198
g2
S'Zinc finger with KRAB and SCAN domain 3 (ZKSCAN3) is overexpressed in invasive colorectal cancer (CRC) cells and regulates the expression of several genes favoring tumor progression, including vascular endothelial growth factor (VEGF) and integrin Beta4.\n'
p2199
sg4
(lp2200
(dp2201
g7
I239
sg8
g127
sg10
I14
sg11
Vintegrin Beta4
p2202
sg13
I2
sa(dp2203
g7
I229
sg8
g127
sg10
I4
sg11
VVEGF
p2204
sg13
I1
sa(dp2205
g7
I193
sg8
g127
sg10
I34
sg11
Vvascular endothelial growth factor
p2206
sg13
I4
sa(dp2207
g7
I41
sg8
g127
sg10
I7
sg11
VZKSCAN3
p2208
sg13
I1
sa(dp2209
g7
I0
sg8
g127
sg10
I39
sg11
VZinc finger with KRAB and SCAN domain 3
p2210
sg13
I8
sasg17
(lp2211
(dp2212
g7
I79
sg20
VC1527249
p2213
sg10
I17
sg11
Vcolorectal cancer
p2214
sg13
I2
sa(dp2215
g7
I164
sg20
VC0178874
p2216
sg10
I17
sg11
Vtumor progression
p2217
sg13
I2
sa(dp2218
g7
I98
sg20
VC1527249
p2219
sg10
I3
sg11
VCRC
p2220
sg13
I1
sasa(dp2221
g2
S'We evaluated the association of ZKSCAN3 and colorectal cancer liver metastasis (CLM) to determine whether it is related to invasive signaling pathways.\n'
p2222
sg4
(lp2223
(dp2224
g7
I32
sg8
g127
sg10
I7
sg11
VZKSCAN3
p2225
sg13
I1
sasg17
(lp2226
(dp2227
g7
I44
sg20
VC1527249
p2228
sg10
I17
sg11
Vcolorectal cancer
p2229
sg13
I2
sa(dp2230
g7
I62
sg20
VC0494165
p2231
sg10
I16
sg11
Vliver metastasis
p2232
sg13
I2
sasa(dp2233
g2
S'Further preliminary data showed that ZKSCAN3 was expressed in a majority of prostate cancer patient samples, but not in normal prostate tissues.\n'
p2234
sg4
(lp2235
(dp2236
g7
I37
sg8
g127
sg10
I7
sg11
VZKSCAN3
p2237
sg13
I1
sasg17
(lp2238
(dp2239
g7
I76
sg20
VC0600139
p2240
sg10
I15
sg11
Vprostate cancer
p2241
sg13
I2
sasa(dp2242
g2
S'Moreover, the ZKSCAN3 protein is highly expressed in the PC3 prostate cancer cell line, which has high metastatic potential, but little expression was observed in non-metastatic prostate cancer cell lines.\n'
p2243
sg4
(lp2244
(dp2245
g7
I14
sg8
g127
sg10
I15
sg11
VZKSCAN3 protein
p2246
sg13
I2
sasg17
(lp2247
(dp2248
g7
I61
sg20
VC0600139
p2249
sg10
I15
sg11
Vprostate cancer
p2250
sg13
I2
sa(dp2251
g7
I167
sg20
VC0936223
p2252
sg10
I26
sg11
Vmetastatic prostate cancer
p2253
sg13
I3
sasa(dp2254
g2
S'Interestingly, the ZKSCAN3 gene was amplified in 26% (5/19) of metastatic prostate cancers and 20% (1/5) of lymph node metastases, but there was no amplification found in primary prostate cancers, further supporting the role of ZKSCAN3 in tumor cell migration.\n'
p2255
sg4
(lp2256
(dp2257
g7
I19
sg8
g127
sg10
I12
sg11
VZKSCAN3 gene
p2258
sg13
I2
sa(dp2259
g7
I19
sg8
g127
sg10
I7
sg11
VZKSCAN3
p2260
sg13
I1
sasg17
(lp2261
(dp2262
g7
I108
sg20
VC0686619
p2263
sg10
I21
sg11
Vlymph node metastases
p2264
sg13
I3
sa(dp2265
g7
I74
sg20
VC0376358
p2266
sg10
I16
sg11
Vprostate cancers
p2267
sg13
I2
sa(dp2268
g7
I74
sg20
VC0376358
p2269
sg10
I16
sg11
Vprostate cancers
p2270
sg13
I2
sa(dp2271
g7
I148
sg20
VC1705759
p2272
sg10
I13
sg11
Vamplification
p2273
sg13
I1
sa(dp2274
g7
I239
sg20
VC0027627
p2275
sg10
I20
sg11
Vtumor cell migration
p2276
sg13
I3
sasa(dp2277
g2
S'Taken together, we provide evidence that ZKSCAN3, a zinc finger transcription factor, plays a critical role in promoting prostate cancer cell migration.\n'
p2278
sg4
(lp2279
(dp2280
g7
I52
sg8
g127
sg10
I32
sg11
Vzinc finger transcription factor
p2281
sg13
I4
sa(dp2282
g7
I41
sg8
g127
sg10
I7
sg11
VZKSCAN3
p2283
sg13
I1
sasg17
(lp2284
(dp2285
g7
I121
sg20
VC0600139
p2286
sg10
I15
sg11
Vprostate cancer
p2287
sg13
I2
sasa(dp2288
g2
S'Analysis of a panel of myeloma cell lines, primary patient samples and datasets from Oncomine and the Multiple Myeloma Genomics Portal (MMGP) revealed expression of ZKSCAN3 messenger RNA (mRNA) in a majority of samples.\n'
p2289
sg4
(lp2290
(dp2291
g7
I165
sg8
g127
sg10
I21
sg11
VZKSCAN3 messenger RNA
p2292
sg13
I3
sasg17
(lp2293
(dp2294
g7
I23
sg20
VC0026764
p2295
sg10
I7
sg11
Vmyeloma
p2296
sg13
I1
sa(dp2297
g7
I102
sg20
VC0026764
p2298
sg10
I16
sg11
VMultiple Myeloma
p2299
sg13
I2
sasa(dp2300
g2
S'Conversely, ZKSCAN3 suppression using small hairpin RNAs (shRNAs) reduced cyclin D2 levels, and, importantly, inhibited myeloma cell line proliferation.\n'
p2301
sg4
(lp2302
(dp2303
g7
I12
sg8
g127
sg10
I7
sg11
VZKSCAN3
p2304
sg13
I1
sa(dp2305
g7
I74
sg8
VP30279
p2306
sg10
I9
sg11
Vcyclin D2
p2307
sg13
I2
sasg17
(lp2308
(dp2309
g7
I138
sg20
VC0334094
p2310
sg10
I13
sg11
Vproliferation
p2311
sg13
I1
sa(dp2312
g7
I120
sg20
VC0026764
p2313
sg10
I7
sg11
Vmyeloma
p2314
sg13
I1
sa(dp2315
g7
I20
sg20
VC0221103
p2316
sg10
I11
sg11
Vsuppression
p2317
sg13
I1
sasa(dp2318
g2
S'Finally, ZKSCAN3 was noted to specifically bind to oligonucleotides representing sequences from the cyclin D2 promoter, and to the endogenous promoter itself in myeloma cells.\n'
p2319
sg4
(lp2320
(dp2321
g7
I9
sg8
g127
sg10
I7
sg11
VZKSCAN3
p2322
sg13
I1
sa(dp2323
g7
I100
sg8
VP30279
p2324
sg10
I18
sg11
Vcyclin D2 promoter
p2325
sg13
I3
sasg17
(lp2326
(dp2327
g7
I161
sg20
VC0026764
p2328
sg10
I7
sg11
Vmyeloma
p2329
sg13
I1
sasa(dp2330
g2
S'Taken together, the data support the conclusion that ZKSCAN3 induction represents a mechanism by which myeloma cells can induce cyclin D2 dysregulation, and contribute to disease pathogenesis.\n'
p2331
sg4
(lp2332
(dp2333
g7
I128
sg8
VP30279
p2334
sg10
I9
sg11
Vcyclin D2
p2335
sg13
I2
sa(dp2336
g7
I53
sg8
g127
sg10
I7
sg11
VZKSCAN3
p2337
sg13
I1
sasg17
(lp2338
(dp2339
g7
I179
sg20
VC0699748
p2340
sg10
I12
sg11
Vpathogenesis
p2341
sg13
I1
sa(dp2342
g7
I103
sg20
VC0026764
p2343
sg10
I7
sg11
Vmyeloma
p2344
sg13
I1
sasa(dp2345
g2
S'We previously described the novel zinc finger protein ZKSCAN3 as a new "driver" of colon cancer progression.\n'
p2346
sg4
(lp2347
(dp2348
g7
I34
sg8
VP13682
p2349
sg10
I27
sg11
Vzinc finger protein ZKSCAN3
p2350
sg13
I4
sasg17
(lp2351
(dp2352
g7
I89
sg20
VC0178874
p2353
sg10
I18
sg11
Vcancer progression
p2354
sg13
I2
sasa(dp2355
g2
S'ZKSCAN3 was pursued for several reasons: (a) its sequence similarity with bowl required for Drosophila hindgut development; (b) it lies in a chromosomal region (6p22.1) amplified in colorectal cancer; and (c) its coding sequence predicts tandem C(2)H(2) zinc finger domains present in a class of proteins gaining attention for their role in oncogenesis/tumor progression.\n'
p2356
sg4
(lp2357
(dp2358
g7
I0
sg8
g127
sg10
I7
sg11
VZKSCAN3
p2359
sg13
I1
sasg17
(lp2360
(dp2361
g7
I341
sg20
VC0007621
p2362
sg10
I11
sg11
Voncogenesis
p2363
sg13
I1
sa(dp2364
g7
I353
sg20
VC0178874
p2365
sg10
I17
sg11
Vtumor progression
p2366
sg13
I2
sa(dp2367
g7
I182
sg20
VC1527249
p2368
sg10
I17
sg11
Vcolorectal cancer
p2369
sg13
I2
sasa(dp2370
g2
S'Intriguingly, the ZKSCAN3 protein was also expressed in tumors wild-type for genes (APC, p53, K-Ras) commonly targeted in colorectal cancer.\n'
p2371
sg4
(lp2372
(dp2373
g7
I84
sg8
VP25054
p2374
sg10
I3
sg11
VAPC
p2375
sg13
I1
sa(dp2376
g7
I94
sg8
VP01116
p2377
sg10
I5
sg11
VK-Ras
p2378
sg13
I1
sa(dp2379
g7
I18
sg8
g127
sg10
I15
sg11
VZKSCAN3 protein
p2380
sg13
I2
sa(dp2381
g7
I89
sg8
VP42771
p2382
sg10
I3
sg11
Vp53
p2383
sg13
I1
sasg17
(lp2384
(dp2385
g7
I56
sg20
VC0027651
p2386
sg10
I6
sg11
Vtumors
p2387
sg13
I1
sa(dp2388
g7
I84
sg20
VC0033036
p2389
sg10
I3
sg11
VAPC
p2390
sg13
I1
sa(dp2391
g7
I122
sg20
VC1527249
p2392
sg10
I17
sg11
Vcolorectal cancer
p2393
sg13
I2
sasa(dp2394
g2
S'ZKSCAN3 knockdown in two independent colon cancer cell lines impaired anchorage-independent growth and orthotopic tumor growth, whereas overexpression in a third cell line had the opposite effect and increased 5-fluorouracil resistance.\n'
p2395
sg4
(lp2396
(dp2397
g7
I0
sg8
g127
sg10
I7
sg11
VZKSCAN3
p2398
sg13
I1
sasg17
(lp2399
(dp2400
g7
I114
sg20
VC0598934
p2401
sg10
I12
sg11
Vtumor growth
p2402
sg13
I2
sa(dp2403
g7
I61
sg20
VC0684336
p2404
sg10
I8
sg11
Vimpaired
p2405
sg13
I1
sa(dp2406
g7
I37
sg20
VC0699790
p2407
sg10
I12
sg11
Vcolon cancer
p2408
sg13
I2
sasa(dp2409
g2
S'Liposomal delivery of a ZKSCAN3-targeting small interfering RNA reduced tumorigenicity of orthotopic colon cancer.\n'
p2410
sg4
(lp2411
(dp2412
g7
I24
sg8
g127
sg10
I7
sg11
VZKSCAN3
p2413
sg13
I1
sasg17
(lp2414
(dp2415
g7
I72
sg20
VC1519697
p2416
sg10
I14
sg11
Vtumorigenicity
p2417
sg13
I1
sa(dp2418
g7
I101
sg20
VC0699790
p2419
sg10
I12
sg11
Vcolon cancer
p2420
sg13
I2
sasa(dp2421
g2
S'Thus, the hitherto uncharacterized ZKSCAN3 adds to an expanding set of encoded products contributing to the progression of colorectal cancer.\n'
p2422
sg4
(lp2423
(dp2424
g7
I35
sg8
g127
sg10
I7
sg11
VZKSCAN3
p2425
sg13
I1
sasg17
(lp2426
(dp2427
g7
I123
sg20
VC1527249
p2428
sg10
I17
sg11
Vcolorectal cancer
p2429
sg13
I2
sasa(dp2430
g2
S'In line with uncontrolled cell cycle progression in SCLC, we find that CDC25A, B and C mRNAs are expressed at significantly higher levels in SCLC, compared to lung adenocarcinoma.\n'
p2431
sg4
(lp2432
(dp2433
g7
I71
sg8
VP30304
p2434
sg10
I6
sg11
VCDC25A
p2435
sg13
I1
sasg17
(lp2436
(dp2437
g7
I52
sg20
VC0149925
p2438
sg10
I4
sg11
VSCLC
p2439
sg13
I1
sa(dp2440
g7
I52
sg20
VC0149925
p2441
sg10
I4
sg11
VSCLC
p2442
sg13
I1
sa(dp2443
g7
I159
sg20
VC0152013
p2444
sg10
I19
sg11
Vlung adenocarcinoma
p2445
sg13
I2
sasa(dp2446
g2
S'Despite its documented role in cell cycle regulation, over-expression of the cyclin-dependent kinase activator CDC25A does not consistently correlate with worse cancer patient outcomes or predict successful clinical response to CDC25A inhibition.\n'
p2447
sg4
(lp2448
(dp2449
g7
I77
sg8
VP49336
p2450
sg10
I40
sg11
Vcyclin-dependent kinase activator CDC25A
p2451
sg13
I4
sa(dp2452
g7
I111
sg8
VP30304
p2453
sg10
I6
sg11
VCDC25A
p2454
sg13
I1
sasg17
(lp2455
(dp2456
g7
I161
sg20
VC0006826
p2457
sg10
I6
sg11
Vcancer
p2458
sg13
I1
sasa(dp2459
g2
S'The current study was undertaken to investigate CDC25A in skin cancer and understand predictors of positive response to CDC25A targeting.\n'
p2460
sg4
(lp2461
(dp2462
g7
I48
sg8
VP30304
p2463
sg10
I6
sg11
VCDC25A
p2464
sg13
I1
sa(dp2465
g7
I48
sg8
VP30304
p2466
sg10
I6
sg11
VCDC25A
p2467
sg13
I1
sasg17
(lp2468
(dp2469
g7
I58
sg20
VC0007114
p2470
sg10
I11
sg11
Vskin cancer
p2471
sg13
I2
sasa(dp2472
g2
S'CDC25A was increased in human squamous cell carcinoma (SCC) associated with a shift from a primarily nuclear localization in skin to a strong cytoplasmic localization in SCC, a pattern that was reproduced in skin cancer cell lines.\n'
p2473
sg4
(lp2474
(dp2475
g7
I0
sg8
VP30304
p2476
sg10
I6
sg11
VCDC25A
p2477
sg13
I1
sasg17
(lp2478
(dp2479
g7
I208
sg20
VC0007114
p2480
sg10
I11
sg11
Vskin cancer
p2481
sg13
I2
sa(dp2482
g7
I30
sg20
VC0007137
p2483
sg10
I23
sg11
Vsquamous cell carcinoma
p2484
sg13
I3
sa(dp2485
g7
I55
sg20
VC0007137
p2486
sg10
I3
sg11
VSCC
p2487
sg13
I1
sa(dp2488
g7
I55
sg20
VC0007137
p2489
sg10
I3
sg11
VSCC
p2490
sg13
I1
sasa(dp2491
g2
S'Additionally, the CDC25A inhibitors Vitamin K3 or NSC663284 were more toxic to SCC than normal keratinocytes, and CDC25A inhibition effectively suppressed skin cancer growth by increasing apoptosis without affecting normal skin biology.\n'
p2492
sg4
(lp2493
(dp2494
g7
I18
sg8
VP30304
p2495
sg10
I6
sg11
VCDC25A
p2496
sg13
I1
sa(dp2497
g7
I18
sg8
VP30304
p2498
sg10
I6
sg11
VCDC25A
p2499
sg13
I1
sa(dp2500
g7
I36
sg8
g127
sg10
I7
sg11
VVitamin
p2501
sg13
I1
sasg17
(lp2502
(dp2503
g7
I155
sg20
VC0007114
p2504
sg10
I11
sg11
Vskin cancer
p2505
sg13
I2
sasa(dp2506
g2
S'These studies provide proof-of-concept evidence for the potential of CDC25A inhibitors for skin cancer treatment and suggest that an assessment of the cytoplasmic localization of CDC25A may be a strategy for identification of skin and other cancers susceptible to CDC25A targeting.\n'
p2507
sg4
(lp2508
(dp2509
g7
I69
sg8
VP30304
p2510
sg10
I6
sg11
VCDC25A
p2511
sg13
I1
sa(dp2512
g7
I69
sg8
VP30304
p2513
sg10
I6
sg11
VCDC25A
p2514
sg13
I1
sa(dp2515
g7
I69
sg8
VP30304
p2516
sg10
I6
sg11
VCDC25A
p2517
sg13
I1
sasg17
(lp2518
(dp2519
g7
I91
sg20
VC0007114
p2520
sg10
I11
sg11
Vskin cancer
p2521
sg13
I2
sa(dp2522
g7
I241
sg20
VC0006826
p2523
sg10
I7
sg11
Vcancers
p2524
sg13
I1
sasa(dp2525
g2
S'Synthesis of twenty nine new 1,2,4-triazoles and some derived thiazolothiadiazoles (structurally-relevant to some reported triazoles with anticancer and/or Cdc25A/B inhibitory activities) is described in this study.\n'
p2526
sg4
(lp2527
(dp2528
g7
I156
sg8
VP30304
p2529
sg10
I8
sg11
VCdc25A/B
p2530
sg13
I1
sasg17
(lp2531
sa(dp2532
g2
S'In addition, a number of Desbuquois dysplasia type II patients have been attributed to mutations in xylosyltransferase 1, encoded by the XYLT1 gene, an enzyme that catalyzes the transfer of UDP-xylose (a marker of cartilage destruction) to serine residues of an acceptor protein, essential for the biosynthesis of proteoglycans.\n'
p2533
sg4
(lp2534
(dp2535
g7
I100
sg8
g127
sg10
I20
sg11
Vxylosyltransferase 1
p2536
sg13
I2
sa(dp2537
g7
I137
sg8
g127
sg10
I10
sg11
VXYLT1 gene
p2538
sg13
I2
sasg17
(lp2539
(dp2540
g7
I25
sg20
VC0432242
p2541
sg10
I20
sg11
VDesbuquois dysplasia
p2542
sg13
I2
sasa(dp2543
g2
S'Desbuquois dysplasia type 2 (DBQD2) is a rare recessively inherited skeletal genetic disorder characterized by severe prenatal and postnatal growth retardation, generalized joint laxity with dislocation of large joints and facial dysmorphism.\n'
p2544
sg4
(lp2545
sg17
(lp2546
(dp2547
g7
I0
sg20
VC0432242
p2548
sg10
I20
sg11
VDesbuquois dysplasia
p2549
sg13
I2
sa(dp2550
g7
I141
sg20
VC0151686
p2551
sg10
I18
sg11
Vgrowth retardation
p2552
sg13
I2
sa(dp2553
g7
I223
sg20
VC0266617
p2554
sg10
I18
sg11
Vfacial dysmorphism
p2555
sg13
I2
sa(dp2556
g7
I77
sg20
VC0019247
p2557
sg10
I16
sg11
Vgenetic disorder
p2558
sg13
I2
sa(dp2559
g7
I173
sg20
VC0086437
p2560
sg10
I12
sg11
Vjoint laxity
p2561
sg13
I2
sasa(dp2562
g2
S'Patients with SUCLA2 gene defects characteristically develop the trias of early hypotonia, progressive dystonia and sensori-neural deafness.\n'
p2563
sg4
(lp2564
(dp2565
g7
I14
sg8
g127
sg10
I11
sg11
VSUCLA2 gene
p2566
sg13
I2
sasg17
(lp2567
(dp2568
g7
I124
sg20
VC0155550
p2569
sg10
I15
sg11
Vneural deafness
p2570
sg13
I2
sa(dp2571
g7
I103
sg20
VC0393593
p2572
sg10
I8
sg11
Vdystonia
p2573
sg13
I1
sa(dp2574
g7
I80
sg20
VC0026827
p2575
sg10
I9
sg11
Vhypotonia
p2576
sg13
I1
sasa(dp2577
g2
S'The authors identified two novel heterozygous missense transitions in the gene for the mitochondrial polymerase gammaA subunit (POLG) in a family with an autosomal recessive syndrome comprising progressive external ophthalmoplegia (PEO), polyneuropathy, ataxia, sensorineural hearing loss, and affective disorders.\n'
p2578
sg4
(lp2579
(dp2580
g7
I101
sg8
VP54098
p2581
sg10
I25
sg11
Vpolymerase gammaA subunit
p2582
sg13
I3
sa(dp2583
g7
I128
sg8
VP54098
p2584
sg10
I4
sg11
VPOLG
p2585
sg13
I1
sasg17
(lp2586
(dp2587
g7
I254
sg20
VC0004134
p2588
sg10
I6
sg11
Vataxia
p2589
sg13
I1
sa(dp2590
g7
I232
sg20
VC0162674
p2591
sg10
I3
sg11
VPEO
p2592
sg13
I1
sa(dp2593
g7
I238
sg20
VC0152025
p2594
sg10
I14
sg11
Vpolyneuropathy
p2595
sg13
I1
sa(dp2596
g7
I262
sg20
VC0018784
p2597
sg10
I26
sg11
Vsensorineural hearing loss
p2598
sg13
I3
sa(dp2599
g7
I194
sg20
VC0162674
p2600
sg10
I36
sg11
Vprogressive external ophthalmoplegia
p2601
sg13
I3
sa(dp2602
g7
I174
sg20
VC0039082
p2603
sg10
I8
sg11
Vsyndrome
p2604
sg13
I1
sa(dp2605
g7
I294
sg20
VC0525045
p2606
sg10
I19
sg11
Vaffective disorders
p2607
sg13
I2
sasa(dp2608
g2
S'Unexpectedly, we found that a set of muscle-specific microRNAs (miRNAs; myomiRs): miR-133, miR-1, and miR-206 was significantly underexpressed in well-differentiated liposarcoma and synovial sarcoma, suggesting that they may function as tumor suppressors as described in muscle-relevant rhabdomyosarcomas.\n'
p2609
sg4
(lp2610
(dp2611
g7
I82
sg8
g127
sg10
I5
sg11
VmiR-1
p2612
sg13
I1
sa(dp2613
g7
I82
sg8
g127
sg10
I7
sg11
VmiR-133
p2614
sg13
I1
sasg17
(lp2615
(dp2616
g7
I237
sg20
VC0027651
p2617
sg10
I5
sg11
Vtumor
p2618
sg13
I1
sa(dp2619
g7
I287
sg20
VC0035412
p2620
sg10
I17
sg11
Vrhabdomyosarcomas
p2621
sg13
I1
sa(dp2622
g7
I182
sg20
VC0039101
p2623
sg10
I16
sg11
Vsynovial sarcoma
p2624
sg13
I2
sa(dp2625
g7
I166
sg20
VC0023827
p2626
sg10
I11
sg11
Vliposarcoma
p2627
sg13
I1
sasa(dp2628
g2
S'In this work, we examined the role of the muscle-specific miRNAs miR-1 and miR-206 in human rhabdomyosarcoma (RMS), a soft tissue sarcoma thought to arise from skeletal muscle progenitors.\n'
p2629
sg4
(lp2630
(dp2631
g7
I65
sg8
g127
sg10
I5
sg11
VmiR-1
p2632
sg13
I1
sa(dp2633
g7
I75
sg8
g127
sg10
I7
sg11
VmiR-206
p2634
sg13
I1
sasg17
(lp2635
(dp2636
g7
I92
sg20
VC0035412
p2637
sg10
I16
sg11
Vrhabdomyosarcoma
p2638
sg13
I1
sa(dp2639
g7
I110
sg20
VC0035412
p2640
sg10
I3
sg11
VRMS
p2641
sg13
I1
sa(dp2642
g7
I118
sg20
VC1261473
p2643
sg10
I19
sg11
Vsoft tissue sarcoma
p2644
sg13
I3
sasa(dp2645
g2
S'This study characterized ID4 gene methylation in patients with MDS and aplastic anemia (AA).\n'
p2646
sg4
(lp2647
(dp2648
g7
I25
sg8
VP47928
p2649
sg10
I8
sg11
VID4 gene
p2650
sg13
I2
sasg17
(lp2651
(dp2652
g7
I71
sg20
VC0002874
p2653
sg10
I15
sg11
Vaplastic anemia
p2654
sg13
I2
sa(dp2655
g7
I63
sg20
VC0265219
p2656
sg10
I3
sg11
VMDS
p2657
sg13
I1
sasa(dp2658
g2
S'The methylation-specific PCR (MS-PCR) and reverse transcription-PCR (RT-PCR) were applied to identify the methylation status and gene expression of ID4 gene in MDS cell line MUTZ1, a patient with aplastic anemia(AA) and a donor with normal bone marrow (NBM).\n'
p2659
sg4
(lp2660
(dp2661
g7
I148
sg8
VP47928
p2662
sg10
I8
sg11
VID4 gene
p2663
sg13
I2
sasg17
(lp2664
(dp2665
g7
I160
sg20
VC0265219
p2666
sg10
I3
sg11
VMDS
p2667
sg13
I1
sa(dp2668
g7
I196
sg20
VC0002874
p2669
sg10
I15
sg11
Vaplastic anemia
p2670
sg13
I2
sasa(dp2671
g2
S'To analyze changes in gene amplification in the mitochondrial genome and in the ID4 gene promoter methylation region in patients with chronic aplastic anemia (CAA) suffering from Kidney (Shen) yin deficiency or Kidney yang deficiency.\n'
p2672
sg4
(lp2673
(dp2674
g7
I80
sg8
VP47928
p2675
sg10
I8
sg11
VID4 gene
p2676
sg13
I2
sasg17
(lp2677
(dp2678
g7
I218
sg20
VC0085258
p2679
sg10
I15
sg11
Vyang deficiency
p2680
sg13
I2
sa(dp2681
g7
I164
sg20
VC0683278
p2682
sg10
I9
sg11
Vsuffering
p2683
sg13
I1
sa(dp2684
g7
I22
sg20
VC1705759
p2685
sg10
I18
sg11
Vgene amplification
p2686
sg13
I2
sa(dp2687
g7
I193
sg20
VC0085257
p2688
sg10
I14
sg11
Vyin deficiency
p2689
sg13
I2
sa(dp2690
g7
I159
sg20
VC1842937
p2691
sg10
I3
sg11
VCAA
p2692
sg13
I1
sa(dp2693
g7
I134
sg20
VC1842937
p2694
sg10
I23
sg11
Vchronic aplastic anemia
p2695
sg13
I3
sasa(dp2696
g2
S'Methylation-specific PCR (MS-PCR) was used to detect the promoter methylation status of ID4 gene in bone marrow samples from 46 AML patients with different subtypes and stage of disease and from 10 patients with iron deficiency anemia (IDA) as a control.\n'
p2697
sg4
(lp2698
(dp2699
g7
I88
sg8
VP47928
p2700
sg10
I8
sg11
VID4 gene
p2701
sg13
I2
sasg17
(lp2702
(dp2703
g7
I236
sg20
VC0162316
p2704
sg10
I3
sg11
VIDA
p2705
sg13
I1
sa(dp2706
g7
I128
sg20
VC0023467
p2707
sg10
I3
sg11
VAML
p2708
sg13
I1
sa(dp2709
g7
I212
sg20
VC0162316
p2710
sg10
I22
sg11
Viron deficiency anemia
p2711
sg13
I3
sasa(dp2712
g2
S'Id4 methylation was also detected in bone marrow samples from patients with iron deficiency anemia which served as control.\n'
p2713
sg4
(lp2714
(dp2715
g7
I0
sg8
VP47928
p2716
sg10
I3
sg11
VId4
p2717
sg13
I1
sasg17
(lp2718
(dp2719
g7
I76
sg20
VC0162316
p2720
sg10
I22
sg11
Viron deficiency anemia
p2721
sg13
I3
sasa(dp2722
g2
S'We previously reported a genome-wide association study that identified common SNPs near the CTSO gene and in ZNF423 associated with development of breast cancer during tamoxifen therapy in the NSABP P-1 and P-2 breast cancer prevention trials.\n'
p2723
sg4
(lp2724
(dp2725
g7
I92
sg8
VP43234
p2726
sg10
I9
sg11
VCTSO gene
p2727
sg13
I2
sa(dp2728
g7
I109
sg8
g127
sg10
I6
sg11
VZNF423
p2729
sg13
I1
sasg17
(lp2730
(dp2731
g7
I147
sg20
VC0678222
p2732
sg10
I13
sg11
Vbreast cancer
p2733
sg13
I2
sa(dp2734
g7
I147
sg20
VC0678222
p2735
sg10
I13
sg11
Vbreast cancer
p2736
sg13
I2
sasa(dp2737
g2
S'Here, we have investigated their roles in ERAlfa-positive breast cancer growth and tamoxifen response, focusing on the mechanism of CTSO.\n'
p2738
sg4
(lp2739
sg17
(lp2740
(dp2741
g7
I58
sg20
VC0678222
p2742
sg10
I13
sg11
Vbreast cancer
p2743
sg13
I2
sasa(dp2744
g2
S'A case-control study from two randomised breast cancer prevention trials of tamoxifen and raloxifene (P-1 and P-2) identified single-nucleotide polymorphisms (SNPs) in or near genes ZNF423 and CTSO as factors which predict which women will derive most anti-cancer benefit from selective oestrogen receptor modulator (SERM) therapy.\n'
p2745
sg4
(lp2746
(dp2747
g7
I287
sg8
VP03372
p2748
sg10
I28
sg11
Voestrogen receptor modulator
p2749
sg13
I3
sa(dp2750
g7
I193
sg8
VP43234
p2751
sg10
I4
sg11
VCTSO
p2752
sg13
I1
sa(dp2753
g7
I182
sg8
g127
sg10
I6
sg11
VZNF423
p2754
sg13
I1
sasg17
(lp2755
(dp2756
g7
I48
sg20
VC0006826
p2757
sg10
I6
sg11
Vcancer
p2758
sg13
I1
sa(dp2759
g7
I41
sg20
VC0678222
p2760
sg10
I13
sg11
Vbreast cancer
p2761
sg13
I2
sasa(dp2762
g2
S'Recently, a genome-wide association study identified two single-nucleotide polymorphisms (SNPs) near or in the CTSO and ZNF423 genes that were associated with breast cancer risk during tamoxifen therapy.\n'
p2763
sg4
(lp2764
(dp2765
g7
I111
sg8
VP43234
p2766
sg10
I4
sg11
VCTSO
p2767
sg13
I1
sa(dp2768
g7
I120
sg8
g127
sg10
I12
sg11
VZNF423 genes
p2769
sg13
I2
sasg17
(lp2770
(dp2771
g7
I159
sg20
VC0678222
p2772
sg10
I13
sg11
Vbreast cancer
p2773
sg13
I2
sasa(dp2774
g2
S'We then investigated the relationship between CTSO rs10030044 genotypes and mRNA expression levels of CTSO and BRCA1 in 290 breast cancer patients.\n'
p2775
sg4
(lp2776
(dp2777
g7
I102
sg8
VP43234
p2778
sg10
I14
sg11
VCTSO and BRCA1
p2779
sg13
I3
sa(dp2780
g7
I46
sg8
VP43234
p2781
sg10
I15
sg11
VCTSO rs10030044
p2782
sg13
I2
sasg17
(lp2783
(dp2784
g7
I124
sg20
VC0678222
p2785
sg10
I13
sg11
Vbreast cancer
p2786
sg13
I2
sasa(dp2787
g2
S'We found a positive correlation between the variant GG genotype of CTSO rs10030044 and shorter disease-free survival, or overall survival in hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.\n'
p2788
sg4
(lp2789
(dp2790
g7
I67
sg8
VP43234
p2791
sg10
I15
sg11
VCTSO rs10030044
p2792
sg13
I2
sasg17
(lp2793
(dp2794
g7
I167
sg20
VC0678222
p2795
sg10
I13
sg11
Vbreast cancer
p2796
sg13
I2
sasa(dp2797
g2
S'We show that a SNP near the CTSO gene is a poor prognostic factor in breast cancer although further research might help to reveal the factors linking this genotype and prognosis.\n'
p2798
sg4
(lp2799
(dp2800
g7
I28
sg8
VP43234
p2801
sg10
I9
sg11
VCTSO gene
p2802
sg13
I2
sasg17
(lp2803
(dp2804
g7
I69
sg20
VC0678222
p2805
sg10
I13
sg11
Vbreast cancer
p2806
sg13
I2
sasa(dp2807
g2
S'An initial discovery genome-wide association study identified common single-nucleotide polymorphisms (SNP) in or near the ZNF423 and CTSO genes that were associated with breast cancer risk during SERM therapy.\n'
p2808
sg4
(lp2809
(dp2810
g7
I122
sg8
g127
sg10
I6
sg11
VZNF423
p2811
sg13
I1
sa(dp2812
g7
I133
sg8
VP43234
p2813
sg10
I10
sg11
VCTSO genes
p2814
sg13
I2
sasg17
(lp2815
(dp2816
g7
I170
sg20
VC0678222
p2817
sg10
I13
sg11
Vbreast cancer
p2818
sg13
I2
sasa(dp2819
g2
S'The OR for differences in breast cancer risk during SERM therapy for subjects homozygous for both protective or both risk alleles for ZNF423 and CTSO was 5.71.\n'
p2820
sg4
(lp2821
(dp2822
g7
I134
sg8
g127
sg10
I6
sg11
VZNF423
p2823
sg13
I1
sasg17
(lp2824
(dp2825
g7
I26
sg20
VC0678222
p2826
sg10
I13
sg11
Vbreast cancer
p2827
sg13
I2
sasa(dp2828
g2
S'The current status of GE pig liver xenotransplantation with world experience, potential factors causing thrombocytopenia, new targets on pig endothelial cells, and novel GE pigs with more genes deletion to avoid remaining antibody response, such as beta1,4-N-acetyl galactosaminyl transferase 2 (Beta4GalNT2), are discussed.\n'
p2829
sg4
(lp2830
sg17
(lp2831
sa(dp2832
g2
S'Cis-regulatory variation at the blood group-related glycosyltransferase B4galnt2 is associated with a phenotype in mice that closely resembles a common human bleeding disorder, von Willebrand disease.\n'
p2833
sg4
(lp2834
(dp2835
g7
I0
sg8
VP12821
p2836
sg10
I3
sg11
VCis
p2837
sg13
I1
sa(dp2838
g7
I52
sg8
g127
sg10
I28
sg11
Vglycosyltransferase B4galnt2
p2839
sg13
I2
sasg17
(lp2840
(dp2841
g7
I177
sg20
VC0042974
p2842
sg10
I22
sg11
Vvon Willebrand disease
p2843
sg13
I3
sa(dp2844
g7
I0
sg20
VC0007099
p2845
sg10
I3
sg11
VCis
p2846
sg13
I1
sa(dp2847
g7
I158
sg20
VC0005779
p2848
sg10
I17
sg11
Vbleeding disorder
p2849
sg13
I2
sasa(dp2850
g2
S'Human ARHGAP33 is associated with brain phenotypes and reduced SORT1 expression is found in patients with schizophrenia.\n'
p2851
sg4
(lp2852
(dp2853
g7
I63
sg8
g127
sg10
I5
sg11
VSORT1
p2854
sg13
I1
sasg17
(lp2855
(dp2856
g7
I106
sg20
VC0036341
p2857
sg10
I13
sg11
Vschizophrenia
p2858
sg13
I1
sasa(dp2859
g2
S'Furthermore, the results of our study revealed that miR-126 is negatively correlated with ADAM9 expression in hepatitis B virus-related hepatocellular carcinoma patients.\n'
p2860
sg4
(lp2861
(dp2862
g7
I52
sg8
g127
sg10
I7
sg11
VmiR-126
p2863
sg13
I1
sa(dp2864
g7
I90
sg8
g127
sg10
I5
sg11
VADAM9
p2865
sg13
I1
sasg17
(lp2866
(dp2867
g7
I110
sg20
VC1333977
p2868
sg10
I50
sg11
Vhepatitis B virus-related hepatocellular carcinoma
p2869
sg13
I5
sasa(dp2870
g2
S'Overexpression of miR-126 was shown to attenuate ADAM9 expression in hepatocellular carcinoma cells, which subsequently inhibits cell migration and invasion in vitro.\n'
p2871
sg4
(lp2872
(dp2873
g7
I18
sg8
g127
sg10
I7
sg11
VmiR-126
p2874
sg13
I1
sa(dp2875
g7
I49
sg8
g127
sg10
I5
sg11
VADAM9
p2876
sg13
I1
sasg17
(lp2877
(dp2878
g7
I69
sg20
VC1512411
p2879
sg10
I24
sg11
Vhepatocellular carcinoma
p2880
sg13
I2
sa(dp2881
g7
I148
sg20
VC2699153
p2882
sg10
I8
sg11
Vinvasion
p2883
sg13
I1
sasa(dp2884
g2
S'In conclusion, we demonstrated that the loss of tumor suppressor miR-126 in hepatitis B virus-related hepatocellular carcinoma cells contributes to the development of metastases through the upregulated expression of its target gene, ADAM9.\n'
p2885
sg4
(lp2886
(dp2887
g7
I233
sg8
g127
sg10
I5
sg11
VADAM9
p2888
sg13
I1
sasg17
(lp2889
(dp2890
g7
I167
sg20
VC0027627
p2891
sg10
I10
sg11
Vmetastases
p2892
sg13
I1
sa(dp2893
g7
I76
sg20
VC1333977
p2894
sg10
I50
sg11
Vhepatitis B virus-related hepatocellular carcinoma
p2895
sg13
I5
sa(dp2896
g7
I48
sg20
VC0027651
p2897
sg10
I5
sg11
Vtumor
p2898
sg13
I1
sasa(dp2899
g2
S'MiR-126-ADAM9 pathway-based therapeutic targeting may represent a novel approach for the inhibition of hepatitis B virus-related hepatocellular carcinoma metastases.\n'
p2900
sg4
(lp2901
(dp2902
g7
I0
sg8
g127
sg10
I13
sg11
VMiR-126-ADAM9
p2903
sg13
I1
sasg17
(lp2904
(dp2905
g7
I103
sg20
VC1333977
p2906
sg10
I50
sg11
Vhepatitis B virus-related hepatocellular carcinoma
p2907
sg13
I5
sa(dp2908
g7
I154
sg20
VC0027627
p2909
sg10
I10
sg11
Vmetastases
p2910
sg13
I1
sasa(dp2911
g2
S'We previously showed that ADAM9 staining was increased in colon cancer tissues.\n'
p2912
sg4
(lp2913
(dp2914
g7
I26
sg8
g127
sg10
I5
sg11
VADAM9
p2915
sg13
I1
sasg17
(lp2916
(dp2917
g7
I58
sg20
VC0699790
p2918
sg10
I12
sg11
Vcolon cancer
p2919
sg13
I2
sasa(dp2920
g2
S'In the present work, we investigated the expression pattern of ADAM9 in colon cell lines, and the effects of overexpression ADAM9 on colon cancer proliferation and invasion.\n'
p2921
sg4
(lp2922
(dp2923
g7
I63
sg8
g127
sg10
I5
sg11
VADAM9
p2924
sg13
I1
sa(dp2925
g7
I63
sg8
g127
sg10
I5
sg11
VADAM9
p2926
sg13
I1
sasg17
(lp2927
(dp2928
g7
I133
sg20
VC0699790
p2929
sg10
I12
sg11
Vcolon cancer
p2930
sg13
I2
sa(dp2931
g7
I146
sg20
VC0334094
p2932
sg10
I13
sg11
Vproliferation
p2933
sg13
I1
sa(dp2934
g7
I164
sg20
VC2699153
p2935
sg10
I8
sg11
Vinvasion
p2936
sg13
I1
sasa(dp2937
g2
S'ADAM9 mRNA expression was determined in colon cancer tissues by RT-PCR assay, meanwhile, ADAM9 DNA and protein levels were measured in colon cancer cell lines by PCR and western blot, respectively.\n'
p2938
sg4
(lp2939
(dp2940
g7
I0
sg8
g127
sg10
I10
sg11
VADAM9 mRNA
p2941
sg13
I2
sa(dp2942
g7
I89
sg8
g127
sg10
I9
sg11
VADAM9 DNA
p2943
sg13
I2
sasg17
(lp2944
(dp2945
g7
I40
sg20
VC0699790
p2946
sg10
I12
sg11
Vcolon cancer
p2947
sg13
I2
sa(dp2948
g7
I40
sg20
VC0699790
p2949
sg10
I12
sg11
Vcolon cancer
p2950
sg13
I2
sasa(dp2951
g2
S'ADAM9 transfection was carried out in HT-29 colon cancer cells, and cell growth was measured by MTT assay, cell invasion ability was assessed by Matrigel assay.\n'
p2952
sg4
(lp2953
(dp2954
g7
I0
sg8
g127
sg10
I5
sg11
VADAM9
p2955
sg13
I1
sasg17
(lp2956
(dp2957
g7
I44
sg20
VC0699790
p2958
sg10
I12
sg11
Vcolon cancer
p2959
sg13
I2
sa(dp2960
g7
I107
sg20
VC2699153
p2961
sg10
I13
sg11
Vcell invasion
p2962
sg13
I2
sasa(dp2963
g2
S'ADAM9 mRNA was upregulated in colon cancer tissues, ADAM9 DNA and protein was overexpressed in Lovo cell lines, while the ADAM9 expression levels in HT-29, HCT-8, and Ls174t cells were below the levels of detection.\n'
p2964
sg4
(lp2965
(dp2966
g7
I0
sg8
g127
sg10
I10
sg11
VADAM9 mRNA
p2967
sg13
I2
sa(dp2968
g7
I52
sg8
g127
sg10
I21
sg11
VADAM9 DNA and protein
p2969
sg13
I4
sa(dp2970
g7
I0
sg8
g127
sg10
I5
sg11
VADAM9
p2971
sg13
I1
sasg17
(lp2972
(dp2973
g7
I30
sg20
VC0699790
p2974
sg10
I12
sg11
Vcolon cancer
p2975
sg13
I2
sasa(dp2976
g2
S'These results suggest that ADAM9 contributes to cell invasion and progression in colon cancer.\n'
p2977
sg4
(lp2978
(dp2979
g7
I27
sg8
g127
sg10
I5
sg11
VADAM9
p2980
sg13
I1
sasg17
(lp2981
(dp2982
g7
I81
sg20
VC0699790
p2983
sg10
I12
sg11
Vcolon cancer
p2984
sg13
I2
sa(dp2985
g7
I48
sg20
VC2699153
p2986
sg10
I13
sg11
Vcell invasion
p2987
sg13
I2
sasa(dp2988
g2
S'We also confirmed that miR-203 and oncogene ADAM9 (a disintegrin and metalloproteinase 9)/oncogenic long non-coding RNA HULC (highly up-regulated in liver cancer) were inversely expressed in hepatocellular carcinoma (HCC) tissues or cell lines.\n'
p2989
sg4
(lp2990
(dp2991
g7
I23
sg8
g127
sg10
I26
sg11
VmiR-203 and oncogene ADAM9
p2992
sg13
I4
sa(dp2993
g7
I51
sg8
VP52888
p2994
sg10
I37
sg11
Va disintegrin and metalloproteinase 9
p2995
sg13
I5
sasg17
(lp2996
(dp2997
g7
I149
sg20
VC0345904
p2998
sg10
I12
sg11
Vliver cancer
p2999
sg13
I2
sa(dp3000
g7
I191
sg20
VC2239176
p3001
sg10
I24
sg11
Vhepatocellular carcinoma
p3002
sg13
I2
sa(dp3003
g7
I217
sg20
VC2239176
p3004
sg10
I3
sg11
VHCC
p3005
sg13
I1
sasa(dp3006
g2
S'This study has identified significant regions in the OSCC genome that were amplified and resulted in consequent over-expression of the MGAM and ADAM9 genes that may be utilized as biological markers for OSCC.\n'
p3007
sg4
(lp3008
(dp3009
g7
I135
sg8
g127
sg10
I4
sg11
VMGAM
p3010
sg13
I1
sa(dp3011
g7
I144
sg8
g127
sg10
I11
sg11
VADAM9 genes
p3012
sg13
I2
sasg17
(lp3013
sa(dp3014
g2
S'Abbreviations used: C: Degree Celsius, ANOVA: Analysis of variance, ATCC: American Type Culture Collection, BCL-2: B-Cell CLL/Lymphoma 2, Bcl-xL: B-cell lymphoma extra-large, BH3: Bcl-2 homology 3, BID: BH3-interacting domain death agonist, BIR: Baculovirus inhibitor of apoptosis protein repeat, Caspases: Cysteinyl aspartate-specific proteases, CDK: Cyclin-dependent kinase, CO2: Carbon dioxide, CST: Cell signaling technologies, DISC: Death-inducing signaling complex, DMSO: Dimethyl sulfoxide, DNA: Deoxyribonucleic acid, DR4: Death receptor 4, DR5: Death receptor 5, E1a: Adenovirus early region 1A, ECL: Enhanced chemiluminescence, EDTA: Ethylenediaminetetraacetic acid, ELISA: Enzyme-linked immunosorbent assay, etc.\n'
p3015
sg4
(lp3016
(dp3017
g7
I198
sg8
VP55957
p3018
sg10
I3
sg11
VBID
p3019
sg13
I1
sa(dp3020
g7
I115
sg8
VP04207
p3021
sg10
I10
sg11
VB-Cell CLL
p3022
sg13
I2
sa(dp3023
g7
I241
sg8
g127
sg10
I3
sg11
VBIR
p3024
sg13
I1
sa(dp3025
g7
I554
sg8
g127
sg10
I16
sg11
VDeath receptor 5
p3026
sg13
I3
sa(dp3027
g7
I180
sg8
VP10415
p3028
sg10
I16
sg11
VBcl-2 homology 3
p3029
sg13
I3
sa(dp3030
g7
I297
sg8
VP39880
p3031
sg10
I8
sg11
VCaspases
p3032
sg13
I1
sa(dp3033
g7
I549
sg8
VP20039
p3034
sg10
I3
sg11
VDR5
p3035
sg13
I1
sa(dp3036
g7
I577
sg8
g127
sg10
I26
sg11
VAdenovirus early region 1A
p3037
sg13
I4
sa(dp3038
g7
I531
sg8
g127
sg10
I16
sg11
VDeath receptor 4
p3039
sg13
I3
sa(dp3040
g7
I526
sg8
g127
sg10
I3
sg11
VDR4
p3041
sg13
I1
sa(dp3042
g7
I138
sg8
g127
sg10
I6
sg11
VBcl-xL
p3043
sg13
I1
sa(dp3044
g7
I108
sg8
VP10415
p3045
sg10
I5
sg11
VBCL-2
p3046
sg13
I1
sa(dp3047
g7
I352
sg8
VP49336
p3048
sg10
I23
sg11
VCyclin-dependent kinase
p3049
sg13
I2
sa(dp3050
g7
I347
sg8
VP24941
p3051
sg10
I3
sg11
VCDK
p3052
sg13
I1
sasg17
(lp3053
(dp3054
g7
I115
sg20
VC0023434
p3055
sg10
I10
sg11
VB-Cell CLL
p3056
sg13
I2
sa(dp3057
g7
I126
sg20
VC0024299
p3058
sg10
I8
sg11
VLymphoma
p3059
sg13
I1
sa(dp3060
g7
I577
sg20
VC0001486
p3061
sg10
I10
sg11
VAdenovirus
p3062
sg13
I1
sa(dp3063
g7
I146
sg20
VC0079731
p3064
sg10
I15
sg11
VB-cell lymphoma
p3065
sg13
I2
sasa(dp3066
g2
S'We proposed that stuttering candidate genes, DRD2 and SLC6A3, might be associated with dyslexia.\n'
p3067
sg4
(lp3068
(dp3069
g7
I54
sg8
g127
sg10
I6
sg11
VSLC6A3
p3070
sg13
I1
sa(dp3071
g7
I45
sg8
VP14416
p3072
sg10
I4
sg11
VDRD2
p3073
sg13
I1
sasg17
(lp3074
(dp3075
g7
I17
sg20
VC0038506
p3076
sg10
I10
sg11
Vstuttering
p3077
sg13
I1
sa(dp3078
g7
I87
sg20
VC0476254
p3079
sg10
I8
sg11
Vdyslexia
p3080
sg13
I1
sasa(dp3081
g2
S'To explore the correlations of dopamine transporter gene (DAT) and dopamine D(2) receptor gene (DRD2) to stuttering.\n'
p3082
sg4
(lp3083
(dp3084
g7
I58
sg8
g127
sg10
I3
sg11
VDAT
p3085
sg13
I1
sa(dp3086
g7
I67
sg8
g127
sg10
I27
sg11
Vdopamine D(2) receptor gene
p3087
sg13
I4
sa(dp3088
g7
I31
sg8
g127
sg10
I25
sg11
Vdopamine transporter gene
p3089
sg13
I3
sa(dp3090
g7
I96
sg8
VP14416
p3091
sg10
I4
sg11
VDRD2
p3092
sg13
I1
sasg17
(lp3093
(dp3094
g7
I105
sg20
VC0038506
p3095
sg10
I10
sg11
Vstuttering
p3096
sg13
I1
sasa(dp3097
g2
S'Since preeclampsia is not known to be associated with an altered water flux to the fetus we propose that AQP9 might not have a key role in water transport in human placenta, but a function in the energy metabolism or the urea uptake and elimination across the placenta.\n'
p3098
sg4
(lp3099
(dp3100
g7
I105
sg8
g127
sg10
I4
sg11
VAQP9
p3101
sg13
I1
sasg17
(lp3102
(dp3103
g7
I6
sg20
VC0032914
p3104
sg10
I12
sg11
Vpreeclampsia
p3105
sg13
I1
sasa(dp3106
g2
S'These results suggest that CFTR expression decreases in preeclampsia and may thus be implicated in the regulation of AQP9 activity.\n'
p3107
sg4
(lp3108
(dp3109
g7
I27
sg8
VP13569
p3110
sg10
I4
sg11
VCFTR
p3111
sg13
I1
sa(dp3112
g7
I117
sg8
g127
sg10
I4
sg11
VAQP9
p3113
sg13
I1
sasg17
(lp3114
(dp3115
g7
I56
sg20
VC0032914
p3116
sg10
I12
sg11
Vpreeclampsia
p3117
sg13
I1
sasa(dp3118
g2
S'Much further work is needed to define whether the overexpression of AQP9 plays a direct role either in the pathogenesis or in the adaptative response of preeclampsia.\n'
p3119
sg4
(lp3120
(dp3121
g7
I68
sg8
g127
sg10
I4
sg11
VAQP9
p3122
sg13
I1
sasg17
(lp3123
(dp3124
g7
I107
sg20
VC0699748
p3125
sg10
I12
sg11
Vpathogenesis
p3126
sg13
I1
sa(dp3127
g7
I153
sg20
VC0032914
p3128
sg10
I12
sg11
Vpreeclampsia
p3129
sg13
I1
sasa(dp3130
g2
S'Specific cross-reacting autoimmunity against recoverin or collapsin response mediator protein (CRMP)-5 is known to cause cancer-associated retinopathy or paraneoplastic optic neuropathy, respectively.\n'
p3131
sg4
(lp3132
(dp3133
g7
I58
sg8
g127
sg10
I44
sg11
Vcollapsin response mediator protein (CRMP)-5
p3134
sg13
I5
sasg17
(lp3135
(dp3136
g7
I24
sg20
VC0004368
p3137
sg10
I12
sg11
Vautoimmunity
p3138
sg13
I1
sa(dp3139
g7
I154
sg20
VC1626206
p3140
sg10
I31
sg11
Vparaneoplastic optic neuropathy
p3141
sg13
I3
sa(dp3142
g7
I121
sg20
VC0730307
p3143
sg10
I29
sg11
Vcancer-associated retinopathy
p3144
sg13
I2
sasa(dp3145
g2
S'Autoantibodies have defined two paraneoplastic visual disorders related to small-cell lung carcinoma: retinopathy ("CAR"-IgG [23kDa, recoverin]) and optic neuritis collapsin response-mediated protein 5 (CRMP-5-IgG [62kDa]).\n'
p3146
sg4
(lp3147
(dp3148
g7
I203
sg8
g127
sg10
I10
sg11
VCRMP-5-IgG
p3149
sg13
I1
sasg17
(lp3150
(dp3151
g7
I102
sg20
VC0035309
p3152
sg10
I11
sg11
Vretinopathy
p3153
sg13
I1
sa(dp3154
g7
I86
sg20
VC0684249
p3155
sg10
I14
sg11
Vlung carcinoma
p3156
sg13
I2
sa(dp3157
g7
I116
sg20
VC2607929
p3158
sg10
I3
sg11
VCAR
p3159
sg13
I1
sa(dp3160
g7
I149
sg20
VC0029134
p3161
sg10
I14
sg11
Voptic neuritis
p3162
sg13
I2
sasa(dp3163
g2
S'Pathogenic relevance of these autoantibodies has been demonstrated only for antibodies against (1) voltage gated calcium channels (VGCC) in Lambert-Eaton myasthenic syndrome, (2) voltage gated potassium channels (VGKC) in neuromyotonia, and (3) recoverin in cancer associated retinopathy.\n'
p3164
sg4
(lp3165
sg17
(lp3166
(dp3167
g7
I222
sg20
VC0242287
p3168
sg10
I13
sg11
Vneuromyotonia
p3169
sg13
I1
sa(dp3170
g7
I140
sg20
VC0022972
p3171
sg10
I33
sg11
VLambert-Eaton myasthenic syndrome
p3172
sg13
I3
sa(dp3173
g7
I258
sg20
VC0730307
p3174
sg10
I29
sg11
Vcancer associated retinopathy
p3175
sg13
I3
sasa(dp3176
g2
S'A number of treatments were shown to be cost-effective, e.g., statin for secondary prevention of cardiovascular disease, aspirin for primary prevention of cardiovascular disease, DOAC for high-risk atrial fibrillation, beta blockers, ACE inhibitors, and ARB for heart failure, sildenafil and bosentan for pulmonary hypertension, CABG for multi-vessel coronary disease, ICD for ventricular tachycardia, and CRT for heart failure with low ejection fraction, while others were not cost-effective, e.g., epoprostenol for pulmonary hypertension and LVAD for end-stage heart failure.\n'
p3177
sg4
(lp3178
(dp3179
g7
I234
sg8
VP12821
p3180
sg10
I3
sg11
VACE
p3181
sg13
I1
sasg17
(lp3182
(dp3183
g7
I305
sg20
VC0020542
p3184
sg10
I22
sg11
Vpulmonary hypertension
p3185
sg13
I2
sa(dp3186
g7
I254
sg20
VC2678493
p3187
sg10
I3
sg11
VARB
p3188
sg13
I1
sa(dp3189
g7
I262
sg20
VC0018802
p3190
sg10
I13
sg11
Vheart failure
p3191
sg13
I2
sa(dp3192
g7
I377
sg20
VC0042514
p3193
sg10
I23
sg11
Vventricular tachycardia
p3194
sg13
I2
sa(dp3195
g7
I198
sg20
VC0004238
p3196
sg10
I19
sg11
Vatrial fibrillation
p3197
sg13
I2
sa(dp3198
g7
I262
sg20
VC0018802
p3199
sg10
I13
sg11
Vheart failure
p3200
sg13
I2
sa(dp3201
g7
I351
sg20
VC0010068
p3202
sg10
I16
sg11
Vcoronary disease
p3203
sg13
I2
sa(dp3204
g7
I97
sg20
VC0007222
p3205
sg10
I22
sg11
Vcardiovascular disease
p3206
sg13
I2
sa(dp3207
g7
I305
sg20
VC0020542
p3208
sg10
I22
sg11
Vpulmonary hypertension
p3209
sg13
I2
sa(dp3210
g7
I97
sg20
VC0007222
p3211
sg10
I22
sg11
Vcardiovascular disease
p3212
sg13
I2
sa(dp3213
g7
I262
sg20
VC0018802
p3214
sg10
I13
sg11
Vheart failure
p3215
sg13
I2
sa(dp3216
g7
I369
sg20
VC0020725
p3217
sg10
I3
sg11
VICD
p3218
sg13
I1
sasa(dp3219
g2
S'Among those with ischemic stroke (n = 108 699), Chinese patients were less likely than other Canadian patients to fill prescriptions for the combination of ACE inhibitor, diuretic and statin (adjusted odds ratio [OR] 0.64 [95% confidence interval (CI) 0.55-0.74]) and, in those with atrial fibrillation, for warfarin (adjusted OR 0.75 [95% CI 0.59-0.95]).\n'
p3220
sg4
(lp3221
(dp3222
g7
I156
sg8
VP12821
p3223
sg10
I3
sg11
VACE
p3224
sg13
I1
sasg17
(lp3225
(dp3226
g7
I283
sg20
VC0004238
p3227
sg10
I19
sg11
Vatrial fibrillation
p3228
sg13
I2
sa(dp3229
g7
I17
sg20
VC3272363
p3230
sg10
I15
sg11
Vischemic stroke
p3231
sg13
I2
sasa(dp3232
g2
S'Significant differences in the local conformations and kinetic properties of heart and lung ACEs demonstrate tissue specificity of ACE and provide a structural base for the development of mAbs able to distinguish heart and lung ACEs as a potential blood test for predicting atrial fibrillation risk.\n'
p3233
sg4
(lp3234
(dp3235
g7
I87
sg8
VP12821
p3236
sg10
I9
sg11
Vlung ACEs
p3237
sg13
I2
sa(dp3238
g7
I87
sg8
VP12821
p3239
sg10
I9
sg11
Vlung ACEs
p3240
sg13
I2
sa(dp3241
g7
I92
sg8
VP12821
p3242
sg10
I3
sg11
VACE
p3243
sg13
I1
sasg17
(lp3244
(dp3245
g7
I274
sg20
VC0004238
p3246
sg10
I19
sg11
Vatrial fibrillation
p3247
sg13
I2
sasa(dp3248
g2
S'Split ends (SPEN) is an ERAlfa corepressor that we have identified as a tumor suppressor protein in ERAlfa-positive breast cancer cells whose hormone-independent roles in breast cancer have never been explored.\n'
p3249
sg4
(lp3250
sg17
(lp3251
(dp3252
g7
I72
sg20
VC0027651
p3253
sg10
I5
sg11
Vtumor
p3254
sg13
I1
sa(dp3255
g7
I116
sg20
VC0678222
p3256
sg10
I13
sg11
Vbreast cancer
p3257
sg13
I2
sa(dp3258
g7
I12
sg20
VC0860451
p3259
sg10
I4
sg11
VSPEN
p3260
sg13
I1
sa(dp3261
g7
I0
sg20
VC0860451
p3262
sg10
I10
sg11
VSplit ends
p3263
sg13
I2
sa(dp3264
g7
I116
sg20
VC0678222
p3265
sg10
I13
sg11
Vbreast cancer
p3266
sg13
I2
sasa(dp3267
g2
S'We determined the hormone-independent transcriptional program regulated by the ERAlfa cofactor SPEN in breast cancer using DNA microarrays.\n'
p3268
sg4
(lp3269
(dp3270
g7
I79
sg8
g127
sg10
I20
sg11
VERAlfa cofactor SPEN
p3271
sg13
I3
sasg17
(lp3272
(dp3273
g7
I103
sg20
VC0678222
p3274
sg10
I13
sg11
Vbreast cancer
p3275
sg13
I2
sasa(dp3276
g2
S'The biological functions regulated by SPEN independently of hormones were studied in vitro in ERAlfa-positive and ERAlfa-negative breast cancer cells.\n'
p3277
sg4
(lp3278
sg17
(lp3279
(dp3280
g7
I130
sg20
VC0678222
p3281
sg10
I13
sg11
Vbreast cancer
p3282
sg13
I2
sasa(dp3283
g2
S'Finally, we examined the clinical relevance of SPEN expression in cohorts of breast cancer samples with outcome data.\n'
p3284
sg4
(lp3285
sg17
(lp3286
(dp3287
g7
I77
sg20
VC0678222
p3288
sg10
I13
sg11
Vbreast cancer
p3289
sg13
I2
sasa(dp3290
g2
S'Finally, we found that high SPEN RNA levels were predictive of early metastasis in two independent cohorts of 77 (HR 2.25, P = 0.03) and 170 (HR = 2.23, P = 0.004) patients with ERAlfa-negative breast cancer.\n'
p3291
sg4
(lp3292
sg17
(lp3293
(dp3294
g7
I69
sg20
VC0027627
p3295
sg10
I10
sg11
Vmetastasis
p3296
sg13
I1
sa(dp3297
g7
I194
sg20
VC0678222
p3298
sg10
I13
sg11
Vbreast cancer
p3299
sg13
I2
sasa(dp3300
g2
S'Together, our data demonstrate a role for SPEN in the regulation of primary cilia formation and cell migration in breast cancer cells, which may collectively explain why its expression is associated with time to metastasis in cohorts of patients with ERAlfa-negative breast cancers.\n'
p3301
sg4
(lp3302
(dp3303
g7
I42
sg8
g127
sg10
I4
sg11
VSPEN
p3304
sg13
I1
sasg17
(lp3305
(dp3306
g7
I267
sg20
VC0006142
p3307
sg10
I14
sg11
Vbreast cancers
p3308
sg13
I2
sa(dp3309
g7
I114
sg20
VC0006142
p3310
sg10
I13
sg11
Vbreast cancer
p3311
sg13
I2
sa(dp3312
g7
I212
sg20
VC0027627
p3313
sg10
I10
sg11
Vmetastasis
p3314
sg13
I1
sasa(dp3315
g2
S'BACKGROUND The reciprocal translocation t(1;22)(p13;q13) involving the RBM15 and MKL1 genes is an uncommon abnormality that occurs in a subset of acute myeloid leukemia with megakaryocytic differentiation (AMKL).\n'
p3316
sg4
(lp3317
(dp3318
g7
I81
sg8
g127
sg10
I10
sg11
VMKL1 genes
p3319
sg13
I2
sa(dp3320
g7
I48
sg8
g127
sg10
I3
sg11
Vp13
p3321
sg13
I1
sasg17
(lp3322
(dp3323
g7
I15
sg20
VC0333714
p3324
sg10
I24
sg11
Vreciprocal translocation
p3325
sg13
I2
sa(dp3326
g7
I146
sg20
VC0023467
p3327
sg10
I22
sg11
Vacute myeloid leukemia
p3328
sg13
I3
sasa(dp3329
g2
S'Three genes with mutations were known cancer associated genes (BAP1, ARHGAP35 and SPEN), but they were mutated in a single sample each, and were missense variants with uncertain functional effects.\n'
p3330
sg4
(lp3331
(dp3332
g7
I63
sg8
g127
sg10
I4
sg11
VBAP1
p3333
sg13
I1
sa(dp3334
g7
I82
sg8
g127
sg10
I4
sg11
VSPEN
p3335
sg13
I1
sa(dp3336
g7
I69
sg8
g127
sg10
I8
sg11
VARHGAP35
p3337
sg13
I1
sasg17
(lp3338
(dp3339
g7
I38
sg20
VC0006826
p3340
sg10
I6
sg11
Vcancer
p3341
sg13
I1
sasa(dp3342
g2
S'Here, we report that an antisense RNA, AS-RBM15, is transcribed in the opposite direction within exon 1 of RBM15 RBM15 is a regulator of megakaryocyte (MK) differentiation and is also involved in a chromosome translocation t(1;22) in acute megakaryocytic leukemia.\n'
p3343
sg4
(lp3344
sg17
(lp3345
(dp3346
g7
I198
sg20
VC0040715
p3347
sg10
I24
sg11
Vchromosome translocation
p3348
sg13
I2
sa(dp3349
g7
I234
sg20
VC0023462
p3350
sg10
I29
sg11
Vacute megakaryocytic leukemia
p3351
sg13
I3
sasa(dp3352
g2
S'Tremor was the sole initial manifestation in some individuals with ANO3 mutations, leading to misdiagnosis as essential tremor.\n'
p3353
sg4
(lp3354
(dp3355
g7
I67
sg8
g127
sg10
I4
sg11
VANO3
p3356
sg13
I1
sasg17
(lp3357
(dp3358
g7
I0
sg20
VC0040822
p3359
sg10
I6
sg11
VTremor
p3360
sg13
I1
sa(dp3361
g7
I110
sg20
VC0270736
p3362
sg10
I16
sg11
Vessential tremor
p3363
sg13
I2
sasa(dp3364
g2
S'After a series of molecular docking and molecular dynamics simulation were performed, we concluded that SAH-M1356 ligand is the most potential SAH-based compound to inhibit NS5 methyltransferase enzyme for treating dengue fever.\n'
p3365
sg4
(lp3366
(dp3367
g7
I173
sg8
VP04049
p3368
sg10
I28
sg11
VNS5 methyltransferase enzyme
p3369
sg13
I3
sasg17
(lp3370
(dp3371
g7
I215
sg20
VC0011311
p3372
sg10
I12
sg11
Vdengue fever
p3373
sg13
I2
sa(dp3374
g7
I173
sg20
VC1969057
p3375
sg10
I3
sg11
VNS5
p3376
sg13
I1
sasa(dp3377
g2
S'Dengue virus NS5 also binds SLAs from different serotypes, indicating that NS5 recognizes the overall shape of SLA as well as specific nucleotides.IMPORTANCE Dengue virus is an important human pathogen responsible for dengue hemorrhagic fever, whose global incidence has increased dramatically over the last several decades.\n'
p3378
sg4
(lp3379
(dp3380
g7
I13
sg8
VP04049
p3381
sg10
I3
sg11
VNS5
p3382
sg13
I1
sa(dp3383
g7
I28
sg8
g127
sg10
I4
sg11
VSLAs
p3384
sg13
I1
sa(dp3385
g7
I13
sg8
VP04049
p3386
sg10
I3
sg11
VNS5
p3387
sg13
I1
sa(dp3388
g7
I28
sg8
g127
sg10
I3
sg11
VSLA
p3389
sg13
I1
sasg17
(lp3390
(dp3391
g7
I13
sg20
VC1969057
p3392
sg10
I3
sg11
VNS5
p3393
sg13
I1
sa(dp3394
g7
I0
sg20
VC0011311
p3395
sg10
I6
sg11
VDengue
p3396
sg13
I1
sa(dp3397
g7
I13
sg20
VC1969057
p3398
sg10
I3
sg11
VNS5
p3399
sg13
I1
sa(dp3400
g7
I218
sg20
VC0019100
p3401
sg10
I24
sg11
Vdengue hemorrhagic fever
p3402
sg13
I3
sa(dp3403
g7
I0
sg20
VC0011311
p3404
sg10
I6
sg11
VDengue
p3405
sg13
I1
sasa(dp3406
g2
S'This NS5 ELISA can also be used to distinguish between primary and secondary dengue fever on the basis of IgM/IgG ratios.\n'
p3407
sg4
(lp3408
(dp3409
g7
I5
sg8
VP04049
p3410
sg10
I3
sg11
VNS5
p3411
sg13
I1
sa(dp3412
g7
I106
sg8
VP29965
p3413
sg10
I3
sg11
VIgM
p3414
sg13
I1
sasg17
(lp3415
(dp3416
g7
I5
sg20
VC1969057
p3417
sg10
I3
sg11
VNS5
p3418
sg13
I1
sa(dp3419
g7
I77
sg20
VC0011311
p3420
sg10
I12
sg11
Vdengue fever
p3421
sg13
I2
sasa(dp3422
g2
S'Druggable pockets in Dengue Fever Virus and West Nile Virus NS3 and NS5 are retained in predicted Zika virus structures.\n'
p3423
sg4
(lp3424
(dp3425
g7
I60
sg8
VP01116
p3426
sg10
I3
sg11
VNS3
p3427
sg13
I1
sa(dp3428
g7
I68
sg8
VP04049
p3429
sg10
I3
sg11
VNS5
p3430
sg13
I1
sasg17
(lp3431
(dp3432
g7
I21
sg20
VC0011311
p3433
sg10
I12
sg11
VDengue Fever
p3434
sg13
I2
sa(dp3435
g7
I60
sg20
VC1860991
p3436
sg10
I3
sg11
VNS3
p3437
sg13
I1
sa(dp3438
g7
I68
sg20
VC1969057
p3439
sg10
I3
sg11
VNS5
p3440
sg13
I1
sa(dp3441
g7
I44
sg20
VC1096184
p3442
sg10
I15
sg11
VWest Nile Virus
p3443
sg13
I3
sasa(dp3444
g2
S'In this study we isolated one Dengue virus 1 serotype, named BR/Alfenas/2012, from a patient with dengue hemorrhagic fever in Alfenas, South Minas Gerais, Brazil and molecular identification was performed based on the analysis of NS5 gene.\n'
p3445
sg4
(lp3446
(dp3447
g7
I230
sg8
VP04049
p3448
sg10
I8
sg11
VNS5 gene
p3449
sg13
I2
sasg17
(lp3450
(dp3451
g7
I98
sg20
VC0019100
p3452
sg10
I24
sg11
Vdengue hemorrhagic fever
p3453
sg13
I3
sa(dp3454
g7
I230
sg20
VC1969057
p3455
sg10
I3
sg11
VNS5
p3456
sg13
I1
sa(dp3457
g7
I30
sg20
VC0011311
p3458
sg10
I6
sg11
VDengue
p3459
sg13
I1
sasa(dp3460
g2
S'The aim of this study was to investigate MC populations expressing tryptase and c-kit in lip squamous cell carcinoma (lip SCC) (n=37), actinic cheilitis (AC) (n=15) and normal lip mucosa (control) (n=6), as well as their relationship with microscopic parameters (collagen degeneration, elastin changes, angiogenesis and proliferative index).\n'
p3461
sg4
(lp3462
(dp3463
g7
I80
sg8
VP10721
p3464
sg10
I5
sg11
Vc-kit
p3465
sg13
I1
sa(dp3466
g7
I286
sg8
VP49918
p3467
sg10
I7
sg11
Velastin
p3468
sg13
I1
sasg17
(lp3469
(dp3470
g7
I272
sg20
VC0011164
p3471
sg10
I12
sg11
Vdegeneration
p3472
sg13
I1
sa(dp3473
g7
I320
sg20
VC0334094
p3474
sg10
I13
sg11
Vproliferative
p3475
sg13
I1
sa(dp3476
g7
I89
sg20
VC0280302
p3477
sg10
I27
sg11
Vlip squamous cell carcinoma
p3478
sg13
I4
sa(dp3479
g7
I118
sg20
VC0280302
p3480
sg10
I7
sg11
Vlip SCC
p3481
sg13
I2
sa(dp3482
g7
I89
sg20
VC0264511
p3483
sg10
I3
sg11
Vlip
p3484
sg13
I1
sa(dp3485
g7
I135
sg20
VC0267026
p3486
sg10
I17
sg11
Vactinic cheilitis
p3487
sg13
I2
sa(dp3488
g7
I154
sg20
VC0267026
p3489
sg10
I2
sg11
VAC
p3490
sg13
I1
sasa(dp3491
g2
S'In control and gingivitis patients, leukocyte elastase and cathepsin G had high comparable elastin solubilizing activities.\n'
p3492
sg4
(lp3493
(dp3494
g7
I59
sg8
VP08311
p3495
sg10
I11
sg11
Vcathepsin G
p3496
sg13
I2
sa(dp3497
g7
I36
sg8
VP08246
p3498
sg10
I18
sg11
Vleukocyte elastase
p3499
sg13
I2
sa(dp3500
g7
I75
sg8
VP49918
p3501
sg10
I23
sg11
Vhigh comparable elastin
p3502
sg13
I3
sasg17
(lp3503
(dp3504
g7
I15
sg20
VC0017574
p3505
sg10
I10
sg11
Vgingivitis
p3506
sg13
I1
sasa(dp3507
g2
S'With young and aged periodontitis patients, the two serine proteinases had weak elastin solubilizing activities.\n'
p3508
sg4
(lp3509
(dp3510
g7
I75
sg8
VP49918
p3511
sg10
I12
sg11
Vweak elastin
p3512
sg13
I2
sa(dp3513
g7
I52
sg8
VP30740
p3514
sg10
I18
sg11
Vserine proteinases
p3515
sg13
I2
sasg17
(lp3516
(dp3517
g7
I20
sg20
VC0031099
p3518
sg10
I13
sg11
Vperiodontitis
p3519
sg13
I1
sasa(dp3520
g2
S'On the other hand, we believe that tumor depth of invasion (&gt;=4 mm), POI, and VEGF-C expression all need to be considered in the preoperative and postoperative planning stages for tongue cancer treatment.\n'
p3521
sg4
(lp3522
(dp3523
g7
I81
sg8
VP49767
p3524
sg10
I6
sg11
VVEGF-C
p3525
sg13
I1
sasg17
(lp3526
(dp3527
g7
I183
sg20
VC0558353
p3528
sg10
I13
sg11
Vtongue cancer
p3529
sg13
I2
sa(dp3530
g7
I35
sg20
VC0027651
p3531
sg10
I5
sg11
Vtumor
p3532
sg13
I1
sa(dp3533
g7
I50
sg20
VC2699153
p3534
sg10
I8
sg11
Vinvasion
p3535
sg13
I1
sasa(dp3536
g2
S'This study aimed to determine the relationship of cyclooxygenase-2 (COX-2) and vascular endothelial growth factor-c (VEGF-C) expression with lymphangiogenesis, lymph node metastasis (LNM), and other clinicopathologic features in human oral tongue cancers.\n'
p3537
sg4
(lp3538
(dp3539
g7
I79
sg8
VP49767
p3540
sg10
I36
sg11
Vvascular endothelial growth factor-c
p3541
sg13
I4
sa(dp3542
g7
I68
sg8
VP35354
p3543
sg10
I5
sg11
VCOX-2
p3544
sg13
I1
sa(dp3545
g7
I50
sg8
VP35354
p3546
sg10
I16
sg11
Vcyclooxygenase-2
p3547
sg13
I1
sa(dp3548
g7
I117
sg8
VP49767
p3549
sg10
I6
sg11
VVEGF-C
p3550
sg13
I1
sasg17
(lp3551
(dp3552
g7
I160
sg20
VC0686619
p3553
sg10
I21
sg11
Vlymph node metastasis
p3554
sg13
I3
sa(dp3555
g7
I183
sg20
VC0686619
p3556
sg10
I3
sg11
VLNM
p3557
sg13
I1
sa(dp3558
g7
I240
sg20
VC0153349
p3559
sg10
I14
sg11
Vtongue cancers
p3560
sg13
I2
sasa(dp3561
g2
S'Forty tongue cancer specimens were immunohistochemically examined for COX-2 and VEGF-C expression and for lymphatic vessel density (LVD).\n'
p3562
sg4
(lp3563
(dp3564
g7
I70
sg8
VP35354
p3565
sg10
I5
sg11
VCOX-2
p3566
sg13
I1
sa(dp3567
g7
I80
sg8
VP49767
p3568
sg10
I6
sg11
VVEGF-C
p3569
sg13
I1
sasg17
(lp3570
(dp3571
g7
I6
sg20
VC0558353
p3572
sg10
I13
sg11
Vtongue cancer
p3573
sg13
I2
sasa(dp3574
g2
S'Our results suggest that examination of immunohistochemical expression of COX-2 and VEGF-C predicts LNM and survival in human oral tongue cancers.\n'
p3575
sg4
(lp3576
(dp3577
g7
I74
sg8
VP35354
p3578
sg10
I5
sg11
VCOX-2
p3579
sg13
I1
sa(dp3580
g7
I84
sg8
VP49767
p3581
sg10
I6
sg11
VVEGF-C
p3582
sg13
I1
sasg17
(lp3583
(dp3584
g7
I131
sg20
VC0153349
p3585
sg10
I14
sg11
Vtongue cancers
p3586
sg13
I2
sasa(dp3587
g2
S'The use of a therapeutic approach which blocks lymphangiogenic factors, such as VEGF-C and VEGF-D, may be beneficial in suppressing the lymphatic spread of tongue cancer with intense intranodal lymphangiogenesis.\n'
p3588
sg4
(lp3589
(dp3590
g7
I80
sg8
VP49767
p3591
sg10
I6
sg11
VVEGF-C
p3592
sg13
I1
sa(dp3593
g7
I91
sg8
g127
sg10
I6
sg11
VVEGF-D
p3594
sg13
I1
sasg17
(lp3595
(dp3596
g7
I156
sg20
VC0558353
p3597
sg10
I13
sg11
Vtongue cancer
p3598
sg13
I2
sasa(dp3599
g2
S'A short hairpin RNA (shRNA)method was used to knock down COX-2 gene expression and investigate the relationship between COX-2 and VEGF-C, and the role of the COX-2 gene for proliferation and invasion was also investigated in the tongue cancer cell Tca8113.\n'
p3600
sg4
(lp3601
(dp3602
g7
I57
sg8
VP35354
p3603
sg10
I5
sg11
VCOX-2
p3604
sg13
I1
sa(dp3605
g7
I130
sg8
VP49767
p3606
sg10
I6
sg11
VVEGF-C
p3607
sg13
I1
sa(dp3608
g7
I57
sg8
VP35354
p3609
sg10
I10
sg11
VCOX-2 gene
p3610
sg13
I2
sa(dp3611
g7
I57
sg8
VP35354
p3612
sg10
I10
sg11
VCOX-2 gene
p3613
sg13
I2
sasg17
(lp3614
(dp3615
g7
I173
sg20
VC0334094
p3616
sg10
I13
sg11
Vproliferation
p3617
sg13
I1
sa(dp3618
g7
I191
sg20
VC2699153
p3619
sg10
I8
sg11
Vinvasion
p3620
sg13
I1
sa(dp3621
g7
I229
sg20
VC0558353
p3622
sg10
I13
sg11
Vtongue cancer
p3623
sg13
I2
sasa(dp3624
g2
S'VEGF, VEGF-C, VEGF-D and MIA expression levels of metastatic tongue cancer HSC-3 cells were higher than those with no metastatic HSC-4 cells, and VEGF, VEGF-C and VEGF-D expression levels were decreased by MIA siRNA treatment in both cells.\n'
p3625
sg4
(lp3626
(dp3627
g7
I14
sg8
g127
sg10
I6
sg11
VVEGF-D
p3628
sg13
I1
sa(dp3629
g7
I6
sg8
VP49767
p3630
sg10
I6
sg11
VVEGF-C
p3631
sg13
I1
sa(dp3632
g7
I206
sg8
g127
sg10
I9
sg11
VMIA siRNA
p3633
sg13
I2
sa(dp3634
g7
I25
sg8
g127
sg10
I3
sg11
VMIA
p3635
sg13
I1
sa(dp3636
g7
I14
sg8
g127
sg10
I6
sg11
VVEGF-D
p3637
sg13
I1
sa(dp3638
g7
I6
sg8
VP49767
p3639
sg10
I6
sg11
VVEGF-C
p3640
sg13
I1
sasg17
(lp3641
(dp3642
g7
I61
sg20
VC0558353
p3643
sg10
I13
sg11
Vtongue cancer
p3644
sg13
I2
sasa(dp3645
g2
S'Here, we identify SH-SY5Y neuroblastoma-derived exosomes comprised of major histocompatibility complex II (MHC II), Hsp90 and flotillin-1.\n'
p3646
sg4
(lp3647
(dp3648
g7
I126
sg8
g127
sg10
I11
sg11
Vflotillin-1
p3649
sg13
I1
sa(dp3650
g7
I107
sg8
VP13747
p3651
sg10
I6
sg11
VMHC II
p3652
sg13
I2
sa(dp3653
g7
I70
sg8
VP18464
p3654
sg10
I35
sg11
Vmajor histocompatibility complex II
p3655
sg13
I4
sa(dp3656
g7
I116
sg8
VP07900
p3657
sg10
I5
sg11
VHsp90
p3658
sg13
I1
sasg17
(lp3659
(dp3660
g7
I26
sg20
VC0027819
p3661
sg10
I13
sg11
Vneuroblastoma
p3662
sg13
I1
sasa(dp3663
g2
S"We investigated the associations between genetic polymorphisms in aquaporin 4 (AQP4, rs2075575), aquaporin 5 (AQP5, rs3736309), and estrogen receptor Alfa (ERAlfa1, rs2234693; ERAlfa2, rs9340799) and susceptibility to Meniere's disease or SSNHL.\n"
p3664
sg4
(lp3665
(dp3666
g7
I79
sg8
VP55087
p3667
sg10
I4
sg11
VAQP4
p3668
sg13
I1
sa(dp3669
g7
I132
sg8
VP03372
p3670
sg10
I22
sg11
Vestrogen receptor Alfa
p3671
sg13
I3
sa(dp3672
g7
I66
sg8
VP55087
p3673
sg10
I11
sg11
Vaquaporin 4
p3674
sg13
I2
sa(dp3675
g7
I110
sg8
VP55064
p3676
sg10
I4
sg11
VAQP5
p3677
sg13
I1
sa(dp3678
g7
I97
sg8
VP55064
p3679
sg10
I11
sg11
Vaquaporin 5
p3680
sg13
I2
sasg17
(lp3681
(dp3682
g7
I218
sg20
VC0025281
p3683
sg10
I17
sg11
VMeniere's disease
p3684
sg13
I2
sasa(dp3685
g2
S"The AQP5 polymorphism entailed no significant risk of SSNHL and the polymorphisms of AQP4, ERAlfa1, and ERAlfa2 entailed no significant risk of Meniere's disease or SSNHL in the additive genetic model, regardless of adjustments for age and sex.\n"
p3686
sg4
(lp3687
(dp3688
g7
I4
sg8
VP55064
p3689
sg10
I4
sg11
VAQP5
p3690
sg13
I1
sa(dp3691
g7
I85
sg8
VP55087
p3692
sg10
I4
sg11
VAQP4
p3693
sg13
I1
sasg17
(lp3694
(dp3695
g7
I144
sg20
VC0025281
p3696
sg10
I17
sg11
VMeniere's disease
p3697
sg13
I2
sasa(dp3698
g2
S"mRNA was extracted from the surgically acquired utricles from subjects with Meniere's disease and acoustic neuroma to conduct quantitative real-time reverse transcription with polymerase chain reaction for AQP1, AQP4, and AQP6.\n"
p3699
sg4
(lp3700
(dp3701
g7
I212
sg8
VP55087
p3702
sg10
I4
sg11
VAQP4
p3703
sg13
I1
sa(dp3704
g7
I206
sg8
VP29972
p3705
sg10
I4
sg11
VAQP1
p3706
sg13
I1
sa(dp3707
g7
I222
sg8
g127
sg10
I4
sg11
VAQP6
p3708
sg13
I1
sasg17
(lp3709
(dp3710
g7
I76
sg20
VC0025281
p3711
sg10
I17
sg11
VMeniere's disease
p3712
sg13
I2
sa(dp3713
g7
I98
sg20
VC0027859
p3714
sg10
I16
sg11
Vacoustic neuroma
p3715
sg13
I2
sasa(dp3716
g2
S"AQP4-IR localized to the epithelial basolateral supporting cells in Meniere's disease, acoustic neuroma, and autopsy.\n"
p3717
sg4
(lp3718
(dp3719
g7
I5
sg8
VP06213
p3720
sg10
I2
sg11
VIR
p3721
sg13
I1
sa(dp3722
g7
I0
sg8
VP55087
p3723
sg10
I4
sg11
VAQP4
p3724
sg13
I1
sasg17
(lp3725
(dp3726
g7
I68
sg20
VC0025281
p3727
sg10
I17
sg11
VMeniere's disease
p3728
sg13
I2
sa(dp3729
g7
I87
sg20
VC0027859
p3730
sg10
I16
sg11
Vacoustic neuroma
p3731
sg13
I2
sasa(dp3732
g2
S"In specimens from subjects with Meniere's disease, AQP4-IR was significantly decreased compared with autopsy and acoustic neuroma specimens.\n"
p3733
sg4
(lp3734
(dp3735
g7
I51
sg8
VP06213
p3736
sg10
I7
sg11
VAQP4-IR
p3737
sg13
I1
sasg17
(lp3738
(dp3739
g7
I32
sg20
VC0025281
p3740
sg10
I17
sg11
VMeniere's disease
p3741
sg13
I2
sa(dp3742
g7
I113
sg20
VC0027859
p3743
sg10
I16
sg11
Vacoustic neuroma
p3744
sg13
I2
sasa(dp3745
g2
S"Expression of AQP1, AQP4, or AQP6 mRNA did not differ in vestibular endorgans from patients with Meniere's disease.\n"
p3746
sg4
(lp3747
(dp3748
g7
I14
sg8
VP29972
p3749
sg10
I4
sg11
VAQP1
p3750
sg13
I1
sa(dp3751
g7
I29
sg8
g127
sg10
I9
sg11
VAQP6 mRNA
p3752
sg13
I2
sa(dp3753
g7
I20
sg8
VP55087
p3754
sg10
I4
sg11
VAQP4
p3755
sg13
I1
sasg17
(lp3756
(dp3757
g7
I97
sg20
VC0025281
p3758
sg10
I17
sg11
VMeniere's disease
p3759
sg13
I2
sasa(dp3760
g2
S"Changes in AQP4 (decreased) and AQP6 (increased) expression in Meniere's disease specimens suggest that the supporting cell might be a cellular target.\n"
p3761
sg4
(lp3762
(dp3763
g7
I32
sg8
g127
sg10
I4
sg11
VAQP6
p3764
sg13
I1
sa(dp3765
g7
I11
sg8
VP55087
p3766
sg10
I4
sg11
VAQP4
p3767
sg13
I1
sasg17
(lp3768
(dp3769
g7
I63
sg20
VC0025281
p3770
sg10
I17
sg11
VMeniere's disease
p3771
sg13
I2
sasa(dp3772
g2
S'Interleukin-13 (IL-13) has recently been reported to be a potential cytokine in the pathogenesis of minimal-change nephrotic syndrome (MCNS).\n'
p3773
sg4
(lp3774
(dp3775
g7
I16
sg8
VP35225
p3776
sg10
I5
sg11
VIL-13
p3777
sg13
I1
sa(dp3778
g7
I0
sg8
VP35225
p3779
sg10
I14
sg11
VInterleukin-13
p3780
sg13
I1
sasg17
(lp3781
(dp3782
g7
I84
sg20
VC0699748
p3783
sg10
I12
sg11
Vpathogenesis
p3784
sg13
I1
sa(dp3785
g7
I115
sg20
VC0027726
p3786
sg10
I18
sg11
Vnephrotic syndrome
p3787
sg13
I2
sasa(dp3788
g2
S'Our established interleukin-13 ( IL-13 ) overexpression rat model of minimal change-like nephropathy provided a platform to study the molecular signalling pathways in T-helper 2 (Th2) cytokine associated minimal change nephrotic syndrome.\n'
p3789
sg4
(lp3790
(dp3791
g7
I16
sg8
VP35225
p3792
sg10
I14
sg11
Vinterleukin-13
p3793
sg13
I1
sa(dp3794
g7
I33
sg8
VP35225
p3795
sg10
I5
sg11
VIL-13
p3796
sg13
I1
sasg17
(lp3797
(dp3798
g7
I204
sg20
VC1704321
p3799
sg10
I33
sg11
Vminimal change nephrotic syndrome
p3800
sg13
I4
sa(dp3801
g7
I89
sg20
VC0022658
p3802
sg10
I11
sg11
Vnephropathy
p3803
sg13
I1
sasa(dp3804
g2
S'Clinical and experimental data indicate roles for cytokines IL-13, TNFAlfa, circulating cardiotrophin-like cytokine factor 1 (member of the IL-6 family), circulating hemopexin, radical oxygen species, and the soluble urokinase-type plasminogen activator receptor (suPAR) in the development of nephrotic syndrome.\n'
p3805
sg4
(lp3806
(dp3807
g7
I140
sg8
VP05231
p3808
sg10
I11
sg11
VIL-6 family
p3809
sg13
I2
sa(dp3810
g7
I107
sg8
VP13236
p3811
sg10
I17
sg11
Vcytokine factor 1
p3812
sg13
I3
sa(dp3813
g7
I50
sg8
VP35225
p3814
sg10
I15
sg11
Vcytokines IL-13
p3815
sg13
I2
sa(dp3816
g7
I166
sg8
VP02790
p3817
sg10
I9
sg11
Vhemopexin
p3818
sg13
I1
sa(dp3819
g7
I264
sg8
VP00747
p3820
sg10
I5
sg11
VsuPAR
p3821
sg13
I1
sa(dp3822
g7
I209
sg8
VP00747
p3823
sg10
I53
sg11
Vsoluble urokinase-type plasminogen activator receptor
p3824
sg13
I5
sasg17
(lp3825
(dp3826
g7
I293
sg20
VC0027726
p3827
sg10
I18
sg11
Vnephrotic syndrome
p3828
sg13
I2
sasa(dp3829
g2
S'The aim of this study was to investigate whether pathologic changes in zonula occludens-1 (ZO-1) are induced by interleukin-13 (IL-13) in the experimental minimal-change nephrotic syndrome (MCNS) model and to determine whether montelukast, a leukotriene receptor antagonist, has an effect on ZO-1 restoration in cultured human podocytes.\n'
p3830
sg4
(lp3831
(dp3832
g7
I112
sg8
VP35225
p3833
sg10
I14
sg11
Vinterleukin-13
p3834
sg13
I1
sa(dp3835
g7
I128
sg8
VP35225
p3836
sg10
I5
sg11
VIL-13
p3837
sg13
I1
sa(dp3838
g7
I242
sg8
g127
sg10
I20
sg11
Vleukotriene receptor
p3839
sg13
I2
sasg17
(lp3840
(dp3841
g7
I170
sg20
VC0027726
p3842
sg10
I18
sg11
Vnephrotic syndrome
p3843
sg13
I2
sasa(dp3844
g2
S'Serum IgE and IL-13 levels were estimated in 40 idiopathic nephrotic syndrome and 16 controls.\n'
p3845
sg4
(lp3846
(dp3847
g7
I14
sg8
VP35225
p3848
sg10
I5
sg11
VIL-13
p3849
sg13
I1
sa(dp3850
g7
I0
sg8
VP01854
p3851
sg10
I9
sg11
VSerum IgE
p3852
sg13
I2
sasg17
(lp3853
(dp3854
g7
I6
sg20
VC0270850
p3855
sg10
I3
sg11
VIgE
p3856
sg13
I1
sa(dp3857
g7
I48
sg20
VC1704321
p3858
sg10
I29
sg11
Vidiopathic nephrotic syndrome
p3859
sg13
I3
sasa(dp3860
g2
S'Serum IgE and IL-13 levels were significantly increased in active nephrotic syndrome and its sub-groups as compared to controls and remission (p &lt; 0.001).\n'
p3861
sg4
(lp3862
(dp3863
g7
I14
sg8
VP35225
p3864
sg10
I5
sg11
VIL-13
p3865
sg13
I1
sa(dp3866
g7
I0
sg8
VP01854
p3867
sg10
I9
sg11
VSerum IgE
p3868
sg13
I2
sasg17
(lp3869
(dp3870
g7
I132
sg20
VC0687702
p3871
sg10
I9
sg11
Vremission
p3872
sg13
I1
sa(dp3873
g7
I66
sg20
VC0027726
p3874
sg10
I18
sg11
Vnephrotic syndrome
p3875
sg13
I2
sa(dp3876
g7
I6
sg20
VC0270850
p3877
sg10
I3
sg11
VIgE
p3878
sg13
I1
sasa(dp3879
g2
S'Thus, raised levels of IgE and IL-13 are found in nephrotic syndrome and could have a role in the pathogenesis of disease.\n'
p3880
sg4
(lp3881
(dp3882
g7
I23
sg8
VP01854
p3883
sg10
I3
sg11
VIgE
p3884
sg13
I1
sa(dp3885
g7
I31
sg8
VP35225
p3886
sg10
I5
sg11
VIL-13
p3887
sg13
I1
sasg17
(lp3888
(dp3889
g7
I23
sg20
VC0270850
p3890
sg10
I3
sg11
VIgE
p3891
sg13
I1
sa(dp3892
g7
I98
sg20
VC0699748
p3893
sg10
I12
sg11
Vpathogenesis
p3894
sg13
I1
sa(dp3895
g7
I50
sg20
VC0027726
p3896
sg10
I18
sg11
Vnephrotic syndrome
p3897
sg13
I2
sasa(dp3898
g2
S'Consistent with these associations, a role for interleukin-13 with minimal change disease has been proposed.\n'
p3899
sg4
(lp3900
(dp3901
g7
I47
sg8
VP35225
p3902
sg10
I14
sg11
Vinterleukin-13
p3903
sg13
I1
sasg17
(lp3904
(dp3905
g7
I67
sg20
VC1704320
p3906
sg10
I22
sg11
Vminimal change disease
p3907
sg13
I3
sasa(dp3908
g2
S'Furthermore, overexpression of the T(H)2 cytokine interleukin 13 in rats induces minimal change disease.\n'
p3909
sg4
(lp3910
(dp3911
g7
I50
sg8
VP35225
p3912
sg10
I14
sg11
Vinterleukin 13
p3913
sg13
I2
sa(dp3914
g7
I35
sg8
VP13236
p3915
sg10
I14
sg11
VT(H)2 cytokine
p3916
sg13
I2
sasg17
(lp3917
(dp3918
g7
I81
sg20
VC1704320
p3919
sg10
I22
sg11
Vminimal change disease
p3920
sg13
I3
sasa(dp3921
g2
S'We conducted a retrospective pharmacogenomic analysis of a prospectively collected community-based cohort of patients with estrogen receptor-positive breast cancer to test for associations between low-activity CYP2D6 genotype and disease outcome in 500 patients treated with adjuvant tamoxifen monotherapy and 500 who did not receive any systemic adjuvant therapy.\n'
p3922
sg4
(lp3923
(dp3924
g7
I210
sg8
VP10635
p3925
sg10
I6
sg11
VCYP2D6
p3926
sg13
I1
sasg17
(lp3927
(dp3928
g7
I150
sg20
VC0678222
p3929
sg10
I13
sg11
Vbreast cancer
p3930
sg13
I2
sasa(dp3931
g2
S'Tamoxifen, a hormonal therapy drug against estrogen receptor-positive breast cancer, can be metabolized by cytochrome P450 enzymes such as CYP3A4 and CYP3A5, and converted to N-desmethyltamoxifen, which is subsequently, metabolized by CYP2D6 and inverted to form 4-hydroxy-N-desmethyltamoxifen (endoxifen).\n'
p3932
sg4
(lp3933
(dp3934
g7
I43
sg8
VP03372
p3935
sg10
I17
sg11
Vestrogen receptor
p3936
sg13
I2
sa(dp3937
g7
I139
sg8
VP08684
p3938
sg10
I6
sg11
VCYP3A4
p3939
sg13
I1
sa(dp3940
g7
I235
sg8
VP10635
p3941
sg10
I6
sg11
VCYP2D6
p3942
sg13
I1
sa(dp3943
g7
I107
sg8
VP20853
p3944
sg10
I23
sg11
Vcytochrome P450 enzymes
p3945
sg13
I3
sa(dp3946
g7
I150
sg8
VP20815
p3947
sg10
I6
sg11
VCYP3A5
p3948
sg13
I1
sasg17
(lp3949
(dp3950
g7
I70
sg20
VC0678222
p3951
sg10
I13
sg11
Vbreast cancer
p3952
sg13
I2
sasa(dp3953
g2
S'Tamoxifen, the most frequently used drug for treating estrogen receptor-positive breast cancer, must be converted into active metabolites to exert its therapeutic efficacy, mainly through CYP2D6 enzymes.\n'
p3954
sg4
(lp3955
(dp3956
g7
I188
sg8
VP10635
p3957
sg10
I14
sg11
VCYP2D6 enzymes
p3958
sg13
I2
sasg17
(lp3959
(dp3960
g7
I81
sg20
VC0678222
p3961
sg10
I13
sg11
Vbreast cancer
p3962
sg13
I2
sasa(dp3963
g2
S'Cardiomyopathy [methylmalonic (MMA) and propionic aciduria (PA)], prolonged QTc interval (PA), optic nerve atrophy [MMA, isovaleric aciduria (IVA)], pancytopenia (PA), and macrocephaly [glutaric aciduria type 1 (GA1)] were exclusively found in OAD patients, whereas hepatic involvement was more frequent in UCD patients, in particular in argininosuccinate lyase (ASL) deficiency.\n'
p3964
sg4
(lp3965
(dp3966
g7
I363
sg8
VP30566
p3967
sg10
I3
sg11
VASL
p3968
sg13
I1
sa(dp3969
g7
I338
sg8
VP04424
p3970
sg10
I23
sg11
Vargininosuccinate lyase
p3971
sg13
I2
sasg17
(lp3972
(dp3973
g7
I186
sg20
VC0268595
p3974
sg10
I24
sg11
Vglutaric aciduria type 1
p3975
sg13
I4
sa(dp3976
g7
I60
sg20
VC2717876
p3977
sg10
I2
sg11
VPA
p3978
sg13
I1
sa(dp3979
g7
I149
sg20
VC0030312
p3980
sg10
I12
sg11
Vpancytopenia
p3981
sg13
I1
sa(dp3982
g7
I121
sg20
VC0268575
p3983
sg10
I19
sg11
Visovaleric aciduria
p3984
sg13
I2
sa(dp3985
g7
I31
sg20
VC0276096
p3986
sg10
I3
sg11
VMMA
p3987
sg13
I1
sa(dp3988
g7
I60
sg20
VC2717876
p3989
sg10
I2
sg11
VPA
p3990
sg13
I1
sa(dp3991
g7
I0
sg20
VC0878544
p3992
sg10
I14
sg11
VCardiomyopathy
p3993
sg13
I1
sa(dp3994
g7
I95
sg20
VC0029124
p3995
sg10
I19
sg11
Voptic nerve atrophy
p3996
sg13
I3
sa(dp3997
g7
I40
sg20
VC2717876
p3998
sg10
I18
sg11
Vpropionic aciduria
p3999
sg13
I2
sa(dp4000
g7
I60
sg20
VC2717876
p4001
sg10
I2
sg11
VPA
p4002
sg13
I1
sa(dp4003
g7
I172
sg20
VC0221355
p4004
sg10
I12
sg11
Vmacrocephaly
p4005
sg13
I1
sa(dp4006
g7
I15
sg20
VC0276096
p4007
sg10
I14
sg11
V[methylmalonic
p4008
sg13
I1
sa(dp4009
g7
I31
sg20
VC0276096
p4010
sg10
I3
sg11
VMMA
p4011
sg13
I1
sa(dp4012
g7
I66
sg20
VC1560305
p4013
sg10
I22
sg11
Vprolonged QTc interval
p4014
sg13
I3
sa(dp4015
g7
I142
sg20
VC0268575
p4016
sg10
I3
sg11
VIVA
p4017
sg13
I1
sasa(dp4018
g2
S'Spinocerebellar ataxia type 7 (SCA7) is caused by an abnormal CAG repeat expansion and includes cerebellar signs associated with visual loss and ophthalmoplegia.\n'
p4019
sg4
(lp4020
(dp4021
g7
I0
sg8
g127
sg10
I29
sg11
VSpinocerebellar ataxia type 7
p4022
sg13
I4
sa(dp4023
g7
I31
sg8
g127
sg10
I4
sg11
VSCA7
p4024
sg13
I1
sasg17
(lp4025
(dp4026
g7
I0
sg20
VC0752125
p4027
sg10
I29
sg11
VSpinocerebellar ataxia type 7
p4028
sg13
I4
sa(dp4029
g7
I31
sg20
VC0752125
p4030
sg10
I4
sg11
VSCA7
p4031
sg13
I1
sa(dp4032
g7
I129
sg20
VC0042798
p4033
sg10
I11
sg11
Vvisual loss
p4034
sg13
I2
sa(dp4035
g7
I145
sg20
VC0029089
p4036
sg10
I15
sg11
Vophthalmoplegia
p4037
sg13
I1
sasa(dp4038
g2
S'The following clinical features have some specific values for predicting a gene defect: slowing of saccades in SCA2, ophthalmoplegia in SCA1, SCA2 and SCA3, pigmentary retinopathy in SCA7, spasticity in SCA3, dyskinesias associated with a mutation in the fibroblast growth factor 14 (FGF 14) gene, cognitive impairment/behavioral symptoms in SCA17 and DRPLA, seizures in SCA10, SCA17 and DRPLA, peripheral neuropathy in SCA1, SCA2, SCA3, SCA4, SCA8, SCA18 and SCA25.\n'
p4039
sg4
(lp4040
(dp4041
g7
I352
sg8
VP54259
p4042
sg10
I5
sg11
VDRPLA
p4043
sg13
I1
sa(dp4044
g7
I371
sg8
g127
sg10
I5
sg11
VSCA10
p4045
sg13
I1
sa(dp4046
g7
I284
sg8
g127
sg10
I6
sg11
VFGF 14
p4047
sg13
I2
sa(dp4048
g7
I136
sg8
VP54253
p4049
sg10
I4
sg11
VSCA1
p4050
sg13
I1
sa(dp4051
g7
I342
sg8
VP20226
p4052
sg10
I5
sg11
VSCA17
p4053
sg13
I1
sa(dp4054
g7
I183
sg8
g127
sg10
I4
sg11
VSCA7
p4055
sg13
I1
sa(dp4056
g7
I342
sg8
VP20226
p4057
sg10
I5
sg11
VSCA17
p4058
sg13
I1
sa(dp4059
g7
I111
sg8
g127
sg10
I4
sg11
VSCA2
p4060
sg13
I1
sa(dp4061
g7
I352
sg8
VP54259
p4062
sg10
I5
sg11
VDRPLA
p4063
sg13
I1
sa(dp4064
g7
I438
sg8
g127
sg10
I4
sg11
VSCA4
p4065
sg13
I1
sa(dp4066
g7
I444
sg8
g127
sg10
I4
sg11
VSCA8
p4067
sg13
I1
sa(dp4068
g7
I136
sg8
VP54253
p4069
sg10
I4
sg11
VSCA1
p4070
sg13
I1
sa(dp4071
g7
I111
sg8
g127
sg10
I4
sg11
VSCA2
p4072
sg13
I1
sa(dp4073
g7
I111
sg8
g127
sg10
I4
sg11
VSCA2
p4074
sg13
I1
sa(dp4075
g7
I255
sg8
g127
sg10
I27
sg11
Vfibroblast growth factor 14
p4076
sg13
I4
sasg17
(lp4077
(dp4078
g7
I352
sg20
VC0751781
p4079
sg10
I5
sg11
VDRPLA
p4080
sg13
I1
sa(dp4081
g7
I111
sg20
VC0752121
p4082
sg10
I4
sg11
VSCA2
p4083
sg13
I1
sa(dp4084
g7
I359
sg20
VC0036572
p4085
sg10
I8
sg11
Vseizures
p4086
sg13
I1
sa(dp4087
g7
I136
sg20
VC0752120
p4088
sg10
I4
sg11
VSCA1
p4089
sg13
I1
sa(dp4090
g7
I136
sg20
VC0752120
p4091
sg10
I4
sg11
VSCA1
p4092
sg13
I1
sa(dp4093
g7
I319
sg20
VC0004941
p4094
sg10
I19
sg11
Vbehavioral symptoms
p4095
sg13
I2
sa(dp4096
g7
I342
sg20
VC1846707
p4097
sg10
I5
sg11
VSCA17
p4098
sg13
I1
sa(dp4099
g7
I352
sg20
VC0751781
p4100
sg10
I5
sg11
VDRPLA
p4101
sg13
I1
sa(dp4102
g7
I151
sg20
VC0024408
p4103
sg10
I4
sg11
VSCA3
p4104
sg13
I1
sa(dp4105
g7
I450
sg20
VC1843884
p4106
sg10
I5
sg11
VSCA18
p4107
sg13
I1
sa(dp4108
g7
I183
sg20
VC0752125
p4109
sg10
I4
sg11
VSCA7
p4110
sg13
I1
sa(dp4111
g7
I117
sg20
VC0029089
p4112
sg10
I15
sg11
Vophthalmoplegia
p4113
sg13
I1
sa(dp4114
g7
I460
sg20
VC1837518
p4115
sg10
I5
sg11
VSCA25
p4116
sg13
I1
sa(dp4117
g7
I151
sg20
VC0024408
p4118
sg10
I4
sg11
VSCA3
p4119
sg13
I1
sa(dp4120
g7
I209
sg20
VC0013384
p4121
sg10
I11
sg11
Vdyskinesias
p4122
sg13
I1
sa(dp4123
g7
I438
sg20
VC0752122
p4124
sg10
I4
sg11
VSCA4
p4125
sg13
I1
sa(dp4126
g7
I444
sg20
VC1837454
p4127
sg10
I4
sg11
VSCA8
p4128
sg13
I1
sa(dp4129
g7
I111
sg20
VC0752121
p4130
sg10
I4
sg11
VSCA2
p4131
sg13
I1
sa(dp4132
g7
I371
sg20
VC1963674
p4133
sg10
I5
sg11
VSCA10
p4134
sg13
I1
sa(dp4135
g7
I298
sg20
VC0338656
p4136
sg10
I20
sg11
Vcognitive impairment
p4137
sg13
I2
sa(dp4138
g7
I342
sg20
VC1846707
p4139
sg10
I5
sg11
VSCA17
p4140
sg13
I1
sa(dp4141
g7
I151
sg20
VC0024408
p4142
sg10
I4
sg11
VSCA3
p4143
sg13
I1
sa(dp4144
g7
I395
sg20
VC0031117
p4145
sg10
I21
sg11
Vperipheral neuropathy
p4146
sg13
I2
sa(dp4147
g7
I157
sg20
VC0035334
p4148
sg10
I22
sg11
Vpigmentary retinopathy
p4149
sg13
I2
sa(dp4150
g7
I189
sg20
VC0026838
p4151
sg10
I10
sg11
Vspasticity
p4152
sg13
I1
sa(dp4153
g7
I111
sg20
VC0752121
p4154
sg10
I4
sg11
VSCA2
p4155
sg13
I1
sasa(dp4156
g2
S'There were characteristic clinical features such as hypotonia and optic atrophy for SCA1; hyporeflexia for SCA2; nystagmus, bulging eye, and dystonia for SCA3; and macular degeneration for SCA7.\n'
p4157
sg4
(lp4158
(dp4159
g7
I84
sg8
VP54253
p4160
sg10
I4
sg11
VSCA1
p4161
sg13
I1
sa(dp4162
g7
I107
sg8
g127
sg10
I4
sg11
VSCA2
p4163
sg13
I1
sa(dp4164
g7
I189
sg8
g127
sg10
I4
sg11
VSCA7
p4165
sg13
I1
sasg17
(lp4166
(dp4167
g7
I52
sg20
VC0026827
p4168
sg10
I9
sg11
Vhypotonia
p4169
sg13
I1
sa(dp4170
g7
I164
sg20
VC0242383
p4171
sg10
I20
sg11
Vmacular degeneration
p4172
sg13
I2
sa(dp4173
g7
I154
sg20
VC0024408
p4174
sg10
I4
sg11
VSCA3
p4175
sg13
I1
sa(dp4176
g7
I107
sg20
VC0752121
p4177
sg10
I4
sg11
VSCA2
p4178
sg13
I1
sa(dp4179
g7
I113
sg20
VC0028738
p4180
sg10
I9
sg11
Vnystagmus
p4181
sg13
I1
sa(dp4182
g7
I84
sg20
VC0752120
p4183
sg10
I4
sg11
VSCA1
p4184
sg13
I1
sa(dp4185
g7
I189
sg20
VC0752125
p4186
sg10
I4
sg11
VSCA7
p4187
sg13
I1
sa(dp4188
g7
I66
sg20
VC0029124
p4189
sg10
I13
sg11
Voptic atrophy
p4190
sg13
I2
sa(dp4191
g7
I141
sg20
VC0393593
p4192
sg10
I8
sg11
Vdystonia
p4193
sg13
I1
sa(dp4194
g7
I124
sg20
VC0015300
p4195
sg10
I11
sg11
Vbulging eye
p4196
sg13
I2
sasa(dp4197
g2
S'This case illustrates a rare association of atrophic maculopathy and external ophthalmoplegia in Machado--Joseph disease, contrasted with the common occurrence of retinal degeneration in spinocerebellar ataxia 7.\n'
p4198
sg4
(lp4199
sg17
(lp4200
(dp4201
g7
I187
sg20
VC0752125
p4202
sg10
I24
sg11
Vspinocerebellar ataxia 7
p4203
sg13
I3
sa(dp4204
g7
I69
sg20
VC0162292
p4205
sg10
I24
sg11
Vexternal ophthalmoplegia
p4206
sg13
I2
sa(dp4207
g7
I106
sg20
VC0024408
p4208
sg10
I14
sg11
VJoseph disease
p4209
sg13
I2
sa(dp4210
g7
I163
sg20
VC0035304
p4211
sg10
I20
sg11
Vretinal degeneration
p4212
sg13
I2
sa(dp4213
g7
I44
sg20
VC0333641
p4214
sg10
I8
sg11
Vatrophic
p4215
sg13
I1
sa(dp4216
g7
I53
sg20
VC0730362
p4217
sg10
I11
sg11
Vmaculopathy
p4218
sg13
I1
sasa(dp4219
g2
S'Pure-tone audiometry confirmed normal-hearing thresholds (&gt;or=15 dB HL) at 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, and 8.0 kHz in NH-Ss and NH-Cs, and confirmed mild, high frequency, sensorineural hearing loss in HI-Ss (HI-Ss were included only to estimate sensitivity and specificity values for preliminary pass or fail criteria that could be used to help identify NH-Ss at risk for music-induced hearing loss).\n'
p4220
sg4
(lp4221
(dp4222
g7
I206
sg8
VP37268
p4223
sg10
I5
sg11
VHI-Ss
p4224
sg13
I1
sa(dp4225
g7
I190
sg8
VP37268
p4226
sg10
I12
sg11
Vhearing loss
p4227
sg13
I2
sa(dp4228
g7
I206
sg8
VP37268
p4229
sg10
I5
sg11
VHI-Ss
p4230
sg13
I1
sa(dp4231
g7
I190
sg8
VP37268
p4232
sg10
I12
sg11
Vhearing loss
p4233
sg13
I2
sasg17
(lp4234
(dp4235
g7
I206
sg20
VC0011053
p4236
sg10
I5
sg11
VHI-Ss
p4237
sg13
I1
sa(dp4238
g7
I176
sg20
VC0018784
p4239
sg10
I26
sg11
Vsensorineural hearing loss
p4240
sg13
I3
sa(dp4241
g7
I206
sg20
VC0011053
p4242
sg10
I5
sg11
VHI-Ss
p4243
sg13
I1
sa(dp4244
g7
I190
sg20
VC0011053
p4245
sg10
I12
sg11
Vhearing loss
p4246
sg13
I2
sasa(dp4247
g2
S'The disease intervals for Nance-Horan syndrome (NHS [MIM 302350]) and X linked congenital cataract (CXN) overlap on Xp22.\n'
p4248
sg4
(lp4249
sg17
(lp4250
(dp4251
g7
I48
sg20
VC0796085
p4252
sg10
I3
sg11
VNHS
p4253
sg13
I1
sa(dp4254
g7
I100
sg20
VC2752078
p4255
sg10
I3
sg11
VCXN
p4256
sg13
I1
sa(dp4257
g7
I26
sg20
VC0796085
p4258
sg10
I20
sg11
VNance-Horan syndrome
p4259
sg13
I2
sa(dp4260
g7
I79
sg20
VC0009691
p4261
sg10
I19
sg11
Vcongenital cataract
p4262
sg13
I2
sasa(dp4263
g2
S'The X-linked congenital cataract (CXN) locus has been mapped to a 3-cM (approximately 3.5 Mb) interval on chromosome Xp22.13, which is syntenic to the mouse cataract disease locus Xcat and encompasses the recently refined Nance-Horan syndrome (NHS) locus.\n'
p4264
sg4
(lp4265
sg17
(lp4266
(dp4267
g7
I244
sg20
VC0796085
p4268
sg10
I3
sg11
VNHS
p4269
sg13
I1
sa(dp4270
g7
I13
sg20
VC0009691
p4271
sg10
I19
sg11
Vcongenital cataract
p4272
sg13
I2
sa(dp4273
g7
I24
sg20
VC0086543
p4274
sg10
I8
sg11
Vcataract
p4275
sg13
I1
sa(dp4276
g7
I34
sg20
VC2752078
p4277
sg10
I3
sg11
VCXN
p4278
sg13
I1
sa(dp4279
g7
I222
sg20
VC0796085
p4280
sg10
I20
sg11
VNance-Horan syndrome
p4281
sg13
I2
sasa(dp4282
g2
S'The t(9;11) has been described in patients with acute myeloid leukemia (AML), and two genes [AF9 (at 9p21) and FBP17 (at 9q34)] have been cloned as fusion partners of the MLL gene.\n'
p4283
sg4
(lp4284
(dp4285
g7
I93
sg8
VP42568
p4286
sg10
I3
sg11
VAF9
p4287
sg13
I1
sa(dp4288
g7
I171
sg8
g127
sg10
I8
sg11
VMLL gene
p4289
sg13
I2
sasg17
(lp4290
(dp4291
g7
I72
sg20
VC0023467
p4292
sg10
I3
sg11
VAML
p4293
sg13
I1
sa(dp4294
g7
I48
sg20
VC0023467
p4295
sg10
I22
sg11
Vacute myeloid leukemia
p4296
sg13
I3
sasa(dp4297
g2
S'In the subsequent studies, we investigated the possible effects of the tested anticancer agents on the DOX-reducing activities of the most potent enzymes (AKR1C3, CBR1 and AKR1A1) and on the DOX metabolism driven by MCF7, HepG2 and human liver cytosols.\n'
p4298
sg4
(lp4299
(dp4300
g7
I163
sg8
VP16152
p4301
sg10
I4
sg11
VCBR1
p4302
sg13
I1
sa(dp4303
g7
I172
sg8
VP14550
p4304
sg10
I6
sg11
VAKR1A1
p4305
sg13
I1
sasg17
(lp4306
sa(dp4307
g2
S'We employed this approach to quantitatively determine the 6 AKR proteins, AKR1A1, AKR1B1, AKR1B10, AKR1C1/C2, AKR1C3, and AKR1C4, in 7 different cancer cell lines and for the first time to obtain the absolute quantities of all the AKR proteins in each cell.\n'
p4308
sg4
(lp4309
(dp4310
g7
I90
sg8
g127
sg10
I7
sg11
VAKR1B10
p4311
sg13
I1
sa(dp4312
g7
I74
sg8
VP14550
p4313
sg10
I6
sg11
VAKR1A1
p4314
sg13
I1
sa(dp4315
g7
I122
sg8
VP17516
p4316
sg10
I6
sg11
VAKR1C4
p4317
sg13
I1
sa(dp4318
g7
I99
sg8
g127
sg10
I6
sg11
VAKR1C1
p4319
sg13
I1
sa(dp4320
g7
I60
sg8
g127
sg10
I12
sg11
VAKR proteins
p4321
sg13
I2
sa(dp4322
g7
I82
sg8
VP15121
p4323
sg10
I6
sg11
VAKR1B1
p4324
sg13
I1
sasg17
(lp4325
(dp4326
g7
I145
sg20
VC0006826
p4327
sg10
I6
sg11
Vcancer
p4328
sg13
I1
sasa(dp4329
g2
S'The staining patterns for nidogen and heparan sulfate proteoglycan were examined in 11 patients with either junctional, dominant dystrophic, or recessive dystrophic epidermolysis bullosa, and were found to be not different from the patterns observed in normal skin.\n'
p4330
sg4
(lp4331
sg17
(lp4332
(dp4333
g7
I144
sg20
VC0079474
p4334
sg10
I42
sg11
Vrecessive dystrophic epidermolysis bullosa
p4335
sg13
I4
sasa(dp4336
g2
S'Our data identify ITCH as a novel component of the ATM-dependent signaling pathway and suggest that the impairment of the correct functionality of ITCH caused by Atm deficiency may contribute to the complex clinical features linked to Ataxia Telangiectasia.\n'
p4337
sg4
(lp4338
(dp4339
g7
I18
sg8
g127
sg10
I4
sg11
VITCH
p4340
sg13
I1
sa(dp4341
g7
I51
sg8
g127
sg10
I3
sg11
VATM
p4342
sg13
I1
sa(dp4343
g7
I162
sg8
g127
sg10
I3
sg11
VAtm
p4344
sg13
I1
sasg17
(lp4345
(dp4346
g7
I104
sg20
VC0684336
p4347
sg10
I10
sg11
Vimpairment
p4348
sg13
I1
sa(dp4349
g7
I18
sg20
VC0033774
p4350
sg10
I4
sg11
VITCH
p4351
sg13
I1
sa(dp4352
g7
I18
sg20
VC0033774
p4353
sg10
I4
sg11
VITCH
p4354
sg13
I1
sa(dp4355
g7
I235
sg20
VC0004135
p4356
sg10
I21
sg11
VAtaxia Telangiectasia
p4357
sg13
I2
sasa(dp4358
g2
S'The expected abnormalities were easily found in samples from patients with purine nucleoside phosphorylase deficiency, ornithine transcarbamylase deficiency, molybdenum cofactor deficiency, adenylosuccinase deficiency, or dihydropyrimidine dehydrogenase deficiency.\n'
p4359
sg4
(lp4360
(dp4361
g7
I158
sg8
g127
sg10
I19
sg11
Vmolybdenum cofactor
p4362
sg13
I2
sa(dp4363
g7
I119
sg8
VP00480
p4364
sg10
I26
sg11
Vornithine transcarbamylase
p4365
sg13
I2
sa(dp4366
g7
I222
sg8
VP49366
p4367
sg10
I31
sg11
Vdihydropyrimidine dehydrogenase
p4368
sg13
I2
sa(dp4369
g7
I190
sg8
VP30566
p4370
sg10
I16
sg11
Vadenylosuccinase
p4371
sg13
I1
sa(dp4372
g7
I75
sg8
VP00491
p4373
sg10
I31
sg11
Vpurine nucleoside phosphorylase
p4374
sg13
I3
sasg17
(lp4375
(dp4376
g7
I222
sg20
VC1959620
p4377
sg10
I42
sg11
Vdihydropyrimidine dehydrogenase deficiency
p4378
sg13
I3
sa(dp4379
g7
I158
sg20
VC0268119
p4380
sg10
I30
sg11
Vmolybdenum cofactor deficiency
p4381
sg13
I3
sa(dp4382
g7
I75
sg20
VC0268125
p4383
sg10
I42
sg11
Vpurine nucleoside phosphorylase deficiency
p4384
sg13
I4
sa(dp4385
g7
I190
sg20
VC0268126
p4386
sg10
I27
sg11
Vadenylosuccinase deficiency
p4387
sg13
I2
sa(dp4388
g7
I119
sg20
VC0268542
p4389
sg10
I37
sg11
Vornithine transcarbamylase deficiency
p4390
sg13
I3
sasa(dp4391
g2
S'To investigate the role of a defective 8-oxo-G repair we performed a germline mutation screening in the genes OGG1, MTH1 and MUTYH, in 81 patients with a clinical phenotype ranging from attenuated or atypical adenomatous polyposis coli including hyperplastic polyps to hereditary non-polyposis colorectal cancer (HNPCC) type X syndrome without mono- or biallelic mutations in either APC, MUTYH or the DNA mismatch repair genes.\n'
p4392
sg4
(lp4393
(dp4394
g7
I116
sg8
VP36639
p4395
sg10
I4
sg11
VMTH1
p4396
sg13
I1
sa(dp4397
g7
I125
sg8
g127
sg10
I5
sg11
VMUTYH
p4398
sg13
I1
sasg17
(lp4399
(dp4400
g7
I327
sg20
VC0039082
p4401
sg10
I8
sg11
Vsyndrome
p4402
sg13
I1
sa(dp4403
g7
I246
sg20
VC0333983
p4404
sg10
I19
sg11
Vhyperplastic polyps
p4405
sg13
I2
sa(dp4406
g7
I313
sg20
VC1333990
p4407
sg10
I5
sg11
VHNPCC
p4408
sg13
I1
sa(dp4409
g7
I209
sg20
VC0032580
p4410
sg10
I26
sg11
Vadenomatous polyposis coli
p4411
sg13
I3
sa(dp4412
g7
I383
sg20
VC0033036
p4413
sg10
I3
sg11
VAPC
p4414
sg13
I1
sa(dp4415
g7
I344
sg20
VC0021345
p4416
sg10
I4
sg11
Vmono
p4417
sg13
I1
sa(dp4418
g7
I269
sg20
VC1333990
p4419
sg10
I42
sg11
Vhereditary non-polyposis colorectal cancer
p4420
sg13
I4
sa(dp4421
g7
I69
sg20
VC1705427
p4422
sg10
I17
sg11
Vgermline mutation
p4423
sg13
I2
sasa(dp4424
g2
S'MYH, OGG1 and MTH1 are members of base excision repair (BER) families, and MYH germline mutations were recently identified in patients with multiple adenomas or familial adenomatous polyposis (FAP).\n'
p4425
sg4
(lp4426
(dp4427
g7
I0
sg8
g127
sg10
I3
sg11
VMYH
p4428
sg13
I1
sa(dp4429
g7
I14
sg8
VP36639
p4430
sg10
I4
sg11
VMTH1
p4431
sg13
I1
sasg17
(lp4432
(dp4433
g7
I149
sg20
VC0001430
p4434
sg10
I8
sg11
Vadenomas
p4435
sg13
I1
sa(dp4436
g7
I161
sg20
VC0032580
p4437
sg10
I30
sg11
Vfamilial adenomatous polyposis
p4438
sg13
I3
sa(dp4439
g7
I193
sg20
VC0032580
p4440
sg10
I3
sg11
VFAP
p4441
sg13
I1
sasa(dp4442
g2
S'A total of 19 hereditary nonpolyposis colorectal cancer (HNPCC), 86 suspected HNPCC, and 246 sporadic colorectal cancer cases were investigated for OGG1 and MYH mutations.\n'
p4443
sg4
(lp4444
(dp4445
g7
I157
sg8
g127
sg10
I3
sg11
VMYH
p4446
sg13
I1
sasg17
(lp4447
(dp4448
g7
I57
sg20
VC1333990
p4449
sg10
I5
sg11
VHNPCC
p4450
sg13
I1
sa(dp4451
g7
I14
sg20
VC1333990
p4452
sg10
I41
sg11
Vhereditary nonpolyposis colorectal cancer
p4453
sg13
I4
sa(dp4454
g7
I57
sg20
VC1333990
p4455
sg10
I5
sg11
VHNPCC
p4456
sg13
I1
sa(dp4457
g7
I38
sg20
VC1527249
p4458
sg10
I17
sg11
Vcolorectal cancer
p4459
sg13
I2
sasa(dp4460
g2
S'Seven risk factors were significantly associated with severe pneumonia, including body temperature, respiratory rate, C-reactive protein, elastase, exotoxin-A, exoenzyme-U and multidrug resistances.\n'
p4461
sg4
(lp4462
(dp4463
g7
I138
sg8
VP30740
p4464
sg10
I8
sg11
Velastase
p4465
sg13
I1
sa(dp4466
g7
I118
sg8
VP02741
p4467
sg10
I18
sg11
VC-reactive protein
p4468
sg13
I2
sasg17
(lp4469
(dp4470
g7
I61
sg20
VC0032285
p4471
sg10
I9
sg11
Vpneumonia
p4472
sg13
I1
sasa(dp4473
g2
S'The prediction models were developed with polytomous logistic regression differentiating "pneumonia" and "other SBIs" from "non-SBIs" using standardized, routinely collected data on clinical signs and symptoms, CRP, and procalcitonin.ResultsA total of 1,085 children were included with a median age of 1.6 years (interquartile range 0.8-3.4); 73 children (7%) had pneumonia and 98 children (9%) had other SBIs.\n'
p4474
sg4
(lp4475
(dp4476
g7
I211
sg8
VP02741
p4477
sg10
I3
sg11
VCRP
p4478
sg13
I1
sa(dp4479
g7
I220
sg8
VP06132
p4480
sg10
I13
sg11
Vprocalcitonin
p4481
sg13
I1
sasg17
(lp4482
(dp4483
g7
I90
sg20
VC0032285
p4484
sg10
I9
sg11
Vpneumonia
p4485
sg13
I1
sa(dp4486
g7
I191
sg20
VC0037088
p4487
sg10
I18
sg11
Vsigns and symptoms
p4488
sg13
I3
sa(dp4489
g7
I90
sg20
VC0032285
p4490
sg10
I9
sg11
Vpneumonia
p4491
sg13
I1
sasa(dp4492
g2
S'In this study we transmitted the disease from a series of 12 French atypical scrapie isolates in a transgenic mouse model (TgOvPrP4) overexpressing in the brain approximately 0.25, 1.5 or 6x the levels of the PrP(ARQ) ovine prion protein under the control of the neuron-specific enolase promoter.\n'
p4493
sg4
(lp4494
(dp4495
g7
I263
sg8
VP09104
p4496
sg10
I32
sg11
Vneuron-specific enolase promoter
p4497
sg13
I3
sasg17
(lp4498
(dp4499
g7
I77
sg20
VC0036457
p4500
sg10
I7
sg11
Vscrapie
p4501
sg13
I1
sa(dp4502
g7
I17
sg20
VC0242781
p4503
sg10
I11
sg11
Vtransmitted
p4504
sg13
I1
sasa(dp4505
g2
S'Transgenic Tg(OvPrP4) mice, which express the ovine prion protein (PrP) gene under the rat neuron-specific enolase promoter on a knockout background, were used to study prion extracerebral circulation after scrapie prions were inoculated via the intracerebral (ic) and the intraperitoneal (ip) route.\n'
p4506
sg4
(lp4507
(dp4508
g7
I46
sg8
VP48637
p4509
sg10
I19
sg11
Vovine prion protein
p4510
sg13
I3
sa(dp4511
g7
I87
sg8
VP09104
p4512
sg10
I36
sg11
Vrat neuron-specific enolase promoter
p4513
sg13
I4
sa(dp4514
g7
I16
sg8
g127
sg10
I3
sg11
VPrP
p4515
sg13
I1
sasg17
(lp4516
(dp4517
g7
I207
sg20
VC0036457
p4518
sg10
I7
sg11
Vscrapie
p4519
sg13
I1
sasa(dp4520
g2
S'Here, two ovine transgenic mouse lines (TgOvPrP4 and TgOvPrP59), expressing the ovine PrP (A136 R154 Q171) under control of the neuron-specific enolase promoter, were studied; they were challenged with brainstem or spinal cord from experimentally BSE-infected sheep (AA136 RR154 QQ171 and AA136 RR154 RR171 genotypes) or brainstem from cattle BSE and natural sheep scrapie.\n'
p4521
sg4
(lp4522
(dp4523
g7
I128
sg8
VP09104
p4524
sg10
I32
sg11
Vneuron-specific enolase promoter
p4525
sg13
I3
sasg17
(lp4526
(dp4527
g7
I247
sg20
VC0085209
p4528
sg10
I3
sg11
VBSE
p4529
sg13
I1
sa(dp4530
g7
I365
sg20
VC0036457
p4531
sg10
I7
sg11
Vscrapie
p4532
sg13
I1
sa(dp4533
g7
I247
sg20
VC0085209
p4534
sg10
I3
sg11
VBSE
p4535
sg13
I1
sa(dp4536
g7
I222
sg20
VC0035334
p4537
sg10
I4
sg11
Vcord
p4538
sg13
I1
sasa(dp4539
g2
S'To investigate the role of PrP expression in different cell types on pathology in retina and brain after scrapie infection, we examined transgenic mice expressing hamster PrP from the PrP promoter (tg7), the neuron-specific enolase promoter (tgNSE), or the astrocyte-specific glial fibrillary acidic protein promoter (tgGFAP).\n'
p4540
sg4
(lp4541
(dp4542
g7
I276
sg8
VP05230
p4543
sg10
I40
sg11
Vglial fibrillary acidic protein promoter
p4544
sg13
I5
sa(dp4545
g7
I27
sg8
g127
sg10
I3
sg11
VPrP
p4546
sg13
I1
sa(dp4547
g7
I208
sg8
VP09104
p4548
sg10
I32
sg11
Vneuron-specific enolase promoter
p4549
sg13
I3
sa(dp4550
g7
I184
sg8
g127
sg10
I12
sg11
VPrP promoter
p4551
sg13
I2
sasg17
(lp4552
(dp4553
g7
I105
sg20
VC0036457
p4554
sg10
I7
sg11
Vscrapie
p4555
sg13
I1
sa(dp4556
g7
I113
sg20
VC0009450
p4557
sg10
I9
sg11
Vinfection
p4558
sg13
I1
sa(dp4559
g7
I69
sg20
VC0677042
p4560
sg10
I9
sg11
Vpathology
p4561
sg13
I1
sasa(dp4562
g2
S'After intraocular inoculation with hamster scrapie, clinical disease developed in tg7 and tgNSE mice by 100 days and in tgGFAP mice by 350 days.\n'
p4563
sg4
(lp4564
sg17
(lp4565
(dp4566
g7
I43
sg20
VC0036457
p4567
sg10
I7
sg11
Vscrapie
p4568
sg13
I1
sasa(dp4569
g2
S'Recently, several variants of BCOR and BCOR-like 1 (BCORL1) chimeric fusion transcripts were reported in human cancers, including acute promyelocytic leukemia, bone sarcoma, and hepatocellular carcinoma.\n'
p4570
sg4
(lp4571
(dp4572
g7
I52
sg8
g127
sg10
I6
sg11
VBCORL1
p4573
sg13
I1
sa(dp4574
g7
I39
sg8
g127
sg10
I11
sg11
VBCOR-like 1
p4575
sg13
I2
sasg17
(lp4576
(dp4577
g7
I178
sg20
VC1512411
p4578
sg10
I24
sg11
Vhepatocellular carcinoma
p4579
sg13
I2
sa(dp4580
g7
I130
sg20
VC0023487
p4581
sg10
I28
sg11
Vacute promyelocytic leukemia
p4582
sg13
I3
sa(dp4583
g7
I111
sg20
VC0006826
p4584
sg10
I7
sg11
Vcancers
p4585
sg13
I1
sa(dp4586
g7
I160
sg20
VC0029463
p4587
sg10
I12
sg11
Vbone sarcoma
p4588
sg13
I2
sasa(dp4589
g2
S'In addition, massively parallel sequencing has identified inactivating somatic BCOR and BCORL1 mutations in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia, medulloblastoma, and retinoblastoma.\n'
p4590
sg4
(lp4591
(dp4592
g7
I88
sg8
g127
sg10
I6
sg11
VBCORL1
p4593
sg13
I1
sasg17
(lp4594
(dp4595
g7
I238
sg20
VC0035335
p4596
sg10
I14
sg11
Vretinoblastoma
p4597
sg13
I1
sa(dp4598
g7
I217
sg20
VC0025149
p4599
sg10
I15
sg11
Vmedulloblastoma
p4600
sg13
I1
sa(dp4601
g7
I152
sg20
VC3463824
p4602
sg10
I24
sg11
Vmyelodysplastic syndrome
p4603
sg13
I2
sa(dp4604
g7
I122
sg20
VC0023467
p4605
sg10
I22
sg11
Vacute myeloid leukemia
p4606
sg13
I3
sa(dp4607
g7
I184
sg20
VC0023480
p4608
sg10
I31
sg11
Vchronic myelomonocytic leukemia
p4609
sg13
I3
sa(dp4610
g7
I178
sg20
VC0265219
p4611
sg10
I3
sg11
VMDS
p4612
sg13
I1
sa(dp4613
g7
I146
sg20
VC0023467
p4614
sg10
I3
sg11
VAML
p4615
sg13
I1
sasa(dp4616
g2
S'(10 isolates) and 14 other yeast species (24 isolates), using a 4-hour urea broth test (Remel), a 24-hour urea broth test (Becton Dickinson), a 4-hour caffeic acid disk test (Hardy Diagnostics and Remel), 40- to 44-hour growth assessment on l-canavanine glycine bromothymol blue (CGB) agar, and intergenic spacer (IGS) sequence analysis.\n'
p4617
sg4
(lp4618
sg17
(lp4619
(dp4620
g7
I314
sg20
VC1306856
p4621
sg10
I3
sg11
VIGS
p4622
sg13
I1
sasa(dp4623
g2
S'gattii isolates (98%) within 4 h. CGB agar or IGS sequencing further differentiated these isolates within 48 h. On CGB, 25 of 27 (93%) C. gattii strains induced a blue color change, in contrast to 0 of 86 C. neoformans isolates.\n'
p4624
sg4
(lp4625
sg17
(lp4626
(dp4627
g7
I46
sg20
VC1306856
p4628
sg10
I3
sg11
VIGS
p4629
sg13
I1
sasa(dp4630
g2
S'Low expression of SDHB strongly was correlated with T classification, clinical stage and cranial nerve palsy.\n'
p4631
sg4
(lp4632
(dp4633
g7
I18
sg8
VP21912
p4634
sg10
I4
sg11
VSDHB
p4635
sg13
I1
sasg17
(lp4636
(dp4637
g7
I89
sg20
VC0151311
p4638
sg10
I19
sg11
Vcranial nerve palsy
p4639
sg13
I3
sasa(dp4640
g2
S'Metabolic disorders appear to result in neuropsychiatric illness either through disruption of late neurodevelopmental processes (metachromatic leukodystrophy, adrenoleukodystrophy, GM2 gangliosidosis, Niemann-Pick type C, cerebrotendinous xanthomatosis, neuronal ceroid lipofuscinosis, and alpha mannosidosis) or via chronic or acute disruption of excitatory/inhibitory or monoaminergic neurotransmitter systems (acute intermittent porphyria, maple syrup urine disease, urea cycle disorders, phenylketonuria and disorders of homocysteine metabolism).\n'
p4641
sg4
(lp4642
sg17
(lp4643
(dp4644
g7
I492
sg20
VC0031485
p4645
sg10
I15
sg11
Vphenylketonuria
p4646
sg13
I1
sa(dp4647
g7
I413
sg20
VC0162565
p4648
sg10
I28
sg11
Vacute intermittent porphyria
p4649
sg13
I3
sa(dp4650
g7
I159
sg20
VC0162309
p4651
sg10
I20
sg11
Vadrenoleukodystrophy
p4652
sg13
I1
sa(dp4653
g7
I254
sg20
VC0027877
p4654
sg10
I30
sg11
Vneuronal ceroid lipofuscinosis
p4655
sg13
I3
sa(dp4656
g7
I181
sg20
VC0268274
p4657
sg10
I18
sg11
VGM2 gangliosidosis
p4658
sg13
I2
sa(dp4659
g7
I222
sg20
VC0238052
p4660
sg10
I30
sg11
Vcerebrotendinous xanthomatosis
p4661
sg13
I2
sa(dp4662
g7
I0
sg20
VC0025517
p4663
sg10
I19
sg11
VMetabolic disorders
p4664
sg13
I2
sa(dp4665
g7
I470
sg20
VC0154246
p4666
sg10
I20
sg11
Vurea cycle disorders
p4667
sg13
I3
sa(dp4668
g7
I129
sg20
VC0023522
p4669
sg10
I28
sg11
Vmetachromatic leukodystrophy
p4670
sg13
I2
sa(dp4671
g7
I443
sg20
VC0024776
p4672
sg10
I25
sg11
Vmaple syrup urine disease
p4673
sg13
I4
sa(dp4674
g7
I290
sg20
VC0024748
p4675
sg10
I18
sg11
Valpha mannosidosis
p4676
sg13
I2
sasa(dp4677
g2
S"We report mainly on metachromatic leukodystrophy, GM2 gangliosidosis, Fabry's disease, Niemann-Pick type C, Kufs disease, adrenoleukodystrophy, cerebro-tendinous xanthomatosis.\n"
p4678
sg4
(lp4679
sg17
(lp4680
(dp4681
g7
I50
sg20
VC0268274
p4682
sg10
I18
sg11
VGM2 gangliosidosis
p4683
sg13
I2
sa(dp4684
g7
I162
sg20
VC0043325
p4685
sg10
I13
sg11
Vxanthomatosis
p4686
sg13
I1
sa(dp4687
g7
I108
sg20
VC2931675
p4688
sg10
I12
sg11
VKufs disease
p4689
sg13
I2
sa(dp4690
g7
I122
sg20
VC0162309
p4691
sg10
I20
sg11
Vadrenoleukodystrophy
p4692
sg13
I1
sa(dp4693
g7
I70
sg20
VC0002986
p4694
sg10
I15
sg11
VFabry's disease
p4695
sg13
I2
sa(dp4696
g7
I20
sg20
VC0023522
p4697
sg10
I28
sg11
Vmetachromatic leukodystrophy
p4698
sg13
I2
sasa(dp4699
g2
S'The variations of cerebrospinal fluid-free amino acids observed in coma have been compared with those reported by other authors in patients affected by epilepsy, multiple sclerosis, infantile amaurotic idiocy (GM2-gangliosidosis) and phenylketonuria.\n'
p4700
sg4
(lp4701
sg17
(lp4702
(dp4703
g7
I152
sg20
VC0014544
p4704
sg10
I8
sg11
Vepilepsy
p4705
sg13
I1
sa(dp4706
g7
I214
sg20
VC0017083
p4707
sg10
I14
sg11
Vgangliosidosis
p4708
sg13
I1
sa(dp4709
g7
I162
sg20
VC0026769
p4710
sg10
I18
sg11
Vmultiple sclerosis
p4711
sg13
I2
sa(dp4712
g7
I234
sg20
VC0031485
p4713
sg10
I15
sg11
Vphenylketonuria
p4714
sg13
I1
sa(dp4715
g7
I192
sg20
VC0865470
p4716
sg10
I16
sg11
Vamaurotic idiocy
p4717
sg13
I2
sa(dp4718
g7
I67
sg20
VC0009421
p4719
sg10
I4
sg11
Vcoma
p4720
sg13
I1
sasa(dp4721
g2
S'Infiltrates of five cases of mycosis fungoides (MF) were studied for the presence of cells reactive with a monoclonal antibody, OKT 6, which detects an antigen present on relatively immature thymocytes and Langerhans cells.\n'
p4722
sg4
(lp4723
(dp4724
g7
I128
sg8
VP04181
p4725
sg10
I5
sg11
VOKT 6
p4726
sg13
I2
sasg17
(lp4727
(dp4728
g7
I29
sg20
VC0026948
p4729
sg10
I17
sg11
Vmycosis fungoides
p4730
sg13
I2
sa(dp4731
g7
I48
sg20
VC0026948
p4732
sg10
I2
sg11
VMF
p4733
sg13
I1
sa(dp4734
g7
I0
sg20
VC0332448
p4735
sg10
I11
sg11
VInfiltrates
p4736
sg13
I1
sasa(dp4737
g2
S"Twelve cases (Mycosis fungoides, Sezary syndrome, cutaneous T-cell lymphoma, chronic lymphocytic leukemia) were OKT3'T4', ie, expressed the phenotype commonly associated with mature T-helper cells.\n"
p4738
sg4
(lp4739
sg17
(lp4740
(dp4741
g7
I14
sg20
VC0026948
p4742
sg10
I17
sg11
VMycosis fungoides
p4743
sg13
I2
sa(dp4744
g7
I50
sg20
VC0079773
p4745
sg10
I25
sg11
Vcutaneous T-cell lymphoma
p4746
sg13
I3
sa(dp4747
g7
I77
sg20
VC0023434
p4748
sg10
I28
sg11
Vchronic lymphocytic leukemia
p4749
sg13
I3
sa(dp4750
g7
I33
sg20
VC0036920
p4751
sg10
I15
sg11
VSezary syndrome
p4752
sg13
I2
sasa(dp4753
g2
S'Fourteen neoplasms with diverse histopathologic features, T-cell chronic lymphocytic leukemia, mycosis fungoides, the Sezary syndrome, T-immunoblastic sarcoma, and a pleomorphic large-cell lymphoma, expressed the T helper cell phenotype, OKT3+T4+.\n'
p4754
sg4
(lp4755
sg17
(lp4756
(dp4757
g7
I95
sg20
VC0026948
p4758
sg10
I17
sg11
Vmycosis fungoides
p4759
sg13
I2
sa(dp4760
g7
I178
sg20
VC0079744
p4761
sg10
I19
sg11
Vlarge-cell lymphoma
p4762
sg13
I2
sa(dp4763
g7
I137
sg20
VC0079746
p4764
sg10
I21
sg11
Vimmunoblastic sarcoma
p4765
sg13
I2
sa(dp4766
g7
I118
sg20
VC0036920
p4767
sg10
I15
sg11
VSezary syndrome
p4768
sg13
I2
sa(dp4769
g7
I9
sg20
VC0027651
p4770
sg10
I9
sg11
Vneoplasms
p4771
sg13
I1
sa(dp4772
g7
I58
sg20
VC0023494
p4773
sg10
I35
sg11
VT-cell chronic lymphocytic leukemia
p4774
sg13
I4
sasa(dp4775
g2
S'Neoplastic lymphocytes from patients with varying phases of cutaneous T cell lymphoma (mycosis fungoides, Sezary syndrome and related presentations) were reactive with OKT1 and OKT3 (pan T cell reagents) and OKT4 (an antibody defining the functional "helper" T cell subset).\n'
p4776
sg4
(lp4777
sg17
(lp4778
(dp4779
g7
I60
sg20
VC0079773
p4780
sg10
I25
sg11
Vcutaneous T cell lymphoma
p4781
sg13
I4
sa(dp4782
g7
I87
sg20
VC0026948
p4783
sg10
I17
sg11
Vmycosis fungoides
p4784
sg13
I2
sa(dp4785
g7
I106
sg20
VC0036920
p4786
sg10
I15
sg11
VSezary syndrome
p4787
sg13
I2
sasa(dp4788
g2
S'The presence of an OKT1+, OKT3+, OKT4+, OKT5-, OKT8- phenotype on the neoplastic T lymphocytes of cutaneous T cell lymphoma (CTCL) supports the clinical impression that all phases of CTCL represent a single disease entity.\n'
p4789
sg4
(lp4790
(dp4791
g7
I98
sg8
g127
sg10
I25
sg11
Vcutaneous T cell lymphoma
p4792
sg13
I4
sa(dp4793
g7
I125
sg8
g127
sg10
I4
sg11
VCTCL
p4794
sg13
I1
sasg17
(lp4795
(dp4796
g7
I125
sg20
VC0079773
p4797
sg10
I4
sg11
VCTCL
p4798
sg13
I1
sa(dp4799
g7
I98
sg20
VC0079773
p4800
sg10
I25
sg11
Vcutaneous T cell lymphoma
p4801
sg13
I4
sa(dp4802
g7
I125
sg20
VC0079773
p4803
sg10
I4
sg11
VCTCL
p4804
sg13
I1
sasa(dp4805
g2
S'NHL of T-lymphocytes detailed in respect of mycosis fungoides and Sezary syndrome (OKT-3, OKT-4, OKT-11), to subtypes of T-CLL with particular emphasis on the "azurophilic" type, to T-zone NHL, and to adult T-cell leukaemia/lymphoma (OKT-3, OKT-4, OKT-11, anti-tac), all of them with the usual immunological phenotype of T-helper (TH) lymphocytes.\n'
p4806
sg4
(lp4807
(dp4808
g7
I121
sg8
VP04207
p4809
sg10
I5
sg11
VT-CLL
p4810
sg13
I1
sa(dp4811
g7
I97
sg8
VP04181
p4812
sg10
I6
sg11
VOKT-11
p4813
sg13
I1
sa(dp4814
g7
I83
sg8
VP04181
p4815
sg10
I5
sg11
VOKT-3
p4816
sg13
I1
sa(dp4817
g7
I83
sg8
VP04181
p4818
sg10
I5
sg11
VOKT-3
p4819
sg13
I1
sa(dp4820
g7
I90
sg8
VP04181
p4821
sg10
I5
sg11
VOKT-4
p4822
sg13
I1
sa(dp4823
g7
I90
sg8
VP04181
p4824
sg10
I5
sg11
VOKT-4
p4825
sg13
I1
sa(dp4826
g7
I97
sg8
VP04181
p4827
sg10
I6
sg11
VOKT-11
p4828
sg13
I1
sasg17
(lp4829
(dp4830
g7
I0
sg20
VC0024305
p4831
sg10
I3
sg11
VNHL
p4832
sg13
I1
sa(dp4833
g7
I0
sg20
VC0024305
p4834
sg10
I3
sg11
VNHL
p4835
sg13
I1
sa(dp4836
g7
I123
sg20
VC0023434
p4837
sg10
I3
sg11
VCLL
p4838
sg13
I1
sa(dp4839
g7
I44
sg20
VC0862196
p4840
sg10
I37
sg11
Vmycosis fungoides and Sezary syndrome
p4841
sg13
I5
sa(dp4842
g7
I201
sg20
VC0023493
p4843
sg10
I31
sg11
Vadult T-cell leukaemia/lymphoma
p4844
sg13
I3
sasa(dp4845
g2
S'OKT 9 reactive cells were identified in all cases of mycosis fungoides examined, in one case of lymphomatoid papulosis, one of two cases of Sezary syndrome, and one of ten cases of large plaque atrophic parapsoriasis.\n'
p4846
sg4
(lp4847
sg17
(lp4848
(dp4849
g7
I187
sg20
VC0011389
p4850
sg10
I6
sg11
Vplaque
p4851
sg13
I1
sa(dp4852
g7
I96
sg20
VC0206182
p4853
sg10
I22
sg11
Vlymphomatoid papulosis
p4854
sg13
I2
sa(dp4855
g7
I203
sg20
VC0030491
p4856
sg10
I13
sg11
Vparapsoriasis
p4857
sg13
I1
sa(dp4858
g7
I194
sg20
VC0333641
p4859
sg10
I8
sg11
Vatrophic
p4860
sg13
I1
sa(dp4861
g7
I53
sg20
VC0026948
p4862
sg10
I17
sg11
Vmycosis fungoides
p4863
sg13
I2
sa(dp4864
g7
I140
sg20
VC0036920
p4865
sg10
I15
sg11
VSezary syndrome
p4866
sg13
I2
sasa(dp4867
g2
S'Because cutaneous melanoma is a malignant tumor associated with poor prognosis, we investigated the expression of c-erbB-2 protein in cutaneous melanoma and in melanoma metastatic to the skin.\n'
p4868
sg4
(lp4869
(dp4870
g7
I114
sg8
VP04626
p4871
sg10
I16
sg11
Vc-erbB-2 protein
p4872
sg13
I2
sasg17
(lp4873
(dp4874
g7
I8
sg20
VC0025202
p4875
sg10
I18
sg11
Vcutaneous melanoma
p4876
sg13
I2
sa(dp4877
g7
I8
sg20
VC0025202
p4878
sg10
I18
sg11
Vcutaneous melanoma
p4879
sg13
I2
sa(dp4880
g7
I32
sg20
VC0006826
p4881
sg10
I15
sg11
Vmalignant tumor
p4882
sg13
I2
sa(dp4883
g7
I160
sg20
VC0278883
p4884
sg10
I19
sg11
Vmelanoma metastatic
p4885
sg13
I2
sasa(dp4886
g2
S'The expression of c-erbB-2 protein in 20 primary cutaneous melanomas and in 10 melanomas metastatic to the skin was investigated using a semi-quantitative immunohistochemical assay.\n'
p4887
sg4
(lp4888
(dp4889
g7
I18
sg8
VP04626
p4890
sg10
I16
sg11
Vc-erbB-2 protein
p4891
sg13
I2
sasg17
(lp4892
(dp4893
g7
I59
sg20
VC0025202
p4894
sg10
I9
sg11
Vmelanomas
p4895
sg13
I1
sa(dp4896
g7
I59
sg20
VC0025202
p4897
sg10
I9
sg11
Vmelanomas
p4898
sg13
I1
sasa(dp4899
g2
S'c-erbB-2 overexpression does not appear to play a role in the development of primary cutaneous melanoma or in the development of metastatic melanoma, indicating that mechanisms other than c-erbB-2 overexpression are involved in the pathogenesis of cutaneous melanoma.\n'
p4900
sg4
(lp4901
(dp4902
g7
I0
sg8
VP04626
p4903
sg10
I8
sg11
Vc-erbB-2
p4904
sg13
I1
sa(dp4905
g7
I0
sg8
VP04626
p4906
sg10
I8
sg11
Vc-erbB-2
p4907
sg13
I1
sasg17
(lp4908
(dp4909
g7
I85
sg20
VC0025202
p4910
sg10
I18
sg11
Vcutaneous melanoma
p4911
sg13
I2
sa(dp4912
g7
I85
sg20
VC0025202
p4913
sg10
I18
sg11
Vcutaneous melanoma
p4914
sg13
I2
sa(dp4915
g7
I129
sg20
VC0278883
p4916
sg10
I19
sg11
Vmetastatic melanoma
p4917
sg13
I2
sa(dp4918
g7
I232
sg20
VC0699748
p4919
sg10
I12
sg11
Vpathogenesis
p4920
sg13
I1
sasa(dp4921
g2
S'ASPM, RFC4, C3orf26, BXDC2, C15orf44, AURKA, C20orf77, and RBMX were upregulated in immortalized cells, cancer cells, and non-small-cell lung cancer (NSCLC) tissues.\n'
p4922
sg4
(lp4923
(dp4924
g7
I6
sg8
VP35249
p4925
sg10
I4
sg11
VRFC4
p4926
sg13
I1
sa(dp4927
g7
I45
sg8
g127
sg10
I8
sg11
VC20orf77
p4928
sg13
I1
sa(dp4929
g7
I12
sg8
g127
sg10
I7
sg11
VC3orf26
p4930
sg13
I1
sa(dp4931
g7
I28
sg8
g127
sg10
I8
sg11
VC15orf44
p4932
sg13
I1
sa(dp4933
g7
I38
sg8
VP17038
p4934
sg10
I5
sg11
VAURKA
p4935
sg13
I1
sa(dp4936
g7
I21
sg8
g127
sg10
I5
sg11
VBXDC2
p4937
sg13
I1
sasg17
(lp4938
(dp4939
g7
I150
sg20
VC0007131
p4940
sg10
I5
sg11
VNSCLC
p4941
sg13
I1
sa(dp4942
g7
I122
sg20
VC0007131
p4943
sg10
I26
sg11
Vnon-small-cell lung cancer
p4944
sg13
I3
sa(dp4945
g7
I104
sg20
VC0006826
p4946
sg10
I6
sg11
Vcancer
p4947
sg13
I1
sasa(dp4948
g2
S'Similarly to il2ra(-/-) mice, DKO showed reduced numbers of regulatory T cells and, consequently, hyper-activation and proliferation of T cells associated with inflammatory disease (ie, colitis), weight loss, and reduced survival.\n'
p4949
sg4
(lp4950
(dp4951
g7
I13
sg8
VP01589
p4952
sg10
I5
sg11
Vil2ra
p4953
sg13
I1
sasg17
(lp4954
(dp4955
g7
I119
sg20
VC0334094
p4956
sg10
I13
sg11
Vproliferation
p4957
sg13
I1
sa(dp4958
g7
I186
sg20
VC0009319
p4959
sg10
I7
sg11
Vcolitis
p4960
sg13
I1
sa(dp4961
g7
I160
sg20
VC1290884
p4962
sg10
I20
sg11
Vinflammatory disease
p4963
sg13
I2
sa(dp4964
g7
I182
sg20
VC1290884
p4965
sg10
I2
sg11
Vie
p4966
sg13
I1
sasa(dp4967
g2
S'These data infer that targeted depletion of cells expressing the IL-2 receptor has therapeutic potential in models of inflammatory colitis, despite depletion of CD25(+) Treg.\n'
p4968
sg4
(lp4969
(dp4970
g7
I65
sg8
VP60568
p4971
sg10
I13
sg11
VIL-2 receptor
p4972
sg13
I2
sasg17
(lp4973
(dp4974
g7
I131
sg20
VC0009319
p4975
sg10
I7
sg11
Vcolitis
p4976
sg13
I1
sasa(dp4977
g2
S'We report 2 cases of sudden BCR/ABL1+ blast crisis in patients with CML who had achieved complete hematologic remission with imatinib therapy but were obligated to discontinue therapy owing to pancytopenia.\n'
p4978
sg4
(lp4979
(dp4980
g7
I32
sg8
VP00519
p4981
sg10
I5
sg11
VABL1+
p4982
sg13
I1
sa(dp4983
g7
I28
sg8
VP11274
p4984
sg10
I3
sg11
VBCR
p4985
sg13
I1
sasg17
(lp4986
(dp4987
g7
I68
sg20
VC0023473
p4988
sg10
I3
sg11
VCML
p4989
sg13
I1
sa(dp4990
g7
I38
sg20
VC0005699
p4991
sg10
I12
sg11
Vblast crisis
p4992
sg13
I2
sa(dp4993
g7
I110
sg20
VC0687702
p4994
sg10
I9
sg11
Vremission
p4995
sg13
I1
sa(dp4996
g7
I193
sg20
VC0030312
p4997
sg10
I12
sg11
Vpancytopenia
p4998
sg13
I1
sasa(dp4999
g2
S'We demonstrated that Tg mice expressing AID in the skin spontaneously developed skin squamous cell carcinoma with Hras and Trp53 mutations.\n'
p5000
sg4
(lp5001
(dp5002
g7
I114
sg8
VP01112
p5003
sg10
I4
sg11
VHras
p5004
sg13
I1
sa(dp5005
g7
I123
sg8
VP42771
p5006
sg10
I5
sg11
VTrp53
p5007
sg13
I1
sasg17
(lp5008
(dp5009
g7
I80
sg20
VC0553723
p5010
sg10
I28
sg11
Vskin squamous cell carcinoma
p5011
sg13
I4
sasa(dp5012
g2
S'In the current study, the expression of C/EBPalpha was evaluated in seven mouse skin squamous cell carcinoma (SCC) cell lines that contain oncogenic Ha-Ras.\n'
p5013
sg4
(lp5014
(dp5015
g7
I139
sg8
VP01112
p5016
sg10
I16
sg11
Voncogenic Ha-Ras
p5017
sg13
I2
sasg17
(lp5018
(dp5019
g7
I80
sg20
VC0553723
p5020
sg10
I28
sg11
Vskin squamous cell carcinoma
p5021
sg13
I4
sasa(dp5022
g2
S'In addition, an activated H-ras gene was detected in a human keratoacanthoma by using a nude mouse tumorigenesis assay after transfection of tumor DNA into NIH 3T3 cells.\n'
p5023
sg4
(lp5024
(dp5025
g7
I16
sg8
VP01112
p5026
sg10
I20
sg11
Vactivated H-ras gene
p5027
sg13
I3
sasg17
(lp5028
(dp5029
g7
I99
sg20
VC0007621
p5030
sg10
I13
sg11
Vtumorigenesis
p5031
sg13
I1
sa(dp5032
g7
I61
sg20
VC0022572
p5033
sg10
I15
sg11
Vkeratoacanthoma
p5034
sg13
I1
sa(dp5035
g7
I99
sg20
VC0027651
p5036
sg10
I5
sg11
Vtumor
p5037
sg13
I1
sasa(dp5038
g2
S'A mouse skin squamous cell carcinoma induced by topical application of the direct-acting alkylating agent beta-propiolactone contains an activated H-ras oncogene with an A----T transversion at the second nucleotide of codon 61.\n'
p5039
sg4
(lp5040
(dp5041
g7
I137
sg8
VP01112
p5042
sg10
I24
sg11
Vactivated H-ras oncogene
p5043
sg13
I3
sasg17
(lp5044
(dp5045
g7
I177
sg20
VC0599157
p5046
sg10
I12
sg11
Vtransversion
p5047
sg13
I1
sa(dp5048
g7
I8
sg20
VC0553723
p5049
sg10
I28
sg11
Vskin squamous cell carcinoma
p5050
sg13
I4
sasa(dp5051
g2
S'Anemia is an important and common problem associated with chronic kidney disease (CKD), which is caused by erythropoietin deficiency, iron-restricted erythropoiesis, inflammation, hypoxia, vitamin D deficiency, hyperparathyroidism, and obesity.\n'
p5052
sg4
(lp5053
(dp5054
g7
I107
sg8
VP01588
p5055
sg10
I14
sg11
Verythropoietin
p5056
sg13
I1
sasg17
(lp5057
(dp5058
g7
I189
sg20
VC0042870
p5059
sg10
I20
sg11
Vvitamin D deficiency
p5060
sg13
I3
sa(dp5061
g7
I236
sg20
VC0028754
p5062
sg10
I7
sg11
Vobesity
p5063
sg13
I1
sa(dp5064
g7
I211
sg20
VC0020502
p5065
sg10
I19
sg11
Vhyperparathyroidism
p5066
sg13
I1
sa(dp5067
g7
I82
sg20
VC1561643
p5068
sg10
I3
sg11
VCKD
p5069
sg13
I1
sa(dp5070
g7
I166
sg20
VC0021368
p5071
sg10
I12
sg11
Vinflammation
p5072
sg13
I1
sa(dp5073
g7
I180
sg20
VC0242184
p5074
sg10
I7
sg11
Vhypoxia
p5075
sg13
I1
sa(dp5076
g7
I0
sg20
VC0002871
p5077
sg10
I6
sg11
VAnemia
p5078
sg13
I1
sa(dp5079
g7
I58
sg20
VC1561643
p5080
sg10
I22
sg11
Vchronic kidney disease
p5081
sg13
I3
sasa(dp5082
g2
S'The relation may guide physician to suspect hyperparathyroidism in chronic kidney disease patients and manage the complications related to hyperparathyroidism like renal mineral bone disease, anemia resistant to erythropoietin.\n'
p5083
sg4
(lp5084
(dp5085
g7
I212
sg8
VP01588
p5086
sg10
I14
sg11
Verythropoietin
p5087
sg13
I1
sasg17
(lp5088
(dp5089
g7
I178
sg20
VC0005940
p5090
sg10
I12
sg11
Vbone disease
p5091
sg13
I2
sa(dp5092
g7
I67
sg20
VC1561643
p5093
sg10
I22
sg11
Vchronic kidney disease
p5094
sg13
I3
sa(dp5095
g7
I44
sg20
VC0020502
p5096
sg10
I19
sg11
Vhyperparathyroidism
p5097
sg13
I1
sa(dp5098
g7
I44
sg20
VC0020502
p5099
sg10
I19
sg11
Vhyperparathyroidism
p5100
sg13
I1
sa(dp5101
g7
I192
sg20
VC0002871
p5102
sg10
I6
sg11
Vanemia
p5103
sg13
I1
sasa(dp5104
g2
S'The responsiveness to recombinant human erythropoietin in hemodialysis (HD) patients with relative hypoparathyroidism [4 &lt;= intact parathyroid hormone (iPTH) &lt;=16.5 pmol/L] remains undetermined.\n'
p5105
sg4
(lp5106
(dp5107
g7
I134
sg8
VP01270
p5108
sg10
I19
sg11
Vparathyroid hormone
p5109
sg13
I2
sa(dp5110
g7
I22
sg8
VP01588
p5111
sg10
I32
sg11
Vrecombinant human erythropoietin
p5112
sg13
I3
sasg17
(lp5113
(dp5114
g7
I99
sg20
VC0020626
p5115
sg10
I18
sg11
Vhypoparathyroidism
p5116
sg13
I1
sasa(dp5117
g2
S'If other factors related to anemia are excluded in chronic HD patients, the lower the iPTH level (relative hypoparathyroidism) the better the responsiveness to recombinant human erythropoietin.\n'
p5118
sg4
(lp5119
(dp5120
g7
I160
sg8
VP01588
p5121
sg10
I32
sg11
Vrecombinant human erythropoietin
p5122
sg13
I3
sasg17
(lp5123
(dp5124
g7
I107
sg20
VC0020626
p5125
sg10
I18
sg11
Vhypoparathyroidism
p5126
sg13
I1
sa(dp5127
g7
I28
sg20
VC0002871
p5128
sg10
I6
sg11
Vanemia
p5129
sg13
I1
sasa(dp5130
g2
S'Given that P2RX7-dependent LP and HSP90 are critically interacting in the ATP-evoked autophagic death of dystrophic muscles, treatments targeting this axis could be of therapeutic benefit in this debilitating and incurable form of muscular dystrophy.\n'
p5131
sg4
(lp5132
(dp5133
g7
I11
sg8
g127
sg10
I18
sg11
VP2RX7-dependent LP
p5134
sg13
I2
sa(dp5135
g7
I34
sg8
VP07900
p5136
sg10
I5
sg11
VHSP90
p5137
sg13
I1
sasg17
(lp5138
(dp5139
g7
I231
sg20
VC0026850
p5140
sg10
I18
sg11
Vmuscular dystrophy
p5141
sg13
I2
sasa(dp5142
g2
S'The focus is especially on the molecular fate of HSPs cardiovascular HSP (HSPB7), AlfaBC (HSPB5), HSP70 (HSPA) and HSP90 (HSPC) in dystrophin-deficient muscles and their involvement in progressive muscular dystrophy.\n'
p5143
sg4
(lp5144
(dp5145
g7
I49
sg8
g127
sg10
I47
sg11
VHSPs cardiovascular HSP (HSPB7), AlfaBC (HSPB5)
p5146
sg13
I6
sa(dp5147
g7
I131
sg8
VP11532
p5148
sg10
I10
sg11
Vdystrophin
p5149
sg13
I1
sa(dp5150
g7
I115
sg8
VP07900
p5151
sg10
I5
sg11
VHSP90
p5152
sg13
I1
sa(dp5153
g7
I98
sg8
VP34932
p5154
sg10
I12
sg11
VHSP70 (HSPA)
p5155
sg13
I2
sa(dp5156
g7
I122
sg8
g127
sg10
I4
sg11
VHSPC
p5157
sg13
I1
sasg17
(lp5158
(dp5159
g7
I185
sg20
VC0026850
p5160
sg10
I30
sg11
Vprogressive muscular dystrophy
p5161
sg13
I3
sa(dp5162
g7
I49
sg20
VC0034152
p5163
sg10
I3
sg11
VHSP
p5164
sg13
I1
sasa(dp5165
g2
S'Regenerating muscle fibers of IIM and muscular dystrophy patients showed increased expression of HSP90 and HSP70, as did atrophic perifascicular muscle fibers of DM and vacuolated fibers of IBM.\n'
p5166
sg4
(lp5167
(dp5168
g7
I97
sg8
VP07900
p5169
sg10
I5
sg11
VHSP90
p5170
sg13
I1
sa(dp5171
g7
I107
sg8
VP34932
p5172
sg10
I5
sg11
VHSP70
p5173
sg13
I1
sasg17
(lp5174
(dp5175
g7
I121
sg20
VC0333641
p5176
sg10
I8
sg11
Vatrophic
p5177
sg13
I1
sa(dp5178
g7
I30
sg20
VC2931785
p5179
sg10
I3
sg11
VIIM
p5180
sg13
I1
sa(dp5181
g7
I38
sg20
VC0026850
p5182
sg10
I18
sg11
Vmuscular dystrophy
p5183
sg13
I2
sa(dp5184
g7
I190
sg20
VC0238190
p5185
sg10
I3
sg11
VIBM
p5186
sg13
I1
sasa(dp5187
g2
S'The 90-kD heat-shock protein (hsp90) and ubiquitin are up-regulated in regenerating fibers and diseased fibers of Duchenne muscular dystrophy.\n'
p5188
sg4
(lp5189
(dp5190
g7
I4
sg8
VP08107
p5191
sg10
I24
sg11
V90-kD heat-shock protein
p5192
sg13
I3
sa(dp5193
g7
I30
sg8
VP07900
p5194
sg10
I5
sg11
Vhsp90
p5195
sg13
I1
sa(dp5196
g7
I41
sg8
VP62979
p5197
sg10
I9
sg11
Vubiquitin
p5198
sg13
I1
sasg17
(lp5199
(dp5200
g7
I114
sg20
VC0013264
p5201
sg10
I27
sg11
VDuchenne muscular dystrophy
p5202
sg13
I3
sasa(dp5203
g2
S'All OMG patients with higher MJ and PAOF values should also be screened for thymoma.\n'
p5204
sg4
(lp5205
sg17
(lp5206
(dp5207
g7
I76
sg20
VC0040100
p5208
sg10
I7
sg11
Vthymoma
p5209
sg13
I1
sasa(dp5210
g2
S'Age of onset (p = 0.034), the onset symptom of ocular MG (OMG; p = 0.023), the first symptom of OMG second generalization (p = 0.040) were different in MG with thymoma from those in MG with normal thymus or thymus hyperplasia.\n'
p5211
sg4
(lp5212
sg17
(lp5213
(dp5214
g7
I36
sg20
VC1457887
p5215
sg10
I7
sg11
Vsymptom
p5216
sg13
I1
sa(dp5217
g7
I207
sg20
VC0040115
p5218
sg10
I18
sg11
Vthymus hyperplasia
p5219
sg13
I2
sa(dp5220
g7
I36
sg20
VC1457887
p5221
sg10
I7
sg11
Vsymptom
p5222
sg13
I1
sa(dp5223
g7
I160
sg20
VC0040100
p5224
sg10
I7
sg11
Vthymoma
p5225
sg13
I1
sasa(dp5226
g2
S'Here, we analyzed surface markers CXCR5, Bcl-6, ICOS and IL-21 on TFH cells in thymus derived from thymoma patients with ocular MG (OMG), generalized MG (GMG) or without MG using immunohistochemical staining, immunofluorescence, western blotting, and real-time PCR analysis.\n'
p5227
sg4
(lp5228
(dp5229
g7
I34
sg8
VP32302
p5230
sg10
I5
sg11
VCXCR5
p5231
sg13
I1
sa(dp5232
g7
I57
sg8
g127
sg10
I5
sg11
VIL-21
p5233
sg13
I1
sa(dp5234
g7
I48
sg8
VP16410
p5235
sg10
I4
sg11
VICOS
p5236
sg13
I1
sa(dp5237
g7
I41
sg8
VP41182
p5238
sg10
I5
sg11
VBcl-6
p5239
sg13
I1
sasg17
(lp5240
(dp5241
g7
I99
sg20
VC0040100
p5242
sg10
I7
sg11
Vthymoma
p5243
sg13
I1
sasa(dp5244
g2
S'Indeed, results show higher expression of all four markers in thymoma with GMG patients compared with both OMG and non-MG patients.\n'
p5245
sg4
(lp5246
(dp5247
g7
I107
sg8
VP23515
p5248
sg10
I3
sg11
VOMG
p5249
sg13
I1
sasg17
(lp5250
(dp5251
g7
I62
sg20
VC0040100
p5252
sg10
I7
sg11
Vthymoma
p5253
sg13
I1
sasa(dp5254
g2
S'Three sub-groups of patients were highlighted: (i) severe, symptomatic chronic neutropenia, detected early in life, and related to a known mutation in the CN spectrum (ELANE); (ii) mild to moderate benign intermittent neutropenia, detected later, and associated with mutations in genes implicated in neurodevelopmental disorders (CHD2, HUWE1); and (iii) moderate to severe intermittent neutropenia as a probably undiagnosed feature of a newly reported syndrome (KAT6A).\n'
p5255
sg4
(lp5256
(dp5257
g7
I330
sg8
g127
sg10
I4
sg11
VCHD2
p5258
sg13
I1
sasg17
(lp5259
(dp5260
g7
I71
sg20
VC0746882
p5261
sg10
I19
sg11
Vchronic neutropenia
p5262
sg13
I2
sa(dp5263
g7
I452
sg20
VC0039082
p5264
sg10
I8
sg11
Vsyndrome
p5265
sg13
I1
sasa(dp5266
g2
S'SSc patients with arthritis, elevated IgG titer, ESR &gt;30 mm/h, and CRP &gt;5 mg/l displayed elevated expression of TL1A, respectively.\n'
p5267
sg4
(lp5268
(dp5269
g7
I70
sg8
VP02741
p5270
sg10
I3
sg11
VCRP
p5271
sg13
I1
sa(dp5272
g7
I118
sg8
g127
sg10
I4
sg11
VTL1A
p5273
sg13
I1
sasg17
(lp5274
(dp5275
g7
I18
sg20
VC0003864
p5276
sg10
I9
sg11
Varthritis
p5277
sg13
I1
sasa(dp5278
g2
S'The interaction of TL1A and DR3 may participate in the pathogenesis of some autoimmune diseases including rheumatoid arthritis (RA).\n'
p5279
sg4
(lp5280
(dp5281
g7
I19
sg8
g127
sg10
I4
sg11
VTL1A
p5282
sg13
I1
sasg17
(lp5283
(dp5284
g7
I76
sg20
VC0004364
p5285
sg10
I19
sg11
Vautoimmune diseases
p5286
sg13
I2
sa(dp5287
g7
I128
sg20
VC0003873
p5288
sg10
I2
sg11
VRA
p5289
sg13
I1
sa(dp5290
g7
I55
sg20
VC0699748
p5291
sg10
I12
sg11
Vpathogenesis
p5292
sg13
I1
sa(dp5293
g7
I106
sg20
VC0003873
p5294
sg10
I20
sg11
Vrheumatoid arthritis
p5295
sg13
I2
sasa(dp5296
g2
S'The purpose of this study was to explore the role of TNF-like ligand 1A (TL1A) gene (TNFST15) polymorphisms (rs3810936, rs7848647, and rs6478109) in the generation of ankylosing spondylitis (AS).\n'
p5297
sg4
(lp5298
(dp5299
g7
I53
sg8
VP01375
p5300
sg10
I18
sg11
VTNF-like ligand 1A
p5301
sg13
I3
sa(dp5302
g7
I73
sg8
g127
sg10
I4
sg11
VTL1A
p5303
sg13
I1
sasg17
(lp5304
(dp5305
g7
I191
sg20
VC0038013
p5306
sg10
I2
sg11
VAS
p5307
sg13
I1
sa(dp5308
g7
I167
sg20
VC0038013
p5309
sg10
I22
sg11
Vankylosing spondylitis
p5310
sg13
I2
sasa(dp5311
g2
S'TNF-like ligand 1A (TL1A), a recently recognized member of the TNF superfamily, and its death domain receptor 3 (DR3), firstly identified for their relevant role in T lymphocyte homeostasis, are now well-known mediators of several immune-inflammatory diseases, ranging from rheumatoid arthritis to inflammatory bowel diseases to psoriasis, whereas no data are available on their involvement in sarcoidosis, a multisystemic granulomatous disease where a deregulated T helper (Th)1/Th17 response takes place.\n'
p5312
sg4
(lp5313
(dp5314
g7
I20
sg8
g127
sg10
I4
sg11
VTL1A
p5315
sg13
I1
sa(dp5316
g7
I63
sg8
VP01375
p5317
sg10
I15
sg11
VTNF superfamily
p5318
sg13
I2
sa(dp5319
g7
I0
sg8
VP01375
p5320
sg10
I18
sg11
VTNF-like ligand 1A
p5321
sg13
I3
sa(dp5322
g7
I88
sg8
g127
sg10
I23
sg11
Vdeath domain receptor 3
p5323
sg13
I4
sasg17
(lp5324
(dp5325
g7
I423
sg20
VC0740451
p5326
sg10
I21
sg11
Vgranulomatous disease
p5327
sg13
I2
sa(dp5328
g7
I394
sg20
VC0036202
p5329
sg10
I11
sg11
Vsarcoidosis
p5330
sg13
I1
sa(dp5331
g7
I298
sg20
VC0021390
p5332
sg10
I27
sg11
Vinflammatory bowel diseases
p5333
sg13
I3
sa(dp5334
g7
I329
sg20
VC0033860
p5335
sg10
I9
sg11
Vpsoriasis
p5336
sg13
I1
sa(dp5337
g7
I274
sg20
VC0003873
p5338
sg10
I20
sg11
Vrheumatoid arthritis
p5339
sg13
I2
sasa(dp5340
g2
S'Intranasal immunization with plasmid pCIA-P encoding pac gene successfully reduces the caries and appears to be a promising approach against dental caries.\n'
p5341
sg4
(lp5342
sg17
(lp5343
(dp5344
g7
I87
sg20
VC0333519
p5345
sg10
I6
sg11
Vcaries
p5346
sg13
I1
sa(dp5347
g7
I141
sg20
VC0333519
p5348
sg10
I13
sg11
Vdental caries
p5349
sg13
I2
sa(dp5350
g7
I53
sg20
VC0033036
p5351
sg10
I3
sg11
Vpac
p5352
sg13
I1
sasa(dp5353
g2
S'Mutations in the PGAP2 gene cause hyperphosphatasia mental retardation syndrome-3.\n'
p5354
sg4
(lp5355
(dp5356
g7
I17
sg8
g127
sg10
I10
sg11
VPGAP2 gene
p5357
sg13
I2
sasg17
(lp5358
(dp5359
g7
I52
sg20
VC0025362
p5360
sg10
I18
sg11
Vmental retardation
p5361
sg13
I2
sa(dp5362
g7
I71
sg20
VC0039082
p5363
sg10
I8
sg11
Vsyndrome
p5364
sg13
I1
sasa(dp5365
g2
S'Among them, mutations in PIGV and PIGO, which are involved in the late stages of GPI-anchor synthesis, and PGAP2, which is involved in fatty-acid GPI-anchor remodeling, are all causative for hyperphosphatasia with mental retardation syndrome (HPMRS).\n'
p5366
sg4
(lp5367
(dp5368
g7
I107
sg8
g127
sg10
I5
sg11
VPGAP2
p5369
sg13
I1
sa(dp5370
g7
I25
sg8
g127
sg10
I4
sg11
VPIGV
p5371
sg13
I1
sa(dp5372
g7
I34
sg8
g127
sg10
I4
sg11
VPIGO
p5373
sg13
I1
sasg17
(lp5374
(dp5375
g7
I233
sg20
VC0039082
p5376
sg10
I8
sg11
Vsyndrome
p5377
sg13
I1
sa(dp5378
g7
I191
sg20
VC1855923
p5379
sg10
I41
sg11
Vhyperphosphatasia with mental retardation
p5380
sg13
I4
sasa(dp5381
g2
S'Three different genes of the glycosylphosphatidylinositol anchor synthesis pathway, PIGV, PIGO, and PGAP2, have recently been implicated in hyperphosphatasia-mental retardation syndrome (HPMRS), also known as Mabry syndrome, a rare autosomal recessive form of intellectual disability.\n'
p5382
sg4
(lp5383
(dp5384
g7
I84
sg8
g127
sg10
I4
sg11
VPIGV
p5385
sg13
I1
sa(dp5386
g7
I100
sg8
g127
sg10
I5
sg11
VPGAP2
p5387
sg13
I1
sa(dp5388
g7
I90
sg8
g127
sg10
I4
sg11
VPIGO
p5389
sg13
I1
sasg17
(lp5390
(dp5391
g7
I209
sg20
VC1855923
p5392
sg10
I14
sg11
VMabry syndrome
p5393
sg13
I2
sa(dp5394
g7
I260
sg20
VC0025362
p5395
sg10
I23
sg11
Vintellectual disability
p5396
sg13
I2
sa(dp5397
g7
I158
sg20
VC0025362
p5398
sg10
I18
sg11
Vmental retardation
p5399
sg13
I2
sa(dp5400
g7
I177
sg20
VC0039082
p5401
sg10
I8
sg11
Vsyndrome
p5402
sg13
I1
sasa(dp5403
g2
S'We developed a diagnostic gene panel for targeting all known genes encoding proteins in the GPI-anchor-synthesis pathway to screen individuals matching these features, and we detected three missense mutations in PGAP2, c.46C&gt;T, c.380T&gt;C, and c.479C&gt;T, in two unrelated individuals with hyperphosphatasia with mental retardation syndrome (HPMRS).\n'
p5404
sg4
(lp5405
(dp5406
g7
I212
sg8
g127
sg10
I5
sg11
VPGAP2
p5407
sg13
I1
sasg17
(lp5408
(dp5409
g7
I295
sg20
VC1855923
p5410
sg10
I41
sg11
Vhyperphosphatasia with mental retardation
p5411
sg13
I4
sa(dp5412
g7
I337
sg20
VC0039082
p5413
sg10
I8
sg11
Vsyndrome
p5414
sg13
I1
sasa(dp5415
g2
S'We performed autozygosity mapping and ultra-deep sequencing followed by stringent filtering and identified two homozygous PGAP2 alterations, p.Tyr99Cys and p.Arg177Pro, in seven offspring with nonspecific autosomal-recessive intellectual disability from two consanguineous families.\n'
p5416
sg4
(lp5417
(dp5418
g7
I122
sg8
g127
sg10
I5
sg11
VPGAP2
p5419
sg13
I1
sasg17
(lp5420
(dp5421
g7
I225
sg20
VC0025362
p5422
sg10
I23
sg11
Vintellectual disability
p5423
sg13
I2
sasa(dp5424
g2
S'Detailed issues of diagnosing and treatment of many rare diseases were also presented, among others Wilson disease, Alstroem syndrome, Cohen syndrome, Rubinstein-Taybi syndrome, Cornelia de Lange syndrome, Poland syndrome, Netherton syndrome, inborn aniridia and congenital arhinia - very rare defect requiring further scientific studies.\n'
p5425
sg4
(lp5426
sg17
(lp5427
(dp5428
g7
I141
sg20
VC0035934
p5429
sg10
I26
sg11
Vsyndrome, Rubinstein-Taybi
p5430
sg13
I2
sa(dp5431
g7
I274
sg20
VC0265740
p5432
sg10
I7
sg11
Varhinia
p5433
sg13
I1
sa(dp5434
g7
I116
sg20
VC0268425
p5435
sg10
I17
sg11
VAlstroem syndrome
p5436
sg13
I2
sa(dp5437
g7
I125
sg20
VC0039082
p5438
sg10
I8
sg11
Vsyndrome
p5439
sg13
I1
sa(dp5440
g7
I213
sg20
VC0265962
p5441
sg10
I19
sg11
Vsyndrome, Netherton
p5442
sg13
I2
sa(dp5443
g7
I178
sg20
VC0270972
p5444
sg10
I26
sg11
VCornelia de Lange syndrome
p5445
sg13
I4
sa(dp5446
g7
I52
sg20
VC0678236
p5447
sg10
I13
sg11
Vrare diseases
p5448
sg13
I2
sa(dp5449
g7
I250
sg20
VC0003076
p5450
sg10
I8
sg11
Vaniridia
p5451
sg13
I1
sa(dp5452
g7
I100
sg20
VC0019202
p5453
sg10
I14
sg11
VWilson disease
p5454
sg13
I2
sa(dp5455
g7
I125
sg20
VC0039082
p5456
sg10
I8
sg11
Vsyndrome
p5457
sg13
I1
sa(dp5458
g7
I196
sg20
VC0032357
p5459
sg10
I16
sg11
Vsyndrome, Poland
p5460
sg13
I2
sasa(dp5461
g2
S'However, the value of RPS4X as a diagnostic and prognostic marker in intrahepatic cholangiocarcinoma (ICC) has not yet been investigated.\n'
p5462
sg4
(lp5463
(dp5464
g7
I22
sg8
VP62701
p5465
sg10
I5
sg11
VRPS4X
p5466
sg13
I1
sasg17
(lp5467
(dp5468
g7
I69
sg20
VC0345905
p5469
sg10
I31
sg11
Vintrahepatic cholangiocarcinoma
p5470
sg13
I2
sa(dp5471
g7
I102
sg20
VC0268074
p5472
sg10
I3
sg11
VICC
p5473
sg13
I1
sasa(dp5474
g2
S'RFX6 heterozygotes have reduced penetrance of diabetes compared to common HNF1A and HNF4A-MODY mutations (27, 70 and 55% at 25 years of age, respectively).\n'
p5475
sg4
(lp5476
(dp5477
g7
I74
sg8
VP20823
p5478
sg10
I5
sg11
VHNF1A
p5479
sg13
I1
sa(dp5480
g7
I0
sg8
g127
sg10
I4
sg11
VRFX6
p5481
sg13
I1
sa(dp5482
g7
I90
sg8
VP19835
p5483
sg10
I4
sg11
VMODY
p5484
sg13
I1
sasg17
(lp5485
(dp5486
g7
I46
sg20
VC0011849
p5487
sg10
I8
sg11
Vdiabetes
p5488
sg13
I1
sa(dp5489
g7
I90
sg20
VC0011860
p5490
sg10
I4
sg11
VMODY
p5491
sg13
I1
sasa(dp5492
g2
S'Our study demonstrates that heterozygous RFX6 protein truncating variants are associated with MODY with reduced penetrance.Maturity-onset diabetes of the young (MODY) is the most common subtype of familial diabetes.\n'
p5493
sg4
(lp5494
(dp5495
g7
I41
sg8
g127
sg10
I32
sg11
VRFX6 protein truncating variants
p5496
sg13
I4
sasg17
(lp5497
(dp5498
g7
I94
sg20
VC0342276
p5499
sg10
I4
sg11
VMODY
p5500
sg13
I1
sa(dp5501
g7
I112
sg20
VC0342276
p5502
sg10
I47
sg11
Vpenetrance.Maturity-onset diabetes of the young
p5503
sg13
I5
sa(dp5504
g7
I94
sg20
VC0342276
p5505
sg10
I4
sg11
VMODY
p5506
sg13
I1
sa(dp5507
g7
I138
sg20
VC0011849
p5508
sg10
I8
sg11
Vdiabetes
p5509
sg13
I1
sasa(dp5510
g2
S'As childhood obesity is a concern in many communities, this study investigated outpatient evaluation and initial management of overweight and obese pediatric patients in U.S. military medical treatment facilities (MTFs).\n'
p5511
sg4
(lp5512
sg17
(lp5513
(dp5514
g7
I127
sg20
VC0497406
p5515
sg10
I10
sg11
Voverweight
p5516
sg13
I1
sa(dp5517
g7
I3
sg20
VC2362324
p5518
sg10
I17
sg11
Vchildhood obesity
p5519
sg13
I2
sa(dp5520
g7
I142
sg20
VC0028754
p5521
sg10
I5
sg11
Vobese
p5522
sg13
I1
sasa(dp5523
g2
S'Eighteen MtFs developed hyperprolactinemia (&gt;=0.6 IU L-1 ).\n'
p5524
sg4
(lp5525
sg17
(lp5526
(dp5527
g7
I24
sg20
VC0020514
p5528
sg10
I18
sg11
Vhyperprolactinemia
p5529
sg13
I1
sasa(dp5530
g2
S'Mitchell-Riley syndrome, an autosomal recessive disorder caused by mutations in the RFX6 gene, is defined as a combination of neonatal diabetes mellitus and serious congenital gastrointestinal defects.\n'
p5531
sg4
(lp5532
(dp5533
g7
I84
sg8
g127
sg10
I9
sg11
VRFX6 gene
p5534
sg13
I2
sasg17
(lp5535
(dp5536
g7
I0
sg20
VC2748662
p5537
sg10
I23
sg11
VMitchell-Riley syndrome
p5538
sg13
I2
sa(dp5539
g7
I126
sg20
VC0158981
p5540
sg10
I26
sg11
Vneonatal diabetes mellitus
p5541
sg13
I3
sasa(dp5542
g2
S'We identified 236 tagSNPs in 9 key genes related to SOCCs and ROCCs (TRPC1, TRPC3, TRPC4, TRPC6, TRPC7, ORAI1, ORAI2, STIM1, and STIM2) and evaluated their association with lung cancer risk in a two-stage case-control study with a total of 2433 lung cancer cases and 2433 cancer-free controls using Illumina high throughput genotyping platform.\n'
p5543
sg4
(lp5544
(dp5545
g7
I111
sg8
g127
sg10
I5
sg11
VORAI2
p5546
sg13
I1
sa(dp5547
g7
I90
sg8
g127
sg10
I5
sg11
VTRPC6
p5548
sg13
I1
sa(dp5549
g7
I118
sg8
g127
sg10
I5
sg11
VSTIM1
p5550
sg13
I1
sa(dp5551
g7
I97
sg8
VP10909
p5552
sg10
I5
sg11
VTRPC7
p5553
sg13
I1
sa(dp5554
g7
I129
sg8
g127
sg10
I5
sg11
VSTIM2
p5555
sg13
I1
sa(dp5556
g7
I69
sg8
VP48995
p5557
sg10
I5
sg11
VTRPC1
p5558
sg13
I1
sa(dp5559
g7
I76
sg8
g127
sg10
I5
sg11
VTRPC3
p5560
sg13
I1
sa(dp5561
g7
I83
sg8
g127
sg10
I5
sg11
VTRPC4
p5562
sg13
I1
sa(dp5563
g7
I104
sg8
g127
sg10
I5
sg11
VORAI1
p5564
sg13
I1
sasg17
(lp5565
(dp5566
g7
I173
sg20
VC0684249
p5567
sg10
I11
sg11
Vlung cancer
p5568
sg13
I2
sa(dp5569
g7
I173
sg20
VC0684249
p5570
sg10
I11
sg11
Vlung cancer
p5571
sg13
I2
sa(dp5572
g7
I178
sg20
VC0006826
p5573
sg10
I6
sg11
Vcancer
p5574
sg13
I1
sasa(dp5575
g2
S'Using ex vivo models of disease we demonstrated that FB28.4.2 protected paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and inhibited both C3 fragment and C5b-9 deposition on ADP-activated HMEC-1 cells, an experimental model for atypical hemolytic uremic syndrome.\n'
p5576
sg4
(lp5577
sg17
(lp5578
(dp5579
g7
I265
sg20
VC2931788
p5580
sg10
I34
sg11
Vatypical hemolytic uremic syndrome
p5581
sg13
I4
sa(dp5582
g7
I72
sg20
VC0024790
p5583
sg10
I35
sg11
Vparoxysmal nocturnal hemoglobinuria
p5584
sg13
I3
sa(dp5585
g7
I146
sg20
VC0019054
p5586
sg10
I9
sg11
Vhemolysis
p5587
sg13
I1
sasa(dp5588
g2
S'Of 214 eligible participants recruited between Sept 1, 2010, and March 31, 2012, 189 had a confirmed diagnosis of idiopathic pulmonary fibrosis and were included in subsequent analyses.\n'
p5589
sg4
(lp5590
sg17
(lp5591
(dp5592
g7
I114
sg20
VC3161101
p5593
sg10
I29
sg11
Vidiopathic pulmonary fibrosis
p5594
sg13
I3
sasa(dp5595
g2
S'KRT5 and KRT6 (KRT6A, KRT6B &amp; KRT6C) gene expression was assessed in publically available serous ovarian cancer data sets, ovarian cancer cell lines and primary serous ovarian cancer cells.\n'
p5596
sg4
(lp5597
(dp5598
g7
I0
sg8
VP13647
p5599
sg10
I4
sg11
VKRT5
p5600
sg13
I1
sa(dp5601
g7
I15
sg8
VP02538
p5602
sg10
I5
sg11
VKRT6A
p5603
sg13
I1
sa(dp5604
g7
I9
sg8
g127
sg10
I4
sg11
VKRT6
p5605
sg13
I1
sa(dp5606
g7
I34
sg8
VP48668
p5607
sg10
I5
sg11
VKRT6C
p5608
sg13
I1
sa(dp5609
g7
I22
sg8
VP08779
p5610
sg10
I5
sg11
VKRT6B
p5611
sg13
I1
sasg17
(lp5612
(dp5613
g7
I101
sg20
VC1140680
p5614
sg10
I14
sg11
Vovarian cancer
p5615
sg13
I2
sa(dp5616
g7
I101
sg20
VC1140680
p5617
sg10
I14
sg11
Vovarian cancer
p5618
sg13
I2
sa(dp5619
g7
I101
sg20
VC1140680
p5620
sg10
I14
sg11
Vovarian cancer
p5621
sg13
I2
sasa(dp5622
g2
S'Survival analyses showed that high KRT5 mRNA in stage III/IV serous ovarian cancers was significantly associated with reduced progression-free (HR 1.38, P &lt; 0.0001) and overall survival (HR 1.28, P = 0.013) whilst high KRT6 mRNA was only associated with reduced progression-free survival (HR 1.2, P = 0.031).\n'
p5623
sg4
(lp5624
(dp5625
g7
I222
sg8
g127
sg10
I9
sg11
VKRT6 mRNA
p5626
sg13
I2
sa(dp5627
g7
I35
sg8
VP13647
p5628
sg10
I9
sg11
VKRT5 mRNA
p5629
sg13
I2
sasg17
(lp5630
(dp5631
g7
I68
sg20
VC1140680
p5632
sg10
I15
sg11
Vovarian cancers
p5633
sg13
I2
sasa(dp5634
g2
S'KRT5 but not KRT6C mRNA expression was increased in chemotherapy resistant primary serous ovarian cancer cells compared to chemotherapy sensitive cells.\n'
p5635
sg4
(lp5636
(dp5637
g7
I0
sg8
VP13647
p5638
sg10
I4
sg11
VKRT5
p5639
sg13
I1
sa(dp5640
g7
I13
sg8
VP48668
p5641
sg10
I10
sg11
VKRT6C mRNA
p5642
sg13
I2
sasg17
(lp5643
(dp5644
g7
I90
sg20
VC1140680
p5645
sg10
I14
sg11
Vovarian cancer
p5646
sg13
I2
sasa(dp5647
g2
S'The incidences of grades 3-4 neutropenia, thrombocytopenia, leukopenia, anemia, deep vein thrombosis, diarrhea, fatigue and rash were 51% (95% CI 30-73%), 31% (95% CI 20-42%), 9% (95% CI 5-13%), 7% (95% CI 2-12%), 3% (95% CI 2-5%), 3% (95% CI 1-5%), 2% (95% CI 1-4%) and 2% (95% CI 1-3%), respectively.\n'
p5648
sg4
(lp5649
sg17
(lp5650
(dp5651
g7
I80
sg20
VC0149871
p5652
sg10
I20
sg11
Vdeep vein thrombosis
p5653
sg13
I3
sa(dp5654
g7
I102
sg20
VC0011991
p5655
sg10
I8
sg11
Vdiarrhea
p5656
sg13
I1
sa(dp5657
g7
I72
sg20
VC0002871
p5658
sg10
I6
sg11
Vanemia
p5659
sg13
I1
sa(dp5660
g7
I112
sg20
VC0015672
p5661
sg10
I7
sg11
Vfatigue
p5662
sg13
I1
sa(dp5663
g7
I124
sg20
VC0015230
p5664
sg10
I4
sg11
Vrash
p5665
sg13
I1
sa(dp5666
g7
I60
sg20
VC0023530
p5667
sg10
I10
sg11
Vleukopenia
p5668
sg13
I1
sasa(dp5669
g2
S'Mowat-Wilson syndrome (MWS) is a genetic disease characterized by distinctive facial features, moderate to severe intellectual disability, and congenital malformations, including Hirschsprung disease, genital and eye anomalies, and congenital heart defects, caused by haploinsufficiency of the ZEB2 gene.\n'
p5670
sg4
(lp5671
(dp5672
g7
I294
sg8
g127
sg10
I9
sg11
VZEB2 gene
p5673
sg13
I2
sasg17
(lp5674
(dp5675
g7
I232
sg20
VC0018798
p5676
sg10
I24
sg11
Vcongenital heart defects
p5677
sg13
I3
sa(dp5678
g7
I33
sg20
VC0019247
p5679
sg10
I15
sg11
Vgenetic disease
p5680
sg13
I2
sa(dp5681
g7
I0
sg20
VC1856113
p5682
sg10
I21
sg11
VMowat-Wilson syndrome
p5683
sg13
I2
sa(dp5684
g7
I143
sg20
VC0000768
p5685
sg10
I24
sg11
Vcongenital malformations
p5686
sg13
I2
sa(dp5687
g7
I179
sg20
VC0019569
p5688
sg10
I20
sg11
VHirschsprung disease
p5689
sg13
I2
sa(dp5690
g7
I114
sg20
VC0025362
p5691
sg10
I23
sg11
Vintellectual disability
p5692
sg13
I2
sa(dp5693
g7
I23
sg20
VC0796033
p5694
sg10
I3
sg11
VMWS
p5695
sg13
I1
sasa(dp5696
g2
S'Eight of these changes affect KMT2D, ZEB2, MAP2K2, GLDC, CASK, MECP2, KDM5C, and POGZ, known to be associated with Kabuki syndrome 1, Mowat-Wilson syndrome, cardiofaciocutaneous syndrome, glycine encephalopathy, mental retardation and microcephaly with pontine and cerebellar hypoplasia, X-linked mental retardation 13, X-linked mental retardation Claes-Jensen type, and White-Sutton syndrome, respectively.\n'
p5697
sg4
(lp5698
(dp5699
g7
I43
sg8
VP36507
p5700
sg10
I6
sg11
VMAP2K2
p5701
sg13
I1
sa(dp5702
g7
I57
sg8
VP07498
p5703
sg10
I4
sg11
VCASK
p5704
sg13
I1
sa(dp5705
g7
I37
sg8
g127
sg10
I4
sg11
VZEB2
p5706
sg13
I1
sa(dp5707
g7
I30
sg8
g127
sg10
I5
sg11
VKMT2D
p5708
sg13
I1
sa(dp5709
g7
I51
sg8
VP23378
p5710
sg10
I4
sg11
VGLDC
p5711
sg13
I1
sa(dp5712
g7
I63
sg8
VP51608
p5713
sg10
I5
sg11
VMECP2
p5714
sg13
I1
sa(dp5715
g7
I70
sg8
VP41229
p5716
sg10
I5
sg11
VKDM5C
p5717
sg13
I1
sasg17
(lp5718
(dp5719
g7
I122
sg20
VC0039082
p5720
sg10
I8
sg11
Vsyndrome
p5721
sg13
I1
sa(dp5722
g7
I188
sg20
VC0751748
p5723
sg10
I22
sg11
Vglycine encephalopathy
p5724
sg13
I2
sa(dp5725
g7
I134
sg20
VC1856113
p5726
sg10
I21
sg11
VMowat-Wilson syndrome
p5727
sg13
I2
sa(dp5728
g7
I157
sg20
VC1275081
p5729
sg10
I29
sg11
Vcardiofaciocutaneous syndrome
p5730
sg13
I2
sa(dp5731
g7
I212
sg20
VC2677903
p5732
sg10
I74
sg11
Vmental retardation and microcephaly with pontine and cerebellar hypoplasia
p5733
sg13
I9
sa(dp5734
g7
I115
sg20
VC0796004
p5735
sg10
I17
sg11
VKabuki syndrome 1
p5736
sg13
I3
sa(dp5737
g7
I288
sg20
VC1136249
p5738
sg10
I27
sg11
VX-linked mental retardation
p5739
sg13
I3
sa(dp5740
g7
I288
sg20
VC1136249
p5741
sg10
I27
sg11
VX-linked mental retardation
p5742
sg13
I3
sasa(dp5743
g2
S'In humans, SIP1 (ZEB2) haploinsufficiency leads to Mowat-Wilson syndrome, a complex congenital anomaly including intellectual disability, epilepsy and Hirschsprung disease.\n'
p5744
sg4
(lp5745
(dp5746
g7
I11
sg8
g127
sg10
I4
sg11
VSIP1
p5747
sg13
I1
sa(dp5748
g7
I17
sg8
g127
sg10
I4
sg11
VZEB2
p5749
sg13
I1
sasg17
(lp5750
(dp5751
g7
I51
sg20
VC1856113
p5752
sg10
I21
sg11
VMowat-Wilson syndrome
p5753
sg13
I2
sa(dp5754
g7
I84
sg20
VC0000768
p5755
sg10
I18
sg11
Vcongenital anomaly
p5756
sg13
I2
sa(dp5757
g7
I151
sg20
VC0019569
p5758
sg10
I20
sg11
VHirschsprung disease
p5759
sg13
I2
sa(dp5760
g7
I113
sg20
VC0025362
p5761
sg10
I23
sg11
Vintellectual disability
p5762
sg13
I2
sa(dp5763
g7
I138
sg20
VC0014544
p5764
sg10
I8
sg11
Vepilepsy
p5765
sg13
I1
sasa(dp5766
g2
S'We report the first confirmed cases of MWS in three children with the typical facial features, mental retardation, absent corpus callosum, epilepsy, and HSCR and novel Zeb2 variations on DNA analysis.\n'
p5767
sg4
(lp5768
(dp5769
g7
I153
sg8
VP14138
p5770
sg10
I4
sg11
VHSCR
p5771
sg13
I1
sa(dp5772
g7
I168
sg8
g127
sg10
I4
sg11
VZeb2
p5773
sg13
I1
sasg17
(lp5774
(dp5775
g7
I95
sg20
VC0025362
p5776
sg10
I18
sg11
Vmental retardation
p5777
sg13
I2
sa(dp5778
g7
I39
sg20
VC0796033
p5779
sg10
I3
sg11
VMWS
p5780
sg13
I1
sa(dp5781
g7
I139
sg20
VC0014544
p5782
sg10
I8
sg11
Vepilepsy
p5783
sg13
I1
sa(dp5784
g7
I115
sg20
VC0175754
p5785
sg10
I22
sg11
Vabsent corpus callosum
p5786
sg13
I3
sa(dp5787
g7
I153
sg20
VC2931876
p5788
sg10
I4
sg11
VHSCR
p5789
sg13
I1
sasa(dp5790
g2
S'Hence, this review is focused to describe thirteen common aminoacidopathies namely: Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Homocystinuria/Methylene Tetrahydrofolate Reductase (MTHFR) deficiency, Tyrosinemia type II, Citrullinemia type I and type II, Argininosuccinic aciduria, Carbamoyl Phosphate Synthetase I (CPS) deficiency, Argininemia (arginase deficiency), Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH) syndrome, N-Acetylglutamate Synthase (NAGS) deficiency, Ornithine Transcarbamylase (OTC) deficiency, and Pyruvate Dehydrogenase (PDH) complex deficiency.\n'
p5791
sg4
(lp5792
(dp5793
g7
I329
sg8
VP00450
p5794
sg10
I3
sg11
VCPS
p5795
sg13
I1
sa(dp5796
g7
I346
sg8
VP05089
p5797
sg10
I11
sg11
VArgininemia
p5798
sg13
I1
sa(dp5799
g7
I107
sg8
VP09622
p5800
sg10
I25
sg11
VMaple Syrup Urine Disease
p5801
sg13
I4
sa(dp5802
g7
I359
sg8
VP05089
p5803
sg10
I8
sg11
Varginase
p5804
sg13
I1
sa(dp5805
g7
I543
sg8
VP49366
p5806
sg10
I22
sg11
VPyruvate Dehydrogenase
p5807
sg13
I2
sa(dp5808
g7
I448
sg8
g127
sg10
I26
sg11
VN-Acetylglutamate Synthase
p5809
sg13
I2
sa(dp5810
g7
I134
sg8
VP12694
p5811
sg10
I4
sg11
VMSUD
p5812
sg13
I1
sa(dp5813
g7
I268
sg8
VP04424
p5814
sg10
I25
sg11
VArgininosuccinic aciduria
p5815
sg13
I2
sa(dp5816
g7
I194
sg8
VP42898
p5817
sg10
I5
sg11
VMTHFR
p5818
sg13
I1
sa(dp5819
g7
I141
sg8
VP42898
p5820
sg10
I51
sg11
VHomocystinuria/Methylene Tetrahydrofolate Reductase
p5821
sg13
I3
sa(dp5822
g7
I476
sg8
g127
sg10
I4
sg11
VNAGS
p5823
sg13
I1
sa(dp5824
g7
I295
sg8
VP31327
p5825
sg10
I32
sg11
VCarbamoyl Phosphate Synthetase I
p5826
sg13
I4
sa(dp5827
g7
I567
sg8
g127
sg10
I3
sg11
VPDH
p5828
sg13
I1
sa(dp5829
g7
I522
sg8
VP00480
p5830
sg10
I3
sg11
VOTC
p5831
sg13
I1
sa(dp5832
g7
I494
sg8
VP00480
p5833
sg10
I26
sg11
VOrnithine Transcarbamylase
p5834
sg13
I2
sasg17
(lp5835
(dp5836
g7
I438
sg20
VC0039082
p5837
sg10
I8
sg11
Vsyndrome
p5838
sg13
I1
sa(dp5839
g7
I141
sg20
VC0019880
p5840
sg10
I14
sg11
VHomocystinuria
p5841
sg13
I1
sa(dp5842
g7
I329
sg20
VC0149958
p5843
sg10
I3
sg11
VCPS
p5844
sg13
I1
sa(dp5845
g7
I213
sg20
VC0268487
p5846
sg10
I19
sg11
VTyrosinemia type II
p5847
sg13
I3
sa(dp5848
g7
I84
sg20
VC0031485
p5849
sg10
I15
sg11
VPhenylketonuria
p5850
sg13
I1
sa(dp5851
g7
I107
sg20
VC0024776
p5852
sg10
I25
sg11
VMaple Syrup Urine Disease
p5853
sg13
I4
sa(dp5854
g7
I359
sg20
VC0268548
p5855
sg10
I19
sg11
Varginase deficiency
p5856
sg13
I2
sa(dp5857
g7
I101
sg20
VC0031485
p5858
sg10
I3
sg11
VPKU
p5859
sg13
I1
sa(dp5860
g7
I58
sg20
VC0002514
p5861
sg10
I17
sg11
Vaminoacidopathies
p5862
sg13
I1
sa(dp5863
g7
I134
sg20
VC0024776
p5864
sg10
I4
sg11
VMSUD
p5865
sg13
I1
sa(dp5866
g7
I268
sg20
VC0268547
p5867
sg10
I25
sg11
VArgininosuccinic aciduria
p5868
sg13
I2
sa(dp5869
g7
I346
sg20
VC0268548
p5870
sg10
I11
sg11
VArgininemia
p5871
sg13
I1
sa(dp5872
g7
I482
sg20
VC0268542
p5873
sg10
I38
sg11
Vdeficiency, Ornithine Transcarbamylase
p5874
sg13
I3
sa(dp5875
g7
I295
sg20
VC0149958
p5876
sg10
I32
sg11
VCarbamoyl Phosphate Synthetase I
p5877
sg13
I4
sa(dp5878
g7
I234
sg20
VC0175683
p5879
sg10
I13
sg11
VCitrullinemia
p5880
sg13
I1
sa(dp5881
g7
I381
sg20
VC0268540
p5882
sg10
I50
sg11
VHyperornithinemia-Hyperammonemia-Homocitrullinuria
p5883
sg13
I1
sa(dp5884
g7
I433
sg20
VC0268540
p5885
sg10
I3
sg11
VHHH
p5886
sg13
I1
sasa(dp5887
g2
S'These include N-acetylglutamate synthase deficiency (NAGSD); Carbamyl phosphate synthetase 1 deficiency (CPS1D); Ornithine transcarbamylase deficiency (OTCD); Argininosuccinate synthetase deficiency (ASSD) (Citrullinemia); Argininosuccinate lyase deficiency (ASLD) (Argininosuccinic aciduria); Arginase deficiency (ARGD, Argininemia); Hyperornithinemia, hyperammonemia, homocitrullinuria (HHH) syndrome (or mitochondrial ornithine transporter 1 deficiency [ORNT1D]); and Citrullinemia type II (mitochondrial aspartate/glutamate carrier deficiency [CITRIN]).\n'
p5888
sg4
(lp5889
(dp5890
g7
I407
sg8
g127
sg10
I37
sg11
Vmitochondrial ornithine transporter 1
p5891
sg13
I4
sa(dp5892
g7
I61
sg8
g127
sg10
I31
sg11
VCarbamyl phosphate synthetase 1
p5893
sg13
I4
sa(dp5894
g7
I223
sg8
VP04424
p5895
sg10
I23
sg11
VArgininosuccinate lyase
p5896
sg13
I2
sa(dp5897
g7
I294
sg8
VP05089
p5898
sg10
I8
sg11
VArginase
p5899
sg13
I1
sa(dp5900
g7
I113
sg8
VP00480
p5901
sg10
I26
sg11
VOrnithine transcarbamylase
p5902
sg13
I2
sa(dp5903
g7
I159
sg8
VP00966
p5904
sg10
I28
sg11
VArgininosuccinate synthetase
p5905
sg13
I2
sa(dp5906
g7
I14
sg8
g127
sg10
I26
sg11
VN-acetylglutamate synthase
p5907
sg13
I2
sa(dp5908
g7
I494
sg8
g127
sg10
I61
sg11
Vmitochondrial aspartate/glutamate carrier deficiency [CITRIN]
p5909
sg13
I5
sasg17
(lp5910
(dp5911
g7
I389
sg20
VC0268540
p5912
sg10
I3
sg11
VHHH
p5913
sg13
I1
sa(dp5914
g7
I335
sg20
VC0599035
p5915
sg10
I17
sg11
VHyperornithinemia
p5916
sg13
I1
sa(dp5917
g7
I394
sg20
VC0039082
p5918
sg10
I8
sg11
Vsyndrome
p5919
sg13
I1
sa(dp5920
g7
I159
sg20
VC0175683
p5921
sg10
I39
sg11
VArgininosuccinate synthetase deficiency
p5922
sg13
I3
sa(dp5923
g7
I14
sg20
VC0268543
p5924
sg10
I37
sg11
VN-acetylglutamate synthase deficiency
p5925
sg13
I3
sa(dp5926
g7
I315
sg20
VC0268548
p5927
sg10
I4
sg11
VARGD
p5928
sg13
I1
sa(dp5929
g7
I223
sg20
VC0268547
p5930
sg10
I34
sg11
VArgininosuccinate lyase deficiency
p5931
sg13
I3
sa(dp5932
g7
I207
sg20
VC0175683
p5933
sg10
I13
sg11
VCitrullinemia
p5934
sg13
I1
sa(dp5935
g7
I152
sg20
VC0268542
p5936
sg10
I4
sg11
VOTCD
p5937
sg13
I1
sa(dp5938
g7
I53
sg20
VC0268543
p5939
sg10
I5
sg11
VNAGSD
p5940
sg13
I1
sa(dp5941
g7
I200
sg20
VC0175683
p5942
sg10
I4
sg11
VASSD
p5943
sg13
I1
sa(dp5944
g7
I259
sg20
VC0268547
p5945
sg10
I4
sg11
VASLD
p5946
sg13
I1
sa(dp5947
g7
I207
sg20
VC0175683
p5948
sg10
I13
sg11
VCitrullinemia
p5949
sg13
I1
sa(dp5950
g7
I321
sg20
VC0268548
p5951
sg10
I11
sg11
VArgininemia
p5952
sg13
I1
sa(dp5953
g7
I266
sg20
VC0268547
p5954
sg10
I25
sg11
VArgininosuccinic aciduria
p5955
sg13
I2
sa(dp5956
g7
I354
sg20
VC0220994
p5957
sg10
I14
sg11
Vhyperammonemia
p5958
sg13
I1
sa(dp5959
g7
I113
sg20
VC0268542
p5960
sg10
I37
sg11
VOrnithine transcarbamylase deficiency
p5961
sg13
I3
sa(dp5962
g7
I294
sg20
VC0268548
p5963
sg10
I19
sg11
VArginase deficiency
p5964
sg13
I2
sasa(dp5965
g2
S'Polymorphisms in TLR1 (R80T), NOD2 (1007fsX1), and MYD88 (-938C&gt;A) were associated with chronic Q fever.\n'
p5966
sg4
(lp5967
(dp5968
g7
I30
sg8
VP22301
p5969
sg10
I4
sg11
VNOD2
p5970
sg13
I1
sa(dp5971
g7
I51
sg8
g127
sg10
I5
sg11
VMYD88
p5972
sg13
I1
sa(dp5973
g7
I17
sg8
g127
sg10
I4
sg11
VTLR1
p5974
sg13
I1
sasg17
(lp5975
(dp5976
g7
I91
sg20
VC1443892
p5977
sg10
I15
sg11
Vchronic Q fever
p5978
sg13
I3
sasa(dp5979
g2
S'Polymorphisms in TLR1 (R80T), NOD2 (L1007fsX1), and MYD88 (-938C&gt;A) are associated with predisposition to development of chronic Q fever.\n'
p5980
sg4
(lp5981
(dp5982
g7
I30
sg8
VP22301
p5983
sg10
I4
sg11
VNOD2
p5984
sg13
I1
sa(dp5985
g7
I17
sg8
g127
sg10
I4
sg11
VTLR1
p5986
sg13
I1
sa(dp5987
g7
I52
sg8
g127
sg10
I5
sg11
VMYD88
p5988
sg13
I1
sasg17
(lp5989
(dp5990
g7
I124
sg20
VC1443892
p5991
sg10
I15
sg11
Vchronic Q fever
p5992
sg13
I3
sasa(dp5993
g2
S'For TLR1, increased interleukin 10 responses to C. burnetii in individuals carrying the risk allele may contribute to the increased risk of chronic Q fever.\n'
p5994
sg4
(lp5995
(dp5996
g7
I20
sg8
VP22301
p5997
sg10
I14
sg11
Vinterleukin 10
p5998
sg13
I2
sa(dp5999
g7
I4
sg8
g127
sg10
I4
sg11
VTLR1
p6000
sg13
I1
sasg17
(lp6001
(dp6002
g7
I140
sg20
VC1443892
p6003
sg10
I15
sg11
Vchronic Q fever
p6004
sg13
I3
sasa(dp6005
g2
S'In sum, SCIN ablation in mice leads to exacerbated ritualistic-like behaviors that affect social performance, providing a link between SCIN dysfunction and the social impairments present in psychiatric disorders.SIGNIFICANCE STATEMENT We sought to uncover the impact of striatal cholinergic interneuron (SCIN) degeneration on perseverative behaviors related to obsessive-compulsive disorder (OCD) and Tourette syndrome (TS).\n'
p6006
sg4
(lp6007
sg17
(lp6008
(dp6009
g7
I420
sg20
VC0040517
p6010
sg10
I2
sg11
VTS
p6011
sg13
I1
sa(dp6012
g7
I361
sg20
VC0028768
p6013
sg10
I29
sg11
Vobsessive-compulsive disorder
p6014
sg13
I2
sa(dp6015
g7
I392
sg20
VC0028768
p6016
sg10
I3
sg11
VOCD
p6017
sg13
I1
sa(dp6018
g7
I310
sg20
VC0011164
p6019
sg10
I12
sg11
Vdegeneration
p6020
sg13
I1
sa(dp6021
g7
I190
sg20
VC0004936
p6022
sg10
I21
sg11
Vpsychiatric disorders
p6023
sg13
I2
sa(dp6024
g7
I401
sg20
VC0040517
p6025
sg10
I17
sg11
VTourette syndrome
p6026
sg13
I2
sasa(dp6027
g2
S'Therefore, perseveration induced by SCIN ablation extends to social performance as occurs in neuropsychiatric conditions such as OCD and TS.\n'
p6028
sg4
(lp6029
sg17
(lp6030
(dp6031
g7
I11
sg20
VC0233651
p6032
sg10
I13
sg11
Vperseveration
p6033
sg13
I1
sa(dp6034
g7
I129
sg20
VC0028768
p6035
sg10
I3
sg11
VOCD
p6036
sg13
I1
sasa(dp6037
g2
S'Expression analysis of glutamate receptor subunits NR1-NR3B, GluR1-GluR7, KA1, KA2 and mGluR1-mGluR8 was performed by means of RT-PCR in human rhabdomyosarcoma/medulloblastoma (TE671), neuroblastoma (SK-NA-S), thyroid carcinoma (FTC 238), lung carcinoma (SK-LU-1), astrocytoma (MOGGCCM), multiple myeloma (RPMI 8226), glioma (U87-MG and U343), lung carcinoma (A549), colon adenocarcinoma (HT 29), T cell leukemia cells (Jurkat E6.1), breast carcinoma (T47D) and colon adenocarcinoma (LS180).\n'
p6038
sg4
(lp6039
(dp6040
g7
I67
sg8
g127
sg10
I5
sg11
VGluR7
p6041
sg13
I1
sa(dp6042
g7
I79
sg8
g127
sg10
I3
sg11
VKA2
p6043
sg13
I1
sa(dp6044
g7
I51
sg8
g127
sg10
I3
sg11
VNR1
p6045
sg13
I1
sa(dp6046
g7
I74
sg8
g127
sg10
I3
sg11
VKA1
p6047
sg13
I1
sa(dp6048
g7
I23
sg8
VP39086
p6049
sg10
I18
sg11
Vglutamate receptor
p6050
sg13
I2
sa(dp6051
g7
I61
sg8
VP42261
p6052
sg10
I5
sg11
VGluR1
p6053
sg13
I1
sa(dp6054
g7
I55
sg8
g127
sg10
I4
sg11
VNR3B
p6055
sg13
I1
sasg17
(lp6056
(dp6057
g7
I143
sg20
VC0035412
p6058
sg10
I16
sg11
Vrhabdomyosarcoma
p6059
sg13
I1
sa(dp6060
g7
I229
sg20
VC0206682
p6061
sg10
I3
sg11
VFTC
p6062
sg13
I1
sa(dp6063
g7
I239
sg20
VC0684249
p6064
sg10
I14
sg11
Vlung carcinoma
p6065
sg13
I2
sa(dp6066
g7
I367
sg20
VC0338106
p6067
sg10
I20
sg11
Vcolon adenocarcinoma
p6068
sg13
I2
sa(dp6069
g7
I397
sg20
VC0023492
p6070
sg10
I15
sg11
VT cell leukemia
p6071
sg13
I3
sa(dp6072
g7
I265
sg20
VC0004114
p6073
sg10
I11
sg11
Vastrocytoma
p6074
sg13
I1
sa(dp6075
g7
I318
sg20
VC0017638
p6076
sg10
I6
sg11
Vglioma
p6077
sg13
I1
sa(dp6078
g7
I239
sg20
VC0684249
p6079
sg10
I14
sg11
Vlung carcinoma
p6080
sg13
I2
sa(dp6081
g7
I210
sg20
VC0549473
p6082
sg10
I17
sg11
Vthyroid carcinoma
p6083
sg13
I2
sa(dp6084
g7
I185
sg20
VC0027819
p6085
sg10
I13
sg11
Vneuroblastoma
p6086
sg13
I1
sa(dp6087
g7
I160
sg20
VC0025149
p6088
sg10
I15
sg11
Vmedulloblastoma
p6089
sg13
I1
sa(dp6090
g7
I367
sg20
VC0338106
p6091
sg10
I20
sg11
Vcolon adenocarcinoma
p6092
sg13
I2
sa(dp6093
g7
I288
sg20
VC0026764
p6094
sg10
I16
sg11
Vmultiple myeloma
p6095
sg13
I2
sa(dp6096
g7
I434
sg20
VC0678222
p6097
sg10
I16
sg11
Vbreast carcinoma
p6098
sg13
I2
sasa(dp6099
g2
S'The neuroprotective potential of mGluR1 and mGluR5 antagonists (group I), EMQMCM and MTEP, respectively was studied using the 3 min forebrain ischemia model in Mongolian gerbils and the hypoxia-ischemia model in 7-day-old rats.\n'
p6100
sg4
(lp6101
(dp6102
g7
I44
sg8
VP41594
p6103
sg10
I6
sg11
VmGluR5
p6104
sg13
I1
sasg17
(lp6105
(dp6106
g7
I142
sg20
VC0022116
p6107
sg10
I8
sg11
Vischemia
p6108
sg13
I1
sa(dp6109
g7
I142
sg20
VC0022116
p6110
sg10
I8
sg11
Vischemia
p6111
sg13
I1
sa(dp6112
g7
I186
sg20
VC0242184
p6113
sg10
I7
sg11
Vhypoxia
p6114
sg13
I1
sasa(dp6115
g2
S'Thus, the antagonists of mGluR1 and mGluR5 show differential neuroprotective ability in two models of brain ischemia.\n'
p6116
sg4
(lp6117
(dp6118
g7
I36
sg8
VP41594
p6119
sg10
I6
sg11
VmGluR5
p6120
sg13
I1
sasg17
(lp6121
(dp6122
g7
I102
sg20
VC0007786
p6123
sg10
I14
sg11
Vbrain ischemia
p6124
sg13
I2
sasa(dp6125
g2
S'MGlu1 receptor antagonists are promising drugs for the treatment of brain ischemia or for the prophylaxis of neuronal damage induced by synaptic hyperactivity.\n'
p6126
sg4
(lp6127
(dp6128
g7
I0
sg8
g127
sg10
I14
sg11
VMGlu1 receptor
p6129
sg13
I2
sasg17
(lp6130
(dp6131
g7
I68
sg20
VC0007786
p6132
sg10
I14
sg11
Vbrain ischemia
p6133
sg13
I2
sasa(dp6134
g2
S'DREAM contains an E2F, a retinoblastoma (RB)-family protein, and the MuvB core (LIN9, LIN37, LIN52, LIN54, and RBBP4).\n'
p6135
sg4
(lp6136
(dp6137
g7
I111
sg8
g127
sg10
I5
sg11
VRBBP4
p6138
sg13
I1
sa(dp6139
g7
I0
sg8
g127
sg10
I5
sg11
VDREAM
p6140
sg13
I1
sa(dp6141
g7
I100
sg8
g127
sg10
I5
sg11
VLIN54
p6142
sg13
I1
sa(dp6143
g7
I93
sg8
g127
sg10
I5
sg11
VLIN52
p6144
sg13
I1
sa(dp6145
g7
I80
sg8
g127
sg10
I4
sg11
VLIN9
p6146
sg13
I1
sa(dp6147
g7
I25
sg8
g127
sg10
I34
sg11
Vretinoblastoma (RB)-family protein
p6148
sg13
I3
sa(dp6149
g7
I86
sg8
g127
sg10
I5
sg11
VLIN37
p6150
sg13
I1
sasg17
(lp6151
(dp6152
g7
I41
sg20
VC0035335
p6153
sg10
I2
sg11
VRB
p6154
sg13
I1
sa(dp6155
g7
I25
sg20
VC0035335
p6156
sg10
I14
sg11
Vretinoblastoma
p6157
sg13
I1
sasa(dp6158
g2
S'This study aimed to identify predictors for shunt-dependent hydrocephalus (SDHC) after aSAH via a systematic review and meta-analysis.\n'
p6159
sg4
(lp6160
sg17
(lp6161
(dp6162
g7
I60
sg20
VC0020255
p6163
sg10
I13
sg11
Vhydrocephalus
p6164
sg13
I1
sasa(dp6165
g2
S'In primary analysis of 14 potential risk factors, 12 were identified as predictors of SDHC after aSAH including age &gt;=50 years, female gender, high Hunt-Hess grade, Glasgow Coma Scale &lt;=8, Fisher grade &gt;=3, acute hydrocephalus, external ventricular drainage insertion, intraventricular hemorrhage, postcirculation aneurysm, anterior communicating artery aneurysm, meningitis, and rebleeding.\n'
p6166
sg4
(lp6167
(dp6168
g7
I86
sg8
g127
sg10
I4
sg11
VSDHC
p6169
sg13
I1
sasg17
(lp6170
(dp6171
g7
I323
sg20
VC0740386
p6172
sg10
I39
sg11
Vaneurysm, anterior communicating artery
p6173
sg13
I4
sa(dp6174
g7
I323
sg20
VC0002940
p6175
sg10
I8
sg11
Vaneurysm
p6176
sg13
I1
sa(dp6177
g7
I278
sg20
VC0240059
p6178
sg10
I27
sg11
Vintraventricular hemorrhage
p6179
sg13
I2
sa(dp6180
g7
I222
sg20
VC0020255
p6181
sg10
I13
sg11
Vhydrocephalus
p6182
sg13
I1
sa(dp6183
g7
I373
sg20
VC0025289
p6184
sg10
I10
sg11
Vmeningitis
p6185
sg13
I1
sa(dp6186
g7
I176
sg20
VC0009421
p6187
sg10
I4
sg11
VComa
p6188
sg13
I1
sasa(dp6189
g2
S'OBJECTIVE Feasible clinical scores for predicting shunt-dependent hydrocephalus (SDHC) after aneurysmal subarachnoid hemorrhage (aSAH) are scarce.\n'
p6190
sg4
(lp6191
sg17
(lp6192
(dp6193
g7
I129
sg20
VC0751530
p6194
sg10
I4
sg11
VaSAH
p6195
sg13
I1
sa(dp6196
g7
I93
sg20
VC0751530
p6197
sg10
I34
sg11
Vaneurysmal subarachnoid hemorrhage
p6198
sg13
I3
sa(dp6199
g7
I66
sg20
VC0020255
p6200
sg10
I13
sg11
Vhydrocephalus
p6201
sg13
I1
sasa(dp6202
g2
S'The chronic hydrocephalus ensuing from SAH score (CHESS) was introduced in 2015 and has a high predictive value for SDHC.\n'
p6203
sg4
(lp6204
(dp6205
g7
I116
sg8
g127
sg10
I4
sg11
VSDHC
p6206
sg13
I1
sasg17
(lp6207
(dp6208
g7
I12
sg20
VC0020255
p6209
sg10
I13
sg11
Vhydrocephalus
p6210
sg13
I1
sasa(dp6211
g2
S'The SDASH score was developed from results of multivariate analysis, which revealed acute hydrocephalus (aHP), a BNI score of &gt;= 3, and a Hunt and Hess (HH) grade of &gt;= 4 to be independent risk factors for SDHC (ORs 5.709 [aHP], 6.804 [BNI], and 4.122 [HH]; p &lt; 0.001).\n'
p6212
sg4
(lp6213
(dp6214
g7
I212
sg8
g127
sg10
I4
sg11
VSDHC
p6215
sg13
I1
sasg17
(lp6216
(dp6217
g7
I84
sg20
VC3279786
p6218
sg10
I19
sg11
Vacute hydrocephalus
p6219
sg13
I2
sa(dp6220
g7
I105
sg20
VC3279786
p6221
sg10
I3
sg11
VaHP
p6222
sg13
I1
sa(dp6223
g7
I105
sg20
VC3279786
p6224
sg10
I3
sg11
VaHP
p6225
sg13
I1
sasa(dp6226
g2
S'All 3 SDHC scores tested (CHESS, BNI, and SDASH) reliably predicted chronic hydrocephalus (ORs 1.533 [CHESS], 2.021 [BNI], and 2.496 [SDASH]; p &lt;= 0.001).\n'
p6227
sg4
(lp6228
sg17
(lp6229
(dp6230
g7
I76
sg20
VC0020255
p6231
sg10
I13
sg11
Vhydrocephalus
p6232
sg13
I1
sasa(dp6233
g2
S'CSF drainage also reduced angiographic vasospasm (OR of 0.35, 95% CI, 0.23-0.51, P &lt; 0.01), symptomatic vasospasm (OR of 0.32, 95% CI, 0.32-0.43, P &lt; 0.01), and DIND (OR of 0.48, 95% CI, 0.25-0.91, P = 0.03), but there was no significant difference between the CSF drainage group and the no CSF drainage group on shunt-dependent hydrocephalus (SDHC) prevention (OR of 1.04, 95% CI, 0.52-2.07, P = 0.91).\n'
p6234
sg4
(lp6235
sg17
(lp6236
(dp6237
g7
I335
sg20
VC0020255
p6238
sg10
I13
sg11
Vhydrocephalus
p6239
sg13
I1
sa(dp6240
g7
I39
sg20
VC0085616
p6241
sg10
I9
sg11
Vvasospasm
p6242
sg13
I1
sa(dp6243
g7
I39
sg20
VC0085616
p6244
sg10
I9
sg11
Vvasospasm
p6245
sg13
I1
sasa(dp6246
g2
S'Under the hypothesis that compartmentalization occurs between the ventricle and subarachnoid space after massive SAH, this study aimed to evaluate the biochemical differences between ventricular and intrathecal cerebrospinal fluid (CSF) and assess the role of CSF lactate in shunt-dependent hydrocephalus (SDHC) after aneurysmal SAH.\n'
p6247
sg4
(lp6248
(dp6249
g7
I260
sg8
VP04141
p6250
sg10
I44
sg11
VCSF lactate in shunt-dependent hydrocephalus
p6251
sg13
I5
sa(dp6252
g7
I306
sg8
g127
sg10
I4
sg11
VSDHC
p6253
sg13
I1
sasg17
(lp6254
(dp6255
g7
I291
sg20
VC0020255
p6256
sg10
I13
sg11
Vhydrocephalus
p6257
sg13
I1
sasa(dp6258
g2
S'The objective of this study was to compare the incidence of ventricular shunt placement for shunt-dependent hydrocephalus (SDHC) after clipping versus coiling of ruptured aneurysms.\n'
p6259
sg4
(lp6260
sg17
(lp6261
(dp6262
g7
I108
sg20
VC0020255
p6263
sg10
I13
sg11
Vhydrocephalus
p6264
sg13
I1
sa(dp6265
g7
I162
sg20
VC0162869
p6266
sg10
I18
sg11
Vruptured aneurysms
p6267
sg13
I2
sasa(dp6268
g2
S'Excluding anti-Ro52, 113 (89.3%) SSc patients were positive for at least one autoAb: anti-Topoisomerase I (anti-Topo) I abs in 54 (41.2%), anti-centromere proteins (anti-CENP) in 37 (28.2%, all reactive with centromere protein-A (CENPA) and centromere protein B (CENPB)), anti-RNA polymerase III(RP11) in 19 (14.5%), anti-RNA polymerase III(RP155) in 13 (9.9%), anti-fibrillarin in 4 (3.1%), anti-Ku in 6 (4.6%), anti-nucleolus-organizing region (anti-NOR90) in 8 (6.1%), anti-PM-Scl100 in 2 (1.5%), and anti-PM-Scl75 in 4 (3.1%).\n'
p6269
sg4
(lp6270
(dp6271
g7
I362
sg8
VP22087
p6272
sg10
I16
sg11
Vanti-fibrillarin
p6273
sg13
I1
sa(dp6274
g7
I413
sg8
g127
sg10
I32
sg11
Vanti-nucleolus-organizing region
p6275
sg13
I2
sa(dp6276
g7
I139
sg8
VP02649
p6277
sg10
I24
sg11
Vanti-centromere proteins
p6278
sg13
I2
sa(dp6279
g7
I219
sg8
VP49450
p6280
sg10
I42
sg11
Vprotein-A (CENPA) and centromere protein B
p6281
sg13
I6
sa(dp6282
g7
I272
sg8
VP24928
p6283
sg10
I23
sg11
Vanti-RNA polymerase III
p6284
sg13
I3
sa(dp6285
g7
I296
sg8
g127
sg10
I4
sg11
VRP11
p6286
sg13
I1
sa(dp6287
g7
I77
sg8
VP11387
p6288
sg10
I28
sg11
VautoAb: anti-Topoisomerase I
p6289
sg13
I3
sa(dp6290
g7
I165
sg8
g127
sg10
I9
sg11
Vanti-CENP
p6291
sg13
I1
sa(dp6292
g7
I272
sg8
VP24928
p6293
sg10
I23
sg11
Vanti-RNA polymerase III
p6294
sg13
I3
sa(dp6295
g7
I263
sg8
VP07199
p6296
sg10
I5
sg11
VCENPB
p6297
sg13
I1
sasg17
(lp6298
(dp6299
g7
I296
sg20
VC1838601
p6300
sg10
I4
sg11
VRP11
p6301
sg13
I1
sasa(dp6302
g2
S'Overall, 102 (77.9%) SSc patients had autoAbs against Topo I, CENPA or CENPB, RP11 or RP155.\n'
p6303
sg4
(lp6304
(dp6305
g7
I71
sg8
VP07199
p6306
sg10
I5
sg11
VCENPB
p6307
sg13
I1
sa(dp6308
g7
I62
sg8
VP49450
p6309
sg10
I5
sg11
VCENPA
p6310
sg13
I1
sa(dp6311
g7
I78
sg8
g127
sg10
I4
sg11
VRP11
p6312
sg13
I1
sasg17
(lp6313
(dp6314
g7
I78
sg20
VC1838601
p6315
sg10
I4
sg11
VRP11
p6316
sg13
I1
sasa(dp6317
g2
S'Reactivity to UL83 HCMV was assessed in relation to clinical manifestations and SSc-related autoantibodies (autoAbs), tested by an IgG SSc autoantibody profile line immunoassay (Euroimmun) that detects autoAbs against Scl-70, CENPA, CENPB, RNA polymerase III subunit 11 (RP11), RP155, fibrillarin, NOR90, Th/To, PM-Scl100, PM-Scl75, Ku, PDGFR and Ro-52.\n'
p6318
sg4
(lp6319
(dp6320
g7
I233
sg8
VP07199
p6321
sg10
I5
sg11
VCENPB
p6322
sg13
I1
sa(dp6323
g7
I226
sg8
VP49450
p6324
sg10
I5
sg11
VCENPA
p6325
sg13
I1
sa(dp6326
g7
I218
sg8
VP17542
p6327
sg10
I6
sg11
VScl-70
p6328
sg13
I1
sa(dp6329
g7
I271
sg8
g127
sg10
I4
sg11
VRP11
p6330
sg13
I1
sa(dp6331
g7
I337
sg8
VP09619
p6332
sg10
I5
sg11
VPDGFR
p6333
sg13
I1
sa(dp6334
g7
I285
sg8
VP22087
p6335
sg10
I11
sg11
Vfibrillarin
p6336
sg13
I1
sa(dp6337
g7
I240
sg8
g127
sg10
I29
sg11
VRNA polymerase III subunit 11
p6338
sg13
I5
sasg17
(lp6339
(dp6340
g7
I240
sg20
VC1838601
p6341
sg10
I29
sg11
VRNA polymerase III subunit 11
p6342
sg13
I5
sa(dp6343
g7
I271
sg20
VC1838601
p6344
sg10
I4
sg11
VRP11
p6345
sg13
I1
sasa(dp6346
g2
S'The EUROLINE (IgG) Systemic Sclerosis panel test kit (which tests for Scl-70, CENP-A, CENP-B, RP11, RP155, Fib, NOR90, Th/To, PM100, PM75, Ku, PDGFR and Ro-52) was selected for the purpose of this study.\n'
p6347
sg4
(lp6348
(dp6349
g7
I70
sg8
VP17542
p6350
sg10
I6
sg11
VScl-70
p6351
sg13
I1
sa(dp6352
g7
I86
sg8
VP07199
p6353
sg10
I6
sg11
VCENP-B
p6354
sg13
I1
sa(dp6355
g7
I107
sg8
VP22087
p6356
sg10
I3
sg11
VFib
p6357
sg13
I1
sa(dp6358
g7
I78
sg8
VP49450
p6359
sg10
I6
sg11
VCENP-A
p6360
sg13
I1
sa(dp6361
g7
I143
sg8
VP09619
p6362
sg10
I5
sg11
VPDGFR
p6363
sg13
I1
sa(dp6364
g7
I94
sg8
g127
sg10
I4
sg11
VRP11
p6365
sg13
I1
sasg17
(lp6366
(dp6367
g7
I94
sg20
VC1838601
p6368
sg10
I4
sg11
VRP11
p6369
sg13
I1
sa(dp6370
g7
I19
sg20
VC0036421
p6371
sg10
I18
sg11
VSystemic Sclerosis
p6372
sg13
I2
sasa(dp6373
g2
S'Of these lcSSc patients, 31 (75.6%) were positive for CENP-A and CENP-B (anti-centromere) antibodies, 12 (29.3%) for Ro-52 antibodies, 5 (12.2%) for RP11 and RP155, 4 (9.8%) for Scl-70 and 1 (2.4%) each for anti-Fib and Th/To antibodies.\n'
p6374
sg4
(lp6375
(dp6376
g7
I149
sg8
g127
sg10
I4
sg11
VRP11
p6377
sg13
I1
sa(dp6378
g7
I178
sg8
VP17542
p6379
sg10
I12
sg11
VScl-70 and 1
p6380
sg13
I3
sa(dp6381
g7
I54
sg8
VP49450
p6382
sg10
I6
sg11
VCENP-A
p6383
sg13
I1
sa(dp6384
g7
I65
sg8
VP07199
p6385
sg10
I6
sg11
VCENP-B
p6386
sg13
I1
sa(dp6387
g7
I207
sg8
VP22087
p6388
sg10
I8
sg11
Vanti-Fib
p6389
sg13
I1
sasg17
(lp6390
(dp6391
g7
I149
sg20
VC1838601
p6392
sg10
I4
sg11
VRP11
p6393
sg13
I1
sasa(dp6394
g2
S'The following marker antibodies were determined: anti-topo I, anti-centromere A and B (CENP A, CENP B), anti-RNA polymerase III (RP11, RP 155), anti-fibrillarin (U3RNP), anti- -NOR90, anti-Th/To, anti-PM-Scl-100, anti-PM-Scl-75, anti-Ku, anti-Ro-52, anti-PDGFR.\n'
p6395
sg4
(lp6396
(dp6397
g7
I196
sg8
g127
sg10
I15
sg11
Vanti-PM-Scl-100
p6398
sg13
I1
sa(dp6399
g7
I213
sg8
g127
sg10
I14
sg11
Vanti-PM-Scl-75
p6400
sg13
I1
sa(dp6401
g7
I144
sg8
VP22087
p6402
sg10
I16
sg11
Vanti-fibrillarin
p6403
sg13
I1
sa(dp6404
g7
I129
sg8
g127
sg10
I4
sg11
VRP11
p6405
sg13
I1
sa(dp6406
g7
I104
sg8
VP24928
p6407
sg10
I23
sg11
Vanti-RNA polymerase III
p6408
sg13
I3
sa(dp6409
g7
I250
sg8
VP09619
p6410
sg10
I10
sg11
Vanti-PDGFR
p6411
sg13
I1
sasg17
(lp6412
(dp6413
g7
I129
sg20
VC1838601
p6414
sg10
I4
sg11
VRP11
p6415
sg13
I1
sasa(dp6416
g2
S'82 patients (94%) had positive antinuclear antibodies; anti-topo I - 29 patients; anti-CENP-A - 20 and anti-CENP-B - 20; anti-RP11 - 9 and anti-RP155 - 7; anti-U3RNP - 1; anti-NOR90 - 6; anti-Th/ To - 3; anti-PM-Scl-100 - 7; anti-PM-Scl-75 - 11; anti-Ku - 5; anti-Ro-52 - 23 patients.\n'
p6417
sg4
(lp6418
(dp6419
g7
I187
sg8
VP07101
p6420
sg10
I15
sg11
Vanti-Th/ To - 3
p6421
sg13
I4
sa(dp6422
g7
I82
sg8
VP49450
p6423
sg10
I16
sg11
Vanti-CENP-A - 20
p6424
sg13
I3
sa(dp6425
g7
I103
sg8
VP07199
p6426
sg10
I16
sg11
Vanti-CENP-B - 20
p6427
sg13
I3
sa(dp6428
g7
I204
sg8
g127
sg10
I19
sg11
Vanti-PM-Scl-100 - 7
p6429
sg13
I3
sa(dp6430
g7
I225
sg8
g127
sg10
I19
sg11
Vanti-PM-Scl-75 - 11
p6431
sg13
I3
sa(dp6432
g7
I121
sg8
g127
sg10
I13
sg11
Vanti-RP11 - 9
p6433
sg13
I3
sasg17
(lp6434
(dp6435
g7
I126
sg20
VC1838601
p6436
sg10
I4
sg11
VRP11
p6437
sg13
I1
sasa(dp6438
g2
S'The sensitivity and the specificity of this assay were as follows: 30.5% and 97.3% for ACA (anti-CENP-B), 29.5% and 96% for ACA (anti-CENP-A), 20% and 99.3% for ATA, 5.7% and 99.3% for anti-RNAP III (RP-155), 5.2% and 100% for anti-RNP III (RP-11), 6.7% and 98% for anti-PMScl (PMScl-100), 10.9% and 93.3% for anti-PMScl (PMscl-75), 3.3% and 98.7% for anti-Th/To, 0.48% and 100% for AFA, 4.8% and 96.7% for anti-hUF/NOR-90, 4.7% and 96% for anti-Ku, 0.95% and 100% for anti-Platelet-Derived Growth Factor Receptor, and 18.1% and 50% for anti-Ro-52, respectively.\n'
p6439
sg4
(lp6440
(dp6441
g7
I266
sg8
g127
sg10
I10
sg11
Vanti-PMScl
p6442
sg13
I1
sa(dp6443
g7
I469
sg8
VP09619
p6444
sg10
I44
sg11
Vanti-Platelet-Derived Growth Factor Receptor
p6445
sg13
I4
sa(dp6446
g7
I92
sg8
g127
sg10
I10
sg11
Vanti-CENP-
p6447
sg13
I1
sa(dp6448
g7
I322
sg8
g127
sg10
I8
sg11
VPMscl-75
p6449
sg13
I1
sa(dp6450
g7
I278
sg8
g127
sg10
I9
sg11
VPMScl-100
p6451
sg13
I1
sa(dp6452
g7
I266
sg8
g127
sg10
I10
sg11
Vanti-PMScl
p6453
sg13
I1
sa(dp6454
g7
I129
sg8
VP49450
p6455
sg10
I11
sg11
Vanti-CENP-A
p6456
sg13
I1
sa(dp6457
g7
I227
sg8
g127
sg10
I12
sg11
Vanti-RNP III
p6458
sg13
I2
sasg17
(lp6459
(dp6460
g7
I383
sg20
VC1862866
p6461
sg10
I3
sg11
VAFA
p6462
sg13
I1
sasa(dp6463
g2
S'Sestrins (Sesns) family, which including three members Sesn1, Sesn2 and Sesn3, is known as stress-inducible proteins and participate in multiple diseases via regulating oxidative stress, inflammatory response and cell apoptosis.\n'
p6464
sg4
(lp6465
(dp6466
g7
I62
sg8
VP58004
p6467
sg10
I5
sg11
VSesn2
p6468
sg13
I1
sa(dp6469
g7
I55
sg8
g127
sg10
I5
sg11
VSesn1
p6470
sg13
I1
sa(dp6471
g7
I72
sg8
VP58005
p6472
sg10
I5
sg11
VSesn3
p6473
sg13
I1
sasg17
(lp6474
(dp6475
g7
I169
sg20
VC0242606
p6476
sg10
I16
sg11
Voxidative stress
p6477
sg13
I2
sa(dp6478
g7
I187
sg20
VC1155266
p6479
sg10
I21
sg11
Vinflammatory response
p6480
sg13
I2
sasa(dp6481
g2
S'Moreover, SESTRIN1 is a direct target of the lymphoma-specific EZH2 gain-of-function mutation (EZH2Y641X ).\n'
p6482
sg4
(lp6483
sg17
(lp6484
(dp6485
g7
I45
sg20
VC0024299
p6486
sg10
I8
sg11
Vlymphoma
p6487
sg13
I1
sasa(dp6488
g2
S'The antitumor efficacy of pharmacological EZH2 inhibition depends on SESTRIN1, indicating that mTORC1 control is a critical function of EZH2 in lymphoma.\n'
p6489
sg4
(lp6490
(dp6491
g7
I42
sg8
g127
sg10
I4
sg11
VEZH2
p6492
sg13
I1
sasg17
(lp6493
(dp6494
g7
I144
sg20
VC0024299
p6495
sg10
I8
sg11
Vlymphoma
p6496
sg13
I1
sasa(dp6497
g2
S'Hence, SESTRIN1 contributes to the genetic and epigenetic control of mTORC1 in lymphoma and influences responses to targeted therapies.\n'
p6498
sg4
(lp6499
sg17
(lp6500
(dp6501
g7
I79
sg20
VC0024299
p6502
sg10
I8
sg11
Vlymphoma
p6503
sg13
I1
sasa(dp6504
g2
S'Microgravity-induced gene expression changes of lipocalin 2 (Lcn2), sestrin 1(Sesn1), phosphatidylinositol 3-kinase, regulatory subunit polypeptide 1 (p85 alpha) (Pik3r1), v-maf musculoaponeurotic fibrosarcoma oncogene family protein B (Mafb), protein kinase C delta (Prkcd), Muscle Atrophy F-box (MAFbx/Atrogin-1/Fbxo32), and Muscle RING Finger 1 (MuRF-1) were further validated by real time qPCR analysis.\n'
p6505
sg4
(lp6506
(dp6507
g7
I163
sg8
VP27986
p6508
sg10
I6
sg11
VPik3r1
p6509
sg13
I1
sa(dp6510
g7
I68
sg8
g127
sg10
I9
sg11
Vsestrin 1
p6511
sg13
I2
sa(dp6512
g7
I237
sg8
g127
sg10
I4
sg11
VMafb
p6513
sg13
I1
sa(dp6514
g7
I151
sg8
VP27986
p6515
sg10
I9
sg11
Vp85 alpha
p6516
sg13
I2
sa(dp6517
g7
I172
sg8
g127
sg10
I63
sg11
Vv-maf musculoaponeurotic fibrosarcoma oncogene family protein B
p6518
sg13
I7
sa(dp6519
g7
I61
sg8
VP80188
p6520
sg10
I4
sg11
VLcn2
p6521
sg13
I1
sa(dp6522
g7
I86
sg8
VP42336
p6523
sg10
I63
sg11
Vphosphatidylinositol 3-kinase, regulatory subunit polypeptide 1
p6524
sg13
I6
sa(dp6525
g7
I304
sg8
g127
sg10
I9
sg11
VAtrogin-1
p6526
sg13
I1
sa(dp6527
g7
I349
sg8
g127
sg10
I6
sg11
VMuRF-1
p6528
sg13
I1
sa(dp6529
g7
I314
sg8
g127
sg10
I6
sg11
VFbxo32
p6530
sg13
I1
sa(dp6531
g7
I268
sg8
g127
sg10
I5
sg11
VPrkcd
p6532
sg13
I1
sa(dp6533
g7
I298
sg8
g127
sg10
I5
sg11
VMAFbx
p6534
sg13
I1
sa(dp6535
g7
I78
sg8
g127
sg10
I5
sg11
VSesn1
p6536
sg13
I1
sa(dp6537
g7
I48
sg8
VP80188
p6538
sg10
I11
sg11
Vlipocalin 2
p6539
sg13
I2
sa(dp6540
g7
I327
sg8
g127
sg10
I20
sg11
VMuscle RING Finger 1
p6541
sg13
I4
sa(dp6542
g7
I276
sg8
g127
sg10
I20
sg11
VMuscle Atrophy F-box
p6543
sg13
I3
sa(dp6544
g7
I244
sg8
g127
sg10
I22
sg11
Vprotein kinase C delta
p6545
sg13
I4
sasg17
(lp6546
(dp6547
g7
I197
sg20
VC0016057
p6548
sg10
I12
sg11
Vfibrosarcoma
p6549
sg13
I1
sa(dp6550
g7
I276
sg20
VC0026846
p6551
sg10
I14
sg11
VMuscle Atrophy
p6552
sg13
I2
sasa(dp6553
g2
S'The expression of Sesn1, Sesn2, and Sesn3 was significantly higher in patients with permanent atrial fibrillation (PmAF) than that in sinus rhythm (SR), and further greater in the left atrium than the right in PmAF patients.\n'
p6554
sg4
(lp6555
(dp6556
g7
I25
sg8
VP58004
p6557
sg10
I5
sg11
VSesn2
p6558
sg13
I1
sa(dp6559
g7
I18
sg8
g127
sg10
I5
sg11
VSesn1
p6560
sg13
I1
sasg17
(lp6561
(dp6562
g7
I134
sg20
VC0016169
p6563
sg10
I5
sg11
Vsinus
p6564
sg13
I1
sa(dp6565
g7
I115
sg20
VC2586056
p6566
sg10
I4
sg11
VPmAF
p6567
sg13
I1
sa(dp6568
g7
I84
sg20
VC2586056
p6569
sg10
I29
sg11
Vpermanent atrial fibrillation
p6570
sg13
I3
sa(dp6571
g7
I115
sg20
VC2586056
p6572
sg10
I4
sg11
VPmAF
p6573
sg13
I1
sasa(dp6574
g2
S"In this study, we evaluated the concentrations of sesn1 and sesn2 in the serum of 41 Alzheimer's disease (AD) patients, 27 mild cognitive impairment (MCI), and 60 elderly controls, by surface plasmon resonance, which was validated by using western blot.\n"
p6575
sg4
(lp6576
(dp6577
g7
I50
sg8
g127
sg10
I5
sg11
Vsesn1
p6578
sg13
I1
sa(dp6579
g7
I60
sg8
VP58004
p6580
sg10
I5
sg11
Vsesn2
p6581
sg13
I1
sasg17
(lp6582
(dp6583
g7
I85
sg20
VC1521724
p6584
sg10
I19
sg11
VAlzheimer's disease
p6585
sg13
I2
sa(dp6586
g7
I123
sg20
VC1270972
p6587
sg10
I25
sg11
Vmild cognitive impairment
p6588
sg13
I3
sa(dp6589
g7
I106
sg20
VC1521724
p6590
sg10
I2
sg11
VAD
p6591
sg13
I1
sa(dp6592
g7
I150
sg20
VC1270972
p6593
sg10
I3
sg11
VMCI
p6594
sg13
I1
sasa(dp6595
g2
S'Results of multivariate analysis indicated that age (p = 0.005), maximum cystometric capacity (MCC; p = 0.002), detrusor overactivity (DO; p = 0.001), pelvic organ prolapse (POP; p = 0.018), recurrent urinary tract infection (p = 0.001), and radical abdominal hysterectomy (RAH; p &lt; 0.001) as independent prognostic factors.\n'
p6596
sg4
(lp6597
sg17
(lp6598
(dp6599
g7
I65
sg20
VC0007129
p6600
sg10
I28
sg11
Vmaximum cystometric capacity
p6601
sg13
I3
sa(dp6602
g7
I191
sg20
VC0262655
p6603
sg10
I33
sg11
Vrecurrent urinary tract infection
p6604
sg13
I4
sa(dp6605
g7
I174
sg20
VC0033377
p6606
sg10
I3
sg11
VPOP
p6607
sg13
I1
sa(dp6608
g7
I95
sg20
VC0007129
p6609
sg10
I3
sg11
VMCC
p6610
sg13
I1
sa(dp6611
g7
I151
sg20
VC0877015
p6612
sg10
I21
sg11
Vpelvic organ prolapse
p6613
sg13
I3
sasa(dp6614
g2
S'Furthermore, our study results indicate that the MCC, urinary tract infection, and a history of RAH have a positive correlation with LCB, whereas, age, POP, and DO have a negative correlation with LCB.\n'
p6615
sg4
(lp6616
(dp6617
g7
I96
sg8
g127
sg10
I3
sg11
VRAH
p6618
sg13
I1
sasg17
(lp6619
(dp6620
g7
I49
sg20
VC0007129
p6621
sg10
I3
sg11
VMCC
p6622
sg13
I1
sa(dp6623
g7
I54
sg20
VC0042029
p6624
sg10
I23
sg11
Vurinary tract infection
p6625
sg13
I3
sasa(dp6626
g2
S'To determine, by means of a retrospective cohort study, the incidence of urinary tract infection (UTI), duration of postoperative hospital stay, and time to trial of voiding in women catheterized suprapubically or transurethrally after RAH for early stage cervical cancer.\n'
p6627
sg4
(lp6628
sg17
(lp6629
(dp6630
g7
I98
sg20
VC0042029
p6631
sg10
I3
sg11
VUTI
p6632
sg13
I1
sa(dp6633
g7
I73
sg20
VC0042029
p6634
sg10
I23
sg11
Vurinary tract infection
p6635
sg13
I3
sa(dp6636
g7
I250
sg20
VC0280232
p6637
sg10
I21
sg11
Vstage cervical cancer
p6638
sg13
I3
sasa(dp6639
g2
S'The tumor-associated antigen Kita-Kyushu lung cancer antigen-1 (KK-LC-1) has been reported as not being expressed in normal tissues, except for the testis, and in the setting of non-small cell lung cancer.\n'
p6640
sg4
(lp6641
(dp6642
g7
I4
sg8
VP51572
p6643
sg10
I58
sg11
Vtumor-associated antigen Kita-Kyushu lung cancer antigen-1
p6644
sg13
I6
sasg17
(lp6645
(dp6646
g7
I4
sg20
VC0027651
p6647
sg10
I5
sg11
Vtumor
p6648
sg13
I1
sa(dp6649
g7
I178
sg20
VC0007131
p6650
sg10
I26
sg11
Vnon-small cell lung cancer
p6651
sg13
I4
sa(dp6652
g7
I41
sg20
VC0684249
p6653
sg10
I11
sg11
Vlung cancer
p6654
sg13
I2
sasa(dp6655
g2
S'For example, HORMAD1, CXorf61, ACTL8, and PRAME are highly enriched in the basal subtype of breast cancer; MAGE and CSAG are most frequently activated in the magnoid subtype of lung adenocarcinoma; and PRAME is highly upregulated in the ccB subtype of clear cell renal cell carcinoma.\n'
p6656
sg4
(lp6657
(dp6658
g7
I13
sg8
g127
sg10
I7
sg11
VHORMAD1
p6659
sg13
I1
sa(dp6660
g7
I22
sg8
g127
sg10
I7
sg11
VCXorf61
p6661
sg13
I1
sa(dp6662
g7
I31
sg8
g127
sg10
I5
sg11
VACTL8
p6663
sg13
I1
sa(dp6664
g7
I42
sg8
VP78395
p6665
sg10
I5
sg11
VPRAME
p6666
sg13
I1
sasg17
(lp6667
(dp6668
g7
I252
sg20
VC0279702
p6669
sg10
I31
sg11
Vclear cell renal cell carcinoma
p6670
sg13
I5
sa(dp6671
g7
I177
sg20
VC0152013
p6672
sg10
I19
sg11
Vlung adenocarcinoma
p6673
sg13
I2
sa(dp6674
g7
I92
sg20
VC0678222
p6675
sg10
I13
sg11
Vbreast cancer
p6676
sg13
I2
sasa(dp6677
g2
S'The expression of Melanoma antigen (MAGE)-A3, MAGE-A4, and Kita-Kyushu lung cancer antigen-1 (KK-LC-1) was positive in 34 (25.0%), 22 (16.2%), and 42 (30.9%) patients, respectively.\n'
p6678
sg4
(lp6679
(dp6680
g7
I94
sg8
VP14209
p6681
sg10
I7
sg11
VKK-LC-1
p6682
sg13
I1
sa(dp6683
g7
I59
sg8
VP14209
p6684
sg10
I33
sg11
VKita-Kyushu lung cancer antigen-1
p6685
sg13
I4
sa(dp6686
g7
I36
sg8
VP43355
p6687
sg10
I4
sg11
VMAGE
p6688
sg13
I1
sa(dp6689
g7
I18
sg8
g127
sg10
I16
sg11
VMelanoma antigen
p6690
sg13
I2
sa(dp6691
g7
I36
sg8
g127
sg10
I4
sg11
VMAGE
p6692
sg13
I1
sasg17
(lp6693
(dp6694
g7
I18
sg20
VC0025202
p6695
sg10
I8
sg11
VMelanoma
p6696
sg13
I1
sa(dp6697
g7
I71
sg20
VC0684249
p6698
sg10
I11
sg11
Vlung cancer
p6699
sg13
I2
sasa(dp6700
g2
S'In the present study, the expressions of CT antigens (MAGE-A3, MAGE-A4, NY-ESO-1 and KK-LC-1) in non-small cell lung cancer (NSCLC) were analyzed by RT-PCR.\n'
p6701
sg4
(lp6702
(dp6703
g7
I54
sg8
VP43355
p6704
sg10
I7
sg11
VMAGE-A3
p6705
sg13
I1
sa(dp6706
g7
I63
sg8
VP43355
p6707
sg10
I7
sg11
VMAGE-A4
p6708
sg13
I1
sa(dp6709
g7
I41
sg8
VP01893
p6710
sg10
I11
sg11
VCT antigens
p6711
sg13
I2
sa(dp6712
g7
I72
sg8
VP78358
p6713
sg10
I8
sg11
VNY-ESO-1
p6714
sg13
I1
sasg17
(lp6715
(dp6716
g7
I125
sg20
VC0007131
p6717
sg10
I5
sg11
VNSCLC
p6718
sg13
I1
sa(dp6719
g7
I97
sg20
VC0007131
p6720
sg10
I26
sg11
Vnon-small cell lung cancer
p6721
sg13
I4
sasa(dp6722
g2
S'The expression rates of MAGE-A3, MAGE-A4, NY-ESO-1 and KK-LC-1 were 23.8%, 20.1%, 10.5% and 32.6% in patients with NSCLC, respectively.\n'
p6723
sg4
(lp6724
(dp6725
g7
I33
sg8
VP43355
p6726
sg10
I7
sg11
VMAGE-A4
p6727
sg13
I1
sa(dp6728
g7
I24
sg8
VP43355
p6729
sg10
I7
sg11
VMAGE-A3
p6730
sg13
I1
sa(dp6731
g7
I42
sg8
VP78358
p6732
sg10
I8
sg11
VNY-ESO-1
p6733
sg13
I1
sasg17
(lp6734
(dp6735
g7
I115
sg20
VC0007131
p6736
sg10
I5
sg11
VNSCLC
p6737
sg13
I1
sasa(dp6738
g2
S'Expression of MAGE-A3, NY-ESO-1 or KK-LC-1 did not affect survival of patients with NSCLC significantly, however, expression of at least one of such CT antigens negatively affect survival of patients with NSCLC (p=0.045).\n'
p6739
sg4
(lp6740
(dp6741
g7
I144
sg8
VP01893
p6742
sg10
I16
sg11
Vsuch CT antigens
p6743
sg13
I3
sa(dp6744
g7
I14
sg8
VP43355
p6745
sg10
I7
sg11
VMAGE-A3
p6746
sg13
I1
sa(dp6747
g7
I23
sg8
VP78358
p6748
sg10
I8
sg11
VNY-ESO-1
p6749
sg13
I1
sasg17
(lp6750
(dp6751
g7
I84
sg20
VC0007131
p6752
sg10
I5
sg11
VNSCLC
p6753
sg13
I1
sa(dp6754
g7
I84
sg20
VC0007131
p6755
sg10
I5
sg11
VNSCLC
p6756
sg13
I1
sasa(dp6757
g2
S'The gene consisted of 556 bp, including an open reading frame consisted of 113 amino acids, designated as Kita-kyushu lung cancer antigen 1 (KK-LC-1).\n'
p6758
sg4
(lp6759
(dp6760
g7
I141
sg8
g127
sg10
I7
sg11
VKK-LC-1
p6761
sg13
I1
sa(dp6762
g7
I106
sg8
g127
sg10
I33
sg11
VKita-kyushu lung cancer antigen 1
p6763
sg13
I5
sasg17
(lp6764
(dp6765
g7
I118
sg20
VC0684249
p6766
sg10
I11
sg11
Vlung cancer
p6767
sg13
I2
sasa(dp6768
g2
S'I provide an example of two kallikreins (KLK6 and KLK10), which are highly elevated in serum of 3%-5% of pancreatic cancer patients at 100% specificity.\n'
p6769
sg4
(lp6770
(dp6771
g7
I41
sg8
VP06870
p6772
sg10
I4
sg11
VKLK6
p6773
sg13
I1
sa(dp6774
g7
I50
sg8
g127
sg10
I5
sg11
VKLK10
p6775
sg13
I1
sa(dp6776
g7
I28
sg8
VP10398
p6777
sg10
I11
sg11
Vkallikreins
p6778
sg13
I1
sasg17
(lp6779
(dp6780
g7
I105
sg20
VC0235974
p6781
sg10
I17
sg11
Vpancreatic cancer
p6782
sg13
I2
sasa(dp6783
g2
S'Our results suggest that KLK10 may serve as a new marker of unfavourable prognosis of colorectal cancer.\n'
p6784
sg4
(lp6785
(dp6786
g7
I25
sg8
g127
sg10
I5
sg11
VKLK10
p6787
sg13
I1
sasg17
(lp6788
(dp6789
g7
I86
sg20
VC1527249
p6790
sg10
I17
sg11
Vcolorectal cancer
p6791
sg13
I2
sasa(dp6792
g2
S'Since KLKs are promising tumor biomarkers, the examination of KLK10 mRNA expression and its association with colorectal cancer (CRC) progression was studied using semi-quantitative PCR.\n'
p6793
sg4
(lp6794
(dp6795
g7
I62
sg8
g127
sg10
I10
sg11
VKLK10 mRNA
p6796
sg13
I2
sa(dp6797
g7
I6
sg8
g127
sg10
I4
sg11
VKLKs
p6798
sg13
I1
sasg17
(lp6799
(dp6800
g7
I128
sg20
VC1527249
p6801
sg10
I3
sg11
VCRC
p6802
sg13
I1
sa(dp6803
g7
I25
sg20
VC0027651
p6804
sg10
I5
sg11
Vtumor
p6805
sg13
I1
sa(dp6806
g7
I109
sg20
VC1527249
p6807
sg10
I17
sg11
Vcolorectal cancer
p6808
sg13
I2
sasa(dp6809
g2
S'Nine KLKs (KLK5-8, KLK10, KLK11, KLK13-15) were measured using ELISA assays in cytosolic extracts of 122 colon cancer tissues and their nearby normal mucosa, obtained during surgery.\n'
p6810
sg4
(lp6811
(dp6812
g7
I5
sg8
g127
sg10
I4
sg11
VKLKs
p6813
sg13
I1
sa(dp6814
g7
I33
sg8
g127
sg10
I8
sg11
VKLK13-15
p6815
sg13
I1
sa(dp6816
g7
I11
sg8
g127
sg10
I6
sg11
VKLK5-8
p6817
sg13
I1
sa(dp6818
g7
I26
sg8
g127
sg10
I5
sg11
VKLK11
p6819
sg13
I1
sa(dp6820
g7
I19
sg8
g127
sg10
I5
sg11
VKLK10
p6821
sg13
I1
sasg17
(lp6822
(dp6823
g7
I105
sg20
VC0699790
p6824
sg10
I12
sg11
Vcolon cancer
p6825
sg13
I2
sasa(dp6826
g2
S'Previous studies suggested an upregulation of KLK10 and KLK6 in pancreatic ductal adenocarcinoma (PDAC).\n'
p6827
sg4
(lp6828
(dp6829
g7
I56
sg8
VP06870
p6830
sg10
I4
sg11
VKLK6
p6831
sg13
I1
sa(dp6832
g7
I46
sg8
g127
sg10
I5
sg11
VKLK10
p6833
sg13
I1
sasg17
(lp6834
(dp6835
g7
I64
sg20
VC1335302
p6836
sg10
I32
sg11
Vpancreatic ductal adenocarcinoma
p6837
sg13
I3
sa(dp6838
g7
I98
sg20
VC1335302
p6839
sg10
I4
sg11
VPDAC
p6840
sg13
I1
sasa(dp6841
g2
S'The aims of this study were to demonstrate expression and single nucleotide polymorphisms of KLK10 in colorectal cancer (CRC) and gastric cancer (GC), and to correlate the relative KLK10 expression level with clinicopathological factors of CRC and GC.\n'
p6842
sg4
(lp6843
(dp6844
g7
I93
sg8
g127
sg10
I5
sg11
VKLK10
p6845
sg13
I1
sa(dp6846
g7
I93
sg8
g127
sg10
I5
sg11
VKLK10
p6847
sg13
I1
sasg17
(lp6848
(dp6849
g7
I121
sg20
VC1527249
p6850
sg10
I3
sg11
VCRC
p6851
sg13
I1
sa(dp6852
g7
I121
sg20
VC1527249
p6853
sg10
I3
sg11
VCRC
p6854
sg13
I1
sa(dp6855
g7
I130
sg20
VC0024623
p6856
sg10
I14
sg11
Vgastric cancer
p6857
sg13
I2
sa(dp6858
g7
I102
sg20
VC1527249
p6859
sg10
I17
sg11
Vcolorectal cancer
p6860
sg13
I2
sa(dp6861
g7
I146
sg20
VC0024623
p6862
sg10
I2
sg11
VGC
p6863
sg13
I1
sa(dp6864
g7
I146
sg20
VC0024623
p6865
sg10
I2
sg11
VGC
p6866
sg13
I1
sasa(dp6867
g2
S'To demonstrate expression and single nucleotide polymorphisms (SNP) of human kallikrein 10 (KLK 10) in colorectal cancer (CRC) and to correlate the KLK 10 expression level with clinicopathological factors of CRC.\n'
p6868
sg4
(lp6869
(dp6870
g7
I71
sg8
g127
sg10
I19
sg11
Vhuman kallikrein 10
p6871
sg13
I3
sa(dp6872
g7
I122
sg8
VP31749
p6873
sg10
I3
sg11
VCRC
p6874
sg13
I1
sa(dp6875
g7
I92
sg8
g127
sg10
I6
sg11
VKLK 10
p6876
sg13
I2
sa(dp6877
g7
I92
sg8
g127
sg10
I6
sg11
VKLK 10
p6878
sg13
I2
sa(dp6879
g7
I103
sg8
VP31749
p6880
sg10
I17
sg11
Vcolorectal cancer
p6881
sg13
I2
sasg17
(lp6882
(dp6883
g7
I122
sg20
VC1527249
p6884
sg10
I3
sg11
VCRC
p6885
sg13
I1
sa(dp6886
g7
I122
sg20
VC1527249
p6887
sg10
I3
sg11
VCRC
p6888
sg13
I1
sa(dp6889
g7
I103
sg20
VC1527249
p6890
sg10
I17
sg11
Vcolorectal cancer
p6891
sg13
I2
sasa(dp6892
g2
S'When investigating possible gene expression network partners of WT1 in a large acute myeloid leukemia (AML) patient cohort, one of the genes with the highest correlation to WT1 was quinolinate phosphoribosyltransferase (QPRT), a key enzyme in the de novo nicotinamide adenine dinucleotide (NAD+) synthesis pathway.\n'
p6893
sg4
(lp6894
(dp6895
g7
I220
sg8
g127
sg10
I4
sg11
VQPRT
p6896
sg13
I1
sa(dp6897
g7
I64
sg8
g127
sg10
I3
sg11
VWT1
p6898
sg13
I1
sa(dp6899
g7
I64
sg8
g127
sg10
I3
sg11
VWT1
p6900
sg13
I1
sa(dp6901
g7
I181
sg8
g127
sg10
I37
sg11
Vquinolinate phosphoribosyltransferase
p6902
sg13
I2
sasg17
(lp6903
(dp6904
g7
I64
sg20
VC0027708
p6905
sg10
I3
sg11
VWT1
p6906
sg13
I1
sa(dp6907
g7
I64
sg20
VC0027708
p6908
sg10
I3
sg11
VWT1
p6909
sg13
I1
sa(dp6910
g7
I79
sg20
VC0023467
p6911
sg10
I22
sg11
Vacute myeloid leukemia
p6912
sg13
I3
sa(dp6913
g7
I103
sg20
VC0023467
p6914
sg10
I3
sg11
VAML
p6915
sg13
I1
sasa(dp6916
g2
S'Upon overexpression in leukemic K562 cells, QPRT conferred partial resistance to the anti-leukemic drug imatinib, indicating possible anti-apoptotic functions, consistent with previous reports on glioma cells.\n'
p6917
sg4
(lp6918
(dp6919
g7
I44
sg8
g127
sg10
I4
sg11
VQPRT
p6920
sg13
I1
sasg17
(lp6921
(dp6922
g7
I196
sg20
VC0017638
p6923
sg10
I6
sg11
Vglioma
p6924
sg13
I1
sasa(dp6925
g2
S'We discovered several ENZ (PYCR1, QPRT, and HSPA6) and PPI (CASC5, ZBTB32, and CSAD) binding sites on proteins that have been seldom explored in cancer.\n'
p6926
sg4
(lp6927
(dp6928
g7
I27
sg8
VP32322
p6929
sg10
I5
sg11
VPYCR1
p6930
sg13
I1
sa(dp6931
g7
I34
sg8
g127
sg10
I4
sg11
VQPRT
p6932
sg13
I1
sa(dp6933
g7
I55
sg8
VP01308
p6934
sg10
I3
sg11
VPPI
p6935
sg13
I1
sa(dp6936
g7
I60
sg8
g127
sg10
I5
sg11
VCASC5
p6937
sg13
I1
sa(dp6938
g7
I67
sg8
g127
sg10
I6
sg11
VZBTB32
p6939
sg13
I1
sa(dp6940
g7
I44
sg8
VP17066
p6941
sg10
I5
sg11
VHSPA6
p6942
sg13
I1
sasg17
(lp6943
(dp6944
g7
I145
sg20
VC0006826
p6945
sg10
I6
sg11
Vcancer
p6946
sg13
I1
sasa(dp6947
g2
S'Based on our comparison of human QPRT structures in the apo and complex forms, we propose a drug design strategy targeting malignant glioma.\n'
p6948
sg4
(lp6949
(dp6950
g7
I56
sg8
g127
sg10
I3
sg11
Vapo
p6951
sg13
I1
sasg17
(lp6952
(dp6953
g7
I123
sg20
VC0555198
p6954
sg10
I16
sg11
Vmalignant glioma
p6955
sg13
I2
sasa(dp6956
g2
S'Human malignant glioma cells, but not nonneoplastic astrocytes, expressed quinolinic acid phosphoribosyltransferase (QPRT) to use quinolinic acid for NAD(+) synthesis and prevent apoptosis when de novo NAD(+) synthesis was blocked.\n'
p6957
sg4
(lp6958
(dp6959
g7
I74
sg8
g127
sg10
I41
sg11
Vquinolinic acid phosphoribosyltransferase
p6960
sg13
I3
sa(dp6961
g7
I117
sg8
g127
sg10
I4
sg11
VQPRT
p6962
sg13
I1
sasg17
(lp6963
(dp6964
g7
I150
sg20
VC1850380
p6965
sg10
I3
sg11
VNAD
p6966
sg13
I1
sa(dp6967
g7
I150
sg20
VC1850380
p6968
sg10
I3
sg11
VNAD
p6969
sg13
I1
sa(dp6970
g7
I6
sg20
VC0555198
p6971
sg10
I16
sg11
Vmalignant glioma
p6972
sg13
I2
sasa(dp6973
g2
S'Oxidative stress, temozolomide, and irradiation induced QPRT in glioma cells.\n'
p6974
sg4
(lp6975
sg17
(lp6976
(dp6977
g7
I0
sg20
VC0242606
p6978
sg10
I16
sg11
VOxidative stress
p6979
sg13
I2
sa(dp6980
g7
I64
sg20
VC0017638
p6981
sg10
I6
sg11
Vglioma
p6982
sg13
I1
sasa(dp6983
g2
S'These findings have implications for therapeutic approaches inducing intracellular NAD(+) depletion, such as alkylating agents or direct NAD(+) synthesis inhibitors, and identify QPRT as a potential therapeutic target in malignant gliomas.\n'
p6984
sg4
(lp6985
(dp6986
g7
I179
sg8
g127
sg10
I4
sg11
VQPRT
p6987
sg13
I1
sa(dp6988
g7
I83
sg8
VP51649
p6989
sg10
I6
sg11
VNAD(+)
p6990
sg13
I1
sasg17
(lp6991
(dp6992
g7
I83
sg20
VC1850380
p6993
sg10
I3
sg11
VNAD
p6994
sg13
I1
sa(dp6995
g7
I83
sg20
VC1850380
p6996
sg10
I3
sg11
VNAD
p6997
sg13
I1
sa(dp6998
g7
I221
sg20
VC0555198
p6999
sg10
I17
sg11
Vmalignant gliomas
p7000
sg13
I2
sasa(dp7001
g2
S'The specificity of the antibody was validated by western blot analysis In gene expression analysis QPRT was detected as differently expressed between follicular thyroid adenoma and follicular thyroid carcinoma.\n'
p7002
sg4
(lp7003
sg17
(lp7004
(dp7005
g7
I181
sg20
VC0206682
p7006
sg10
I28
sg11
Vfollicular thyroid carcinoma
p7007
sg13
I3
sa(dp7008
g7
I161
sg20
VC0151468
p7009
sg10
I15
sg11
Vthyroid adenoma
p7010
sg13
I2
sasa(dp7011
g2
S'QPRT protein could be detected by immunohistochemistry in 65% of follicular thyroid carcinomas including minimal invasive variant and only 22% of follicular adenomas.\n'
p7012
sg4
(lp7013
(dp7014
g7
I0
sg8
g127
sg10
I12
sg11
VQPRT protein
p7015
sg13
I2
sasg17
(lp7016
(dp7017
g7
I146
sg20
VC0205647
p7018
sg10
I19
sg11
Vfollicular adenomas
p7019
sg13
I2
sa(dp7020
g7
I65
sg20
VC0206682
p7021
sg10
I29
sg11
Vfollicular thyroid carcinomas
p7022
sg13
I3
sasa(dp7023
g2
S'To analyze retinal thickness (RT) and choroidal thickness (ChT) changes in patients with unilateral nongranulomatous acute anterior uveitis (AAU) using three-dimensional (3D) 1060-nm optical coherence tomography (OCT).\n'
p7024
sg4
(lp7025
sg17
(lp7026
(dp7027
g7
I141
sg20
VC0701807
p7028
sg10
I3
sg11
VAAU
p7029
sg13
I1
sa(dp7030
g7
I117
sg20
VC0701807
p7031
sg10
I22
sg11
Vacute anterior uveitis
p7032
sg13
I3
sasa(dp7033
g2
S'Refraction under cycloplegia, axial length, and subfoveal ChT were measured at baseline with comparative investigations at 15 months follow-up.\n'
p7034
sg4
(lp7035
sg17
(lp7036
(dp7037
g7
I17
sg20
VC0235238
p7038
sg10
I11
sg11
Vcycloplegia
p7039
sg13
I1
sasa(dp7040
g2
S'PurposeTo follow choroidal thickness (ChT) over time in birdshot retinochoroiditis (BRC) using enhanced depth imaging optical coherence tomography (EDI-OCT) and study the effect of early and sustained treatment on ChT.Patients and methodsEighteen patients were included and EDI-OCT measurements of ChT were analyzed retrospectively in five groups of patients with follow-up times ranging from 1 year to &gt;=15 years.\n'
p7041
sg4
(lp7042
sg17
(lp7043
(dp7044
g7
I65
sg20
VC0008513
p7045
sg10
I17
sg11
Vretinochoroiditis
p7046
sg13
I1
sasa(dp7047
g2
S'To investigate the changes in choroidal thickness (ChT) following panretinal photocoagulation (PRP) for diabetic retinopathy (DR) and compare ChT in relation to DR severity.\n'
p7048
sg4
(lp7049
(dp7050
g7
I95
sg8
g127
sg10
I3
sg11
VPRP
p7051
sg13
I1
sa(dp7052
g7
I66
sg8
g127
sg10
I27
sg11
Vpanretinal photocoagulation
p7053
sg13
I2
sasg17
(lp7054
(dp7055
g7
I126
sg20
VC0011884
p7056
sg10
I2
sg11
VDR
p7057
sg13
I1
sa(dp7058
g7
I126
sg20
VC0011884
p7059
sg10
I2
sg11
VDR
p7060
sg13
I1
sa(dp7061
g7
I104
sg20
VC0011884
p7062
sg10
I20
sg11
Vdiabetic retinopathy
p7063
sg13
I2
sasa(dp7064
g2
S'The central field ChT of severe NPDR (323.2 +/- 61.3 mym) was significantly thicker than that of normal (248.3 +/- 70.7 mym) and mild to moderate NPDR (230.0 +/- 70.3 mym, P = 0.0455 and 0.0099, respectively).\n'
p7065
sg4
(lp7066
sg17
(lp7067
(dp7068
g7
I25
sg20
VC0730278
p7069
sg10
I11
sg11
Vsevere NPDR
p7070
sg13
I2
sasa(dp7071
g2
S'ChT of severe NPDR and PDR was significantly thicker than that of mild to moderate NPDR.\n'
p7072
sg4
(lp7073
(dp7074
g7
I0
sg8
g127
sg10
I3
sg11
VChT
p7075
sg13
I1
sasg17
(lp7076
(dp7077
g7
I15
sg20
VC1845050
p7078
sg10
I3
sg11
VPDR
p7079
sg13
I1
sa(dp7080
g7
I7
sg20
VC0730278
p7081
sg10
I11
sg11
Vsevere NPDR
p7082
sg13
I2
sasa(dp7083
g2
S'Ten cases of presumed endophthalmitis were documented: 4 in 50,721 at CHT (95% CI: 0.0071-0.0087%), 2 in 44,666 at ZUH (95% CI: 0.0039-0.0051%), and 4 in 39,314 at UCB (95% CI: 0.0092-0.011%).\n'
p7084
sg4
(lp7085
sg17
(lp7086
(dp7087
g7
I22
sg20
VC0014236
p7088
sg10
I15
sg11
Vendophthalmitis
p7089
sg13
I1
sasa(dp7090
g2
S'To investigate longitudinal changes in intraocular pressure (IOP), axial length (AL), and choroidal thickness (ChT) in primary open-angle glaucoma (POAG) eyes after trabeculectomy and to evaluate the parameters that might influence those changes.\n'
p7091
sg4
(lp7092
sg17
(lp7093
(dp7094
g7
I39
sg20
VC0595921
p7095
sg10
I20
sg11
Vintraocular pressure
p7096
sg13
I2
sa(dp7097
g7
I148
sg20
VC0339573
p7098
sg10
I4
sg11
VPOAG
p7099
sg13
I1
sa(dp7100
g7
I61
sg20
VC0595921
p7101
sg10
I3
sg11
VIOP
p7102
sg13
I1
sa(dp7103
g7
I119
sg20
VC0339573
p7104
sg10
I27
sg11
Vprimary open-angle glaucoma
p7105
sg13
I3
sasa(dp7106
g2
S'The association between subfoveal ChT and systemic, as well as ocular factors, including age, sex, height, weight, body mass index, axial length, refractive error, intraocular pressure, preterm history, and the refractive status of parents were studied.\n'
p7107
sg4
(lp7108
sg17
(lp7109
(dp7110
g7
I146
sg20
VC0034951
p7111
sg10
I16
sg11
Vrefractive error
p7112
sg13
I2
sa(dp7113
g7
I164
sg20
VC0595921
p7114
sg10
I20
sg11
Vintraocular pressure
p7115
sg13
I2
sasa(dp7116
g2
S'ChT differed significantly between males and females 2-mm temporal to the fovea in the emmetropia group (P&lt;0.05), and 1-mm temporal to the fovea in the mild myopia group (P&lt;0.05).\n'
p7117
sg4
(lp7118
sg17
(lp7119
(dp7120
g7
I160
sg20
VC0027092
p7121
sg10
I6
sg11
Vmyopia
p7122
sg13
I1
sasa(dp7123
g2
S'Further analysis indicates that TNFAIP2, as a single diagnostic marker, is more sensitive (sensitivity=87%) and specific (specificity=96%) than TRAF1, nuclear cRel, or CD23 for distinguishing the malignant B cells of primary mediastinal (thymic) large B-cell lymphoma from those of its morphologic and immunophenotypic mimic, diffuse large B-cell lymphoma, not otherwise specified.\n'
p7124
sg4
(lp7125
(dp7126
g7
I144
sg8
g127
sg10
I5
sg11
VTRAF1
p7127
sg13
I1
sa(dp7128
g7
I32
sg8
g127
sg10
I7
sg11
VTNFAIP2
p7129
sg13
I1
sa(dp7130
g7
I168
sg8
VP06734
p7131
sg10
I4
sg11
VCD23
p7132
sg13
I1
sasg17
(lp7133
(dp7134
g7
I217
sg20
VC0855152
p7135
sg10
I50
sg11
Vprimary mediastinal (thymic) large B-cell lymphoma
p7136
sg13
I6
sa(dp7137
g7
I326
sg20
VC2699777
p7138
sg10
I54
sg11
Vdiffuse large B-cell lymphoma, not otherwise specified
p7139
sg13
I7
sasa(dp7140
g2
S'We demonstrate that the expression of TRAF1 and activated c-Rel, two proteins that function in signaling events downstream of activated CD30 in Reed-Sternberg cells, reliably distinguish classical Hodgkin lymphoma from anaplastic large cell lymphoma, nodular lymphocyte predominant Hodgkin lymphoma, and nonmediastinal diffuse large B-cell lymphoma.\n'
p7141
sg4
(lp7142
(dp7143
g7
I58
sg8
g127
sg10
I5
sg11
Vc-Rel
p7144
sg13
I1
sa(dp7145
g7
I38
sg8
g127
sg10
I5
sg11
VTRAF1
p7146
sg13
I1
sa(dp7147
g7
I136
sg8
VP28908
p7148
sg10
I4
sg11
VCD30
p7149
sg13
I1
sasg17
(lp7150
(dp7151
g7
I187
sg20
VC1333064
p7152
sg10
I26
sg11
Vclassical Hodgkin lymphoma
p7153
sg13
I3
sa(dp7154
g7
I219
sg20
VC0206180
p7155
sg10
I30
sg11
Vanaplastic large cell lymphoma
p7156
sg13
I4
sa(dp7157
g7
I251
sg20
VC1334968
p7158
sg10
I47
sg11
Vnodular lymphocyte predominant Hodgkin lymphoma
p7159
sg13
I5
sa(dp7160
g7
I319
sg20
VC0079744
p7161
sg10
I29
sg11
Vdiffuse large B-cell lymphoma
p7162
sg13
I4
sasa(dp7163
g2
S'In contrast, strong TRAF1 staining was present in only 1 of 17 cases of anaplastic large cell lymphoma, 0 of 15 cases of lymphocyte predominant Hodgkin lymphoma, and 2 of 36 cases of nonmediastinal diffuse large B-cell lymphoma.\n'
p7164
sg4
(lp7165
(dp7166
g7
I20
sg8
g127
sg10
I5
sg11
VTRAF1
p7167
sg13
I1
sasg17
(lp7168
(dp7169
g7
I72
sg20
VC0206180
p7170
sg10
I30
sg11
Vanaplastic large cell lymphoma
p7171
sg13
I4
sa(dp7172
g7
I144
sg20
VC0019829
p7173
sg10
I16
sg11
VHodgkin lymphoma
p7174
sg13
I2
sa(dp7175
g7
I198
sg20
VC0079744
p7176
sg10
I29
sg11
Vdiffuse large B-cell lymphoma
p7177
sg13
I4
sasa(dp7178
g2
S'Only some cases of diffuse large B-cell lymphoma showed a moderate to high TRAF1 signal.\n'
p7179
sg4
(lp7180
(dp7181
g7
I75
sg8
g127
sg10
I5
sg11
VTRAF1
p7182
sg13
I1
sasg17
(lp7183
(dp7184
g7
I19
sg20
VC0079744
p7185
sg10
I29
sg11
Vdiffuse large B-cell lymphoma
p7186
sg13
I4
sasa(dp7187
g2
S'The association of GWAS-identified obesity risk alleles (FTO, MC4R, SH2B1, BDNF, INSIG2, TNNI3K, NISCH-STAB1, MTIF3, MAP2K5, QPCTL/GIPR, and PPARG) with dietary intake, measured through food-frequency questionnaires, was investigated in 2075 participants from the Look AHEAD (Action for Health in Diabetes) clinical trial.\n'
p7188
sg4
(lp7189
(dp7190
g7
I97
sg8
g127
sg10
I5
sg11
VNISCH
p7191
sg13
I1
sa(dp7192
g7
I103
sg8
g127
sg10
I5
sg11
VSTAB1
p7193
sg13
I1
sa(dp7194
g7
I125
sg8
g127
sg10
I5
sg11
VQPCTL
p7195
sg13
I1
sa(dp7196
g7
I68
sg8
g127
sg10
I5
sg11
VSH2B1
p7197
sg13
I1
sa(dp7198
g7
I81
sg8
g127
sg10
I6
sg11
VINSIG2
p7199
sg13
I1
sa(dp7200
g7
I131
sg8
VP48546
p7201
sg10
I4
sg11
VGIPR
p7202
sg13
I1
sa(dp7203
g7
I89
sg8
g127
sg10
I6
sg11
VTNNI3K
p7204
sg13
I1
sa(dp7205
g7
I57
sg8
g127
sg10
I3
sg11
VFTO
p7206
sg13
I1
sa(dp7207
g7
I62
sg8
VP32245
p7208
sg10
I4
sg11
VMC4R
p7209
sg13
I1
sa(dp7210
g7
I110
sg8
g127
sg10
I5
sg11
VMTIF3
p7211
sg13
I1
sa(dp7212
g7
I117
sg8
g127
sg10
I6
sg11
VMAP2K5
p7213
sg13
I1
sa(dp7214
g7
I141
sg8
g127
sg10
I5
sg11
VPPARG
p7215
sg13
I1
sasg17
(lp7216
(dp7217
g7
I35
sg20
VC0028754
p7218
sg10
I7
sg11
Vobesity
p7219
sg13
I1
sa(dp7220
g7
I297
sg20
VC0011849
p7221
sg10
I8
sg11
VDiabetes
p7222
sg13
I1
sasa(dp7223
g2
S'FEEL-1/stabilin-1 is a multifunctional transmembrane glycoprotein that is implicated in bacterial infection, diabetes, atherosclerosis, wound healing, and innate immunity.\n'
p7224
sg4
(lp7225
(dp7226
g7
I0
sg8
g127
sg10
I17
sg11
VFEEL-1/stabilin-1
p7227
sg13
I1
sasg17
(lp7228
(dp7229
g7
I119
sg20
VC0004153
p7230
sg10
I15
sg11
Vatherosclerosis
p7231
sg13
I1
sa(dp7232
g7
I88
sg20
VC0004623
p7233
sg10
I19
sg11
Vbacterial infection
p7234
sg13
I2
sa(dp7235
g7
I109
sg20
VC0011849
p7236
sg10
I8
sg11
Vdiabetes
p7237
sg13
I1
sasa(dp7238
g2
S'Our study analyzed the RNA cargoes of EVs derived from 4 liver-cancer cell lines: HuH7, Hep3B, HepG2 (hepato-cellular carcinoma) and HuH6 (hepatoblastoma), generating two different sets of sequencing libraries for each.\n'
p7239
sg4
(lp7240
sg17
(lp7241
(dp7242
g7
I139
sg20
VC0206624
p7243
sg10
I14
sg11
Vhepatoblastoma
p7244
sg13
I1
sa(dp7245
g7
I63
sg20
VC0006826
p7246
sg10
I6
sg11
Vcancer
p7247
sg13
I1
sa(dp7248
g7
I118
sg20
VC0007097
p7249
sg10
I9
sg11
Vcarcinoma
p7250
sg13
I1
sasa(dp7251
g2
S'The efficiency of AZA on inhibition of proliferation differs in the evaluated cell lines as follows: HepG2 (an experimental model of hepatoblastoma)&gt;Hep3B (derived from a hepatocellular carcinoma)&gt;HuH6 (derived from a hepatoblastoma)&gt;&gt;HuH7 (derived from a hepatocellular carcinoma)=Chang Liver cells (a non-malignant cellular model).\n'
p7252
sg4
(lp7253
sg17
(lp7254
(dp7255
g7
I174
sg20
VC1512411
p7256
sg10
I24
sg11
Vhepatocellular carcinoma
p7257
sg13
I2
sa(dp7258
g7
I133
sg20
VC0206624
p7259
sg10
I14
sg11
Vhepatoblastoma
p7260
sg13
I1
sa(dp7261
g7
I39
sg20
VC0334094
p7262
sg10
I13
sg11
Vproliferation
p7263
sg13
I1
sa(dp7264
g7
I133
sg20
VC0206624
p7265
sg10
I14
sg11
Vhepatoblastoma
p7266
sg13
I1
sa(dp7267
g7
I174
sg20
VC1512411
p7268
sg10
I24
sg11
Vhepatocellular carcinoma
p7269
sg13
I2
sasa(dp7270
g2
S'HBF-0079 caused irreversible growth arrest and apoptosis of the HCC lines Huh7, Hep3B, HepaRG as well as the hepatoblastoma line HepG2, with CC50 values from ~0.7-7.7 myM, while more than 45 myM was needed to achieve CC50 values for the immortalized normal hepatocyte lines THLE-2 and PH5CH.\n'
p7271
sg4
(lp7272
(dp7273
g7
I141
sg8
g127
sg10
I29
sg11
VCC50 values from ~0.7-7.7 myM
p7274
sg13
I5
sasg17
(lp7275
(dp7276
g7
I64
sg20
VC2239176
p7277
sg10
I3
sg11
VHCC
p7278
sg13
I1
sa(dp7279
g7
I29
sg20
VC0333951
p7280
sg10
I13
sg11
Vgrowth arrest
p7281
sg13
I2
sa(dp7282
g7
I109
sg20
VC0206624
p7283
sg10
I14
sg11
Vhepatoblastoma
p7284
sg13
I1
sasa(dp7285
g2
S'Hepatoma Hep3B and Huh7 cells displayed stronger ATX expression than hepatoblastoma HepG2 cells and normal hepatocytes did.\n'
p7286
sg4
(lp7287
(dp7288
g7
I49
sg8
g127
sg10
I3
sg11
VATX
p7289
sg13
I1
sasg17
(lp7290
(dp7291
g7
I69
sg20
VC0206624
p7292
sg10
I14
sg11
Vhepatoblastoma
p7293
sg13
I1
sa(dp7294
g7
I0
sg20
VC0023903
p7295
sg10
I8
sg11
VHepatoma
p7296
sg13
I1
sasa(dp7297
g2
S"Eight databases (Embase, Medline, CINAHL, Web of Science, PsychInfo, ASSIA, ERIC and ProQuest Dissertations) were searched in 2016 to identify qualitative studies exploring children's views about self-managing diabetes.\n"
p7298
sg4
(lp7299
sg17
(lp7300
(dp7301
g7
I42
sg20
VC0332875
p7302
sg10
I3
sg11
VWeb
p7303
sg13
I1
sa(dp7304
g7
I210
sg20
VC0011849
p7305
sg10
I8
sg11
Vdiabetes
p7306
sg13
I1
sasa(dp7307
g2
S'Only 25% of double compound Gata4/Gata5 heterozygotes survive to adulthood and these mice have aortic stenosis.\n'
p7308
sg4
(lp7309
(dp7310
g7
I28
sg8
VP43694
p7311
sg10
I5
sg11
VGata4
p7312
sg13
I1
sa(dp7313
g7
I34
sg8
g127
sg10
I5
sg11
VGata5
p7314
sg13
I1
sasg17
(lp7315
(dp7316
g7
I95
sg20
VC0003507
p7317
sg10
I15
sg11
Vaortic stenosis
p7318
sg13
I2
sasa(dp7319
g2
S'Our findings confirm that IR exists in gout patients and implicate that febuxostat can effectively control the level of serum UA and increase insulin sensitivity in primary gout patients.\n'
p7320
sg4
(lp7321
(dp7322
g7
I142
sg8
VP01308
p7323
sg10
I7
sg11
Vinsulin
p7324
sg13
I1
sa(dp7325
g7
I26
sg8
VP06213
p7326
sg10
I2
sg11
VIR
p7327
sg13
I1
sasg17
(lp7328
(dp7329
g7
I39
sg20
VC0018099
p7330
sg10
I4
sg11
Vgout
p7331
sg13
I1
sa(dp7332
g7
I165
sg20
VC0149896
p7333
sg10
I12
sg11
Vprimary gout
p7334
sg13
I2
sa(dp7335
g7
I142
sg20
VC0920563
p7336
sg10
I19
sg11
Vinsulin sensitivity
p7337
sg13
I2
sasa(dp7338
g2
S'The study demonstrated compensatory hyperinsulinemia and insulin resistance, hypoadiponectinemia, hyperleptinemia, left ventricular hypertrophy, diastolic dysfunction, and intact ventricular contractility in patients with type 2 diabetes, gout, and their combination.\n'
p7339
sg4
(lp7340
(dp7341
g7
I41
sg8
VP01308
p7342
sg10
I7
sg11
Vinsulin
p7343
sg13
I1
sasg17
(lp7344
(dp7345
g7
I239
sg20
VC0018099
p7346
sg10
I4
sg11
Vgout
p7347
sg13
I1
sa(dp7348
g7
I145
sg20
VC0520863
p7349
sg10
I21
sg11
Vdiastolic dysfunction
p7350
sg13
I2
sa(dp7351
g7
I222
sg20
VC0011860
p7352
sg10
I15
sg11
Vtype 2 diabetes
p7353
sg13
I3
sa(dp7354
g7
I115
sg20
VC0149721
p7355
sg10
I28
sg11
Vleft ventricular hypertrophy
p7356
sg13
I3
sa(dp7357
g7
I23
sg20
VC1257965
p7358
sg10
I29
sg11
Vcompensatory hyperinsulinemia
p7359
sg13
I2
sa(dp7360
g7
I57
sg20
VC0021655
p7361
sg10
I18
sg11
Vinsulin resistance
p7362
sg13
I2
sa(dp7363
g7
I77
sg20
VC2675519
p7364
sg10
I19
sg11
Vhypoadiponectinemia
p7365
sg13
I1
sasa(dp7366
g2
S'Teneurin transmembrane protein 1 (TENM1) expression was highly upregulated in cancerous tissues and negative in benign thyroid tissues.\n'
p7367
sg4
(lp7368
(dp7369
g7
I0
sg8
VP14222
p7370
sg10
I32
sg11
VTeneurin transmembrane protein 1
p7371
sg13
I4
sa(dp7372
g7
I34
sg8
g127
sg10
I5
sg11
VTENM1
p7373
sg13
I1
sasg17
(lp7374
sa(dp7375
g2
S'By immunohistochemistry, TENM1 expression in papillary thyroid cancer was associated with the classical subtype (p = 0.018), extrathyroidal invasion (p = 0.001), BRAF V600E mutation (p &lt; 0.001), and an advanced stage (p = 0.019).\n'
p7376
sg4
(lp7377
(dp7378
g7
I162
sg8
VP15056
p7379
sg10
I10
sg11
VBRAF V600E
p7380
sg13
I2
sa(dp7381
g7
I25
sg8
g127
sg10
I5
sg11
VTENM1
p7382
sg13
I1
sasg17
(lp7383
(dp7384
g7
I162
sg20
VC3273990
p7385
sg10
I10
sg11
VBRAF V600E
p7386
sg13
I2
sa(dp7387
g7
I140
sg20
VC2699153
p7388
sg10
I8
sg11
Vinvasion
p7389
sg13
I1
sa(dp7390
g7
I45
sg20
VC0238463
p7391
sg10
I24
sg11
Vpapillary thyroid cancer
p7392
sg13
I3
sasa(dp7393
g2
S'Taken together, our results indicate that distinct pathways are involved in papillary thyroid cancer progression, and TENM1 is a potential marker of cancer progression.\n'
p7394
sg4
(lp7395
(dp7396
g7
I118
sg8
g127
sg10
I5
sg11
VTENM1
p7397
sg13
I1
sasg17
(lp7398
(dp7399
g7
I94
sg20
VC0178874
p7400
sg10
I18
sg11
Vcancer progression
p7401
sg13
I2
sa(dp7402
g7
I76
sg20
VC0238463
p7403
sg10
I24
sg11
Vpapillary thyroid cancer
p7404
sg13
I3
sasa(dp7405
g2
S'We describe that ODZ1 (also known as TENM1), a type II transmembrane protein involved in fetal brain development, plays a crucial role in the invasion of GBM cells.\n'
p7406
sg4
(lp7407
(dp7408
g7
I47
sg8
VP27037
p7409
sg10
I29
sg11
Vtype II transmembrane protein
p7410
sg13
I4
sa(dp7411
g7
I17
sg8
g127
sg10
I4
sg11
VODZ1
p7412
sg13
I1
sa(dp7413
g7
I37
sg8
g127
sg10
I5
sg11
VTENM1
p7414
sg13
I1
sasg17
(lp7415
(dp7416
g7
I154
sg20
VC0017636
p7417
sg10
I3
sg11
VGBM
p7418
sg13
I1
sa(dp7419
g7
I142
sg20
VC2699153
p7420
sg10
I8
sg11
Vinvasion
p7421
sg13
I1
sasa(dp7422
g2
S'The intracellular fragment of ODZ1 promotes cytoskeletal remodelling of GBM cells and invasion of the surrounding environment both in vitro and in vivo.\n'
p7423
sg4
(lp7424
(dp7425
g7
I30
sg8
g127
sg10
I4
sg11
VODZ1
p7426
sg13
I1
sasg17
(lp7427
(dp7428
g7
I86
sg20
VC2699153
p7429
sg10
I8
sg11
Vinvasion
p7430
sg13
I1
sa(dp7431
g7
I72
sg20
VC0017636
p7432
sg10
I3
sg11
VGBM
p7433
sg13
I1
sasa(dp7434
g2
S'Absence of ODZ1 by gene deletion or downregulation of ODZ1 by small interfering RNAs drastically reduces the invasive capacity of GBM cells.\n'
p7435
sg4
(lp7436
(dp7437
g7
I11
sg8
g127
sg10
I4
sg11
VODZ1
p7438
sg13
I1
sa(dp7439
g7
I11
sg8
g127
sg10
I4
sg11
VODZ1
p7440
sg13
I1
sasg17
(lp7441
(dp7442
g7
I130
sg20
VC0017636
p7443
sg10
I3
sg11
VGBM
p7444
sg13
I1
sa(dp7445
g7
I19
sg20
VC1442161
p7446
sg10
I13
sg11
Vgene deletion
p7447
sg13
I2
sasa(dp7448
g2
S'Overexpression of ODZ1 in GBM cells reduced survival of xenografted mice.\n'
p7449
sg4
(lp7450
(dp7451
g7
I18
sg8
g127
sg10
I4
sg11
VODZ1
p7452
sg13
I1
sasg17
(lp7453
(dp7454
g7
I26
sg20
VC0017636
p7455
sg10
I3
sg11
VGBM
p7456
sg13
I1
sasa(dp7457
g2
S'Consistently, analysis of 122 GBM tumour samples revealed that the number of ODZ1-positive cells inversely correlated with overall and progression-free survival.\n'
p7458
sg4
(lp7459
(dp7460
g7
I77
sg8
g127
sg10
I4
sg11
VODZ1
p7461
sg13
I1
sasg17
(lp7462
(dp7463
g7
I30
sg20
VC0017636
p7464
sg10
I3
sg11
VGBM
p7465
sg13
I1
sa(dp7466
g7
I34
sg20
VC0027651
p7467
sg10
I6
sg11
Vtumour
p7468
sg13
I1
sasa(dp7469
g2
S'ODZ3 deletion was detected in seven eGBMs and two ePXAs.\n'
p7470
sg4
(lp7471
(dp7472
g7
I0
sg8
g127
sg10
I4
sg11
VODZ3
p7473
sg13
I1
sasg17
(lp7474
sa(dp7475
g2
S'Higher p14 mRNA transcript levels were associated with non-cancerous background tissue specimens (median copy numbers: 103 vs. 4, p=0.0095), with better overall and disease-free survival, and in TNM2 stage tumours (TNM2 vs. TNM1, 27.2 vs. 3.5, p=0.049; TNM1/TNM2 vs. TNM3/4, 26 vs. 2, p=0.009).\n'
p7476
sg4
(lp7477
(dp7478
g7
I195
sg8
g127
sg10
I4
sg11
VTNM2
p7479
sg13
I1
sa(dp7480
g7
I265
sg8
g127
sg10
I8
sg11
V. TNM3/4
p7481
sg13
I2
sa(dp7482
g7
I7
sg8
VP03971
p7483
sg10
I19
sg11
Vp14 mRNA transcript
p7484
sg13
I3
sa(dp7485
g7
I224
sg8
g127
sg10
I4
sg11
VTNM1
p7486
sg13
I1
sasg17
(lp7487
(dp7488
g7
I206
sg20
VC0027651
p7489
sg10
I7
sg11
Vtumours
p7490
sg13
I1
sasa(dp7491
g2
S'Since glutamic acid decarboxylase (GAD) is a candidate primary autoantigen, we examined the possible linkage between IDDM and the genes encoding GAD65 (GAD2, 10p11-12) and GAD67 (GAD1, 2q31) in 58 Danish IDDM affected sib pairs.\n'
p7492
sg4
(lp7493
(dp7494
g7
I6
sg8
g127
sg10
I27
sg11
Vglutamic acid decarboxylase
p7495
sg13
I3
sa(dp7496
g7
I145
sg8
g127
sg10
I5
sg11
VGAD65
p7497
sg13
I1
sa(dp7498
g7
I179
sg8
g127
sg10
I4
sg11
VGAD1
p7499
sg13
I1
sa(dp7500
g7
I35
sg8
VP49419
p7501
sg10
I3
sg11
VGAD
p7502
sg13
I1
sa(dp7503
g7
I152
sg8
g127
sg10
I4
sg11
VGAD2
p7504
sg13
I1
sa(dp7505
g7
I172
sg8
VP49419
p7506
sg10
I5
sg11
VGAD67
p7507
sg13
I1
sasg17
(lp7508
(dp7509
g7
I6
sg20
VC0270549
p7510
sg10
I27
sg11
Vglutamic acid decarboxylase
p7511
sg13
I3
sa(dp7512
g7
I117
sg20
VC0011854
p7513
sg10
I4
sg11
VIDDM
p7514
sg13
I1
sa(dp7515
g7
I35
sg20
VC0270549
p7516
sg10
I3
sg11
VGAD
p7517
sg13
I1
sa(dp7518
g7
I117
sg20
VC0011854
p7519
sg10
I4
sg11
VIDDM
p7520
sg13
I1
sasa(dp7521
g2
S'In addition, chronic lymphocytic leukemia patients with unmutated IGHV and high COBLL1 show impaired motility and chemotaxis towards CCL19 and CXCL12 as well as enhanced B-cell receptor signaling pathway activation demonstrated by increased PLCGamma2 and SYK phosphorylation after IgM stimulation.\n'
p7522
sg4
(lp7523
(dp7524
g7
I281
sg8
VP29965
p7525
sg10
I3
sg11
VIgM
p7526
sg13
I1
sa(dp7527
g7
I241
sg8
VP16885
p7528
sg10
I9
sg11
VPLCGamma2
p7529
sg13
I1
sa(dp7530
g7
I170
sg8
g127
sg10
I15
sg11
VB-cell receptor
p7531
sg13
I2
sa(dp7532
g7
I133
sg8
g127
sg10
I5
sg11
VCCL19
p7533
sg13
I1
sa(dp7534
g7
I143
sg8
VP48061
p7535
sg10
I6
sg11
VCXCL12
p7536
sg13
I1
sa(dp7537
g7
I75
sg8
g127
sg10
I11
sg11
Vhigh COBLL1
p7538
sg13
I2
sa(dp7539
g7
I66
sg8
VP01764
p7540
sg10
I4
sg11
VIGHV
p7541
sg13
I1
sa(dp7542
g7
I255
sg8
VP43405
p7543
sg10
I3
sg11
VSYK
p7544
sg13
I1
sasg17
(lp7545
(dp7546
g7
I13
sg20
VC0023434
p7547
sg10
I28
sg11
Vchronic lymphocytic leukemia
p7548
sg13
I3
sa(dp7549
g7
I92
sg20
VC0684336
p7550
sg10
I8
sg11
Vimpaired
p7551
sg13
I1
sasa(dp7552
g2
S'The results suggested that DEGs, including IL6, STAT1, MMP9, SYK, BLNK, PLCG2 and CD79B, and the pathways of B cell receptor signaling, Epstein-Barr virus infection and transcriptional misregulation in cancer have strong potential to be useful as targets for diagnosis or treatment of cHL.\n'
p7553
sg4
(lp7554
(dp7555
g7
I66
sg8
g127
sg10
I4
sg11
VBLNK
p7556
sg13
I1
sa(dp7557
g7
I285
sg8
g127
sg10
I3
sg11
VcHL
p7558
sg13
I1
sa(dp7559
g7
I43
sg8
VP05231
p7560
sg10
I3
sg11
VIL6
p7561
sg13
I1
sa(dp7562
g7
I109
sg8
g127
sg10
I15
sg11
VB cell receptor
p7563
sg13
I3
sa(dp7564
g7
I27
sg8
g127
sg10
I4
sg11
VDEGs
p7565
sg13
I1
sa(dp7566
g7
I82
sg8
VP40259
p7567
sg10
I5
sg11
VCD79B
p7568
sg13
I1
sa(dp7569
g7
I48
sg8
VP42224
p7570
sg10
I5
sg11
VSTAT1
p7571
sg13
I1
sa(dp7572
g7
I61
sg8
VP43405
p7573
sg10
I3
sg11
VSYK
p7574
sg13
I1
sa(dp7575
g7
I55
sg8
VP14780
p7576
sg10
I4
sg11
VMMP9
p7577
sg13
I1
sa(dp7578
g7
I72
sg8
VP16885
p7579
sg10
I5
sg11
VPLCG2
p7580
sg13
I1
sasg17
(lp7581
(dp7582
g7
I202
sg20
VC0006826
p7583
sg10
I6
sg11
Vcancer
p7584
sg13
I1
sa(dp7585
g7
I136
sg20
VC0149678
p7586
sg10
I28
sg11
VEpstein-Barr virus infection
p7587
sg13
I3
sasa(dp7588
g2
S'Clinical examination indicated he had a history of latent syphilis with negative nontreponemal and specific antitreponemal IgM tests.\n'
p7589
sg4
(lp7590
(dp7591
g7
I123
sg8
VP29965
p7592
sg10
I3
sg11
VIgM
p7593
sg13
I1
sasg17
(lp7594
(dp7595
g7
I51
sg20
VC0039133
p7596
sg10
I15
sg11
Vlatent syphilis
p7597
sg13
I2
sasa(dp7598
g2
S'No target TP-IgM was detected in subjects with latent syphilis.\n'
p7599
sg4
(lp7600
(dp7601
g7
I13
sg8
VP29965
p7602
sg10
I3
sg11
VIgM
p7603
sg13
I1
sasg17
(lp7604
(dp7605
g7
I47
sg20
VC0039133
p7606
sg10
I15
sg11
Vlatent syphilis
p7607
sg13
I2
sasa(dp7608
g2
S'Compared with primary syphilis, secondary and latent syphilis showed a slower serological response of VDRL (P = .092 and P &lt; .001) and Pathozyme-IgM tests (P &lt; .001 and P = .012).\n'
p7609
sg4
(lp7610
(dp7611
g7
I138
sg8
VP29965
p7612
sg10
I13
sg11
VPathozyme-IgM
p7613
sg13
I1
sasg17
(lp7614
(dp7615
g7
I46
sg20
VC0039133
p7616
sg10
I15
sg11
Vlatent syphilis
p7617
sg13
I2
sa(dp7618
g7
I22
sg20
VC0149985
p7619
sg10
I19
sg11
Vsyphilis, secondary
p7620
sg13
I2
sa(dp7621
g7
I14
sg20
VC0007939
p7622
sg10
I16
sg11
Vprimary syphilis
p7623
sg13
I2
sasa(dp7624
g2
S'The overall sensitivity of the IgM-PoCT was 82% and varied with clinical stage, being highest in secondary (10/10 EIA positives) but lower in primary (2/4 EIA positives) and early latent syphilis (2/3 EIA positives).\n'
p7625
sg4
(lp7626
(dp7627
g7
I31
sg8
VP29965
p7628
sg10
I3
sg11
VIgM
p7629
sg13
I1
sasg17
(lp7630
(dp7631
g7
I114
sg20
VC0014661
p7632
sg10
I3
sg11
VEIA
p7633
sg13
I1
sa(dp7634
g7
I114
sg20
VC0014661
p7635
sg10
I3
sg11
VEIA
p7636
sg13
I1
sa(dp7637
g7
I180
sg20
VC0039133
p7638
sg10
I15
sg11
Vlatent syphilis
p7639
sg13
I2
sa(dp7640
g7
I114
sg20
VC0014661
p7641
sg10
I3
sg11
VEIA
p7642
sg13
I1
sasa(dp7643
g2
S'In 72 cases of early latent syphilis, the Murex EIA screening test was positive in 68 (94%) patients, the Mercia IgM EIA in 50 (69%) cases, the VDRL in 61 (85%) cases and the TPPA in 68 (94%) cases.\n'
p7644
sg4
(lp7645
(dp7646
g7
I106
sg8
VP29965
p7647
sg10
I14
sg11
VMercia IgM EIA
p7648
sg13
I3
sasg17
(lp7649
(dp7650
g7
I48
sg20
VC0014661
p7651
sg10
I3
sg11
VEIA
p7652
sg13
I1
sa(dp7653
g7
I21
sg20
VC0039133
p7654
sg10
I15
sg11
Vlatent syphilis
p7655
sg13
I2
sa(dp7656
g7
I48
sg20
VC0014661
p7657
sg10
I3
sg11
VEIA
p7658
sg13
I1
sasa(dp7659
g2
S'Many example illustrate the lack of impact of genetic information on the treatment outcome: we do not treat Dravet syndrome more successfully since SCN1A testing became available; we do not treat Lafora disease more successfully since testing for laforin and malin became available; we do not need to know the genetic nature of Unverricht-Lundborg disease or test for the cystatin B mutation in order to select or avoid certain drugs; we do not treat Rett syndrome more successfully since MECP2 testing became available; we do not treat JME more successfully since we know its genetic origin; we do not treat autosomal dominant nocturnal frontal lobe epilepsy more successfully since we know its genetic origin and can test for its mutation.\n'
p7660
sg4
(lp7661
(dp7662
g7
I148
sg8
VP35498
p7663
sg10
I5
sg11
VSCN1A
p7664
sg13
I1
sa(dp7665
g7
I372
sg8
VP04080
p7666
sg10
I10
sg11
Vcystatin B
p7667
sg13
I2
sasg17
(lp7668
(dp7669
g7
I196
sg20
VC0751783
p7670
sg10
I14
sg11
VLafora disease
p7671
sg13
I2
sa(dp7672
g7
I328
sg20
VC0751785
p7673
sg10
I27
sg11
VUnverricht-Lundborg disease
p7674
sg13
I2
sa(dp7675
g7
I638
sg20
VC0085541
p7676
sg10
I21
sg11
Vfrontal lobe epilepsy
p7677
sg13
I3
sa(dp7678
g7
I537
sg20
VC0270853
p7679
sg10
I3
sg11
VJME
p7680
sg13
I1
sa(dp7681
g7
I451
sg20
VC0035372
p7682
sg10
I13
sg11
VRett syndrome
p7683
sg13
I2
sa(dp7684
g7
I108
sg20
VC0751122
p7685
sg10
I15
sg11
VDravet syndrome
p7686
sg13
I2
sasa(dp7687
g2
S'We detected anti-periplakin IgG antibodies in 47/260 (18 %) patients with asthma, with no association with severity or atopy.\n'
p7688
sg4
(lp7689
(dp7690
g7
I12
sg8
g127
sg10
I30
sg11
Vanti-periplakin IgG antibodies
p7691
sg13
I3
sasg17
(lp7692
(dp7693
g7
I119
sg20
VC0392707
p7694
sg10
I5
sg11
Vatopy
p7695
sg13
I1
sa(dp7696
g7
I74
sg20
VC0004096
p7697
sg10
I6
sg11
Vasthma
p7698
sg13
I1
sasa(dp7699
g2
S'Whether periplakin autoimmunity (both IgG and IgE auto-antibodies) is involved in asthma pathogenesis remains to be studied during the disease course of these patients.\n'
p7700
sg4
(lp7701
(dp7702
g7
I46
sg8
VP01854
p7703
sg10
I19
sg11
VIgE auto-antibodies
p7704
sg13
I2
sasg17
(lp7705
(dp7706
g7
I19
sg20
VC0004368
p7707
sg10
I12
sg11
Vautoimmunity
p7708
sg13
I1
sa(dp7709
g7
I82
sg20
VC0004096
p7710
sg10
I6
sg11
Vasthma
p7711
sg13
I1
sa(dp7712
g7
I46
sg20
VC0270850
p7713
sg10
I3
sg11
VIgE
p7714
sg13
I1
sa(dp7715
g7
I89
sg20
VC0699748
p7716
sg10
I12
sg11
Vpathogenesis
p7717
sg13
I1
sasa(dp7718
g2
S'Recent genome-wide association studies have shown associations between variants in loci (4q28.1, 6p21.32, 6p21.1, 6q16.1, 10q22.1 and 10q22.3) and chronic obstructive pulmonary disease (COPD) or smoking behaviors.\n'
p7719
sg4
(lp7720
sg17
(lp7721
(dp7722
g7
I186
sg20
VC0024117
p7723
sg10
I4
sg11
VCOPD
p7724
sg13
I1
sa(dp7725
g7
I147
sg20
VC0024117
p7726
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p7727
sg13
I4
sasa(dp7728
g2
S'A remarkable decrease in the expression of palmitoylated proteins, functionally related to axonal elongation (GAP43, CRMP1 and NEFM) and of the synaptic marker SNAP25, specifically in SH-p.wtCLN1 cells was confirmed by immunoblotting.\n'
p7729
sg4
(lp7730
(dp7731
g7
I110
sg8
VP17677
p7732
sg10
I5
sg11
VGAP43
p7733
sg13
I1
sa(dp7734
g7
I127
sg8
VP07197
p7735
sg10
I4
sg11
VNEFM
p7736
sg13
I1
sa(dp7737
g7
I117
sg8
g127
sg10
I5
sg11
VCRMP1
p7738
sg13
I1
sasg17
(lp7739
sa(dp7740
g2
S'This study aimed to investigate the association between the synaptosomal-associated protein 25 kDa (SNAP-25) genotype and performance on the continuous performance test (CPT) in Korean children with attention-deficit/hyperactivity disorder (ADHD).\n'
p7741
sg4
(lp7742
(dp7743
g7
I60
sg8
g127
sg10
I38
sg11
Vsynaptosomal-associated protein 25 kDa
p7744
sg13
I4
sa(dp7745
g7
I100
sg8
g127
sg10
I7
sg11
VSNAP-25
p7746
sg13
I1
sasg17
(lp7747
(dp7748
g7
I241
sg20
VC1263846
p7749
sg10
I4
sg11
VADHD
p7750
sg13
I1
sa(dp7751
g7
I199
sg20
VC1263846
p7752
sg10
I40
sg11
Vattention-deficit/hyperactivity disorder
p7753
sg13
I2
sasa(dp7754
g2
S'Our results suggest the possible involvement of the SNAP-25 1065 T&gt;G polymorphism in the inattention phenotype in children with ADHD.\n'
p7755
sg4
(lp7756
(dp7757
g7
I131
sg8
g127
sg10
I4
sg11
VADHD
p7758
sg13
I1
sa(dp7759
g7
I52
sg8
g127
sg10
I7
sg11
VSNAP-25
p7760
sg13
I1
sasg17
(lp7761
(dp7762
g7
I92
sg20
VC0424101
p7763
sg10
I11
sg11
Vinattention
p7764
sg13
I1
sa(dp7765
g7
I131
sg20
VC1263846
p7766
sg10
I4
sg11
VADHD
p7767
sg13
I1
sasa(dp7768
g2
S'Notably, these neoplasms shared significant associations with 5 ADs (immune thrombocytopenic purpura, polymyositis/dermatomyositis, rheumatoid arthritis, Sjogren syndrome and systemic lupus erythematosis).\n'
p7769
sg4
(lp7770
sg17
(lp7771
(dp7772
g7
I15
sg20
VC0027651
p7773
sg10
I9
sg11
Vneoplasms
p7774
sg13
I1
sa(dp7775
g7
I102
sg20
VC0085655
p7776
sg10
I12
sg11
Vpolymyositis
p7777
sg13
I1
sa(dp7778
g7
I175
sg20
VC0024141
p7779
sg10
I28
sg11
Vsystemic lupus erythematosis
p7780
sg13
I3
sa(dp7781
g7
I115
sg20
VC0221056
p7782
sg10
I15
sg11
Vdermatomyositis
p7783
sg13
I1
sa(dp7784
g7
I132
sg20
VC0003873
p7785
sg10
I20
sg11
Vrheumatoid arthritis
p7786
sg13
I2
sa(dp7787
g7
I154
sg20
VC1527336
p7788
sg10
I16
sg11
VSjogren syndrome
p7789
sg13
I2
sa(dp7790
g7
I69
sg20
VC0398650
p7791
sg10
I31
sg11
Vimmune thrombocytopenic purpura
p7792
sg13
I3
sasa(dp7793
g2
S'We have investigated a possible association between recurrence of otitis media and low concentrations of mannan-binding protein (MBP) in plasma and upper-airway secretions.\n'
p7794
sg4
(lp7795
(dp7796
g7
I129
sg8
VP13727
p7797
sg10
I3
sg11
VMBP
p7798
sg13
I1
sa(dp7799
g7
I105
sg8
VP11226
p7800
sg10
I22
sg11
Vmannan-binding protein
p7801
sg13
I2
sasg17
(lp7802
(dp7803
g7
I66
sg20
VC0029882
p7804
sg10
I12
sg11
Votitis media
p7805
sg13
I2
sa(dp7806
g7
I52
sg20
VC1458156
p7807
sg10
I10
sg11
Vrecurrence
p7808
sg13
I1
sasa(dp7809
g2
S'Moreover, genetic polymorphisms associated with low MBP plasma levels were investigated in DNA from nasopharyngeal tonsils of 89 children with recurrence of otitis media.\n'
p7810
sg4
(lp7811
(dp7812
g7
I52
sg8
VP13727
p7813
sg10
I3
sg11
VMBP
p7814
sg13
I1
sasg17
(lp7815
(dp7816
g7
I143
sg20
VC1458156
p7817
sg10
I10
sg11
Vrecurrence
p7818
sg13
I1
sa(dp7819
g7
I157
sg20
VC0029882
p7820
sg10
I12
sg11
Votitis media
p7821
sg13
I2
sasa(dp7822
g2
S'Thus, our results do not support the assumption that low concentration and/or MBP deficiency alone predispose to recurrence of otitis media in Caucasian children.\n'
p7823
sg4
(lp7824
(dp7825
g7
I78
sg8
VP13727
p7826
sg10
I3
sg11
VMBP
p7827
sg13
I1
sasg17
(lp7828
(dp7829
g7
I113
sg20
VC1458156
p7830
sg10
I10
sg11
Vrecurrence
p7831
sg13
I1
sa(dp7832
g7
I127
sg20
VC0029882
p7833
sg10
I12
sg11
Votitis media
p7834
sg13
I2
sa(dp7835
g7
I78
sg20
VC3280586
p7836
sg10
I14
sg11
VMBP deficiency
p7837
sg13
I2
sasa(dp7838
g2
S'The expressions of DVL-3 mRNA and Delta-catenin mRNA were significantly higher in malignant than in benign lung disease (P &lt; 0.01) and were obviously higher than cytology in adenocarcinoma (P &lt; 0.01).\n'
p7839
sg4
(lp7840
(dp7841
g7
I19
sg8
VP54792
p7842
sg10
I10
sg11
VDVL-3 mRNA
p7843
sg13
I2
sa(dp7844
g7
I34
sg8
VP28072
p7845
sg10
I18
sg11
VDelta-catenin mRNA
p7846
sg13
I2
sasg17
(lp7847
(dp7848
g7
I107
sg20
VC0024115
p7849
sg10
I12
sg11
Vlung disease
p7850
sg13
I2
sa(dp7851
g7
I177
sg20
VC0001418
p7852
sg10
I14
sg11
Vadenocarcinoma
p7853
sg13
I1
sasa(dp7854
g2
S'Furthermore, SERPINB12 mRNA and protein increase significantly in GE of cancerous ovaries of laying hens with epithelia-derived ovarian cancer.\n'
p7855
sg4
(lp7856
(dp7857
g7
I13
sg8
g127
sg10
I14
sg11
VSERPINB12 mRNA
p7858
sg13
I2
sasg17
(lp7859
(dp7860
g7
I128
sg20
VC1140680
p7861
sg10
I14
sg11
Vovarian cancer
p7862
sg13
I2
sasa(dp7863
g2
S"Serum alkaline phosphatase (ALP) (EC 3.1.3.1), 5'nucleotidase (5'NT) (EC 3.1.3.5), aldolase (ALD) (EC 4.1.2.13) and sorbitol dehydrogenase (SDH) (EC 1.1.1.14) were estimated in infective hepatitis, alcoholic hepatitis, chronic active hepatitis, obstructive jaundice, cirrhosis of liver and amoebic liver abscess.\n"
p7864
sg4
(lp7865
(dp7866
g7
I28
sg8
VP03973
p7867
sg10
I3
sg11
VALP
p7868
sg13
I1
sa(dp7869
g7
I116
sg8
g127
sg10
I22
sg11
Vsorbitol dehydrogenase
p7870
sg13
I2
sa(dp7871
g7
I140
sg8
g127
sg10
I3
sg11
VSDH
p7872
sg13
I1
sa(dp7873
g7
I0
sg8
VP02743
p7874
sg10
I26
sg11
VSerum alkaline phosphatase
p7875
sg13
I3
sa(dp7876
g7
I93
sg8
VP33897
p7877
sg10
I3
sg11
VALD
p7878
sg13
I1
sa(dp7879
g7
I83
sg8
VP33897
p7880
sg10
I8
sg11
Valdolase
p7881
sg13
I1
sasg17
(lp7882
(dp7883
g7
I187
sg20
VC0019159
p7884
sg10
I9
sg11
Vhepatitis
p7885
sg13
I1
sa(dp7886
g7
I198
sg20
VC0524610
p7887
sg10
I28
sg11
Valcoholic hepatitis, chronic
p7888
sg13
I3
sa(dp7889
g7
I140
sg20
VC0018946
p7890
sg10
I3
sg11
VSDH
p7891
sg13
I1
sa(dp7892
g7
I116
sg20
VC0018946
p7893
sg10
I22
sg11
Vsorbitol dehydrogenase
p7894
sg13
I2
sa(dp7895
g7
I245
sg20
VC0022354
p7896
sg10
I20
sg11
Vobstructive jaundice
p7897
sg13
I2
sa(dp7898
g7
I93
sg20
VC0162309
p7899
sg10
I3
sg11
VALD
p7900
sg13
I1
sa(dp7901
g7
I290
sg20
VC0023886
p7902
sg10
I21
sg11
Vamoebic liver abscess
p7903
sg13
I3
sa(dp7904
g7
I83
sg20
VC0162309
p7905
sg10
I8
sg11
Valdolase
p7906
sg13
I1
sa(dp7907
g7
I267
sg20
VC0023890
p7908
sg10
I18
sg11
Vcirrhosis of liver
p7909
sg13
I3
sasa(dp7910
g2
S'Although ADH activity under pathological conditions usually parallels that of other enzymes, e.g., sorbitol dehydrogenase (EC 1.1.1.14) (SDH) and alanine transaminase (EC 2.6.1.2) (ALT), its relative elevation above the upper normal limit is generally greater, particularly in the early stages of viral hepatitis.\n'
p7911
sg4
(lp7912
(dp7913
g7
I146
sg8
VP24298
p7914
sg10
I20
sg11
Valanine transaminase
p7915
sg13
I2
sa(dp7916
g7
I181
sg8
VP13716
p7917
sg10
I3
sg11
VALT
p7918
sg13
I1
sa(dp7919
g7
I137
sg8
g127
sg10
I3
sg11
VSDH
p7920
sg13
I1
sa(dp7921
g7
I9
sg8
VP07327
p7922
sg10
I3
sg11
VADH
p7923
sg13
I1
sa(dp7924
g7
I99
sg8
g127
sg10
I22
sg11
Vsorbitol dehydrogenase
p7925
sg13
I2
sasg17
(lp7926
(dp7927
g7
I297
sg20
VC0042721
p7928
sg10
I15
sg11
Vviral hepatitis
p7929
sg13
I2
sa(dp7930
g7
I137
sg20
VC0018946
p7931
sg10
I3
sg11
VSDH
p7932
sg13
I1
sasa(dp7933
g2
S'have determined the levels of argininesuccinatolyase (ASAL), sorbitoldehydrogenase (SDH) and guanase (GUA) in 65 cases of hepatitis of infancy, by comparison with the corresponding levels of transaminases.\n'
p7934
sg4
(lp7935
(dp7936
g7
I93
sg8
g127
sg10
I7
sg11
Vguanase
p7937
sg13
I1
sa(dp7938
g7
I102
sg8
g127
sg10
I3
sg11
VGUA
p7939
sg13
I1
sa(dp7940
g7
I84
sg8
g127
sg10
I3
sg11
VSDH
p7941
sg13
I1
sa(dp7942
g7
I30
sg8
VP04424
p7943
sg10
I52
sg11
Vargininesuccinatolyase (ASAL), sorbitoldehydrogenase
p7944
sg13
I3
sasg17
(lp7945
(dp7946
g7
I84
sg20
VC0018946
p7947
sg10
I3
sg11
VSDH
p7948
sg13
I1
sa(dp7949
g7
I122
sg20
VC0019159
p7950
sg10
I9
sg11
Vhepatitis
p7951
sg13
I1
sasa(dp7952
g2
S'Through the use of AhR-CA mice, whose keratinocytes express constitutively active AhR and that develop atopic-dermatitis-like phenotypes, we identified Artn as a keratinocyte-specific AhR target gene whose product (the neurotrophic factor artemin) was responsible for epidermal hyper-innervation that led to hypersensitivity to pruritus.\n'
p7953
sg4
(lp7954
(dp7955
g7
I19
sg8
VP35869
p7956
sg10
I3
sg11
VAhR
p7957
sg13
I1
sa(dp7958
g7
I19
sg8
VP35869
p7959
sg10
I6
sg11
VAhR-CA
p7960
sg13
I1
sa(dp7961
g7
I19
sg8
VP35869
p7962
sg10
I3
sg11
VAhR
p7963
sg13
I1
sa(dp7964
g7
I152
sg8
g127
sg10
I4
sg11
VArtn
p7965
sg13
I1
sasg17
(lp7966
(dp7967
g7
I308
sg20
VC0020517
p7968
sg10
I16
sg11
Vhypersensitivity
p7969
sg13
I1
sa(dp7970
g7
I328
sg20
VC0033774
p7971
sg10
I8
sg11
Vpruritus
p7972
sg13
I1
sa(dp7973
g7
I110
sg20
VC0011603
p7974
sg10
I10
sg11
Vdermatitis
p7975
sg13
I1
sa(dp7976
g7
I103
sg20
VC0392707
p7977
sg10
I6
sg11
Vatopic
p7978
sg13
I1
sasa(dp7979
g2
S'AhR activation and ARTN expression were positively correlated in the epidermis of patients with atopic dermatitis.\n'
p7980
sg4
(lp7981
(dp7982
g7
I0
sg8
VP35869
p7983
sg10
I3
sg11
VAhR
p7984
sg13
I1
sa(dp7985
g7
I19
sg8
g127
sg10
I4
sg11
VARTN
p7986
sg13
I1
sasg17
(lp7987
(dp7988
g7
I96
sg20
VC0011615
p7989
sg10
I17
sg11
Vatopic dermatitis
p7990
sg13
I2
sasa(dp7991
g2
S'There was a positive association between transferrin saturation &gt;45% and the severity of periodontitis (adjusted odds ratio = 5.49, p = .002).\n'
p7992
sg4
(lp7993
(dp7994
g7
I41
sg8
VP02787
p7995
sg10
I11
sg11
Vtransferrin
p7996
sg13
I1
sasg17
(lp7997
(dp7998
g7
I92
sg20
VC0031099
p7999
sg10
I13
sg11
Vperiodontitis
p8000
sg13
I1
sasa(dp8001
g2
S'The aim of the present investigation was to evaluate changes in the transferrin serum levels subsequent to non-surgical treatment of chronic periodontal disease.\n'
p8002
sg4
(lp8003
(dp8004
g7
I68
sg8
VP02787
p8005
sg10
I11
sg11
Vtransferrin
p8006
sg13
I1
sasg17
(lp8007
(dp8008
g7
I141
sg20
VC0031090
p8009
sg10
I19
sg11
Vperiodontal disease
p8010
sg13
I2
sasa(dp8011
g2
S'The mean transferrin serum level in patients with chronic periodontitis (213.1 +/- 9.2 mg/dL) was significantly less than that in periodontally healthy subjects (307.8 +/- 11.7 mg/dL).\n'
p8012
sg4
(lp8013
(dp8014
g7
I9
sg8
VP02787
p8015
sg10
I11
sg11
Vtransferrin
p8016
sg13
I1
sasg17
(lp8017
(dp8018
g7
I50
sg20
VC0266929
p8019
sg10
I21
sg11
Vchronic periodontitis
p8020
sg13
I2
sasa(dp8021
g2
S'The decrease and increase in transferrin serum levels with periodontal disease and periodontal treatment, respectively, indicated an inverse relationship between transferrin serum levels and chronic periodontitis.\n'
p8022
sg4
(lp8023
(dp8024
g7
I29
sg8
VP02787
p8025
sg10
I11
sg11
Vtransferrin
p8026
sg13
I1
sa(dp8027
g7
I29
sg8
VP02787
p8028
sg10
I11
sg11
Vtransferrin
p8029
sg13
I1
sasg17
(lp8030
(dp8031
g7
I191
sg20
VC0266929
p8032
sg10
I21
sg11
Vchronic periodontitis
p8033
sg13
I2
sa(dp8034
g7
I59
sg20
VC0031090
p8035
sg10
I19
sg11
Vperiodontal disease
p8036
sg13
I2
sasa(dp8037
g2
S'In this study, C.rectus was detected and quantified by using 16s rDNA based PCR in chronic periodontitis and compared with the levels of serum iron, total iron binding capacity and transferrin in chronic periodontitis and healthy sites.\n'
p8038
sg4
(lp8039
(dp8040
g7
I181
sg8
VP02787
p8041
sg10
I11
sg11
Vtransferrin
p8042
sg13
I1
sasg17
(lp8043
(dp8044
g7
I83
sg20
VC0266929
p8045
sg10
I21
sg11
Vchronic periodontitis
p8046
sg13
I2
sa(dp8047
g7
I83
sg20
VC0266929
p8048
sg10
I21
sg11
Vchronic periodontitis
p8049
sg13
I2
sasa(dp8050
g2
S'TIBC and transferrin levels were elevated in periodontitis.\n'
p8051
sg4
(lp8052
(dp8053
g7
I9
sg8
VP02787
p8054
sg10
I11
sg11
Vtransferrin
p8055
sg13
I1
sasg17
(lp8056
(dp8057
g7
I45
sg20
VC0031099
p8058
sg10
I13
sg11
Vperiodontitis
p8059
sg13
I1
sasa(dp8060
g2
S'Here we report that the transcriptional modulator megakaryocytic leukemia 1 (MKL1) is associated with a histone H3K4 methyltransferase activity.\n'
p8061
sg4
(lp8062
(dp8063
g7
I104
sg8
VP62805
p8064
sg10
I30
sg11
Vhistone H3K4 methyltransferase
p8065
sg13
I3
sa(dp8066
g7
I50
sg8
g127
sg10
I25
sg11
Vmegakaryocytic leukemia 1
p8067
sg13
I3
sa(dp8068
g7
I77
sg8
g127
sg10
I4
sg11
VMKL1
p8069
sg13
I1
sasg17
(lp8070
(dp8071
g7
I50
sg20
VC0023462
p8072
sg10
I23
sg11
Vmegakaryocytic leukemia
p8073
sg13
I2
sasa(dp8074
g2
S'Five novel in-frame fusion transcripts were identified and verified in 40 EACs and in a validation cohort of 15 additional EACs (55 patients in all): fibroblast growth factor receptor 2 (FGFR2)-GRB2-associated binding protein 2 (GAB2) in 2 of 55 or 3.6%, Niemann-Pick C1 (NPC1)-maternal embryonic leucine zipper kinase (MELK) in 2 of 55 or 3.6%, ubiquitin-specific peptidase 54 (USP54)-calcium/calmodulin dependent protein kinase II Gamma (CAMK2G) in 2 of 55 or 3.6%, megakaryoblastic leukemia (translocation) 1 (MKL1)-fibulin 1 (FBLN1) in 1 of 55 or 1.8%, and CCR4-NOT transcription complex subunit 2 (CNOT2)-chromosome 12 open reading frame 49 (C12orf49) in 1 of 55 or 1.8%.\n'
p8075
sg4
(lp8076
(dp8077
g7
I277
sg8
g127
sg10
I41
sg11
V-maternal embryonic leucine zipper kinase
p8078
sg13
I5
sa(dp8079
g7
I150
sg8
g127
sg10
I35
sg11
Vfibroblast growth factor receptor 2
p8080
sg13
I5
sa(dp8081
g7
I193
sg8
g127
sg10
I34
sg11
V-GRB2-associated binding protein 2
p8082
sg13
I4
sa(dp8083
g7
I394
sg8
g127
sg10
I10
sg11
Vcalmodulin
p8084
sg13
I1
sa(dp8085
g7
I229
sg8
g127
sg10
I4
sg11
VGAB2
p8086
sg13
I1
sa(dp8087
g7
I320
sg8
g127
sg10
I4
sg11
VMELK
p8088
sg13
I1
sa(dp8089
g7
I365
sg8
g127
sg10
I12
sg11
Vpeptidase 54
p8090
sg13
I2
sa(dp8091
g7
I415
sg8
VP33981
p8092
sg10
I23
sg11
Vprotein kinase II Gamma
p8093
sg13
I4
sa(dp8094
g7
I187
sg8
g127
sg10
I5
sg11
VFGFR2
p8095
sg13
I1
sa(dp8096
g7
I255
sg8
g127
sg10
I15
sg11
VNiemann-Pick C1
p8097
sg13
I2
sa(dp8098
g7
I561
sg8
g127
sg10
I40
sg11
VCCR4-NOT transcription complex subunit 2
p8099
sg13
I5
sa(dp8100
g7
I346
sg8
VP62979
p8101
sg10
I9
sg11
Vubiquitin
p8102
sg13
I1
sa(dp8103
g7
I272
sg8
g127
sg10
I4
sg11
VNPC1
p8104
sg13
I1
sa(dp8105
g7
I603
sg8
g127
sg10
I5
sg11
VCNOT2
p8106
sg13
I1
sa(dp8107
g7
I510
sg8
g127
sg10
I18
sg11
V1 (MKL1)-fibulin 1
p8108
sg13
I3
sasg17
(lp8109
(dp8110
g7
I468
sg20
VC0023462
p8111
sg10
I25
sg11
Vmegakaryoblastic leukemia
p8112
sg13
I2
sa(dp8113
g7
I255
sg20
VC3179455
p8114
sg10
I15
sg11
VNiemann-Pick C1
p8115
sg13
I2
sa(dp8116
g7
I495
sg20
VC0040715
p8117
sg10
I13
sg11
Vtranslocation
p8118
sg13
I1
sa(dp8119
g7
I272
sg20
VC3179455
p8120
sg10
I4
sg11
VNPC1
p8121
sg13
I1
sasa(dp8122
g2
S'Previously we have reported that the transcriptional regulator megakaryocytic leukemia 1 (MKL1) plays a role programming cellular inflammatory response by modulating NF-KB activity.\n'
p8123
sg4
(lp8124
(dp8125
g7
I90
sg8
g127
sg10
I4
sg11
VMKL1
p8126
sg13
I1
sa(dp8127
g7
I63
sg8
g127
sg10
I25
sg11
Vmegakaryocytic leukemia 1
p8128
sg13
I3
sasg17
(lp8129
(dp8130
g7
I130
sg20
VC1155266
p8131
sg10
I21
sg11
Vinflammatory response
p8132
sg13
I2
sa(dp8133
g7
I63
sg20
VC0023462
p8134
sg10
I23
sg11
Vmegakaryocytic leukemia
p8135
sg13
I2
sasa(dp8136
g2
S'Both (megakaryoblastic leukemia)/myocardin-like 1 (MKL-1) and Signal transducer and activator of transcription 3 (STAT3) have been implicated in the control of cellular metabolism, survival and growth.\n'
p8137
sg4
(lp8138
(dp8139
g7
I62
sg8
VP40763
p8140
sg10
I50
sg11
VSignal transducer and activator of transcription 3
p8141
sg13
I7
sa(dp8142
g7
I51
sg8
g127
sg10
I5
sg11
VMKL-1
p8143
sg13
I1
sa(dp8144
g7
I114
sg8
VP40763
p8145
sg10
I5
sg11
VSTAT3
p8146
sg13
I1
sa(dp8147
g7
I33
sg8
g127
sg10
I16
sg11
Vmyocardin-like 1
p8148
sg13
I2
sasg17
(lp8149
(dp8150
g7
I6
sg20
VC0023462
p8151
sg10
I25
sg11
Vmegakaryoblastic leukemia
p8152
sg13
I2
sasa(dp8153
g2
S'BACKGROUND The reciprocal translocation t(1;22)(p13;q13) involving the RBM15 and MKL1 genes is an uncommon abnormality that occurs in a subset of acute myeloid leukemia with megakaryocytic differentiation (AMKL).\n'
p8154
sg4
(lp8155
(dp8156
g7
I81
sg8
g127
sg10
I10
sg11
VMKL1 genes
p8157
sg13
I2
sa(dp8158
g7
I48
sg8
g127
sg10
I3
sg11
Vp13
p8159
sg13
I1
sasg17
(lp8160
(dp8161
g7
I15
sg20
VC0333714
p8162
sg10
I24
sg11
Vreciprocal translocation
p8163
sg13
I2
sa(dp8164
g7
I146
sg20
VC0023467
p8165
sg10
I22
sg11
Vacute myeloid leukemia
p8166
sg13
I3
sasa(dp8167
g2
S'We show here that megakaryocytic leukemia 1 (MKL1) is an epigenetic mediator of TNF-Alfa-induced proinflammatory transcription.\n'
p8168
sg4
(lp8169
(dp8170
g7
I80
sg8
VP01375
p8171
sg10
I8
sg11
VTNF-Alfa
p8172
sg13
I1
sa(dp8173
g7
I45
sg8
g127
sg10
I4
sg11
VMKL1
p8174
sg13
I1
sa(dp8175
g7
I18
sg8
g127
sg10
I25
sg11
Vmegakaryocytic leukemia 1
p8176
sg13
I3
sasg17
(lp8177
(dp8178
g7
I18
sg20
VC0023462
p8179
sg10
I23
sg11
Vmegakaryocytic leukemia
p8180
sg13
I2
sasa(dp8181
g2
S'We identified that among the candidate targets, twinfilin (TWF1) rescues the miR-206 phenotype in invasion by enhancing the actin cytoskeleton dynamics and the activity of the mesenchymal lineage transcription factors, megakaryoblastic leukemia (translocation) 1 (MKL1), and serum response factor (SRF).\n'
p8182
sg4
(lp8183
(dp8184
g7
I275
sg8
VP11831
p8185
sg10
I21
sg11
Vserum response factor
p8186
sg13
I3
sa(dp8187
g7
I124
sg8
VP41240
p8188
sg10
I27
sg11
Vactin cytoskeleton dynamics
p8189
sg13
I3
sa(dp8190
g7
I77
sg8
g127
sg10
I7
sg11
VmiR-206
p8191
sg13
I1
sa(dp8192
g7
I298
sg8
g127
sg10
I3
sg11
VSRF
p8193
sg13
I1
sa(dp8194
g7
I264
sg8
g127
sg10
I4
sg11
VMKL1
p8195
sg13
I1
sasg17
(lp8196
(dp8197
g7
I246
sg20
VC0040715
p8198
sg10
I13
sg11
Vtranslocation
p8199
sg13
I1
sa(dp8200
g7
I219
sg20
VC0023462
p8201
sg10
I25
sg11
Vmegakaryoblastic leukemia
p8202
sg13
I2
sa(dp8203
g7
I98
sg20
VC2699153
p8204
sg10
I8
sg11
Vinvasion
p8205
sg13
I1
sasa(dp8206
g2
S'This was a rare case of sarcoidosis associated with symptomatic tumoral calcinosis and hypercalcemia.\n'
p8207
sg4
(lp8208
sg17
(lp8209
(dp8210
g7
I87
sg20
VC0020437
p8211
sg10
I13
sg11
Vhypercalcemia
p8212
sg13
I1
sa(dp8213
g7
I64
sg20
VC0263628
p8214
sg10
I18
sg11
Vtumoral calcinosis
p8215
sg13
I2
sa(dp8216
g7
I24
sg20
VC0036202
p8217
sg10
I11
sg11
Vsarcoidosis
p8218
sg13
I1
sasa(dp8219
g2
S'This is the third case of tumoral calcinosis with sarcoidosis documented in the literature.\n'
p8220
sg4
(lp8221
sg17
(lp8222
(dp8223
g7
I50
sg20
VC0036202
p8224
sg10
I11
sg11
Vsarcoidosis
p8225
sg13
I1
sa(dp8226
g7
I26
sg20
VC0263628
p8227
sg10
I18
sg11
Vtumoral calcinosis
p8228
sg13
I2
sasa(dp8229
g2
S'However, these are the first published bone and gallium scans in a patient with a history of sarcoidosis and tumoral calcinosis.\n'
p8230
sg4
(lp8231
sg17
(lp8232
(dp8233
g7
I109
sg20
VC0263628
p8234
sg10
I18
sg11
Vtumoral calcinosis
p8235
sg13
I2
sa(dp8236
g7
I93
sg20
VC0036202
p8237
sg10
I11
sg11
Vsarcoidosis
p8238
sg13
I1
sasa(dp8239
g2
S'In disorders of overadaptation, the intestinal tract absorbs excessive amounts of Ca due to overproduction of 1,25-D, as in absorptive hypercalciuria, sarcoidosis, primary hyperparathyroidism, and tumoral calcinosis.\n'
p8240
sg4
(lp8241
sg17
(lp8242
(dp8243
g7
I164
sg20
VC0221002
p8244
sg10
I27
sg11
Vprimary hyperparathyroidism
p8245
sg13
I2
sa(dp8246
g7
I151
sg20
VC0036202
p8247
sg10
I11
sg11
Vsarcoidosis
p8248
sg13
I1
sa(dp8249
g7
I135
sg20
VC0020438
p8250
sg10
I14
sg11
Vhypercalciuria
p8251
sg13
I1
sa(dp8252
g7
I197
sg20
VC0263628
p8253
sg10
I18
sg11
Vtumoral calcinosis
p8254
sg13
I2
sasa(dp8255
g2
S'In all, 153 patients met the preliminary diagnostic criteria for PSR: transient worsening of residual poststroke focal neurologic deficits or transient recurrence of prior stroke-related focal deficits, admission magnetic resonance imaging showing a chronic stroke but no acute infarct or hemorrhage, no evidence of transient ischemic attack or seizure, no acute lesion on diffusion-weighted imaging, and no clinical or electroencephalographic evidence of seizure around the time of the event.\n'
p8256
sg4
(lp8257
sg17
(lp8258
(dp8259
g7
I345
sg20
VC0036572
p8260
sg10
I7
sg11
Vseizure
p8261
sg13
I1
sa(dp8262
g7
I316
sg20
VC0007787
p8263
sg10
I25
sg11
Vtransient ischemic attack
p8264
sg13
I3
sa(dp8265
g7
I106
sg20
VC0038454
p8266
sg10
I6
sg11
Vstroke
p8267
sg13
I1
sa(dp8268
g7
I272
sg20
VC0333548
p8269
sg10
I13
sg11
Vacute infarct
p8270
sg13
I2
sa(dp8271
g7
I289
sg20
VC0019080
p8272
sg10
I10
sg11
Vhemorrhage
p8273
sg13
I1
sa(dp8274
g7
I106
sg20
VC0038454
p8275
sg10
I6
sg11
Vstroke
p8276
sg13
I1
sa(dp8277
g7
I152
sg20
VC1458156
p8278
sg10
I10
sg11
Vrecurrence
p8279
sg13
I1
sa(dp8280
g7
I345
sg20
VC0036572
p8281
sg10
I7
sg11
Vseizure
p8282
sg13
I1
sasa(dp8283
g2
S'The PSR features identified in the study should enable prompt diagnosis and distinguish recrudescence from mimics, such as transient ischemic attacks, migraine, Todd paralysis, and Uhthoff phenomenon.\n'
p8284
sg4
(lp8285
sg17
(lp8286
(dp8287
g7
I123
sg20
VC0007787
p8288
sg10
I26
sg11
Vtransient ischemic attacks
p8289
sg13
I3
sa(dp8290
g7
I151
sg20
VC0149931
p8291
sg10
I8
sg11
Vmigraine
p8292
sg13
I1
sa(dp8293
g7
I161
sg20
VC0234544
p8294
sg10
I14
sg11
VTodd paralysis
p8295
sg13
I2
sasa(dp8296
g2
S'Prolonged inhibition of PSR after ischemia has been shown to be a sensitive marker of neuronal cell damage.\n'
p8297
sg4
(lp8298
sg17
(lp8299
(dp8300
g7
I34
sg20
VC0022116
p8301
sg10
I8
sg11
Vischemia
p8302
sg13
I1
sa(dp8303
g7
I95
sg20
VC0599732
p8304
sg10
I11
sg11
Vcell damage
p8305
sg13
I2
sasa(dp8306
g2
S'MiR-639 has been reported to act as tumor promoter in various types of cancer.\n'
p8307
sg4
(lp8308
(dp8309
g7
I0
sg8
g127
sg10
I7
sg11
VMiR-639
p8310
sg13
I1
sasg17
(lp8311
(dp8312
g7
I36
sg20
VC0027651
p8313
sg10
I5
sg11
Vtumor
p8314
sg13
I1
sa(dp8315
g7
I71
sg20
VC0006826
p8316
sg10
I6
sg11
Vcancer
p8317
sg13
I1
sasa(dp8318
g2
S'However, the biological function and underlying molecular mechanism of miR-639 in thyroid carcinoma (TC) have not been intensively investigated.\n'
p8319
sg4
(lp8320
sg17
(lp8321
(dp8322
g7
I82
sg20
VC0549473
p8323
sg10
I17
sg11
Vthyroid carcinoma
p8324
sg13
I2
sa(dp8325
g7
I101
sg20
VC0549473
p8326
sg10
I2
sg11
VTC
p8327
sg13
I1
sasa(dp8328
g2
S'To address this question, TSCC cell lines SCC9 and CAL27 were treated with human recombinant TGFBeta1 for 48 h. miRNA microarray illustrated that miR-639 was significantly downregulated in TGFBeta-treated SCC9 cells.\n'
p8329
sg4
(lp8330
(dp8331
g7
I93
sg8
VP01137
p8332
sg10
I7
sg11
VTGFBeta
p8333
sg13
I1
sasg17
(lp8334
sa(dp8335
g2
S'Clinically, reduced miR-639 expression was associated with metastasis in TSCC and poor patient survival.\n'
p8336
sg4
(lp8337
sg17
(lp8338
(dp8339
g7
I59
sg20
VC0027627
p8340
sg10
I10
sg11
Vmetastasis
p8341
sg13
I1
sasa(dp8342
g2
S'The data from the present study suggest that reduced expression of miR-639 underscores the mechanism of TGFBeta-induced EMT in TSCC by targeting FOXC1 and may serve as therapeutic targets in the process of metastasis.\n'
p8343
sg4
(lp8344
(dp8345
g7
I145
sg8
g127
sg10
I5
sg11
VFOXC1
p8346
sg13
I1
sa(dp8347
g7
I104
sg8
VP01137
p8348
sg10
I7
sg11
VTGFBeta
p8349
sg13
I1
sasg17
(lp8350
(dp8351
g7
I206
sg20
VC0027627
p8352
sg10
I10
sg11
Vmetastasis
p8353
sg13
I1
sasa(dp8354
g2
S'In this study, we have first confirmed that miR-639 is up-regulated in metastatic breast cancer tissues and cell line with highly invasive capacity.\n'
p8355
sg4
(lp8356
(dp8357
g7
I44
sg8
g127
sg10
I7
sg11
VmiR-639
p8358
sg13
I1
sasg17
(lp8359
(dp8360
g7
I71
sg20
VC0278488
p8361
sg10
I24
sg11
Vmetastatic breast cancer
p8362
sg13
I3
sasa(dp8363
g2
S'Furthermore, we provided evidence to demonstrate that up-regulation of miR-639 contributes breast cancer invasion and metastasis.\n'
p8364
sg4
(lp8365
sg17
(lp8366
(dp8367
g7
I91
sg20
VC0678222
p8368
sg10
I13
sg11
Vbreast cancer
p8369
sg13
I2
sa(dp8370
g7
I118
sg20
VC0027627
p8371
sg10
I10
sg11
Vmetastasis
p8372
sg13
I1
sa(dp8373
g7
I105
sg20
VC2699153
p8374
sg10
I8
sg11
Vinvasion
p8375
sg13
I1
sasa(dp8376
g2
S'These data reveal a key role of miR-639 in breast cancer metastasis and support biological and clinical links between miR-639 and breast cancer.\n'
p8377
sg4
(lp8378
sg17
(lp8379
(dp8380
g7
I43
sg20
VC0678222
p8381
sg10
I13
sg11
Vbreast cancer
p8382
sg13
I2
sa(dp8383
g7
I43
sg20
VC0678222
p8384
sg10
I13
sg11
Vbreast cancer
p8385
sg13
I2
sa(dp8386
g7
I57
sg20
VC0027627
p8387
sg10
I10
sg11
Vmetastasis
p8388
sg13
I1
sasa(dp8389
g2
S'The analysis of serum microRNA levels in the marker identification cohort indicated that serum miR-141 and miR-639 levels were increased in bladder cancer patients compared to CTRL.\n'
p8390
sg4
(lp8391
(dp8392
g7
I176
sg8
VP40313
p8393
sg10
I4
sg11
VCTRL
p8394
sg13
I1
sasg17
(lp8395
(dp8396
g7
I140
sg20
VC0699885
p8397
sg10
I14
sg11
Vbladder cancer
p8398
sg13
I2
sasa(dp8399
g2
S'The analysis of these miR-141 and miR-639 in the validation cohort demonstrated that microRNA levels were similar in bladder cancer patients and control subjects.\n'
p8400
sg4
(lp8401
(dp8402
g7
I34
sg8
g127
sg10
I7
sg11
VmiR-639
p8403
sg13
I1
sa(dp8404
g7
I22
sg8
g127
sg10
I7
sg11
VmiR-141
p8405
sg13
I1
sasg17
(lp8406
(dp8407
g7
I117
sg20
VC0699885
p8408
sg10
I14
sg11
Vbladder cancer
p8409
sg13
I2
sasa(dp8410
g2
S'The genotypes of three DNA sequence variants in exons 1a1, 7 and 11 of the GABABR1 gene were assessed in 234 German controls and 350 German alcohol-dependent subjects, including three more homogeneous subgroups of alcoholics, marked by (1) history of parental alcoholism (n = 121); (2) history of alcohol withdrawal seizure or delirium (n = 108); and (3) comorbidity of dissocial personality disorder (n = 60).\n'
p8411
sg4
(lp8412
sg17
(lp8413
(dp8414
g7
I251
sg20
VC0683362
p8415
sg10
I19
sg11
Vparental alcoholism
p8416
sg13
I2
sa(dp8417
g7
I297
sg20
VC0586323
p8418
sg10
I26
sg11
Valcohol withdrawal seizure
p8419
sg13
I3
sa(dp8420
g7
I327
sg20
VC0011206
p8421
sg10
I8
sg11
Vdelirium
p8422
sg13
I1
sa(dp8423
g7
I370
sg20
VC0003431
p8424
sg10
I30
sg11
Vdissocial personality disorder
p8425
sg13
I3
sasa(dp8426
g2
S'Patients with hyposmia had older age (p = 0.001), later onset age (p = 0.020), higher SCOPA-AUT scores (p = 0.011), higher percentage of chronic constipation (p = 0.001) and cpRBD (p = 0.003).\n'
p8427
sg4
(lp8428
sg17
(lp8429
(dp8430
g7
I137
sg20
VC0401149
p8431
sg10
I20
sg11
Vchronic constipation
p8432
sg13
I2
sasa(dp8433
g2
S'Myocardial MIBG uptake correlated significantly (p &lt; 0.05) with several items of the SCOPA-AUT scale (in female patients: perspiration during the night, in male patients: sum score, saliva dribbling of the mouth, difficulty swallowing, fainting, constipation), of the standardized medical history (in male patients: swollen ankles) and of the autonomic nervous system testing (all patients: sum score, Ewing orthostasis test).\n'
p8434
sg4
(lp8435
sg17
(lp8436
(dp8437
g7
I192
sg20
VC0013132
p8438
sg10
I9
sg11
Vdribbling
p8439
sg13
I1
sa(dp8440
g7
I249
sg20
VC0009806
p8441
sg10
I12
sg11
Vconstipation
p8442
sg13
I1
sa(dp8443
g7
I411
sg20
VC0149746
p8444
sg10
I11
sg11
Vorthostasis
p8445
sg13
I1
sa(dp8446
g7
I356
sg20
VC0027769
p8447
sg10
I7
sg11
Vnervous
p8448
sg13
I1
sa(dp8449
g7
I216
sg20
VC0011168
p8450
sg10
I21
sg11
Vdifficulty swallowing
p8451
sg13
I2
sa(dp8452
g7
I239
sg20
VC0039070
p8453
sg10
I8
sg11
Vfainting
p8454
sg13
I1
sasa(dp8455
g2
S"Self-report assessments included Beck's Depression Inventory (BDI), Spielberger Trait Anxiety Inventory (STAI), Scales for Outcomes in Parkinson's disease-Autonomic (SCOPA-AUT), Modified Constipation Assessment Scale (MCAS) and Freezing of Gait Questionnaire (FOG-Q).\n"
p8456
sg4
(lp8457
sg17
(lp8458
(dp8459
g7
I40
sg20
VC0011581
p8460
sg10
I10
sg11
VDepression
p8461
sg13
I1
sa(dp8462
g7
I187
sg20
VC0009806
p8463
sg10
I12
sg11
VConstipation
p8464
sg13
I1
sa(dp8465
g7
I135
sg20
VC0030567
p8466
sg10
I19
sg11
VParkinson's disease
p8467
sg13
I2
sa(dp8468
g7
I228
sg20
VC0860515
p8469
sg10
I16
sg11
VFreezing of Gait
p8470
sg13
I3
sasa(dp8471
g2
S'Among the global scales, the Scales for Outcomes in PD-Autonomic (SCOPA-AUT) and Nonmotor Symptoms Questionnaire for PD (NMSQuest) both met criteria for Recommended, and the Nonmotor Symptoms Scale (NMSS) met criteria for Suggested; however, none specifically focuses on the target gastrointestinal symptoms (sialorrhea, dysphagia, and constipation) of this report.\n'
p8472
sg4
(lp8473
sg17
(lp8474
(dp8475
g7
I282
sg20
VC0426576
p8476
sg10
I25
sg11
Vgastrointestinal symptoms
p8477
sg13
I2
sa(dp8478
g7
I309
sg20
VC0037036
p8479
sg10
I10
sg11
Vsialorrhea
p8480
sg13
I1
sa(dp8481
g7
I321
sg20
VC0011168
p8482
sg10
I9
sg11
Vdysphagia
p8483
sg13
I1
sa(dp8484
g7
I336
sg20
VC0009806
p8485
sg10
I12
sg11
Vconstipation
p8486
sg13
I1
sasa(dp8487
g2
S'The main clinical signs of the rabbits were depression, reduction in body temperature and intermittent diarrhea and the hematological findings observed were elevation in WBC, RBC, PCV, TP, BUN, AST, AUT and creatinine values and reduction in glucose, K+ and pH of blood.\n'
p8488
sg4
(lp8489
(dp8490
g7
I194
sg8
VP51689
p8491
sg10
I3
sg11
VAST
p8492
sg13
I1
sasg17
(lp8493
(dp8494
g7
I90
sg20
VC0239181
p8495
sg10
I21
sg11
Vintermittent diarrhea
p8496
sg13
I2
sa(dp8497
g7
I44
sg20
VC0011581
p8498
sg10
I10
sg11
Vdepression
p8499
sg13
I1
sasa(dp8500
g2
S'It is believed to result from a combination of paralytic ileus of the transverse colon and spasm of the ascending colon, and once appreciated, becomes a valuable asset in the plain film assessment of appendicitis.\n'
p8501
sg4
(lp8502
sg17
(lp8503
(dp8504
g7
I200
sg20
VC0003615
p8505
sg10
I12
sg11
Vappendicitis
p8506
sg13
I1
sa(dp8507
g7
I47
sg20
VC0030446
p8508
sg10
I15
sg11
Vparalytic ileus
p8509
sg13
I2
sa(dp8510
g7
I91
sg20
VC0037763
p8511
sg10
I5
sg11
Vspasm
p8512
sg13
I1
sasa(dp8513
g2
S'A structural and functional interaction between A(2A) adenosine receptors and D(2) dopamine receptors has been implicated in the pathophysiology of impulse control disorders.\n'
p8514
sg4
(lp8515
(dp8516
g7
I48
sg8
VP14416
p8517
sg10
I53
sg11
VA(2A) adenosine receptors and D(2) dopamine receptors
p8518
sg13
I7
sasg17
(lp8519
(dp8520
g7
I148
sg20
VC0021122
p8521
sg10
I25
sg11
Vimpulse control disorders
p8522
sg13
I3
sasa(dp8523
g2
S'Recent studies have suggested the involvement of the dopaminergic system in addictions and impulse control disorders and associations of dopamine receptor genes (DRD1, DRD2, and DRD4) and PG have been reported.\n'
p8524
sg4
(lp8525
(dp8526
g7
I178
sg8
VP21917
p8527
sg10
I4
sg11
VDRD4
p8528
sg13
I1
sa(dp8529
g7
I168
sg8
VP14416
p8530
sg10
I4
sg11
VDRD2
p8531
sg13
I1
sa(dp8532
g7
I162
sg8
VP21728
p8533
sg10
I4
sg11
VDRD1
p8534
sg13
I1
sa(dp8535
g7
I137
sg8
g127
sg10
I23
sg11
Vdopamine receptor genes
p8536
sg13
I3
sasg17
(lp8537
(dp8538
g7
I76
sg20
VC0085281
p8539
sg10
I10
sg11
Vaddictions
p8540
sg13
I1
sa(dp8541
g7
I91
sg20
VC0021122
p8542
sg10
I25
sg11
Vimpulse control disorders
p8543
sg13
I3
sasa(dp8544
g2
S'To explore the correlation between effect of PIO (pioglitazone, PIO) on learning as well as memory and ERK1/2 (extracellular signal regulated kinase 1/2, ERK1/2) pathway in T2DM (type 2 diabetes mellitus, T2DM) rats, further to elucidate the potential mechanism of PIO in improvement of learning and memory.\n'
p8545
sg4
(lp8546
(dp8547
g7
I111
sg8
VP53778
p8548
sg10
I41
sg11
Vextracellular signal regulated kinase 1/2
p8549
sg13
I5
sa(dp8550
g7
I103
sg8
VP27361
p8551
sg10
I6
sg11
VERK1/2
p8552
sg13
I1
sa(dp8553
g7
I103
sg8
VP27361
p8554
sg10
I6
sg11
VERK1/2
p8555
sg13
I1
sasg17
(lp8556
(dp8557
g7
I173
sg20
VC0011860
p8558
sg10
I4
sg11
VT2DM
p8559
sg13
I1
sa(dp8560
g7
I173
sg20
VC0011860
p8561
sg10
I4
sg11
VT2DM
p8562
sg13
I1
sa(dp8563
g7
I179
sg20
VC0011860
p8564
sg10
I24
sg11
Vtype 2 diabetes mellitus
p8565
sg13
I4
sasa(dp8566
g2
S'This report demonstrates the utilization of a suite of soluble OTP(n) reagents for facile (triazolyl)methylation of 10 MACOS-derived sultam scaffolds in purification-free process for parallel synthesis of small molecule collections for HTS.\n'
p8567
sg4
(lp8568
sg17
(lp8569
(dp8570
g7
I236
sg20
VC1854310
p8571
sg10
I3
sg11
VHTS
p8572
sg13
I1
sasa(dp8573
g2
S'All the recruited members were screened for 3 exons (8, 20, and 21) of KIF21A mutations using the polymerase chain reaction (PCR) amplification and direct sequencing of corresponding PCR products.All patients shared the clinical characteristics including bilateral ophthalmoplegia, blepharoptosis, hypertropic, and exotropic position with inability to raise either eye above the midline and a chin-up head position.\n'
p8574
sg4
(lp8575
sg17
(lp8576
(dp8577
g7
I265
sg20
VC0029089
p8578
sg10
I15
sg11
Vophthalmoplegia
p8579
sg13
I1
sa(dp8580
g7
I282
sg20
VC0005745
p8581
sg10
I14
sg11
Vblepharoptosis
p8582
sg13
I1
sa(dp8583
g7
I130
sg20
VC1705759
p8584
sg10
I13
sg11
Vamplification
p8585
sg13
I1
sasa(dp8586
g2
S'CFEOM presents with congenital ptosis and restricted eye movements, and can be caused by heterozygous missense mutations in the kinesin motor protein KIF21A or in the Beta-tubulin isotypes TUBB3 or TUBB2B.\n'
p8587
sg4
(lp8588
(dp8589
g7
I128
sg8
g127
sg10
I28
sg11
Vkinesin motor protein KIF21A
p8590
sg13
I4
sa(dp8591
g7
I198
sg8
g127
sg10
I6
sg11
VTUBB2B
p8592
sg13
I1
sa(dp8593
g7
I167
sg8
VP68371
p8594
sg10
I12
sg11
VBeta-tubulin
p8595
sg13
I1
sa(dp8596
g7
I189
sg8
VP04350
p8597
sg10
I5
sg11
VTUBB3
p8598
sg13
I1
sasg17
(lp8599
(dp8600
g7
I20
sg20
VC0266573
p8601
sg10
I17
sg11
Vcongenital ptosis
p8602
sg13
I2
sasa(dp8603
g2
S'Congenital fibrosis of the extraocular muscles (CFEOM1) is classically a congenital, non-progressive, restrictive strabismus syndrome characterized by bilateral ptosis and ophthalmoplegia with an infraducted position of the globes.\n'
p8604
sg4
(lp8605
sg17
(lp8606
(dp8607
g7
I102
sg20
VC1998196
p8608
sg10
I22
sg11
Vrestrictive strabismus
p8609
sg13
I2
sa(dp8610
g7
I48
sg20
VC1851102
p8611
sg10
I6
sg11
VCFEOM1
p8612
sg13
I1
sa(dp8613
g7
I161
sg20
VC0005745
p8614
sg10
I6
sg11
Vptosis
p8615
sg13
I1
sa(dp8616
g7
I125
sg20
VC0039082
p8617
sg10
I8
sg11
Vsyndrome
p8618
sg13
I1
sa(dp8619
g7
I11
sg20
VC0016059
p8620
sg10
I8
sg11
Vfibrosis
p8621
sg13
I1
sa(dp8622
g7
I172
sg20
VC0029089
p8623
sg10
I15
sg11
Vophthalmoplegia
p8624
sg13
I1
sasa(dp8625
g2
S'CCDDs have been associated with dominant or recessive monogenic mutations in at least 7 different genes (CHN1, SALL4, HOXA1, KIF21A, PHOX2A, TUBB3, ROBO3) that cause phenotypes such as Duane retraction syndrome, congenital fibrosis of the extraocular muscles, and horizontal gaze palsy with progressive scoliosis.\n'
p8626
sg4
(lp8627
(dp8628
g7
I148
sg8
g127
sg10
I5
sg11
VROBO3
p8629
sg13
I1
sa(dp8630
g7
I105
sg8
VP15882
p8631
sg10
I4
sg11
VCHN1
p8632
sg13
I1
sa(dp8633
g7
I118
sg8
VP49639
p8634
sg10
I5
sg11
VHOXA1
p8635
sg13
I1
sa(dp8636
g7
I141
sg8
VP04350
p8637
sg10
I5
sg11
VTUBB3
p8638
sg13
I1
sa(dp8639
g7
I133
sg8
g127
sg10
I6
sg11
VPHOX2A
p8640
sg13
I1
sa(dp8641
g7
I111
sg8
g127
sg10
I5
sg11
VSALL4
p8642
sg13
I1
sasg17
(lp8643
(dp8644
g7
I185
sg20
VC0013261
p8645
sg10
I25
sg11
VDuane retraction syndrome
p8646
sg13
I3
sa(dp8647
g7
I264
sg20
VC0339651
p8648
sg10
I21
sg11
Vhorizontal gaze palsy
p8649
sg13
I3
sa(dp8650
g7
I223
sg20
VC0016059
p8651
sg10
I8
sg11
Vfibrosis
p8652
sg13
I1
sa(dp8653
g7
I303
sg20
VC0700208
p8654
sg10
I9
sg11
Vscoliosis
p8655
sg13
I1
sasa(dp8656
g2
S'Secondly, we tested whether adrenomedullary function is altered in children with SAA, as it is in congenital adrenal hyperplasia (CAH) also causing adrenal hyperandrogenism.\n'
p8657
sg4
(lp8658
sg17
(lp8659
(dp8660
g7
I156
sg20
VC0206081
p8661
sg10
I16
sg11
Vhyperandrogenism
p8662
sg13
I1
sa(dp8663
g7
I130
sg20
VC0520463
p8664
sg10
I3
sg11
VCAH
p8665
sg13
I1
sa(dp8666
g7
I98
sg20
VC0001627
p8667
sg10
I30
sg11
Vcongenital adrenal hyperplasia
p8668
sg13
I3
sasa(dp8669
g2
S'Among the hospitalized patients with diagnostic code of PUB, we ruled out patients with endoscopic removal of gastric adenoma or peritonitis, and selected patients who had been administered intravenous proton pump inhibitor.\n'
p8670
sg4
(lp8671
(dp8672
g7
I56
sg8
g127
sg10
I3
sg11
VPUB
p8673
sg13
I1
sasg17
(lp8674
(dp8675
g7
I129
sg20
VC0031154
p8676
sg10
I11
sg11
Vperitonitis
p8677
sg13
I1
sa(dp8678
g7
I110
sg20
VC0149826
p8679
sg10
I15
sg11
Vgastric adenoma
p8680
sg13
I2
sasa(dp8681
g2
S'In IPMN with low-grade, intermediate-grade, high-grade dysplasia, associated carcinoma, the expression of hsa-miR-96 was 67%(9/13), 64%(7/11), 43%(3/7) and 27%(7/26) respectively, while the expression of hsa-miR-217 was 77%(10/13), 64%(7/11), 29%(2/7) and 38%(10/26).\n'
p8682
sg4
(lp8683
(dp8684
g7
I106
sg8
g127
sg10
I7
sg11
Vhsa-miR
p8685
sg13
I1
sa(dp8686
g7
I106
sg8
g127
sg10
I7
sg11
Vhsa-miR
p8687
sg13
I1
sasg17
(lp8688
(dp8689
g7
I55
sg20
VC0334044
p8690
sg10
I9
sg11
Vdysplasia
p8691
sg13
I1
sa(dp8692
g7
I77
sg20
VC0007097
p8693
sg10
I9
sg11
Vcarcinoma
p8694
sg13
I1
sa(dp8695
g7
I106
sg20
VC0393754
p8696
sg10
I3
sg11
Vhsa
p8697
sg13
I1
sa(dp8698
g7
I106
sg20
VC0393754
p8699
sg10
I3
sg11
Vhsa
p8700
sg13
I1
sasa(dp8701
g2
S'Abnormal expression of hsa-miR-96 and of hsa-miR-217 was observed in premalignant lesions (PanINs and IPMNs) of pancreatic carcinoma and down-regulated with increasing grades of PanINs and IPMNs.\n'
p8702
sg4
(lp8703
(dp8704
g7
I41
sg8
g127
sg10
I11
sg11
Vhsa-miR-217
p8705
sg13
I1
sa(dp8706
g7
I23
sg8
g127
sg10
I10
sg11
Vhsa-miR-96
p8707
sg13
I1
sasg17
(lp8708
(dp8709
g7
I112
sg20
VC0235974
p8710
sg10
I20
sg11
Vpancreatic carcinoma
p8711
sg13
I2
sa(dp8712
g7
I69
sg20
VC0032927
p8713
sg10
I12
sg11
Vpremalignant
p8714
sg13
I1
sa(dp8715
g7
I23
sg20
VC0393754
p8716
sg10
I3
sg11
Vhsa
p8717
sg13
I1
sa(dp8718
g7
I23
sg20
VC0393754
p8719
sg10
I3
sg11
Vhsa
p8720
sg13
I1
sasa(dp8721
g2
S'However, the expression and role of miR-217 in the development of cutaneous squamous cell carcinoma (cSCC) remain unclear.\n'
p8722
sg4
(lp8723
(dp8724
g7
I36
sg8
g127
sg10
I7
sg11
VmiR-217
p8725
sg13
I1
sasg17
(lp8726
(dp8727
g7
I101
sg20
VC0553723
p8728
sg10
I4
sg11
VcSCC
p8729
sg13
I1
sa(dp8730
g7
I66
sg20
VC0553723
p8731
sg10
I33
sg11
Vcutaneous squamous cell carcinoma
p8732
sg13
I4
sasa(dp8733
g2
S'Fluorescence in situ hybridization and quantitative real-time PCR were conducted to profile the cell distribution and expression of circ-TTBK2 and microRNA-217 (miR-217) in glioma tissues and cells.\n'
p8734
sg4
(lp8735
(dp8736
g7
I161
sg8
g127
sg10
I7
sg11
VmiR-217
p8737
sg13
I1
sa(dp8738
g7
I147
sg8
g127
sg10
I12
sg11
VmicroRNA-217
p8739
sg13
I1
sa(dp8740
g7
I137
sg8
g127
sg10
I5
sg11
VTTBK2
p8741
sg13
I1
sasg17
(lp8742
(dp8743
g7
I173
sg20
VC0017638
p8744
sg10
I6
sg11
Vglioma
p8745
sg13
I1
sasa(dp8746
g2
S'Stable knockdown of circ-TTBK2 or overexpression of miR-217 glioma cell lines (U87 and U251) were established to explore the function of circ-TTBK2 and miR-217 in glioma cells.\n'
p8747
sg4
(lp8748
(dp8749
g7
I52
sg8
g127
sg10
I7
sg11
VmiR-217
p8750
sg13
I1
sa(dp8751
g7
I20
sg8
g127
sg10
I10
sg11
Vcirc-TTBK2
p8752
sg13
I1
sa(dp8753
g7
I20
sg8
g127
sg10
I10
sg11
Vcirc-TTBK2
p8754
sg13
I1
sasg17
(lp8755
(dp8756
g7
I60
sg20
VC0017638
p8757
sg10
I6
sg11
Vglioma
p8758
sg13
I1
sa(dp8759
g7
I60
sg20
VC0017638
p8760
sg10
I6
sg11
Vglioma
p8761
sg13
I1
sasa(dp8762
g2
S'MiR-217 was downregulated in glioma tissues and cell lines.\n'
p8763
sg4
(lp8764
(dp8765
g7
I0
sg8
g127
sg10
I7
sg11
VMiR-217
p8766
sg13
I1
sasg17
(lp8767
(dp8768
g7
I29
sg20
VC0017638
p8769
sg10
I6
sg11
Vglioma
p8770
sg13
I1
sasa(dp8771
g2
S'Moreover, reintroduction of miR-217 significantly reversed circ-TTBK2-mediated promotion of glioma progression.\n'
p8772
sg4
(lp8773
(dp8774
g7
I64
sg8
g127
sg10
I5
sg11
VTTBK2
p8775
sg13
I1
sasg17
(lp8776
(dp8777
g7
I92
sg20
VC0017638
p8778
sg10
I6
sg11
Vglioma
p8779
sg13
I1
sasa(dp8780
g2
S'HNF1Beta was a direct target of miR-217, and played oncogenic role in glioma cells.\n'
p8781
sg4
(lp8782
(dp8783
g7
I0
sg8
VP35680
p8784
sg10
I8
sg11
VHNF1Beta
p8785
sg13
I1
sa(dp8786
g7
I32
sg8
g127
sg10
I7
sg11
VmiR-217
p8787
sg13
I1
sasg17
(lp8788
(dp8789
g7
I70
sg20
VC0017638
p8790
sg10
I6
sg11
Vglioma
p8791
sg13
I1
sasa(dp8792
g2
S'Herein, we found that the expression of miR-217 was significantly down-regulated in glioma tissues as compared with adjacent normal brain tissues.\n'
p8793
sg4
(lp8794
(dp8795
g7
I40
sg8
g127
sg10
I7
sg11
VmiR-217
p8796
sg13
I1
sasg17
(lp8797
(dp8798
g7
I84
sg20
VC0017638
p8799
sg10
I6
sg11
Vglioma
p8800
sg13
I1
sasa(dp8801
g2
S'Clinical association analysis disclosed that low-expression of miR-217 was evidently negative associated with advanced tumor stage (grade III + IV) in glioma.\n'
p8802
sg4
(lp8803
(dp8804
g7
I63
sg8
g127
sg10
I7
sg11
VmiR-217
p8805
sg13
I1
sasg17
(lp8806
(dp8807
g7
I119
sg20
VC0027651
p8808
sg10
I5
sg11
Vtumor
p8809
sg13
I1
sa(dp8810
g7
I151
sg20
VC0017638
p8811
sg10
I6
sg11
Vglioma
p8812
sg13
I1
sasa(dp8813
g2
S'Further function assays showed that miR-217 inhibited proliferation, colony formation, invasion and migration of glioma cells.\n'
p8814
sg4
(lp8815
sg17
(lp8816
(dp8817
g7
I113
sg20
VC0017638
p8818
sg10
I6
sg11
Vglioma
p8819
sg13
I1
sa(dp8820
g7
I54
sg20
VC0334094
p8821
sg10
I13
sg11
Vproliferation
p8822
sg13
I1
sa(dp8823
g7
I87
sg20
VC2699153
p8824
sg10
I8
sg11
Vinvasion
p8825
sg13
I1
sasa(dp8826
g2
S'Notably, runt-related transcription factors 2 (Runx2) was identified as a functional target of miR-217 in glioma.\n'
p8827
sg4
(lp8828
(dp8829
g7
I47
sg8
g127
sg10
I5
sg11
VRunx2
p8830
sg13
I1
sa(dp8831
g7
I9
sg8
VP19883
p8832
sg10
I36
sg11
Vrunt-related transcription factors 2
p8833
sg13
I4
sa(dp8834
g7
I95
sg8
g127
sg10
I7
sg11
VmiR-217
p8835
sg13
I1
sasg17
(lp8836
(dp8837
g7
I9
sg20
VC0013336
p8838
sg10
I4
sg11
Vrunt
p8839
sg13
I1
sa(dp8840
g7
I106
sg20
VC0017638
p8841
sg10
I6
sg11
Vglioma
p8842
sg13
I1
sasa(dp8843
g2
S'Furthermore, an inverse correlation between miR-217 and Runx2 expression was observed in glioma tissues.\n'
p8844
sg4
(lp8845
(dp8846
g7
I44
sg8
g127
sg10
I7
sg11
VmiR-217
p8847
sg13
I1
sa(dp8848
g7
I56
sg8
g127
sg10
I5
sg11
VRunx2
p8849
sg13
I1
sasg17
(lp8850
(dp8851
g7
I89
sg20
VC0017638
p8852
sg10
I6
sg11
Vglioma
p8853
sg13
I1
sasa(dp8854
g2
S'Taken together, these results suggest a critical role of miR-217 in suppressing proliferation, migration, and invasion of glioma by targeting Runx2.\n'
p8855
sg4
(lp8856
(dp8857
g7
I57
sg8
g127
sg10
I7
sg11
VmiR-217
p8858
sg13
I1
sa(dp8859
g7
I142
sg8
g127
sg10
I5
sg11
VRunx2
p8860
sg13
I1
sasg17
(lp8861
(dp8862
g7
I122
sg20
VC0017638
p8863
sg10
I6
sg11
Vglioma
p8864
sg13
I1
sa(dp8865
g7
I110
sg20
VC2699153
p8866
sg10
I8
sg11
Vinvasion
p8867
sg13
I1
sa(dp8868
g7
I80
sg20
VC0334094
p8869
sg10
I13
sg11
Vproliferation
p8870
sg13
I1
sasa(dp8871
g2
S'Expression levels of miR-21, miR-34a and miR-198 were significantly higher, whereas levels of miR-217 were significantly lower in pancreatic ductal adenocarcinomas compared to healthy tissues and tissues of chronic pancreatitis.\n'
p8872
sg4
(lp8873
(dp8874
g7
I21
sg8
g127
sg10
I6
sg11
VmiR-21
p8875
sg13
I1
sa(dp8876
g7
I41
sg8
g127
sg10
I7
sg11
VmiR-198
p8877
sg13
I1
sa(dp8878
g7
I29
sg8
g127
sg10
I7
sg11
VmiR-34a
p8879
sg13
I1
sasg17
(lp8880
(dp8881
g7
I207
sg20
VC0149521
p8882
sg10
I20
sg11
Vchronic pancreatitis
p8883
sg13
I2
sa(dp8884
g7
I148
sg20
VC0001418
p8885
sg10
I15
sg11
Vadenocarcinomas
p8886
sg13
I1
sasa(dp8887
g2
S'Prominent among differentially expressed genes were miR-375, miR-217 and miR-216a, which were found overexpressed in SCLC compared to lung adenocarcinomas.\n'
p8888
sg4
(lp8889
(dp8890
g7
I73
sg8
g127
sg10
I8
sg11
VmiR-216a
p8891
sg13
I1
sa(dp8892
g7
I61
sg8
g127
sg10
I7
sg11
VmiR-217
p8893
sg13
I1
sa(dp8894
g7
I52
sg8
g127
sg10
I7
sg11
VmiR-375
p8895
sg13
I1
sasg17
(lp8896
(dp8897
g7
I139
sg20
VC0001418
p8898
sg10
I15
sg11
Vadenocarcinomas
p8899
sg13
I1
sa(dp8900
g7
I117
sg20
VC0149925
p8901
sg10
I4
sg11
VSCLC
p8902
sg13
I1
sasa(dp8903
g2
S'We therefore investigated whether succinate receptor 1 (SUCNR1) could play a role in the development of adipose tissue inflammation and type 2 diabetes.\n'
p8904
sg4
(lp8905
(dp8906
g7
I34
sg8
g127
sg10
I20
sg11
Vsuccinate receptor 1
p8907
sg13
I3
sa(dp8908
g7
I56
sg8
g127
sg10
I6
sg11
VSUCNR1
p8909
sg13
I1
sasg17
(lp8910
(dp8911
g7
I136
sg20
VC0011860
p8912
sg10
I15
sg11
Vtype 2 diabetes
p8913
sg13
I3
sa(dp8914
g7
I119
sg20
VC0021368
p8915
sg10
I12
sg11
Vinflammation
p8916
sg13
I1
sasa(dp8917
g2
S'Our results reveal that activation of SUCNR1 in macrophages is important for both infiltration and inflammation of adipose tissue in obesity, and suggest that SUCNR1 is a promising therapeutic target in obesity-induced type 2 diabetes.\n'
p8918
sg4
(lp8919
(dp8920
g7
I38
sg8
g127
sg10
I6
sg11
VSUCNR1
p8921
sg13
I1
sa(dp8922
g7
I38
sg8
g127
sg10
I6
sg11
VSUCNR1
p8923
sg13
I1
sasg17
(lp8924
(dp8925
g7
I82
sg20
VC0332448
p8926
sg10
I12
sg11
Vinfiltration
p8927
sg13
I1
sa(dp8928
g7
I133
sg20
VC0028754
p8929
sg10
I7
sg11
Vobesity
p8930
sg13
I1
sa(dp8931
g7
I99
sg20
VC0021368
p8932
sg10
I12
sg11
Vinflammation
p8933
sg13
I1
sa(dp8934
g7
I133
sg20
VC0028754
p8935
sg10
I7
sg11
Vobesity
p8936
sg13
I1
sa(dp8937
g7
I219
sg20
VC0011860
p8938
sg10
I15
sg11
Vtype 2 diabetes
p8939
sg13
I3
sasa(dp8940
g2
S'G-protein-coupled receptor 91 is a BMP6 target and Hjv deletion enhances BMP signaling in retina, thus underscoring a role for excess iron and hemochromatosis in abnormal retinal vascularization.\n'
p8941
sg4
(lp8942
(dp8943
g7
I51
sg8
g127
sg10
I3
sg11
VHjv
p8944
sg13
I1
sa(dp8945
g7
I35
sg8
VP18075
p8946
sg10
I3
sg11
VBMP
p8947
sg13
I1
sa(dp8948
g7
I35
sg8
VP22004
p8949
sg10
I4
sg11
VBMP6
p8950
sg13
I1
sa(dp8951
g7
I0
sg8
g127
sg10
I29
sg11
VG-protein-coupled receptor 91
p8952
sg13
I3
sasg17
(lp8953
(dp8954
g7
I143
sg20
VC0018995
p8955
sg10
I15
sg11
Vhemochromatosis
p8956
sg13
I1
sa(dp8957
g7
I179
sg20
VC0027686
p8958
sg10
I15
sg11
Vvascularization
p8959
sg13
I1
sa(dp8960
g7
I127
sg20
VC0282193
p8961
sg10
I11
sg11
Vexcess iron
p8962
sg13
I2
sasa(dp8963
g2
S'To develop the first radiotracer targeting GPR91, a cell membrane-bound receptor that modulates the cellular response to hyperglycemia and hypoxia, we designed and prepared a small series of compounds based on a published series of 1,8-naphthyridines with high affinity to GPR91.\n'
p8964
sg4
(lp8965
(dp8966
g7
I43
sg8
g127
sg10
I5
sg11
VGPR91
p8967
sg13
I1
sa(dp8968
g7
I43
sg8
g127
sg10
I5
sg11
VGPR91
p8969
sg13
I1
sasg17
(lp8970
(dp8971
g7
I139
sg20
VC0242184
p8972
sg10
I7
sg11
Vhypoxia
p8973
sg13
I1
sa(dp8974
g7
I121
sg20
VC0020456
p8975
sg10
I13
sg11
Vhyperglycemia
p8976
sg13
I1
sasa(dp8977
g2
S'Sucnr1 deletion also protected mice from obesity on HFD, but only during the initial period; at later stages, body weight of HFD-fed Sucnr1(-/-) mice was almost comparable with wild-type (WT) mice, but WAT content was greater.\n'
p8978
sg4
(lp8979
(dp8980
g7
I133
sg8
g127
sg10
I11
sg11
VSucnr1(-/-)
p8981
sg13
I1
sa(dp8982
g7
I0
sg8
g127
sg10
I6
sg11
VSucnr1
p8983
sg13
I1
sasg17
(lp8984
(dp8985
g7
I41
sg20
VC0028754
p8986
sg10
I7
sg11
Vobesity
p8987
sg13
I1
sasa(dp8988
g2
S'These findings suggest that Sucnr1 is a sensor for dietary energy and raise the interesting possibility that protocols to modulate Sucnr1 might have therapeutic utility in the setting of obesity.\n'
p8989
sg4
(lp8990
(dp8991
g7
I28
sg8
g127
sg10
I6
sg11
VSucnr1
p8992
sg13
I1
sa(dp8993
g7
I28
sg8
g127
sg10
I6
sg11
VSucnr1
p8994
sg13
I1
sasg17
(lp8995
(dp8996
g7
I187
sg20
VC0028754
p8997
sg10
I7
sg11
Vobesity
p8998
sg13
I1
sasa(dp8999
g2
S'In this study, we examined the signaling pathways involved in GPR91-dependent VEGF release during the early stages of retinal vascular change in streptozotocin-induced diabetes.\n'
p9000
sg4
(lp9001
(dp9002
g7
I62
sg8
g127
sg10
I20
sg11
VGPR91-dependent VEGF
p9003
sg13
I2
sasg17
(lp9004
(dp9005
g7
I118
sg20
VC0549652
p9006
sg10
I16
sg11
Vretinal vascular
p9007
sg13
I2
sa(dp9008
g7
I168
sg20
VC0011849
p9009
sg10
I8
sg11
Vdiabetes
p9010
sg13
I1
sasa(dp9011
g2
S'Our data suggest that hyperglycemia causes succinate accumulation and GPR91 activity in retinal ganglion cells, which mediate VEGF-induced retinal vascular change via the ERK1/2/COX-2/PGE2 pathway.\n'
p9012
sg4
(lp9013
(dp9014
g7
I70
sg8
g127
sg10
I5
sg11
VGPR91
p9015
sg13
I1
sa(dp9016
g7
I171
sg8
VP27361
p9017
sg10
I6
sg11
VERK1/2
p9018
sg13
I1
sa(dp9019
g7
I178
sg8
VP35354
p9020
sg10
I5
sg11
VCOX-2
p9021
sg13
I1
sasg17
(lp9022
(dp9023
g7
I22
sg20
VC0020456
p9024
sg10
I13
sg11
Vhyperglycemia
p9025
sg13
I1
sa(dp9026
g7
I96
sg20
VC1258666
p9027
sg10
I8
sg11
Vganglion
p9028
sg13
I1
sa(dp9029
g7
I139
sg20
VC0549652
p9030
sg10
I16
sg11
Vretinal vascular
p9031
sg13
I2
sasa(dp9032
g2
S"This study has been performed to evaluate the chemopreventive efficacy of vanillic acid (a bio flavonoid) on endometrial carcinoma (EC) by assessing the levels of thiobarbituric acid reactive substances (TBARS), lipid hydroperoxides (LOOH), cytochrome P450, antioxidants-superoxide dismutase (SOD), catalase (CAT), glutathione peroxides (GPx), reduced glutathione (GSH), vitamins C and E, matrix metalloproteinases (MMP-2 and 9) and cell cycle check point protein (cyclin D1) in N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) induced carcinogenic rats.\n"
p9033
sg4
(lp9034
(dp9035
g7
I241
sg8
VP20853
p9036
sg10
I15
sg11
Vcytochrome P450
p9037
sg13
I2
sa(dp9038
g7
I465
sg8
VP24385
p9039
sg10
I9
sg11
Vcyclin D1
p9040
sg13
I2
sa(dp9041
g7
I299
sg8
VP04040
p9042
sg10
I8
sg11
Vcatalase
p9043
sg13
I1
sa(dp9044
g7
I258
sg8
VP00441
p9045
sg10
I33
sg11
Vantioxidants-superoxide dismutase
p9046
sg13
I2
sa(dp9047
g7
I293
sg8
VP00441
p9048
sg10
I3
sg11
VSOD
p9049
sg13
I1
sa(dp9050
g7
I309
sg8
VP04040
p9051
sg10
I3
sg11
VCAT
p9052
sg13
I1
sasg17
(lp9053
(dp9054
g7
I109
sg20
VC0476089
p9055
sg10
I21
sg11
Vendometrial carcinoma
p9056
sg13
I2
sa(dp9057
g7
I365
sg20
VC1260386
p9058
sg10
I3
sg11
VGSH
p9059
sg13
I1
sa(dp9060
g7
I132
sg20
VC0476089
p9061
sg10
I2
sg11
VEC
p9062
sg13
I1
sasa(dp9063
g2
S'HE4 and MMP2 are both proteins whose serum levels increase in endometrial cancer.\n'
p9064
sg4
(lp9065
(dp9066
g7
I8
sg8
VP08253
p9067
sg10
I4
sg11
VMMP2
p9068
sg13
I1
sasg17
(lp9069
(dp9070
g7
I62
sg20
VC0476089
p9071
sg10
I18
sg11
Vendometrial cancer
p9072
sg13
I2
sasa(dp9073
g2
S'To explore the diagnostic potential of the serum levels of HE4 and MMP2 in patients with endometrial cancer and benign endometrial diseases.\n'
p9074
sg4
(lp9075
(dp9076
g7
I67
sg8
VP08253
p9077
sg10
I4
sg11
VMMP2
p9078
sg13
I1
sasg17
(lp9079
(dp9080
g7
I89
sg20
VC0476089
p9081
sg10
I18
sg11
Vendometrial cancer
p9082
sg13
I2
sa(dp9083
g7
I119
sg20
VC1720816
p9084
sg10
I20
sg11
Vendometrial diseases
p9085
sg13
I2
sasa(dp9086
g2
S'To assess the relationship between the serum levels of HE4 and MMP2 and the typical prognostic factors in patients with endometrial cancer.\n'
p9087
sg4
(lp9088
(dp9089
g7
I63
sg8
VP08253
p9090
sg10
I4
sg11
VMMP2
p9091
sg13
I1
sasg17
(lp9092
(dp9093
g7
I120
sg20
VC0476089
p9094
sg10
I18
sg11
Vendometrial cancer
p9095
sg13
I2
sasa(dp9096
g2
S'We observed statistically significant differences in mean serum levels of HE4 and MMP2 between the group of endometrial cancer patients and the group of patients with no changes in the endometrium (P=0.002/0.003).\n'
p9097
sg4
(lp9098
(dp9099
g7
I82
sg8
VP08253
p9100
sg10
I4
sg11
VMMP2
p9101
sg13
I1
sasg17
(lp9102
(dp9103
g7
I108
sg20
VC0476089
p9104
sg10
I18
sg11
Vendometrial cancer
p9105
sg13
I2
sasa(dp9106
g2
S'HE4 and MMP2 are characterized by high specificity and may be useful as biomarkers in the diagnostics of endometrial cancer.\n'
p9107
sg4
(lp9108
(dp9109
g7
I8
sg8
VP08253
p9110
sg10
I4
sg11
VMMP2
p9111
sg13
I1
sasg17
(lp9112
(dp9113
g7
I105
sg20
VC0476089
p9114
sg10
I18
sg11
Vendometrial cancer
p9115
sg13
I2
sasa(dp9116
g2
S'Although OX40 has been reported to be a target gene of human T-cell leukemia virus type-1 (HTLV-1) viral transactivator Tax and is overexpressed in vivo in adult T-cell leukemia (ATL) cells, an association between OX40 and HTLV-1-associated inflammatory disorders, such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), has not yet been established.\n'
p9117
sg4
(lp9118
(dp9119
g7
I9
sg8
VP43489
p9120
sg10
I4
sg11
VOX40
p9121
sg13
I1
sa(dp9122
g7
I9
sg8
VP43489
p9123
sg10
I4
sg11
VOX40
p9124
sg13
I1
sa(dp9125
g7
I120
sg8
g127
sg10
I3
sg11
VTax
p9126
sg13
I1
sa(dp9127
g7
I332
sg8
g127
sg10
I3
sg11
VHAM
p9128
sg13
I1
sa(dp9129
g7
I336
sg8
VP07996
p9130
sg10
I3
sg11
VTSP
p9131
sg13
I1
sasg17
(lp9132
(dp9133
g7
I61
sg20
VC0023492
p9134
sg10
I15
sg11
VT-cell leukemia
p9135
sg13
I2
sa(dp9136
g7
I302
sg20
VC0030481
p9137
sg10
I28
sg11
Vtropical spastic paraparesis
p9138
sg13
I3
sa(dp9139
g7
I179
sg20
VC0023492
p9140
sg10
I3
sg11
VATL
p9141
sg13
I1
sa(dp9142
g7
I156
sg20
VC0023492
p9143
sg10
I21
sg11
Vadult T-cell leukemia
p9144
sg13
I3
sa(dp9145
g7
I332
sg20
VC0030481
p9146
sg10
I3
sg11
VHAM
p9147
sg13
I1
sa(dp9148
g7
I273
sg20
VC0030481
p9149
sg10
I28
sg11
VHTLV-1-associated myelopathy
p9150
sg13
I2
sasa(dp9151
g2
S'Recent studies indicate that OX40/OX40L system mediates the adhesion and infiltration of adult T cell leukemia (ATL).\n'
p9152
sg4
(lp9153
(dp9154
g7
I29
sg8
VP43489
p9155
sg10
I4
sg11
VOX40
p9156
sg13
I1
sa(dp9157
g7
I34
sg8
VP23510
p9158
sg10
I5
sg11
VOX40L
p9159
sg13
I1
sasg17
(lp9160
(dp9161
g7
I112
sg20
VC0023492
p9162
sg10
I3
sg11
VATL
p9163
sg13
I1
sa(dp9164
g7
I60
sg20
VC0001511
p9165
sg10
I8
sg11
Vadhesion
p9166
sg13
I1
sa(dp9167
g7
I73
sg20
VC0332448
p9168
sg10
I12
sg11
Vinfiltration
p9169
sg13
I1
sa(dp9170
g7
I89
sg20
VC0023492
p9171
sg10
I21
sg11
Vadult T cell leukemia
p9172
sg13
I4
sasa(dp9173
g2
S'We reported previously that OX40, a member of the tumor necrosis factor receptor family, is expressed constitutively on fresh leukemia/lymphoma cells isolated from patients with adult T-cell leukemia (ATL).\n'
p9174
sg4
(lp9175
(dp9176
g7
I28
sg8
VP43489
p9177
sg10
I4
sg11
VOX40
p9178
sg13
I1
sa(dp9179
g7
I50
sg8
VP01375
p9180
sg10
I37
sg11
Vtumor necrosis factor receptor family
p9181
sg13
I5
sasg17
(lp9182
(dp9183
g7
I50
sg20
VC0333516
p9184
sg10
I14
sg11
Vtumor necrosis
p9185
sg13
I2
sa(dp9186
g7
I135
sg20
VC0024299
p9187
sg10
I8
sg11
Vlymphoma
p9188
sg13
I1
sa(dp9189
g7
I201
sg20
VC0023492
p9190
sg10
I3
sg11
VATL
p9191
sg13
I1
sa(dp9192
g7
I126
sg20
VC0023418
p9193
sg10
I8
sg11
Vleukemia
p9194
sg13
I1
sa(dp9195
g7
I178
sg20
VC0023492
p9196
sg10
I21
sg11
Vadult T-cell leukemia
p9197
sg13
I3
sasa(dp9198
g2
S'Similar findings were obtained in OX40(+)- human T-cell leukemia virus type I-transformed T-cell lines.\n'
p9199
sg4
(lp9200
sg17
(lp9201
(dp9202
g7
I49
sg20
VC0023492
p9203
sg10
I15
sg11
VT-cell leukemia
p9204
sg13
I2
sasa(dp9205
g2
S'We demonstrated previously that OX40 and its ligand, gp34, directly mediate adhesion of activated normal CD4+ T cells, as well as human T-cell leukemia virus type I (HTLV-I)-transformed T cells to vascular endothelial cells.\n'
p9206
sg4
(lp9207
(dp9208
g7
I105
sg8
VP01730
p9209
sg10
I4
sg11
VCD4+
p9210
sg13
I1
sa(dp9211
g7
I53
sg8
VP23510
p9212
sg10
I4
sg11
Vgp34
p9213
sg13
I1
sa(dp9214
g7
I32
sg8
VP43489
p9215
sg10
I4
sg11
VOX40
p9216
sg13
I1
sasg17
(lp9217
(dp9218
g7
I76
sg20
VC0001511
p9219
sg10
I8
sg11
Vadhesion
p9220
sg13
I1
sa(dp9221
g7
I136
sg20
VC0023492
p9222
sg10
I15
sg11
VT-cell leukemia
p9223
sg13
I2
sasa(dp9224
g2
S'In the present study, we examined expression of OX40 on fresh leukemic cells from patients with adult T-cell leukemia (ATL) and its possible involvement in cell adhesion.\n'
p9225
sg4
(lp9226
(dp9227
g7
I48
sg8
VP43489
p9228
sg10
I4
sg11
VOX40
p9229
sg13
I1
sasg17
(lp9230
(dp9231
g7
I119
sg20
VC0023492
p9232
sg10
I3
sg11
VATL
p9233
sg13
I1
sa(dp9234
g7
I161
sg20
VC0001511
p9235
sg10
I8
sg11
Vadhesion
p9236
sg13
I1
sa(dp9237
g7
I96
sg20
VC0023492
p9238
sg10
I21
sg11
Vadult T-cell leukemia
p9239
sg13
I3
sasa(dp9240
g2
S'In this study, we used polychromatic flow cytometry to characterize CD8(+) T-cell subsets specific for EBV-derived lytic (BMFL1 and BRLF1) and latent (LMP1, LMP2, and EBNA3C) antigens in individuals with divergent malaria exposure.\n'
p9241
sg4
(lp9242
(dp9243
g7
I68
sg8
VP01732
p9244
sg10
I3
sg11
VCD8
p9245
sg13
I1
sa(dp9246
g7
I157
sg8
VP28065
p9247
sg10
I4
sg11
VLMP2
p9248
sg13
I1
sa(dp9249
g7
I151
sg8
g127
sg10
I4
sg11
VLMP1
p9250
sg13
I1
sasg17
(lp9251
(dp9252
g7
I214
sg20
VC0024530
p9253
sg10
I7
sg11
Vmalaria
p9254
sg13
I1
sa(dp9255
g7
I115
sg20
VC0024348
p9256
sg10
I5
sg11
Vlytic
p9257
sg13
I1
sasa(dp9258
g2
S'The distribution of gene variants of the antigen processing proteins transporter associated with antigen processing type 1 (TAP1) and proteasome subunit beta type 9 (PSMB9) and of their shared bidirectional promoter was assessed in children with either mild or severe malaria.\n'
p9259
sg4
(lp9260
(dp9261
g7
I134
sg8
VP28065
p9262
sg10
I30
sg11
Vproteasome subunit beta type 9
p9263
sg13
I5
sa(dp9264
g7
I166
sg8
VP28065
p9265
sg10
I5
sg11
VPSMB9
p9266
sg13
I1
sa(dp9267
g7
I124
sg8
g127
sg10
I4
sg11
VTAP1
p9268
sg13
I1
sa(dp9269
g7
I69
sg8
g127
sg10
I53
sg11
Vtransporter associated with antigen processing type 1
p9270
sg13
I7
sasg17
(lp9271
(dp9272
g7
I268
sg20
VC0024530
p9273
sg10
I7
sg11
Vmalaria
p9274
sg13
I1
sasa(dp9275
g2
S'GSEA and IPA associated Nur77 to osteoarthritis, chronic obstructive pulmonary disease, rheumatoid arthritis, psoriasis, and allergic airway inflammatory diseases.\n'
p9276
sg4
(lp9277
(dp9278
g7
I24
sg8
VP22736
p9279
sg10
I5
sg11
VNur77
p9280
sg13
I1
sasg17
(lp9281
(dp9282
g7
I110
sg20
VC0033860
p9283
sg10
I9
sg11
Vpsoriasis
p9284
sg13
I1
sa(dp9285
g7
I33
sg20
VC0029408
p9286
sg10
I14
sg11
Vosteoarthritis
p9287
sg13
I1
sa(dp9288
g7
I49
sg20
VC0024117
p9289
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p9290
sg13
I4
sa(dp9291
g7
I88
sg20
VC0003873
p9292
sg10
I20
sg11
Vrheumatoid arthritis
p9293
sg13
I2
sasa(dp9294
g2
S'Accordingly, Nr4a1 mediated the anti-inflammatory properties of ACs in vivo and was required for maintenance of self-tolerance in the murine model of pristane-induced lupus.\n'
p9295
sg4
(lp9296
(dp9297
g7
I13
sg8
VP22736
p9298
sg10
I5
sg11
VNr4a1
p9299
sg13
I1
sasg17
(lp9300
(dp9301
g7
I117
sg20
VC0020963
p9302
sg10
I9
sg11
Vtolerance
p9303
sg13
I1
sa(dp9304
g7
I167
sg20
VC0024131
p9305
sg10
I5
sg11
Vlupus
p9306
sg13
I1
sasa(dp9307
g2
S'This study investigated roles of serum ST2, IL-33 and BNP in predicting major adverse cardiovascular events (MACEs) in acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI).\n'
p9308
sg4
(lp9309
(dp9310
g7
I33
sg8
VP10767
p9311
sg10
I9
sg11
Vserum ST2
p9312
sg13
I2
sasg17
(lp9313
(dp9314
g7
I119
sg20
VC0155626
p9315
sg10
I27
sg11
Vacute myocardial infarction
p9316
sg13
I3
sa(dp9317
g7
I148
sg20
VC0155626
p9318
sg10
I3
sg11
VAMI
p9319
sg13
I1
sasa(dp9320
g2
S'Recombinant human B-type natriuretic peptide (rhBNP) has been shown to be efficacious in the treatment of acute decompensated heart failure and acute myocardial infarction.\n'
p9321
sg4
(lp9322
(dp9323
g7
I46
sg8
VP16860
p9324
sg10
I5
sg11
VrhBNP
p9325
sg13
I1
sa(dp9326
g7
I0
sg8
VP16860
p9327
sg10
I44
sg11
VRecombinant human B-type natriuretic peptide
p9328
sg13
I5
sasg17
(lp9329
(dp9330
g7
I144
sg20
VC0155626
p9331
sg10
I27
sg11
Vacute myocardial infarction
p9332
sg13
I3
sa(dp9333
g7
I106
sg20
VC1609524
p9334
sg10
I33
sg11
Vacute decompensated heart failure
p9335
sg13
I4
sasa(dp9336
g2
S'###############(percutaneous coronary intervention, PCI)########(acute myocardial infarction, AMI)#######, ########PCI##AMI########################2010#1##2014#12#############PCI##AMI#####, #######################, ####################################22%(67/304)###t###X2#######, ###(brain natriuretic peptide, BNP), #####, ######&gt;75#, Killip##&gt;=2#, ####### ##(thrombolysis in myocardial infarction, TIMI)##&lt;=2#, #############, ##2 h ST####&lt;50%, ########(door-to-balloon, D2B)###########(P&lt;0.05), #####logistic####, ###########(red blood cell specific volume, HCT)#N #########(N-terminal pro-brain natriuretic peptide, NT-proBNP)#Killip##&gt;=2####TIMI##&lt;=2####2 h ST####&lt;50%##D2B#######################HCT, NT-proBNP, Killip##&gt;=2#, ##TIMI##&lt;=2#, ##2 h ST### #&lt;50%##D2B###################, #################, ######AMI####PCI#####, ##############.\n'
p9337
sg4
(lp9338
sg17
(lp9339
(dp9340
g7
I94
sg20
VC0155626
p9341
sg10
I3
sg11
VAMI
p9342
sg13
I1
sa(dp9343
g7
I94
sg20
VC0155626
p9344
sg10
I3
sg11
VAMI
p9345
sg13
I1
sa(dp9346
g7
I65
sg20
VC0155626
p9347
sg10
I27
sg11
Vacute myocardial infarction
p9348
sg13
I3
sa(dp9349
g7
I94
sg20
VC0155626
p9350
sg10
I3
sg11
VAMI
p9351
sg13
I1
sa(dp9352
g7
I71
sg20
VC0027051
p9353
sg10
I21
sg11
Vmyocardial infarction
p9354
sg13
I2
sa(dp9355
g7
I94
sg20
VC0155626
p9356
sg10
I3
sg11
VAMI
p9357
sg13
I1
sasa(dp9358
g2
S'The levels of NT-proBNP in the acute myocardial infarction (AMI) group were higher compared with unstable angina pectoris (UAP), stable angina pectoris (SAP), and control groups, and the levels of NT-proBNP in UAP were higher compared to the SAP and control groups.\n'
p9359
sg4
(lp9360
sg17
(lp9361
(dp9362
g7
I31
sg20
VC0155626
p9363
sg10
I27
sg11
Vacute myocardial infarction
p9364
sg13
I3
sa(dp9365
g7
I99
sg20
VC0699826
p9366
sg10
I22
sg11
Vstable angina pectoris
p9367
sg13
I3
sa(dp9368
g7
I60
sg20
VC0155626
p9369
sg10
I3
sg11
VAMI
p9370
sg13
I1
sa(dp9371
g7
I153
sg20
VC0002962
p9372
sg10
I3
sg11
VSAP
p9373
sg13
I1
sa(dp9374
g7
I153
sg20
VC0002962
p9375
sg10
I3
sg11
VSAP
p9376
sg13
I1
sa(dp9377
g7
I123
sg20
VC0002965
p9378
sg10
I3
sg11
VUAP
p9379
sg13
I1
sa(dp9380
g7
I123
sg20
VC0002965
p9381
sg10
I3
sg11
VUAP
p9382
sg13
I1
sa(dp9383
g7
I97
sg20
VC0002965
p9384
sg10
I24
sg11
Vunstable angina pectoris
p9385
sg13
I3
sasa(dp9386
g2
S'After cisplatin and bleomycin-containing chemotherapy (CTx) for testicular cancer, part of the patients may develop acute or long-term cardiovascular toxicity.\n'
p9387
sg4
(lp9388
sg17
(lp9389
(dp9390
g7
I64
sg20
VC0153594
p9391
sg10
I17
sg11
Vtesticular cancer
p9392
sg13
I2
sa(dp9393
g7
I55
sg20
VC0238052
p9394
sg10
I3
sg11
VCTx
p9395
sg13
I1
sasa(dp9396
g2
S'The risk of causing factors of thromboembolism in patients with testicular cancer under cisplatin and bleomycin-containing CTx should be evaluated.\n'
p9397
sg4
(lp9398
sg17
(lp9399
(dp9400
g7
I64
sg20
VC0153594
p9401
sg10
I17
sg11
Vtesticular cancer
p9402
sg13
I2
sa(dp9403
g7
I123
sg20
VC0238052
p9404
sg10
I3
sg11
VCTx
p9405
sg13
I1
sa(dp9406
g7
I31
sg20
VC0040038
p9407
sg10
I15
sg11
Vthromboembolism
p9408
sg13
I1
sasa(dp9409
g2
S'Hypoparathyroidism, sensorineural hearing loss, and renal disease (HDR) syndrome, also known as Barakat syndrome, is a rare genetic disorder with high phenotypic heterogeneity caused by haploinsufficiency of the GATA3 gene on chromosome 10p14-p15.\n'
p9410
sg4
(lp9411
(dp9412
g7
I243
sg8
VP53999
p9413
sg10
I3
sg11
Vp15
p9414
sg13
I1
sa(dp9415
g7
I212
sg8
VP23771
p9416
sg10
I10
sg11
VGATA3 gene
p9417
sg13
I2
sasg17
(lp9418
(dp9419
g7
I20
sg20
VC0018784
p9420
sg10
I26
sg11
Vsensorineural hearing loss
p9421
sg13
I3
sa(dp9422
g7
I67
sg20
VC1840333
p9423
sg10
I3
sg11
VHDR
p9424
sg13
I1
sa(dp9425
g7
I72
sg20
VC0039082
p9426
sg10
I8
sg11
Vsyndrome
p9427
sg13
I1
sa(dp9428
g7
I0
sg20
VC0020626
p9429
sg10
I18
sg11
VHypoparathyroidism
p9430
sg13
I1
sa(dp9431
g7
I124
sg20
VC0019247
p9432
sg10
I16
sg11
Vgenetic disorder
p9433
sg13
I2
sa(dp9434
g7
I96
sg20
VC1840333
p9435
sg10
I16
sg11
VBarakat syndrome
p9436
sg13
I2
sa(dp9437
g7
I52
sg20
VC0022658
p9438
sg10
I13
sg11
Vrenal disease
p9439
sg13
I2
sasa(dp9440
g2
S'Hypoparathyroidism, sensorineural deafness, and renal dysplasia (HDR) syndrome is a rare autosomal dominant disease caused by GATA3 mutations.\n'
p9441
sg4
(lp9442
(dp9443
g7
I126
sg8
VP23771
p9444
sg10
I15
sg11
VGATA3 mutations
p9445
sg13
I2
sasg17
(lp9446
(dp9447
g7
I70
sg20
VC0039082
p9448
sg10
I8
sg11
Vsyndrome
p9449
sg13
I1
sa(dp9450
g7
I48
sg20
VC0266313
p9451
sg10
I15
sg11
Vrenal dysplasia
p9452
sg13
I2
sa(dp9453
g7
I20
sg20
VC0018784
p9454
sg10
I22
sg11
Vsensorineural deafness
p9455
sg13
I2
sa(dp9456
g7
I0
sg20
VC0020626
p9457
sg10
I18
sg11
VHypoparathyroidism
p9458
sg13
I1
sa(dp9459
g7
I65
sg20
VC1840333
p9460
sg10
I3
sg11
VHDR
p9461
sg13
I1
sasa(dp9462
g2
S'We concluded that: (1) CD13 and GATA-3 immunostains may serve as a diagnostic aid in differentiating subtypes of RCC; (2) CD13 is always absent in chromophobe RCC and oncocytomas, whereas CD10 can be immunoexpressed in both; (3) CD13 should be included in a panel of antibodies to distinguish "proximal renal tumors" from "distal renal tumors" and between clear cell RCC versus microphthalmia transcription factor family translocations RCCs; and (4) when present, GATA-3 is specific for clear cell papillary RCC.\n'
p9463
sg4
(lp9464
(dp9465
g7
I23
sg8
VP15144
p9466
sg10
I4
sg11
VCD13
p9467
sg13
I1
sa(dp9468
g7
I23
sg8
VP15144
p9469
sg10
I4
sg11
VCD13
p9470
sg13
I1
sa(dp9471
g7
I188
sg8
VP08473
p9472
sg10
I4
sg11
VCD10
p9473
sg13
I1
sa(dp9474
g7
I32
sg8
VP23771
p9475
sg10
I6
sg11
VGATA-3
p9476
sg13
I1
sa(dp9477
g7
I32
sg8
VP23771
p9478
sg10
I6
sg11
VGATA-3
p9479
sg13
I1
sa(dp9480
g7
I23
sg8
VP15144
p9481
sg10
I4
sg11
VCD13
p9482
sg13
I1
sasg17
(lp9483
(dp9484
g7
I303
sg20
VC0022665
p9485
sg10
I12
sg11
Vrenal tumors
p9486
sg13
I2
sa(dp9487
g7
I436
sg20
VC0007134
p9488
sg10
I4
sg11
VRCCs
p9489
sg13
I1
sa(dp9490
g7
I303
sg20
VC0022665
p9491
sg10
I12
sg11
Vrenal tumors
p9492
sg13
I2
sa(dp9493
g7
I113
sg20
VC0007134
p9494
sg10
I3
sg11
VRCC
p9495
sg13
I1
sa(dp9496
g7
I356
sg20
VC2931852
p9497
sg10
I14
sg11
Vclear cell RCC
p9498
sg13
I3
sa(dp9499
g7
I113
sg20
VC0007134
p9500
sg10
I3
sg11
VRCC
p9501
sg13
I1
sa(dp9502
g7
I378
sg20
VC0026010
p9503
sg10
I14
sg11
Vmicrophthalmia
p9504
sg13
I1
sa(dp9505
g7
I167
sg20
VC0949541
p9506
sg10
I11
sg11
Voncocytomas
p9507
sg13
I1
sa(dp9508
g7
I113
sg20
VC0007134
p9509
sg10
I3
sg11
VRCC
p9510
sg13
I1
sasa(dp9511
g2
S'Genome-wide significant signals were detected for three of the four transitions: (1) for smoking cessation on 10p14 (P = 4.47e-08 for rs72779075 flanked by RP11-575N15 and GATA3), (2) for tolerance on 11p13 (P = 1.29e-08 for rs11031684 in RP1-65P5.1), mediated by smoking quantity, and on 9q34.12 (P = 3.81e-08 for rs2304808 in FUBP3), independent of smoking quantity, and (3) for smoking initiation on 19q13.33 (P = 3.37e-08 for rs73050610 flanked by TRPM4 and SLC6A16) in analysis adjusted for first time sensations.\n'
p9512
sg4
(lp9513
(dp9514
g7
I452
sg8
g127
sg10
I5
sg11
VTRPM4
p9515
sg13
I1
sa(dp9516
g7
I239
sg8
VP56715
p9517
sg10
I10
sg11
VRP1-65P5.1
p9518
sg13
I1
sa(dp9519
g7
I462
sg8
g127
sg10
I7
sg11
VSLC6A16
p9520
sg13
I1
sa(dp9521
g7
I172
sg8
VP23771
p9522
sg10
I5
sg11
VGATA3
p9523
sg13
I1
sa(dp9524
g7
I156
sg8
g127
sg10
I11
sg11
VRP11-575N15
p9525
sg13
I1
sa(dp9526
g7
I328
sg8
g127
sg10
I5
sg11
VFUBP3
p9527
sg13
I1
sasg17
(lp9528
(dp9529
g7
I156
sg20
VC1838601
p9530
sg10
I4
sg11
VRP11
p9531
sg13
I1
sa(dp9532
g7
I156
sg20
VC0220701
p9533
sg10
I3
sg11
VRP1
p9534
sg13
I1
sa(dp9535
g7
I188
sg20
VC0020963
p9536
sg10
I9
sg11
Vtolerance
p9537
sg13
I1
sasa(dp9538
g2
S'Nevertheless, the PRLR neutralizing antibody LFA102 tested recently in a Phase I trial in advanced, PRLR-positive prostate cancer and breast cancer patients failed to provide any clinical benefit.\n'
p9539
sg4
(lp9540
(dp9541
g7
I18
sg8
g127
sg10
I33
sg11
VPRLR neutralizing antibody LFA102
p9542
sg13
I4
sasg17
(lp9543
(dp9544
g7
I134
sg20
VC0678222
p9545
sg10
I13
sg11
Vbreast cancer
p9546
sg13
I2
sa(dp9547
g7
I114
sg20
VC0600139
p9548
sg10
I15
sg11
Vprostate cancer
p9549
sg13
I2
sasa(dp9550
g2
S'In contrast, PRLR/STAT5 signaling was recently proposed to prevent breast cancer cell dissemination and to predict favorable clinical outcomes.\n'
p9551
sg4
(lp9552
(dp9553
g7
I18
sg8
VP42229
p9554
sg10
I5
sg11
VSTAT5
p9555
sg13
I1
sa(dp9556
g7
I13
sg8
g127
sg10
I4
sg11
VPRLR
p9557
sg13
I1
sasg17
(lp9558
(dp9559
g7
I67
sg20
VC0678222
p9560
sg10
I13
sg11
Vbreast cancer
p9561
sg13
I2
sasa(dp9562
g2
S'Our studies have demonstrated the essential role of endogenous PRL and CDK7 in the upregulation of PRLR by E2 and provide insights for therapeutic approaches that will mitigate the transcription/expression of PRLR and its participation in breast cancer progression fueled by E2 and PRL via their cognate receptors.\n'
p9563
sg4
(lp9564
(dp9565
g7
I63
sg8
VP01236
p9566
sg10
I3
sg11
VPRL
p9567
sg13
I1
sa(dp9568
g7
I99
sg8
g127
sg10
I4
sg11
VPRLR
p9569
sg13
I1
sa(dp9570
g7
I63
sg8
VP01236
p9571
sg10
I3
sg11
VPRL
p9572
sg13
I1
sa(dp9573
g7
I71
sg8
VP50613
p9574
sg10
I4
sg11
VCDK7
p9575
sg13
I1
sa(dp9576
g7
I99
sg8
g127
sg10
I4
sg11
VPRLR
p9577
sg13
I1
sasg17
(lp9578
(dp9579
g7
I246
sg20
VC0178874
p9580
sg10
I18
sg11
Vcancer progression
p9581
sg13
I2
sasa(dp9582
g2
S'The Prolactin Receptor (PRLR) is a type 1 cytokine receptor that is expressed in a subset of breast cancers and may contribute to its pathogenesis.\n'
p9583
sg4
(lp9584
(dp9585
g7
I4
sg8
VP01236
p9586
sg10
I18
sg11
VProlactin Receptor
p9587
sg13
I2
sa(dp9588
g7
I35
sg8
g127
sg10
I24
sg11
Vtype 1 cytokine receptor
p9589
sg13
I4
sa(dp9590
g7
I24
sg8
g127
sg10
I4
sg11
VPRLR
p9591
sg13
I1
sasg17
(lp9592
(dp9593
g7
I93
sg20
VC0006142
p9594
sg10
I14
sg11
Vbreast cancers
p9595
sg13
I2
sa(dp9596
g7
I134
sg20
VC0699748
p9597
sg10
I12
sg11
Vpathogenesis
p9598
sg13
I1
sasa(dp9599
g2
S'We developed an anti-PRLR antibody-drug conjugate (ADC), to target PRLR-positive breast cancer.\n'
p9600
sg4
(lp9601
(dp9602
g7
I16
sg8
g127
sg10
I18
sg11
Vanti-PRLR antibody
p9603
sg13
I2
sa(dp9604
g7
I21
sg8
g127
sg10
I4
sg11
VPRLR
p9605
sg13
I1
sasg17
(lp9606
(dp9607
g7
I81
sg20
VC0678222
p9608
sg10
I13
sg11
Vbreast cancer
p9609
sg13
I2
sasa(dp9610
g2
S'These results illustrate promising antitumor activity against PRLR-positive breast cancer xenografts and support the evaluation of anti-PRLR ADCs as potential therapeutic agents in breast cancer.\n'
p9611
sg4
(lp9612
(dp9613
g7
I131
sg8
g127
sg10
I14
sg11
Vanti-PRLR ADCs
p9614
sg13
I2
sa(dp9615
g7
I62
sg8
g127
sg10
I4
sg11
VPRLR
p9616
sg13
I1
sasg17
(lp9617
(dp9618
g7
I76
sg20
VC0678222
p9619
sg10
I13
sg11
Vbreast cancer
p9620
sg13
I2
sa(dp9621
g7
I76
sg20
VC0678222
p9622
sg10
I13
sg11
Vbreast cancer
p9623
sg13
I2
sasa(dp9624
g2
S'In this study, we compared the trafficking of HER2, which is the target of the clinically approved ADC ado-trastuzumab emtansine (T-DM1), with that of prolactin receptor (PRLR), another potential target in breast cancer.\n'
p9625
sg4
(lp9626
(dp9627
g7
I99
sg8
VP20711
p9628
sg10
I29
sg11
VADC ado-trastuzumab emtansine
p9629
sg13
I3
sa(dp9630
g7
I130
sg8
g127
sg10
I5
sg11
VT-DM1
p9631
sg13
I1
sa(dp9632
g7
I151
sg8
VP01236
p9633
sg10
I18
sg11
Vprolactin receptor
p9634
sg13
I2
sa(dp9635
g7
I46
sg8
VP04626
p9636
sg10
I4
sg11
VHER2
p9637
sg13
I1
sa(dp9638
g7
I171
sg8
g127
sg10
I4
sg11
VPRLR
p9639
sg13
I1
sasg17
(lp9640
(dp9641
g7
I206
sg20
VC0678222
p9642
sg10
I13
sg11
Vbreast cancer
p9643
sg13
I2
sa(dp9644
g7
I132
sg20
VC2931688
p9645
sg10
I3
sg11
VDM1
p9646
sg13
I1
sasa(dp9647
g2
S'Furthermore, in breast cancer cells that coexpress HER2 and PRLR, a HER2xPRLR bispecific ADC kills more effectively than HER2 ADC.\n'
p9648
sg4
(lp9649
(dp9650
g7
I51
sg8
VP04626
p9651
sg10
I4
sg11
VHER2
p9652
sg13
I1
sa(dp9653
g7
I60
sg8
g127
sg10
I4
sg11
VPRLR
p9654
sg13
I1
sa(dp9655
g7
I121
sg8
VP04626
p9656
sg10
I8
sg11
VHER2 ADC
p9657
sg13
I2
sasg17
(lp9658
(dp9659
g7
I16
sg20
VC0678222
p9660
sg10
I13
sg11
Vbreast cancer
p9661
sg13
I2
sasa(dp9662
g2
S'In conclusion, truncating mutations of PRLR promote tumor growth in a model of human ERAlfa+ breast cancer and warrant further investigation.\n'
p9663
sg4
(lp9664
(dp9665
g7
I39
sg8
g127
sg10
I4
sg11
VPRLR
p9666
sg13
I1
sasg17
(lp9667
(dp9668
g7
I52
sg20
VC0598934
p9669
sg10
I12
sg11
Vtumor growth
p9670
sg13
I2
sa(dp9671
g7
I93
sg20
VC0678222
p9672
sg10
I13
sg11
Vbreast cancer
p9673
sg13
I2
sasa(dp9674
g2
S'As all antipsychotics (although differences with respect to PRL elevation are large) have the propensity to induce hyperprolactinemia (HPRL), questions have arisen concerning the influence of PRL-elevating antipsychotic medications on breast cancer risk.\n'
p9675
sg4
(lp9676
(dp9677
g7
I60
sg8
VP01236
p9678
sg10
I3
sg11
VPRL
p9679
sg13
I1
sa(dp9680
g7
I115
sg8
VP01236
p9681
sg10
I18
sg11
Vhyperprolactinemia
p9682
sg13
I1
sa(dp9683
g7
I60
sg8
VP01236
p9684
sg10
I3
sg11
VPRL
p9685
sg13
I1
sa(dp9686
g7
I135
sg8
VP01236
p9687
sg10
I4
sg11
VHPRL
p9688
sg13
I1
sasg17
(lp9689
(dp9690
g7
I115
sg20
VC0020514
p9691
sg10
I18
sg11
Vhyperprolactinemia
p9692
sg13
I1
sa(dp9693
g7
I235
sg20
VC0678222
p9694
sg10
I13
sg11
Vbreast cancer
p9695
sg13
I2
sa(dp9696
g7
I135
sg20
VC0020514
p9697
sg10
I4
sg11
VHPRL
p9698
sg13
I1
sasa(dp9699
g2
S'A literature search (until January 2016), using the MEDLINE database, was conducted for English-language published clinical studies to identify and synthesize data of the current state of knowledge concerning the relationship between HPRL, breast cancer risk (factors) and antipsychotic medication.\n'
p9700
sg4
(lp9701
(dp9702
g7
I234
sg8
VP01236
p9703
sg10
I4
sg11
VHPRL
p9704
sg13
I1
sasg17
(lp9705
(dp9706
g7
I240
sg20
VC0678222
p9707
sg10
I13
sg11
Vbreast cancer
p9708
sg13
I2
sasa(dp9709
g2
S'Vaccination with DNA encoding for Gad65, secretogranin 5, pancreas/duodenum homeobox protein 1 (Pdx1), carboxyl ester lipase, glucagon and control hepatitis B surface antigen (HBsAg) induced diabetes in &lt;20% of mice.\n'
p9710
sg4
(lp9711
(dp9712
g7
I41
sg8
g127
sg10
I15
sg11
Vsecretogranin 5
p9713
sg13
I2
sa(dp9714
g7
I58
sg8
VP52945
p9715
sg10
I36
sg11
Vpancreas/duodenum homeobox protein 1
p9716
sg13
I4
sa(dp9717
g7
I147
sg8
g127
sg10
I27
sg11
Vhepatitis B surface antigen
p9718
sg13
I4
sa(dp9719
g7
I176
sg8
g127
sg10
I5
sg11
VHBsAg
p9720
sg13
I1
sa(dp9721
g7
I126
sg8
VP01275
p9722
sg10
I8
sg11
Vglucagon
p9723
sg13
I1
sa(dp9724
g7
I96
sg8
VP52945
p9725
sg10
I4
sg11
VPdx1
p9726
sg13
I1
sa(dp9727
g7
I103
sg8
VP04118
p9728
sg10
I21
sg11
Vcarboxyl ester lipase
p9729
sg13
I3
sa(dp9730
g7
I34
sg8
g127
sg10
I5
sg11
VGad65
p9731
sg13
I1
sasg17
(lp9732
(dp9733
g7
I191
sg20
VC0011849
p9734
sg10
I8
sg11
Vdiabetes
p9735
sg13
I1
sa(dp9736
g7
I147
sg20
VC0019163
p9737
sg10
I11
sg11
Vhepatitis B
p9738
sg13
I2
sasa(dp9739
g2
S'ProSAAS and 7B2 may perform a chaperone role as secretory anti-aggregants in normal islet cell function and in type 2 diabetes.\n'
p9740
sg4
(lp9741
(dp9742
g7
I0
sg8
g127
sg10
I7
sg11
VProSAAS
p9743
sg13
I1
sa(dp9744
g7
I12
sg8
VP05408
p9745
sg10
I3
sg11
V7B2
p9746
sg13
I1
sasg17
(lp9747
(dp9748
g7
I111
sg20
VC0011860
p9749
sg10
I15
sg11
Vtype 2 diabetes
p9750
sg13
I3
sasa(dp9751
g2
S'In the brains of APP/PSEN1 mice, a model of AD amyloidosis, immunoreactive 7B2 co-localized with aggregation-prone proteins and their respective aggregates.\n'
p9752
sg4
(lp9753
(dp9754
g7
I21
sg8
VP49768
p9755
sg10
I5
sg11
VPSEN1
p9756
sg13
I1
sa(dp9757
g7
I17
sg8
g127
sg10
I3
sg11
VAPP
p9758
sg13
I1
sasg17
(lp9759
(dp9760
g7
I47
sg20
VC0002726
p9761
sg10
I11
sg11
Vamyloidosis
p9762
sg13
I1
sasa(dp9763
g2
S'Apoptosis signal-regulating kinase 1 (ASK1) activates the proapoptotic c-Jun NH2-terminal kinase 1/2 (JNK1/2) leading to apoptosis, suggesting a possible role of ASK1 in diabetes-induced heart defects.\n'
p9764
sg4
(lp9765
(dp9766
g7
I38
sg8
g127
sg10
I4
sg11
VASK1
p9767
sg13
I1
sa(dp9768
g7
I0
sg8
g127
sg10
I36
sg11
VApoptosis signal-regulating kinase 1
p9769
sg13
I4
sa(dp9770
g7
I38
sg8
g127
sg10
I4
sg11
VASK1
p9771
sg13
I1
sa(dp9772
g7
I102
sg8
VP45983
p9773
sg10
I6
sg11
VJNK1/2
p9774
sg13
I1
sa(dp9775
g7
I71
sg8
VP05412
p9776
sg10
I29
sg11
Vc-Jun NH2-terminal kinase 1/2
p9777
sg13
I4
sasg17
(lp9778
(dp9779
g7
I187
sg20
VC0018798
p9780
sg10
I13
sg11
Vheart defects
p9781
sg13
I2
sa(dp9782
g7
I170
sg20
VC0011849
p9783
sg10
I8
sg11
Vdiabetes
p9784
sg13
I1
sasa(dp9785
g2
S'We aimed to investigate whether ASK1 is activated in the heart and whether deleting the Ask1 gene blocks diabetes-induced adverse events and heart defect formation.\n'
p9786
sg4
(lp9787
(dp9788
g7
I32
sg8
g127
sg10
I4
sg11
VASK1
p9789
sg13
I1
sa(dp9790
g7
I88
sg8
g127
sg10
I9
sg11
VAsk1 gene
p9791
sg13
I2
sasg17
(lp9792
(dp9793
g7
I105
sg20
VC0011849
p9794
sg10
I8
sg11
Vdiabetes
p9795
sg13
I1
sa(dp9796
g7
I141
sg20
VC0018798
p9797
sg10
I12
sg11
Vheart defect
p9798
sg13
I2
sasa(dp9799
g2
S'Deleting Ask1 gene significantly reduced the rate of heart defects, including ventricular septal defects (VSDs) and persistent truncus arteriosus (PTA).\n'
p9800
sg4
(lp9801
(dp9802
g7
I9
sg8
g127
sg10
I9
sg11
VAsk1 gene
p9803
sg13
I2
sasg17
(lp9804
(dp9805
g7
I147
sg20
VC0041207
p9806
sg10
I3
sg11
VPTA
p9807
sg13
I1
sa(dp9808
g7
I116
sg20
VC0041207
p9809
sg10
I29
sg11
Vpersistent truncus arteriosus
p9810
sg13
I3
sa(dp9811
g7
I78
sg20
VC0018818
p9812
sg10
I26
sg11
Vventricular septal defects
p9813
sg13
I3
sa(dp9814
g7
I106
sg20
VC0018818
p9815
sg10
I4
sg11
VVSDs
p9816
sg13
I1
sa(dp9817
g7
I53
sg20
VC0018798
p9818
sg10
I13
sg11
Vheart defects
p9819
sg13
I2
sasa(dp9820
g2
S'The CC16 serum level is elevated in patients with pulmonary fibrosis, but its predictive value on lung disease progression has not yet been studied.\n'
p9821
sg4
(lp9822
sg17
(lp9823
(dp9824
g7
I98
sg20
VC0024115
p9825
sg10
I12
sg11
Vlung disease
p9826
sg13
I2
sa(dp9827
g7
I103
sg20
VC0242656
p9828
sg10
I19
sg11
Vdisease progression
p9829
sg13
I2
sa(dp9830
g7
I50
sg20
VC0034069
p9831
sg10
I18
sg11
Vpulmonary fibrosis
p9832
sg13
I2
sasa(dp9833
g2
S'We aimed to assess the value of serum CC16 concentration in predicting lung disease deterioration in patients with systemic sclerosis (SSc).\n'
p9834
sg4
(lp9835
sg17
(lp9836
(dp9837
g7
I135
sg20
VC0036421
p9838
sg10
I3
sg11
VSSc
p9839
sg13
I1
sa(dp9840
g7
I115
sg20
VC0036421
p9841
sg10
I18
sg11
Vsystemic sclerosis
p9842
sg13
I2
sa(dp9843
g7
I71
sg20
VC0024115
p9844
sg10
I12
sg11
Vlung disease
p9845
sg13
I2
sasa(dp9846
g2
S'Progression of lung disease evaluated by a mean time-to-event differed between patients with high baseline serum CC16 (42.8 mos, 36.3-49.3) and those with low serum CC16 (56.3 mos, 50.9-61.7; log-rank test, p &lt; 0.001).\n'
p9847
sg4
(lp9848
(dp9849
g7
I165
sg8
VP11684
p9850
sg10
I14
sg11
VCC16 (56.3 mos
p9851
sg13
I3
sasg17
(lp9852
(dp9853
g7
I124
sg20
VC0026987
p9854
sg10
I3
sg11
Vmos
p9855
sg13
I1
sa(dp9856
g7
I124
sg20
VC0026987
p9857
sg10
I3
sg11
Vmos
p9858
sg13
I1
sa(dp9859
g7
I15
sg20
VC0024115
p9860
sg10
I12
sg11
Vlung disease
p9861
sg13
I2
sasa(dp9862
g2
S'High baseline serum CC16 predicts lung disease worsening in patients with SSc.\n'
p9863
sg4
(lp9864
sg17
(lp9865
(dp9866
g7
I34
sg20
VC0024115
p9867
sg10
I12
sg11
Vlung disease
p9868
sg13
I2
sasa(dp9869
g2
S'We evaluated CC-16 as a candidate biomarker for respiratory failure in amyotrophic lateral sclerosis (ALS).\n'
p9870
sg4
(lp9871
sg17
(lp9872
(dp9873
g7
I48
sg20
VC1145670
p9874
sg10
I19
sg11
Vrespiratory failure
p9875
sg13
I2
sa(dp9876
g7
I71
sg20
VC0002736
p9877
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p9878
sg13
I3
sa(dp9879
g7
I102
sg20
VC0002736
p9880
sg10
I3
sg11
VALS
p9881
sg13
I1
sasa(dp9882
g2
S'We propose that increased CC-16 levels is a marker of lung inflammatory response that associated with ventilatory insufficiency are related to impending respiratory failure, not fully predicted by conventional respiratory tests.\n'
p9883
sg4
(lp9884
sg17
(lp9885
(dp9886
g7
I153
sg20
VC1145670
p9887
sg10
I19
sg11
Vrespiratory failure
p9888
sg13
I2
sa(dp9889
g7
I59
sg20
VC1155266
p9890
sg10
I21
sg11
Vinflammatory response
p9891
sg13
I2
sasa(dp9892
g2
S"The aim of this pilot study was to determine Clara cell protein (CC16) concentration in bronchoalveolar lavages (BAL) fluid from full-term and preterm (&lt;37 weeks' gestational age) neonates requiring respiratory support, having symptoms of neonatal respiratory distress syndrome, and at risk of bronchopulmonary dysplasia (BPD).\n"
p9893
sg4
(lp9894
sg17
(lp9895
(dp9896
g7
I242
sg20
VC0035220
p9897
sg10
I38
sg11
Vneonatal respiratory distress syndrome
p9898
sg13
I4
sa(dp9899
g7
I297
sg20
VC0006287
p9900
sg10
I26
sg11
Vbronchopulmonary dysplasia
p9901
sg13
I2
sa(dp9902
g7
I325
sg20
VC0006012
p9903
sg10
I3
sg11
VBPD
p9904
sg13
I1
sasa(dp9905
g2
S'With regard to ARDS, initial levels of cytokeratin fragment 21-1, the soluble fragment of cytokeratin 19 (CYFRA21-1) and of the club cell protein 16 (CC16) provided significant results in each statistical analysis.\n'
p9906
sg4
(lp9907
(dp9908
g7
I39
sg8
g127
sg10
I25
sg11
Vcytokeratin fragment 21-1
p9909
sg13
I3
sasg17
(lp9910
(dp9911
g7
I15
sg20
VC0035222
p9912
sg10
I4
sg11
VARDS
p9913
sg13
I1
sasa(dp9914
g2
S'With regard to pneumonia, each statistical analysis supplied significant results for both initial and day-2 levels of CYFRA21-1 and CC16.\n'
p9915
sg4
(lp9916
(dp9917
g7
I132
sg8
VP11684
p9918
sg10
I4
sg11
VCC16
p9919
sg13
I1
sasg17
(lp9920
(dp9921
g7
I15
sg20
VC0032285
p9922
sg10
I9
sg11
Vpneumonia
p9923
sg13
I1
sasa(dp9924
g2
S'Consistently, initial CYFRA21-1 levels were identified as the most promising predictor of ARDS, whereas day-2 CC16 levels have to be considered as most appropriate for predicting pneumonia.\n'
p9925
sg4
(lp9926
sg17
(lp9927
(dp9928
g7
I179
sg20
VC0032285
p9929
sg10
I9
sg11
Vpneumonia
p9930
sg13
I1
sa(dp9931
g7
I90
sg20
VC0035222
p9932
sg10
I4
sg11
VARDS
p9933
sg13
I1
sasa(dp9934
g2
S'However, CC16 levels exceeding 30.51 ng/ml on day 2 may allow a firmer diagnosis for the development of pneumonia.\n'
p9935
sg4
(lp9936
sg17
(lp9937
(dp9938
g7
I104
sg20
VC0032285
p9939
sg10
I9
sg11
Vpneumonia
p9940
sg13
I1
sasa(dp9941
g2
S'In 8- to 24-month-old children with previously manifested pneumonia, serum CC16 was lower in atopic (2.9 ng/mL) in relation to nonatopic children (3.7 ng/mL), P=.029 (serum CC16 &lt;=3.4 ng/mL indicating atopy in the group of children with pneumonia, sensitivity 100%, and specificity 77%).\n'
p9942
sg4
(lp9943
sg17
(lp9944
(dp9945
g7
I58
sg20
VC0032285
p9946
sg10
I9
sg11
Vpneumonia
p9947
sg13
I1
sa(dp9948
g7
I93
sg20
VC0392707
p9949
sg10
I6
sg11
Vatopic
p9950
sg13
I1
sa(dp9951
g7
I204
sg20
VC0392707
p9952
sg10
I5
sg11
Vatopy
p9953
sg13
I1
sa(dp9954
g7
I58
sg20
VC0032285
p9955
sg10
I9
sg11
Vpneumonia
p9956
sg13
I1
sasa(dp9957
g2
S'Atopic 8- to 24-month-old children with previously manifested pneumonia had lower CC16 in relation to other atopic children in this age (P=.021) (for cutoff CC16&lt;=3.4 ng/mL sensitivity 100%, specificity 77%), and also often chronic wheezing (atopic with pneumonia 83.3%, n=5/6 vs atopic without pneumonia 21.4%, n=3/14), P=.018.\n'
p9958
sg4
(lp9959
sg17
(lp9960
(dp9961
g7
I62
sg20
VC0032285
p9962
sg10
I9
sg11
Vpneumonia
p9963
sg13
I1
sa(dp9964
g7
I108
sg20
VC0392707
p9965
sg10
I6
sg11
Vatopic
p9966
sg13
I1
sa(dp9967
g7
I62
sg20
VC0032285
p9968
sg10
I9
sg11
Vpneumonia
p9969
sg13
I1
sa(dp9970
g7
I62
sg20
VC0032285
p9971
sg10
I9
sg11
Vpneumonia
p9972
sg13
I1
sa(dp9973
g7
I108
sg20
VC0392707
p9974
sg10
I6
sg11
Vatopic
p9975
sg13
I1
sa(dp9976
g7
I108
sg20
VC0392707
p9977
sg10
I6
sg11
Vatopic
p9978
sg13
I1
sa(dp9979
g7
I227
sg20
VC1735643
p9980
sg10
I16
sg11
Vchronic wheezing
p9981
sg13
I2
sa(dp9982
g7
I0
sg20
VC0392707
p9983
sg10
I6
sg11
VAtopic
p9984
sg13
I1
sasa(dp9985
g2
S'Low serum CC16 is associated with previously expressed pneumonia and chronic wheezing in atopic children.\n'
p9986
sg4
(lp9987
(dp9988
g7
I4
sg8
VP11684
p9989
sg10
I10
sg11
Vserum CC16
p9990
sg13
I2
sasg17
(lp9991
(dp9992
g7
I55
sg20
VC0032285
p9993
sg10
I9
sg11
Vpneumonia
p9994
sg13
I1
sa(dp9995
g7
I69
sg20
VC1735643
p9996
sg10
I16
sg11
Vchronic wheezing
p9997
sg13
I2
sa(dp9998
g7
I89
sg20
VC0392707
p9999
sg10
I6
sg11
Vatopic
p10000
sg13
I1
sasa(dp10001
g2
S'Also, we explored the usefulness of serum levels of CC16 for the differential diagnosis of IPF (n = 85), compared with non-IPF interstitial lung diseases [chronic hypersensitivity pneumonitis (cHP; n = 85) and connective tissue diseases (CTD-ILD; n = 85)].\n'
p10002
sg4
(lp10003
(dp10004
g7
I52
sg8
VP11684
p10005
sg10
I4
sg11
VCC16
p10006
sg13
I1
sasg17
(lp10007
(dp10008
g7
I127
sg20
VC0206062
p10009
sg10
I26
sg11
Vinterstitial lung diseases
p10010
sg13
I3
sa(dp10011
g7
I163
sg20
VC0002390
p10012
sg10
I28
sg11
Vhypersensitivity pneumonitis
p10013
sg13
I2
sa(dp10014
g7
I210
sg20
VC0009782
p10015
sg10
I26
sg11
Vconnective tissue diseases
p10016
sg13
I3
sasa(dp10017
g2
S'TBX22 encodes a T-box containing transcription factor and mutations in this gene are responsible for X-linked cleft palate and ankyloglossia.\n'
p10018
sg4
(lp10019
(dp10020
g7
I0
sg8
g127
sg10
I5
sg11
VTBX22
p10021
sg13
I1
sasg17
(lp10022
(dp10023
g7
I127
sg20
VC0152415
p10024
sg10
I13
sg11
Vankyloglossia
p10025
sg13
I1
sa(dp10026
g7
I101
sg20
VC1844830
p10027
sg10
I21
sg11
VX-linked cleft palate
p10028
sg13
I3
sasa(dp10029
g2
S'Moreover, EMSA and ChIP assays demonstrated that the allele A disrupts the binding site of ETS-1, thus markedly decreases the activity of the TBX22 promoter, which is likely to lead to the birth defect of the CPO without ankyloglossia.\n'
p10030
sg4
(lp10031
(dp10032
g7
I142
sg8
g127
sg10
I14
sg11
VTBX22 promoter
p10033
sg13
I2
sa(dp10034
g7
I91
sg8
VP14921
p10035
sg10
I5
sg11
VETS-1
p10036
sg13
I1
sasg17
(lp10037
(dp10038
g7
I189
sg20
VC1737329
p10039
sg10
I12
sg11
Vbirth defect
p10040
sg13
I2
sa(dp10041
g7
I221
sg20
VC0152415
p10042
sg10
I13
sg11
Vankyloglossia
p10043
sg13
I1
sasa(dp10044
g2
S'Four mutations in TBX22 exon 5 in X-linked cleft palate with ankyloglossia (CPX) patients had been identified in the previous studies.\n'
p10045
sg4
(lp10046
(dp10047
g7
I18
sg8
g127
sg10
I10
sg11
VTBX22 exon
p10048
sg13
I2
sasg17
(lp10049
(dp10050
g7
I76
sg20
VC1844830
p10051
sg10
I3
sg11
VCPX
p10052
sg13
I1
sa(dp10053
g7
I43
sg20
VC1844831
p10054
sg10
I31
sg11
Vcleft palate with ankyloglossia
p10055
sg13
I4
sasa(dp10056
g2
S'X-linked cleft palate (CPX) is caused by mutations in the gene encoding the TBX22 transcription factor and is known to exhibit phenotypic variability, usually involving either a complete, partial or submucous cleft palate, with or without ankyloglossia.\n'
p10057
sg4
(lp10058
(dp10059
g7
I76
sg8
g127
sg10
I26
sg11
VTBX22 transcription factor
p10060
sg13
I3
sasg17
(lp10061
(dp10062
g7
I0
sg20
VC1844830
p10063
sg10
I21
sg11
VX-linked cleft palate
p10064
sg13
I3
sa(dp10065
g7
I23
sg20
VC1844830
p10066
sg10
I3
sg11
VCPX
p10067
sg13
I1
sa(dp10068
g7
I199
sg20
VC0432103
p10069
sg10
I22
sg11
Vsubmucous cleft palate
p10070
sg13
I3
sa(dp10071
g7
I239
sg20
VC0152415
p10072
sg10
I13
sg11
Vankyloglossia
p10073
sg13
I1
sasa(dp10074
g2
S'To resolve if TBX22 mutations cause isolated tongue-tie in the Finnish population.\n'
p10075
sg4
(lp10076
(dp10077
g7
I14
sg8
g127
sg10
I15
sg11
VTBX22 mutations
p10078
sg13
I2
sasg17
(lp10079
(dp10080
g7
I45
sg20
VC0152415
p10081
sg10
I10
sg11
Vtongue-tie
p10082
sg13
I1
sasa(dp10083
g2
S'Mutation analysis of the coding region of the TBX22 gene in 50 Finnish isolated tongue-tie patients and 61 control samples.\n'
p10084
sg4
(lp10085
(dp10086
g7
I46
sg8
g127
sg10
I10
sg11
VTBX22 gene
p10087
sg13
I2
sasg17
(lp10088
(dp10089
g7
I80
sg20
VC0152415
p10090
sg10
I10
sg11
Vtongue-tie
p10091
sg13
I1
sasa(dp10092
g2
S'Mutations in the coding region of the TBX22 gene are not a major cause of ankyloglossia in the Finnish population and do not explain the sex difference or inheritance of tongue-tie.\n'
p10093
sg4
(lp10094
(dp10095
g7
I38
sg8
g127
sg10
I10
sg11
VTBX22 gene
p10096
sg13
I2
sasg17
(lp10097
(dp10098
g7
I170
sg20
VC0152415
p10099
sg10
I10
sg11
Vtongue-tie
p10100
sg13
I1
sa(dp10101
g7
I74
sg20
VC0152415
p10102
sg10
I13
sg11
Vankyloglossia
p10103
sg13
I1
sasa(dp10104
g2
S'Mutations in TBX22 are known causes of cleft palate with/without ankyloglossia.\n'
p10105
sg4
(lp10106
(dp10107
g7
I13
sg8
g127
sg10
I5
sg11
VTBX22
p10108
sg13
I1
sasg17
(lp10109
(dp10110
g7
I39
sg20
VC0008925
p10111
sg10
I12
sg11
Vcleft palate
p10112
sg13
I2
sa(dp10113
g7
I65
sg20
VC0152415
p10114
sg10
I13
sg11
Vankyloglossia
p10115
sg13
I1
sasa(dp10116
g2
S'Our study has demonstrated that TBX22 mutation is associated not only with cleft palate and ankyloglossia, but also cleft lip and palate and tooth agenesis.\n'
p10117
sg4
(lp10118
(dp10119
g7
I32
sg8
g127
sg10
I14
sg11
VTBX22 mutation
p10120
sg13
I2
sasg17
(lp10121
(dp10122
g7
I116
sg20
VC0158646
p10123
sg10
I20
sg11
Vcleft lip and palate
p10124
sg13
I4
sa(dp10125
g7
I147
sg20
VC0332907
p10126
sg10
I8
sg11
Vagenesis
p10127
sg13
I1
sa(dp10128
g7
I75
sg20
VC0008925
p10129
sg10
I12
sg11
Vcleft palate
p10130
sg13
I2
sa(dp10131
g7
I92
sg20
VC0152415
p10132
sg10
I13
sg11
Vankyloglossia
p10133
sg13
I1
sasa(dp10134
g2
S'X-linked cleft palate and ankyloglossia (CPX) are caused by mutations in the TBX22 transcription factor.\n'
p10135
sg4
(lp10136
(dp10137
g7
I77
sg8
g127
sg10
I26
sg11
VTBX22 transcription factor
p10138
sg13
I3
sasg17
(lp10139
(dp10140
g7
I0
sg20
VC1844830
p10141
sg10
I21
sg11
VX-linked cleft palate
p10142
sg13
I3
sa(dp10143
g7
I26
sg20
VC0152415
p10144
sg10
I13
sg11
Vankyloglossia
p10145
sg13
I1
sa(dp10146
g7
I41
sg20
VC1844830
p10147
sg10
I3
sg11
VCPX
p10148
sg13
I1
sasa(dp10149
g2
S'To investigate whether patients with ankyloglossia alone or in the presence of other craniofacial features including hypodontia or CLP might be caused by TBX22 mutations, we analyzed 45 Thai patients with isolated ankyloglossia, 2 unusual CPA families, and 282 non-syndromic Thai and UK patients with CLP.\n'
p10150
sg4
(lp10151
(dp10152
g7
I154
sg8
g127
sg10
I5
sg11
VTBX22
p10153
sg13
I1
sasg17
(lp10154
(dp10155
g7
I37
sg20
VC0152415
p10156
sg10
I13
sg11
Vankyloglossia
p10157
sg13
I1
sa(dp10158
g7
I117
sg20
VC0020608
p10159
sg10
I10
sg11
Vhypodontia
p10160
sg13
I1
sa(dp10161
g7
I37
sg20
VC0152415
p10162
sg10
I13
sg11
Vankyloglossia
p10163
sg13
I1
sasa(dp10164
g2
S'Mutations in the gene encoding the T-box transcription factor TBX22 cause X-linked cleft palate and ankyloglossia in humans.\n'
p10165
sg4
(lp10166
(dp10167
g7
I35
sg8
g127
sg10
I32
sg11
VT-box transcription factor TBX22
p10168
sg13
I4
sasg17
(lp10169
(dp10170
g7
I74
sg20
VC1844830
p10171
sg10
I21
sg11
VX-linked cleft palate
p10172
sg13
I3
sa(dp10173
g7
I100
sg20
VC0152415
p10174
sg10
I13
sg11
Vankyloglossia
p10175
sg13
I1
sasa(dp10176
g2
S'It frequently accompanies X-linked cleft palate and is sometimes seen alone due to mutations in the gene encoding the transcription factor TBX22, while knockout of Lgr5 in the mouse results in ankyloglossia.\n'
p10177
sg4
(lp10178
(dp10179
g7
I164
sg8
g127
sg10
I4
sg11
VLgr5
p10180
sg13
I1
sa(dp10181
g7
I118
sg8
VP35398
p10182
sg10
I26
sg11
Vtranscription factor TBX22
p10183
sg13
I3
sasg17
(lp10184
(dp10185
g7
I26
sg20
VC1844830
p10186
sg10
I21
sg11
VX-linked cleft palate
p10187
sg13
I3
sa(dp10188
g7
I193
sg20
VC0152415
p10189
sg10
I13
sg11
Vankyloglossia
p10190
sg13
I1
sasa(dp10191
g2
S'Mutations in Tbx22 have been reported in families with X-linked cleft palate and ankyloglossia, but the underlying pathogenetic mechanism remains unknown.\n'
p10192
sg4
(lp10193
(dp10194
g7
I13
sg8
g127
sg10
I5
sg11
VTbx22
p10195
sg13
I1
sasg17
(lp10196
(dp10197
g7
I81
sg20
VC0152415
p10198
sg10
I13
sg11
Vankyloglossia
p10199
sg13
I1
sa(dp10200
g7
I55
sg20
VC1844830
p10201
sg10
I21
sg11
VX-linked cleft palate
p10202
sg13
I3
sasa(dp10203
g2
S'Because overexpression of COX-2 has been demonstrated to be a master regulator in endometriosis progression, our data demonstrate the critical function of proinflammatory cytokines and the COUP-TFII regulatory gene network in the progression of endometriosis.\n'
p10204
sg4
(lp10205
(dp10206
g7
I26
sg8
VP35354
p10207
sg10
I5
sg11
VCOX-2
p10208
sg13
I1
sa(dp10209
g7
I189
sg8
VP24468
p10210
sg10
I9
sg11
VCOUP-TFII
p10211
sg13
I1
sasg17
(lp10212
(dp10213
g7
I82
sg20
VC0014175
p10214
sg10
I13
sg11
Vendometriosis
p10215
sg13
I1
sa(dp10216
g7
I82
sg20
VC0014175
p10217
sg10
I13
sg11
Vendometriosis
p10218
sg13
I1
sasa(dp10219
g2
S'We observed that, as in mice, COUP-TFII is robustly expressed in the endometrial stroma of healthy women, and its expression is reduced in the ectopic lesions of women with endometriosis.\n'
p10220
sg4
(lp10221
(dp10222
g7
I30
sg8
VP24468
p10223
sg10
I9
sg11
VCOUP-TFII
p10224
sg13
I1
sasg17
(lp10225
(dp10226
g7
I173
sg20
VC0014175
p10227
sg10
I13
sg11
Vendometriosis
p10228
sg13
I1
sasa(dp10229
g2
S'The determination that COUP-TFII plays a role in inflammation may add insight into the role of COUP-TFII in embryo implantation and in endometrial diseases such as endometriosis.\n'
p10230
sg4
(lp10231
(dp10232
g7
I23
sg8
VP24468
p10233
sg10
I9
sg11
VCOUP-TFII
p10234
sg13
I1
sa(dp10235
g7
I23
sg8
VP24468
p10236
sg10
I9
sg11
VCOUP-TFII
p10237
sg13
I1
sasg17
(lp10238
(dp10239
g7
I66
sg20
VC0004269
p10240
sg10
I3
sg11
Vadd
p10241
sg13
I1
sa(dp10242
g7
I164
sg20
VC0014175
p10243
sg10
I13
sg11
Vendometriosis
p10244
sg13
I1
sa(dp10245
g7
I135
sg20
VC1720816
p10246
sg10
I20
sg11
Vendometrial diseases
p10247
sg13
I2
sa(dp10248
g7
I49
sg20
VC0021368
p10249
sg10
I12
sg11
Vinflammation
p10250
sg13
I1
sasa(dp10251
g2
S"In addition, the results of the RD3 and ET3 immunostains clearly explain for the first time the presence of both 3R and 4R tau isoforms in preparations of insoluble tau from some Pick's disease cases.\n"
p10252
sg4
(lp10253
(dp10254
g7
I32
sg8
g127
sg10
I3
sg11
VRD3
p10255
sg13
I1
sa(dp10256
g7
I40
sg8
VP14138
p10257
sg10
I16
sg11
VET3 immunostains
p10258
sg13
I2
sasg17
(lp10259
(dp10260
g7
I179
sg20
VC0236642
p10261
sg10
I14
sg11
VPick's disease
p10262
sg13
I2
sasa(dp10263
g2
S'Beginning at the age of 6 months, Myc(His) transgenic mice developed B-cell and plasma neoplasms, such as IgM(+) lymphoblastic B-cell lymphomas, Bcl-6(+) diffuse large B-cell lymphomas, and CD138(+) plasmacytomas, with an overall incidence of 68% by 21 months.\n'
p10264
sg4
(lp10265
(dp10266
g7
I190
sg8
VP18827
p10267
sg10
I5
sg11
VCD138
p10268
sg13
I1
sa(dp10269
g7
I106
sg8
VP29965
p10270
sg10
I3
sg11
VIgM
p10271
sg13
I1
sa(dp10272
g7
I145
sg8
VP41182
p10273
sg10
I5
sg11
VBcl-6
p10274
sg13
I1
sasg17
(lp10275
(dp10276
g7
I199
sg20
VC0032131
p10277
sg10
I13
sg11
Vplasmacytomas
p10278
sg13
I1
sa(dp10279
g7
I87
sg20
VC0027651
p10280
sg10
I9
sg11
Vneoplasms
p10281
sg13
I1
sa(dp10282
g7
I127
sg20
VC0079731
p10283
sg10
I16
sg11
VB-cell lymphomas
p10284
sg13
I2
sa(dp10285
g7
I127
sg20
VC0079731
p10286
sg10
I16
sg11
VB-cell lymphomas
p10287
sg13
I2
sasa(dp10288
g2
S'The purpose of this study was to examine the role of cytokines in the pathogenesis of infantile spasm by investigating cytokine levels before and 1month after adrenocorticotropic hormone (ACTH) therapy in patients diagnosed with the condition.\n'
p10289
sg4
(lp10290
(dp10291
g7
I188
sg8
VP01189
p10292
sg10
I4
sg11
VACTH
p10293
sg13
I1
sa(dp10294
g7
I159
sg8
VP01189
p10295
sg10
I27
sg11
Vadrenocorticotropic hormone
p10296
sg13
I2
sasg17
(lp10297
(dp10298
g7
I86
sg20
VC0037769
p10299
sg10
I15
sg11
Vinfantile spasm
p10300
sg13
I2
sa(dp10301
g7
I70
sg20
VC0699748
p10302
sg10
I12
sg11
Vpathogenesis
p10303
sg13
I1
sa(dp10304
g7
I233
sg20
VC0012634
p10305
sg10
I9
sg11
Vcondition
p10306
sg13
I1
sasa(dp10307
g2
S'Treatment of infantile spasms has little class I data, but adrenocorticotropic hormone (ACTH), prednisolone and vigabatrin have the best evidence as first-line medications.\n'
p10308
sg4
(lp10309
(dp10310
g7
I59
sg8
VP01189
p10311
sg10
I27
sg11
Vadrenocorticotropic hormone
p10312
sg13
I2
sa(dp10313
g7
I88
sg8
VP01189
p10314
sg10
I4
sg11
VACTH
p10315
sg13
I1
sasg17
(lp10316
(dp10317
g7
I13
sg20
VC0037769
p10318
sg10
I16
sg11
Vinfantile spasms
p10319
sg13
I2
sasa(dp10320
g2
S'Newly diagnosed infants with West syndrome were randomized to receive 14 days of oral prednisolone (40-60 mg/day) or a synthetically prepared intramuscular long-acting adrenocorticotropic hormone (40-60 IU/every other day [0.5-0.75 mg]) according to the United Kingdom Infantile Spasm Study protocol.\n'
p10321
sg4
(lp10322
(dp10323
g7
I168
sg8
VP01189
p10324
sg10
I27
sg11
Vadrenocorticotropic hormone
p10325
sg13
I2
sasg17
(lp10326
(dp10327
g7
I269
sg20
VC0037769
p10328
sg10
I15
sg11
VInfantile Spasm
p10329
sg13
I2
sa(dp10330
g7
I29
sg20
VC0037769
p10331
sg10
I13
sg11
VWest syndrome
p10332
sg13
I2
sasa(dp10333
g2
S'By day 14, cessation of infantile spasms occurred in 28/48 (58.3%) infants on prednisolone compared with only 18/49 (36.7%) infants given adrenocorticotropic hormone (P = 0.03) and electroclinical remission in 21 on prednisolone compared with nine on adrenocorticotropic hormone (P = 0.007).\n'
p10334
sg4
(lp10335
sg17
(lp10336
(dp10337
g7
I24
sg20
VC0037769
p10338
sg10
I16
sg11
Vinfantile spasms
p10339
sg13
I2
sa(dp10340
g7
I197
sg20
VC0687702
p10341
sg10
I9
sg11
Vremission
p10342
sg13
I1
sasa(dp10343
g2
S'The third patient had electrographic remission with previous adrenocorticotropic hormone treatment but infantile spasm remission only after receiving topiramate.\n'
p10344
sg4
(lp10345
(dp10346
g7
I61
sg8
VP01189
p10347
sg10
I27
sg11
Vadrenocorticotropic hormone
p10348
sg13
I2
sasg17
(lp10349
(dp10350
g7
I103
sg20
VC0037769
p10351
sg10
I15
sg11
Vinfantile spasm
p10352
sg13
I2
sa(dp10353
g7
I37
sg20
VC0687702
p10354
sg10
I9
sg11
Vremission
p10355
sg13
I1
sa(dp10356
g7
I37
sg20
VC0687702
p10357
sg10
I9
sg11
Vremission
p10358
sg13
I1
sasa(dp10359
g2
S'Heart rate variability analysis found lower heart rate variability parameters in patients with infantile spasm at the onset of the syndrome, prior to treatment with ACTH.\n'
p10360
sg4
(lp10361
(dp10362
g7
I165
sg8
VP01189
p10363
sg10
I4
sg11
VACTH
p10364
sg13
I1
sasg17
(lp10365
(dp10366
g7
I131
sg20
VC0039082
p10367
sg10
I8
sg11
Vsyndrome
p10368
sg13
I1
sa(dp10369
g7
I95
sg20
VC0037769
p10370
sg10
I15
sg11
Vinfantile spasm
p10371
sg13
I2
sasa(dp10372
g2
S'Our data suggest that patients with infantile spasm exhibit lower heart rate variability parameters, and the treatment of spasms with ACTH and B6 together diminished the autonomic dysfunction in our cohort.\n'
p10373
sg4
(lp10374
(dp10375
g7
I134
sg8
VP01189
p10376
sg10
I4
sg11
VACTH
p10377
sg13
I1
sasg17
(lp10378
(dp10379
g7
I170
sg20
VC0741307
p10380
sg10
I21
sg11
Vautonomic dysfunction
p10381
sg13
I2
sa(dp10382
g7
I122
sg20
VC0037763
p10383
sg10
I6
sg11
Vspasms
p10384
sg13
I1
sa(dp10385
g7
I36
sg20
VC0037769
p10386
sg10
I15
sg11
Vinfantile spasm
p10387
sg13
I2
sasa(dp10388
g2
S'We describe an 8-month-old infant with infantile spasms treated with adrenocorticotropic hormone (ACTH) who presented with fatal Legionella pneumophila and Pneumocystis jirovecii infection.\n'
p10389
sg4
(lp10390
(dp10391
g7
I69
sg8
VP01189
p10392
sg10
I27
sg11
Vadrenocorticotropic hormone
p10393
sg13
I2
sa(dp10394
g7
I98
sg8
VP01189
p10395
sg10
I4
sg11
VACTH
p10396
sg13
I1
sasg17
(lp10397
(dp10398
g7
I39
sg20
VC0037769
p10399
sg10
I16
sg11
Vinfantile spasms
p10400
sg13
I2
sa(dp10401
g7
I156
sg20
VC0032305
p10402
sg10
I12
sg11
VPneumocystis
p10403
sg13
I1
sa(dp10404
g7
I179
sg20
VC0009450
p10405
sg10
I9
sg11
Vinfection
p10406
sg13
I1
sasa(dp10407
g2
S'In the present study, the contribution of 5-HTT polymorphisms to the risk of infantile spasm (IS) and the responsiveness to adrenocorticotropic hormone (ACTH) were investigated.\n'
p10408
sg4
(lp10409
(dp10410
g7
I153
sg8
VP01189
p10411
sg10
I4
sg11
VACTH
p10412
sg13
I1
sa(dp10413
g7
I124
sg8
VP01189
p10414
sg10
I27
sg11
Vadrenocorticotropic hormone
p10415
sg13
I2
sasg17
(lp10416
(dp10417
g7
I77
sg20
VC0037769
p10418
sg10
I15
sg11
Vinfantile spasm
p10419
sg13
I2
sa(dp10420
g7
I94
sg20
VC0037769
p10421
sg10
I2
sg11
VIS
p10422
sg13
I1
sasa(dp10423
g2
S'Thus, our results show (1) that NPM-ALK and TPM3-ALK oncogenes are sufficient for lymphoma/leukemia development and required for tumor maintenance, hence validating ALK as potentially effective therapeutic target; and (2) for the first time, in vivo, the equal tumorigenic potential of the NPM-ALK and TPM3-ALK oncogenic tyrosine kinases.\n'
p10424
sg4
(lp10425
(dp10426
g7
I36
sg8
g127
sg10
I3
sg11
VALK
p10427
sg13
I1
sa(dp10428
g7
I36
sg8
g127
sg10
I3
sg11
VALK
p10429
sg13
I1
sa(dp10430
g7
I44
sg8
VP06753
p10431
sg10
I4
sg11
VTPM3
p10432
sg13
I1
sa(dp10433
g7
I36
sg8
g127
sg10
I3
sg11
VALK
p10434
sg13
I1
sa(dp10435
g7
I36
sg8
g127
sg10
I3
sg11
VALK
p10436
sg13
I1
sa(dp10437
g7
I321
sg8
VP29401
p10438
sg10
I16
sg11
Vtyrosine kinases
p10439
sg13
I2
sa(dp10440
g7
I32
sg8
g127
sg10
I3
sg11
VNPM
p10441
sg13
I1
sa(dp10442
g7
I32
sg8
g127
sg10
I3
sg11
VNPM
p10443
sg13
I1
sa(dp10444
g7
I36
sg8
g127
sg10
I3
sg11
VALK
p10445
sg13
I1
sa(dp10446
g7
I44
sg8
VP06753
p10447
sg10
I4
sg11
VTPM3
p10448
sg13
I1
sasg17
(lp10449
(dp10450
g7
I91
sg20
VC0023418
p10451
sg10
I8
sg11
Vleukemia
p10452
sg13
I1
sa(dp10453
g7
I82
sg20
VC0024299
p10454
sg10
I8
sg11
Vlymphoma
p10455
sg13
I1
sa(dp10456
g7
I129
sg20
VC0027651
p10457
sg10
I5
sg11
Vtumor
p10458
sg13
I1
sasa(dp10459
g2
S'In anaplastic large-cell lymphomas positive for anaplastic lymphoma kinase (ALK) protein, the ALK gene is most commonly fused to the NPM gene, and less commonly to TPM3, TFG, ATIC, and other rare genes.\n'
p10460
sg4
(lp10461
(dp10462
g7
I133
sg8
g127
sg10
I8
sg11
VNPM gene
p10463
sg13
I2
sa(dp10464
g7
I170
sg8
g127
sg10
I3
sg11
VTFG
p10465
sg13
I1
sa(dp10466
g7
I76
sg8
g127
sg10
I3
sg11
VALK
p10467
sg13
I1
sa(dp10468
g7
I48
sg8
g127
sg10
I26
sg11
Vanaplastic lymphoma kinase
p10469
sg13
I3
sa(dp10470
g7
I94
sg8
g127
sg10
I8
sg11
VALK gene
p10471
sg13
I2
sa(dp10472
g7
I175
sg8
VP31939
p10473
sg10
I4
sg11
VATIC
p10474
sg13
I1
sa(dp10475
g7
I164
sg8
VP06753
p10476
sg10
I4
sg11
VTPM3
p10477
sg13
I1
sasg17
(lp10478
(dp10479
g7
I3
sg20
VC0206180
p10480
sg10
I31
sg11
Vanaplastic large-cell lymphomas
p10481
sg13
I3
sa(dp10482
g7
I48
sg20
VC1321546
p10483
sg10
I19
sg11
Vanaplastic lymphoma
p10484
sg13
I2
sasa(dp10485
g2
S'They are made of cadherin-23 and protocadherin-15, products of the Usher syndrome type 1 genes USH1D and USH1F, respectively.\n'
p10486
sg4
(lp10487
(dp10488
g7
I105
sg8
VP33778
p10489
sg10
I5
sg11
VUSH1F
p10490
sg13
I1
sa(dp10491
g7
I17
sg8
g127
sg10
I11
sg11
Vcadherin-23
p10492
sg13
I1
sa(dp10493
g7
I33
sg8
g127
sg10
I16
sg11
Vprotocadherin-15
p10494
sg13
I1
sa(dp10495
g7
I95
sg8
g127
sg10
I5
sg11
VUSH1D
p10496
sg13
I1
sasg17
(lp10497
(dp10498
g7
I67
sg20
VC1568247
p10499
sg10
I21
sg11
VUsher syndrome type 1
p10500
sg13
I4
sa(dp10501
g7
I105
sg20
VC1865885
p10502
sg10
I5
sg11
VUSH1F
p10503
sg13
I1
sa(dp10504
g7
I95
sg20
VC1832845
p10505
sg10
I5
sg11
VUSH1D
p10506
sg13
I1
sasa(dp10507
g2
S'To date, five USH1 genes have been identified: MYO7A (USH1B), CDH23 (USH1D), PCDH15 (USH1F), USH1C(USH1C), and USH1G(USH1G).\n'
p10508
sg4
(lp10509
(dp10510
g7
I54
sg8
g127
sg10
I5
sg11
VUSH1B
p10511
sg13
I1
sa(dp10512
g7
I69
sg8
g127
sg10
I5
sg11
VUSH1D
p10513
sg13
I1
sa(dp10514
g7
I14
sg8
g127
sg10
I38
sg11
VUSH1 genes have been identified: MYO7A
p10515
sg13
I6
sa(dp10516
g7
I77
sg8
g127
sg10
I14
sg11
VPCDH15 (USH1F)
p10517
sg13
I2
sa(dp10518
g7
I62
sg8
g127
sg10
I5
sg11
VCDH23
p10519
sg13
I1
sa(dp10520
g7
I93
sg8
g127
sg10
I5
sg11
VUSH1C
p10521
sg13
I1
sa(dp10522
g7
I93
sg8
g127
sg10
I5
sg11
VUSH1C
p10523
sg13
I1
sa(dp10524
g7
I111
sg8
g127
sg10
I5
sg11
VUSH1G
p10525
sg13
I1
sa(dp10526
g7
I111
sg8
g127
sg10
I5
sg11
VUSH1G
p10527
sg13
I1
sasg17
(lp10528
(dp10529
g7
I54
sg20
VC1848638
p10530
sg10
I5
sg11
VUSH1B
p10531
sg13
I1
sa(dp10532
g7
I69
sg20
VC1832845
p10533
sg10
I5
sg11
VUSH1D
p10534
sg13
I1
sa(dp10535
g7
I14
sg20
VC1848638
p10536
sg10
I38
sg11
VUSH1 genes have been identified: MYO7A
p10537
sg13
I6
sa(dp10538
g7
I85
sg20
VC1865885
p10539
sg10
I5
sg11
VUSH1F
p10540
sg13
I1
sa(dp10541
g7
I93
sg20
VC1848604
p10542
sg10
I5
sg11
VUSH1C
p10543
sg13
I1
sa(dp10544
g7
I93
sg20
VC1848604
p10545
sg10
I5
sg11
VUSH1C
p10546
sg13
I1
sa(dp10547
g7
I111
sg20
VC1847089
p10548
sg10
I5
sg11
VUSH1G
p10549
sg13
I1
sa(dp10550
g7
I111
sg20
VC1847089
p10551
sg10
I5
sg11
VUSH1G
p10552
sg13
I1
sasa(dp10553
g2
S'There are five known USH1 molecules: the molecular motor myosin VIIa (USH1B); the two cell-cell adhesion cadherin proteins, cadherin 23 (USH1D) and protocadherin 15, (USH1F) and the scaffold proteins, harmonin (USH1C) and SANS (USH1G).\n'
p10554
sg4
(lp10555
(dp10556
g7
I21
sg8
g127
sg10
I14
sg11
VUSH1 molecules
p10557
sg13
I2
sa(dp10558
g7
I167
sg8
VP33778
p10559
sg10
I5
sg11
VUSH1F
p10560
sg13
I1
sa(dp10561
g7
I211
sg8
g127
sg10
I5
sg11
VUSH1C
p10562
sg13
I1
sa(dp10563
g7
I201
sg8
g127
sg10
I8
sg11
Vharmonin
p10564
sg13
I1
sa(dp10565
g7
I222
sg8
g127
sg10
I4
sg11
VSANS
p10566
sg13
I1
sa(dp10567
g7
I137
sg8
g127
sg10
I5
sg11
VUSH1D
p10568
sg13
I1
sa(dp10569
g7
I57
sg8
g127
sg10
I11
sg11
Vmyosin VIIa
p10570
sg13
I2
sa(dp10571
g7
I124
sg8
g127
sg10
I11
sg11
Vcadherin 23
p10572
sg13
I2
sa(dp10573
g7
I228
sg8
g127
sg10
I5
sg11
VUSH1G
p10574
sg13
I1
sa(dp10575
g7
I70
sg8
g127
sg10
I5
sg11
VUSH1B
p10576
sg13
I1
sa(dp10577
g7
I148
sg8
g127
sg10
I16
sg11
Vprotocadherin 15
p10578
sg13
I2
sa(dp10579
g7
I86
sg8
g127
sg10
I36
sg11
Vcell-cell adhesion cadherin proteins
p10580
sg13
I4
sasg17
(lp10581
(dp10582
g7
I167
sg20
VC1865885
p10583
sg10
I5
sg11
VUSH1F
p10584
sg13
I1
sa(dp10585
g7
I21
sg20
VC1568247
p10586
sg10
I4
sg11
VUSH1
p10587
sg13
I1
sa(dp10588
g7
I96
sg20
VC0001511
p10589
sg10
I8
sg11
Vadhesion
p10590
sg13
I1
sa(dp10591
g7
I137
sg20
VC1832845
p10592
sg10
I5
sg11
VUSH1D
p10593
sg13
I1
sa(dp10594
g7
I211
sg20
VC1848604
p10595
sg10
I5
sg11
VUSH1C
p10596
sg13
I1
sa(dp10597
g7
I228
sg20
VC1847089
p10598
sg10
I5
sg11
VUSH1G
p10599
sg13
I1
sa(dp10600
g7
I70
sg20
VC1848638
p10601
sg10
I5
sg11
VUSH1B
p10602
sg13
I1
sasa(dp10603
g2
S'We found that PAK5 was highly expressed in the tumor tissues of glioma patients and human glioma cell lines.\n'
p10604
sg4
(lp10605
(dp10606
g7
I14
sg8
g127
sg10
I4
sg11
VPAK5
p10607
sg13
I1
sasg17
(lp10608
(dp10609
g7
I47
sg20
VC0027651
p10610
sg10
I5
sg11
Vtumor
p10611
sg13
I1
sa(dp10612
g7
I64
sg20
VC0017638
p10613
sg10
I6
sg11
Vglioma
p10614
sg13
I1
sa(dp10615
g7
I64
sg20
VC0017638
p10616
sg10
I6
sg11
Vglioma
p10617
sg13
I1
sasa(dp10618
g2
S'We then used a lentivirus-delivered short hairpin RNA to stably silence PAK5 expression in glioma cells and explore its influence.\n'
p10619
sg4
(lp10620
(dp10621
g7
I72
sg8
g127
sg10
I4
sg11
VPAK5
p10622
sg13
I1
sasg17
(lp10623
(dp10624
g7
I91
sg20
VC0017638
p10625
sg10
I6
sg11
Vglioma
p10626
sg13
I1
sa(dp10627
g7
I64
sg20
VC0858952
p10628
sg10
I7
sg11
Vsilence
p10629
sg13
I1
sasa(dp10630
g2
S'The results showed that the inhibition of PAK5 reduced cell viability and delayed the cell cycle at the G0/G1 phase in the glioma cells with PAK5 high expression.\n'
p10631
sg4
(lp10632
(dp10633
g7
I42
sg8
g127
sg10
I4
sg11
VPAK5
p10634
sg13
I1
sa(dp10635
g7
I42
sg8
g127
sg10
I4
sg11
VPAK5
p10636
sg13
I1
sasg17
(lp10637
(dp10638
g7
I123
sg20
VC0017638
p10639
sg10
I6
sg11
Vglioma
p10640
sg13
I1
sasa(dp10641
g2
S'In conclusion, our results suggest that the inhibition of PAK5 by RNA interference might efficiently suppress tumor development of glioma cells with PAK5 high expression.\n'
p10642
sg4
(lp10643
(dp10644
g7
I58
sg8
g127
sg10
I4
sg11
VPAK5
p10645
sg13
I1
sa(dp10646
g7
I58
sg8
g127
sg10
I4
sg11
VPAK5
p10647
sg13
I1
sasg17
(lp10648
(dp10649
g7
I131
sg20
VC0017638
p10650
sg10
I6
sg11
Vglioma
p10651
sg13
I1
sa(dp10652
g7
I110
sg20
VC0027651
p10653
sg10
I5
sg11
Vtumor
p10654
sg13
I1
sasa(dp10655
g2
S'Little is known regarding the mechanisms underlying the downstream targets of PAK5, and information concerning its biological significance in glioma is lacking.\n'
p10656
sg4
(lp10657
(dp10658
g7
I78
sg8
g127
sg10
I4
sg11
VPAK5
p10659
sg13
I1
sasg17
(lp10660
(dp10661
g7
I142
sg20
VC0017638
p10662
sg10
I6
sg11
Vglioma
p10663
sg13
I1
sasa(dp10664
g2
S'In this study, we investigated the effects of PAK5 on proliferation, migration, invasion, and apoptosis in human U87 and U251 glioma cells and examined the underlying molecular mechanism.\n'
p10665
sg4
(lp10666
(dp10667
g7
I46
sg8
g127
sg10
I4
sg11
VPAK5
p10668
sg13
I1
sasg17
(lp10669
(dp10670
g7
I126
sg20
VC0017638
p10671
sg10
I6
sg11
Vglioma
p10672
sg13
I1
sa(dp10673
g7
I54
sg20
VC0334094
p10674
sg10
I13
sg11
Vproliferation
p10675
sg13
I1
sa(dp10676
g7
I80
sg20
VC2699153
p10677
sg10
I8
sg11
Vinvasion
p10678
sg13
I1
sasa(dp10679
g2
S'We demonstrated that suppression of PAK5 in glioma cells significantly inhibited cell migration and invasion.\n'
p10680
sg4
(lp10681
(dp10682
g7
I36
sg8
g127
sg10
I4
sg11
VPAK5
p10683
sg13
I1
sasg17
(lp10684
(dp10685
g7
I100
sg20
VC2699153
p10686
sg10
I8
sg11
Vinvasion
p10687
sg13
I1
sa(dp10688
g7
I44
sg20
VC0017638
p10689
sg10
I6
sg11
Vglioma
p10690
sg13
I1
sa(dp10691
g7
I21
sg20
VC0221103
p10692
sg10
I11
sg11
Vsuppression
p10693
sg13
I1
sasa(dp10694
g2
S'We also observed that suppression of PAK5 in human glioma cell lines inhibited cell growth because of G1 phase arrest.\n'
p10695
sg4
(lp10696
(dp10697
g7
I37
sg8
g127
sg10
I4
sg11
VPAK5
p10698
sg13
I1
sasg17
(lp10699
(dp10700
g7
I22
sg20
VC0221103
p10701
sg10
I11
sg11
Vsuppression
p10702
sg13
I1
sa(dp10703
g7
I51
sg20
VC0017638
p10704
sg10
I6
sg11
Vglioma
p10705
sg13
I1
sasa(dp10706
g2
S'This syndrome is characterized by the presence of multiple osteochondromas in limbs, hypertrichosis, and facial phenotype that includes sparse scalp hair, large laterally protruding ears, a long nose with a bulbous tip.\n'
p10707
sg4
(lp10708
sg17
(lp10709
(dp10710
g7
I50
sg20
VC0015306
p10711
sg10
I24
sg11
Vmultiple osteochondromas
p10712
sg13
I2
sa(dp10713
g7
I171
sg20
VC0333056
p10714
sg10
I10
sg11
Vprotruding
p10715
sg13
I1
sa(dp10716
g7
I85
sg20
VC0020555
p10717
sg10
I14
sg11
Vhypertrichosis
p10718
sg13
I1
sa(dp10719
g7
I5
sg20
VC0039082
p10720
sg10
I8
sg11
Vsyndrome
p10721
sg13
I1
sasa(dp10722
g2
S'Two ongoing phase II clinical trials (RENEW and SYNERGY) have been developed to test the efficacy of anti-LINGO-1 antibodies in acute optic neuritis and relapsing forms of multiple sclerosis, respectively.\n'
p10723
sg4
(lp10724
(dp10725
g7
I101
sg8
g127
sg10
I23
sg11
Vanti-LINGO-1 antibodies
p10726
sg13
I2
sasg17
(lp10727
(dp10728
g7
I172
sg20
VC0026769
p10729
sg10
I18
sg11
Vmultiple sclerosis
p10730
sg13
I2
sa(dp10731
g7
I134
sg20
VC0029134
p10732
sg10
I14
sg11
Voptic neuritis
p10733
sg13
I2
sasa(dp10734
g2
S'Understanding the regulation of myelination by oligodendrocytes is therefore critical for developing therapies for the treatment of MS. We previously demonstrated that leucine-rich repeat and Ig-like domain-containing Nogo receptor interacting protein 1 (LINGO-1) is a negative regulator of oligodendrocyte differentiation and that anti-LINGO-1 promotes remyelination in preclinical animal models for MS and in a phase II acute optic neuritis clinical trial (RENEW).\n'
p10735
sg4
(lp10736
(dp10737
g7
I255
sg8
g127
sg10
I7
sg11
VLINGO-1
p10738
sg13
I1
sa(dp10739
g7
I192
sg8
g127
sg10
I61
sg11
VIg-like domain-containing Nogo receptor interacting protein 1
p10740
sg13
I7
sa(dp10741
g7
I332
sg8
g127
sg10
I12
sg11
Vanti-LINGO-1
p10742
sg13
I1
sasg17
(lp10743
(dp10744
g7
I428
sg20
VC0029134
p10745
sg10
I14
sg11
Voptic neuritis
p10746
sg13
I2
sasa(dp10747
g2
S'An antibody against a Nogo receptor subunit, leucine rich repeat and immunoglobulin-like domain-containing protein 1 (LINGO-1), was recently shown to improve outcome in patients with acute optic neuritis in a phase II study.\n'
p10748
sg4
(lp10749
(dp10750
g7
I118
sg8
g127
sg10
I7
sg11
VLINGO-1
p10751
sg13
I1
sa(dp10752
g7
I22
sg8
VP30740
p10753
sg10
I42
sg11
VNogo receptor subunit, leucine rich repeat
p10754
sg13
I6
sa(dp10755
g7
I69
sg8
VP14222
p10756
sg10
I47
sg11
Vimmunoglobulin-like domain-containing protein 1
p10757
sg13
I4
sasg17
(lp10758
(dp10759
g7
I189
sg20
VC0029134
p10760
sg10
I14
sg11
Voptic neuritis
p10761
sg13
I2
sasa(dp10762
g2
S'Optic neuritis has been used in a series of recent pilot studies investigating the effects of erythropoietin, simvastatin, autologous mesenchymal stem cells, phenytoin, as well as blockade of LINGO-1 (opicinumab).\n'
p10763
sg4
(lp10764
(dp10765
g7
I192
sg8
g127
sg10
I7
sg11
VLINGO-1
p10766
sg13
I1
sa(dp10767
g7
I94
sg8
VP01588
p10768
sg10
I14
sg11
Verythropoietin
p10769
sg13
I1
sasg17
(lp10770
(dp10771
g7
I0
sg20
VC0029134
p10772
sg10
I14
sg11
VOptic neuritis
p10773
sg13
I2
sasa(dp10774
g2
S'In animal models, LINGO-1 expression is upregulated in rat spinal cord injury, experimental autoimmune encephalomyelitis, 6-hydroxydopamine neurotoxic lesions and glaucoma models.\n'
p10775
sg4
(lp10776
(dp10777
g7
I18
sg8
g127
sg10
I7
sg11
VLINGO-1
p10778
sg13
I1
sasg17
(lp10779
(dp10780
g7
I103
sg20
VC0014070
p10781
sg10
I17
sg11
Vencephalomyelitis
p10782
sg13
I1
sa(dp10783
g7
I163
sg20
VC0017601
p10784
sg10
I8
sg11
Vglaucoma
p10785
sg13
I1
sa(dp10786
g7
I66
sg20
VC0035334
p10787
sg10
I4
sg11
Vcord
p10788
sg13
I1
sa(dp10789
g7
I92
sg20
VC0443146
p10790
sg10
I10
sg11
Vautoimmune
p10791
sg13
I1
sasa(dp10792
g2
S'The antagonism of LINGO-1, a CNS-specific negative regulator of neuronal survival, was shown to promote short-term survival of retinal ganglion cell (RGC) in an ocular hypertension model.\n'
p10793
sg4
(lp10794
(dp10795
g7
I18
sg8
g127
sg10
I7
sg11
VLINGO-1
p10796
sg13
I1
sasg17
(lp10797
(dp10798
g7
I161
sg20
VC0028840
p10799
sg10
I19
sg11
Vocular hypertension
p10800
sg13
I2
sa(dp10801
g7
I135
sg20
VC1258666
p10802
sg10
I8
sg11
Vganglion
p10803
sg13
I1
sasa(dp10804
g2
S'To determine the relationship between LINGO-1 and BDNF/TrkB receptor in neuronal protection, we show here that LINGO-1 forms a receptor complex with TrkB and negatively regulates its activation in the retina after ocular hypertension injury.\n'
p10805
sg4
(lp10806
(dp10807
g7
I38
sg8
g127
sg10
I7
sg11
VLINGO-1
p10808
sg13
I1
sa(dp10809
g7
I55
sg8
g127
sg10
I13
sg11
VTrkB receptor
p10810
sg13
I2
sa(dp10811
g7
I38
sg8
g127
sg10
I7
sg11
VLINGO-1
p10812
sg13
I1
sa(dp10813
g7
I55
sg8
g127
sg10
I4
sg11
VTrkB
p10814
sg13
I1
sasg17
(lp10815
(dp10816
g7
I214
sg20
VC0028840
p10817
sg10
I19
sg11
Vocular hypertension
p10818
sg13
I2
sasa(dp10819
g2
S'LINGO-1 antagonism therefore promotes RGC survival by regulating the BDNF and TrkB signaling pathway after ocular hypertension.\n'
p10820
sg4
(lp10821
(dp10822
g7
I0
sg8
g127
sg10
I7
sg11
VLINGO-1
p10823
sg13
I1
sa(dp10824
g7
I78
sg8
g127
sg10
I4
sg11
VTrkB
p10825
sg13
I1
sasg17
(lp10826
(dp10827
g7
I107
sg20
VC0028840
p10828
sg10
I19
sg11
Vocular hypertension
p10829
sg13
I2
sasa(dp10830
g2
S'Fibulin-1 is an extracellular matrix (ECM) protein, levels of which are elevated in serum and lung tissue from patients with idiopathic pulmonary fibrosis compared to healthy volunteers.\n'
p10831
sg4
(lp10832
(dp10833
g7
I16
sg8
g127
sg10
I34
sg11
Vextracellular matrix (ECM) protein
p10834
sg13
I4
sasg17
(lp10835
(dp10836
g7
I125
sg20
VC3161101
p10837
sg10
I29
sg11
Vidiopathic pulmonary fibrosis
p10838
sg13
I3
sasa(dp10839
g2
S"Emerging evidence suggests that alpha-processing single transmembrane proteins, amyloid precursor protein (APP) and anti-aging protein Klotho, are likely to be involved in the progression of Alzheimer's disease (AD).\n"
p10840
sg4
(lp10841
(dp10842
g7
I107
sg8
g127
sg10
I3
sg11
VAPP
p10843
sg13
I1
sa(dp10844
g7
I80
sg8
VP17342
p10845
sg10
I25
sg11
Vamyloid precursor protein
p10846
sg13
I3
sasg17
(lp10847
(dp10848
g7
I212
sg20
VC1521724
p10849
sg10
I2
sg11
VAD
p10850
sg13
I1
sa(dp10851
g7
I80
sg20
VC0011560
p10852
sg10
I7
sg11
Vamyloid
p10853
sg13
I1
sa(dp10854
g7
I176
sg20
VC1735366
p10855
sg10
I34
sg11
Vprogression of Alzheimer's disease
p10856
sg13
I4
sasa(dp10857
g2
S"Amyloid-Beta (ABeta) peptides occur in the brains of patients with Alzheimer's disease (AD), but their role in functional impairment is still debated.\n"
p10858
sg4
(lp10859
(dp10860
g7
I0
sg8
g127
sg10
I12
sg11
VAmyloid-Beta
p10861
sg13
I1
sa(dp10862
g7
I14
sg8
g127
sg10
I5
sg11
VABeta
p10863
sg13
I1
sasg17
(lp10864
(dp10865
g7
I88
sg20
VC1521724
p10866
sg10
I2
sg11
VAD
p10867
sg13
I1
sa(dp10868
g7
I0
sg20
VC0011560
p10869
sg10
I7
sg11
VAmyloid
p10870
sg13
I1
sa(dp10871
g7
I67
sg20
VC1521724
p10872
sg10
I19
sg11
VAlzheimer's disease
p10873
sg13
I2
sa(dp10874
g7
I122
sg20
VC0684336
p10875
sg10
I10
sg11
Vimpairment
p10876
sg13
I1
sasa(dp10877
g2
S"Regulation of the amyloid precursor protein (APP) processing by Alfa- and Beta-secretases is of special interest to Alzheimer's disease (AD), as these proteases prevent or mediate amyloid beta formation, respectively.\n"
p10878
sg4
(lp10879
(dp10880
g7
I45
sg8
g127
sg10
I3
sg11
VAPP
p10881
sg13
I1
sa(dp10882
g7
I18
sg8
VP17342
p10883
sg10
I25
sg11
Vamyloid precursor protein
p10884
sg13
I3
sa(dp10885
g7
I74
sg8
VP56817
p10886
sg10
I15
sg11
VBeta-secretases
p10887
sg13
I1
sasg17
(lp10888
(dp10889
g7
I18
sg20
VC0011560
p10890
sg10
I7
sg11
Vamyloid
p10891
sg13
I1
sa(dp10892
g7
I116
sg20
VC1521724
p10893
sg10
I19
sg11
VAlzheimer's disease
p10894
sg13
I2
sa(dp10895
g7
I18
sg20
VC0011560
p10896
sg10
I7
sg11
Vamyloid
p10897
sg13
I1
sa(dp10898
g7
I137
sg20
VC1521724
p10899
sg10
I2
sg11
VAD
p10900
sg13
I1
sasa(dp10901
g2
S'By perusing publicly available data sets, four potential peptides of interest seem common to stress induction and/or are highly conserved; potential peptides from the MMP24-AS1, ZFAS1, RP11-622K12.1, and MIR22HG genes.\n'
p10902
sg4
(lp10903
(dp10904
g7
I185
sg8
g127
sg10
I13
sg11
VRP11-622K12.1
p10905
sg13
I1
sa(dp10906
g7
I204
sg8
VP01893
p10907
sg10
I13
sg11
VMIR22HG genes
p10908
sg13
I2
sa(dp10909
g7
I167
sg8
g127
sg10
I9
sg11
VMMP24-AS1
p10910
sg13
I1
sasg17
(lp10911
(dp10912
g7
I185
sg20
VC1838601
p10913
sg10
I4
sg11
VRP11
p10914
sg13
I1
sa(dp10915
g7
I173
sg20
VC1846534
p10916
sg10
I3
sg11
VAS1
p10917
sg13
I1
sasa(dp10918
g2
S'Here, we report focussed and comprehensive investigations of MYCC, MYCN and MYCL in an extensive medulloblastoma cohort (n = 292), aimed to define more precisely their biological significance and optimal clinical application to direct improved disease risk-stratification and individualisation of therapy.\n'
p10919
sg4
(lp10920
(dp10921
g7
I67
sg8
VP04198
p10922
sg10
I4
sg11
VMYCN
p10923
sg13
I1
sa(dp10924
g7
I76
sg8
VP12524
p10925
sg10
I4
sg11
VMYCL
p10926
sg13
I1
sasg17
(lp10927
(dp10928
g7
I97
sg20
VC0025149
p10929
sg10
I15
sg11
Vmedulloblastoma
p10930
sg13
I1
sasa(dp10931
g2
S'Amplifications in this series included MYCL, MYCN and MYC previously implicated in medulloblastoma pathogenesis, as well as novel amplicons on chromosomes 2, 4, 11 and 12.\n'
p10932
sg4
(lp10933
(dp10934
g7
I39
sg8
VP12524
p10935
sg10
I3
sg11
VMYC
p10936
sg13
I1
sa(dp10937
g7
I45
sg8
VP04198
p10938
sg10
I4
sg11
VMYCN
p10939
sg13
I1
sa(dp10940
g7
I39
sg8
VP12524
p10941
sg10
I4
sg11
VMYCL
p10942
sg13
I1
sasg17
(lp10943
(dp10944
g7
I99
sg20
VC0699748
p10945
sg10
I12
sg11
Vpathogenesis
p10946
sg13
I1
sa(dp10947
g7
I83
sg20
VC0025149
p10948
sg10
I15
sg11
Vmedulloblastoma
p10949
sg13
I1
sasa(dp10950
g2
S'Usher syndrome type III (USH3), characterized by progressive deafness, variable balance disorder and blindness, is caused by destabilizing mutations in the gene encoding the clarin-1 (CLRN1) protein.\n'
p10951
sg4
(lp10952
(dp10953
g7
I25
sg8
VP58418
p10954
sg10
I4
sg11
VUSH3
p10955
sg13
I1
sa(dp10956
g7
I184
sg8
VP58418
p10957
sg10
I5
sg11
VCLRN1
p10958
sg13
I1
sa(dp10959
g7
I174
sg8
VP58418
p10960
sg10
I8
sg11
Vclarin-1
p10961
sg13
I1
sasg17
(lp10962
(dp10963
g7
I25
sg20
VC1568248
p10964
sg10
I4
sg11
VUSH3
p10965
sg13
I1
sa(dp10966
g7
I61
sg20
VC0011053
p10967
sg10
I8
sg11
Vdeafness
p10968
sg13
I1
sa(dp10969
g7
I101
sg20
VC0456909
p10970
sg10
I9
sg11
Vblindness
p10971
sg13
I1
sa(dp10972
g7
I0
sg20
VC0271097
p10973
sg10
I14
sg11
VUsher syndrome
p10974
sg13
I2
sa(dp10975
g7
I80
sg20
VC0575090
p10976
sg10
I16
sg11
Vbalance disorder
p10977
sg13
I2
sasa(dp10978
g2
S'Usher syndrome type III (USH3A) is an autosomal recessive disorder caused by mutations in clarin-1 (CLRN1) gene, leading to progressive retinal degeneration and sensorineural deafness.\n'
p10979
sg4
(lp10980
(dp10981
g7
I25
sg8
VP58418
p10982
sg10
I5
sg11
VUSH3A
p10983
sg13
I1
sa(dp10984
g7
I90
sg8
VP58418
p10985
sg10
I8
sg11
Vclarin-1
p10986
sg13
I1
sa(dp10987
g7
I100
sg8
VP58418
p10988
sg10
I5
sg11
VCLRN1
p10989
sg13
I1
sasg17
(lp10990
(dp10991
g7
I25
sg20
VC1568248
p10992
sg10
I5
sg11
VUSH3A
p10993
sg13
I1
sa(dp10994
g7
I136
sg20
VC0035304
p10995
sg10
I20
sg11
Vretinal degeneration
p10996
sg13
I2
sa(dp10997
g7
I0
sg20
VC0271097
p10998
sg10
I14
sg11
VUsher syndrome
p10999
sg13
I2
sa(dp11000
g7
I161
sg20
VC0018784
p11001
sg10
I22
sg11
Vsensorineural deafness
p11002
sg13
I2
sasa(dp11003
g2
S'Mutations in CDH23, PCDH15, VLGR1 and clarin-1 cause Usher syndrome, characterized by congenital deafness, vestibular dysfunction and retinitis pigmentosa.\n'
p11004
sg4
(lp11005
(dp11006
g7
I28
sg8
g127
sg10
I5
sg11
VVLGR1
p11007
sg13
I1
sa(dp11008
g7
I13
sg8
g127
sg10
I5
sg11
VCDH23
p11009
sg13
I1
sa(dp11010
g7
I38
sg8
VP58418
p11011
sg10
I8
sg11
Vclarin-1
p11012
sg13
I1
sa(dp11013
g7
I20
sg8
g127
sg10
I6
sg11
VPCDH15
p11014
sg13
I1
sasg17
(lp11015
(dp11016
g7
I86
sg20
VC0339789
p11017
sg10
I19
sg11
Vcongenital deafness
p11018
sg13
I2
sa(dp11019
g7
I134
sg20
VC0035334
p11020
sg10
I20
sg11
Vretinitis pigmentosa
p11021
sg13
I2
sa(dp11022
g7
I53
sg20
VC0271097
p11023
sg10
I14
sg11
VUsher syndrome
p11024
sg13
I2
sasa(dp11025
g2
S'To describe the mutations in the CLRN1 gene in patients from 2 consanguineous Pakistani families diagnosed with autosomal recessive retinitis pigmentosa (arRP).\n'
p11026
sg4
(lp11027
(dp11028
g7
I33
sg8
VP58418
p11029
sg10
I10
sg11
VCLRN1 gene
p11030
sg13
I2
sasg17
(lp11031
(dp11032
g7
I154
sg20
VC0339526
p11033
sg10
I4
sg11
VarRP
p11034
sg13
I1
sa(dp11035
g7
I112
sg20
VC0339526
p11036
sg10
I40
sg11
Vautosomal recessive retinitis pigmentosa
p11037
sg13
I4
sasa(dp11038
g2
S'Mutations in the CLRN1 gene cause Usher syndrome type 3 (USH3), a human disease characterized by progressive blindness and deafness.\n'
p11039
sg4
(lp11040
(dp11041
g7
I57
sg8
VP58418
p11042
sg10
I4
sg11
VUSH3
p11043
sg13
I1
sa(dp11044
g7
I17
sg8
VP58418
p11045
sg10
I10
sg11
VCLRN1 gene
p11046
sg13
I2
sa(dp11047
g7
I34
sg8
VP58418
p11048
sg10
I21
sg11
VUsher syndrome type 3
p11049
sg13
I4
sasg17
(lp11050
(dp11051
g7
I109
sg20
VC0456909
p11052
sg10
I9
sg11
Vblindness
p11053
sg13
I1
sa(dp11054
g7
I34
sg20
VC1568248
p11055
sg10
I21
sg11
VUsher syndrome type 3
p11056
sg13
I4
sa(dp11057
g7
I57
sg20
VC1568248
p11058
sg10
I4
sg11
VUSH3
p11059
sg13
I1
sa(dp11060
g7
I123
sg20
VC0011053
p11061
sg10
I8
sg11
Vdeafness
p11062
sg13
I1
sasa(dp11063
g2
S'Clrn1 KO mice do not develop a retinal degeneration phenotype, but exhibit progressive loss of sensory hair cells in the cochlea and deterioration of the organ of Corti by 4 months.\n'
p11064
sg4
(lp11065
(dp11066
g7
I0
sg8
VP58418
p11067
sg10
I8
sg11
VClrn1 KO
p11068
sg13
I2
sasg17
(lp11069
(dp11070
g7
I31
sg20
VC0035304
p11071
sg10
I20
sg11
Vretinal degeneration
p11072
sg13
I2
sasa(dp11073
g2
S'If CLRN1 expression in humans is comparable to the expression pattern observed in mice, this is the first report of an inner retinal protein that, when mutated, causes retinal degeneration.\n'
p11074
sg4
(lp11075
(dp11076
g7
I3
sg8
VP58418
p11077
sg10
I5
sg11
VCLRN1
p11078
sg13
I1
sasg17
(lp11079
(dp11080
g7
I168
sg20
VC0035304
p11081
sg10
I20
sg11
Vretinal degeneration
p11082
sg13
I2
sasa(dp11083
g2
S'To compare ultrasound-derived resistive indices (RIs) obtained at the level of the thalamus via fast Doppler ultrasound with traditional anterior cerebral artery measures in a model of neonatal hypoxic-ischemic encephalopathy and to correlate each with clinical outcomes.\n'
p11084
sg4
(lp11085
sg17
(lp11086
(dp11087
g7
I194
sg20
VC0752304
p11088
sg10
I31
sg11
Vhypoxic-ischemic encephalopathy
p11089
sg13
I2
sasa(dp11090
g2
S'However, in the cases developing PMDs, the PIs were 1.09+/-0.17, 0.95+/-0.21 and 0.78+/-0.07 and RIs 0.66+/-0.07, 0.60+/-0.07 and 0.54+/-0.04, respectively (P&lt;0.05).\n'
p11091
sg4
(lp11092
sg17
(lp11093
(dp11094
g7
I33
sg20
VC1849930
p11095
sg10
I4
sg11
VPMDs
p11096
sg13
I1
sasa(dp11097
g2
S'Tonsillectomy, traditionally performed using reusable instruments (RIs), has recently been performed using disposable instruments (DIs), to prevent the theoretical risk of spreading new variant Creutzfeldt-Jakob disease.\n'
p11098
sg4
(lp11099
sg17
(lp11100
(dp11101
g7
I182
sg20
VC0376329
p11102
sg10
I37
sg11
Vnew variant Creutzfeldt-Jakob disease
p11103
sg13
I4
sasa(dp11104
g2
S'Ictal and interictal RIs were similar in 9 patients suffering from migraine without aura.\n'
p11105
sg4
(lp11106
sg17
(lp11107
(dp11108
g7
I52
sg20
VC0683278
p11109
sg10
I9
sg11
Vsuffering
p11110
sg13
I1
sa(dp11111
g7
I67
sg20
VC0338480
p11112
sg10
I21
sg11
Vmigraine without aura
p11113
sg13
I3
sasa(dp11114
g2
S'During nitroglycerin-induced headache, the RIs were no different from those recorded during migraine attacks and in non-nitroglycerin-provoked healthy controls (p &gt; 0.05, ANOVA and multiple range test).\n'
p11115
sg4
(lp11116
sg17
(lp11117
(dp11118
g7
I29
sg20
VC0018681
p11119
sg10
I8
sg11
Vheadache
p11120
sg13
I1
sa(dp11121
g7
I92
sg20
VC0149931
p11122
sg10
I8
sg11
Vmigraine
p11123
sg13
I1
sasa(dp11124
g2
S"Two independent epigenome-wide association studies of Alzheimer's disease cohorts have identified overlapping methylation signals in four loci, ANK1, RPL13, RHBDF2 and CDH23, not previously associated with Alzheimer's disease.\n"
p11125
sg4
(lp11126
(dp11127
g7
I144
sg8
VP16157
p11128
sg10
I4
sg11
VANK1
p11129
sg13
I1
sa(dp11130
g7
I150
sg8
VP26373
p11131
sg10
I5
sg11
VRPL13
p11132
sg13
I1
sa(dp11133
g7
I168
sg8
g127
sg10
I5
sg11
VCDH23
p11134
sg13
I1
sa(dp11135
g7
I157
sg8
g127
sg10
I6
sg11
VRHBDF2
p11136
sg13
I1
sasg17
(lp11137
(dp11138
g7
I54
sg20
VC1521724
p11139
sg10
I19
sg11
VAlzheimer's disease
p11140
sg13
I2
sa(dp11141
g7
I54
sg20
VC1521724
p11142
sg10
I19
sg11
VAlzheimer's disease
p11143
sg13
I2
sasa(dp11144
g2
S"In multivariate logistic regression model adjusting for age, gender, diabetes, systolic blood pressure and left ventricle mass index, epicardial fat thickness from LAX (and not from SAX) was the only independent predictor of e' [e' sep &lt; 8: OR = 1.8, 95%CI = 1.1-2.9; e' lat&lt;10: OR = 1.6, 95%CI = 1.01-2.6].\n"
p11145
sg4
(lp11146
sg17
(lp11147
(dp11148
g7
I69
sg20
VC0011849
p11149
sg10
I8
sg11
Vdiabetes
p11150
sg13
I1
sasa(dp11151
g2
S'This might reflect insufficient titration effort or lax adherence, but these issues could in some cases result from concerns about hypoglycaemia.\n'
p11152
sg4
(lp11153
sg17
(lp11154
(dp11155
g7
I131
sg20
VC0020615
p11156
sg10
I13
sg11
Vhypoglycaemia
p11157
sg13
I1
sasa(dp11158
g2
S'These obstacles begin with defining obesity and include lax application of scientific standards of review, tenuous assumption making, flawed measurement and other methods, constrained discourse limiting examination of alternative explanations of cause, and policies that determine funding priorities.\n'
p11159
sg4
(lp11160
(dp11161
g7
I56
sg8
g127
sg10
I3
sg11
Vlax
p11162
sg13
I1
sasg17
(lp11163
(dp11164
g7
I36
sg20
VC0028754
p11165
sg10
I7
sg11
Vobesity
p11166
sg13
I1
sasa(dp11167
g2
S'In this study, we investigated the influence of GRIM19 in a DSS induced colitis mouse model.\n'
p11168
sg4
(lp11169
(dp11170
g7
I48
sg8
g127
sg10
I6
sg11
VGRIM19
p11171
sg13
I1
sasg17
(lp11172
(dp11173
g7
I60
sg20
VC0011195
p11174
sg10
I3
sg11
VDSS
p11175
sg13
I1
sa(dp11176
g7
I72
sg20
VC0009319
p11177
sg10
I7
sg11
Vcolitis
p11178
sg13
I1
sasa(dp11179
g2
S'We hypothesized that Grim19 would ameliorate DSS induced colitis by altering STAT3 activity and intestinal inflammation.\n'
p11180
sg4
(lp11181
(dp11182
g7
I77
sg8
VP40763
p11183
sg10
I5
sg11
VSTAT3
p11184
sg13
I1
sa(dp11185
g7
I21
sg8
g127
sg10
I6
sg11
VGrim19
p11186
sg13
I1
sasg17
(lp11187
(dp11188
g7
I45
sg20
VC0011195
p11189
sg10
I3
sg11
VDSS
p11190
sg13
I1
sa(dp11191
g7
I107
sg20
VC0021368
p11192
sg10
I12
sg11
Vinflammation
p11193
sg13
I1
sa(dp11194
g7
I57
sg20
VC0009319
p11195
sg10
I7
sg11
Vcolitis
p11196
sg13
I1
sasa(dp11197
g2
S'Grim19 ameliorated DSS induced colitis severity and protected intestinal tissue.\n'
p11198
sg4
(lp11199
(dp11200
g7
I0
sg8
g127
sg10
I6
sg11
VGrim19
p11201
sg13
I1
sasg17
(lp11202
(dp11203
g7
I31
sg20
VC0009319
p11204
sg10
I7
sg11
Vcolitis
p11205
sg13
I1
sa(dp11206
g7
I19
sg20
VC0011195
p11207
sg10
I3
sg11
VDSS
p11208
sg13
I1
sasa(dp11209
g2
S'Moreover, DSS induced colitis progression in a Grim19 transgenic mouse line was inhibited in association with a reduction in STAT3 and IL-17 expression.\n'
p11210
sg4
(lp11211
(dp11212
g7
I47
sg8
g127
sg10
I6
sg11
VGrim19
p11213
sg13
I1
sa(dp11214
g7
I125
sg8
VP40763
p11215
sg10
I5
sg11
VSTAT3
p11216
sg13
I1
sasg17
(lp11217
(dp11218
g7
I22
sg20
VC0009319
p11219
sg10
I7
sg11
Vcolitis
p11220
sg13
I1
sa(dp11221
g7
I10
sg20
VC0011195
p11222
sg10
I3
sg11
VDSS
p11223
sg13
I1
sasa(dp11224
g2
S'These results suggest that Grim19 attenuates DSS induced colitis by suppressing the excessive inflammatory response mediated by STAT3 activation.\n'
p11225
sg4
(lp11226
(dp11227
g7
I45
sg8
VP51843
p11228
sg10
I3
sg11
VDSS
p11229
sg13
I1
sa(dp11230
g7
I128
sg8
VP40763
p11231
sg10
I5
sg11
VSTAT3
p11232
sg13
I1
sa(dp11233
g7
I27
sg8
g127
sg10
I6
sg11
VGrim19
p11234
sg13
I1
sasg17
(lp11235
(dp11236
g7
I45
sg20
VC0011195
p11237
sg10
I3
sg11
VDSS
p11238
sg13
I1
sa(dp11239
g7
I57
sg20
VC0009319
p11240
sg10
I7
sg11
Vcolitis
p11241
sg13
I1
sa(dp11242
g7
I94
sg20
VC1155266
p11243
sg10
I21
sg11
Vinflammatory response
p11244
sg13
I2
sasa(dp11245
g2
S'We found high levels of PSMA, TERT, and PDEF protein by Western blot and immunofluorescence in the malignant tumor of the prostate.\n'
p11246
sg4
(lp11247
(dp11248
g7
I40
sg8
g127
sg10
I12
sg11
VPDEF protein
p11249
sg13
I2
sa(dp11250
g7
I30
sg8
g127
sg10
I4
sg11
VTERT
p11251
sg13
I1
sasg17
(lp11252
(dp11253
g7
I99
sg20
VC0376358
p11254
sg10
I31
sg11
Vmalignant tumor of the prostate
p11255
sg13
I5
sasa(dp11256
g2
S'We also detected upregulation of PSMA, TERT, and PDEF mRNA in the malignant tumor of the prostate, suggesting complex regulation of these three genes in prostate cancer.\n'
p11257
sg4
(lp11258
(dp11259
g7
I49
sg8
g127
sg10
I9
sg11
VPDEF mRNA
p11260
sg13
I2
sa(dp11261
g7
I39
sg8
g127
sg10
I4
sg11
VTERT
p11262
sg13
I1
sasg17
(lp11263
(dp11264
g7
I66
sg20
VC0376358
p11265
sg10
I31
sg11
Vmalignant tumor of the prostate
p11266
sg13
I5
sa(dp11267
g7
I153
sg20
VC0376358
p11268
sg10
I15
sg11
Vprostate cancer
p11269
sg13
I2
sasa(dp11270
g2
S'Variance analysis showed statistically significant differences comparing the expression of PSMA, TERT, and PDEF in the malignant tumor of the prostate and normal tissues.\n'
p11271
sg4
(lp11272
(dp11273
g7
I97
sg8
g127
sg10
I4
sg11
VTERT
p11274
sg13
I1
sa(dp11275
g7
I107
sg8
g127
sg10
I4
sg11
VPDEF
p11276
sg13
I1
sasg17
(lp11277
(dp11278
g7
I119
sg20
VC0376358
p11279
sg10
I31
sg11
Vmalignant tumor of the prostate
p11280
sg13
I5
sasa(dp11281
g2
S'The high expression of PSMA, TERT, and PDEF in the malignant tumor of the prostate suggests the important roles of these three factors in the occurrence and development of the malignant tumors of the prostate.\n'
p11282
sg4
(lp11283
(dp11284
g7
I39
sg8
g127
sg10
I4
sg11
VPDEF
p11285
sg13
I1
sa(dp11286
g7
I29
sg8
g127
sg10
I4
sg11
VTERT
p11287
sg13
I1
sasg17
(lp11288
(dp11289
g7
I51
sg20
VC0376358
p11290
sg10
I31
sg11
Vmalignant tumor of the prostate
p11291
sg13
I5
sa(dp11292
g7
I176
sg20
VC0006826
p11293
sg10
I16
sg11
Vmalignant tumors
p11294
sg13
I2
sasa(dp11295
g2
S'PSMA, TERT, and PDEF may serve as a reference for clinical diagnosis and as potential targets for the malignant tumor of the prostate therapeutics.\n'
p11296
sg4
(lp11297
(dp11298
g7
I16
sg8
g127
sg10
I4
sg11
VPDEF
p11299
sg13
I1
sa(dp11300
g7
I6
sg8
g127
sg10
I4
sg11
VTERT
p11301
sg13
I1
sasg17
(lp11302
(dp11303
g7
I102
sg20
VC0376358
p11304
sg10
I31
sg11
Vmalignant tumor of the prostate
p11305
sg13
I5
sasa(dp11306
g2
S'In prostate cancer cell lines, AR signaling stimulated the activity of the transcription factor SPDEF, which repressed the expression of TGFBI ADT, AR antagonism, or overexpression of TGFBI inhibited the activity of SPDEF and enhanced the proliferation rates of prostate cancer cells.\n'
p11307
sg4
(lp11308
(dp11309
g7
I96
sg8
g127
sg10
I5
sg11
VSPDEF
p11310
sg13
I1
sa(dp11311
g7
I75
sg8
VP35398
p11312
sg10
I26
sg11
Vtranscription factor SPDEF
p11313
sg13
I3
sasg17
(lp11314
(dp11315
g7
I239
sg20
VC0334094
p11316
sg10
I13
sg11
Vproliferation
p11317
sg13
I1
sa(dp11318
g7
I3
sg20
VC0600139
p11319
sg10
I15
sg11
Vprostate cancer
p11320
sg13
I2
sa(dp11321
g7
I3
sg20
VC0600139
p11322
sg10
I15
sg11
Vprostate cancer
p11323
sg13
I2
sasa(dp11324
g2
S'These interesting attributes coupled with its aberrant expression in cancer have rendered PDEF a focus of increasing interest by tumor biologists.\n'
p11325
sg4
(lp11326
(dp11327
g7
I90
sg8
g127
sg10
I4
sg11
VPDEF
p11328
sg13
I1
sasg17
(lp11329
(dp11330
g7
I129
sg20
VC0027651
p11331
sg10
I5
sg11
Vtumor
p11332
sg13
I1
sa(dp11333
g7
I69
sg20
VC0006826
p11334
sg10
I6
sg11
Vcancer
p11335
sg13
I1
sasa(dp11336
g2
S'This review provides a current understanding of the characteristics of PDEF expression and its role in breast cancer.\n'
p11337
sg4
(lp11338
(dp11339
g7
I71
sg8
g127
sg10
I4
sg11
VPDEF
p11340
sg13
I1
sasg17
(lp11341
(dp11342
g7
I103
sg20
VC0678222
p11343
sg10
I13
sg11
Vbreast cancer
p11344
sg13
I2
sasa(dp11345
g2
S'The bulk of the evidence is consistent with PDEF overexpression in most breast tumors and an oncogenic role for this transcription factor in breast cancer.\n'
p11346
sg4
(lp11347
(dp11348
g7
I44
sg8
g127
sg10
I4
sg11
VPDEF
p11349
sg13
I1
sasg17
(lp11350
(dp11351
g7
I72
sg20
VC1458155
p11352
sg10
I13
sg11
Vbreast tumors
p11353
sg13
I2
sa(dp11354
g7
I141
sg20
VC0678222
p11355
sg10
I13
sg11
Vbreast cancer
p11356
sg13
I2
sasa(dp11357
g2
S'In addition, high PDEF expression in estrogen receptor-positive breast tumors showed significant correlation with poor overall survival in several independent cohorts of breast cancer patients.\n'
p11358
sg4
(lp11359
(dp11360
g7
I37
sg8
VP03372
p11361
sg10
I17
sg11
Vestrogen receptor
p11362
sg13
I2
sa(dp11363
g7
I18
sg8
g127
sg10
I4
sg11
VPDEF
p11364
sg13
I1
sasg17
(lp11365
(dp11366
g7
I170
sg20
VC0678222
p11367
sg10
I13
sg11
Vbreast cancer
p11368
sg13
I2
sa(dp11369
g7
I64
sg20
VC1458155
p11370
sg10
I13
sg11
Vbreast tumors
p11371
sg13
I2
sasa(dp11372
g2
S'Together, these findings demonstrate PDEF to be an oncogenic driver of breast cancer and a biomarker of poor prognosis in this cancer.\n'
p11373
sg4
(lp11374
(dp11375
g7
I37
sg8
g127
sg10
I4
sg11
VPDEF
p11376
sg13
I1
sasg17
(lp11377
(dp11378
g7
I78
sg20
VC0006826
p11379
sg10
I6
sg11
Vcancer
p11380
sg13
I1
sa(dp11381
g7
I71
sg20
VC0678222
p11382
sg10
I13
sg11
Vbreast cancer
p11383
sg13
I2
sasa(dp11384
g2
S'Based on this understanding and the limited expression of PDEF in normal human tissues, the development of PDEF-based therapeutics for prevention and treatment of breast cancer is also discussed.\n'
p11385
sg4
(lp11386
(dp11387
g7
I58
sg8
g127
sg10
I4
sg11
VPDEF
p11388
sg13
I1
sasg17
(lp11389
(dp11390
g7
I163
sg20
VC0678222
p11391
sg10
I13
sg11
Vbreast cancer
p11392
sg13
I2
sasa(dp11393
g2
S'We investigated these mechanisms and the effects of SPDEF on Beta-catenin activity in mouse models of colorectal cancer (CRC), CRC cell lines, and mouse and human normal and cancer colonoids.\n'
p11394
sg4
(lp11395
(dp11396
g7
I61
sg8
VP35222
p11397
sg10
I12
sg11
VBeta-catenin
p11398
sg13
I1
sa(dp11399
g7
I52
sg8
g127
sg10
I5
sg11
VSPDEF
p11400
sg13
I1
sasg17
(lp11401
(dp11402
g7
I113
sg20
VC0006826
p11403
sg10
I6
sg11
Vcancer
p11404
sg13
I1
sa(dp11405
g7
I121
sg20
VC1527249
p11406
sg10
I3
sg11
VCRC
p11407
sg13
I1
sa(dp11408
g7
I121
sg20
VC1527249
p11409
sg10
I3
sg11
VCRC
p11410
sg13
I1
sa(dp11411
g7
I102
sg20
VC1527249
p11412
sg10
I17
sg11
Vcolorectal cancer
p11413
sg13
I2
sasa(dp11414
g2
S'We generated SPDEF-inducible human colonoids, including a line derived from normal rectal mucosa (control) and an adenocarcinoma line derived from a patient with germline MUTYH mutation.\n'
p11415
sg4
(lp11416
(dp11417
g7
I13
sg8
g127
sg10
I5
sg11
VSPDEF
p11418
sg13
I1
sasg17
(lp11419
(dp11420
g7
I114
sg20
VC0001418
p11421
sg10
I14
sg11
Vadenocarcinoma
p11422
sg13
I1
sasa(dp11423
g2
S'FOXA3 and SPDEF induced MUC5AC and MUC5B, while HNF4A induced MUC3 in human mucinous lung cancer cells harboring a KRAS mutation.\n'
p11424
sg4
(lp11425
(dp11426
g7
I10
sg8
g127
sg10
I5
sg11
VSPDEF
p11427
sg13
I1
sa(dp11428
g7
I0
sg8
VP55318
p11429
sg10
I5
sg11
VFOXA3
p11430
sg13
I1
sa(dp11431
g7
I115
sg8
VP01116
p11432
sg10
I4
sg11
VKRAS
p11433
sg13
I1
sa(dp11434
g7
I62
sg8
g127
sg10
I4
sg11
VMUC3
p11435
sg13
I1
sasg17
(lp11436
(dp11437
g7
I85
sg20
VC0684249
p11438
sg10
I11
sg11
Vlung cancer
p11439
sg13
I2
sasa(dp11440
g2
S'We applied the MINDy (Modulator Inference by Network Dynamics) algorithm to four TFs (ESR1, FOXA1, GATA3 and SPDEF) that are key drivers of estrogen receptor-positive (ER+) breast cancer risk, as well as cancer progression.\n'
p11441
sg4
(lp11442
(dp11443
g7
I92
sg8
VP55317
p11444
sg10
I5
sg11
VFOXA1
p11445
sg13
I1
sa(dp11446
g7
I109
sg8
g127
sg10
I5
sg11
VSPDEF
p11447
sg13
I1
sa(dp11448
g7
I86
sg8
VP03372
p11449
sg10
I4
sg11
VESR1
p11450
sg13
I1
sa(dp11451
g7
I140
sg8
VP03372
p11452
sg10
I17
sg11
Vestrogen receptor
p11453
sg13
I2
sa(dp11454
g7
I99
sg8
VP23771
p11455
sg10
I5
sg11
VGATA3
p11456
sg13
I1
sasg17
(lp11457
(dp11458
g7
I204
sg20
VC0178874
p11459
sg10
I18
sg11
Vcancer progression
p11460
sg13
I2
sa(dp11461
g7
I173
sg20
VC0678222
p11462
sg10
I13
sg11
Vbreast cancer
p11463
sg13
I2
sasa(dp11464
g2
S'Microarray data analysis and immunostaining of patient tissue samples clearly showed decreased expression levels of DGAT1 and integrin Beta1 in patients who have nodular cirrhosis without fatty degeneration.\n'
p11465
sg4
(lp11466
(dp11467
g7
I116
sg8
g127
sg10
I5
sg11
VDGAT1
p11468
sg13
I1
sasg17
(lp11469
(dp11470
g7
I188
sg20
VC0152254
p11471
sg10
I18
sg11
Vfatty degeneration
p11472
sg13
I2
sa(dp11473
g7
I170
sg20
VC0023890
p11474
sg10
I9
sg11
Vcirrhosis
p11475
sg13
I1
sasa(dp11476
g2
S'Expression of integrin Beta1 is regulated by the mechanical stiffness of the ECM, and correlates with the invasion and metastasis events of HCC in patients with cirrhosis.\n'
p11477
sg4
(lp11478
sg17
(lp11479
(dp11480
g7
I161
sg20
VC0023890
p11481
sg10
I9
sg11
Vcirrhosis
p11482
sg13
I1
sa(dp11483
g7
I60
sg20
VC0427008
p11484
sg10
I9
sg11
Vstiffness
p11485
sg13
I1
sa(dp11486
g7
I140
sg20
VC2239176
p11487
sg10
I3
sg11
VHCC
p11488
sg13
I1
sa(dp11489
g7
I106
sg20
VC2699153
p11490
sg10
I8
sg11
Vinvasion
p11491
sg13
I1
sa(dp11492
g7
I119
sg20
VC0027627
p11493
sg10
I10
sg11
Vmetastasis
p11494
sg13
I1
sasa(dp11495
g2
S'To investigate the expression of integrin beta 1 in hepatic cirrhosis (HC) and hepatocellular carcinoma (HCC).\n'
p11496
sg4
(lp11497
sg17
(lp11498
(dp11499
g7
I52
sg20
VC0023890
p11500
sg10
I17
sg11
Vhepatic cirrhosis
p11501
sg13
I2
sa(dp11502
g7
I71
sg20
VC0023890
p11503
sg10
I2
sg11
VHC
p11504
sg13
I1
sa(dp11505
g7
I105
sg20
VC2239176
p11506
sg10
I3
sg11
VHCC
p11507
sg13
I1
sa(dp11508
g7
I79
sg20
VC2239176
p11509
sg10
I24
sg11
Vhepatocellular carcinoma
p11510
sg13
I2
sasa(dp11511
g2
S'Integrin beta 1 may play an important role in the development of hepatic fibrosis, hepatic cirrhosis and hepatocellular carcinoma.\n'
p11512
sg4
(lp11513
sg17
(lp11514
(dp11515
g7
I105
sg20
VC1512411
p11516
sg10
I24
sg11
Vhepatocellular carcinoma
p11517
sg13
I2
sa(dp11518
g7
I83
sg20
VC0023890
p11519
sg10
I17
sg11
Vhepatic cirrhosis
p11520
sg13
I2
sa(dp11521
g7
I65
sg20
VC0239946
p11522
sg10
I16
sg11
Vhepatic fibrosis
p11523
sg13
I2
sasa(dp11524
g2
S'CD29 was strongly expressed on the cell membrane of hepatocytes in 18/20 patients with cirrhosis, in 17/18 with alcoholic hepatitis without cirrhosis, in 5/9 of fatty liver and in all six with hepatitis C. CD45RA was present in 5/18 cases of alcoholic hepatitis and in 3/20 cases of cirrhosis on the hepatocytes plasma membrane, in none of the controls, and rarely on lymphocytes.\n'
p11525
sg4
(lp11526
sg17
(lp11527
(dp11528
g7
I112
sg20
VC0019187
p11529
sg10
I19
sg11
Valcoholic hepatitis
p11530
sg13
I2
sa(dp11531
g7
I161
sg20
VC0015695
p11532
sg10
I11
sg11
Vfatty liver
p11533
sg13
I2
sa(dp11534
g7
I87
sg20
VC0023890
p11535
sg10
I9
sg11
Vcirrhosis
p11536
sg13
I1
sa(dp11537
g7
I87
sg20
VC0023890
p11538
sg10
I9
sg11
Vcirrhosis
p11539
sg13
I1
sa(dp11540
g7
I87
sg20
VC0023890
p11541
sg10
I9
sg11
Vcirrhosis
p11542
sg13
I1
sa(dp11543
g7
I112
sg20
VC0019187
p11544
sg10
I19
sg11
Valcoholic hepatitis
p11545
sg13
I2
sa(dp11546
g7
I193
sg20
VC0019196
p11547
sg10
I11
sg11
Vhepatitis C
p11548
sg13
I2
sasa(dp11549
g2
S'This study described the distribution, pattern and intensity of cytokine TGFa, adhesion molecules CD 34 and CD 44 and integrins a2, a3, CD 29 (beta 1 chain) and CD 61 (beta 3 chain) in hepatocellular carcinoma (HCC), metastatic liver tumors and hepatic cirrhosis.\n'
p11550
sg4
(lp11551
sg17
(lp11552
(dp11553
g7
I185
sg20
VC2239176
p11554
sg10
I24
sg11
Vhepatocellular carcinoma
p11555
sg13
I2
sa(dp11556
g7
I211
sg20
VC2239176
p11557
sg10
I3
sg11
VHCC
p11558
sg13
I1
sa(dp11559
g7
I228
sg20
VC0023903
p11560
sg10
I12
sg11
Vliver tumors
p11561
sg13
I2
sa(dp11562
g7
I79
sg20
VC0001511
p11563
sg10
I8
sg11
Vadhesion
p11564
sg13
I1
sa(dp11565
g7
I245
sg20
VC0023890
p11566
sg10
I17
sg11
Vhepatic cirrhosis
p11567
sg13
I2
sasa(dp11568
g2
S'Peripheral blood lymphocytes from patients with alcoholic cirrhosis, alcohol-induced fatty liver, and healthy controls were analyzed for helper-inducer (CD4+CD29w+) and suppressor-inducer (CD4+CD45R+) T lymphocytes.\n'
p11569
sg4
(lp11570
sg17
(lp11571
(dp11572
g7
I48
sg20
VC0023891
p11573
sg10
I19
sg11
Valcoholic cirrhosis
p11574
sg13
I2
sa(dp11575
g7
I85
sg20
VC0015695
p11576
sg10
I11
sg11
Vfatty liver
p11577
sg13
I2
sasa(dp11578
g2
S'Within the CD4+ T-cell population a change in the relative proportion of two complementary lymphocyte subsets (CD4+CD29+ helper-inducer and CD4+CD45R+ suppressor-inducer T cells) was observed in patients with alcoholic cirrhosis: a higher percentage of CD4+CD29w+ helper-inducer T cells were circulating in their peripheral blood than in healthy controls (median, 33% versus 28%; p = 0.0036), whereas the CD4+CD45R+ suppressor-inducer T-cell subset did not differ (median, 21% versus 21%) between the two groups.\n'
p11579
sg4
(lp11580
(dp11581
g7
I140
sg8
VP01730
p11582
sg10
I10
sg11
VCD4+CD45R+
p11583
sg13
I1
sa(dp11584
g7
I11
sg8
VP01730
p11585
sg10
I4
sg11
VCD4+
p11586
sg13
I1
sa(dp11587
g7
I140
sg8
VP01730
p11588
sg10
I10
sg11
VCD4+CD45R+
p11589
sg13
I1
sasg17
(lp11590
(dp11591
g7
I209
sg20
VC0023891
p11592
sg10
I19
sg11
Valcoholic cirrhosis
p11593
sg13
I2
sasa(dp11594
g2
S'These findings show that SCF may play a pivotal role in the recruitment of mast cells in allergic rhinitis.\n'
p11595
sg4
(lp11596
(dp11597
g7
I25
sg8
VP21583
p11598
sg10
I3
sg11
VSCF
p11599
sg13
I1
sasg17
(lp11600
(dp11601
g7
I89
sg20
VC2607914
p11602
sg10
I17
sg11
Vallergic rhinitis
p11603
sg13
I2
sa(dp11604
g7
I60
sg20
VC0271510
p11605
sg10
I11
sg11
Vrecruitment
p11606
sg13
I1
sasa(dp11607
g2
S'Patients with XLF mutation exhibit microcephaly, lymphopenia, and growth retardation, and are immunodeficient and radiosensitive.\n'
p11608
sg4
(lp11609
sg17
(lp11610
(dp11611
g7
I94
sg20
VC0021051
p11612
sg10
I15
sg11
Vimmunodeficient
p11613
sg13
I1
sa(dp11614
g7
I49
sg20
VC0024312
p11615
sg10
I11
sg11
Vlymphopenia
p11616
sg13
I1
sa(dp11617
g7
I35
sg20
VC0025958
p11618
sg10
I12
sg11
Vmicrocephaly
p11619
sg13
I1
sa(dp11620
g7
I66
sg20
VC0151686
p11621
sg10
I18
sg11
Vgrowth retardation
p11622
sg13
I2
sasa(dp11623
g2
S'Here, we investigated the role of XRCC4-like factor (XLF), a core member of the non-homologous end joining (NHEJ) repair pathway, in chemoresistance in hepatocellular carcinoma (HCC).\n'
p11624
sg4
(lp11625
(dp11626
g7
I53
sg8
g127
sg10
I3
sg11
VXLF
p11627
sg13
I1
sa(dp11628
g7
I34
sg8
g127
sg10
I17
sg11
VXRCC4-like factor
p11629
sg13
I2
sasg17
(lp11630
(dp11631
g7
I178
sg20
VC2239176
p11632
sg10
I3
sg11
VHCC
p11633
sg13
I1
sa(dp11634
g7
I152
sg20
VC2239176
p11635
sg10
I24
sg11
Vhepatocellular carcinoma
p11636
sg13
I2
sasa(dp11637
g2
S'These results indicate that XLF facilitates DNA end-joining and therefore promotes NHEJ activity in cancer cells.\n'
p11638
sg4
(lp11639
(dp11640
g7
I28
sg8
g127
sg10
I3
sg11
VXLF
p11641
sg13
I1
sasg17
(lp11642
(dp11643
g7
I100
sg20
VC0006826
p11644
sg10
I6
sg11
Vcancer
p11645
sg13
I1
sasa(dp11646
g2
S'NHEJ1-patients develop severe progressive lymphocytopenia and premature aging of hematopoietic stem cells (HSCs) at a young age.\n'
p11647
sg4
(lp11648
(dp11649
g7
I0
sg8
g127
sg10
I5
sg11
VNHEJ1
p11650
sg13
I1
sasg17
(lp11651
(dp11652
g7
I62
sg20
VC0231341
p11653
sg10
I15
sg11
Vpremature aging
p11654
sg13
I2
sa(dp11655
g7
I42
sg20
VC0024312
p11656
sg10
I15
sg11
Vlymphocytopenia
p11657
sg13
I1
sasa(dp11658
g2
S'Here we show a patient with a homozygous-NHEJ1 mutation identified by whole exome-sequencing that developed severe pancytopenia and bone marrow aplasia correlating with the presence of short telomeres.\n'
p11659
sg4
(lp11660
(dp11661
g7
I41
sg8
g127
sg10
I5
sg11
VNHEJ1
p11662
sg13
I1
sasg17
(lp11663
(dp11664
g7
I132
sg20
VC0002874
p11665
sg10
I19
sg11
Vbone marrow aplasia
p11666
sg13
I3
sa(dp11667
g7
I115
sg20
VC0030312
p11668
sg10
I12
sg11
Vpancytopenia
p11669
sg13
I1
sasa(dp11670
g2
S'In this study, we have found that XLF is over-expressed in HPV(+) versus HPV(-) head and neck squamous cell carcinoma (HNSCC) and significantly down-regulated in the HNSCC cell lines expressing high level of mutant p53 protein versus those cell lines harboring wild-type TP53 gene with low p53 protein expression.\n'
p11671
sg4
(lp11672
(dp11673
g7
I208
sg8
VP42771
p11674
sg10
I18
sg11
Vmutant p53 protein
p11675
sg13
I3
sa(dp11676
g7
I261
sg8
g127
sg10
I19
sg11
Vwild-type TP53 gene
p11677
sg13
I3
sa(dp11678
g7
I215
sg8
VP42771
p11679
sg10
I11
sg11
Vp53 protein
p11680
sg13
I2
sa(dp11681
g7
I34
sg8
g127
sg10
I3
sg11
VXLF
p11682
sg13
I1
sasg17
(lp11683
(dp11684
g7
I119
sg20
VC1168401
p11685
sg10
I5
sg11
VHNSCC
p11686
sg13
I1
sa(dp11687
g7
I208
sg20
VC0596988
p11688
sg10
I6
sg11
Vmutant
p11689
sg13
I1
sa(dp11690
g7
I119
sg20
VC1168401
p11691
sg10
I5
sg11
VHNSCC
p11692
sg13
I1
sa(dp11693
g7
I80
sg20
VC1168401
p11694
sg10
I37
sg11
Vhead and neck squamous cell carcinoma
p11695
sg13
I6
sasa(dp11696
g2
S'As a result, the expression of XLF in these cancer cells is significantly suppressed.\n'
p11697
sg4
(lp11698
(dp11699
g7
I31
sg8
g127
sg10
I3
sg11
VXLF
p11700
sg13
I1
sasg17
(lp11701
(dp11702
g7
I44
sg20
VC0006826
p11703
sg10
I6
sg11
Vcancer
p11704
sg13
I1
sasa(dp11705
g2
S'Defects in DNA cross-link repair 1C (DCLRE1C), protein kinase DNA activated catalytic polypeptide (PRKDC), ligase 4 (LIG4), NHEJ1, and NBS1 involving the nonhomologous end-joining (NHEJ) DNA repair pathway result in radiation-sensitive severe combined immunodeficiency (SCID).\n'
p11706
sg4
(lp11707
(dp11708
g7
I117
sg8
VP49917
p11709
sg10
I4
sg11
VLIG4
p11710
sg13
I1
sa(dp11711
g7
I124
sg8
g127
sg10
I5
sg11
VNHEJ1
p11712
sg13
I1
sa(dp11713
g7
I107
sg8
VP49917
p11714
sg10
I8
sg11
Vligase 4
p11715
sg13
I2
sa(dp11716
g7
I135
sg8
g127
sg10
I4
sg11
VNBS1
p11717
sg13
I1
sa(dp11718
g7
I47
sg8
VP33981
p11719
sg10
I18
sg11
Vprotein kinase DNA
p11720
sg13
I3
sasg17
(lp11721
(dp11722
g7
I236
sg20
VC0085110
p11723
sg10
I32
sg11
Vsevere combined immunodeficiency
p11724
sg13
I3
sa(dp11725
g7
I270
sg20
VC0085110
p11726
sg10
I4
sg11
VSCID
p11727
sg13
I1
sasa(dp11728
g2
S'The FISH result of case 2 was 47,XX,+mar.ish r(10)(p11.2q11.2) (cep10+, RP11-232C13+, RP11-178A10+)[25]/46,XX[10].\n'
p11729
sg4
(lp11730
(dp11731
g7
I51
sg8
VP60903
p11732
sg10
I33
sg11
Vp11.2q11.2) (cep10+, RP11-232C13+
p11733
sg13
I3
sa(dp11734
g7
I86
sg8
g127
sg10
I12
sg11
VRP11-178A10+
p11735
sg13
I1
sasg17
(lp11736
(dp11737
g7
I41
sg20
VC0406582
p11738
sg10
I3
sg11
Vish
p11739
sg13
I1
sa(dp11740
g7
I72
sg20
VC1838601
p11741
sg10
I4
sg11
VRP11
p11742
sg13
I1
sa(dp11743
g7
I72
sg20
VC1838601
p11744
sg10
I4
sg11
VRP11
p11745
sg13
I1
sa(dp11746
g7
I36
sg20
VC0740302
p11747
sg10
I4
sg11
V+mar
p11748
sg13
I1
sasa(dp11749
g2
S'Interphase fluorescence in situ hybridization (FISH) analysis on uncultured amniocytes using a 2q11.1-specific probe RP11-468G5 (spectrum green) showed three green signals in 11 of 47 uncultured amniocytes, indicating 23.4% mosaicism for trisomy 2.\n'
p11750
sg4
(lp11751
sg17
(lp11752
(dp11753
g7
I224
sg20
VC0392053
p11754
sg10
I9
sg11
Vmosaicism
p11755
sg13
I1
sa(dp11756
g7
I117
sg20
VC1838601
p11757
sg10
I4
sg11
VRP11
p11758
sg13
I1
sa(dp11759
g7
I238
sg20
VC0795801
p11760
sg10
I9
sg11
Vtrisomy 2
p11761
sg13
I2
sasa(dp11762
g2
S'Taken together, our data show that BACE1 plays a critical role in retinal homeostasis and that the use of BACE inhibitors for AD should be viewed with extreme caution as they could lead to retinal pathology and exacerbate conditions such as age-related macular degeneration.\n'
p11763
sg4
(lp11764
(dp11765
g7
I35
sg8
VP56817
p11766
sg10
I5
sg11
VBACE1
p11767
sg13
I1
sasg17
(lp11768
(dp11769
g7
I241
sg20
VC0242383
p11770
sg10
I32
sg11
Vage-related macular degeneration
p11771
sg13
I3
sa(dp11772
g7
I197
sg20
VC0677042
p11773
sg10
I9
sg11
Vpathology
p11774
sg13
I1
sasa(dp11775
g2
S'To report a new phenotype with additional data on the oculo-dental syndrome of cone-rod dystrophy (CRD) and amelogenesis imperfecta (AI) caused by mutations on CNNM4, a metal transporter, with linkage at achromatopsia locus 2q11 (Jalili syndrome).\n'
p11776
sg4
(lp11777
(dp11778
g7
I160
sg8
g127
sg10
I5
sg11
VCNNM4
p11779
sg13
I1
sasg17
(lp11780
(dp11781
g7
I67
sg20
VC0039082
p11782
sg10
I8
sg11
Vsyndrome
p11783
sg13
I1
sa(dp11784
g7
I204
sg20
VC0152200
p11785
sg10
I13
sg11
Vachromatopsia
p11786
sg13
I1
sa(dp11787
g7
I99
sg20
VC0035334
p11788
sg10
I3
sg11
VCRD
p11789
sg13
I1
sa(dp11790
g7
I108
sg20
VC0002452
p11791
sg10
I23
sg11
Vamelogenesis imperfecta
p11792
sg13
I2
sa(dp11793
g7
I230
sg20
VC1857588
p11794
sg10
I15
sg11
VJalili syndrome
p11795
sg13
I2
sa(dp11796
g7
I133
sg20
VC0002452
p11797
sg10
I2
sg11
VAI
p11798
sg13
I1
sa(dp11799
g7
I79
sg20
VC0035334
p11800
sg10
I18
sg11
Vcone-rod dystrophy
p11801
sg13
I2
sasa(dp11802
g2
S'The combination of recessively inherited cone-rod dystrophy (CRD) and amelogenesis imperfecta (AI) was first reported by Jalili and Smith in 1988 in a family subsequently linked to a locus on chromosome 2q11, and it has since been reported in a second small family.\n'
p11803
sg4
(lp11804
sg17
(lp11805
(dp11806
g7
I41
sg20
VC0035334
p11807
sg10
I18
sg11
Vcone-rod dystrophy
p11808
sg13
I2
sa(dp11809
g7
I61
sg20
VC0035334
p11810
sg10
I3
sg11
VCRD
p11811
sg13
I1
sa(dp11812
g7
I95
sg20
VC0002452
p11813
sg10
I2
sg11
VAI
p11814
sg13
I1
sa(dp11815
g7
I70
sg20
VC0002452
p11816
sg10
I23
sg11
Vamelogenesis imperfecta
p11817
sg13
I2
sasa(dp11818
g2
S'In essential thrombocythemia (ET), JAK2 V617F mutation, splenomegaly, and mutations in SH2B3, SF3B1, U2AF1, TP53, IDH2, and EZH2 were found to be additional negative prognostic factors.\n'
p11819
sg4
(lp11820
(dp11821
g7
I101
sg8
g127
sg10
I5
sg11
VU2AF1
p11822
sg13
I1
sa(dp11823
g7
I87
sg8
g127
sg10
I5
sg11
VSH2B3
p11824
sg13
I1
sa(dp11825
g7
I114
sg8
VP48735
p11826
sg10
I4
sg11
VIDH2
p11827
sg13
I1
sa(dp11828
g7
I124
sg8
g127
sg10
I4
sg11
VEZH2
p11829
sg13
I1
sa(dp11830
g7
I35
sg8
g127
sg10
I10
sg11
VJAK2 V617F
p11831
sg13
I2
sa(dp11832
g7
I94
sg8
g127
sg10
I5
sg11
VSF3B1
p11833
sg13
I1
sasg17
(lp11834
(dp11835
g7
I30
sg20
VC0040028
p11836
sg10
I2
sg11
VET
p11837
sg13
I1
sa(dp11838
g7
I3
sg20
VC0040028
p11839
sg10
I25
sg11
Vessential thrombocythemia
p11840
sg13
I2
sasa(dp11841
g2
S'For essential thrombocythemia, reported risk factors for leukemic transformation include advanced age, extreme thrombocytosis, anemia, leukocytosis, and sequence variants/mutations involving TP53 and EZH2 (for expansion of gene symbols, see www.genenames.org); for polycythemia vera, advanced age, leukocytosis, abnormal karyotype, mutations involving SRSF2 and IDH2, and treatment with pipobroman, chlorambucil, or P32; and for PMF, increased blast percentage, thrombocytopenia, abnormal karyotype, triple-negative driver mutational status, and sequence variants/mutations involving SRSF2, RUNX1, CEBPA, and SH2B3.\n'
p11842
sg4
(lp11843
(dp11844
g7
I598
sg8
VP49715
p11845
sg10
I5
sg11
VCEBPA
p11846
sg13
I1
sa(dp11847
g7
I200
sg8
g127
sg10
I4
sg11
VEZH2
p11848
sg13
I1
sa(dp11849
g7
I362
sg8
VP48735
p11850
sg10
I4
sg11
VIDH2
p11851
sg13
I1
sa(dp11852
g7
I609
sg8
g127
sg10
I5
sg11
VSH2B3
p11853
sg13
I1
sasg17
(lp11854
(dp11855
g7
I265
sg20
VC0032463
p11856
sg10
I17
sg11
Vpolycythemia vera
p11857
sg13
I2
sa(dp11858
g7
I4
sg20
VC0040028
p11859
sg10
I25
sg11
Vessential thrombocythemia
p11860
sg13
I2
sa(dp11861
g7
I66
sg20
VC1510411
p11862
sg10
I14
sg11
Vtransformation
p11863
sg13
I1
sa(dp11864
g7
I135
sg20
VC0023518
p11865
sg10
I12
sg11
Vleukocytosis
p11866
sg13
I1
sa(dp11867
g7
I127
sg20
VC0002871
p11868
sg10
I6
sg11
Vanemia
p11869
sg13
I1
sa(dp11870
g7
I135
sg20
VC0023518
p11871
sg10
I12
sg11
Vleukocytosis
p11872
sg13
I1
sa(dp11873
g7
I111
sg20
VC0836924
p11874
sg10
I14
sg11
Vthrombocytosis
p11875
sg13
I1
sasa(dp11876
g2
S'AAH expression was examined in 50 surgically resected primary ICCs, 12 samples of normal liver, and 12 cases of primary sclerosing cholangitis (PSC).\n'
p11877
sg4
(lp11878
sg17
(lp11879
(dp11880
g7
I144
sg20
VC0566602
p11881
sg10
I3
sg11
VPSC
p11882
sg13
I1
sa(dp11883
g7
I112
sg20
VC0566602
p11884
sg10
I30
sg11
Vprimary sclerosing cholangitis
p11885
sg13
I3
sasa(dp11886
g2
S'However, what kind of role hepaCAM plays in colorectal cancer (CRC) remains unknown.\n'
p11887
sg4
(lp11888
(dp11889
g7
I27
sg8
g127
sg10
I7
sg11
VhepaCAM
p11890
sg13
I1
sasg17
(lp11891
(dp11892
g7
I44
sg20
VC1527249
p11893
sg10
I17
sg11
Vcolorectal cancer
p11894
sg13
I2
sa(dp11895
g7
I63
sg20
VC1527249
p11896
sg10
I3
sg11
VCRC
p11897
sg13
I1
sasa(dp11898
g2
S'Previously, we reported the identification of a novel immunoglobulin-like cell adhesion molecule hepaCAM that is frequently downregulated and inhibits cell growth in hepatocellular carcinoma.\n'
p11899
sg4
(lp11900
(dp11901
g7
I54
sg8
g127
sg10
I50
sg11
Vimmunoglobulin-like cell adhesion molecule hepaCAM
p11902
sg13
I5
sasg17
(lp11903
(dp11904
g7
I79
sg20
VC0001511
p11905
sg10
I8
sg11
Vadhesion
p11906
sg13
I1
sa(dp11907
g7
I166
sg20
VC1512411
p11908
sg10
I24
sg11
Vhepatocellular carcinoma
p11909
sg13
I2
sasa(dp11910
g2
S'The same protein was recently published under the name hepaCAM and was suggested to be associated with hepatocellular carcinoma.\n'
p11911
sg4
(lp11912
(dp11913
g7
I55
sg8
g127
sg10
I7
sg11
VhepaCAM
p11914
sg13
I1
sasg17
(lp11915
(dp11916
g7
I103
sg20
VC1512411
p11917
sg10
I24
sg11
Vhepatocellular carcinoma
p11918
sg13
I2
sasa(dp11919
g2
S'We investigated the expression of transforming growth factor-Beta1 (TGF-Beta1) and connective tissue growth factor (CTGF) in the liver tissue of infants with congenital biliary atresia and neonatal hepatitis, as well as the relationship between the expression of the two factors and liver fibrosis.\n'
p11920
sg4
(lp11921
(dp11922
g7
I83
sg8
VP29279
p11923
sg10
I31
sg11
Vconnective tissue growth factor
p11924
sg13
I4
sa(dp11925
g7
I34
sg8
VP01137
p11926
sg10
I32
sg11
Vtransforming growth factor-Beta1
p11927
sg13
I3
sa(dp11928
g7
I116
sg8
VP29279
p11929
sg10
I4
sg11
VCTGF
p11930
sg13
I1
sa(dp11931
g7
I68
sg8
VP01137
p11932
sg10
I9
sg11
VTGF-Beta1
p11933
sg13
I1
sasg17
(lp11934
(dp11935
g7
I283
sg20
VC0239946
p11936
sg10
I14
sg11
Vliver fibrosis
p11937
sg13
I2
sa(dp11938
g7
I189
sg20
VC0027613
p11939
sg10
I18
sg11
Vneonatal hepatitis
p11940
sg13
I2
sa(dp11941
g7
I158
sg20
VC0005411
p11942
sg10
I26
sg11
Vcongenital biliary atresia
p11943
sg13
I3
sasa(dp11944
g2
S'In the neonatal hepatitis patients, CTGF and TGF-Beta1 were mainly expressed in the hepatocytes, while they were expressed in both hepatocytes and biliary epithelial cells in the congenital biliary atresia patients, and in these patients the expression was significantly stronger than in the neonatal hepatitis patients (P &lt; 0.01).\n'
p11945
sg4
(lp11946
(dp11947
g7
I45
sg8
VP01137
p11948
sg10
I9
sg11
VTGF-Beta1
p11949
sg13
I1
sa(dp11950
g7
I36
sg8
VP29279
p11951
sg10
I4
sg11
VCTGF
p11952
sg13
I1
sasg17
(lp11953
(dp11954
g7
I7
sg20
VC0027613
p11955
sg10
I18
sg11
Vneonatal hepatitis
p11956
sg13
I2
sa(dp11957
g7
I7
sg20
VC0027613
p11958
sg10
I18
sg11
Vneonatal hepatitis
p11959
sg13
I2
sa(dp11960
g7
I179
sg20
VC0005411
p11961
sg10
I26
sg11
Vcongenital biliary atresia
p11962
sg13
I3
sasa(dp11963
g2
S'Early expression of CTGF and TGF-Beta1 in biliary epithelial cells may be involved in the pathogenesis of congenital biliary atresia.\n'
p11964
sg4
(lp11965
(dp11966
g7
I29
sg8
VP01137
p11967
sg10
I9
sg11
VTGF-Beta1
p11968
sg13
I1
sa(dp11969
g7
I20
sg8
VP29279
p11970
sg10
I4
sg11
VCTGF
p11971
sg13
I1
sasg17
(lp11972
(dp11973
g7
I90
sg20
VC0699748
p11974
sg10
I12
sg11
Vpathogenesis
p11975
sg13
I1
sa(dp11976
g7
I106
sg20
VC0005411
p11977
sg10
I26
sg11
Vcongenital biliary atresia
p11978
sg13
I3
sasa(dp11979
g2
S'Therefore, ESUBFs might be a preferred alternative to cure hyperuricemia and gout.\n'
p11980
sg4
(lp11981
sg17
(lp11982
(dp11983
g7
I77
sg20
VC0018099
p11984
sg10
I4
sg11
Vgout
p11985
sg13
I1
sa(dp11986
g7
I59
sg20
VC0740394
p11987
sg10
I13
sg11
Vhyperuricemia
p11988
sg13
I1
sasa(dp11989
g2
S'We have characterized an anti-NOR (nucleolar organizer region) serum (P419) from a patient with rheumatoid arthritis and show that it contains antibodies directed against the RNA polymerase I-specific transcription initiation factor UBF.\n'
p11990
sg4
(lp11991
(dp11992
g7
I175
sg8
VP24928
p11993
sg10
I61
sg11
VRNA polymerase I-specific transcription initiation factor UBF
p11994
sg13
I7
sasg17
(lp11995
(dp11996
g7
I96
sg20
VC0003873
p11997
sg10
I20
sg11
Vrheumatoid arthritis
p11998
sg13
I2
sasa(dp11999
g2
S'The aim of this study was to investigate the expression of multidrug resistance-associated protein 1 (MRP1) and to assess the possible associations with clinicopathological variables and patient outcome in primary ovarian carcinoma.\n'
p12000
sg4
(lp12001
(dp12002
g7
I102
sg8
VP08183
p12003
sg10
I4
sg11
VMRP1
p12004
sg13
I1
sa(dp12005
g7
I59
sg8
VP14222
p12006
sg10
I41
sg11
Vmultidrug resistance-associated protein 1
p12007
sg13
I4
sasg17
(lp12008
(dp12009
g7
I214
sg20
VC0029925
p12010
sg10
I17
sg11
Vovarian carcinoma
p12011
sg13
I2
sasa(dp12012
g2
S'The aim of the present study was to investigate the prognostic value of drug resistance-associated proteins P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1), canalicular multispecific organic anion transporter (c-MOAT/MRP2), and lung resistance protein (LRP) in ovarian carcinoma.\n'
p12013
sg4
(lp12014
(dp12015
g7
I131
sg8
VP14222
p12016
sg10
I41
sg11
Vmultidrug resistance-associated protein 1
p12017
sg13
I4
sa(dp12018
g7
I207
sg8
g127
sg10
I25
sg11
Vorganic anion transporter
p12019
sg13
I3
sa(dp12020
g7
I277
sg8
g127
sg10
I3
sg11
VLRP
p12021
sg13
I1
sa(dp12022
g7
I124
sg8
VP08183
p12023
sg10
I4
sg11
VP-gp
p12024
sg13
I1
sa(dp12025
g7
I241
sg8
g127
sg10
I4
sg11
VMRP2
p12026
sg13
I1
sa(dp12027
g7
I108
sg8
VP08183
p12028
sg10
I14
sg11
VP-glycoprotein
p12029
sg13
I1
sa(dp12030
g7
I252
sg8
g127
sg10
I23
sg11
Vlung resistance protein
p12031
sg13
I3
sa(dp12032
g7
I174
sg8
VP08183
p12033
sg10
I4
sg11
VMRP1
p12034
sg13
I1
sasg17
(lp12035
(dp12036
g7
I285
sg20
VC0029925
p12037
sg10
I17
sg11
Vovarian carcinoma
p12038
sg13
I2
sasa(dp12039
g2
S'Expression of P-gp, MRP1, MRP2, and LRP was determined by immunohistochemistry of frozen tissue sections of 115 ovarian carcinoma patients and related to clinicopathological factors, response to chemotherapy, and progression-free survival.\n'
p12040
sg4
(lp12041
(dp12042
g7
I20
sg8
VP08183
p12043
sg10
I4
sg11
VMRP1
p12044
sg13
I1
sa(dp12045
g7
I26
sg8
g127
sg10
I4
sg11
VMRP2
p12046
sg13
I1
sa(dp12047
g7
I14
sg8
g127
sg10
I4
sg11
VP-gp
p12048
sg13
I1
sa(dp12049
g7
I36
sg8
g127
sg10
I3
sg11
VLRP
p12050
sg13
I1
sasg17
(lp12051
(dp12052
g7
I112
sg20
VC0029925
p12053
sg10
I17
sg11
Vovarian carcinoma
p12054
sg13
I2
sasa(dp12055
g2
S'In conclusion, in ovarian carcinoma, MRP1 expression is associated with MRP2 and P-gp expression, whereas LRP expression is associated with favorable clinicopathological characteristics.\n'
p12056
sg4
(lp12057
(dp12058
g7
I37
sg8
VP08183
p12059
sg10
I4
sg11
VMRP1
p12060
sg13
I1
sa(dp12061
g7
I81
sg8
g127
sg10
I4
sg11
VP-gp
p12062
sg13
I1
sa(dp12063
g7
I106
sg8
g127
sg10
I3
sg11
VLRP
p12064
sg13
I1
sa(dp12065
g7
I72
sg8
g127
sg10
I4
sg11
VMRP2
p12066
sg13
I1
sasg17
(lp12067
(dp12068
g7
I18
sg20
VC0029925
p12069
sg10
I17
sg11
Vovarian carcinoma
p12070
sg13
I2
sasa(dp12071
g2
S'Assessment of P-gp, MRP1, MRP2, or LRP does not allow prediction of response to chemotherapy or survival in ovarian carcinoma.\n'
p12072
sg4
(lp12073
(dp12074
g7
I20
sg8
VP08183
p12075
sg10
I4
sg11
VMRP1
p12076
sg13
I1
sa(dp12077
g7
I26
sg8
g127
sg10
I4
sg11
VMRP2
p12078
sg13
I1
sa(dp12079
g7
I14
sg8
g127
sg10
I4
sg11
VP-gp
p12080
sg13
I1
sasg17
(lp12081
(dp12082
g7
I108
sg20
VC0029925
p12083
sg10
I17
sg11
Vovarian carcinoma
p12084
sg13
I2
sasa(dp12085
g2
S'PTPRN2 is not yet linked to a genetic syndrome, although its expression has been identified in the adult human brain, in certain tumors, and in association with type 1 diabetes mellitus.\n'
p12086
sg4
(lp12087
(dp12088
g7
I0
sg8
g127
sg10
I6
sg11
VPTPRN2
p12089
sg13
I1
sasg17
(lp12090
(dp12091
g7
I30
sg20
VC0567439
p12092
sg10
I16
sg11
Vgenetic syndrome
p12093
sg13
I2
sa(dp12094
g7
I129
sg20
VC0027651
p12095
sg10
I6
sg11
Vtumors
p12096
sg13
I1
sa(dp12097
g7
I161
sg20
VC0011854
p12098
sg10
I24
sg11
Vtype 1 diabetes mellitus
p12099
sg13
I4
sasa(dp12100
g2
S'IA-2 (also known as islet cell antigen ICA-512) and IA-2 beta (also known as phogrin, phosphatase homologue in granules of insulinoma) are major autoantigens in insulin-dependent diabetes mellitus (IDDM).\n'
p12101
sg4
(lp12102
(dp12103
g7
I39
sg8
g127
sg10
I7
sg11
VICA-512
p12104
sg13
I1
sa(dp12105
g7
I0
sg8
g127
sg10
I4
sg11
VIA-2
p12106
sg13
I1
sa(dp12107
g7
I123
sg8
VP01308
p12108
sg10
I7
sg11
Vinsulin
p12109
sg13
I1
sa(dp12110
g7
I77
sg8
g127
sg10
I7
sg11
Vphogrin
p12111
sg13
I1
sa(dp12112
g7
I52
sg8
g127
sg10
I9
sg11
VIA-2 beta
p12113
sg13
I2
sasg17
(lp12114
(dp12115
g7
I198
sg20
VC0011854
p12116
sg10
I4
sg11
VIDDM
p12117
sg13
I1
sa(dp12118
g7
I161
sg20
VC0011854
p12119
sg10
I35
sg11
Vinsulin-dependent diabetes mellitus
p12120
sg13
I3
sa(dp12121
g7
I123
sg20
VC0021670
p12122
sg10
I10
sg11
Vinsulinoma
p12123
sg13
I1
sasa(dp12124
g2
S'The aim of this work was to assess the maturation of the humoral immune response to the protein tyrosine phosphatase(PTP)-related proteins (IA-2 and IA-2beta) in preclinical type I diabetes (TID).\n'
p12125
sg4
(lp12126
(dp12127
g7
I140
sg8
g127
sg10
I4
sg11
VIA-2
p12128
sg13
I1
sa(dp12129
g7
I88
sg8
VP60484
p12130
sg10
I28
sg11
Vprotein tyrosine phosphatase
p12131
sg13
I3
sa(dp12132
g7
I117
sg8
g127
sg10
I3
sg11
VPTP
p12133
sg13
I1
sa(dp12134
g7
I149
sg8
g127
sg10
I8
sg11
VIA-2beta
p12135
sg13
I1
sasg17
(lp12136
(dp12137
g7
I174
sg20
VC0011854
p12138
sg10
I15
sg11
Vtype I diabetes
p12139
sg13
I3
sa(dp12140
g7
I117
sg20
VC0398648
p12141
sg10
I3
sg11
VPTP
p12142
sg13
I1
sa(dp12143
g7
I191
sg20
VC0011854
p12144
sg10
I3
sg11
VTID
p12145
sg13
I1
sasa(dp12146
g2
S'The RPTP-like proteins IA-2 and IA-2beta, major autoantigens in insulin-dependent diabetes mellitus, contain just a single enzymatically inactive PTP-like domain.\n'
p12147
sg4
(lp12148
(dp12149
g7
I64
sg8
VP01308
p12150
sg10
I7
sg11
Vinsulin
p12151
sg13
I1
sa(dp12152
g7
I4
sg8
g127
sg10
I18
sg11
VRPTP-like proteins
p12153
sg13
I2
sa(dp12154
g7
I23
sg8
g127
sg10
I4
sg11
VIA-2
p12155
sg13
I1
sa(dp12156
g7
I42
sg8
VP29372
p12157
sg10
I18
sg11
Vmajor autoantigens
p12158
sg13
I2
sa(dp12159
g7
I32
sg8
g127
sg10
I8
sg11
VIA-2beta
p12160
sg13
I1
sa(dp12161
g7
I146
sg8
g127
sg10
I15
sg11
VPTP-like domain
p12162
sg13
I2
sasg17
(lp12163
(dp12164
g7
I64
sg20
VC0011854
p12165
sg10
I35
sg11
Vinsulin-dependent diabetes mellitus
p12166
sg13
I3
sa(dp12167
g7
I5
sg20
VC0398648
p12168
sg10
I3
sg11
VPTP
p12169
sg13
I1
sasa(dp12170
g2
S'Genetic mutations associated with canine glaucoma include those affecting ADAMTS10, ADAMTS17, Myocilin, Nebulin, COL1A2, RAB22A, and SRBD1.\n'
p12171
sg4
(lp12172
(dp12173
g7
I84
sg8
g127
sg10
I8
sg11
VADAMTS17
p12174
sg13
I1
sa(dp12175
g7
I104
sg8
VP20929
p12176
sg10
I7
sg11
VNebulin
p12177
sg13
I1
sa(dp12178
g7
I94
sg8
g127
sg10
I8
sg11
VMyocilin
p12179
sg13
I1
sa(dp12180
g7
I74
sg8
g127
sg10
I8
sg11
VADAMTS10
p12181
sg13
I1
sa(dp12182
g7
I133
sg8
g127
sg10
I5
sg11
VSRBD1
p12183
sg13
I1
sa(dp12184
g7
I121
sg8
g127
sg10
I6
sg11
VRAB22A
p12185
sg13
I1
sasg17
(lp12186
(dp12187
g7
I41
sg20
VC0017601
p12188
sg10
I8
sg11
Vglaucoma
p12189
sg13
I1
sasa(dp12190
g2
S'Using exome-sequencing analysis, a possibly damaging, non-synonymous variant in the gene Nebulin (NEB) was found to segregate with PACG which alters a phylogenetically conserved Lysine residue.\n'
p12191
sg4
(lp12192
(dp12193
g7
I98
sg8
VP20929
p12194
sg10
I3
sg11
VNEB
p12195
sg13
I1
sa(dp12196
g7
I84
sg8
VP20929
p12197
sg10
I12
sg11
Vgene Nebulin
p12198
sg13
I2
sasg17
(lp12199
sa(dp12200
g2
S'99m Tc-MIP-1404 (Progenics Pharmaceuticals, Inc., New York, NY) is a novel, SPECT-compatible 99m Tc-labeled PSMA inhibitor for the detection of prostate cancer.\n'
p12201
sg4
(lp12202
(dp12203
g7
I4
sg8
g127
sg10
I11
sg11
VTc-MIP-1404
p12204
sg13
I1
sasg17
(lp12205
(dp12206
g7
I144
sg20
VC0600139
p12207
sg10
I15
sg11
Vprostate cancer
p12208
sg13
I2
sa(dp12209
g7
I7
sg20
VC1851100
p12210
sg10
I3
sg11
VMIP
p12211
sg13
I1
sasa(dp12212
g2
S'From April 2013 to April 2017, 99m Tc-MIP1404-scintigraphy was performed in 225 patients for workup of PSA biochemical relapse of prostate cancer.\n'
p12213
sg4
(lp12214
(dp12215
g7
I103
sg8
VP55786
p12216
sg10
I3
sg11
VPSA
p12217
sg13
I1
sasg17
(lp12218
(dp12219
g7
I103
sg20
VC1519176
p12220
sg10
I3
sg11
VPSA
p12221
sg13
I1
sa(dp12222
g7
I130
sg20
VC0600139
p12223
sg10
I15
sg11
Vprostate cancer
p12224
sg13
I2
sa(dp12225
g7
I119
sg20
VC0277556
p12226
sg10
I7
sg11
Vrelapse
p12227
sg13
I1
sasa(dp12228
g2
S'Mutations in PEX13 and other peroxin proteins are associated with Zellweger syndrome spectrum (ZSS) disorders, a subtype of peroxisome biogenesis disorder characterized by prominent neurological, hepatic, and renal abnormalities leading to neonatal death.\n'
p12229
sg4
(lp12230
(dp12231
g7
I13
sg8
g127
sg10
I5
sg11
VPEX13
p12232
sg13
I1
sa(dp12233
g7
I29
sg8
VP02649
p12234
sg10
I16
sg11
Vperoxin proteins
p12235
sg13
I2
sasg17
(lp12236
(dp12237
g7
I66
sg20
VC0043459
p12238
sg10
I18
sg11
VZellweger syndrome
p12239
sg13
I2
sa(dp12240
g7
I240
sg20
VC0410916
p12241
sg10
I14
sg11
Vneonatal death
p12242
sg13
I2
sasa(dp12243
g2
S'Similar effects were observed for both cultured embryonic fibroblasts and brain neurons from a PEX13-null mouse with a Zellweger-syndrome-like phenotype, and a less-pronounced effect was observed for fibroblasts from an infantile Refsum patient who was homozygous for a milder PEX1 mutation.\n'
p12244
sg4
(lp12245
(dp12246
g7
I95
sg8
g127
sg10
I5
sg11
VPEX13
p12247
sg13
I1
sa(dp12248
g7
I95
sg8
g127
sg10
I4
sg11
VPEX1
p12249
sg13
I1
sasg17
(lp12250
(dp12251
g7
I129
sg20
VC0039082
p12252
sg10
I8
sg11
Vsyndrome
p12253
sg13
I1
sasa(dp12254
g2
S'The mRNA levels of PGC-1Alfa and ERRGamma in the endometrial carcinoma tissues and hyperplasic endometrial tissues were significantly greater than those in the normal endometria.\n'
p12255
sg4
(lp12256
(dp12257
g7
I19
sg8
VP20142
p12258
sg10
I9
sg11
VPGC-1Alfa
p12259
sg13
I1
sasg17
(lp12260
(dp12261
g7
I49
sg20
VC0476089
p12262
sg10
I21
sg11
Vendometrial carcinoma
p12263
sg13
I2
sasa(dp12264
g2
S'The mRNA levels of PGC-1Alfa and ERRGamma in the endometrial carcinoma patients with type 2 diabetes were higher than those in patients without diabetes.\n'
p12265
sg4
(lp12266
(dp12267
g7
I19
sg8
VP20142
p12268
sg10
I9
sg11
VPGC-1Alfa
p12269
sg13
I1
sasg17
(lp12270
(dp12271
g7
I85
sg20
VC0011860
p12272
sg10
I15
sg11
Vtype 2 diabetes
p12273
sg13
I3
sa(dp12274
g7
I92
sg20
VC0011849
p12275
sg10
I8
sg11
Vdiabetes
p12276
sg13
I1
sa(dp12277
g7
I49
sg20
VC0476089
p12278
sg10
I21
sg11
Vendometrial carcinoma
p12279
sg13
I2
sasa(dp12280
g2
S'The mRNA levels of PGC-1Alfa and ERRGamma in the endometrial adenocarcinomas increased with clinical staging, depth of myometrial invasion, and increases in the number of metastatic lymph nodes.\n'
p12281
sg4
(lp12282
(dp12283
g7
I19
sg8
VP20142
p12284
sg10
I9
sg11
VPGC-1Alfa
p12285
sg13
I1
sasg17
(lp12286
(dp12287
g7
I130
sg20
VC2699153
p12288
sg10
I8
sg11
Vinvasion
p12289
sg13
I1
sa(dp12290
g7
I61
sg20
VC0001418
p12291
sg10
I15
sg11
Vadenocarcinomas
p12292
sg13
I1
sasa(dp12293
g2
S'The PGC-1Alfa mRNA level was positively correlated with ERRGamma in the endometrial carcinoma tissues.\n'
p12294
sg4
(lp12295
(dp12296
g7
I4
sg8
VP20142
p12297
sg10
I14
sg11
VPGC-1Alfa mRNA
p12298
sg13
I2
sasg17
(lp12299
(dp12300
g7
I72
sg20
VC0476089
p12301
sg10
I21
sg11
Vendometrial carcinoma
p12302
sg13
I2
sasa(dp12303
g2
S'The mRNA levels of PGC-1Alfa were positively correlated with the concentrations of pyruvate kinase and isocitrate dehydrogenase in the endometrial carcinoma tissues, and similar results were found for ERRGamma.\n'
p12304
sg4
(lp12305
(dp12306
g7
I83
sg8
VP30613
p12307
sg10
I15
sg11
Vpyruvate kinase
p12308
sg13
I2
sa(dp12309
g7
I19
sg8
VP20142
p12310
sg10
I9
sg11
VPGC-1Alfa
p12311
sg13
I1
sa(dp12312
g7
I103
sg8
VP48735
p12313
sg10
I24
sg11
Visocitrate dehydrogenase
p12314
sg13
I2
sasg17
(lp12315
(dp12316
g7
I135
sg20
VC0476089
p12317
sg10
I21
sg11
Vendometrial carcinoma
p12318
sg13
I2
sasa(dp12319
g2
S'Our results suggested that the upregulation of PGC-1Alfa and ERRGamma in endometrial cancer might be a requirement for cancer cell energy metabolism, which contributes to the development of endometrial cancer.\n'
p12320
sg4
(lp12321
(dp12322
g7
I47
sg8
VP20142
p12323
sg10
I9
sg11
VPGC-1Alfa
p12324
sg13
I1
sasg17
(lp12325
(dp12326
g7
I85
sg20
VC0006826
p12327
sg10
I6
sg11
Vcancer
p12328
sg13
I1
sa(dp12329
g7
I73
sg20
VC0476089
p12330
sg10
I18
sg11
Vendometrial cancer
p12331
sg13
I2
sa(dp12332
g7
I73
sg20
VC0476089
p12333
sg10
I18
sg11
Vendometrial cancer
p12334
sg13
I2
sasa(dp12335
g2
S'The objective of this study was to explore the effects and underlying mechanism of estrogen-related receptor Gamma (ERRGamma) on the proliferation of endometrial carcinoma cells.\n'
p12336
sg4
(lp12337
(dp12338
g7
I83
sg8
VP11474
p12339
sg10
I31
sg11
Vestrogen-related receptor Gamma
p12340
sg13
I3
sa(dp12341
g7
I116
sg8
VP11474
p12342
sg10
I8
sg11
VERRGamma
p12343
sg13
I1
sasg17
(lp12344
(dp12345
g7
I133
sg20
VC0334094
p12346
sg10
I13
sg11
Vproliferation
p12347
sg13
I1
sa(dp12348
g7
I150
sg20
VC0476089
p12349
sg10
I21
sg11
Vendometrial carcinoma
p12350
sg13
I2
sasa(dp12351
g2
S'Our data showed that ERRGamma mediated the effects of estrogen on the proliferation of endometrial cancer cells through the activation AKT and ERK1/2 signaling pathways, which indicated that ERRGamma plays a key role in endometrial cancer.\n'
p12352
sg4
(lp12353
(dp12354
g7
I135
sg8
g127
sg10
I3
sg11
VAKT
p12355
sg13
I1
sa(dp12356
g7
I143
sg8
VP27361
p12357
sg10
I6
sg11
VERK1/2
p12358
sg13
I1
sasg17
(lp12359
(dp12360
g7
I87
sg20
VC0476089
p12361
sg10
I18
sg11
Vendometrial cancer
p12362
sg13
I2
sa(dp12363
g7
I87
sg20
VC0476089
p12364
sg10
I18
sg11
Vendometrial cancer
p12365
sg13
I2
sa(dp12366
g7
I70
sg20
VC0334094
p12367
sg10
I13
sg11
Vproliferation
p12368
sg13
I1
sasa(dp12369
g2
S'We aimed to measure the expression of ERRGamma and determine its association with the ER-mediated pathway in human endometrial cancer.\n'
p12370
sg4
(lp12371
sg17
(lp12372
(dp12373
g7
I115
sg20
VC0476089
p12374
sg10
I18
sg11
Vendometrial cancer
p12375
sg13
I2
sasa(dp12376
g2
S'The association between ERRGamma and ERAlfa expressions was determined by immunohistochemical analysis in uterine endometrial cancer tissues.\n'
p12377
sg4
(lp12378
sg17
(lp12379
(dp12380
g7
I106
sg20
VC0476089
p12381
sg10
I26
sg11
Vuterine endometrial cancer
p12382
sg13
I3
sasa(dp12383
g2
S'The stable overexpression of ERRGamma regulated the in vitro cell growth in the ERAlfa-positive and ERAlfa-negative endometrial cancer cell lines.\n'
p12384
sg4
(lp12385
sg17
(lp12386
(dp12387
g7
I116
sg20
VC0476089
p12388
sg10
I18
sg11
Vendometrial cancer
p12389
sg13
I2
sasa(dp12390
g2
S'A selective ERRGamma agonist, DY131, inhibited the growth of the ERAlfa-positive endometrial cancer cells but promoted that of the ERAlfa-negative cancer cells.\n'
p12391
sg4
(lp12392
sg17
(lp12393
(dp12394
g7
I81
sg20
VC0476089
p12395
sg10
I18
sg11
Vendometrial cancer
p12396
sg13
I2
sa(dp12397
g7
I93
sg20
VC0006826
p12398
sg10
I6
sg11
Vcancer
p12399
sg13
I1
sasa(dp12400
g2
S'Furthermore, we found that ERRGamma is expressed in the nuclei of human uterine endometrial cancer tissues.\n'
p12401
sg4
(lp12402
sg17
(lp12403
(dp12404
g7
I72
sg20
VC0476089
p12405
sg10
I26
sg11
Vuterine endometrial cancer
p12406
sg13
I3
sasa(dp12407
g2
S'The uterine endometrial cancer tissues with ERRGamma-positive/ERAlfa-negative status may have a significantly poor prognosis.\n'
p12408
sg4
(lp12409
sg17
(lp12410
(dp12411
g7
I4
sg20
VC0476089
p12412
sg10
I26
sg11
Vuterine endometrial cancer
p12413
sg13
I3
sasa(dp12414
g2
S'The relationship between ERRGamma and ERAlfa status could be a predictive marker for the treatment of uterine endometrial cancer, which provides an impetus for the identification of ligands for nuclear orphan receptor ERRGamma.\n'
p12415
sg4
(lp12416
sg17
(lp12417
(dp12418
g7
I102
sg20
VC0476089
p12419
sg10
I26
sg11
Vuterine endometrial cancer
p12420
sg13
I3
sasa(dp12421
g2
S'The expression rate and relative level of ERRalpha mRNA in ERalpha-positive endometrial adenocarcinomas were lower than in normal endometriums (P= 0.049 and P= 0.023), whereas the relative level of ERRgamma mRNA in ERalpha-positive endometrial adenocarcinomas was higher than in normal endometriums (P= 0.014).\n'
p12422
sg4
(lp12423
(dp12424
g7
I42
sg8
VP11474
p12425
sg10
I13
sg11
VERRalpha mRNA
p12426
sg13
I2
sa(dp12427
g7
I59
sg8
VP03372
p12428
sg10
I7
sg11
VERalpha
p12429
sg13
I1
sa(dp12430
g7
I59
sg8
VP03372
p12431
sg10
I7
sg11
VERalpha
p12432
sg13
I1
sasg17
(lp12433
(dp12434
g7
I88
sg20
VC0001418
p12435
sg10
I15
sg11
Vadenocarcinomas
p12436
sg13
I1
sa(dp12437
g7
I88
sg20
VC0001418
p12438
sg10
I15
sg11
Vadenocarcinomas
p12439
sg13
I1
sasa(dp12440
g2
S'Results suggested that ERRalpha and ERRgamma might participate in the tumorigenesis of endometrial adenocarcinoma.\n'
p12441
sg4
(lp12442
(dp12443
g7
I23
sg8
VP11474
p12444
sg10
I8
sg11
VERRalpha
p12445
sg13
I1
sasg17
(lp12446
(dp12447
g7
I87
sg20
VC1153706
p12448
sg10
I26
sg11
Vendometrial adenocarcinoma
p12449
sg13
I2
sa(dp12450
g7
I70
sg20
VC0007621
p12451
sg10
I13
sg11
Vtumorigenesis
p12452
sg13
I1
sasa(dp12453
g2
S'ERRalpha and ERRgamma are promising to be new prognostic factors in endometrial adenocarcinoma.\n'
p12454
sg4
(lp12455
(dp12456
g7
I0
sg8
VP11474
p12457
sg10
I8
sg11
VERRalpha
p12458
sg13
I1
sasg17
(lp12459
(dp12460
g7
I68
sg20
VC1153706
p12461
sg10
I26
sg11
Vendometrial adenocarcinoma
p12462
sg13
I2
sasa(dp12463
g2
S'In ERalpha-positive endometrial carcinoma, the expression level of ERRgamma mRNA (0.93 +/- 0.24) was higher than normal endometrium (0.72 +/- 0.21; P = 0.023).\n'
p12464
sg4
(lp12465
(dp12466
g7
I3
sg8
VP03372
p12467
sg10
I7
sg11
VERalpha
p12468
sg13
I1
sasg17
(lp12469
(dp12470
g7
I20
sg20
VC0476089
p12471
sg10
I21
sg11
Vendometrial carcinoma
p12472
sg13
I2
sasa(dp12473
g2
S'ERRalpha may serve as a biomarker of poor prognosis and ERRgamma as a favorable biomarker in endometrial carcinoma.\n'
p12474
sg4
(lp12475
(dp12476
g7
I0
sg8
VP11474
p12477
sg10
I8
sg11
VERRalpha
p12478
sg13
I1
sasg17
(lp12479
(dp12480
g7
I93
sg20
VC0476089
p12481
sg10
I21
sg11
Vendometrial carcinoma
p12482
sg13
I2
sasa(dp12483
g2
S'In this study, we determined the expression levels of TRPM7 in pancreatic tissue microarrays and correlated these measurements in pancreatic adenocarcinoma with the clinicopathological features.\n'
p12484
sg4
(lp12485
(dp12486
g7
I54
sg8
g127
sg10
I5
sg11
VTRPM7
p12487
sg13
I1
sasg17
(lp12488
(dp12489
g7
I130
sg20
VC0281361
p12490
sg10
I25
sg11
Vpancreatic adenocarcinoma
p12491
sg13
I2
sasa(dp12492
g2
S'In the majority of pancreatic adenocarcinoma specimens examined, TRPM7 is expressed at either moderate-level or high-level.\n'
p12493
sg4
(lp12494
(dp12495
g7
I65
sg8
g127
sg10
I5
sg11
VTRPM7
p12496
sg13
I1
sasg17
(lp12497
(dp12498
g7
I19
sg20
VC0281361
p12499
sg10
I25
sg11
Vpancreatic adenocarcinoma
p12500
sg13
I2
sasa(dp12501
g2
S'Anti-TRPM7 immunoreactivity in pancreatic adenocarcinoma significantly correlates with the size and stages of tumors.\n'
p12502
sg4
(lp12503
(dp12504
g7
I0
sg8
g127
sg10
I10
sg11
VAnti-TRPM7
p12505
sg13
I1
sasg17
(lp12506
(dp12507
g7
I31
sg20
VC0281361
p12508
sg10
I25
sg11
Vpancreatic adenocarcinoma
p12509
sg13
I2
sa(dp12510
g7
I110
sg20
VC0027651
p12511
sg10
I6
sg11
Vtumors
p12512
sg13
I1
sasa(dp12513
g2
S'In human pancreatic adenocarcinoma cells in which TRPM7 is highly expressed, short hairpin RNA-mediated suppression of TRPM7 impairs cell invasion.\n'
p12514
sg4
(lp12515
(dp12516
g7
I50
sg8
g127
sg10
I5
sg11
VTRPM7
p12517
sg13
I1
sa(dp12518
g7
I50
sg8
g127
sg10
I5
sg11
VTRPM7
p12519
sg13
I1
sasg17
(lp12520
(dp12521
g7
I133
sg20
VC2699153
p12522
sg10
I13
sg11
Vcell invasion
p12523
sg13
I2
sa(dp12524
g7
I104
sg20
VC0221103
p12525
sg10
I11
sg11
Vsuppression
p12526
sg13
I1
sa(dp12527
g7
I9
sg20
VC0281361
p12528
sg10
I25
sg11
Vpancreatic adenocarcinoma
p12529
sg13
I2
sasa(dp12530
g2
S'TRPM7 is generally overexpressed in human pancreatic adenocarcinoma.\n'
p12531
sg4
(lp12532
(dp12533
g7
I0
sg8
g127
sg10
I5
sg11
VTRPM7
p12534
sg13
I1
sasg17
(lp12535
(dp12536
g7
I42
sg20
VC0281361
p12537
sg10
I25
sg11
Vpancreatic adenocarcinoma
p12538
sg13
I2
sasa(dp12539
g2
S'To assess the changes in phosphodiester (PDE)-levels, detected by 31P magnetic resonance spectroscopy (MRS), over 24-months to determine the potential of PDE as marker for muscle tissue changes in Duchenne Muscular Dystrophy (DMD) patients.\n'
p12540
sg4
(lp12541
sg17
(lp12542
(dp12543
g7
I41
sg20
VC1849508
p12544
sg10
I3
sg11
VPDE
p12545
sg13
I1
sa(dp12546
g7
I103
sg20
VC0025235
p12547
sg10
I3
sg11
VMRS
p12548
sg13
I1
sa(dp12549
g7
I41
sg20
VC1849508
p12550
sg10
I3
sg11
VPDE
p12551
sg13
I1
sa(dp12552
g7
I226
sg20
VC0013264
p12553
sg10
I3
sg11
VDMD
p12554
sg13
I1
sa(dp12555
g7
I197
sg20
VC0013264
p12556
sg10
I27
sg11
VDuchenne Muscular Dystrophy
p12557
sg13
I3
sa(dp12558
g7
I70
sg20
VC0025235
p12559
sg10
I31
sg11
Vmagnetic resonance spectroscopy
p12560
sg13
I3
sa(dp12561
g7
I25
sg20
VC1849508
p12562
sg10
I14
sg11
Vphosphodiester
p12563
sg13
I1
sasa(dp12564
g2
S'The stable two-fold increase in PDE-levels found in DMD patients in muscles with different levels of muscle wasting over 2-year time, including DMD patients as young as 5.5 years-old, suggests that PDE-levels may increase very rapidly early in the disease process and remain elevated thereafter.\n'
p12565
sg4
(lp12566
(dp12567
g7
I32
sg8
VP49419
p12568
sg10
I3
sg11
VPDE
p12569
sg13
I1
sasg17
(lp12570
(dp12571
g7
I32
sg20
VC1849508
p12572
sg10
I3
sg11
VPDE
p12573
sg13
I1
sa(dp12574
g7
I101
sg20
VC0026846
p12575
sg10
I14
sg11
Vmuscle wasting
p12576
sg13
I2
sa(dp12577
g7
I52
sg20
VC0013264
p12578
sg10
I3
sg11
VDMD
p12579
sg13
I1
sa(dp12580
g7
I32
sg20
VC1849508
p12581
sg10
I3
sg11
VPDE
p12582
sg13
I1
sa(dp12583
g7
I52
sg20
VC0013264
p12584
sg10
I3
sg11
VDMD
p12585
sg13
I1
sasa(dp12586
g2
S'The identification of compounds, especially PDE inhibitors, that moderate the muscle phenotype in these dystrophin-null zebrafish validates the screening protocol described here and may lead to candidate molecules to be used as therapeutic interventions in human muscular dystrophy.\n'
p12587
sg4
(lp12588
(dp12589
g7
I44
sg8
VP49419
p12590
sg10
I3
sg11
VPDE
p12591
sg13
I1
sa(dp12592
g7
I104
sg8
VP11532
p12593
sg10
I10
sg11
Vdystrophin
p12594
sg13
I1
sasg17
(lp12595
(dp12596
g7
I44
sg20
VC1849508
p12597
sg10
I3
sg11
VPDE
p12598
sg13
I1
sa(dp12599
g7
I263
sg20
VC0026850
p12600
sg10
I18
sg11
Vmuscular dystrophy
p12601
sg13
I2
sasa(dp12602
g2
S"Total PDE activity was found to be elevated in tissue extracts from a mouse model of Duchenne's muscular dystrophy.\n"
p12603
sg4
(lp12604
(dp12605
g7
I6
sg8
VP49419
p12606
sg10
I3
sg11
VPDE
p12607
sg13
I1
sasg17
(lp12608
(dp12609
g7
I85
sg20
VC0013264
p12610
sg10
I29
sg11
VDuchenne's muscular dystrophy
p12611
sg13
I3
sa(dp12612
g7
I6
sg20
VC1849508
p12613
sg10
I3
sg11
VPDE
p12614
sg13
I1
sasa(dp12615
g2
S'Compared with the controls, there were increases in the levels of PDE (+22%, P = 0.032) and Pi (+19%, P = 0.019) in the spectra of fibromyalgia patients, but there was no difference in pH.\n'
p12616
sg4
(lp12617
(dp12618
g7
I66
sg8
VP49419
p12619
sg10
I3
sg11
VPDE
p12620
sg13
I1
sasg17
(lp12621
(dp12622
g7
I66
sg20
VC1849508
p12623
sg10
I3
sg11
VPDE
p12624
sg13
I1
sa(dp12625
g7
I131
sg20
VC0016053
p12626
sg10
I12
sg11
Vfibromyalgia
p12627
sg13
I1
sasa(dp12628
g2
S'We examined potential association of the single nucleotide polymorphisms (SNPs) of the HA synthesizing gene - hyaluronan synthase 2 (HAS2), hyaluronan binding protein 1 (HABP1) and HA catabolic gene hyaluronidase 3 (HYAL3) in the primary open angle glaucoma (POAG) patients in the Indian population.\n'
p12629
sg4
(lp12630
(dp12631
g7
I170
sg8
g127
sg10
I5
sg11
VHABP1
p12632
sg13
I1
sa(dp12633
g7
I181
sg8
g127
sg10
I33
sg11
VHA catabolic gene hyaluronidase 3
p12634
sg13
I5
sa(dp12635
g7
I87
sg8
g127
sg10
I81
sg11
VHA synthesizing gene - hyaluronan synthase 2 (HAS2), hyaluronan binding protein 1
p12636
sg13
I12
sa(dp12637
g7
I216
sg8
VP38567
p12638
sg10
I5
sg11
VHYAL3
p12639
sg13
I1
sasg17
(lp12640
(dp12641
g7
I230
sg20
VC0339573
p12642
sg10
I27
sg11
Vprimary open angle glaucoma
p12643
sg13
I4
sa(dp12644
g7
I259
sg20
VC0339573
p12645
sg10
I4
sg11
VPOAG
p12646
sg13
I1
sasa(dp12647
g2
S'Thirteen tagged SNPs (6 for HAS2, 3 for HABP1 and 4 for HYAL3) were genotyped in 116 high tension (HTG), 321 non-high tension glaucoma (NHTG) samples and 96 unrelated, age-matched, glaucoma-negative, control samples.\n'
p12648
sg4
(lp12649
(dp12650
g7
I56
sg8
VP38567
p12651
sg10
I5
sg11
VHYAL3
p12652
sg13
I1
sa(dp12653
g7
I40
sg8
g127
sg10
I11
sg11
VHABP1 and 4
p12654
sg13
I3
sasg17
(lp12655
(dp12656
g7
I90
sg20
VC0233494
p12657
sg10
I7
sg11
Vtension
p12658
sg13
I1
sa(dp12659
g7
I126
sg20
VC0017601
p12660
sg10
I8
sg11
Vglaucoma
p12661
sg13
I1
sa(dp12662
g7
I90
sg20
VC0233494
p12663
sg10
I7
sg11
Vtension
p12664
sg13
I1
sa(dp12665
g7
I126
sg20
VC0017601
p12666
sg10
I8
sg11
Vglaucoma
p12667
sg13
I1
sasa(dp12668
g2
S'We demonstrate its use in identifying ARTN as a strong candidate gene within the 1p34.1-p32 mapped locus for a hereditary form of ptosis.\n'
p12669
sg4
(lp12670
(dp12671
g7
I38
sg8
g127
sg10
I4
sg11
VARTN
p12672
sg13
I1
sa(dp12673
g7
I88
sg8
VP01732
p12674
sg10
I3
sg11
Vp32
p12675
sg13
I1
sasg17
(lp12676
(dp12677
g7
I130
sg20
VC0005745
p12678
sg10
I6
sg11
Vptosis
p12679
sg13
I1
sasa(dp12680
g2
S'It occurs in a number of forms including congenital bilateral isolated ptosis, which may be familial and for which two linkage groups are known on chromosomes 1p32-34.1 and Xq24-27.1.\n'
p12681
sg4
(lp12682
sg17
(lp12683
(dp12684
g7
I71
sg20
VC0005745
p12685
sg10
I6
sg11
Vptosis
p12686
sg13
I1
sasa(dp12687
g2
S'T cells expressing a CAR incorporating the single-chain variable fragment sequence of the ALK48 mAb linked to a 4-1BB-CD3Zeta signaling domain lysed ALK-expressing tumor lines and produced interferon-gamma upon antigen stimulation but had limited anti-tumor efficacy in two xenograft models of human neuroblastoma.\n'
p12688
sg4
(lp12689
(dp12690
g7
I90
sg8
g127
sg10
I3
sg11
VALK
p12691
sg13
I1
sa(dp12692
g7
I189
sg8
VP01579
p12693
sg10
I16
sg11
Vinterferon-gamma
p12694
sg13
I1
sa(dp12695
g7
I112
sg8
g127
sg10
I5
sg11
V4-1BB
p12696
sg13
I1
sasg17
(lp12697
(dp12698
g7
I164
sg20
VC0027651
p12699
sg10
I5
sg11
Vtumor
p12700
sg13
I1
sa(dp12701
g7
I300
sg20
VC0027819
p12702
sg10
I13
sg11
Vneuroblastoma
p12703
sg13
I1
sa(dp12704
g7
I21
sg20
VC2607929
p12705
sg10
I3
sg11
VCAR
p12706
sg13
I1
sa(dp12707
g7
I143
sg20
VC0024348
p12708
sg10
I5
sg11
Vlysed
p12709
sg13
I1
sa(dp12710
g7
I164
sg20
VC0027651
p12711
sg10
I5
sg11
Vtumor
p12712
sg13
I1
sasa(dp12713
g2
S'T cells engineered to express a third-generation GD2-CAR incorporating the 14g2a-scFv with the CD28, OX40, and CD3Zeta signaling domains (14g2a.CD28.OX40.Zeta) mediated efficient and comparable lysis of both GD2+ sarcoma and neuroblastoma cell lines in vitro However, in xenograft models, GD2-CAR T cells had no antitumor effect against GD2+ sarcoma, despite effectively controlling GD2+ neuroblastoma.\n'
p12714
sg4
(lp12715
(dp12716
g7
I95
sg8
VP33681
p12717
sg10
I4
sg11
VCD28
p12718
sg13
I1
sa(dp12719
g7
I95
sg8
VP33681
p12720
sg10
I4
sg11
VCD28
p12721
sg13
I1
sa(dp12722
g7
I101
sg8
VP43489
p12723
sg10
I4
sg11
VOX40
p12724
sg13
I1
sa(dp12725
g7
I149
sg8
VP43489
p12726
sg10
I9
sg11
VOX40.Zeta
p12727
sg13
I1
sasg17
(lp12728
(dp12729
g7
I53
sg20
VC2607929
p12730
sg10
I3
sg11
VCAR
p12731
sg13
I1
sa(dp12732
g7
I225
sg20
VC0027819
p12733
sg10
I13
sg11
Vneuroblastoma
p12734
sg13
I1
sa(dp12735
g7
I213
sg20
VC1261473
p12736
sg10
I7
sg11
Vsarcoma
p12737
sg13
I1
sa(dp12738
g7
I53
sg20
VC2607929
p12739
sg10
I3
sg11
VCAR
p12740
sg13
I1
sa(dp12741
g7
I225
sg20
VC0027819
p12742
sg10
I13
sg11
Vneuroblastoma
p12743
sg13
I1
sa(dp12744
g7
I194
sg20
VC0024348
p12745
sg10
I5
sg11
Vlysis
p12746
sg13
I1
sa(dp12747
g7
I213
sg20
VC1261473
p12748
sg10
I7
sg11
Vsarcoma
p12749
sg13
I1
sasa(dp12750
g2
S'Many studies have reported a significant association of CDKN2B-AS, also known as ANRIL which is located within the p15, p16, p14 gene cluster at 9p21 locus, with cardiovascular diseases as well as many other diseases like diabetes and cancers.\n'
p12751
sg4
(lp12752
(dp12753
g7
I120
sg8
VP42771
p12754
sg10
I3
sg11
Vp16
p12755
sg13
I1
sa(dp12756
g7
I56
sg8
VP42772
p12757
sg10
I6
sg11
VCDKN2B
p12758
sg13
I1
sa(dp12759
g7
I115
sg8
VP53999
p12760
sg10
I3
sg11
Vp15
p12761
sg13
I1
sa(dp12762
g7
I125
sg8
VP03971
p12763
sg10
I16
sg11
Vp14 gene cluster
p12764
sg13
I3
sasg17
(lp12765
(dp12766
g7
I162
sg20
VC0007222
p12767
sg10
I23
sg11
Vcardiovascular diseases
p12768
sg13
I2
sa(dp12769
g7
I235
sg20
VC0006826
p12770
sg10
I7
sg11
Vcancers
p12771
sg13
I1
sa(dp12772
g7
I222
sg20
VC0011849
p12773
sg10
I8
sg11
Vdiabetes
p12774
sg13
I1
sasa(dp12775
g2
S'We report a patient case with uncontrolled porphyria cutanea tarda treated with chemoradiation for p16-positive oropharyngeal cancer.\n'
p12776
sg4
(lp12777
(dp12778
g7
I99
sg8
VP42771
p12779
sg10
I3
sg11
Vp16
p12780
sg13
I1
sasg17
(lp12781
(dp12782
g7
I43
sg20
VC0162566
p12783
sg10
I23
sg11
Vporphyria cutanea tarda
p12784
sg13
I3
sa(dp12785
g7
I112
sg20
VC0153382
p12786
sg10
I20
sg11
Voropharyngeal cancer
p12787
sg13
I2
sasa(dp12788
g2
S'Antisense noncoding RNA in the INK4 locus (ANRIL), which was coded on the Chr9p21.3 loci, participates in the pathogenesis of tumor, coronary artery disease, type 2 diabetes mellitus, and other diseases.\n'
p12789
sg4
(lp12790
(dp12791
g7
I31
sg8
VP42771
p12792
sg10
I10
sg11
VINK4 locus
p12793
sg13
I2
sasg17
(lp12794
(dp12795
g7
I133
sg20
VC1956346
p12796
sg10
I23
sg11
Vcoronary artery disease
p12797
sg13
I3
sa(dp12798
g7
I126
sg20
VC0027651
p12799
sg10
I5
sg11
Vtumor
p12800
sg13
I1
sa(dp12801
g7
I158
sg20
VC0011860
p12802
sg10
I24
sg11
Vtype 2 diabetes mellitus
p12803
sg13
I4
sa(dp12804
g7
I110
sg20
VC0699748
p12805
sg10
I12
sg11
Vpathogenesis
p12806
sg13
I1
sasa(dp12807
g2
S'ADNP de novo mutations in humans result in a syndromic form of autism-like spectrum disorder (ASD), including cognitive and motor deficits, the ADNP syndrome (Helsmoortel-Van Der Aa).\n'
p12808
sg4
(lp12809
(dp12810
g7
I0
sg8
g127
sg10
I4
sg11
VADNP
p12811
sg13
I1
sasg17
(lp12812
(dp12813
g7
I94
sg20
VC1510586
p12814
sg10
I3
sg11
VASD
p12815
sg13
I1
sa(dp12816
g7
I149
sg20
VC0039082
p12817
sg10
I8
sg11
Vsyndrome
p12818
sg13
I1
sa(dp12819
g7
I63
sg20
VC1510586
p12820
sg10
I29
sg11
Vautism-like spectrum disorder
p12821
sg13
I3
sasa(dp12822
g2
S'One of the most important cellular processes associated with ADNP is the autophagy pathway, recently discovered by us as a key player in the pathophysiology of schizophrenia.\n'
p12823
sg4
(lp12824
(dp12825
g7
I61
sg8
g127
sg10
I4
sg11
VADNP
p12826
sg13
I1
sasg17
(lp12827
(dp12828
g7
I160
sg20
VC0036341
p12829
sg10
I13
sg11
Vschizophrenia
p12830
sg13
I1
sasa(dp12831
g2
S"Thus, linking autophagy and ADNP is proposed as a major target for intervention in brain diseases from autism to Alzheimer's disease (AD) and our findings introduce autophagy as a possible novel target for treating schizophrenia.\n"
p12832
sg4
(lp12833
(dp12834
g7
I28
sg8
g127
sg10
I4
sg11
VADNP
p12835
sg13
I1
sasg17
(lp12836
(dp12837
g7
I28
sg20
VC1521724
p12838
sg10
I2
sg11
VAD
p12839
sg13
I1
sa(dp12840
g7
I215
sg20
VC0036341
p12841
sg10
I13
sg11
Vschizophrenia
p12842
sg13
I1
sa(dp12843
g7
I113
sg20
VC1521724
p12844
sg10
I19
sg11
VAlzheimer's disease
p12845
sg13
I2
sa(dp12846
g7
I83
sg20
VC0006111
p12847
sg10
I14
sg11
Vbrain diseases
p12848
sg13
I2
sa(dp12849
g7
I103
sg20
VC0004352
p12850
sg10
I6
sg11
Vautism
p12851
sg13
I1
sasa(dp12852
g2
S'Activity-dependent neuroprotective protein (ADNP) is one of the most prevalent de novo mutated genes in syndromic autism spectrum disorders, driving a general interest in the gene and the syndrome.\n'
p12853
sg4
(lp12854
(dp12855
g7
I44
sg8
g127
sg10
I4
sg11
VADNP
p12856
sg13
I1
sa(dp12857
g7
I0
sg8
g127
sg10
I42
sg11
VActivity-dependent neuroprotective protein
p12858
sg13
I3
sasg17
(lp12859
(dp12860
g7
I114
sg20
VC1510586
p12861
sg10
I25
sg11
Vautism spectrum disorders
p12862
sg13
I3
sa(dp12863
g7
I188
sg20
VC0039082
p12864
sg10
I8
sg11
Vsyndrome
p12865
sg13
I1
sasa(dp12866
g2
S'Heterozygous truncating mutations in ADNP are associated with a syndromic form of intellectual disability known as Helsmoortel-van der Aa syndrome.\n'
p12867
sg4
(lp12868
(dp12869
g7
I37
sg8
g127
sg10
I4
sg11
VADNP
p12870
sg13
I1
sasg17
(lp12871
(dp12872
g7
I82
sg20
VC0025362
p12873
sg10
I23
sg11
Vintellectual disability
p12874
sg13
I2
sa(dp12875
g7
I138
sg20
VC0039082
p12876
sg10
I8
sg11
Vsyndrome
p12877
sg13
I1
sasa(dp12878
g2
S'From a clinical standpoint, a differential diagnosis of patients with blepharophimosis should include ADNP mutations in addition to blepharophimosis ptosis epicanthus inversus syndrome, especially when intellectual disability is present.\n'
p12879
sg4
(lp12880
(dp12881
g7
I102
sg8
g127
sg10
I14
sg11
VADNP mutations
p12882
sg13
I2
sasg17
(lp12883
(dp12884
g7
I202
sg20
VC0025362
p12885
sg10
I23
sg11
Vintellectual disability
p12886
sg13
I2
sa(dp12887
g7
I156
sg20
VC0678230
p12888
sg10
I10
sg11
Vepicanthus
p12889
sg13
I1
sa(dp12890
g7
I70
sg20
VC0005744
p12891
sg10
I16
sg11
Vblepharophimosis
p12892
sg13
I1
sa(dp12893
g7
I70
sg20
VC0005744
p12894
sg10
I16
sg11
Vblepharophimosis
p12895
sg13
I1
sa(dp12896
g7
I149
sg20
VC0005745
p12897
sg10
I6
sg11
Vptosis
p12898
sg13
I1
sa(dp12899
g7
I176
sg20
VC0039082
p12900
sg10
I8
sg11
Vsyndrome
p12901
sg13
I1
sasa(dp12902
g2
S'Joint modeling examined relationships among BMI, IIS, and ADNP in the overall sample and stratified by initial visit Clinical Dementia Rating score.\n'
p12903
sg4
(lp12904
(dp12905
g7
I58
sg8
g127
sg10
I4
sg11
VADNP
p12906
sg13
I1
sasg17
(lp12907
(dp12908
g7
I126
sg20
VC0497327
p12909
sg10
I8
sg11
VDementia
p12910
sg13
I1
sasa(dp12911
g2
S'Activity-dependent neuroprotective protein (ADNP), vital for brain formation and cognitive function, is mutated in autism and linked to neurodegenerative/psychiatric diseases.\n'
p12912
sg4
(lp12913
(dp12914
g7
I44
sg8
g127
sg10
I4
sg11
VADNP
p12915
sg13
I1
sa(dp12916
g7
I0
sg8
g127
sg10
I42
sg11
VActivity-dependent neuroprotective protein
p12917
sg13
I3
sasg17
(lp12918
(dp12919
g7
I115
sg20
VC0004352
p12920
sg10
I6
sg11
Vautism
p12921
sg13
I1
sasa(dp12922
g2
S"We estimated rates of clinical progression and tested whether associations between clinical progression and Alzheimer's disease neuropathology (ADNP) were modified by co-occurring Lewy body disease (LBD) or vascular brain injury (VBI).\n"
p12923
sg4
(lp12924
(dp12925
g7
I144
sg8
g127
sg10
I4
sg11
VADNP
p12926
sg13
I1
sa(dp12927
g7
I108
sg8
g127
sg10
I34
sg11
VAlzheimer's disease neuropathology
p12928
sg13
I3
sasg17
(lp12929
(dp12930
g7
I180
sg20
VC0752347
p12931
sg10
I17
sg11
VLewy body disease
p12932
sg13
I3
sa(dp12933
g7
I128
sg20
VC1540677
p12934
sg10
I14
sg11
Vneuropathology
p12935
sg13
I1
sa(dp12936
g7
I199
sg20
VC0751783
p12937
sg10
I3
sg11
VLBD
p12938
sg13
I1
sa(dp12939
g7
I108
sg20
VC1521724
p12940
sg10
I19
sg11
VAlzheimer's disease
p12941
sg13
I2
sasa(dp12942
g2
S'ADNP key functions extend from mice to men, with mutations causing ADNP-related ID/autism syndrome, also known as the Helsmoortel-Van der Aa syndrome.\n'
p12943
sg4
(lp12944
(dp12945
g7
I0
sg8
g127
sg10
I4
sg11
VADNP
p12946
sg13
I1
sa(dp12947
g7
I0
sg8
g127
sg10
I4
sg11
VADNP
p12948
sg13
I1
sasg17
(lp12949
(dp12950
g7
I90
sg20
VC0039082
p12951
sg10
I8
sg11
Vsyndrome
p12952
sg13
I1
sa(dp12953
g7
I90
sg20
VC0039082
p12954
sg10
I8
sg11
Vsyndrome
p12955
sg13
I1
sa(dp12956
g7
I83
sg20
VC0004352
p12957
sg10
I6
sg11
Vautism
p12958
sg13
I1
sasa(dp12959
g2
S"ADNP mRNA increases in lymphocytes derived from schizophrenia patients and in patients suffering from mild cognitive impairment (MCI) and further increases in Alzheimer's disease patients compared with controls.\n"
p12960
sg4
(lp12961
(dp12962
g7
I0
sg8
g127
sg10
I9
sg11
VADNP mRNA
p12963
sg13
I2
sasg17
(lp12964
(dp12965
g7
I129
sg20
VC1270972
p12966
sg10
I3
sg11
VMCI
p12967
sg13
I1
sa(dp12968
g7
I159
sg20
VC1521724
p12969
sg10
I19
sg11
VAlzheimer's disease
p12970
sg13
I2
sa(dp12971
g7
I102
sg20
VC1270972
p12972
sg10
I25
sg11
Vmild cognitive impairment
p12973
sg13
I3
sa(dp12974
g7
I48
sg20
VC0036341
p12975
sg10
I13
sg11
Vschizophrenia
p12976
sg13
I1
sa(dp12977
g7
I87
sg20
VC0683278
p12978
sg10
I9
sg11
Vsuffering
p12979
sg13
I1
sasa(dp12980
g2
S"NAP (davunetide), an ADNP snippet drug candidate, protects cognition in patients suffering from amnestic MCI preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.\n"
p12981
sg4
(lp12982
(dp12983
g7
I21
sg8
g127
sg10
I4
sg11
VADNP
p12984
sg13
I1
sasg17
(lp12985
(dp12986
g7
I81
sg20
VC0683278
p12987
sg10
I9
sg11
Vsuffering
p12988
sg13
I1
sa(dp12989
g7
I105
sg20
VC1270972
p12990
sg10
I3
sg11
VMCI
p12991
sg13
I1
sa(dp12992
g7
I197
sg20
VC0036341
p12993
sg10
I13
sg11
Vschizophrenia
p12994
sg13
I1
sa(dp12995
g7
I119
sg20
VC1521724
p12996
sg10
I19
sg11
VAlzheimer's disease
p12997
sg13
I2
sasa(dp12998
g2
S'It is important to note that ADNP is sexually regulated in the brains of birds, mice, and men and in lymphocytes of patients suffering from schizophrenia.\n'
p12999
sg4
(lp13000
(dp13001
g7
I29
sg8
g127
sg10
I4
sg11
VADNP
p13002
sg13
I1
sasg17
(lp13003
(dp13004
g7
I125
sg20
VC0683278
p13005
sg10
I9
sg11
Vsuffering
p13006
sg13
I1
sa(dp13007
g7
I140
sg20
VC0036341
p13008
sg10
I13
sg11
Vschizophrenia
p13009
sg13
I1
sasa(dp13010
g2
S'Activity-dependent neuroprotective protein (ADNP), essential for brain formation, is a frequent autism spectrum disorder (ASD)-mutated gene.\n'
p13011
sg4
(lp13012
(dp13013
g7
I44
sg8
g127
sg10
I4
sg11
VADNP
p13014
sg13
I1
sa(dp13015
g7
I0
sg8
g127
sg10
I42
sg11
VActivity-dependent neuroprotective protein
p13016
sg13
I3
sasg17
(lp13017
(dp13018
g7
I96
sg20
VC1510586
p13019
sg10
I24
sg11
Vautism spectrum disorder
p13020
sg13
I3
sa(dp13021
g7
I122
sg20
VC1510586
p13022
sg10
I3
sg11
VASD
p13023
sg13
I1
sasa(dp13024
g2
S'Women with (1) FMS + irritable bowel syndrome (IBS); (2) FMS + primary dysmenorrhea (Dys); (3) FMS + Dys secondary to endometriosis (Endo); (4) FMS + colon diverticulosis (Div) were compared with FMS-only women, for fibromyalgia pain (number and intensity of episodes and analgesic consumption) over comparable periods and for somatic hyperalgesia (electrical and pressure pain thresholds) in painful (tender points) and control areas (trapezius, deltoid, quadriceps muscles, and overlying subcutis and skin).\n'
p13025
sg4
(lp13026
sg17
(lp13027
(dp13028
g7
I63
sg20
VC0149875
p13029
sg10
I20
sg11
Vprimary dysmenorrhea
p13030
sg13
I2
sa(dp13031
g7
I15
sg20
VC0016053
p13032
sg10
I3
sg11
VFMS
p13033
sg13
I1
sa(dp13034
g7
I85
sg20
VC0013364
p13035
sg10
I3
sg11
VDys
p13036
sg13
I1
sa(dp13037
g7
I393
sg20
VC0030193
p13038
sg10
I7
sg11
Vpainful
p13039
sg13
I1
sa(dp13040
g7
I118
sg20
VC0014175
p13041
sg10
I13
sg11
Vendometriosis
p13042
sg13
I1
sa(dp13043
g7
I85
sg20
VC0013364
p13044
sg10
I3
sg11
VDys
p13045
sg13
I1
sa(dp13046
g7
I47
sg20
VC0022104
p13047
sg10
I3
sg11
VIBS
p13048
sg13
I1
sa(dp13049
g7
I15
sg20
VC0016053
p13050
sg10
I3
sg11
VFMS
p13051
sg13
I1
sa(dp13052
g7
I216
sg20
VC0016053
p13053
sg10
I12
sg11
Vfibromyalgia
p13054
sg13
I1
sa(dp13055
g7
I21
sg20
VC0022104
p13056
sg10
I24
sg11
Virritable bowel syndrome
p13057
sg13
I3
sa(dp13058
g7
I15
sg20
VC0016053
p13059
sg10
I3
sg11
VFMS
p13060
sg13
I1
sa(dp13061
g7
I15
sg20
VC0016053
p13062
sg10
I3
sg11
VFMS
p13063
sg13
I1
sa(dp13064
g7
I335
sg20
VC0020429
p13065
sg10
I12
sg11
Vhyperalgesia
p13066
sg13
I1
sa(dp13067
g7
I172
sg20
VC1510475
p13068
sg10
I3
sg11
VDiv
p13069
sg13
I1
sa(dp13070
g7
I133
sg20
VC0014175
p13071
sg10
I4
sg11
VEndo
p13072
sg13
I1
sa(dp13073
g7
I15
sg20
VC0016053
p13074
sg10
I3
sg11
VFMS
p13075
sg13
I1
sa(dp13076
g7
I150
sg20
VC0012819
p13077
sg10
I20
sg11
Vcolon diverticulosis
p13078
sg13
I2
sasa(dp13079
g2
S'Fibromyalgia syndrome pain and hyperalgesia in all tissues and all sites significantly decreased in patients after visceral comorbidity treatment (dietary for 6 months [IBS], hormonal for 6 months [dysmenorrhea], laser [endometriosis], and surgery [diverticulosis]) (0.05 &lt; P &lt; 0.0001) vs no change in untreated patients.\n'
p13080
sg4
(lp13081
sg17
(lp13082
(dp13083
g7
I220
sg20
VC0014175
p13084
sg10
I13
sg11
Vendometriosis
p13085
sg13
I1
sa(dp13086
g7
I169
sg20
VC0022104
p13087
sg10
I3
sg11
VIBS
p13088
sg13
I1
sa(dp13089
g7
I31
sg20
VC0020429
p13090
sg10
I12
sg11
Vhyperalgesia
p13091
sg13
I1
sa(dp13092
g7
I198
sg20
VC0013390
p13093
sg10
I12
sg11
Vdysmenorrhea
p13094
sg13
I1
sa(dp13095
g7
I249
sg20
VC1510475
p13096
sg10
I14
sg11
Vdiverticulosis
p13097
sg13
I1
sa(dp13098
g7
I13
sg20
VC0391976
p13099
sg10
I13
sg11
Vsyndrome pain
p13100
sg13
I2
sa(dp13101
g7
I0
sg20
VC0016053
p13102
sg10
I21
sg11
VFibromyalgia syndrome
p13103
sg13
I2
sasa(dp13104
g2
S'Thrombotic and inflammatory agents, released from platelets, may trigger disease-specific complications (e.g., extraarticular features, fibrosis in systemic sclerosis) and propagate endothelial dysfunction.\n'
p13105
sg4
(lp13106
sg17
(lp13107
(dp13108
g7
I148
sg20
VC0036421
p13109
sg10
I18
sg11
Vsystemic sclerosis
p13110
sg13
I2
sa(dp13111
g7
I136
sg20
VC0016059
p13112
sg10
I8
sg11
Vfibrosis
p13113
sg13
I1
sa(dp13114
g7
I182
sg20
VC0856169
p13115
sg10
I23
sg11
Vendothelial dysfunction
p13116
sg13
I2
sasa(dp13117
g2
S'This was tested by genotyping 73 single-nucleotide polymorphisms (SNPs) from six candidate genes (DUSP1, HRB, IKBKAP, MAP3K1, MAP3K14 and TANK) in a large UK cohort of rheumatoid arthritis patients (n=642).\n'
p13118
sg4
(lp13119
(dp13120
g7
I118
sg8
g127
sg10
I6
sg11
VMAP3K1
p13121
sg13
I1
sa(dp13122
g7
I138
sg8
g127
sg10
I4
sg11
VTANK
p13123
sg13
I1
sa(dp13124
g7
I126
sg8
g127
sg10
I7
sg11
VMAP3K14
p13125
sg13
I1
sa(dp13126
g7
I110
sg8
g127
sg10
I6
sg11
VIKBKAP
p13127
sg13
I1
sa(dp13128
g7
I105
sg8
VP52594
p13129
sg10
I3
sg11
VHRB
p13130
sg13
I1
sa(dp13131
g7
I98
sg8
VP28562
p13132
sg10
I5
sg11
VDUSP1
p13133
sg13
I1
sasg17
(lp13134
(dp13135
g7
I168
sg20
VC0003873
p13136
sg10
I20
sg11
Vrheumatoid arthritis
p13137
sg13
I2
sasa(dp13138
g2
S'Moreover, TLR3 negatively manipulated the inflammation-related long noncoding RNA lnc-IL7R, which was upregulated during this chemotherapy.\n'
p13139
sg4
(lp13140
(dp13141
g7
I10
sg8
g127
sg10
I4
sg11
VTLR3
p13142
sg13
I1
sasg17
(lp13143
(dp13144
g7
I42
sg20
VC0021368
p13145
sg10
I12
sg11
Vinflammation
p13146
sg13
I1
sasa(dp13147
g2
S'Upon in vitro TLR3 activation, a decreased frequency of CD8(+) T cells secreting IFN-Gamma, IL-17a or IL-22 was detected in the CVID group compared to the control group.\n'
p13148
sg4
(lp13149
(dp13150
g7
I56
sg8
VP01732
p13151
sg10
I3
sg11
VCD8
p13152
sg13
I1
sa(dp13153
g7
I14
sg8
g127
sg10
I4
sg11
VTLR3
p13154
sg13
I1
sa(dp13155
g7
I102
sg8
g127
sg10
I5
sg11
VIL-22
p13156
sg13
I1
sa(dp13157
g7
I81
sg8
VP01579
p13158
sg10
I9
sg11
VIFN-Gamma
p13159
sg13
I1
sasg17
(lp13160
(dp13161
g7
I128
sg20
VC0009447
p13162
sg10
I4
sg11
VCVID
p13163
sg13
I1
sasa(dp13164
g2
S'Importantly, reduced TLR3-triggered activation of human NK cells was observed in Btk-deficient patients with X-linked agammaglobulinemia, as evidenced by the reduced IFN-Gamma, CD69, and CD107a expression and cytotoxic activity.\n'
p13165
sg4
(lp13166
(dp13167
g7
I177
sg8
g127
sg10
I4
sg11
VCD69
p13168
sg13
I1
sa(dp13169
g7
I187
sg8
VP11279
p13170
sg10
I6
sg11
VCD107a
p13171
sg13
I1
sa(dp13172
g7
I81
sg8
g127
sg10
I3
sg11
VBtk
p13173
sg13
I1
sa(dp13174
g7
I166
sg8
VP01579
p13175
sg10
I9
sg11
VIFN-Gamma
p13176
sg13
I1
sa(dp13177
g7
I21
sg8
g127
sg10
I4
sg11
VTLR3
p13178
sg13
I1
sasg17
(lp13179
(dp13180
g7
I109
sg20
VC0221026
p13181
sg10
I27
sg11
VX-linked agammaglobulinemia
p13182
sg13
I2
sasa(dp13183
g2
S'These TLR defects are restricted because CVID PBMCs stimulated with TLR ligands produced normal amounts of TNF-alpha, IL-6, and IL-12; TLR3-mediated expression of IFN-beta by CVID fibroblasts was normal.\n'
p13184
sg4
(lp13185
(dp13186
g7
I118
sg8
VP05231
p13187
sg10
I4
sg11
VIL-6
p13188
sg13
I1
sa(dp13189
g7
I135
sg8
g127
sg10
I4
sg11
VTLR3
p13190
sg13
I1
sa(dp13191
g7
I163
sg8
VP01574
p13192
sg10
I8
sg11
VIFN-beta
p13193
sg13
I1
sa(dp13194
g7
I107
sg8
VP01375
p13195
sg10
I9
sg11
VTNF-alpha
p13196
sg13
I1
sasg17
(lp13197
(dp13198
g7
I41
sg20
VC0009447
p13199
sg10
I4
sg11
VCVID
p13200
sg13
I1
sa(dp13201
g7
I41
sg20
VC0009447
p13202
sg10
I4
sg11
VCVID
p13203
sg13
I1
sasa(dp13204
g2
S'Multivariate analysis showed pretransplant valvular heart disease (P=0.0372), posttransplant enlarged left atrium (P=0.0066), posttransplant mitral regurgitation (P=0.0370), and non-total orthotopic HTX (P=0.0112) as risk factors for AF.\n'
p13205
sg4
(lp13206
sg17
(lp13207
(dp13208
g7
I43
sg20
VC0018824
p13209
sg10
I22
sg11
Vvalvular heart disease
p13210
sg13
I3
sa(dp13211
g7
I141
sg20
VC0026266
p13212
sg10
I20
sg11
Vmitral regurgitation
p13213
sg13
I2
sasa(dp13214
g2
S'When added to a prognostic baseline model including male sex, heart failure duration, New York Heart Association functional classes III to IV, LVEF, significant mitral regurgitation, and beta-blockers, LVRR, New York Heart Association functional classes III to IV, and significant mitral regurgitation after 24 months emerged as independent predictors of death/HTx and heart failure death/HTx.\n'
p13215
sg4
(lp13216
sg17
(lp13217
(dp13218
g7
I161
sg20
VC0026266
p13219
sg10
I20
sg11
Vmitral regurgitation
p13220
sg13
I2
sa(dp13221
g7
I161
sg20
VC0026266
p13222
sg10
I20
sg11
Vmitral regurgitation
p13223
sg13
I2
sa(dp13224
g7
I62
sg20
VC0018802
p13225
sg10
I13
sg11
Vheart failure
p13226
sg13
I2
sa(dp13227
g7
I62
sg20
VC0018802
p13228
sg10
I13
sg11
Vheart failure
p13229
sg13
I2
sasa(dp13230
g2
S'In conclusion, tricuspid regurgitation has a higher prevalence than mitral regurgitation and occurs in most patients immediately after HTX; mitral regurgitation was less frequent than tricuspid regurgitation and was not correlated to the hemodynamic parameters or to the distortion of atrial geometry; tricuspid regurgitation was significantly correlated to the ratio of recipient/donor right atrium; surgical techniques reducing the recipient atrium may decrease the occurrence and the degree of tricuspid regurgitation.\n'
p13231
sg4
(lp13232
sg17
(lp13233
(dp13234
g7
I15
sg20
VC0040961
p13235
sg10
I23
sg11
Vtricuspid regurgitation
p13236
sg13
I2
sa(dp13237
g7
I15
sg20
VC0040961
p13238
sg10
I23
sg11
Vtricuspid regurgitation
p13239
sg13
I2
sa(dp13240
g7
I68
sg20
VC0026266
p13241
sg10
I20
sg11
Vmitral regurgitation
p13242
sg13
I2
sa(dp13243
g7
I15
sg20
VC0040961
p13244
sg10
I23
sg11
Vtricuspid regurgitation
p13245
sg13
I2
sa(dp13246
g7
I68
sg20
VC0026266
p13247
sg10
I20
sg11
Vmitral regurgitation
p13248
sg13
I2
sa(dp13249
g7
I15
sg20
VC0040961
p13250
sg10
I23
sg11
Vtricuspid regurgitation
p13251
sg13
I2
sa(dp13252
g7
I271
sg20
VC0332482
p13253
sg10
I10
sg11
Vdistortion
p13254
sg13
I1
sasa(dp13255
g2
S'EA stimulation of both LI 18 and LI 4-PC 6 and TAES of LI 4-PC 6 combined with anesthetics have a better effect in inducing analgesia and controlling MAP and HR, and need lower dosages of anesthetics for patients undergoing thyroidectomy, for which LI 18 and LI 4-PC 6 are evidently superior to GB 34 and non-acupoint.\n'
p13256
sg4
(lp13257
sg17
(lp13258
(dp13259
g7
I124
sg20
VC0344307
p13260
sg10
I9
sg11
Vanalgesia
p13261
sg13
I1
sasa(dp13262
g2
S'anesthesia induction, electroacupuncture (EA) was applied to Hegu (LI 4), Neiguan (PC 6) , Houxi (SI 3) and Zhigou (TE 6) for 30 min; during surgery, EA and intravenous medication were combined at the same acupoints as those before surgery; after surgery, moxibustion and the analgesia pump were applied in combination for analgesia.\n'
p13263
sg4
(lp13264
sg17
(lp13265
(dp13266
g7
I276
sg20
VC0344307
p13267
sg10
I9
sg11
Vanalgesia
p13268
sg13
I1
sa(dp13269
g7
I276
sg20
VC0344307
p13270
sg10
I9
sg11
Vanalgesia
p13271
sg13
I1
sa(dp13272
g7
I0
sg20
VC0278134
p13273
sg10
I10
sg11
Vanesthesia
p13274
sg13
I1
sasa(dp13275
g2
S'In this study, we investigated mRNA expression of TLR-1,-2,-4 and cytokines/receptors (IL-2,-2R,-10,-10R, TGFb1) in pseudosynovial tissue obtained from 55 patients with aseptically failed THAs/TKAs and 37 control patients with hip/knee primary osteoarthritis (OA) using quantitative RT-PCR.\n'
p13276
sg4
(lp13277
(dp13278
g7
I50
sg8
g127
sg10
I11
sg11
VTLR-1,-2,-4
p13279
sg13
I1
sa(dp13280
g7
I87
sg8
VP60568
p13281
sg10
I4
sg11
VIL-2
p13282
sg13
I1
sa(dp13283
g7
I106
sg8
VP01137
p13284
sg10
I5
sg11
VTGFb1
p13285
sg13
I1
sa(dp13286
g7
I66
sg8
VP01374
p13287
sg10
I19
sg11
Vcytokines/receptors
p13288
sg13
I1
sasg17
(lp13289
(dp13290
g7
I188
sg20
VC0559483
p13291
sg10
I4
sg11
VTHAs
p13292
sg13
I1
sa(dp13293
g7
I236
sg20
VC1384584
p13294
sg10
I22
sg11
Vprimary osteoarthritis
p13295
sg13
I2
sasa(dp13296
g2
S'We studied TLR1, TLR2, TLR4, and TLR9 mRNA (qRT-PCR) and receptor proteins (by immunostaining) in primary mature healthy chondrocytes, developing chondrocytes, and degenerated chondrocytes in osteoarthritis (OA) tissue sections of different OARSI grades.\n'
p13297
sg4
(lp13298
(dp13299
g7
I11
sg8
g127
sg10
I4
sg11
VTLR1
p13300
sg13
I1
sa(dp13301
g7
I17
sg8
g127
sg10
I4
sg11
VTLR2
p13302
sg13
I1
sa(dp13303
g7
I33
sg8
g127
sg10
I9
sg11
VTLR9 mRNA
p13304
sg13
I2
sasg17
(lp13305
(dp13306
g7
I164
sg20
VC0011164
p13307
sg10
I11
sg11
Vdegenerated
p13308
sg13
I1
sa(dp13309
g7
I208
sg20
VC0029408
p13310
sg10
I2
sg11
VOA
p13311
sg13
I1
sa(dp13312
g7
I192
sg20
VC0029408
p13313
sg10
I14
sg11
Vosteoarthritis
p13314
sg13
I1
sasa(dp13315
g2
S'IMD-4482 inhibited in vitro cell adhesion to vitronectin in PAI-1-positive ovarian cancer cells, followed by the inhibition of extracellular signal-regulated kinase and focal adhesion kinase phosphorylation through dissociation of the PAI-urokinase receptor complex from integrin AlfaVBeta3.\n'
p13316
sg4
(lp13317
(dp13318
g7
I169
sg8
g127
sg10
I21
sg11
Vfocal adhesion kinase
p13319
sg13
I3
sa(dp13320
g7
I127
sg8
VP53779
p13321
sg10
I37
sg11
Vextracellular signal-regulated kinase
p13322
sg13
I3
sa(dp13323
g7
I60
sg8
VP05121
p13324
sg10
I5
sg11
VPAI-1
p13325
sg13
I1
sa(dp13326
g7
I45
sg8
VP04004
p13327
sg10
I11
sg11
Vvitronectin
p13328
sg13
I1
sa(dp13329
g7
I235
sg8
VP05120
p13330
sg10
I30
sg11
VPAI-urokinase receptor complex
p13331
sg13
I3
sasg17
(lp13332
(dp13333
g7
I33
sg20
VC0001511
p13334
sg10
I8
sg11
Vadhesion
p13335
sg13
I1
sa(dp13336
g7
I215
sg20
VC0086168
p13337
sg10
I12
sg11
Vdissociation
p13338
sg13
I1
sa(dp13339
g7
I33
sg20
VC0001511
p13340
sg10
I8
sg11
Vadhesion
p13341
sg13
I1
sa(dp13342
g7
I75
sg20
VC1140680
p13343
sg10
I14
sg11
Vovarian cancer
p13344
sg13
I2
sasa(dp13345
g2
S'Background Increased expression of vitronectin (VN) by smooth muscle cells (SMCs) promotes neointima formation after vascular injury, and may contribute to chronic vascular diseases, such as atherosclerosis.\n'
p13346
sg4
(lp13347
(dp13348
g7
I48
sg8
VP04004
p13349
sg10
I2
sg11
VVN
p13350
sg13
I1
sa(dp13351
g7
I35
sg8
VP04004
p13352
sg10
I11
sg11
Vvitronectin
p13353
sg13
I1
sasg17
(lp13354
(dp13355
g7
I164
sg20
VC0042373
p13356
sg10
I17
sg11
Vvascular diseases
p13357
sg13
I2
sa(dp13358
g7
I91
sg20
VC2936381
p13359
sg10
I19
sg11
Vneointima formation
p13360
sg13
I2
sa(dp13361
g7
I191
sg20
VC0004153
p13362
sg10
I15
sg11
Vatherosclerosis
p13363
sg13
I1
sasa(dp13364
g2
S'We found that this mutation, like those causing dominant Cole disease, impairs homo-dimerization of the ENPP1 enzyme which is mediated by its two somatomedin-B-like domains.\n'
p13365
sg4
(lp13366
(dp13367
g7
I104
sg8
VP22413
p13368
sg10
I12
sg11
VENPP1 enzyme
p13369
sg13
I2
sa(dp13370
g7
I146
sg8
VP04004
p13371
sg10
I26
sg11
Vsomatomedin-B-like domains
p13372
sg13
I2
sasg17
(lp13373
sa(dp13374
g2
S'OSCC from CCL3-/- mice exhibited lower infiltration of eosinophils and reduced expression of Egf, Fgf1, Tgf-Beta1, Vegfa, Vegfb, Itga-4, Vtn, Mmp-1a, Mmp-2 and Mmp-9 than WT mice.\n'
p13375
sg4
(lp13376
(dp13377
g7
I129
sg8
VP38570
p13378
sg10
I6
sg11
VItga-4
p13379
sg13
I1
sa(dp13380
g7
I142
sg8
g127
sg10
I6
sg11
VMmp-1a
p13381
sg13
I1
sa(dp13382
g7
I122
sg8
VP49765
p13383
sg10
I5
sg11
VVegfb
p13384
sg13
I1
sa(dp13385
g7
I160
sg8
VP14780
p13386
sg10
I5
sg11
VMmp-9
p13387
sg13
I1
sa(dp13388
g7
I150
sg8
VP08253
p13389
sg10
I5
sg11
VMmp-2
p13390
sg13
I1
sa(dp13391
g7
I98
sg8
VP05230
p13392
sg10
I4
sg11
VFgf1
p13393
sg13
I1
sa(dp13394
g7
I93
sg8
VP01133
p13395
sg10
I3
sg11
VEgf
p13396
sg13
I1
sa(dp13397
g7
I137
sg8
VP04004
p13398
sg10
I3
sg11
VVtn
p13399
sg13
I1
sa(dp13400
g7
I104
sg8
VP01137
p13401
sg10
I9
sg11
VTgf-Beta1
p13402
sg13
I1
sasg17
(lp13403
(dp13404
g7
I39
sg20
VC0332448
p13405
sg10
I12
sg11
Vinfiltration
p13406
sg13
I1
sasa(dp13407
g2
S'Germline mutations in the SDHD tumour suppressor gene (11q23.1) predispose to phaeochromocytomas and paragangliomas (PPGL) mainly on a paternal transmission.\n'
p13408
sg4
(lp13409
(dp13410
g7
I26
sg8
g127
sg10
I4
sg11
VSDHD
p13411
sg13
I1
sasg17
(lp13412
(dp13413
g7
I31
sg20
VC0027651
p13414
sg10
I6
sg11
Vtumour
p13415
sg13
I1
sa(dp13416
g7
I101
sg20
VC0030421
p13417
sg10
I14
sg11
Vparagangliomas
p13418
sg13
I1
sasa(dp13419
g2
S'At least 12 genes (FH, HIF2A, MAX, NF1, RET, SDHA, SDHB, SDHC, SDHD, SDHAF2, TMEM127, and VHL) have been implicated in inherited predisposition to phaeochromocytoma (PCC), paraganglioma (PGL), or head and neck paraganglioma (HNPGL) and a germline mutation may be detected in more than 30% of cases.\n'
p13420
sg4
(lp13421
(dp13422
g7
I69
sg8
g127
sg10
I6
sg11
VSDHAF2
p13423
sg13
I1
sa(dp13424
g7
I90
sg8
VP40337
p13425
sg10
I3
sg11
VVHL
p13426
sg13
I1
sa(dp13427
g7
I57
sg8
g127
sg10
I4
sg11
VSDHC
p13428
sg13
I1
sa(dp13429
g7
I63
sg8
g127
sg10
I4
sg11
VSDHD
p13430
sg13
I1
sa(dp13431
g7
I23
sg8
g127
sg10
I5
sg11
VHIF2A
p13432
sg13
I1
sa(dp13433
g7
I51
sg8
VP21912
p13434
sg10
I4
sg11
VSDHB
p13435
sg13
I1
sa(dp13436
g7
I45
sg8
VP31040
p13437
sg10
I4
sg11
VSDHA
p13438
sg13
I1
sa(dp13439
g7
I77
sg8
g127
sg10
I7
sg11
VTMEM127
p13440
sg13
I1
sa(dp13441
g7
I40
sg8
VP07949
p13442
sg10
I3
sg11
VRET
p13443
sg13
I1
sa(dp13444
g7
I35
sg8
VP21359
p13445
sg10
I3
sg11
VNF1
p13446
sg13
I1
sasg17
(lp13447
(dp13448
g7
I238
sg20
VC1705427
p13449
sg10
I17
sg11
Vgermline mutation
p13450
sg13
I2
sa(dp13451
g7
I90
sg20
VC0019562
p13452
sg10
I3
sg11
VVHL
p13453
sg13
I1
sa(dp13454
g7
I172
sg20
VC0030421
p13455
sg10
I13
sg11
Vparaganglioma
p13456
sg13
I1
sa(dp13457
g7
I196
sg20
VC1333944
p13458
sg10
I27
sg11
Vhead and neck paraganglioma
p13459
sg13
I4
sa(dp13460
g7
I187
sg20
VC0030421
p13461
sg10
I3
sg11
VPGL
p13462
sg13
I1
sa(dp13463
g7
I147
sg20
VC0031511
p13464
sg10
I17
sg11
Vphaeochromocytoma
p13465
sg13
I1
sa(dp13466
g7
I166
sg20
VC1832526
p13467
sg10
I3
sg11
VPCC
p13468
sg13
I1
sa(dp13469
g7
I35
sg20
VC0027831
p13470
sg10
I3
sg11
VNF1
p13471
sg13
I1
sa(dp13472
g7
I225
sg20
VC1333944
p13473
sg10
I5
sg11
VHNPGL
p13474
sg13
I1
sasa(dp13475
g2
S"Cabazitaxel antitumor activity was assessed in mice bearing intracranial human glioblastoma (SF295; U251) xenografts, and subcutaneous cell line-derived human pediatric sarcoma (rhabdomyosarcoma RH-30; Ewing's sarcoma TC-71 and SK-ES-1) or patient-derived pediatric sarcoma (osteosarcoma DM77 and DM113; Ewing's sarcoma DM101) xenografts.\n"
p13476
sg4
(lp13477
sg17
(lp13478
(dp13479
g7
I178
sg20
VC0035412
p13480
sg10
I16
sg11
Vrhabdomyosarcoma
p13481
sg13
I1
sa(dp13482
g7
I169
sg20
VC1261473
p13483
sg10
I7
sg11
Vsarcoma
p13484
sg13
I1
sa(dp13485
g7
I202
sg20
VC0553580
p13486
sg10
I15
sg11
VEwing's sarcoma
p13487
sg13
I2
sa(dp13488
g7
I275
sg20
VC0029463
p13489
sg10
I12
sg11
Vosteosarcoma
p13490
sg13
I1
sa(dp13491
g7
I202
sg20
VC0553580
p13492
sg10
I15
sg11
VEwing's sarcoma
p13493
sg13
I2
sa(dp13494
g7
I79
sg20
VC0017636
p13495
sg10
I12
sg11
Vglioblastoma
p13496
sg13
I1
sa(dp13497
g7
I169
sg20
VC1261473
p13498
sg10
I7
sg11
Vsarcoma
p13499
sg13
I1
sasa(dp13500
g2
S"We investigated the future therapeutic use of LAK adoptive immunotherapy by examining LAK in vitro cytotoxicity from both neonatal and adult mononuclear cells against solid tumor cell lines of relevance to pediatric oncology: SH-SY5Y (neuroblastoma), SK-NM-C (neuroblastoma-neuroepithelioma), NEP-1 (Wilms' tumor), SK-ES-1 (Ewing's sarcoma), and A-204 (rhabdomyosarcoma).\n"
p13501
sg4
(lp13502
(dp13503
g7
I46
sg8
VP56559
p13504
sg10
I3
sg11
VLAK
p13505
sg13
I1
sa(dp13506
g7
I293
sg8
VP08473
p13507
sg10
I5
sg11
VNEP-1
p13508
sg13
I1
sa(dp13509
g7
I46
sg8
VP56559
p13510
sg10
I3
sg11
VLAK
p13511
sg13
I1
sasg17
(lp13512
(dp13513
g7
I274
sg20
VC0027828
p13514
sg10
I16
sg11
Vneuroepithelioma
p13515
sg13
I1
sa(dp13516
g7
I99
sg20
VC0596402
p13517
sg10
I12
sg11
Vcytotoxicity
p13518
sg13
I1
sa(dp13519
g7
I324
sg20
VC0553580
p13520
sg10
I15
sg11
VEwing's sarcoma
p13521
sg13
I2
sa(dp13522
g7
I235
sg20
VC0027819
p13523
sg10
I13
sg11
Vneuroblastoma
p13524
sg13
I1
sa(dp13525
g7
I353
sg20
VC0035412
p13526
sg10
I16
sg11
Vrhabdomyosarcoma
p13527
sg13
I1
sa(dp13528
g7
I167
sg20
VC0280100
p13529
sg10
I11
sg11
Vsolid tumor
p13530
sg13
I2
sa(dp13531
g7
I300
sg20
VC0027708
p13532
sg10
I12
sg11
VWilms' tumor
p13533
sg13
I2
sa(dp13534
g7
I235
sg20
VC0027819
p13535
sg10
I13
sg11
Vneuroblastoma
p13536
sg13
I1
sasa(dp13537
g2
S'The DD genotype of the angiotensin-converting enzyme (ACE) gene is over-represented in Finnish patients with obstetric cholestasis (OC).\n'
p13538
sg4
(lp13539
(dp13540
g7
I23
sg8
VP12821
p13541
sg10
I29
sg11
Vangiotensin-converting enzyme
p13542
sg13
I2
sa(dp13543
g7
I54
sg8
VP12821
p13544
sg10
I3
sg11
VACE
p13545
sg13
I1
sasg17
(lp13546
(dp13547
g7
I119
sg20
VC0008370
p13548
sg10
I11
sg11
Vcholestasis
p13549
sg13
I1
sasa(dp13550
g2
S'We examined the effect of an aqueous garlic extract (AGE) on the ACE activity, cholestasis-induced liver fibrosis, and associated renal dysfunction in comparison with the effect of the standard drug enalapril.\n'
p13551
sg4
(lp13552
(dp13553
g7
I65
sg8
VP12821
p13554
sg10
I3
sg11
VACE
p13555
sg13
I1
sasg17
(lp13556
(dp13557
g7
I99
sg20
VC0239946
p13558
sg10
I14
sg11
Vliver fibrosis
p13559
sg13
I2
sa(dp13560
g7
I79
sg20
VC0008370
p13561
sg10
I11
sg11
Vcholestasis
p13562
sg13
I1
sasa(dp13563
g2
S'Laboratory studies detected: cholestasis, pancytopenia and elevaton of angiotensin-converting enzyme.\n'
p13564
sg4
(lp13565
(dp13566
g7
I71
sg8
VP12821
p13567
sg10
I29
sg11
Vangiotensin-converting enzyme
p13568
sg13
I2
sasg17
(lp13569
(dp13570
g7
I42
sg20
VC0030312
p13571
sg10
I12
sg11
Vpancytopenia
p13572
sg13
I1
sa(dp13573
g7
I29
sg20
VC0008370
p13574
sg10
I11
sg11
Vcholestasis
p13575
sg13
I1
sasa(dp13576
g2
S'The aim of this study was to examine the preventative and therapeutic effects of an angiotensin-converting enzyme inhibitor, perindopril, on cholestasis-induced liver fibrosis.\n'
p13577
sg4
(lp13578
(dp13579
g7
I84
sg8
VP12821
p13580
sg10
I29
sg11
Vangiotensin-converting enzyme
p13581
sg13
I2
sasg17
(lp13582
(dp13583
g7
I161
sg20
VC0239946
p13584
sg10
I14
sg11
Vliver fibrosis
p13585
sg13
I2
sa(dp13586
g7
I141
sg20
VC0008370
p13587
sg10
I11
sg11
Vcholestasis
p13588
sg13
I1
sasa(dp13589
g2
S'Mutations in Krev1 interaction trapped gene 1 (KRIT1) cause cerebral cavernous malformation, an autosomal dominant disease featuring malformation of cerebral capillaries resulting in cerebral hemorrhage, strokes, and seizures.\n'
p13590
sg4
(lp13591
(dp13592
g7
I47
sg8
g127
sg10
I5
sg11
VKRIT1
p13593
sg13
I1
sa(dp13594
g7
I13
sg8
g127
sg10
I32
sg11
VKrev1 interaction trapped gene 1
p13595
sg13
I5
sasg17
(lp13596
(dp13597
g7
I79
sg20
VC0000768
p13598
sg10
I12
sg11
Vmalformation
p13599
sg13
I1
sa(dp13600
g7
I183
sg20
VC2937358
p13601
sg10
I19
sg11
Vcerebral hemorrhage
p13602
sg13
I2
sa(dp13603
g7
I217
sg20
VC0036572
p13604
sg10
I8
sg11
Vseizures
p13605
sg13
I1
sa(dp13606
g7
I60
sg20
VC2919945
p13607
sg10
I31
sg11
Vcerebral cavernous malformation
p13608
sg13
I3
sa(dp13609
g7
I204
sg20
VC0038454
p13610
sg10
I7
sg11
Vstrokes
p13611
sg13
I1
sasa(dp13612
g2
S'As evidence was shown that abnormal shortening of telomeres begins to accumulate in myelodysplastic syndrome (MDS) patients, this study was conducted to determine the relationship between the mRNA expression levels of telomere-binding proteins (TRF1/TRF2/TIN2/TPP1/POT1/RAP1) and the risk level in MDS.\n'
p13613
sg4
(lp13614
(dp13615
g7
I265
sg8
g127
sg10
I4
sg11
VPOT1
p13616
sg13
I1
sa(dp13617
g7
I260
sg8
VP49638
p13618
sg10
I4
sg11
VTPP1
p13619
sg13
I1
sa(dp13620
g7
I218
sg8
VP63244
p13621
sg10
I25
sg11
Vtelomere-binding proteins
p13622
sg13
I2
sa(dp13623
g7
I270
sg8
VP52306
p13624
sg10
I4
sg11
VRAP1
p13625
sg13
I1
sa(dp13626
g7
I245
sg8
VP54274
p13627
sg10
I4
sg11
VTRF1
p13628
sg13
I1
sa(dp13629
g7
I255
sg8
g127
sg10
I4
sg11
VTIN2
p13630
sg13
I1
sa(dp13631
g7
I250
sg8
VP62380
p13632
sg10
I4
sg11
VTRF2
p13633
sg13
I1
sasg17
(lp13634
(dp13635
g7
I110
sg20
VC0265219
p13636
sg10
I3
sg11
VMDS
p13637
sg13
I1
sa(dp13638
g7
I110
sg20
VC0265219
p13639
sg10
I3
sg11
VMDS
p13640
sg13
I1
sa(dp13641
g7
I84
sg20
VC3463824
p13642
sg10
I24
sg11
Vmyelodysplastic syndrome
p13643
sg13
I2
sasa(dp13644
g2
S'Radiation risks of multiple myeloma and chronic lymphocytic leukemia were found.Molecular effects of remote period after radiation exposure include changes in gene expression TERF1, TERF2, CCND1, telomere length, the protein expression of cyclin D1, histone gamma H2AX.\n'
p13645
sg4
(lp13646
(dp13647
g7
I189
sg8
VP24385
p13648
sg10
I5
sg11
VCCND1
p13649
sg13
I1
sa(dp13650
g7
I182
sg8
g127
sg10
I5
sg11
VTERF2
p13651
sg13
I1
sa(dp13652
g7
I239
sg8
VP24385
p13653
sg10
I9
sg11
Vcyclin D1
p13654
sg13
I2
sa(dp13655
g7
I175
sg8
VP54274
p13656
sg10
I5
sg11
VTERF1
p13657
sg13
I1
sa(dp13658
g7
I250
sg8
VP16104
p13659
sg10
I18
sg11
Vhistone gamma H2AX
p13660
sg13
I3
sasg17
(lp13661
(dp13662
g7
I19
sg20
VC0026764
p13663
sg10
I16
sg11
Vmultiple myeloma
p13664
sg13
I2
sa(dp13665
g7
I40
sg20
VC0023434
p13666
sg10
I28
sg11
Vchronic lymphocytic leukemia
p13667
sg13
I3
sasa(dp13668
g2
S'Key points include the research results of XRCC1 and XPD gene polymorphism in thyroid cancer patients, CD38 gene GG genotype as a risk factor for chronic lymphocytic leukemia, frequency of 185delAG and 5382insC mutations in BRCA1 gene in women with breast cancer, cognitive function and TERF1, TERF2, TERT gene expression both with telomere length in human under the low dose radiation exposure.\n'
p13669
sg4
(lp13670
(dp13671
g7
I43
sg8
VP18887
p13672
sg10
I5
sg11
VXRCC1
p13673
sg13
I1
sa(dp13674
g7
I294
sg8
g127
sg10
I5
sg11
VTERF2
p13675
sg13
I1
sa(dp13676
g7
I53
sg8
VP18074
p13677
sg10
I8
sg11
VXPD gene
p13678
sg13
I2
sa(dp13679
g7
I103
sg8
VP28907
p13680
sg10
I9
sg11
VCD38 gene
p13681
sg13
I2
sa(dp13682
g7
I224
sg8
VP38398
p13683
sg10
I10
sg11
VBRCA1 gene
p13684
sg13
I2
sa(dp13685
g7
I301
sg8
g127
sg10
I9
sg11
VTERT gene
p13686
sg13
I2
sa(dp13687
g7
I287
sg8
VP54274
p13688
sg10
I5
sg11
VTERF1
p13689
sg13
I1
sasg17
(lp13690
(dp13691
g7
I146
sg20
VC0023434
p13692
sg10
I28
sg11
Vchronic lymphocytic leukemia
p13693
sg13
I3
sa(dp13694
g7
I53
sg20
VC0268138
p13695
sg10
I3
sg11
VXPD
p13696
sg13
I1
sa(dp13697
g7
I78
sg20
VC0007115
p13698
sg10
I14
sg11
Vthyroid cancer
p13699
sg13
I2
sa(dp13700
g7
I249
sg20
VC0678222
p13701
sg10
I13
sg11
Vbreast cancer
p13702
sg13
I2
sasa(dp13703
g2
S'Moreover, we found that Beta-TrCP1 is essential for regulation of promyelocytic leukemia body recruitment of TRF1 in U2OS cells.\n'
p13704
sg4
(lp13705
(dp13706
g7
I109
sg8
VP54274
p13707
sg10
I4
sg11
VTRF1
p13708
sg13
I1
sa(dp13709
g7
I24
sg8
g127
sg10
I10
sg11
VBeta-TrCP1
p13710
sg13
I1
sasg17
(lp13711
(dp13712
g7
I66
sg20
VC2745900
p13713
sg10
I22
sg11
Vpromyelocytic leukemia
p13714
sg13
I2
sa(dp13715
g7
I94
sg20
VC0271510
p13716
sg10
I11
sg11
Vrecruitment
p13717
sg13
I1
sasa(dp13718
g2
S'Two regions have been previously implicated in autoimmune disease: KLRG1 (P = 6 x 10-7 [Asian cluster]) and SH2D2A (P = 2 x 10-6 [all participants]).\n'
p13719
sg4
(lp13720
(dp13721
g7
I108
sg8
g127
sg10
I6
sg11
VSH2D2A
p13722
sg13
I1
sa(dp13723
g7
I67
sg8
g127
sg10
I5
sg11
VKLRG1
p13724
sg13
I1
sasg17
(lp13725
(dp13726
g7
I47
sg20
VC0004364
p13727
sg10
I18
sg11
Vautoimmune disease
p13728
sg13
I2
sasa(dp13729
g2
S'Studies in mouse and man have indicated that reduced expression of TSAd in T cells may predispose toward the development of autoimmune disease.\n'
p13730
sg4
(lp13731
sg17
(lp13732
(dp13733
g7
I124
sg20
VC0004364
p13734
sg10
I18
sg11
Vautoimmune disease
p13735
sg13
I2
sasa(dp13736
g2
S'In lupus-prone TSAd-deficient mice the development of autoimmunity is associated with an impaired T cell death response to antigens in vivo.\n'
p13737
sg4
(lp13738
sg17
(lp13739
(dp13740
g7
I54
sg20
VC0004368
p13741
sg10
I12
sg11
Vautoimmunity
p13742
sg13
I1
sa(dp13743
g7
I89
sg20
VC0684336
p13744
sg10
I8
sg11
Vimpaired
p13745
sg13
I1
sa(dp13746
g7
I3
sg20
VC0024131
p13747
sg10
I5
sg11
Vlupus
p13748
sg13
I1
sasa(dp13749
g2
S'We now show that TSAd-deficient mice are susceptible to lupus-like autoimmune disease.\n'
p13750
sg4
(lp13751
(dp13752
g7
I17
sg8
g127
sg10
I4
sg11
VTSAd
p13753
sg13
I1
sasg17
(lp13754
(dp13755
g7
I67
sg20
VC0004364
p13756
sg10
I18
sg11
Vautoimmune disease
p13757
sg13
I2
sa(dp13758
g7
I56
sg20
VC0024131
p13759
sg10
I5
sg11
Vlupus
p13760
sg13
I1
sasa(dp13761
g2
S'We further show that immunization of younger C57BL/6 TSAd-deficient mice (at age 2 mo) with pristane, a recognized nonspecific inflammatory trigger of lupus, results in more severe glomerulonephritis compared with C57BL/6 controls and the production of high titer ss and ds DNA antibodies of the IgG subclass that are not normally produced by C57BL/6 mice in this model.\n'
p13762
sg4
(lp13763
sg17
(lp13764
(dp13765
g7
I151
sg20
VC0024131
p13766
sg10
I5
sg11
Vlupus
p13767
sg13
I1
sa(dp13768
g7
I181
sg20
VC0017658
p13769
sg10
I18
sg11
Vglomerulonephritis
p13770
sg13
I1
sasa(dp13771
g2
S'CD5+ DLBCL presenting as splenic infarct is very rare.\n'
p13772
sg4
(lp13773
(dp13774
g7
I0
sg8
VP06127
p13775
sg10
I4
sg11
VCD5+
p13776
sg13
I1
sasg17
(lp13777
(dp13778
g7
I25
sg20
VC0037998
p13779
sg10
I15
sg11
Vsplenic infarct
p13780
sg13
I2
sasa(dp13781
g2
S'In a murine model of Duchenne muscular dystrophy, mdx mice, cysteine-nitrosylation of the calcium release channel/ryanodine receptor type 1 (RyR1) on the skeletal muscle sarcoplasmic reticulum causes depletion of the stabilizing subunit calstabin1 (FKBP12) from the RyR1 macromolecular complex.\n'
p13782
sg4
(lp13783
(dp13784
g7
I106
sg8
VP21817
p13785
sg10
I33
sg11
Vchannel/ryanodine receptor type 1
p13786
sg13
I4
sa(dp13787
g7
I249
sg8
VP62942
p13788
sg10
I6
sg11
VFKBP12
p13789
sg13
I1
sa(dp13790
g7
I141
sg8
VP21817
p13791
sg10
I4
sg11
VRyR1
p13792
sg13
I1
sa(dp13793
g7
I141
sg8
VP21817
p13794
sg10
I4
sg11
VRyR1
p13795
sg13
I1
sasg17
(lp13796
(dp13797
g7
I21
sg20
VC0013264
p13798
sg10
I27
sg11
VDuchenne muscular dystrophy
p13799
sg13
I3
sa(dp13800
g7
I50
sg20
VC1839839
p13801
sg10
I3
sg11
Vmdx
p13802
sg13
I1
sasa(dp13803
g2
S'On the basis of these findings, we propose that sarcoplasmic reticulum Ca2+ leak via RyR1 due to S-nitrosylation of the channel and calstabin-1 depletion contributes to muscle weakness in muscular dystrophy, and that preventing the RyR1-mediated sarcoplasmic reticulum Ca2+ leak may provide a new therapeutic approach.\n'
p13804
sg4
(lp13805
(dp13806
g7
I85
sg8
VP21817
p13807
sg10
I4
sg11
VRyR1
p13808
sg13
I1
sa(dp13809
g7
I85
sg8
VP21817
p13810
sg10
I4
sg11
VRyR1
p13811
sg13
I1
sasg17
(lp13812
(dp13813
g7
I169
sg20
VC0030552
p13814
sg10
I15
sg11
Vmuscle weakness
p13815
sg13
I2
sa(dp13816
g7
I188
sg20
VC0026850
p13817
sg10
I18
sg11
Vmuscular dystrophy
p13818
sg13
I2
sasa(dp13819
g2
S'We here describe the genetic background of this disorder: some of the most mutated genes that are responsible for the disease are (G4.5 (tafazzin gene): alpha-dystrobrevin gene (DTNA); FKBP-12 gene; lamin A/C gene; Cypher/ZASP (LIM, LDB3) gene); and some genotype-phenotype correlations (Becker muscular dystrophy, Emery-Dreifuss muscular dystrophy or Barth syndrome) based on the literature review.\n'
p13820
sg4
(lp13821
(dp13822
g7
I185
sg8
g127
sg10
I12
sg11
VFKBP-12 gene
p13823
sg13
I2
sa(dp13824
g7
I228
sg8
g127
sg10
I3
sg11
VLIM
p13825
sg13
I1
sa(dp13826
g7
I199
sg8
VP02545
p13827
sg10
I14
sg11
Vlamin A/C gene
p13828
sg13
I3
sa(dp13829
g7
I215
sg8
VP62937
p13830
sg10
I6
sg11
VCypher
p13831
sg13
I1
sasg17
(lp13832
(dp13833
g7
I295
sg20
VC0026850
p13834
sg10
I18
sg11
Vmuscular dystrophy
p13835
sg13
I2
sa(dp13836
g7
I352
sg20
VC0574083
p13837
sg10
I14
sg11
VBarth syndrome
p13838
sg13
I2
sa(dp13839
g7
I295
sg20
VC0410189
p13840
sg10
I34
sg11
Vmuscular dystrophy, Emery-Dreifuss
p13841
sg13
I3
sasa(dp13842
g2
S'Histologically, the PNET-like component showed morphological features akin to anaplastic medulloblastoma highlighted by widespread immunoreactivity for BetaIII-tubulin (TUBB3) and nonphosphorylated neurofilament protein, and to a lesser degree, Neu-N, synaptophysin, and CD99, whereas the gliomatous component was demarcated by glial fibrillary acidic protein (GFAP) labeling.\n'
p13843
sg4
(lp13844
(dp13845
g7
I328
sg8
VP05230
p13846
sg10
I31
sg11
Vglial fibrillary acidic protein
p13847
sg13
I4
sa(dp13848
g7
I361
sg8
VP05230
p13849
sg10
I4
sg11
VGFAP
p13850
sg13
I1
sa(dp13851
g7
I271
sg8
VP14209
p13852
sg10
I4
sg11
VCD99
p13853
sg13
I1
sa(dp13854
g7
I169
sg8
VP04350
p13855
sg10
I5
sg11
VTUBB3
p13856
sg13
I1
sa(dp13857
g7
I245
sg8
VP04626
p13858
sg10
I5
sg11
VNeu-N
p13859
sg13
I1
sa(dp13860
g7
I252
sg8
VP08247
p13861
sg10
I13
sg11
Vsynaptophysin
p13862
sg13
I1
sasg17
(lp13863
(dp13864
g7
I20
sg20
VC0206093
p13865
sg10
I4
sg11
VPNET
p13866
sg13
I1
sa(dp13867
g7
I78
sg20
VC2985220
p13868
sg10
I26
sg11
Vanaplastic medulloblastoma
p13869
sg13
I2
sasa(dp13870
g2
S'To compare bladder cancer incidence between patients initiating pioglitazone treatment and patients initiating treatment with dipeptidyl-peptidase-4 inhibitors [DPP-4s] or sulfonylureas.\n'
p13871
sg4
(lp13872
(dp13873
g7
I126
sg8
g127
sg10
I22
sg11
Vdipeptidyl-peptidase-4
p13874
sg13
I1
sa(dp13875
g7
I161
sg8
g127
sg10
I6
sg11
VDPP-4s
p13876
sg13
I1
sasg17
(lp13877
(dp13878
g7
I11
sg20
VC0699885
p13879
sg10
I14
sg11
Vbladder cancer
p13880
sg13
I2
sasa(dp13881
g2
S'Pioglitazone initiators had an increased incidence of bladder cancer (308 vs 204 [DPP-4s] or 231 [sulfonylureas] per 100 000 person-years; aHR, 1.57 [1.23-2.00] vs DPP-4s and 1.32 [1.02-1.70] vs sulfonylureas).\n'
p13882
sg4
(lp13883
(dp13884
g7
I82
sg8
g127
sg10
I6
sg11
VDPP-4s
p13885
sg13
I1
sasg17
(lp13886
(dp13887
g7
I54
sg20
VC0699885
p13888
sg10
I14
sg11
Vbladder cancer
p13889
sg13
I2
sasa(dp13890
g2
S'Pioglitazone was associated with an elevated risk of bladder cancer compared with DPP-4s and sulfonylureas.\n'
p13891
sg4
(lp13892
(dp13893
g7
I82
sg8
g127
sg10
I6
sg11
VDPP-4s
p13894
sg13
I1
sasg17
(lp13895
(dp13896
g7
I53
sg20
VC0699885
p13897
sg10
I14
sg11
Vbladder cancer
p13898
sg13
I2
sasa(dp13899
g2
S'In this report, we show that binding of soluble anti-CD26 monoclonal antibody (mAb) inhibits the growth of the human renal carcinoma cells in both in vitro and in vivo experiments.\n'
p13900
sg4
(lp13901
(dp13902
g7
I48
sg8
VP27487
p13903
sg10
I35
sg11
Vanti-CD26 monoclonal antibody (mAb)
p13904
sg13
I4
sasg17
(lp13905
(dp13906
g7
I117
sg20
VC0007134
p13907
sg10
I15
sg11
Vrenal carcinoma
p13908
sg13
I2
sasa(dp13909
g2
S'The in vivo growth-inhibitory effect of anti-CD26 mAb was also assessed in a human renal carcinoma mouse xenograft model.\n'
p13910
sg4
(lp13911
(dp13912
g7
I40
sg8
VP27487
p13913
sg10
I13
sg11
Vanti-CD26 mAb
p13914
sg13
I2
sasg17
(lp13915
(dp13916
g7
I83
sg20
VC0007134
p13917
sg10
I15
sg11
Vrenal carcinoma
p13918
sg13
I2
sasa(dp13919
g2
S'Experiments with a mouse xenograft model involving human renal carcinoma cells show that anti-CD26 mAb treatment drastically inhibits tumor growth in tumor-bearing mice, resulting in enhanced survival.\n'
p13920
sg4
(lp13921
(dp13922
g7
I89
sg8
VP27487
p13923
sg10
I13
sg11
Vanti-CD26 mAb
p13924
sg13
I2
sasg17
(lp13925
(dp13926
g7
I57
sg20
VC0007134
p13927
sg10
I15
sg11
Vrenal carcinoma
p13928
sg13
I2
sa(dp13929
g7
I134
sg20
VC0027651
p13930
sg10
I5
sg11
Vtumor
p13931
sg13
I1
sa(dp13932
g7
I134
sg20
VC0598934
p13933
sg10
I12
sg11
Vtumor growth
p13934
sg13
I2
sasa(dp13935
g2
S'Taken together, our data strongly suggest that anti-CD26 mAb treatment may have potential clinical use for CD26-positive renal cell carcinomas.\n'
p13936
sg4
(lp13937
(dp13938
g7
I52
sg8
VP27487
p13939
sg10
I4
sg11
VCD26
p13940
sg13
I1
sa(dp13941
g7
I47
sg8
VP27487
p13942
sg10
I13
sg11
Vanti-CD26 mAb
p13943
sg13
I2
sasg17
(lp13944
(dp13945
g7
I121
sg20
VC0007134
p13946
sg10
I21
sg11
Vrenal cell carcinomas
p13947
sg13
I3
sasa(dp13948
g2
S'Previously, we have reported that overexpression of IHPK2 (inositol hexakisphosphate kinase 2) sensitized NIH-OVCAR-3 ovarian carcinoma cell lines to the growth-suppressive and apoptotic effects of IFN-beta (interferon-beta) treatment and gamma-irradiation.\n'
p13949
sg4
(lp13950
(dp13951
g7
I59
sg8
g127
sg10
I34
sg11
Vinositol hexakisphosphate kinase 2
p13952
sg13
I4
sa(dp13953
g7
I52
sg8
g127
sg10
I5
sg11
VIHPK2
p13954
sg13
I1
sa(dp13955
g7
I208
sg8
VP01563
p13956
sg10
I15
sg11
Vinterferon-beta
p13957
sg13
I1
sa(dp13958
g7
I198
sg8
VP01574
p13959
sg10
I8
sg11
VIFN-beta
p13960
sg13
I1
sasg17
(lp13961
(dp13962
g7
I118
sg20
VC0029925
p13963
sg10
I17
sg11
Vovarian carcinoma
p13964
sg13
I2
sasa(dp13965
g2
S'Apo2L/TRAIL expression and nuclear localization of IHPK2 are both required for the induction of apoptosis by IFN-beta in ovarian carcinoma.\n'
p13966
sg4
(lp13967
(dp13968
g7
I51
sg8
g127
sg10
I5
sg11
VIHPK2
p13969
sg13
I1
sa(dp13970
g7
I6
sg8
VP50591
p13971
sg10
I5
sg11
VTRAIL
p13972
sg13
I1
sa(dp13973
g7
I109
sg8
VP01574
p13974
sg10
I8
sg11
VIFN-beta
p13975
sg13
I1
sa(dp13976
g7
I0
sg8
VP50591
p13977
sg10
I5
sg11
VApo2L
p13978
sg13
I1
sasg17
(lp13979
(dp13980
g7
I121
sg20
VC0029925
p13981
sg10
I17
sg11
Vovarian carcinoma
p13982
sg13
I2
sasa(dp13983
g2
S'IP6K2 is post-transcriptionally induced by IFN-beta in ovarian carcinoma cells.\n'
p13984
sg4
(lp13985
(dp13986
g7
I43
sg8
VP01574
p13987
sg10
I8
sg11
VIFN-beta
p13988
sg13
I1
sa(dp13989
g7
I0
sg8
g127
sg10
I5
sg11
VIP6K2
p13990
sg13
I1
sasg17
(lp13991
(dp13992
g7
I55
sg20
VC0029925
p13993
sg10
I17
sg11
Vovarian carcinoma
p13994
sg13
I2
sasa(dp13995
g2
S'The histamine H1-receptor antagonist bepotastine improved encephalomyocarditis viral myocarditis.\n'
p13996
sg4
(lp13997
(dp13998
g7
I4
sg8
g127
sg10
I21
sg11
Vhistamine H1-receptor
p13999
sg13
I2
sasg17
(lp14000
(dp14001
g7
I79
sg20
VC0276138
p14002
sg10
I17
sg11
Vviral myocarditis
p14003
sg13
I2
sasa(dp14004
g2
S'Histamine H1 receptor expression has been reported to change in disorders such as allergic rhinitis, autoimmune myocarditis, rheumatoid arthritis and atherosclerosis.\n'
p14005
sg4
(lp14006
(dp14007
g7
I0
sg8
VP35367
p14008
sg10
I21
sg11
VHistamine H1 receptor
p14009
sg13
I3
sasg17
(lp14010
(dp14011
g7
I150
sg20
VC0004153
p14012
sg10
I15
sg11
Vatherosclerosis
p14013
sg13
I1
sa(dp14014
g7
I101
sg20
VC1608389
p14015
sg10
I22
sg11
Vautoimmune myocarditis
p14016
sg13
I2
sa(dp14017
g7
I82
sg20
VC2607914
p14018
sg10
I17
sg11
Vallergic rhinitis
p14019
sg13
I2
sa(dp14020
g7
I125
sg20
VC0003873
p14021
sg10
I20
sg11
Vrheumatoid arthritis
p14022
sg13
I2
sasa(dp14023
g2
S'Recent evidence indicates that a few human microRNAs (miRNAs), in particular hsa-miR-199a-3p and hsa-miR-590-3p, stimulate proliferation of cardiomyocytes and, once expressed in the mouse heart using viral vectors, induce cardiac regeneration after myocardial infarction.\n'
p14024
sg4
(lp14025
(dp14026
g7
I77
sg8
g127
sg10
I15
sg11
Vhsa-miR-199a-3p
p14027
sg13
I1
sa(dp14028
g7
I97
sg8
g127
sg10
I14
sg11
Vhsa-miR-590-3p
p14029
sg13
I1
sasg17
(lp14030
(dp14031
g7
I77
sg20
VC0393754
p14032
sg10
I3
sg11
Vhsa
p14033
sg13
I1
sa(dp14034
g7
I123
sg20
VC0334094
p14035
sg10
I13
sg11
Vproliferation
p14036
sg13
I1
sa(dp14037
g7
I249
sg20
VC0027051
p14038
sg10
I21
sg11
Vmyocardial infarction
p14039
sg13
I2
sa(dp14040
g7
I77
sg20
VC0393754
p14041
sg10
I3
sg11
Vhsa
p14042
sg13
I1
sasa(dp14043
g2
S"The present study focuses on the role of hsa-miR-590-3p and its function in Parkinson's disease (PD).\n"
p14044
sg4
(lp14045
(dp14046
g7
I41
sg8
g127
sg10
I14
sg11
Vhsa-miR-590-3p
p14047
sg13
I1
sasg17
(lp14048
(dp14049
g7
I97
sg20
VC0030567
p14050
sg10
I2
sg11
VPD
p14051
sg13
I1
sa(dp14052
g7
I76
sg20
VC0030567
p14053
sg10
I19
sg11
VParkinson's disease
p14054
sg13
I2
sa(dp14055
g7
I41
sg20
VC0393754
p14056
sg10
I3
sg11
Vhsa
p14057
sg13
I1
sasa(dp14058
g2
S'To investigate whether rs12731181 (A-&gt;G) interrupted miR-590-3p-mediated suppression of the prostaglandin F2Alfa receptor (FP) and whether it is associated with essential hypertension in the Chinese population.\n'
p14059
sg4
(lp14060
(dp14061
g7
I56
sg8
g127
sg10
I10
sg11
VmiR-590-3p
p14062
sg13
I1
sa(dp14063
g7
I95
sg8
g127
sg10
I29
sg11
Vprostaglandin F2Alfa receptor
p14064
sg13
I3
sasg17
(lp14065
(dp14066
g7
I164
sg20
VC0085580
p14067
sg10
I22
sg11
Vessential hypertension
p14068
sg13
I2
sa(dp14069
g7
I76
sg20
VC0221103
p14070
sg10
I11
sg11
Vsuppression
p14071
sg13
I1
sasa(dp14072
g2
S'rs12731181 in the seed region of the miR-590-3p target site is associated with increased risk of essential hypertension and represents a new paradigm for FP involvement in blood pressure regulation.\n'
p14073
sg4
(lp14074
(dp14075
g7
I37
sg8
g127
sg10
I22
sg11
VmiR-590-3p target site
p14076
sg13
I3
sasg17
(lp14077
(dp14078
g7
I97
sg20
VC0085580
p14079
sg10
I22
sg11
Vessential hypertension
p14080
sg13
I2
sasa(dp14081
g2
S'The meta-analysis showed that anti-VEGF/VEGFR agents were associated with smaller size (standardized mean difference (SMD) -0.96, 95% CI -1.31 to -0.62; P &lt; 0.0001) and weight (SMD -1.70, 95% CI -2.75 to -0.65; P = 0.002) of endometriosis lesions, relative to the untreated controls, as well as a lower incidence rate of endometriosis (risk ratio 0.26, 95% CI 0.07 to 0.93; P = 0.038) and endometriosis score (SMD -1.17, 95% CI -1.65 to -0.69; P &lt; 0.0001); the number of follicles were similar (SMD -0.78, 95% CI -1.65 to 0.09; P = 0.08).\n'
p14082
sg4
(lp14083
(dp14084
g7
I40
sg8
VP35968
p14085
sg10
I5
sg11
VVEGFR
p14086
sg13
I1
sasg17
(lp14087
(dp14088
g7
I118
sg20
VC0700635
p14089
sg10
I3
sg11
VSMD
p14090
sg13
I1
sa(dp14091
g7
I228
sg20
VC0014175
p14092
sg10
I13
sg11
Vendometriosis
p14093
sg13
I1
sa(dp14094
g7
I118
sg20
VC0700635
p14095
sg10
I3
sg11
VSMD
p14096
sg13
I1
sa(dp14097
g7
I228
sg20
VC0014175
p14098
sg10
I13
sg11
Vendometriosis
p14099
sg13
I1
sa(dp14100
g7
I118
sg20
VC0700635
p14101
sg10
I3
sg11
VSMD
p14102
sg13
I1
sa(dp14103
g7
I228
sg20
VC0014175
p14104
sg10
I13
sg11
Vendometriosis
p14105
sg13
I1
sa(dp14106
g7
I118
sg20
VC0700635
p14107
sg10
I3
sg11
VSMD
p14108
sg13
I1
sasa(dp14109
g2
S'CA125 was associated with endometriosis in the overall population (SMD 0.82, 95% CI 0.72, 0.92), Caucasian subgroup (SMD 1.08, 95% CI 0.96, 1.19), and early (SMD 1.20, 95% CI 0.93, 1.48) or advanced disease (SMD 1.29, 95% CI 1.04, 1.55).\n'
p14110
sg4
(lp14111
(dp14112
g7
I0
sg8
g127
sg10
I5
sg11
VCA125
p14113
sg13
I1
sasg17
(lp14114
(dp14115
g7
I67
sg20
VC0700635
p14116
sg10
I3
sg11
VSMD
p14117
sg13
I1
sa(dp14118
g7
I67
sg20
VC0700635
p14119
sg10
I3
sg11
VSMD
p14120
sg13
I1
sa(dp14121
g7
I67
sg20
VC0700635
p14122
sg10
I3
sg11
VSMD
p14123
sg13
I1
sa(dp14124
g7
I26
sg20
VC0014175
p14125
sg10
I13
sg11
Vendometriosis
p14126
sg13
I1
sa(dp14127
g7
I67
sg20
VC0700635
p14128
sg10
I3
sg11
VSMD
p14129
sg13
I1
sasa(dp14130
g2
S'Prospective clinical trials are mandatory to analyze the safety of ACE-inhibitors and benzodiazepines in elderly patients with diabetes.\n'
p14131
sg4
(lp14132
(dp14133
g7
I67
sg8
VP12821
p14134
sg10
I3
sg11
VACE
p14135
sg13
I1
sasg17
(lp14136
(dp14137
g7
I127
sg20
VC0011849
p14138
sg10
I8
sg11
Vdiabetes
p14139
sg13
I1
sasa(dp14140
g2
S'5A5A and 5A6A genotypes of MMP-3 (odds ratio (OR) 1.5; P = 0.021), II and ID genotypes of ACE (OR 1.7; P = 0.006) along with traditional ischaemic heart disease risk factors such as smoking (OR 4.9; P = 0.001), hypertension (OR 2.0; P = 0.001), diabetes mellitus (OR 2.9; P = 0.001) and dyslipidaemia (OR 2.1; P = 0.001) increased the risk of STEMI.\n'
p14141
sg4
(lp14142
(dp14143
g7
I90
sg8
VP12821
p14144
sg10
I3
sg11
VACE
p14145
sg13
I1
sa(dp14146
g7
I27
sg8
VP08254
p14147
sg10
I5
sg11
VMMP-3
p14148
sg13
I1
sasg17
(lp14149
(dp14150
g7
I211
sg20
VC0020538
p14151
sg10
I12
sg11
Vhypertension
p14152
sg13
I1
sa(dp14153
g7
I287
sg20
VC0242339
p14154
sg10
I13
sg11
Vdyslipidaemia
p14155
sg13
I1
sa(dp14156
g7
I245
sg20
VC0011849
p14157
sg10
I17
sg11
Vdiabetes mellitus
p14158
sg13
I2
sa(dp14159
g7
I137
sg20
VC0151744
p14160
sg10
I23
sg11
Vischaemic heart disease
p14161
sg13
I3
sa(dp14162
g7
I343
sg20
VC1536220
p14163
sg10
I5
sg11
VSTEMI
p14164
sg13
I1
sasa(dp14165
g2
S'To determine if elderly women &gt; 60 who practice physical activity regularly had differences in sarcopenic obesity according to the I/D polymorphism from the ACE (angiotensin converter enzyme) gen. Cross-sectional study of 300 elderly women who have practiced physical exercise at least twice a week for the past two years.\n'
p14166
sg4
(lp14167
(dp14168
g7
I134
sg8
VP22304
p14169
sg10
I3
sg11
VI/D
p14170
sg13
I1
sa(dp14171
g7
I195
sg8
g127
sg10
I3
sg11
Vgen
p14172
sg13
I1
sa(dp14173
g7
I165
sg8
VP21549
p14174
sg10
I28
sg11
Vangiotensin converter enzyme
p14175
sg13
I3
sa(dp14176
g7
I160
sg8
VP12821
p14177
sg10
I3
sg11
VACE
p14178
sg13
I1
sasg17
(lp14179
(dp14180
g7
I109
sg20
VC0028754
p14181
sg10
I7
sg11
Vobesity
p14182
sg13
I1
sasa(dp14183
g2
S'Anthropometric data, physical activity and sedentary behaviour questionnaire, sarcopenic obesity (determining the percentage of fat mass and total muscle mass by electrical impedance and grouping the quintiles of these values into four groups) and physical fitness assessment, as well as ACE gen genotype measured by oral mucosa sample, were evaluated.\n'
p14184
sg4
(lp14185
(dp14186
g7
I288
sg8
VP12821
p14187
sg10
I16
sg11
VACE gen genotype
p14188
sg13
I3
sasg17
(lp14189
(dp14190
g7
I89
sg20
VC0028754
p14191
sg10
I7
sg11
Vobesity
p14192
sg13
I1
sasa(dp14193
g2
S'There were significant differences (p &lt; 0.05) in sarcopenic obesity according to ACE I/D genotype (SO values: 2.18 ACE DD vs 2.48 ACE II + ACE ID).\n'
p14194
sg4
(lp14195
(dp14196
g7
I84
sg8
VP12821
p14197
sg10
I16
sg11
VACE I/D genotype
p14198
sg13
I3
sa(dp14199
g7
I115
sg8
VP12821
p14200
sg10
I33
sg11
V18 ACE DD vs 2.48 ACE II + ACE ID
p14201
sg13
I10
sasg17
(lp14202
(dp14203
g7
I63
sg20
VC0028754
p14204
sg10
I7
sg11
Vobesity
p14205
sg13
I1
sasa(dp14206
g2
S'Women who were ACE DD presented lower risk of sarcopenic obesity than those in the ACE II and ACE ID groups.\n'
p14207
sg4
(lp14208
(dp14209
g7
I83
sg8
VP12821
p14210
sg10
I6
sg11
VACE II
p14211
sg13
I2
sa(dp14212
g7
I15
sg8
VP12821
p14213
sg10
I3
sg11
VACE
p14214
sg13
I1
sasg17
(lp14215
(dp14216
g7
I57
sg20
VC0028754
p14217
sg10
I7
sg11
Vobesity
p14218
sg13
I1
sasa(dp14219
g2
S'To determine the prevalence of obesity according to the AACE/ACE framework based on a complications-centric model with further application of the Cardiometabolic Disease Staging (CMDS) system in Venezuelan population.\n'
p14220
sg4
(lp14221
(dp14222
g7
I57
sg8
VP12821
p14223
sg10
I3
sg11
VACE
p14224
sg13
I1
sasg17
(lp14225
(dp14226
g7
I31
sg20
VC0028754
p14227
sg10
I7
sg11
Vobesity
p14228
sg13
I1
sasa(dp14229
g2
S'AACE/ACE framework definitions: overweight: body mass index (BMI) 25 to 29.9 kg/m2 and no obesity-related complications (ORC); obesity stage 0: BMI &gt;= 30 and no ORC; stage 1: BMI &gt;= 25 and one or more mild-to-moderate ORC; and stage 2: BMI &gt;= 25 and one or more severe ORC.\n'
p14230
sg4
(lp14231
(dp14232
g7
I1
sg8
VP12821
p14233
sg10
I3
sg11
VACE
p14234
sg13
I1
sasg17
(lp14235
(dp14236
g7
I90
sg20
VC0028754
p14237
sg10
I7
sg11
Vobesity
p14238
sg13
I1
sa(dp14239
g7
I32
sg20
VC0497406
p14240
sg10
I10
sg11
Voverweight
p14241
sg13
I1
sa(dp14242
g7
I90
sg20
VC0028754
p14243
sg10
I7
sg11
Vobesity
p14244
sg13
I1
sasa(dp14245
g2
S'The prevalence of obesity according to the AACE/ACE framework was 63.5%: overweight 3.0% (95% CI: 2.1 - 3.9); obesity stage 0: 0.1% (0.07 - 0.27); obesity stage 1: 26.6% (24.2 - 29.0); and obesity stage 2: 36.4% (33.8 - 39.0).\n'
p14246
sg4
(lp14247
(dp14248
g7
I44
sg8
VP12821
p14249
sg10
I3
sg11
VACE
p14250
sg13
I1
sasg17
(lp14251
(dp14252
g7
I18
sg20
VC0028754
p14253
sg10
I7
sg11
Vobesity
p14254
sg13
I1
sa(dp14255
g7
I73
sg20
VC0497406
p14256
sg10
I10
sg11
Voverweight
p14257
sg13
I1
sa(dp14258
g7
I18
sg20
VC0028754
p14259
sg10
I7
sg11
Vobesity
p14260
sg13
I1
sa(dp14261
g7
I18
sg20
VC0028754
p14262
sg10
I7
sg11
Vobesity
p14263
sg13
I1
sa(dp14264
g7
I18
sg20
VC0028754
p14265
sg10
I7
sg11
Vobesity
p14266
sg13
I1
sasa(dp14267
g2
S'In a general population study, applying the AACE/ACE framework for obesity and CMDS increased the detection of ORC and therefore higher risk subjects compared to classic anthropometric measurements.\n'
p14268
sg4
(lp14269
(dp14270
g7
I45
sg8
VP12821
p14271
sg10
I3
sg11
VACE
p14272
sg13
I1
sasg17
(lp14273
(dp14274
g7
I67
sg20
VC0028754
p14275
sg10
I7
sg11
Vobesity
p14276
sg13
I1
sasa(dp14277
g2
S'Among Shors, the following factors increased AH risk: female sex, age, hypercholesterolemia, hyperbetacholesterinemia, hypertriglyceridemia, obesity (including transabdominal obesity), glucose intolerance, and the DD ACE, CT MTHFR, and AA ADRB1 genotypes; among the non-indigenous population, the main factors were age, hypercholesterolemia, hyperbetacholesterinemia, hypoalfacholesterinemia, hypertriglyceridemia, obesity (including transabdominal obesity), and ID ACE genotype.\n'
p14278
sg4
(lp14279
(dp14280
g7
I222
sg8
VP42898
p14281
sg10
I8
sg11
VCT MTHFR
p14282
sg13
I2
sa(dp14283
g7
I236
sg8
VP08588
p14284
sg10
I8
sg11
VAA ADRB1
p14285
sg13
I2
sa(dp14286
g7
I463
sg8
VP12821
p14287
sg10
I6
sg11
VID ACE
p14288
sg13
I2
sa(dp14289
g7
I214
sg8
VP12821
p14290
sg10
I6
sg11
VDD ACE
p14291
sg13
I2
sasg17
(lp14292
(dp14293
g7
I71
sg20
VC0020443
p14294
sg10
I20
sg11
Vhypercholesterolemia
p14295
sg13
I1
sa(dp14296
g7
I141
sg20
VC0028754
p14297
sg10
I7
sg11
Vobesity
p14298
sg13
I1
sa(dp14299
g7
I141
sg20
VC0028754
p14300
sg10
I7
sg11
Vobesity
p14301
sg13
I1
sa(dp14302
g7
I141
sg20
VC0028754
p14303
sg10
I7
sg11
Vobesity
p14304
sg13
I1
sa(dp14305
g7
I141
sg20
VC0028754
p14306
sg10
I7
sg11
Vobesity
p14307
sg13
I1
sa(dp14308
g7
I71
sg20
VC0020443
p14309
sg10
I20
sg11
Vhypercholesterolemia
p14310
sg13
I1
sa(dp14311
g7
I185
sg20
VC0271650
p14312
sg10
I19
sg11
Vglucose intolerance
p14313
sg13
I2
sasa(dp14314
g2
S'We examined whether Beta-blockers and ACE inhibitors (ACEI) are associated with differential effects on mortality in CHF patients with and without diabetes.\n'
p14315
sg4
(lp14316
(dp14317
g7
I38
sg8
VP12821
p14318
sg10
I3
sg11
VACE
p14319
sg13
I1
sasg17
(lp14320
(dp14321
g7
I117
sg20
VC0018802
p14322
sg10
I3
sg11
VCHF
p14323
sg13
I1
sa(dp14324
g7
I147
sg20
VC0011849
p14325
sg10
I8
sg11
Vdiabetes
p14326
sg13
I1
sasa(dp14327
g2
S'Patients with diabetes were prescribed larger doses of Beta-blocker and ACEI than were patients without diabetes.\n'
p14328
sg4
(lp14329
sg17
(lp14330
(dp14331
g7
I14
sg20
VC0011849
p14332
sg10
I8
sg11
Vdiabetes
p14333
sg13
I1
sa(dp14334
g7
I14
sg20
VC0011849
p14335
sg10
I8
sg11
Vdiabetes
p14336
sg13
I1
sasa(dp14337
g2
S'Increasing ACEI dose was associated with lower mortality in patients with diabetes (5.9% per mg/day; 95% CI 2.5-9.2) and without diabetes (5.1% per mg/day; 95% CI 2.6-7.6), with similar effect size in these groups (interaction P = 0.76).\n'
p14338
sg4
(lp14339
sg17
(lp14340
(dp14341
g7
I74
sg20
VC0011849
p14342
sg10
I8
sg11
Vdiabetes
p14343
sg13
I1
sa(dp14344
g7
I74
sg20
VC0011849
p14345
sg10
I8
sg11
Vdiabetes
p14346
sg13
I1
sasa(dp14347
g2
S'We report on a prenatal diagnosis of severe ventriculomegaly in association with spinal dysraphism that was indicative of a Currarino syndrome (CS) due to a c.584delA, p.H195fsX28 truncated mutation within the HLXB9 gene.\n'
p14348
sg4
(lp14349
(dp14350
g7
I210
sg8
VP50219
p14351
sg10
I10
sg11
VHLXB9 gene
p14352
sg13
I2
sasg17
(lp14353
(dp14354
g7
I124
sg20
VC1531773
p14355
sg10
I18
sg11
VCurrarino syndrome
p14356
sg13
I2
sa(dp14357
g7
I81
sg20
VC0080178
p14358
sg10
I17
sg11
Vspinal dysraphism
p14359
sg13
I2
sa(dp14360
g7
I144
sg20
VC1531773
p14361
sg10
I2
sg11
VCS
p14362
sg13
I1
sasa(dp14363
g2
S'This study demonstrated that immunotherapy with both IL-2 and GM-CSF may be useful to treat multidrug resistant tuberculosis (MDR-TB).\n'
p14364
sg4
(lp14365
(dp14366
g7
I62
sg8
VP04141
p14367
sg10
I6
sg11
VGM-CSF
p14368
sg13
I1
sa(dp14369
g7
I53
sg8
VP60568
p14370
sg10
I4
sg11
VIL-2
p14371
sg13
I1
sasg17
(lp14372
(dp14373
g7
I126
sg20
VC0206526
p14374
sg10
I6
sg11
VMDR-TB
p14375
sg13
I1
sa(dp14376
g7
I92
sg20
VC0206526
p14377
sg10
I32
sg11
Vmultidrug resistant tuberculosis
p14378
sg13
I3
sasa(dp14379
g2
S'Neuroblastomas with poor prognosis are often characterized by 1p36 deletion, containing the kinesin gene KIF1B.\n'
p14380
sg4
(lp14381
(dp14382
g7
I92
sg8
g127
sg10
I18
sg11
Vkinesin gene KIF1B
p14383
sg13
I3
sasg17
(lp14384
(dp14385
g7
I0
sg20
VC0027819
p14386
sg10
I14
sg11
VNeuroblastomas
p14387
sg13
I1
sasa(dp14388
g2
S'KIF1B is a candidate tumor-suppressor gene in neuroblastoma whose function is to mediate apoptosis when nerve growth factor becomes limiting in the developing nervous system.\n'
p14389
sg4
(lp14390
(dp14391
g7
I104
sg8
VP01138
p14392
sg10
I19
sg11
Vnerve growth factor
p14393
sg13
I3
sa(dp14394
g7
I21
sg8
g127
sg10
I21
sg11
Vtumor-suppressor gene
p14395
sg13
I2
sasg17
(lp14396
(dp14397
g7
I21
sg20
VC0027651
p14398
sg10
I5
sg11
Vtumor
p14399
sg13
I1
sa(dp14400
g7
I46
sg20
VC0027819
p14401
sg10
I13
sg11
Vneuroblastoma
p14402
sg13
I1
sa(dp14403
g7
I159
sg20
VC0027769
p14404
sg10
I7
sg11
Vnervous
p14405
sg13
I1
sasa(dp14406
g2
S'Inherited KIF1B loss-of-function mutations in neuroblastomas and pheochromocytomas implicate the kinesin KIF1B as a 1p36.2 tumor suppressor.\n'
p14407
sg4
(lp14408
(dp14409
g7
I97
sg8
g127
sg10
I13
sg11
Vkinesin KIF1B
p14410
sg13
I2
sasg17
(lp14411
(dp14412
g7
I46
sg20
VC0027819
p14413
sg10
I14
sg11
Vneuroblastomas
p14414
sg13
I1
sa(dp14415
g7
I123
sg20
VC0027651
p14416
sg10
I5
sg11
Vtumor
p14417
sg13
I1
sa(dp14418
g7
I65
sg20
VC0031511
p14419
sg10
I17
sg11
Vpheochromocytomas
p14420
sg13
I1
sasa(dp14421
g2
S'Moreover, neuroblastomas with chromosomal deletion of 1p36 exhibit loss of KIF1BBeta expression and impaired DHX9 nuclear localization, implicating the loss of DHX9 nuclear activity in neuroblastoma pathogenesis.\n'
p14422
sg4
(lp14423
(dp14424
g7
I109
sg8
g127
sg10
I4
sg11
VDHX9
p14425
sg13
I1
sa(dp14426
g7
I109
sg8
g127
sg10
I4
sg11
VDHX9
p14427
sg13
I1
sasg17
(lp14428
(dp14429
g7
I30
sg20
VC0008628
p14430
sg10
I20
sg11
Vchromosomal deletion
p14431
sg13
I2
sa(dp14432
g7
I10
sg20
VC0027819
p14433
sg10
I14
sg11
Vneuroblastomas
p14434
sg13
I1
sa(dp14435
g7
I100
sg20
VC0684336
p14436
sg10
I8
sg11
Vimpaired
p14437
sg13
I1
sa(dp14438
g7
I10
sg20
VC0027819
p14439
sg10
I13
sg11
Vneuroblastoma
p14440
sg13
I1
sa(dp14441
g7
I199
sg20
VC0699748
p14442
sg10
I12
sg11
Vpathogenesis
p14443
sg13
I1
sasa(dp14444
g2
S'KIF1BBeta has neuroblastoma tumor-suppressor properties and promotes and requires nuclear-localized DHX9 for its apoptotic function by activating XAF1 expression.\n'
p14445
sg4
(lp14446
(dp14447
g7
I100
sg8
g127
sg10
I4
sg11
VDHX9
p14448
sg13
I1
sa(dp14449
g7
I146
sg8
g127
sg10
I4
sg11
VXAF1
p14450
sg13
I1
sasg17
(lp14451
(dp14452
g7
I14
sg20
VC0027819
p14453
sg10
I13
sg11
Vneuroblastoma
p14454
sg13
I1
sa(dp14455
g7
I28
sg20
VC0027651
p14456
sg10
I5
sg11
Vtumor
p14457
sg13
I1
sasa(dp14458
g2
S'At least three genes (HDNB1/UFD2, KIAA0591F/KIF1B-beta, and PEX14) were differentially expressed at high levels in favorable and at low levels in unfavorable subsets of primary neuroblastoma.\n'
p14459
sg4
(lp14460
(dp14461
g7
I22
sg8
g127
sg10
I5
sg11
VHDNB1
p14462
sg13
I1
sa(dp14463
g7
I28
sg8
g127
sg10
I4
sg11
VUFD2
p14464
sg13
I1
sa(dp14465
g7
I60
sg8
g127
sg10
I5
sg11
VPEX14
p14466
sg13
I1
sasg17
(lp14467
(dp14468
g7
I177
sg20
VC0027819
p14469
sg10
I13
sg11
Vneuroblastoma
p14470
sg13
I1
sasa(dp14471
g2
S'KIAA0591 was expressed in favorable NBLs at higher levels than in unfavorable NBLs, although RT-PCR SSCP analysis showed no mutation within the coding region of the KIAA0591 gene, when 8 neuroblastoma tissues and 15 neuroblastoma-derived cell lines were examined.\n'
p14472
sg4
(lp14473
sg17
(lp14474
(dp14475
g7
I187
sg20
VC0027819
p14476
sg10
I13
sg11
Vneuroblastoma
p14477
sg13
I1
sa(dp14478
g7
I187
sg20
VC0027819
p14479
sg10
I13
sg11
Vneuroblastoma
p14480
sg13
I1
sasa(dp14481
g2
S'The CMRS, PTGi, and plethysmography total power index (PTGVLFi) differed significantly between the diabetes patients and healthy participants.\n'
p14482
sg4
(lp14483
sg17
(lp14484
(dp14485
g7
I99
sg20
VC0011849
p14486
sg10
I8
sg11
Vdiabetes
p14487
sg13
I1
sasa(dp14488
g2
S'The specificity and sensitivity for the CMRS, PTGi, and PTVLFi comparing the diabetes patients with healthy controls were high.\n'
p14489
sg4
(lp14490
sg17
(lp14491
(dp14492
g7
I77
sg20
VC0011849
p14493
sg10
I8
sg11
Vdiabetes
p14494
sg13
I1
sasa(dp14495
g2
S'In conclusion, type-2 diabetes is associated with higher COX-2 expression, but lower eNOS and PGIS expression in subcutaneous arteries.\n'
p14496
sg4
(lp14497
(dp14498
g7
I57
sg8
VP35354
p14499
sg10
I5
sg11
VCOX-2
p14500
sg13
I1
sasg17
(lp14501
(dp14502
g7
I22
sg20
VC0011849
p14503
sg10
I8
sg11
Vdiabetes
p14504
sg13
I1
sasa(dp14505
g2
S'Eplerenone did not affect obesity-induced upregulation of cyclooxygenase (COX)-1 or prostacyclin synthase.\n'
p14506
sg4
(lp14507
(dp14508
g7
I58
sg8
VP23219
p14509
sg10
I22
sg11
Vcyclooxygenase (COX)-1
p14510
sg13
I2
sa(dp14511
g7
I84
sg8
g127
sg10
I21
sg11
Vprostacyclin synthase
p14512
sg13
I2
sasg17
(lp14513
(dp14514
g7
I26
sg20
VC0028754
p14515
sg10
I7
sg11
Vobesity
p14516
sg13
I1
sasa(dp14517
g2
S"Five proteins potentially associated with CHD (beta-2 microglobulin (B2M), alpha-1-acid glycoprotein 1 (ORM1), thrombospondin-1(THBS1), complement factor D pre-protein (CFD), and insulin-like growth factor binding protein 1 (IGFBP1)) and five potentially associated with stroke (B2M, IGFBP2, IGFBP4, IGFBP6, and hemopexin (HPX)) had high discovery phase significance level ranking and an available ELISA assay, and were included in case-control validation studies within the Women's Health Initiative (WHI) hormone therapy trials.\n"
p14518
sg4
(lp14519
(dp14520
g7
I104
sg8
VP02763
p14521
sg10
I4
sg11
VORM1
p14522
sg13
I1
sa(dp14523
g7
I69
sg8
VP61769
p14524
sg10
I3
sg11
VB2M
p14525
sg13
I1
sa(dp14526
g7
I75
sg8
VP02763
p14527
sg10
I27
sg11
Valpha-1-acid glycoprotein 1
p14528
sg13
I3
sa(dp14529
g7
I225
sg8
VP01343
p14530
sg10
I6
sg11
VIGFBP1
p14531
sg13
I1
sa(dp14532
g7
I323
sg8
VP02790
p14533
sg10
I3
sg11
VHPX
p14534
sg13
I1
sa(dp14535
g7
I292
sg8
VP22692
p14536
sg10
I6
sg11
VIGFBP4
p14537
sg13
I1
sa(dp14538
g7
I69
sg8
VP61769
p14539
sg10
I3
sg11
VB2M
p14540
sg13
I1
sa(dp14541
g7
I169
sg8
VP00746
p14542
sg10
I3
sg11
VCFD
p14543
sg13
I1
sa(dp14544
g7
I128
sg8
VP07996
p14545
sg10
I5
sg11
VTHBS1
p14546
sg13
I1
sa(dp14547
g7
I47
sg8
VP61769
p14548
sg10
I20
sg11
Vbeta-2 microglobulin
p14549
sg13
I2
sa(dp14550
g7
I179
sg8
VP01308
p14551
sg10
I44
sg11
Vinsulin-like growth factor binding protein 1
p14552
sg13
I6
sa(dp14553
g7
I111
sg8
VP07996
p14554
sg10
I16
sg11
Vthrombospondin-1
p14555
sg13
I1
sa(dp14556
g7
I42
sg8
g127
sg10
I3
sg11
VCHD
p14557
sg13
I1
sa(dp14558
g7
I312
sg8
VP02790
p14559
sg10
I9
sg11
Vhemopexin
p14560
sg13
I1
sa(dp14561
g7
I136
sg8
VP00746
p14562
sg10
I31
sg11
Vcomplement factor D pre-protein
p14563
sg13
I4
sa(dp14564
g7
I284
sg8
VP18065
p14565
sg10
I6
sg11
VIGFBP2
p14566
sg13
I1
sa(dp14567
g7
I300
sg8
VP24592
p14568
sg10
I6
sg11
VIGFBP6
p14569
sg13
I1
sasg17
(lp14570
(dp14571
g7
I169
sg20
VC1562113
p14572
sg10
I3
sg11
VCFD
p14573
sg13
I1
sa(dp14574
g7
I271
sg20
VC0038454
p14575
sg10
I6
sg11
Vstroke
p14576
sg13
I1
sa(dp14577
g7
I136
sg20
VC1562113
p14578
sg10
I31
sg11
Vcomplement factor D pre-protein
p14579
sg13
I4
sasa(dp14580
g2
S'B2M, THBS1, and CFD were confirmed (P &lt;0.05) as novel CHD risk markers, and B2M, IGFBP2, and IGFBP4 were confirmed as novel stroke disease risk markers, while the assay for HPX proved to be unreliable.\n'
p14581
sg4
(lp14582
(dp14583
g7
I96
sg8
VP22692
p14584
sg10
I6
sg11
VIGFBP4
p14585
sg13
I1
sa(dp14586
g7
I5
sg8
VP07996
p14587
sg10
I5
sg11
VTHBS1
p14588
sg13
I1
sa(dp14589
g7
I0
sg8
VP61769
p14590
sg10
I3
sg11
VB2M
p14591
sg13
I1
sa(dp14592
g7
I0
sg8
VP61769
p14593
sg10
I3
sg11
VB2M
p14594
sg13
I1
sa(dp14595
g7
I16
sg8
VP00746
p14596
sg10
I3
sg11
VCFD
p14597
sg13
I1
sa(dp14598
g7
I84
sg8
VP18065
p14599
sg10
I6
sg11
VIGFBP2
p14600
sg13
I1
sasg17
(lp14601
(dp14602
g7
I16
sg20
VC1562113
p14603
sg10
I3
sg11
VCFD
p14604
sg13
I1
sa(dp14605
g7
I127
sg20
VC0038454
p14606
sg10
I6
sg11
Vstroke
p14607
sg13
I1
sasa(dp14608
g2
S'Our study provides a new insight into the potential neuroprotective role of HPX as a contributing factor of endogenous protective mechanisms against focal cerebral ischemia injury, and HPX might be developed as a potential agent for treatment of ischemic stroke.\n'
p14609
sg4
(lp14610
(dp14611
g7
I76
sg8
VP02790
p14612
sg10
I3
sg11
VHPX
p14613
sg13
I1
sa(dp14614
g7
I76
sg8
VP02790
p14615
sg10
I3
sg11
VHPX
p14616
sg13
I1
sasg17
(lp14617
(dp14618
g7
I246
sg20
VC3272363
p14619
sg10
I15
sg11
Vischemic stroke
p14620
sg13
I2
sa(dp14621
g7
I155
sg20
VC0917798
p14622
sg10
I17
sg11
Vcerebral ischemia
p14623
sg13
I2
sasa(dp14624
g2
S'Hemopexin provides neuroprotection in mouse models of stroke and intracerebral hemorrhage and protects neurons in vitro against heme or reactive oxygen species (ROS) toxicity via heme oxygenase-1 (HO1) activity.\n'
p14625
sg4
(lp14626
(dp14627
g7
I197
sg8
VP09601
p14628
sg10
I3
sg11
VHO1
p14629
sg13
I1
sa(dp14630
g7
I179
sg8
VP09601
p14631
sg10
I16
sg11
Vheme oxygenase-1
p14632
sg13
I2
sa(dp14633
g7
I0
sg8
VP02790
p14634
sg10
I9
sg11
VHemopexin
p14635
sg13
I1
sasg17
(lp14636
(dp14637
g7
I65
sg20
VC2937358
p14638
sg10
I24
sg11
Vintracerebral hemorrhage
p14639
sg13
I2
sa(dp14640
g7
I54
sg20
VC0038454
p14641
sg10
I6
sg11
Vstroke
p14642
sg13
I1
sasa(dp14643
g2
S'Hemopexin is a serum, CSF, and neuronal protein that is protective after experimental stroke.\n'
p14644
sg4
(lp14645
(dp14646
g7
I22
sg8
VP04141
p14647
sg10
I3
sg11
VCSF
p14648
sg13
I1
sa(dp14649
g7
I0
sg8
VP02790
p14650
sg10
I9
sg11
VHemopexin
p14651
sg13
I1
sasg17
(lp14652
(dp14653
g7
I86
sg20
VC0038454
p14654
sg10
I6
sg11
Vstroke
p14655
sg13
I1
sasa(dp14656
g2
S'We found six proteins that were upregulated in IIH (sterol regulatory element-binding protein 1, zinc-alpha-2-glycoprotein, immunoglobulin heavy constant alpha 1 [IGHA1], alpha-1-antitrypsin [SERPINA1], serotransferrin, haptoglobin) and four proteins that were downregulated (hemopexin, angiotensinogen, vitamin-D-binding protein, transthyretin).\n'
p14657
sg4
(lp14658
(dp14659
g7
I331
sg8
VP02766
p14660
sg10
I13
sg11
Vtransthyretin
p14661
sg13
I1
sa(dp14662
g7
I220
sg8
VP00738
p14663
sg10
I11
sg11
Vhaptoglobin
p14664
sg13
I1
sa(dp14665
g7
I203
sg8
VP02787
p14666
sg10
I15
sg11
Vserotransferrin
p14667
sg13
I1
sa(dp14668
g7
I124
sg8
VP01876
p14669
sg10
I45
sg11
Vimmunoglobulin heavy constant alpha 1 [IGHA1]
p14670
sg13
I6
sa(dp14671
g7
I287
sg8
VP01019
p14672
sg10
I42
sg11
Vangiotensinogen, vitamin-D-binding protein
p14673
sg13
I3
sa(dp14674
g7
I52
sg8
VP36956
p14675
sg10
I43
sg11
Vsterol regulatory element-binding protein 1
p14676
sg13
I5
sa(dp14677
g7
I97
sg8
VP25311
p14678
sg10
I25
sg11
Vzinc-alpha-2-glycoprotein
p14679
sg13
I1
sa(dp14680
g7
I171
sg8
VP25100
p14681
sg10
I19
sg11
Valpha-1-antitrypsin
p14682
sg13
I1
sa(dp14683
g7
I276
sg8
VP02790
p14684
sg10
I9
sg11
Vhemopexin
p14685
sg13
I1
sasg17
(lp14686
sa(dp14687
g2
S'We propose that the heme-HPX system protects against stroke-related damage by maintaining a tight balance between free and bound heme.\n'
p14688
sg4
(lp14689
sg17
(lp14690
(dp14691
g7
I53
sg20
VC0038454
p14692
sg10
I6
sg11
Vstroke
p14693
sg13
I1
sasa(dp14694
g2
S'The aim of this study was to determine whether endothelial nitric oxide synthase (eNOS) polymorphisms are associated with susceptibility to systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).\n'
p14695
sg4
(lp14696
(dp14697
g7
I47
sg8
g127
sg10
I33
sg11
Vendothelial nitric oxide synthase
p14698
sg13
I4
sa(dp14699
g7
I82
sg8
g127
sg10
I4
sg11
VeNOS
p14700
sg13
I1
sasg17
(lp14701
(dp14702
g7
I170
sg20
VC0024141
p14703
sg10
I3
sg11
VSLE
p14704
sg13
I1
sa(dp14705
g7
I140
sg20
VC0024141
p14706
sg10
I28
sg11
Vsystemic lupus erythematosus
p14707
sg13
I3
sa(dp14708
g7
I179
sg20
VC0003873
p14709
sg10
I20
sg11
Vrheumatoid arthritis
p14710
sg13
I2
sa(dp14711
g7
I201
sg20
VC0003873
p14712
sg10
I2
sg11
VRA
p14713
sg13
I1
sasa(dp14714
g2
S'To analyze the prognostic value of the polymorphisms of the thrombophilic genes: plasminogen activator inhibitor type 1 (PAI-1) (-675 4G/5G), factor XIII (FXIII) (G485T), fibrinogen (FBG) (G(-455)A), glycoprotein Ia (GPIa) (C807T), glycoprotein IIIa (GPIIIa) (T106C), and p22phox (C242T), as well as protein genes involved in the pathogenesis of endothelial dysfunction: subunits of p22phox NADH-oxidase (p22phox) (C242T), endothelial NO-synthase (eNOS) (G894T), and methylenetetrahydrofolate reductase (MTHFR) (C677T) for the development of antiphospholipid syndrome (APS) and a type of progressive lupous nephritis (LN) in patients with systemic lupus erythematosus (SLE).\n'
p14715
sg4
(lp14716
(dp14717
g7
I200
sg8
g127
sg10
I15
sg11
Vglycoprotein Ia
p14718
sg13
I2
sa(dp14719
g7
I232
sg8
VP05106
p14720
sg10
I17
sg11
Vglycoprotein IIIa
p14721
sg13
I2
sa(dp14722
g7
I171
sg8
VP22087
p14723
sg10
I10
sg11
Vfibrinogen
p14724
sg13
I1
sa(dp14725
g7
I121
sg8
VP05121
p14726
sg10
I5
sg11
VPAI-1
p14727
sg13
I1
sa(dp14728
g7
I467
sg8
VP42898
p14729
sg10
I35
sg11
Vmethylenetetrahydrofolate reductase
p14730
sg13
I2
sa(dp14731
g7
I504
sg8
VP42898
p14732
sg10
I5
sg11
VMTHFR
p14733
sg13
I1
sa(dp14734
g7
I81
sg8
VP00747
p14735
sg10
I38
sg11
Vplasminogen activator inhibitor type 1
p14736
sg13
I5
sa(dp14737
g7
I217
sg8
VP17301
p14738
sg10
I4
sg11
VGPIa
p14739
sg13
I1
sa(dp14740
g7
I272
sg8
VP13498
p14741
sg10
I7
sg11
Vp22phox
p14742
sg13
I1
sa(dp14743
g7
I272
sg8
VP13498
p14744
sg10
I7
sg11
Vp22phox
p14745
sg13
I1
sa(dp14746
g7
I383
sg8
VP13498
p14747
sg10
I20
sg11
Vp22phox NADH-oxidase
p14748
sg13
I2
sa(dp14749
g7
I183
sg8
VP22087
p14750
sg10
I3
sg11
VFBG
p14751
sg13
I1
sa(dp14752
g7
I251
sg8
VP05106
p14753
sg10
I6
sg11
VGPIIIa
p14754
sg13
I1
sa(dp14755
g7
I448
sg8
g127
sg10
I4
sg11
VeNOS
p14756
sg13
I1
sa(dp14757
g7
I142
sg8
g127
sg10
I27
sg11
Vfactor XIII (FXIII) (G485T)
p14758
sg13
I4
sa(dp14759
g7
I423
sg8
g127
sg10
I23
sg11
Vendothelial NO-synthase
p14760
sg13
I2
sasg17
(lp14761
(dp14762
g7
I346
sg20
VC0856169
p14763
sg10
I23
sg11
Vendothelial dysfunction
p14764
sg13
I2
sa(dp14765
g7
I607
sg20
VC0027697
p14766
sg10
I9
sg11
Vnephritis
p14767
sg13
I1
sa(dp14768
g7
I330
sg20
VC0699748
p14769
sg10
I12
sg11
Vpathogenesis
p14770
sg13
I1
sa(dp14771
g7
I569
sg20
VC0085409
p14772
sg10
I3
sg11
VAPS
p14773
sg13
I1
sa(dp14774
g7
I542
sg20
VC0085278
p14775
sg10
I25
sg11
Vantiphospholipid syndrome
p14776
sg13
I2
sa(dp14777
g7
I639
sg20
VC0024141
p14778
sg10
I28
sg11
Vsystemic lupus erythematosus
p14779
sg13
I3
sa(dp14780
g7
I669
sg20
VC0024141
p14781
sg10
I3
sg11
VSLE
p14782
sg13
I1
sasa(dp14783
g2
S'The aim of this study was to examine the distribution of lectin-like oxidised LDL receptor-1 (LOX-1) levels in patients with active BD, possible association of LOX-1 with the oxidised LDL (oxLDL), endothelial nitric oxide synthase (eNOS), nitric oxide (NO), endothelin-1 (ET-1) levels, and to characterise the differences between patients with active BD and those with systemic lupus erythematosus( SLE) in terms of these parameters compared with healthy controls.\n'
p14784
sg4
(lp14785
(dp14786
g7
I94
sg8
VP78380
p14787
sg10
I5
sg11
VLOX-1
p14788
sg13
I1
sa(dp14789
g7
I94
sg8
VP78380
p14790
sg10
I5
sg11
VLOX-1
p14791
sg13
I1
sa(dp14792
g7
I258
sg8
VP20800
p14793
sg10
I12
sg11
Vendothelin-1
p14794
sg13
I1
sa(dp14795
g7
I272
sg8
VP05305
p14796
sg10
I4
sg11
VET-1
p14797
sg13
I1
sa(dp14798
g7
I184
sg8
g127
sg10
I46
sg11
VLDL (oxLDL), endothelial nitric oxide synthase
p14799
sg13
I6
sa(dp14800
g7
I57
sg8
VP78380
p14801
sg10
I35
sg11
Vlectin-like oxidised LDL receptor-1
p14802
sg13
I4
sasg17
(lp14803
(dp14804
g7
I369
sg20
VC0024141
p14805
sg10
I28
sg11
Vsystemic lupus erythematosus
p14806
sg13
I3
sa(dp14807
g7
I399
sg20
VC0024141
p14808
sg10
I3
sg11
VSLE
p14809
sg13
I1
sasa(dp14810
g2
S'Therapeutic application of TRAIL or agonistic anti-DR5 mAb (MD5-1) dramatically improved survival of S. pneumoniae-infected WT mice.\n'
p14811
sg4
(lp14812
(dp14813
g7
I27
sg8
VP50591
p14814
sg10
I5
sg11
VTRAIL
p14815
sg13
I1
sa(dp14816
g7
I46
sg8
VP20039
p14817
sg10
I12
sg11
Vanti-DR5 mAb
p14818
sg13
I2
sasg17
(lp14819
sa(dp14820
g2
S'We have identified a previously unrecognized mechanism by which neutrophil-derived TRAIL induces apoptosis of DR5-expressing macrophages, thus promoting early bacterial killing in pneumococcal pneumonia.\n'
p14821
sg4
(lp14822
(dp14823
g7
I83
sg8
VP50591
p14824
sg10
I5
sg11
VTRAIL
p14825
sg13
I1
sasg17
(lp14826
(dp14827
g7
I180
sg20
VC0155862
p14828
sg10
I22
sg11
Vpneumococcal pneumonia
p14829
sg13
I2
sasa(dp14830
g2
S'Previously, we have shown that an AP-1 family member, FRA-2, is constitutively expressed in adult T-cell leukemia/lymphoma (ATL) and, together with JUND, upregulates CCR4 and promotes ATL cell growth.\n'
p14831
sg4
(lp14832
(dp14833
g7
I166
sg8
VP51679
p14834
sg10
I4
sg11
VCCR4
p14835
sg13
I1
sa(dp14836
g7
I34
sg8
VP01100
p14837
sg10
I18
sg11
VAP-1 family member
p14838
sg13
I3
sa(dp14839
g7
I54
sg8
VP15408
p14840
sg10
I5
sg11
VFRA-2
p14841
sg13
I1
sasg17
(lp14842
(dp14843
g7
I124
sg20
VC0023493
p14844
sg10
I3
sg11
VATL
p14845
sg13
I1
sa(dp14846
g7
I54
sg20
VC1858361
p14847
sg10
I3
sg11
VFRA
p14848
sg13
I1
sa(dp14849
g7
I92
sg20
VC0023493
p14850
sg10
I30
sg11
Vadult T-cell leukemia/lymphoma
p14851
sg13
I3
sa(dp14852
g7
I124
sg20
VC0023493
p14853
sg10
I3
sg11
VATL
p14854
sg13
I1
sasa(dp14855
g2
S'Previously, we investigated the transcriptional control of CCR4 expression in ATLL and have found that an activating protein 1 (AP1) family member, FBJ murine osteosarcoma viral oncogene homolog (FOS)-related antigen 2 (FRA2), is consistently expressed at high levels in ATLL and, together with v-JUN avian sarcoma virus 17 oncogene homolog D (JUND), up-regulates the expression of CCR4 as well as that of several proto-oncogenes such as v-MYB myeloblastosis viral oncogene homolog (MYB), murine double minute 2 homolog (MDM2), and B-cell lymphoma 6 (BCL6).\n'
p14856
sg4
(lp14857
(dp14858
g7
I106
sg8
VP14222
p14859
sg10
I20
sg11
Vactivating protein 1
p14860
sg13
I3
sa(dp14861
g7
I438
sg8
VP10243
p14862
sg10
I81
sg11
Vv-MYB myeloblastosis viral oncogene homolog (MYB), murine double minute 2 homolog
p14863
sg13
I11
sa(dp14864
g7
I59
sg8
VP51679
p14865
sg10
I4
sg11
VCCR4
p14866
sg13
I1
sa(dp14867
g7
I344
sg8
VP17535
p14868
sg10
I4
sg11
VJUND
p14869
sg13
I1
sa(dp14870
g7
I59
sg8
VP51679
p14871
sg10
I4
sg11
VCCR4
p14872
sg13
I1
sa(dp14873
g7
I128
sg8
VP27695
p14874
sg10
I3
sg11
VAP1
p14875
sg13
I1
sa(dp14876
g7
I148
sg8
VP01100
p14877
sg10
I70
sg11
VFBJ murine osteosarcoma viral oncogene homolog (FOS)-related antigen 2
p14878
sg13
I9
sa(dp14879
g7
I220
sg8
VP15408
p14880
sg10
I4
sg11
VFRA2
p14881
sg13
I1
sa(dp14882
g7
I295
sg8
VP05412
p14883
sg10
I47
sg11
Vv-JUN avian sarcoma virus 17 oncogene homolog D
p14884
sg13
I8
sasg17
(lp14885
(dp14886
g7
I78
sg20
VC0023493
p14887
sg10
I4
sg11
VATLL
p14888
sg13
I1
sa(dp14889
g7
I532
sg20
VC0079731
p14890
sg10
I15
sg11
VB-cell lymphoma
p14891
sg13
I2
sa(dp14892
g7
I159
sg20
VC0029463
p14893
sg10
I12
sg11
Vosteosarcoma
p14894
sg13
I1
sa(dp14895
g7
I78
sg20
VC0023493
p14896
sg10
I4
sg11
VATLL
p14897
sg13
I1
sa(dp14898
g7
I301
sg20
VC0004426
p14899
sg10
I13
sg11
Vavian sarcoma
p14900
sg13
I2
sa(dp14901
g7
I444
sg20
VC0679427
p14902
sg10
I14
sg11
Vmyeloblastosis
p14903
sg13
I1
sasa(dp14904
g2
S'The aim of this study was to evaluate the serum GDF-15 levels and their relationship with disease-related characteristics in patients with rheumatoid arthritis (RA).\n'
p14905
sg4
(lp14906
(dp14907
g7
I48
sg8
g127
sg10
I6
sg11
VGDF-15
p14908
sg13
I1
sasg17
(lp14909
(dp14910
g7
I139
sg20
VC0003873
p14911
sg10
I20
sg11
Vrheumatoid arthritis
p14912
sg13
I2
sa(dp14913
g7
I161
sg20
VC0003873
p14914
sg10
I2
sg11
VRA
p14915
sg13
I1
sasa(dp14916
g2
S'GDF-15 may play a role in the pathway of disease activity, joint involvement, and atherosclerosis in patients with rheumatoid arthritis.\n'
p14917
sg4
(lp14918
(dp14919
g7
I0
sg8
g127
sg10
I6
sg11
VGDF-15
p14920
sg13
I1
sasg17
(lp14921
(dp14922
g7
I82
sg20
VC0004153
p14923
sg10
I15
sg11
Vatherosclerosis
p14924
sg13
I1
sa(dp14925
g7
I115
sg20
VC0003873
p14926
sg10
I20
sg11
Vrheumatoid arthritis
p14927
sg13
I2
sasa(dp14928
g2
S'Serum GDF-15 levels were positively correlated with findings for peripheral arthritis and CRP, and with BDCAF erythema nodosum, BDCAF arthralgia, and BDCAF arthritis scores.\n'
p14929
sg4
(lp14930
(dp14931
g7
I0
sg8
g127
sg10
I12
sg11
VSerum GDF-15
p14932
sg13
I2
sa(dp14933
g7
I90
sg8
VP02741
p14934
sg10
I3
sg11
VCRP
p14935
sg13
I1
sasg17
(lp14936
(dp14937
g7
I76
sg20
VC0003864
p14938
sg10
I9
sg11
Varthritis
p14939
sg13
I1
sa(dp14940
g7
I76
sg20
VC0003864
p14941
sg10
I9
sg11
Varthritis
p14942
sg13
I1
sa(dp14943
g7
I110
sg20
VC0014743
p14944
sg10
I16
sg11
Verythema nodosum
p14945
sg13
I2
sa(dp14946
g7
I134
sg20
VC0003862
p14947
sg10
I10
sg11
Varthralgia
p14948
sg13
I1
sasa(dp14949
g2
S'Serum ESR, CRP, white blood cell counts, and GDF-15 levels were significantly higher in the group that was positive for peripheral arthritis (P &lt; 0.05).\n'
p14950
sg4
(lp14951
(dp14952
g7
I6
sg8
VP03372
p14953
sg10
I3
sg11
VESR
p14954
sg13
I1
sa(dp14955
g7
I11
sg8
VP02741
p14956
sg10
I3
sg11
VCRP
p14957
sg13
I1
sa(dp14958
g7
I45
sg8
g127
sg10
I6
sg11
VGDF-15
p14959
sg13
I1
sasg17
(lp14960
(dp14961
g7
I131
sg20
VC0003864
p14962
sg10
I9
sg11
Varthritis
p14963
sg13
I1
sasa(dp14964
g2
S'Supplementation of corticosterone and cortisol promoted leptin production in murine adipocytes from the 3T3-L1 cell strain and human adipocytes from the Simpson Golabi-Behmel syndrome (SGBS) cell strain, respectively.\n'
p14965
sg4
(lp14966
(dp14967
g7
I56
sg8
VP41159
p14968
sg10
I6
sg11
Vleptin
p14969
sg13
I1
sasg17
(lp14970
(dp14971
g7
I153
sg20
VC0796154
p14972
sg10
I30
sg11
VSimpson Golabi-Behmel syndrome
p14973
sg13
I3
sa(dp14974
g7
I185
sg20
VC0796154
p14975
sg10
I4
sg11
VSGBS
p14976
sg13
I1
sasa(dp14977
g2
S'When SGBS adipocytes were cultured in these CMs, leptin production was positively associated with cortisol concentrations.\n'
p14978
sg4
(lp14979
(dp14980
g7
I49
sg8
VP41159
p14981
sg10
I6
sg11
Vleptin
p14982
sg13
I1
sasg17
(lp14983
(dp14984
g7
I5
sg20
VC0796154
p14985
sg10
I4
sg11
VSGBS
p14986
sg13
I1
sasa(dp14987
g2
S'Leptin gene expression and secretion by cultured human primary adipocytes and Simpson-Golabi-Behmel Syndrome adipocytes increased upon coculture with human enterocytic Caco-2 cells or incubation in conditioned medium of Caco-2 cells.\n'
p14988
sg4
(lp14989
(dp14990
g7
I0
sg8
VP41159
p14991
sg10
I11
sg11
VLeptin gene
p14992
sg13
I2
sasg17
(lp14993
(dp14994
g7
I78
sg20
VC0796154
p14995
sg10
I30
sg11
VSimpson-Golabi-Behmel Syndrome
p14996
sg13
I2
sasa(dp14997
g2
S'SGBS adipocytes are capable of fat cell-specific metabolic functions such as insulin-stimulated glucose uptake, insulin-stimulated de novo lipogenesis and Beta-adrenergic-stimulated lipolysis and they secrete typical adipokines including leptin, adiponectin, and RBP4.\n'
p14998
sg4
(lp14999
(dp15000
g7
I263
sg8
VP02753
p15001
sg10
I4
sg11
VRBP4
p15002
sg13
I1
sa(dp15003
g7
I246
sg8
g127
sg10
I11
sg11
Vadiponectin
p15004
sg13
I1
sa(dp15005
g7
I77
sg8
VP01308
p15006
sg10
I7
sg11
Vinsulin
p15007
sg13
I1
sa(dp15008
g7
I77
sg8
VP01308
p15009
sg10
I7
sg11
Vinsulin
p15010
sg13
I1
sa(dp15011
g7
I238
sg8
VP41159
p15012
sg10
I6
sg11
Vleptin
p15013
sg13
I1
sasg17
(lp15014
(dp15015
g7
I0
sg20
VC0796154
p15016
sg10
I4
sg11
VSGBS
p15017
sg13
I1
sasa(dp15018
g2
S'Induction of hypoxia significantly induced mRNA expression of leptin and apelin in differentiated SGBS adipocytes compared with the normoxic control condition.\n'
p15019
sg4
(lp15020
(dp15021
g7
I73
sg8
g127
sg10
I6
sg11
Vapelin
p15022
sg13
I1
sa(dp15023
g7
I62
sg8
VP41159
p15024
sg10
I6
sg11
Vleptin
p15025
sg13
I1
sasg17
(lp15026
(dp15027
g7
I13
sg20
VC0242184
p15028
sg10
I7
sg11
Vhypoxia
p15029
sg13
I1
sa(dp15030
g7
I98
sg20
VC0796154
p15031
sg10
I4
sg11
VSGBS
p15032
sg13
I1
sa(dp15033
g7
I149
sg20
VC0012634
p15034
sg10
I9
sg11
Vcondition
p15035
sg13
I1
sasa(dp15036
g2
S'During the differentiation process SGBS cells developed a gene expression pattern similar to that found in differentiating human preadipocytes with a characteristic increase in fat cell-specific mRNAs encoding lipoprotein lipase (LPL), glycero-3-phosphate dehydrogenase (GPDH), GLUT4, leptin and others.\n'
p15037
sg4
(lp15038
(dp15039
g7
I230
sg8
VP06858
p15040
sg10
I3
sg11
VLPL
p15041
sg13
I1
sa(dp15042
g7
I285
sg8
VP41159
p15043
sg10
I6
sg11
Vleptin
p15044
sg13
I1
sa(dp15045
g7
I236
sg8
VP49366
p15046
sg10
I33
sg11
Vglycero-3-phosphate dehydrogenase
p15047
sg13
I2
sa(dp15048
g7
I278
sg8
VP14672
p15049
sg10
I5
sg11
VGLUT4
p15050
sg13
I1
sa(dp15051
g7
I210
sg8
VP06858
p15052
sg10
I18
sg11
Vlipoprotein lipase
p15053
sg13
I2
sa(dp15054
g7
I271
sg8
VP49366
p15055
sg10
I4
sg11
VGPDH
p15056
sg13
I1
sasg17
(lp15057
(dp15058
g7
I35
sg20
VC0796154
p15059
sg10
I4
sg11
VSGBS
p15060
sg13
I1
sasa(dp15061
g2
S'Body mass index (BMI), serum follicle stimulating hormone (FSH), luteinizing hormone (LH), progesterone, estradiol, testosterone, dehydroepiandrosterone sulfate, fasting glucose, low density lipoprotein (LDL-C), total cholesterol, high density lipoprotein (HDL-C) high sensitive CRP, c-peptide, insulin, insulin sensitivity and carotid intima thickness were compared among different phenotype groups of PCOS: Group 1-PCO (polycystic ovaries)-anovulation (n = 34), Group 2-Hyperandrogenemia (HA)-anovulation (n = 30), Group 3-HA-PCO (n = 32), and Group 4-HA-PCO-anovulation (n = 43).\n'
p15062
sg4
(lp15063
(dp15064
g7
I65
sg8
g127
sg10
I19
sg11
Vluteinizing hormone
p15065
sg13
I2
sa(dp15066
g7
I86
sg8
g127
sg10
I2
sg11
VLH
p15067
sg13
I1
sa(dp15068
g7
I179
sg8
VP02652
p15069
sg10
I23
sg11
Vlow density lipoprotein
p15070
sg13
I3
sa(dp15071
g7
I295
sg8
VP01308
p15072
sg10
I7
sg11
Vinsulin
p15073
sg13
I1
sa(dp15074
g7
I23
sg8
g127
sg10
I34
sg11
Vserum follicle stimulating hormone
p15075
sg13
I4
sa(dp15076
g7
I257
sg8
VP28845
p15077
sg10
I5
sg11
VHDL-C
p15078
sg13
I1
sa(dp15079
g7
I279
sg8
VP02741
p15080
sg10
I3
sg11
VCRP
p15081
sg13
I1
sa(dp15082
g7
I204
sg8
g127
sg10
I5
sg11
VLDL-C
p15083
sg13
I1
sa(dp15084
g7
I284
sg8
VP27708
p15085
sg10
I9
sg11
Vc-peptide
p15086
sg13
I1
sa(dp15087
g7
I59
sg8
VP01225
p15088
sg10
I3
sg11
VFSH
p15089
sg13
I1
sa(dp15090
g7
I295
sg8
VP01308
p15091
sg10
I7
sg11
Vinsulin
p15092
sg13
I1
sa(dp15093
g7
I231
sg8
VP28845
p15094
sg10
I24
sg11
Vhigh density lipoprotein
p15095
sg13
I3
sasg17
(lp15096
(dp15097
g7
I403
sg20
VC0032460
p15098
sg10
I3
sg11
VPCO
p15099
sg13
I1
sa(dp15100
g7
I403
sg20
VC0032460
p15101
sg10
I3
sg11
VPCO
p15102
sg13
I1
sa(dp15103
g7
I422
sg20
VC0032460
p15104
sg10
I18
sg11
Vpolycystic ovaries
p15105
sg13
I2
sa(dp15106
g7
I442
sg20
VC0003128
p15107
sg10
I11
sg11
Vanovulation
p15108
sg13
I1
sa(dp15109
g7
I403
sg20
VC0032460
p15110
sg10
I4
sg11
VPCOS
p15111
sg13
I1
sa(dp15112
g7
I304
sg20
VC0920563
p15113
sg10
I19
sg11
Vinsulin sensitivity
p15114
sg13
I2
sa(dp15115
g7
I442
sg20
VC0003128
p15116
sg10
I11
sg11
Vanovulation
p15117
sg13
I1
sa(dp15118
g7
I442
sg20
VC0003128
p15119
sg10
I11
sg11
Vanovulation
p15120
sg13
I1
sa(dp15121
g7
I403
sg20
VC0032460
p15122
sg10
I3
sg11
VPCO
p15123
sg13
I1
sasa(dp15124
g2
S'Only 7 of the 23 (30%) reported PYGL alleles carry nonsense, splice site or frameshift mutations compared to 68-80% of affected alleles of the highly homologous muscle glycogen phosphorylase gene, PYGM, that underlie McArdle disease.\n'
p15125
sg4
(lp15126
(dp15127
g7
I197
sg8
VP11217
p15128
sg10
I4
sg11
VPYGM
p15129
sg13
I1
sa(dp15130
g7
I150
sg8
VP11217
p15131
sg10
I40
sg11
Vhomologous muscle glycogen phosphorylase
p15132
sg13
I4
sa(dp15133
g7
I32
sg8
VP06737
p15134
sg10
I12
sg11
VPYGL alleles
p15135
sg13
I2
sasg17
(lp15136
(dp15137
g7
I217
sg20
VC0017924
p15138
sg10
I15
sg11
VMcArdle disease
p15139
sg13
I2
sa(dp15140
g7
I76
sg20
VC0079380
p15141
sg10
I20
sg11
Vframeshift mutations
p15142
sg13
I2
sasa(dp15143
g2
S'Glycogen storage disease type VI (GSD6) defines a group of disorders that cause hepatomegaly and hypoglycemia with reduced liver phosphorylase activity.\n'
p15144
sg4
(lp15145
sg17
(lp15146
(dp15147
g7
I0
sg20
VC0017925
p15148
sg10
I32
sg11
VGlycogen storage disease type VI
p15149
sg13
I5
sa(dp15150
g7
I97
sg20
VC0020615
p15151
sg10
I12
sg11
Vhypoglycemia
p15152
sg13
I1
sa(dp15153
g7
I80
sg20
VC0019209
p15154
sg10
I12
sg11
Vhepatomegaly
p15155
sg13
I1
sasa(dp15156
g2
S'We report the identification of the first mutations in PYGL, the gene encoding the liver isoform of glycogen phosphorylase, in three patients with Hers disease.\n'
p15157
sg4
(lp15158
(dp15159
g7
I55
sg8
VP06737
p15160
sg10
I4
sg11
VPYGL
p15161
sg13
I1
sa(dp15162
g7
I100
sg8
VP06737
p15163
sg10
I22
sg11
Vglycogen phosphorylase
p15164
sg13
I2
sasg17
(lp15165
(dp15166
g7
I147
sg20
VC0017925
p15167
sg10
I12
sg11
VHers disease
p15168
sg13
I2
sasa(dp15169
g2
S'Our findings demonstrate that PYGL mutations cause Hers disease, and they may improve laboratory diagnosis of deficiencies of the liver phosphorylase system.\n'
p15170
sg4
(lp15171
(dp15172
g7
I30
sg8
VP06737
p15173
sg10
I4
sg11
VPYGL
p15174
sg13
I1
sasg17
(lp15175
(dp15176
g7
I51
sg20
VC0017925
p15177
sg10
I12
sg11
VHers disease
p15178
sg13
I2
sasa(dp15179
g2
S'The enzyme deficient in glycogen storage disease type VI, liver glycogen phosphorylase (PYGL), has been localized by in situ hybridization to 14q21--&gt;q22, near the q21--&gt;q22 band interface.\n'
p15180
sg4
(lp15181
(dp15182
g7
I64
sg8
VP06737
p15183
sg10
I22
sg11
Vglycogen phosphorylase
p15184
sg13
I2
sa(dp15185
g7
I88
sg8
VP06737
p15186
sg10
I4
sg11
VPYGL
p15187
sg13
I1
sasg17
(lp15188
(dp15189
g7
I24
sg20
VC0017925
p15190
sg10
I32
sg11
Vglycogen storage disease type VI
p15191
sg13
I5
sasa(dp15192
g2
S"To investigate the characteristics of blood lipids, insulin metabolism, and paraoxonase-2-311 (PON2-311) polymorphism among patients with Alzheimer's disease with different types of dementia.\n"
p15193
sg4
(lp15194
(dp15195
g7
I52
sg8
VP01308
p15196
sg10
I7
sg11
Vinsulin
p15197
sg13
I1
sa(dp15198
g7
I76
sg8
VP14222
p15199
sg10
I17
sg11
Vparaoxonase-2-311
p15200
sg13
I1
sa(dp15201
g7
I95
sg8
VP14222
p15202
sg10
I8
sg11
VPON2-311
p15203
sg13
I1
sasg17
(lp15204
(dp15205
g7
I182
sg20
VC0497327
p15206
sg10
I8
sg11
Vdementia
p15207
sg13
I1
sa(dp15208
g7
I138
sg20
VC1521724
p15209
sg10
I19
sg11
VAlzheimer's disease
p15210
sg13
I2
sasa(dp15211
g2
S"No significant differences were found for PON2-311 genotypes or allele frequencies in patients with dementia due to Alzheimer's disease.\n"
p15212
sg4
(lp15213
(dp15214
g7
I42
sg8
g127
sg10
I18
sg11
VPON2-311 genotypes
p15215
sg13
I2
sasg17
(lp15216
(dp15217
g7
I100
sg20
VC0497327
p15218
sg10
I8
sg11
Vdementia
p15219
sg13
I1
sa(dp15220
g7
I116
sg20
VC1521724
p15221
sg10
I19
sg11
VAlzheimer's disease
p15222
sg13
I2
sasa(dp15223
g2
S"Alzheimer's disease-related genes, such as APOE, A2M, PON2 and MAP4, and cardiovascular disease-associated genes, including COMT, CBS and WNK1, all congregated in a single module.\n"
p15224
sg4
(lp15225
(dp15226
g7
I124
sg8
VP21964
p15227
sg10
I4
sg11
VCOMT
p15228
sg13
I1
sa(dp15229
g7
I63
sg8
VP27816
p15230
sg10
I4
sg11
VMAP4
p15231
sg13
I1
sa(dp15232
g7
I130
sg8
VP07858
p15233
sg10
I3
sg11
VCBS
p15234
sg13
I1
sa(dp15235
g7
I49
sg8
VP01023
p15236
sg10
I3
sg11
VA2M
p15237
sg13
I1
sa(dp15238
g7
I54
sg8
g127
sg10
I4
sg11
VPON2
p15239
sg13
I1
sa(dp15240
g7
I43
sg8
VP02649
p15241
sg10
I4
sg11
VAPOE
p15242
sg13
I1
sa(dp15243
g7
I138
sg8
g127
sg10
I4
sg11
VWNK1
p15244
sg13
I1
sasg17
(lp15245
(dp15246
g7
I73
sg20
VC0007222
p15247
sg10
I22
sg11
Vcardiovascular disease
p15248
sg13
I2
sa(dp15249
g7
I0
sg20
VC1521724
p15250
sg10
I19
sg11
VAlzheimer's disease
p15251
sg13
I2
sasa(dp15252
g2
S"The common polymorphism at codon 311 (C311S) of paraoxonase 2 gene (PON2) was investigated in 165 patients with sporadic late-onset Alzheimer's disease (LOAD) and 174 controls in Chinese.\n"
p15253
sg4
(lp15254
(dp15255
g7
I48
sg8
VP14222
p15256
sg10
I18
sg11
Vparaoxonase 2 gene
p15257
sg13
I3
sa(dp15258
g7
I68
sg8
g127
sg10
I4
sg11
VPON2
p15259
sg13
I1
sasg17
(lp15260
(dp15261
g7
I132
sg20
VC1521724
p15262
sg10
I19
sg11
VAlzheimer's disease
p15263
sg13
I2
sasa(dp15264
g2
S"(3-8) The importance of cardiovascular risk factors in the pathomechanism of Alzheimer's disease (AD) and vascular dementia (VD)(9-13) prompted us to examine the genetic effect of PON2 gene codon 311 (Cys--&gt;Ser; PON2*S) polymorphism and the relationship between the PON2*S allele and the other dementia risk factor, the apoE polymorphism in these dementias.\n"
p15265
sg4
(lp15266
(dp15267
g7
I269
sg8
g127
sg10
I13
sg11
VPON2*S allele
p15268
sg13
I2
sa(dp15269
g7
I323
sg8
VP02649
p15270
sg10
I4
sg11
VapoE
p15271
sg13
I1
sasg17
(lp15272
(dp15273
g7
I350
sg20
VC0497327
p15274
sg10
I9
sg11
Vdementias
p15275
sg13
I1
sa(dp15276
g7
I115
sg20
VC0497327
p15277
sg10
I8
sg11
Vdementia
p15278
sg13
I1
sa(dp15279
g7
I77
sg20
VC1521724
p15280
sg10
I19
sg11
VAlzheimer's disease
p15281
sg13
I2
sa(dp15282
g7
I106
sg20
VC0011269
p15283
sg10
I17
sg11
Vvascular dementia
p15284
sg13
I2
sasa(dp15285
g2
S'The clinical charts of 152 patients with hereditary glaucoma from18 Spanish eye centres were reviewed in order to make an epidemiologic description of the type of glaucoma and associated factors.\n'
p15286
sg4
(lp15287
sg17
(lp15288
(dp15289
g7
I52
sg20
VC0017601
p15290
sg10
I8
sg11
Vglaucoma
p15291
sg13
I1
sa(dp15292
g7
I52
sg20
VC0017601
p15293
sg10
I8
sg11
Vglaucoma
p15294
sg13
I1
sasa(dp15295
g2
S'Transgenic mice overexpressing Norrin in the retina (Pax6-Norrin) were generated and crossed with DBA/2J mice with hereditary glaucoma and optic nerve axonal degeneration.\n'
p15296
sg4
(lp15297
(dp15298
g7
I31
sg8
g127
sg10
I6
sg11
VNorrin
p15299
sg13
I1
sa(dp15300
g7
I53
sg8
g127
sg10
I11
sg11
VPax6-Norrin
p15301
sg13
I1
sasg17
(lp15302
(dp15303
g7
I126
sg20
VC0017601
p15304
sg10
I8
sg11
Vglaucoma
p15305
sg13
I1
sa(dp15306
g7
I98
sg20
VC0398550
p15307
sg10
I3
sg11
VDBA
p15308
sg13
I1
sa(dp15309
g7
I158
sg20
VC0011164
p15310
sg10
I12
sg11
Vdegeneration
p15311
sg13
I1
sasa(dp15312
g2
S'The association of the WDR36 gene with glaucoma has been controversial in the literature.\n'
p15313
sg4
(lp15314
(dp15315
g7
I23
sg8
g127
sg10
I10
sg11
VWDR36 gene
p15316
sg13
I2
sasg17
(lp15317
(dp15318
g7
I39
sg20
VC0017601
p15319
sg10
I8
sg11
Vglaucoma
p15320
sg13
I1
sasa(dp15321
g2
S'We therefore conducted a systematic review and meta-analysis to assess the association of all reported common polymorphisms in WDR36 with primary open angle glaucoma (POAG) and its subtypes: high tension glaucoma (HTG) and normal tension glaucoma (NTG).\n'
p15322
sg4
(lp15323
(dp15324
g7
I127
sg8
g127
sg10
I5
sg11
VWDR36
p15325
sg13
I1
sasg17
(lp15326
(dp15327
g7
I223
sg20
VC0152136
p15328
sg10
I23
sg11
Vnormal tension glaucoma
p15329
sg13
I3
sa(dp15330
g7
I196
sg20
VC0233494
p15331
sg10
I7
sg11
Vtension
p15332
sg13
I1
sa(dp15333
g7
I138
sg20
VC0339573
p15334
sg10
I27
sg11
Vprimary open angle glaucoma
p15335
sg13
I4
sa(dp15336
g7
I248
sg20
VC0152136
p15337
sg10
I3
sg11
VNTG
p15338
sg13
I1
sa(dp15339
g7
I167
sg20
VC0339573
p15340
sg10
I4
sg11
VPOAG
p15341
sg13
I1
sa(dp15342
g7
I157
sg20
VC0017601
p15343
sg10
I8
sg11
Vglaucoma
p15344
sg13
I1
sasa(dp15345
g2
S'Enrichment of qualifying variants toward glaucoma was present in all genes except WDR36, in which controls harbored more variants, and TBK1, in which no qualifying variants were detected in cases or controls.\n'
p15346
sg4
(lp15347
(dp15348
g7
I82
sg8
g127
sg10
I5
sg11
VWDR36
p15349
sg13
I1
sa(dp15350
g7
I135
sg8
g127
sg10
I4
sg11
VTBK1
p15351
sg13
I1
sasg17
(lp15352
(dp15353
g7
I41
sg20
VC0017601
p15354
sg10
I8
sg11
Vglaucoma
p15355
sg13
I1
sasa(dp15356
g2
S'We report two unrelated patients with features of cranio-osteoarthropathy, both of whom also had a history of congenital heart disease.\n'
p15357
sg4
(lp15358
sg17
(lp15359
(dp15360
g7
I110
sg20
VC0152021
p15361
sg10
I24
sg11
Vcongenital heart disease
p15362
sg13
I3
sa(dp15363
g7
I57
sg20
VC0263661
p15364
sg10
I16
sg11
Vosteoarthropathy
p15365
sg13
I1
sasa(dp15366
g2
S'We speculate that the clinical observation that prenatal glucocorticoid treatment reduces the incidence of patent ductus arteriosus in premature infants may in part be due to the stimulatory effect of glucocorticoid on the activity of 15-PGDH in fetal and neonatal lung and possibly other organs.\n'
p15367
sg4
(lp15368
(dp15369
g7
I235
sg8
VP52209
p15370
sg10
I7
sg11
V15-PGDH
p15371
sg13
I1
sasg17
(lp15372
(dp15373
g7
I107
sg20
VC0013274
p15374
sg10
I24
sg11
Vpatent ductus arteriosus
p15375
sg13
I3
sasa(dp15376
g2
S'The aim of our study was to determine if BRCA2 mutation carriers were more likely than noncarriers to demonstrate chronic pancreatitis-like changes on EUS.\n'
p15377
sg4
(lp15378
(dp15379
g7
I41
sg8
VP51587
p15380
sg10
I14
sg11
VBRCA2 mutation
p15381
sg13
I2
sasg17
(lp15382
(dp15383
g7
I114
sg20
VC0149521
p15384
sg10
I20
sg11
Vchronic pancreatitis
p15385
sg13
I2
sa(dp15386
g7
I41
sg20
VC1511024
p15387
sg10
I14
sg11
VBRCA2 mutation
p15388
sg13
I2
sasa(dp15389
g2
S'Compared with controls, BRCA2 mutation carriers had a higher prevalence of solid pancreas lesions (16.2% vs 1.08%; P = 0.005), pancreatic cysts (21.6% vs 6.1%; P = 0.01), Rosemont "consistent with chronic pancreatitis" definition changes (13.5% vs 1%; P = 0.002), and Rosemont "suggestive of chronic pancreatitis" definition changes (16.2% vs 2.1%; P = 0.003).\n'
p15390
sg4
(lp15391
(dp15392
g7
I24
sg8
VP51587
p15393
sg10
I14
sg11
VBRCA2 mutation
p15394
sg13
I2
sasg17
(lp15395
(dp15396
g7
I127
sg20
VC0030283
p15397
sg10
I16
sg11
Vpancreatic cysts
p15398
sg13
I2
sa(dp15399
g7
I197
sg20
VC0149521
p15400
sg10
I20
sg11
Vchronic pancreatitis
p15401
sg13
I2
sa(dp15402
g7
I197
sg20
VC0149521
p15403
sg10
I20
sg11
Vchronic pancreatitis
p15404
sg13
I2
sa(dp15405
g7
I24
sg20
VC1511024
p15406
sg10
I14
sg11
VBRCA2 mutation
p15407
sg13
I2
sasa(dp15408
g2
S'After adjusting for age, alcohol use, and smoking, BRCA2 mutation carriers were almost 25 times more likely to demonstrate chronic pancreatitis-like changes.\n'
p15409
sg4
(lp15410
(dp15411
g7
I51
sg8
VP51587
p15412
sg10
I14
sg11
VBRCA2 mutation
p15413
sg13
I2
sasg17
(lp15414
(dp15415
g7
I123
sg20
VC0149521
p15416
sg10
I20
sg11
Vchronic pancreatitis
p15417
sg13
I2
sa(dp15418
g7
I51
sg20
VC1511024
p15419
sg10
I14
sg11
VBRCA2 mutation
p15420
sg13
I2
sasa(dp15421
g2
S'Chronic pancreatitis-like changes, along with solid and cystic pancreatic lesions, were significantly more common in BRCA2 mutation carriers than in noncarriers.\n'
p15422
sg4
(lp15423
(dp15424
g7
I117
sg8
VP51587
p15425
sg10
I14
sg11
VBRCA2 mutation
p15426
sg13
I2
sasg17
(lp15427
(dp15428
g7
I117
sg20
VC1511024
p15429
sg10
I14
sg11
VBRCA2 mutation
p15430
sg13
I2
sa(dp15431
g7
I0
sg20
VC0149521
p15432
sg10
I20
sg11
VChronic pancreatitis
p15433
sg13
I2
sasa(dp15434
g2
S'Such subsets of familial pancreatic cancer involve germline cationic trypsinogen or PRSS1 mutations (hereditary pancreatitis), BRCA2 mutations (usually in association with hereditary breast-ovarian cancer syndrome), CDKN2 mutations (familial atypical mole and multiple melanoma), or DNA repair gene mutations (e.g., ATM and PALB2, apart from those in BRCA2).\n'
p15435
sg4
(lp15436
(dp15437
g7
I216
sg8
VP42771
p15438
sg10
I5
sg11
VCDKN2
p15439
sg13
I1
sa(dp15440
g7
I127
sg8
VP51587
p15441
sg10
I5
sg11
VBRCA2
p15442
sg13
I1
sa(dp15443
g7
I324
sg8
g127
sg10
I5
sg11
VPALB2
p15444
sg13
I1
sa(dp15445
g7
I127
sg8
VP51587
p15446
sg10
I15
sg11
VBRCA2 mutations
p15447
sg13
I2
sa(dp15448
g7
I84
sg8
VP07478
p15449
sg10
I5
sg11
VPRSS1
p15450
sg13
I1
sa(dp15451
g7
I316
sg8
g127
sg10
I3
sg11
VATM
p15452
sg13
I1
sa(dp15453
g7
I283
sg8
g127
sg10
I25
sg11
VDNA repair gene mutations
p15454
sg13
I4
sa(dp15455
g7
I51
sg8
VP07478
p15456
sg10
I29
sg11
Vgermline cationic trypsinogen
p15457
sg13
I3
sasg17
(lp15458
(dp15459
g7
I16
sg20
VC2931038
p15460
sg10
I26
sg11
Vfamilial pancreatic cancer
p15461
sg13
I3
sa(dp15462
g7
I251
sg20
VC1456781
p15463
sg10
I4
sg11
Vmole
p15464
sg13
I1
sa(dp15465
g7
I205
sg20
VC0039082
p15466
sg10
I8
sg11
Vsyndrome
p15467
sg13
I1
sa(dp15468
g7
I190
sg20
VC1140680
p15469
sg10
I14
sg11
Vovarian cancer
p15470
sg13
I2
sa(dp15471
g7
I269
sg20
VC0025202
p15472
sg10
I8
sg11
Vmelanoma
p15473
sg13
I1
sa(dp15474
g7
I101
sg20
VC0238339
p15475
sg10
I23
sg11
Vhereditary pancreatitis
p15476
sg13
I2
sasa(dp15477
g2
S'DIS, IDHAS, and no confirmable syndrome typing were dominant in asymptomatic HIV infection patients.\n'
p15478
sg4
(lp15479
(dp15480
g7
I0
sg8
VP21145
p15481
sg10
I3
sg11
VDIS
p15482
sg13
I1
sasg17
(lp15483
(dp15484
g7
I31
sg20
VC0039082
p15485
sg10
I8
sg11
Vsyndrome
p15486
sg13
I1
sa(dp15487
g7
I64
sg20
VC0343751
p15488
sg10
I26
sg11
Vasymptomatic HIV infection
p15489
sg13
I3
sasa(dp15490
g2
S'Immunization in a prime-boost strategy using DNA and LC16m8Delta expressing SIV Gag elicited 7-30-fold more IFN-gamma-producing T cells in mice than that using DNA and non-replicating vaccinia DIs recombinant strain.\n'
p15491
sg4
(lp15492
(dp15493
g7
I108
sg8
VP01579
p15494
sg10
I9
sg11
VIFN-gamma
p15495
sg13
I1
sa(dp15496
g7
I184
sg8
VP21145
p15497
sg10
I12
sg11
Vvaccinia DIs
p15498
sg13
I2
sasg17
(lp15499
(dp15500
g7
I184
sg20
VC0042214
p15501
sg10
I8
sg11
Vvaccinia
p15502
sg13
I1
sa(dp15503
g7
I76
sg20
VC0037221
p15504
sg10
I3
sg11
VSIV
p15505
sg13
I1
sasa(dp15506
g2
S'These results suggest that genome dimerization or DIS/DLS itself also plays an important role in the early stages of virus infection.\n'
p15507
sg4
(lp15508
sg17
(lp15509
(dp15510
g7
I117
sg20
VC0042769
p15511
sg10
I15
sg11
Vvirus infection
p15512
sg13
I2
sasa(dp15513
g2
S'A highly attenuated vaccinia virus substrain of Dairen-I (DIs) shows promise as a candidate vector for eliciting positive immunity against immune deficiency virus.\n'
p15514
sg4
(lp15515
sg17
(lp15516
(dp15517
g7
I139
sg20
VC0850497
p15518
sg10
I17
sg11
Vimmune deficiency
p15519
sg13
I2
sa(dp15520
g7
I20
sg20
VC0042214
p15521
sg10
I8
sg11
Vvaccinia
p15522
sg13
I1
sasa(dp15523
g2
S'To investigate the impact of that deletion and of the subsequent insertion of a foreign gene into that region of DIs on the ability of the DIs recombinant to induce antigen-specific immunity, we generated a recombinant vaccinia DIs expressing fulllength gag and pol genes of simian immunodeficiency virus (SIV) (rDIsSIV gag/pol) and studied the biological and immunological characteristics of the recombinant natural mutant.\n'
p15524
sg4
(lp15525
(dp15526
g7
I262
sg8
VP10266
p15527
sg10
I9
sg11
Vpol genes
p15528
sg13
I2
sa(dp15529
g7
I262
sg8
VP10266
p15530
sg10
I3
sg11
Vpol
p15531
sg13
I1
sa(dp15532
g7
I207
sg8
VP21145
p15533
sg10
I24
sg11
Vrecombinant vaccinia DIs
p15534
sg13
I3
sa(dp15535
g7
I254
sg8
VP87889
p15536
sg10
I3
sg11
Vgag
p15537
sg13
I1
sa(dp15538
g7
I254
sg8
VP87889
p15539
sg10
I3
sg11
Vgag
p15540
sg13
I1
sasg17
(lp15541
(dp15542
g7
I306
sg20
VC0037221
p15543
sg10
I3
sg11
VSIV
p15544
sg13
I1
sa(dp15545
g7
I275
sg20
VC0037221
p15546
sg10
I29
sg11
Vsimian immunodeficiency virus
p15547
sg13
I3
sa(dp15548
g7
I219
sg20
VC0042214
p15549
sg10
I8
sg11
Vvaccinia
p15550
sg13
I1
sa(dp15551
g7
I417
sg20
VC0596988
p15552
sg10
I6
sg11
Vmutant
p15553
sg13
I1
sasa(dp15554
g2
S'While rDIsSIV gag/pol produces SIV proteins in mammalian HeLa and CV-1 cells, recombinant modified vaccinia Ankara strain (MVA) expressing SIV gag and pol genes (MVA/SIV239 gag/pol) clearly replicates in HeLa and CV-1 cell lines under synchronized growth conditions and produces the SIV protein in all cell lines.\n'
p15555
sg4
(lp15556
(dp15557
g7
I166
sg8
VP87889
p15558
sg10
I10
sg11
VSIV239 gag
p15559
sg13
I2
sa(dp15560
g7
I10
sg8
g127
sg10
I7
sg11
VSIV gag
p15561
sg13
I2
sa(dp15562
g7
I18
sg8
VP10266
p15563
sg10
I3
sg11
Vpol
p15564
sg13
I1
sa(dp15565
g7
I6
sg8
VP87889
p15566
sg10
I11
sg11
VrDIsSIV gag
p15567
sg13
I2
sa(dp15568
g7
I18
sg8
VP10266
p15569
sg10
I3
sg11
Vpol
p15570
sg13
I1
sa(dp15571
g7
I151
sg8
VP10266
p15572
sg10
I9
sg11
Vpol genes
p15573
sg13
I2
sasg17
(lp15574
(dp15575
g7
I10
sg20
VC0037221
p15576
sg10
I3
sg11
VSIV
p15577
sg13
I1
sa(dp15578
g7
I10
sg20
VC0037221
p15579
sg10
I3
sg11
VSIV
p15580
sg13
I1
sa(dp15581
g7
I99
sg20
VC0042214
p15582
sg10
I8
sg11
Vvaccinia
p15583
sg13
I1
sa(dp15584
g7
I10
sg20
VC0037221
p15585
sg10
I3
sg11
VSIV
p15586
sg13
I1
sasa(dp15587
g2
S'Among the signaling pathways in persistently infected cells, Akt and JNK were phosphorylated in SARS-CoV-nucleocapsid (N) protein-expressing Vero E6 cells using vaccinia viral vector (DIs), strongly suggesting that N protein-induced phosphorylation of Akt and JNK are necessary to establish persistence.\n'
p15588
sg4
(lp15589
(dp15590
g7
I61
sg8
g127
sg10
I3
sg11
VAkt
p15591
sg13
I1
sa(dp15592
g7
I69
sg8
VP53779
p15593
sg10
I3
sg11
VJNK
p15594
sg13
I1
sa(dp15595
g7
I61
sg8
g127
sg10
I3
sg11
VAkt
p15596
sg13
I1
sa(dp15597
g7
I69
sg8
VP53779
p15598
sg10
I3
sg11
VJNK
p15599
sg13
I1
sasg17
(lp15600
(dp15601
g7
I161
sg20
VC0042214
p15602
sg10
I8
sg11
Vvaccinia
p15603
sg13
I1
sa(dp15604
g7
I96
sg20
VC1175175
p15605
sg10
I4
sg11
VSARS
p15606
sg13
I1
sasa(dp15607
g2
S'We constructed a series of recombinant DIs (rDIs), a highly attenuated vaccinia strain, expressing a gene encoding four structural proteins (E, M, N and S) of SARS-CoV individually or simultaneously.\n'
p15608
sg4
(lp15609
(dp15610
g7
I159
sg8
VP49591
p15611
sg10
I8
sg11
VSARS-CoV
p15612
sg13
I1
sasg17
(lp15613
(dp15614
g7
I71
sg20
VC0042214
p15615
sg10
I8
sg11
Vvaccinia
p15616
sg13
I1
sa(dp15617
g7
I159
sg20
VC1175175
p15618
sg10
I4
sg11
VSARS
p15619
sg13
I1
sasa(dp15620
g2
S'To assess their potential for a vaccine, we used Mycobacterium bovis bacillus Calmette-Guerin (BCG)-Tokyo and a replication-deficient vaccinia virus strain (DIs) as vectors to express full-length gag from simian immunodeficiency viruses (SIVs) (rBCG-SIVgag and rDIsSIVgag).\n'
p15621
sg4
(lp15622
(dp15623
g7
I184
sg8
VP87889
p15624
sg10
I15
sg11
Vfull-length gag
p15625
sg13
I2
sasg17
(lp15626
(dp15627
g7
I212
sg20
VC0021051
p15628
sg10
I16
sg11
Vimmunodeficiency
p15629
sg13
I1
sa(dp15630
g7
I134
sg20
VC0042214
p15631
sg10
I8
sg11
Vvaccinia
p15632
sg13
I1
sasa(dp15633
g2
S'These results suggest that a recombinant M. bovis BCG-based vector may have potential as an HIV/AIDS vaccine when administered in combination with a replication-deficient vaccinia virus DIs vector in a priming-boosting strategy.\n'
p15634
sg4
(lp15635
sg17
(lp15636
(dp15637
g7
I92
sg20
VC0497169
p15638
sg10
I8
sg11
VHIV/AIDS
p15639
sg13
I1
sa(dp15640
g7
I171
sg20
VC0042214
p15641
sg10
I8
sg11
Vvaccinia
p15642
sg13
I1
sasa(dp15643
g2
S'The results indicated that of the 56 acupoints for facial palsy collected in the literature, Shuigou (GV 26), Dicang (ST 4), Jiache (ST 6), Hegu(LI 4), Fengchi(GB 20), Zusanli (ST 36), Neiting (ST 44), Tinghui (GB 2), Chengjiang (CV 24) and Shangguan (GB 3) are the core acupoints in clinical application.\n'
p15644
sg4
(lp15645
sg17
(lp15646
(dp15647
g7
I51
sg20
VC0015469
p15648
sg10
I12
sg11
Vfacial palsy
p15649
sg13
I2
sasa(dp15650
g2
S"In this study, we sought to probe the central mechanisms of the specific correlation between LI4 and orofacial part in Bell's palsy patients.\n"
p15651
sg4
(lp15652
sg17
(lp15653
(dp15654
g7
I119
sg20
VC0015469
p15655
sg10
I12
sg11
VBell's palsy
p15656
sg13
I2
sa(dp15657
g7
I93
sg20
VC3151377
p15658
sg10
I3
sg11
VLI4
p15659
sg13
I1
sasa(dp15660
g2
S"In total, 36 patients with left Bell's palsy were divided into three groups in random order, and each group received transcutaneous electrical acupoint stimulation (TEAS) at only one of three acupoints (LI4, ST6, and a sham point).\n"
p15661
sg4
(lp15662
(dp15663
g7
I208
sg8
VP27701
p15664
sg10
I3
sg11
VST6
p15665
sg13
I1
sasg17
(lp15666
(dp15667
g7
I203
sg20
VC3151377
p15668
sg10
I3
sg11
VLI4
p15669
sg13
I1
sa(dp15670
g7
I32
sg20
VC0015469
p15671
sg10
I12
sg11
VBell's palsy
p15672
sg13
I2
sasa(dp15673
g2
S'The densities of chromogranin A, serotonin, peptide YY and oxyntomodulin cells were significantly higher, and those of pancreatic peptide and somatostatin cells were lower in rats with DSS-induced colitis than in the controls.\n'
p15674
sg4
(lp15675
(dp15676
g7
I17
sg8
VP10645
p15677
sg10
I14
sg11
Vchromogranin A
p15678
sg13
I2
sasg17
(lp15679
(dp15680
g7
I185
sg20
VC0011195
p15681
sg10
I3
sg11
VDSS
p15682
sg13
I1
sa(dp15683
g7
I197
sg20
VC0009319
p15684
sg10
I7
sg11
Vcolitis
p15685
sg13
I1
sasa(dp15686
g2
S'Thus we hypothesized that NHE8 expression is inhibited during colitis and that SST treatment during pathological conditions can restore NHE8 expression.\n'
p15687
sg4
(lp15688
(dp15689
g7
I79
sg8
VP61278
p15690
sg10
I3
sg11
VSST
p15691
sg13
I1
sa(dp15692
g7
I26
sg8
g127
sg10
I4
sg11
VNHE8
p15693
sg13
I1
sa(dp15694
g7
I26
sg8
g127
sg10
I4
sg11
VNHE8
p15695
sg13
I1
sasg17
(lp15696
(dp15697
g7
I62
sg20
VC0009319
p15698
sg10
I7
sg11
Vcolitis
p15699
sg13
I1
sasa(dp15700
g2
S'Our study uncovered a novel mechanism of SST stimulation of NHE8 expression in colitis.\n'
p15701
sg4
(lp15702
(dp15703
g7
I41
sg8
VP61278
p15704
sg10
I3
sg11
VSST
p15705
sg13
I1
sa(dp15706
g7
I60
sg8
g127
sg10
I4
sg11
VNHE8
p15707
sg13
I1
sasg17
(lp15708
(dp15709
g7
I79
sg20
VC0009319
p15710
sg10
I7
sg11
Vcolitis
p15711
sg13
I1
sasa(dp15712
g2
S'Somatostatin receptors also mediate the complex effects of somatostatin on the gastrointestinal tract and may be defensive in inflammatory bowel diseases, such as ulcerative colitis.\n'
p15713
sg4
(lp15714
(dp15715
g7
I59
sg8
VP61278
p15716
sg10
I12
sg11
Vsomatostatin
p15717
sg13
I1
sa(dp15718
g7
I0
sg8
VP61278
p15719
sg10
I22
sg11
VSomatostatin receptors
p15720
sg13
I2
sasg17
(lp15721
(dp15722
g7
I163
sg20
VC0009324
p15723
sg10
I18
sg11
Vulcerative colitis
p15724
sg13
I2
sa(dp15725
g7
I126
sg20
VC0021390
p15726
sg10
I27
sg11
Vinflammatory bowel diseases
p15727
sg13
I3
sasa(dp15728
g2
S'A 58-year-old female patient with diagnosis of acromegaly and ulcerative colitis was started on long-acting somatostatin treatment as a first-line treatment for acromegaly as she refused to undergo transsphenoidal surgery.\n'
p15729
sg4
(lp15730
(dp15731
g7
I108
sg8
VP61278
p15732
sg10
I12
sg11
Vsomatostatin
p15733
sg13
I1
sasg17
(lp15734
(dp15735
g7
I62
sg20
VC0009324
p15736
sg10
I18
sg11
Vulcerative colitis
p15737
sg13
I2
sa(dp15738
g7
I47
sg20
VC0001206
p15739
sg10
I10
sg11
Vacromegaly
p15740
sg13
I1
sa(dp15741
g7
I47
sg20
VC0001206
p15742
sg10
I10
sg11
Vacromegaly
p15743
sg13
I1
sasa(dp15744
g2
S'The expression levels of melanoma-associated antigen (MAGE) A, MAGE-C1/CT7, cancer/testis antigen 1B (CTAG1B) and G antigen (GAGE) were analyzed by immunohistochemistry.\n'
p15745
sg4
(lp15746
(dp15747
g7
I76
sg8
VP78358
p15748
sg10
I24
sg11
Vcancer/testis antigen 1B
p15749
sg13
I3
sa(dp15750
g7
I125
sg8
VP14209
p15751
sg10
I4
sg11
VGAGE
p15752
sg13
I1
sa(dp15753
g7
I114
sg8
VP14209
p15754
sg10
I9
sg11
VG antigen
p15755
sg13
I2
sa(dp15756
g7
I54
sg8
VP43355
p15757
sg10
I4
sg11
VMAGE
p15758
sg13
I1
sa(dp15759
g7
I25
sg8
VP08962
p15760
sg10
I27
sg11
Vmelanoma-associated antigen
p15761
sg13
I2
sa(dp15762
g7
I54
sg8
VP43355
p15763
sg10
I4
sg11
VMAGE
p15764
sg13
I1
sa(dp15765
g7
I102
sg8
VP78358
p15766
sg10
I6
sg11
VCTAG1B
p15767
sg13
I1
sa(dp15768
g7
I71
sg8
g127
sg10
I3
sg11
VCT7
p15769
sg13
I1
sasg17
(lp15770
(dp15771
g7
I25
sg20
VC0025202
p15772
sg10
I8
sg11
Vmelanoma
p15773
sg13
I1
sa(dp15774
g7
I76
sg20
VC0006826
p15775
sg10
I6
sg11
Vcancer
p15776
sg13
I1
sasa(dp15777
g2
S'In papillary and follicular carcinoma, MAGE-A was present in 8.1% of cases, GAGE in 10.8% and CT/7MAGE-C1 and CTAG1B in 2.7% each.\n'
p15778
sg4
(lp15779
sg17
(lp15780
(dp15781
g7
I3
sg20
VC0206683
p15782
sg10
I34
sg11
Vpapillary and follicular carcinoma
p15783
sg13
I4
sasa(dp15784
g2
S'In medullary carcinoma, CT antigen expression was as follows: MAGE-A in 42.9% of patients; MAGE-C1/CT7 in 46.5%; GAGE in 92.9%; and CTAG1B in 3.6%.\n'
p15785
sg4
(lp15786
(dp15787
g7
I24
sg8
VP14209
p15788
sg10
I10
sg11
VCT antigen
p15789
sg13
I2
sa(dp15790
g7
I62
sg8
VP43355
p15791
sg10
I6
sg11
VMAGE-A
p15792
sg13
I1
sasg17
(lp15793
(dp15794
g7
I3
sg20
VC0238462
p15795
sg10
I19
sg11
Vmedullary carcinoma
p15796
sg13
I2
sasa(dp15797
g2
S'In poorly differentiated and anaplastic carcinoma cases, CT antigen expression was as follows: MAGE-A in 61.8% of cases; MAGE-C1 in 57.1%; GAGE in 66.7%; and CTAG1B in 14.4%.\n'
p15798
sg4
(lp15799
(dp15800
g7
I57
sg8
VP14209
p15801
sg10
I10
sg11
VCT antigen
p15802
sg13
I2
sasg17
(lp15803
(dp15804
g7
I29
sg20
VC0205698
p15805
sg10
I20
sg11
Vanaplastic carcinoma
p15806
sg13
I2
sasa(dp15807
g2
S'A vaccine consisting of 9 MHC class I-restricted breast cancer-associated peptides (from MAGE-A1, -A3, and -A10, CEA, NY-ESO-1, and HER2 proteins) was combined with a TLR3 agonist, poly-ICLC, along with a helper peptide derived from tetanus toxoid.\n'
p15808
sg4
(lp15809
(dp15810
g7
I132
sg8
VP04626
p15811
sg10
I13
sg11
VHER2 proteins
p15812
sg13
I2
sa(dp15813
g7
I118
sg8
VP78358
p15814
sg10
I8
sg11
VNY-ESO-1
p15815
sg13
I1
sa(dp15816
g7
I26
sg8
VP30486
p15817
sg10
I56
sg11
VMHC class I-restricted breast cancer-associated peptides
p15818
sg13
I6
sa(dp15819
g7
I167
sg8
g127
sg10
I4
sg11
VTLR3
p15820
sg13
I1
sa(dp15821
g7
I113
sg8
VP40198
p15822
sg10
I3
sg11
VCEA
p15823
sg13
I1
sasg17
(lp15824
(dp15825
g7
I49
sg20
VC0678222
p15826
sg10
I13
sg11
Vbreast cancer
p15827
sg13
I2
sa(dp15828
g7
I233
sg20
VC0039614
p15829
sg10
I7
sg11
Vtetanus
p15830
sg13
I1
sasa(dp15831
g2
S'We assessed expression of HM1.24 and the CTAs MAGE-A3, NY-ESO-1/2, WT-1 and HMMR in CD138-purified myeloma cell samples of previously untreated myeloma patients in the GMMG-MM5 multicenter-trial by gene expression profiling (GEP; n = 458) and RNA-sequencing (n = 152) as potential population regarding vaccination trials.\n'
p15832
sg4
(lp15833
(dp15834
g7
I76
sg8
g127
sg10
I4
sg11
VHMMR
p15835
sg13
I1
sa(dp15836
g7
I84
sg8
VP18827
p15837
sg10
I5
sg11
VCD138
p15838
sg13
I1
sa(dp15839
g7
I41
sg8
VP43355
p15840
sg10
I12
sg11
VCTAs MAGE-A3
p15841
sg13
I2
sa(dp15842
g7
I55
sg8
VP78358
p15843
sg10
I10
sg11
VNY-ESO-1/2
p15844
sg13
I1
sa(dp15845
g7
I26
sg8
VP11229
p15846
sg10
I6
sg11
VHM1.24
p15847
sg13
I1
sasg17
(lp15848
(dp15849
g7
I99
sg20
VC0026764
p15850
sg10
I7
sg11
Vmyeloma
p15851
sg13
I1
sa(dp15852
g7
I99
sg20
VC0026764
p15853
sg10
I7
sg11
Vmyeloma
p15854
sg13
I1
sasa(dp15855
g2
S'In this phase I dose escalation study, we treated eight patients with high-risk surgically resected stage II-IV melanoma with intravenous autologous monocyte-derived DCs loaded with the NKT cell agonist Alfa-GalCer and peptides derived from the cancer testis antigen NY-ESO-1.\n'
p15856
sg4
(lp15857
(dp15858
g7
I252
sg8
VP15735
p15859
sg10
I23
sg11
Vtestis antigen NY-ESO-1
p15860
sg13
I3
sasg17
(lp15861
(dp15862
g7
I112
sg20
VC0025202
p15863
sg10
I8
sg11
Vmelanoma
p15864
sg13
I1
sa(dp15865
g7
I245
sg20
VC0153594
p15866
sg10
I13
sg11
Vcancer testis
p15867
sg13
I2
sa(dp15868
g7
I166
sg20
VC0268238
p15869
sg10
I3
sg11
VDCs
p15870
sg13
I1
sasa(dp15871
g2
S"Lung cancer cell line demethylation resulting from 5-Aza-2'-deoxycytidine treatment was associated with both NY-ESO-1 and PD-L1 re-expression in vitro but not increased chemosensitivity.\n"
p15872
sg4
(lp15873
(dp15874
g7
I109
sg8
VP78358
p15875
sg10
I8
sg11
VNY-ESO-1
p15876
sg13
I1
sasg17
(lp15877
(dp15878
g7
I0
sg20
VC0684249
p15879
sg10
I11
sg11
VLung cancer
p15880
sg13
I2
sasa(dp15881
g2
S'Collectively, these results provided supporting evidence for the potential use of NY-ESO-1 hypomethylation as a prognostic biomarker in stage 3 NSCLCs.\n'
p15882
sg4
(lp15883
sg17
(lp15884
sa(dp15885
g2
S'Twenty-eight out of 38 cancer specimens exhibited NY-ESO-1 protein expression, 2/38 showed a strong universal (4+) NY-ESO-1 staining, and 9/40 cancer lesions exhibited a strong (4+) staining for survivin.\n'
p15886
sg4
(lp15887
sg17
(lp15888
(dp15889
g7
I23
sg20
VC0006826
p15890
sg10
I6
sg11
Vcancer
p15891
sg13
I1
sa(dp15892
g7
I23
sg20
VC0006826
p15893
sg10
I6
sg11
Vcancer
p15894
sg13
I1
sasa(dp15895
g2
S'NY-ESO-1 or survivin expression in glioma represents viable targets for anticancer-directed T-cells for the biological therapy of patients with glioma.\n'
p15896
sg4
(lp15897
(dp15898
g7
I0
sg8
VP78358
p15899
sg10
I8
sg11
VNY-ESO-1
p15900
sg13
I1
sasg17
(lp15901
(dp15902
g7
I35
sg20
VC0017638
p15903
sg10
I6
sg11
Vglioma
p15904
sg13
I1
sa(dp15905
g7
I35
sg20
VC0017638
p15906
sg10
I6
sg11
Vglioma
p15907
sg13
I1
sasa(dp15908
g2
S'Fifteen patients with II to III stage positive HLA -A0201+ and NY-ESO-1+ were enrolled in the Cancer Hospital Chinese Academy of Medical Sciences on the basis of preclinical experiments from November 2014 to October 2015, and their peripheral blood mononuclear cells (PBMCs) and peripheral blood lymphocytes (PBLs) were isolated.\n'
p15909
sg4
(lp15910
(dp15911
g7
I63
sg8
VP78358
p15912
sg10
I9
sg11
VNY-ESO-1+
p15913
sg13
I1
sa(dp15914
g7
I47
sg8
VP30486
p15915
sg10
I11
sg11
VHLA -A0201+
p15916
sg13
I2
sasg17
(lp15917
(dp15918
g7
I94
sg20
VC0006826
p15919
sg10
I6
sg11
VCancer
p15920
sg13
I1
sasa(dp15921
g2
S'Auto-DCs pulsed with NY-ESO-1 peptides can induce the proliferation of allogenic CTLs, which elicit specific immune responses ex vivo or in vivo, and boost anticancer immunity markedly.\n'
p15922
sg4
(lp15923
(dp15924
g7
I21
sg8
VP78358
p15925
sg10
I17
sg11
VNY-ESO-1 peptides
p15926
sg13
I2
sa(dp15927
g7
I0
sg8
g127
sg10
I8
sg11
VAuto-DCs
p15928
sg13
I1
sasg17
(lp15929
(dp15930
g7
I54
sg20
VC0334094
p15931
sg10
I13
sg11
Vproliferation
p15932
sg13
I1
sa(dp15933
g7
I5
sg20
VC0268238
p15934
sg10
I3
sg11
VDCs
p15935
sg13
I1
sasa(dp15936
g2
S'Data from these analyses indicated that GATA-binding protein 4 (GATA4) was able to mediate NOX4 transcription and is downregulated in human umbilical vein endothelial cells (HUVECs) that were exposed to hyperglycemic conditions as well as in the endothelial cells of a mouse diabetes model.\n'
p15937
sg4
(lp15938
(dp15939
g7
I91
sg8
g127
sg10
I4
sg11
VNOX4
p15940
sg13
I1
sa(dp15941
g7
I64
sg8
VP43694
p15942
sg10
I5
sg11
VGATA4
p15943
sg13
I1
sa(dp15944
g7
I40
sg8
VP43694
p15945
sg10
I22
sg11
VGATA-binding protein 4
p15946
sg13
I3
sasg17
(lp15947
(dp15948
g7
I275
sg20
VC0011849
p15949
sg10
I8
sg11
Vdiabetes
p15950
sg13
I1
sasa(dp15951
g2
S'Results from these experiments demonstrated that GATA4 may inhibit diabetes-induced endothelial dysfunction by acting as a transcription factor for NOX4 expression and increasing NO production.\n'
p15952
sg4
(lp15953
(dp15954
g7
I148
sg8
g127
sg10
I4
sg11
VNOX4
p15955
sg13
I1
sa(dp15956
g7
I49
sg8
VP43694
p15957
sg10
I5
sg11
VGATA4
p15958
sg13
I1
sasg17
(lp15959
(dp15960
g7
I84
sg20
VC0856169
p15961
sg10
I23
sg11
Vendothelial dysfunction
p15962
sg13
I2
sa(dp15963
g7
I67
sg20
VC0011849
p15964
sg10
I8
sg11
Vdiabetes
p15965
sg13
I1
sasa(dp15966
g2
S'Furthermore, hyperglycemia markedly increased Nox4 activity and reduced the activation of Nrf2 by suppressing its up-stream regulatory Akt as well as down-stream target HO-1.\n'
p15967
sg4
(lp15968
(dp15969
g7
I90
sg8
g127
sg10
I4
sg11
VNrf2
p15970
sg13
I1
sa(dp15971
g7
I46
sg8
g127
sg10
I4
sg11
VNox4
p15972
sg13
I1
sa(dp15973
g7
I135
sg8
g127
sg10
I3
sg11
VAkt
p15974
sg13
I1
sasg17
(lp15975
(dp15976
g7
I13
sg20
VC0020456
p15977
sg10
I13
sg11
Vhyperglycemia
p15978
sg13
I1
sasa(dp15979
g2
S'Our results provide evidence indicating that JQ1 treatment could modulate Nox4-Nrf2 redox imbalance in the hippocampus and may be a promising agent for diabetes-associated cognitive dysfunction.\n'
p15980
sg4
(lp15981
(dp15982
g7
I74
sg8
g127
sg10
I4
sg11
VNox4
p15983
sg13
I1
sa(dp15984
g7
I79
sg8
g127
sg10
I4
sg11
VNrf2
p15985
sg13
I1
sasg17
(lp15986
(dp15987
g7
I90
sg20
VC1397014
p15988
sg10
I9
sg11
Vimbalance
p15989
sg13
I1
sa(dp15990
g7
I172
sg20
VC0338656
p15991
sg10
I21
sg11
Vcognitive dysfunction
p15992
sg13
I2
sa(dp15993
g7
I152
sg20
VC0011849
p15994
sg10
I8
sg11
Vdiabetes
p15995
sg13
I1
sasa(dp15996
g2
S'However, Nox4 deletion did not affect the metabolic profile under a high-fat diet in males or females, but increased glucose intolerance in females.\n'
p15997
sg4
(lp15998
(dp15999
g7
I9
sg8
g127
sg10
I4
sg11
VNox4
p16000
sg13
I1
sasg17
(lp16001
(dp16002
g7
I117
sg20
VC0271650
p16003
sg10
I19
sg11
Vglucose intolerance
p16004
sg13
I2
sasa(dp16005
g2
S'Summer in both species and diabetes in rats downregulated myocardial Nox4 while reciprocally upregulating Nox2 and Nox5 in guinea-pigs, and Nox2 in rats.\n'
p16006
sg4
(lp16007
(dp16008
g7
I115
sg8
g127
sg10
I4
sg11
VNox5
p16009
sg13
I1
sa(dp16010
g7
I106
sg8
VP04839
p16011
sg10
I4
sg11
VNox2
p16012
sg13
I1
sa(dp16013
g7
I106
sg8
VP04839
p16014
sg10
I4
sg11
VNox2
p16015
sg13
I1
sa(dp16016
g7
I69
sg8
g127
sg10
I4
sg11
VNox4
p16017
sg13
I1
sasg17
(lp16018
(dp16019
g7
I27
sg20
VC0011849
p16020
sg10
I8
sg11
Vdiabetes
p16021
sg13
I1
sasa(dp16022
g2
S'In this study, we aimed to investigate norbin expression patterns in epilepsy and to elucidate the relationships between norbin and mGluR5 and p-CaMKII in epilepsy.\n'
p16023
sg4
(lp16024
(dp16025
g7
I39
sg8
g127
sg10
I6
sg11
Vnorbin
p16026
sg13
I1
sa(dp16027
g7
I39
sg8
g127
sg10
I6
sg11
Vnorbin
p16028
sg13
I1
sa(dp16029
g7
I143
sg8
g127
sg10
I8
sg11
Vp-CaMKII
p16030
sg13
I1
sa(dp16031
g7
I132
sg8
VP41594
p16032
sg10
I6
sg11
VmGluR5
p16033
sg13
I1
sasg17
(lp16034
(dp16035
g7
I69
sg20
VC0014544
p16036
sg10
I8
sg11
Vepilepsy
p16037
sg13
I1
sa(dp16038
g7
I69
sg20
VC0014544
p16039
sg10
I8
sg11
Vepilepsy
p16040
sg13
I1
sasa(dp16041
g2
S'Thus, our results indicate norbin participates in the pathogenesis of epilepsy, perhaps by modulating mGluR5 signaling, regulating CaMKII phosphorylation, and may exert antiepileptic effects.\n'
p16042
sg4
(lp16043
(dp16044
g7
I102
sg8
VP41594
p16045
sg10
I6
sg11
VmGluR5
p16046
sg13
I1
sa(dp16047
g7
I131
sg8
g127
sg10
I6
sg11
VCaMKII
p16048
sg13
I1
sasg17
(lp16049
(dp16050
g7
I54
sg20
VC0699748
p16051
sg10
I12
sg11
Vpathogenesis
p16052
sg13
I1
sa(dp16053
g7
I70
sg20
VC0014544
p16054
sg10
I8
sg11
Vepilepsy
p16055
sg13
I1
sasa(dp16056
g2
S'Metabotropic glutamate receptor type 5 (mGluR5) abnormalities have been described in tissue resected from epilepsy patients with focal cortical dysplasia (FCD).\n'
p16057
sg4
(lp16058
(dp16059
g7
I40
sg8
VP41594
p16060
sg10
I6
sg11
VmGluR5
p16061
sg13
I1
sa(dp16062
g7
I0
sg8
VP41594
p16063
sg10
I38
sg11
VMetabotropic glutamate receptor type 5
p16064
sg13
I5
sasg17
(lp16065
(dp16066
g7
I129
sg20
VC2938983
p16067
sg10
I24
sg11
Vfocal cortical dysplasia
p16068
sg13
I3
sa(dp16069
g7
I155
sg20
VC1562113
p16070
sg10
I3
sg11
VFCD
p16071
sg13
I1
sa(dp16072
g7
I106
sg20
VC0014544
p16073
sg10
I8
sg11
Vepilepsy
p16074
sg13
I1
sasa(dp16075
g2
S'To determine if these abnormalities could be identified in vivo, we investigated mGluR5 availability in 10 patients with focal epilepsy and an MRI diagnosis of FCD using positron-emission tomography (PET) and the radioligand [11C]ABP688.\n'
p16076
sg4
(lp16077
sg17
(lp16078
(dp16079
g7
I121
sg20
VC0014547
p16080
sg10
I14
sg11
Vfocal epilepsy
p16081
sg13
I2
sa(dp16082
g7
I160
sg20
VC1562113
p16083
sg10
I3
sg11
VFCD
p16084
sg13
I1
sasa(dp16085
g2
S'mGluR1Alfa (LY367385) and mGluR5 (MPEP) antagonists were administered 2h following KA-induced status epilepticus and animals were examined after 7days.\n'
p16086
sg4
(lp16087
(dp16088
g7
I26
sg8
VP41594
p16089
sg10
I6
sg11
VmGluR5
p16090
sg13
I1
sasg17
(lp16091
(dp16092
g7
I94
sg20
VC0038220
p16093
sg10
I18
sg11
Vstatus epilepticus
p16094
sg13
I2
sasa(dp16095
g2
S'Congenital cranial dysinnervation disorders (CCDDs) comprise a heterogeneous spectrum of diseases characterized by congenital, non-progressive impairment of eye, eyelid and/or facial movements including Moebius syndrome, Duane retraction syndrome, congenital ptosis, and congenital fibrosis of the extraocular muscles.\n'
p16096
sg4
(lp16097
sg17
(lp16098
(dp16099
g7
I143
sg20
VC0684336
p16100
sg10
I10
sg11
Vimpairment
p16101
sg13
I1
sa(dp16102
g7
I282
sg20
VC0016059
p16103
sg10
I8
sg11
Vfibrosis
p16104
sg13
I1
sa(dp16105
g7
I203
sg20
VC0221060
p16106
sg10
I16
sg11
VMoebius syndrome
p16107
sg13
I2
sa(dp16108
g7
I248
sg20
VC0266573
p16109
sg10
I17
sg11
Vcongenital ptosis
p16110
sg13
I2
sa(dp16111
g7
I211
sg20
VC0013261
p16112
sg10
I26
sg11
Vsyndrome, Duane retraction
p16113
sg13
I3
sa(dp16114
g7
I211
sg20
VC0039082
p16115
sg10
I8
sg11
Vsyndrome
p16116
sg13
I1
sasa(dp16117
g2
S'CCDDs are congenital, non-progressive ophthalmoplegia with restriction of globe movement in one or more fields of gaze.\n'
p16118
sg4
(lp16119
sg17
(lp16120
(dp16121
g7
I38
sg20
VC0029089
p16122
sg10
I15
sg11
Vophthalmoplegia
p16123
sg13
I1
sasa(dp16124
g2
S'Currently, congenital fibrosis of the extraocular muscles, Duane syndrome, Moebius syndrome, Horizontal gaze palsy and progressive scoliosis, and synergistic divergence are included as CCDDs.\n'
p16125
sg4
(lp16126
sg17
(lp16127
(dp16128
g7
I22
sg20
VC0016059
p16129
sg10
I8
sg11
Vfibrosis
p16130
sg13
I1
sa(dp16131
g7
I75
sg20
VC0221060
p16132
sg10
I16
sg11
VMoebius syndrome
p16133
sg13
I2
sa(dp16134
g7
I93
sg20
VC0339651
p16135
sg10
I21
sg11
VHorizontal gaze palsy
p16136
sg13
I3
sa(dp16137
g7
I59
sg20
VC0013261
p16138
sg10
I14
sg11
VDuane syndrome
p16139
sg13
I2
sa(dp16140
g7
I131
sg20
VC0700208
p16141
sg10
I9
sg11
Vscoliosis
p16142
sg13
I1
sasa(dp16143
g2
S'CCDDs have been associated with dominant or recessive monogenic mutations in at least 7 different genes (CHN1, SALL4, HOXA1, KIF21A, PHOX2A, TUBB3, ROBO3) that cause phenotypes such as Duane retraction syndrome, congenital fibrosis of the extraocular muscles, and horizontal gaze palsy with progressive scoliosis.\n'
p16144
sg4
(lp16145
(dp16146
g7
I148
sg8
g127
sg10
I5
sg11
VROBO3
p16147
sg13
I1
sa(dp16148
g7
I105
sg8
VP15882
p16149
sg10
I4
sg11
VCHN1
p16150
sg13
I1
sa(dp16151
g7
I118
sg8
VP49639
p16152
sg10
I5
sg11
VHOXA1
p16153
sg13
I1
sa(dp16154
g7
I141
sg8
VP04350
p16155
sg10
I5
sg11
VTUBB3
p16156
sg13
I1
sa(dp16157
g7
I133
sg8
g127
sg10
I6
sg11
VPHOX2A
p16158
sg13
I1
sa(dp16159
g7
I111
sg8
g127
sg10
I5
sg11
VSALL4
p16160
sg13
I1
sasg17
(lp16161
(dp16162
g7
I185
sg20
VC0013261
p16163
sg10
I25
sg11
VDuane retraction syndrome
p16164
sg13
I3
sa(dp16165
g7
I264
sg20
VC0339651
p16166
sg10
I21
sg11
Vhorizontal gaze palsy
p16167
sg13
I3
sa(dp16168
g7
I223
sg20
VC0016059
p16169
sg10
I8
sg11
Vfibrosis
p16170
sg13
I1
sa(dp16171
g7
I303
sg20
VC0700208
p16172
sg10
I9
sg11
Vscoliosis
p16173
sg13
I1
sasa(dp16174
g2
S'Recent literature contains new genotypic and phenotypic descriptions of Duane retraction syndrome, Moebius syndrome, and other CCDDs.\n'
p16175
sg4
(lp16176
sg17
(lp16177
(dp16178
g7
I99
sg20
VC0221060
p16179
sg10
I16
sg11
VMoebius syndrome
p16180
sg13
I2
sa(dp16181
g7
I72
sg20
VC0013261
p16182
sg10
I25
sg11
VDuane retraction syndrome
p16183
sg13
I3
sasa(dp16184
g2
S'Certain forms of congenital incomitant strabismus are associated with abnormal cranial nerve development and resultant abnormal orbital innervation (eg, Duane retraction syndrome, congenital fibrosis of the extraocular muscles [CFEOM]); such conditions can be considered congenital cranial dysinnervation disorders (CCDDs).\n'
p16185
sg4
(lp16186
sg17
(lp16187
(dp16188
g7
I153
sg20
VC0013261
p16189
sg10
I25
sg11
VDuane retraction syndrome
p16190
sg13
I3
sa(dp16191
g7
I39
sg20
VC0038379
p16192
sg10
I10
sg11
Vstrabismus
p16193
sg13
I1
sa(dp16194
g7
I191
sg20
VC0016059
p16195
sg10
I8
sg11
Vfibrosis
p16196
sg13
I1
sasa(dp16197
g2
S'In addition to duction limitation and/or ptosis, orbital CCDD phenotypes include inappropriate extraocular muscle and/or levator innervation by nerves intended for innervation of other structures (eg, some of the innervation intended for the medial rectus muscle inappropriately innervating the ipsilateral lateral rectus muscle in Duane retraction syndrome).\n'
p16198
sg4
(lp16199
sg17
(lp16200
(dp16201
g7
I332
sg20
VC0013261
p16202
sg10
I25
sg11
VDuane retraction syndrome
p16203
sg13
I3
sa(dp16204
g7
I41
sg20
VC0005745
p16205
sg10
I6
sg11
Vptosis
p16206
sg13
I1
sasa(dp16207
g2
S"Further CCDD syndromes include the following phenotypes: congenital ptosis, Duane syndrome, horizontal gaze palsy, Moebius' syndrome, and congenital facial palsy.\n"
p16208
sg4
(lp16209
sg17
(lp16210
(dp16211
g7
I92
sg20
VC0339651
p16212
sg10
I21
sg11
Vhorizontal gaze palsy
p16213
sg13
I3
sa(dp16214
g7
I57
sg20
VC0266573
p16215
sg10
I17
sg11
Vcongenital ptosis
p16216
sg13
I2
sa(dp16217
g7
I13
sg20
VC0039082
p16218
sg10
I9
sg11
Vsyndromes
p16219
sg13
I1
sa(dp16220
g7
I13
sg20
VC0039082
p16221
sg10
I8
sg11
Vsyndrome
p16222
sg13
I1
sa(dp16223
g7
I149
sg20
VC0015469
p16224
sg10
I12
sg11
Vfacial palsy
p16225
sg13
I2
sa(dp16226
g7
I76
sg20
VC0013261
p16227
sg10
I14
sg11
VDuane syndrome
p16228
sg13
I2
sasa(dp16229
g2
S'Massive GI bleeding (33.3%) and bacteremia (25%) were the major causes of pre-fatal leukocytosis in the deceased patients; 33.3% of the patients with pre-fatal profound thrombocytopenia (&lt;20,000/myL), and 50% of the patients with pre-fatal prothrombin time (PT) prolongation experienced massive GI bleeding.\n'
p16230
sg4
(lp16231
(dp16232
g7
I243
sg8
VP00734
p16233
sg10
I11
sg11
Vprothrombin
p16234
sg13
I1
sa(dp16235
g7
I198
sg8
VP29590
p16236
sg10
I3
sg11
VmyL
p16237
sg13
I1
sasg17
(lp16238
(dp16239
g7
I84
sg20
VC0023518
p16240
sg10
I12
sg11
Vleukocytosis
p16241
sg13
I1
sa(dp16242
g7
I32
sg20
VC0004610
p16243
sg10
I10
sg11
Vbacteremia
p16244
sg13
I1
sa(dp16245
g7
I8
sg20
VC0017181
p16246
sg10
I11
sg11
VGI bleeding
p16247
sg13
I2
sa(dp16248
g7
I8
sg20
VC0017181
p16249
sg10
I11
sg11
VGI bleeding
p16250
sg13
I2
sasa(dp16251
g2
S'The prevalence of two single nucleotide polymorphisms (SNP) in MFGE8 was studied in two exsudative or "wet" Age-related Macular Degeneration (AMD) groups and two corresponding control groups.\n'
p16252
sg4
(lp16253
(dp16254
g7
I63
sg8
g127
sg10
I5
sg11
VMFGE8
p16255
sg13
I1
sasg17
(lp16256
(dp16257
g7
I142
sg20
VC0242383
p16258
sg10
I3
sg11
VAMD
p16259
sg13
I1
sa(dp16260
g7
I108
sg20
VC0242383
p16261
sg10
I32
sg11
VAge-related Macular Degeneration
p16262
sg13
I3
sasa(dp16263
g2
S'The antibodies applied were second workshop codes: 3(CAM 5.2), 45 (MOV15), 54 (NCCST433), 75 (PE35), 81 (HMFG-1), 95 (LCA1/L38) and HMFG-2 123C3, F4 and MOC-21.\n'
p16264
sg4
(lp16265
(dp16266
g7
I105
sg8
g127
sg10
I6
sg11
VHMFG-1
p16267
sg13
I1
sa(dp16268
g7
I53
sg8
VP01768
p16269
sg10
I7
sg11
VCAM 5.2
p16270
sg13
I2
sa(dp16271
g7
I118
sg8
g127
sg10
I4
sg11
VLCA1
p16272
sg13
I1
sa(dp16273
g7
I132
sg8
g127
sg10
I12
sg11
VHMFG-2 123C3
p16274
sg13
I2
sasg17
(lp16275
(dp16276
g7
I53
sg20
VC1861821
p16277
sg10
I3
sg11
VCAM
p16278
sg13
I1
sa(dp16279
g7
I118
sg20
VC2931258
p16280
sg10
I4
sg11
VLCA1
p16281
sg13
I1
sasa(dp16282
g2
S'Seven monoclonal antibodies raised against epithelial antigens (CAM 5.2, MOV 15, NCCST 433, PE 35, LCA1/L38, HMFG 1 AND HMFG 2) were applied on bone marrow sections from three groups of patients (pts): (1) 19 pts in whom SCLC-metastases were detected by CE, (2) 44 pts with SCLC in whom metastases could not be detected by CE, and (3) 20 pts with non-malignant bone marrow diseases.\n'
p16283
sg4
(lp16284
(dp16285
g7
I221
sg8
VP41162
p16286
sg10
I15
sg11
VSCLC-metastases
p16287
sg13
I1
sa(dp16288
g7
I64
sg8
VP48147
p16289
sg10
I33
sg11
VCAM 5.2, MOV 15, NCCST 433, PE 35
p16290
sg13
I8
sa(dp16291
g7
I99
sg8
g127
sg10
I4
sg11
VLCA1
p16292
sg13
I1
sa(dp16293
g7
I120
sg8
g127
sg10
I6
sg11
VHMFG 2
p16294
sg13
I2
sa(dp16295
g7
I109
sg8
g127
sg10
I6
sg11
VHMFG 1
p16296
sg13
I2
sa(dp16297
g7
I43
sg8
VP12830
p16298
sg10
I19
sg11
Vepithelial antigens
p16299
sg13
I2
sasg17
(lp16300
(dp16301
g7
I221
sg20
VC0149925
p16302
sg10
I4
sg11
VSCLC
p16303
sg13
I1
sa(dp16304
g7
I99
sg20
VC2931258
p16305
sg10
I4
sg11
VLCA1
p16306
sg13
I1
sa(dp16307
g7
I361
sg20
VC0005956
p16308
sg10
I20
sg11
Vbone marrow diseases
p16309
sg13
I3
sa(dp16310
g7
I226
sg20
VC0027627
p16311
sg10
I10
sg11
Vmetastases
p16312
sg13
I1
sa(dp16313
g7
I64
sg20
VC1861821
p16314
sg10
I3
sg11
VCAM
p16315
sg13
I1
sa(dp16316
g7
I226
sg20
VC0027627
p16317
sg10
I10
sg11
Vmetastases
p16318
sg13
I1
sa(dp16319
g7
I221
sg20
VC0149925
p16320
sg10
I4
sg11
VSCLC
p16321
sg13
I1
sasa(dp16322
g2
S'In this study, we demonstrated that both mature forms of miRNA-485, miR-485-3p and miR-485-5p were involved in regulating mitochondrial respiration, cell migration and cell invasion in breast cancer cells by directly targeting and inhibiting the expression of PGC-1Alfa.\n'
p16323
sg4
(lp16324
(dp16325
g7
I83
sg8
g127
sg10
I10
sg11
VmiR-485-5p
p16326
sg13
I1
sa(dp16327
g7
I68
sg8
g127
sg10
I10
sg11
VmiR-485-3p
p16328
sg13
I1
sa(dp16329
g7
I260
sg8
VP20142
p16330
sg10
I9
sg11
VPGC-1Alfa
p16331
sg13
I1
sasg17
(lp16332
(dp16333
g7
I185
sg20
VC0678222
p16334
sg10
I13
sg11
Vbreast cancer
p16335
sg13
I2
sa(dp16336
g7
I168
sg20
VC2699153
p16337
sg10
I13
sg11
Vcell invasion
p16338
sg13
I2
sasa(dp16339
g2
S'Specifically, the expression levels of both miR-485-3p and miR-485-5p were decreased in breast cancer tissues.\n'
p16340
sg4
(lp16341
(dp16342
g7
I59
sg8
g127
sg10
I10
sg11
VmiR-485-5p
p16343
sg13
I1
sa(dp16344
g7
I44
sg8
g127
sg10
I10
sg11
VmiR-485-3p
p16345
sg13
I1
sasg17
(lp16346
(dp16347
g7
I88
sg20
VC0678222
p16348
sg10
I13
sg11
Vbreast cancer
p16349
sg13
I2
sasa(dp16350
g2
S'Overexpression of miR-485-3p and miR-485-5p suppressed mitochondrial respiration and potential for cell migration and invasion in vitro, and also inhibited spontaneous metastasis of breast cancer cells in vivo.\n'
p16351
sg4
(lp16352
(dp16353
g7
I18
sg8
g127
sg10
I10
sg11
VmiR-485-3p
p16354
sg13
I1
sa(dp16355
g7
I33
sg8
g127
sg10
I10
sg11
VmiR-485-5p
p16356
sg13
I1
sasg17
(lp16357
(dp16358
g7
I168
sg20
VC0027627
p16359
sg10
I10
sg11
Vmetastasis
p16360
sg13
I1
sa(dp16361
g7
I118
sg20
VC2699153
p16362
sg10
I8
sg11
Vinvasion
p16363
sg13
I1
sa(dp16364
g7
I182
sg20
VC0678222
p16365
sg10
I13
sg11
Vbreast cancer
p16366
sg13
I2
sasa(dp16367
g2
S'Treatment with miRNA-664 (miR-664), miR-485-3p, and miR-495 siRNAs reduced tumor growth, invasion, and metastasis in an orthotopic liver cancer model.\n'
p16368
sg4
(lp16369
(dp16370
g7
I52
sg8
g127
sg10
I14
sg11
VmiR-495 siRNAs
p16371
sg13
I2
sa(dp16372
g7
I36
sg8
g127
sg10
I10
sg11
VmiR-485-3p
p16373
sg13
I1
sasg17
(lp16374
(dp16375
g7
I75
sg20
VC0598934
p16376
sg10
I12
sg11
Vtumor growth
p16377
sg13
I2
sa(dp16378
g7
I89
sg20
VC2699153
p16379
sg10
I8
sg11
Vinvasion
p16380
sg13
I1
sa(dp16381
g7
I103
sg20
VC0027627
p16382
sg10
I10
sg11
Vmetastasis
p16383
sg13
I1
sa(dp16384
g7
I131
sg20
VC0345904
p16385
sg10
I12
sg11
Vliver cancer
p16386
sg13
I2
sasa(dp16387
g2
S'These results reveal the presence of distinct genetic architectures between Caucasian ethnic groups that likely have clinical relevance, among them PROX1 gene is a strong candidate of early onset of diabetes with variations depending on ethnicity.\n'
p16388
sg4
(lp16389
(dp16390
g7
I148
sg8
g127
sg10
I10
sg11
VPROX1 gene
p16391
sg13
I2
sasg17
(lp16392
(dp16393
g7
I199
sg20
VC0011849
p16394
sg10
I8
sg11
Vdiabetes
p16395
sg13
I1
sasa(dp16396
g2
S'HHEX and PROX1 are genetic loci associated with diabetes mellitus type 2.\n'
p16397
sg4
(lp16398
(dp16399
g7
I9
sg8
g127
sg10
I5
sg11
VPROX1
p16400
sg13
I1
sa(dp16401
g7
I0
sg8
g127
sg10
I4
sg11
VHHEX
p16402
sg13
I1
sasg17
(lp16403
(dp16404
g7
I48
sg20
VC0011860
p16405
sg10
I24
sg11
Vdiabetes mellitus type 2
p16406
sg13
I4
sasa(dp16407
g2
S'HHEX and PROX1 play significant roles in carbohydrate intolerance and diabetes because these transcription factors may be involved in the regulation of insulin secretion and in glucose and lipid metabolism.\n'
p16408
sg4
(lp16409
(dp16410
g7
I152
sg8
VP01308
p16411
sg10
I7
sg11
Vinsulin
p16412
sg13
I1
sa(dp16413
g7
I9
sg8
g127
sg10
I5
sg11
VPROX1
p16414
sg13
I1
sa(dp16415
g7
I0
sg8
g127
sg10
I4
sg11
VHHEX
p16416
sg13
I1
sasg17
(lp16417
(dp16418
g7
I41
sg20
VC1401162
p16419
sg10
I24
sg11
Vcarbohydrate intolerance
p16420
sg13
I2
sa(dp16421
g7
I70
sg20
VC0011849
p16422
sg10
I8
sg11
Vdiabetes
p16423
sg13
I1
sasa(dp16424
g2
S'Large-scale meta-analyses of genome-wide association studies have recently confirmed that the rs340874 single-nucleotide polymorphism in PROX1 gene is associated with fasting glycemia and type 2 diabetes mellitus; however, the mechanism of this link was not well established.\n'
p16425
sg4
(lp16426
(dp16427
g7
I137
sg8
g127
sg10
I10
sg11
VPROX1 gene
p16428
sg13
I2
sasg17
(lp16429
(dp16430
g7
I188
sg20
VC0011860
p16431
sg10
I24
sg11
Vtype 2 diabetes mellitus
p16432
sg13
I4
sasa(dp16433
g2
S'Our observations suggest that the PROX1 variants have pleiotropic effect on disease pathways and it seem to be a very interesting goal of research on prevention of obesity and type 2 diabetes mellitus.\n'
p16434
sg4
(lp16435
(dp16436
g7
I34
sg8
g127
sg10
I14
sg11
VPROX1 variants
p16437
sg13
I2
sasg17
(lp16438
(dp16439
g7
I176
sg20
VC0011860
p16440
sg10
I24
sg11
Vtype 2 diabetes mellitus
p16441
sg13
I4
sa(dp16442
g7
I164
sg20
VC0028754
p16443
sg10
I7
sg11
Vobesity
p16444
sg13
I1
sasa(dp16445
g2
S"Fifteen cases of angiokeratoma corporis diffusum, 10 cases of Fordyce angiokeratoma, 10 cases of Mibelli angiokeratoma and 10 cases of solitary angiokeratoma were examined by immunohistochemical analysis using CD31, D2-40, Prox1 and Wilms' tumor 1 (WT-1).\n"
p16446
sg4
(lp16447
(dp16448
g7
I210
sg8
VP69905
p16449
sg10
I4
sg11
VCD31
p16450
sg13
I1
sa(dp16451
g7
I249
sg8
g127
sg10
I4
sg11
VWT-1
p16452
sg13
I1
sa(dp16453
g7
I223
sg8
g127
sg10
I5
sg11
VProx1
p16454
sg13
I1
sa(dp16455
g7
I233
sg8
g127
sg10
I14
sg11
VWilms' tumor 1
p16456
sg13
I3
sasg17
(lp16457
(dp16458
g7
I233
sg20
VC0027708
p16459
sg10
I12
sg11
VWilms' tumor
p16460
sg13
I2
sa(dp16461
g7
I17
sg20
VC0002986
p16462
sg10
I31
sg11
Vangiokeratoma corporis diffusum
p16463
sg13
I3
sa(dp16464
g7
I17
sg20
VC0002985
p16465
sg10
I13
sg11
Vangiokeratoma
p16466
sg13
I1
sa(dp16467
g7
I17
sg20
VC0002985
p16468
sg10
I13
sg11
Vangiokeratoma
p16469
sg13
I1
sa(dp16470
g7
I62
sg20
VC0263639
p16471
sg10
I21
sg11
VFordyce angiokeratoma
p16472
sg13
I2
sasa(dp16473
g2
S'The vessels of angiokeratoma corporis diffusum, Fordyce angiokeratoma and solitary angiokeratoma were usually focally positive for D2-40 and positive for Prox1, whereas the vessels of Mibelli angiokeratoma were negative for D2-40 and positive for Prox1.\n'
p16474
sg4
(lp16475
(dp16476
g7
I154
sg8
g127
sg10
I5
sg11
VProx1
p16477
sg13
I1
sa(dp16478
g7
I154
sg8
g127
sg10
I5
sg11
VProx1
p16479
sg13
I1
sasg17
(lp16480
(dp16481
g7
I15
sg20
VC0002986
p16482
sg10
I31
sg11
Vangiokeratoma corporis diffusum
p16483
sg13
I3
sa(dp16484
g7
I15
sg20
VC0002985
p16485
sg10
I13
sg11
Vangiokeratoma
p16486
sg13
I1
sa(dp16487
g7
I48
sg20
VC0263639
p16488
sg10
I21
sg11
VFordyce angiokeratoma
p16489
sg13
I2
sa(dp16490
g7
I15
sg20
VC0002985
p16491
sg10
I13
sg11
Vangiokeratoma
p16492
sg13
I1
sasa(dp16493
g2
S'These data suggest that PROX1 SNP rs340874, discovered in fasting glucose GWAS, may also be a pharmacogenetic risk factor for antihypertensive-induced hyperglycemia.\n'
p16494
sg4
(lp16495
(dp16496
g7
I24
sg8
g127
sg10
I18
sg11
VPROX1 SNP rs340874
p16497
sg13
I3
sasg17
(lp16498
(dp16499
g7
I151
sg20
VC0020456
p16500
sg10
I13
sg11
Vhyperglycemia
p16501
sg13
I1
sasa(dp16502
g2
S'The aim of this study was to analyze whether in chronic lymphocytic leukemia the cytosolic release of histone H1.2, a new apoptogenic mechanism induced by DNA damage, was associated with the presence of genetic abnormalities and with the response to treatment.\n'
p16503
sg4
(lp16504
(dp16505
g7
I102
sg8
VP16403
p16506
sg10
I12
sg11
Vhistone H1.2
p16507
sg13
I2
sasg17
(lp16508
(dp16509
g7
I155
sg20
VC0012860
p16510
sg10
I10
sg11
VDNA damage
p16511
sg13
I2
sa(dp16512
g7
I48
sg20
VC0023434
p16513
sg10
I28
sg11
Vchronic lymphocytic leukemia
p16514
sg13
I3
sasa(dp16515
g2
S'Primary tumoral chronic lymphocytic leukemia cells from 25 patients were investigated for histone H1.2 cytosolic release after treatment with genotoxic (fludarabine, mitoxantrone, etoposide, or X-ray radiation) and non-genotoxic (dexamethasone) agents.\n'
p16516
sg4
(lp16517
(dp16518
g7
I90
sg8
VP16403
p16519
sg10
I12
sg11
Vhistone H1.2
p16520
sg13
I2
sasg17
(lp16521
(dp16522
g7
I16
sg20
VC0023434
p16523
sg10
I28
sg11
Vchronic lymphocytic leukemia
p16524
sg13
I3
sasa(dp16525
g2
S'Non-DNA-damaging agents induced release of H1.2 in both p53-deleted and non-deleted chronic lymphocytic leukemia cases.\n'
p16526
sg4
(lp16527
(dp16528
g7
I43
sg8
VP16403
p16529
sg10
I4
sg11
VH1.2
p16530
sg13
I1
sa(dp16531
g7
I56
sg8
VP42771
p16532
sg10
I3
sg11
Vp53
p16533
sg13
I1
sasg17
(lp16534
(dp16535
g7
I84
sg20
VC0023434
p16536
sg10
I28
sg11
Vchronic lymphocytic leukemia
p16537
sg13
I3
sasa(dp16538
g2
S'In chronic lymphocytic leukemia cells, histone H1.2 traffic was dependent on the p53-status after genotoxic treatment, but could also be induced after treatments that acted independently of p53.\n'
p16539
sg4
(lp16540
(dp16541
g7
I81
sg8
VP42771
p16542
sg10
I3
sg11
Vp53
p16543
sg13
I1
sa(dp16544
g7
I39
sg8
VP16403
p16545
sg10
I10
sg11
Vhistone H1
p16546
sg13
I2
sa(dp16547
g7
I81
sg8
VP42771
p16548
sg10
I3
sg11
Vp53
p16549
sg13
I1
sasg17
(lp16550
(dp16551
g7
I3
sg20
VC0023434
p16552
sg10
I28
sg11
Vchronic lymphocytic leukemia
p16553
sg13
I3
sasa(dp16554
g2
S'Nuclear histone H1.2 release appears to be an important element in apoptosis induction in chronic lymphocytic leukemia, particularly in cases with abnormal p53 function resistant to conventional treatment.\n'
p16555
sg4
(lp16556
(dp16557
g7
I0
sg8
VP16403
p16558
sg10
I20
sg11
VNuclear histone H1.2
p16559
sg13
I3
sa(dp16560
g7
I156
sg8
VP42771
p16561
sg10
I3
sg11
Vp53
p16562
sg13
I1
sasg17
(lp16563
(dp16564
g7
I90
sg20
VC0023434
p16565
sg10
I28
sg11
Vchronic lymphocytic leukemia
p16566
sg13
I3
sasa(dp16567
g2
S'Our analysis provides evidence that the use of CDK 4/6 inhibitors is associated with an increased risk of all-grade and high-grade hematological adverse events, which seems to be a class-effect, but not of febrile neutropenia compared with hormonal therapy alone.\n'
p16568
sg4
(lp16569
(dp16570
g7
I47
sg8
VP24941
p16571
sg10
I7
sg11
VCDK 4/6
p16572
sg13
I2
sasg17
(lp16573
(dp16574
g7
I206
sg20
VC0746883
p16575
sg10
I19
sg11
Vfebrile neutropenia
p16576
sg13
I2
sasa(dp16577
g2
S'The highest class-specific risks were neutropenia grade 3-4 for CDK4/6 inhibitors (OR 40.77; 95% CI 19.52-85.19), stomatitis grade 3-4 for mTOR inhibitors (OR 11.92; 95% CI 3.68-38.57), hyperglycemia grade 3-4 for PI3K inhibitors (OR 40.93; 95% CI 10.08-166.22) and diarrhea for anti-HER2 agents (OR 9.93; 95% CI 4.71-20.95).\n'
p16578
sg4
(lp16579
(dp16580
g7
I214
sg8
VP42336
p16581
sg10
I4
sg11
VPI3K
p16582
sg13
I1
sa(dp16583
g7
I139
sg8
VP42345
p16584
sg10
I4
sg11
VmTOR
p16585
sg13
I1
sa(dp16586
g7
I64
sg8
VP11802
p16587
sg10
I6
sg11
VCDK4/6
p16588
sg13
I1
sa(dp16589
g7
I279
sg8
VP04626
p16590
sg10
I9
sg11
Vanti-HER2
p16591
sg13
I1
sasg17
(lp16592
(dp16593
g7
I266
sg20
VC0011991
p16594
sg10
I8
sg11
Vdiarrhea
p16595
sg13
I1
sa(dp16596
g7
I114
sg20
VC0038362
p16597
sg10
I10
sg11
Vstomatitis
p16598
sg13
I1
sa(dp16599
g7
I186
sg20
VC0020456
p16600
sg10
I13
sg11
Vhyperglycemia
p16601
sg13
I1
sasa(dp16602
g2
S'However, the neutropenia associated with CDK4/6 inhibitors is distinct from chemotherapy-induced neutropenia in that it is rapidly reversible, reflecting a cytostatic effect on neutrophil precursors in the bone marrow.\n'
p16603
sg4
(lp16604
(dp16605
g7
I41
sg8
VP11802
p16606
sg10
I6
sg11
VCDK4/6
p16607
sg13
I1
sasg17
(lp16608
(dp16609
g7
I76
sg20
VC1827687
p16610
sg10
I32
sg11
Vchemotherapy-induced neutropenia
p16611
sg13
I2
sasa(dp16612
g2
S'Patients treated with CDK 4/6 inhibitors had an AR of grade 3/4 neutropenia of 61%; neutropenic fever and infections were rare (1% and 3%, respectively).\n'
p16613
sg4
(lp16614
(dp16615
g7
I22
sg8
VP24941
p16616
sg10
I7
sg11
VCDK 4/6
p16617
sg13
I2
sasg17
(lp16618
(dp16619
g7
I84
sg20
VC0746883
p16620
sg10
I17
sg11
Vneutropenic fever
p16621
sg13
I2
sa(dp16622
g7
I106
sg20
VC0021311
p16623
sg10
I10
sg11
Vinfections
p16624
sg13
I1
sasa(dp16625
g2
S'Neutropenia is the most commonly reported hematologic toxicity following treatment with palbociclib, a cyclin-dependent kinase 4/6 inhibitor approved for metastatic breast cancer.\n'
p16626
sg4
(lp16627
(dp16628
g7
I103
sg8
VP11802
p16629
sg10
I27
sg11
Vcyclin-dependent kinase 4/6
p16630
sg13
I3
sasg17
(lp16631
(dp16632
g7
I154
sg20
VC0278488
p16633
sg10
I24
sg11
Vmetastatic breast cancer
p16634
sg13
I3
sasa(dp16635
g2
S'Knockout of Gnb3 in mice results in dysfunction of cone photoreceptors and ON-bipolar cells and a naturally occurring chicken mutation leads to retinal degeneration.\n'
p16636
sg4
(lp16637
(dp16638
g7
I12
sg8
VP16520
p16639
sg10
I4
sg11
VGnb3
p16640
sg13
I1
sasg17
(lp16641
(dp16642
g7
I144
sg20
VC0035304
p16643
sg10
I20
sg11
Vretinal degeneration
p16644
sg13
I2
sasa(dp16645
g2
S'Whole-exome sequencing of a family screened negative for mutations in genes associated with CSNB identified biallelic mutations in the guanine nucleotide-binding protein subunit beta-3 gene (GNB3).\n'
p16646
sg4
(lp16647
(dp16648
g7
I135
sg8
VP09471
p16649
sg10
I54
sg11
Vguanine nucleotide-binding protein subunit beta-3 gene
p16650
sg13
I6
sa(dp16651
g7
I191
sg8
VP16520
p16652
sg10
I4
sg11
VGNB3
p16653
sg13
I1
sasg17
(lp16654
sa(dp16655
g2
S'Mutational analysis of GNB3 in a cohort of 58 subjects with CSNB identified a sporadic case individual with a homozygous GNB3 mutation (c.200C&gt;T [p.Ser67Phe]).\n'
p16656
sg4
(lp16657
(dp16658
g7
I23
sg8
VP16520
p16659
sg10
I4
sg11
VGNB3
p16660
sg13
I1
sa(dp16661
g7
I121
sg8
VP16520
p16662
sg10
I13
sg11
VGNB3 mutation
p16663
sg13
I2
sasg17
(lp16664
sa(dp16665
g2
S'Homozygosity mapping ruled out most known CSNB candidates as well as CACNA2D4 and GNB3.\n'
p16666
sg4
(lp16667
(dp16668
g7
I69
sg8
g127
sg10
I8
sg11
VCACNA2D4
p16669
sg13
I1
sa(dp16670
g7
I82
sg8
VP16520
p16671
sg10
I4
sg11
VGNB3
p16672
sg13
I1
sasg17
(lp16673
sa(dp16674
g2
S'The 3-locus MDR model comprising FTO rs8050136C/A and GNB3 rs1129649T/C and rs5443C/T emerged as the best disease conferring model.\n'
p16675
sg4
(lp16676
(dp16677
g7
I54
sg8
VP16520
p16678
sg10
I17
sg11
VGNB3 rs1129649T/C
p16679
sg13
I2
sa(dp16680
g7
I33
sg8
g127
sg10
I16
sg11
VFTO rs8050136C/A
p16681
sg13
I2
sasg17
(lp16682
(dp16683
g7
I101
sg20
VC0339510
p16684
sg10
I12
sg11
Vbest disease
p16685
sg13
I2
sasa(dp16686
g2
S'Lack of GNB3 signalling causes reduced phosphorylation activity of ERK2 and AKT leading to severe pathological phenotypes such as blindness and renal abnormalities in rge chickens.\n'
p16687
sg4
(lp16688
(dp16689
g7
I8
sg8
VP16520
p16690
sg10
I4
sg11
VGNB3
p16691
sg13
I1
sa(dp16692
g7
I67
sg8
VP28482
p16693
sg10
I4
sg11
VERK2
p16694
sg13
I1
sa(dp16695
g7
I76
sg8
g127
sg10
I3
sg11
VAKT
p16696
sg13
I1
sa(dp16697
g7
I167
sg8
g127
sg10
I12
sg11
Vrge chickens
p16698
sg13
I2
sasg17
(lp16699
(dp16700
g7
I130
sg20
VC0456909
p16701
sg10
I9
sg11
Vblindness
p16702
sg13
I1
sasa(dp16703
g2
S'We investigated the prevalence of common polymorphisms that have been associated with diseases, such as atherosclerosis (ALOX5), hypertension (CYP3A5, AGT, GNB3), diabetes (CAPN10, TCF7L2, PTPN22), prostate cancer (DG8S737, rs1447295), Hirschsprung disease (RET), and age-related macular degeneration (CFH, LOC387715).\n'
p16704
sg4
(lp16705
(dp16706
g7
I151
sg8
VP21549
p16707
sg10
I3
sg11
VAGT
p16708
sg13
I1
sa(dp16709
g7
I236
sg8
VP14138
p16710
sg10
I20
sg11
VHirschsprung disease
p16711
sg13
I2
sa(dp16712
g7
I121
sg8
VP09917
p16713
sg10
I5
sg11
VALOX5
p16714
sg13
I1
sa(dp16715
g7
I189
sg8
g127
sg10
I6
sg11
VPTPN22
p16716
sg13
I1
sa(dp16717
g7
I258
sg8
VP07949
p16718
sg10
I3
sg11
VRET
p16719
sg13
I1
sa(dp16720
g7
I156
sg8
VP16520
p16721
sg10
I4
sg11
VGNB3
p16722
sg13
I1
sa(dp16723
g7
I143
sg8
VP20815
p16724
sg10
I6
sg11
VCYP3A5
p16725
sg13
I1
sasg17
(lp16726
(dp16727
g7
I236
sg20
VC0019569
p16728
sg10
I20
sg11
VHirschsprung disease
p16729
sg13
I2
sa(dp16730
g7
I268
sg20
VC0242383
p16731
sg10
I32
sg11
Vage-related macular degeneration
p16732
sg13
I3
sa(dp16733
g7
I129
sg20
VC0020538
p16734
sg10
I12
sg11
Vhypertension
p16735
sg13
I1
sa(dp16736
g7
I163
sg20
VC0011849
p16737
sg10
I8
sg11
Vdiabetes
p16738
sg13
I1
sa(dp16739
g7
I198
sg20
VC0600139
p16740
sg10
I15
sg11
Vprostate cancer
p16741
sg13
I2
sa(dp16742
g7
I104
sg20
VC0004153
p16743
sg10
I15
sg11
Vatherosclerosis
p16744
sg13
I1
sasa.